<SEC-DOCUMENT>0001213809-20-000018.txt : 20200330
<SEC-HEADER>0001213809-20-000018.hdr.sgml : 20200330
<ACCEPTANCE-DATETIME>20200330170335
ACCESSION NUMBER:		0001213809-20-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200330
DATE AS OF CHANGE:		20200330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		20758034

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dyai-20191231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700,d:ec2c361ab60c4fe685fbbfdcc5343b30--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:dyai="http://www.dyadic.com/20191231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dyai-20191231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV8yLTEtMS0xLTA_ba53f6d8-cd26-4785-a704-951913e56a8c">0001213809</ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV83LTEtMS0xLTA_0023a8a1-7d05-4717-81d3-481f98eb64c6">2019</ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV84LTEtMS0xLTA_81c565b9-374f-4a31-9e07-66503cbb4d1d">FY</ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV85LTEtMS0xLTA_502157b9-48ff-4d14-97b0-dc9e4899fa68">false</ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGV4dHJlZ2lvbjozODJjMDI5NjQ4MWQ0YzFjYWVlNGVjNTIwOTk3ODM1NF83Njk2NTgxMzk0NDg5_698f3f57-f491-46cc-8b1f-d12e473a9c3a">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630" name="dyai:CollaborativeArrangementDurationOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTEyODE_d817c484-c349-4120-9e27-b9d41a8a4fa5">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="if27f58e0337f49bb8ec1e7259b6b9d13_D20160216-20160216" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzOTk_fe3a9107-bbfc-41d2-8697-3542846d9e85">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i9a925883745043b79550f0b480045c4d_D20170816-20170816" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU0MDc_b5a00c4c-c973-45db-864c-25377b84925f">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ia0bcf71b74b44c64a5fefb97fc5d4f58_D20200102-20200102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzM_c9472d93-1ce1-40be-b972-3b905785428b">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i5cbfdfcf598049ba91e61b13c391bc2d_D20200102-20200102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc3OTA_d684f154-2502-42b6-b981-631a93c5af69">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i9b18c77ea83b43abad5be0ac6b14adb2_D20200102-20200102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ2OTQ_7df95ba7-825f-4aa9-b588-d426d336e7e5">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i9c008cca145a43649702102a7b393308_D20200102-20200102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MDA_a7899946-65d3-4626-88f3-03385835ab46">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="dyai-20191231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie8cd6541c2fd4adca3eeb4ed8924a2ca_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i97c30979e4144b5c936703e3411b72bd_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b49ea3f208487698c65394dc8f911a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae10429d4274acc9056aa942fe63b3d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4de0689e804b61b0bd848a5639b725_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e158a241d64af0ad4e2292194137b8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b2621c2b374e3f8ec9d1de2ab3fc52_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e3dd249fbe405fbe111f88491fcb2e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88159e705b6a4615876d7c6373a3230c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecbd8cb44d614d22957374499806e91c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ba3c275bba44c591c298eb6a627117_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5edff09f5d5488092a0f305677b0c0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08882e216601446183c1dc051db938c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12769ae146f64d729004412e0968967d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8345599e828744799c4f0e1e745684b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dyai:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6c8e876d3f1e4b23851e168d3e26723c_D20151231-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:DuPontDaniscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dyai:IndustrialTechnologyBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-31</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>dyai:customer</xbrli:measure></xbrli:unit><xbrli:context id="i5de8574c1d5e40d3b0ee4417bbf0e3d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33feba3cff3d453ab0847ab48f7a65a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4937506a337c49d99f6df9684958c7bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acc47f3ac6c42bfafac0b07049ab969_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539512523cd84b16a4f3e7301273b71d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i853d7cb039e94bbc88573c26b6d2967e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9853caf57ff412fbe8e87c65c083f8a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1ccd95b9f9482f99ac9a39b030913d_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d4c32edf3a47d5ace56c907b84788c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3379be565248d6aae983a9754e0b90_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c18e0290e174928ae53f25f7ad4d742_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794a21883a2f49e885e5e5758820ee30_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716bbd9d30fd4e1fb46f0dee71737323_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199ba6975f9b4d35a19f028f6e3ba9d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c48aca2c334edbae2d056c94cf1c1f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdff80401db4bfd883cc689a5f6c3ca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948cb60e266243f196d1d44762dba391_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68ec379e62f42fd82d9df05be6cc9e3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20de3bbc09b47a58d79e76de605acff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003f72c2db6a4420aae1b41052590348_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca615a626c84646a9e3cd9ee505f251_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9923848bb21f4a459e82cf269761b053_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd519b1fc8643db943ce2a10915099e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic730d04e8b0b4df4a4a422154c714345_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530ce590a54f4e1294cb6cb83802e421_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ia1d98d4756224c909d6e5d6c8a30310a_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e634d7aaec046188c2ed66d34824a19_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4169bf7db9fb46a59c822fcd3015e062_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:VLPbioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2447768dc81342fbbc93c99cf36d4175_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4223a15c84f40d98227848c11916461_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa774688910149949c16b496a421bb9a_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5457c0415a45cb96e692134cbf8975_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c228ac1d4cd4e89b60866a524343d7d_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840867cee002461092e9bb1d28ebe22d_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c8a3fd19f84be7bcf4484ebc536193_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10445b9bcd248c392f6a26e44521761_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355318ed17ba4b0ba24061da681d9010_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491f41e970764c248af615c0fd65548e_I20190426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:NovovetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-05</xbrli:startDate><xbrli:endDate>2019-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="antibody_and_vaccine"><xbrli:measure>dyai:antibody_and_vaccine</xbrli:measure></xbrli:unit><xbrli:context id="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="protein"><xbrli:measure>dyai:protein</xbrli:measure></xbrli:unit><xbrli:context id="if8a37c03b9a24f5f805e876d96fb8eca_D20190507-20190507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id144ebaa808a4539bac88f64f1ae1856_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46135fb3b51c476a969413b90769ef8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfFinanceIndiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i067425fd93584c7f8114ab5e1571995d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:JupiterFloridaHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8211dee89c274d37bf293694b115ff85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:JupiterFloridaHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fc32e45fcc49988560c5d708fe090a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67696ba89b140ea84bb3079e5ab8ed6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a13c798877437492fa7b0a4354cb9c_I20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91f496dcbb044758f163cbd859eb73a_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce85b8cbbff401ab8f9208885798348_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-28</xbrli:startDate><xbrli:endDate>2019-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5359f3a055db4f1886c3bd132f79cdb1_I20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22c697beb7d4b0ab318ca61134fe993_D20191025-20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-25</xbrli:startDate><xbrli:endDate>2019-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f1835196484e3c945b149529822d3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2006PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c9d6b0788b439c9ff3572a031dea3d_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87754620edec4143a42a41e6727c2af7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia095586e60d44997a6ddefe3f667eb8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf44cd91f594d6e9d9f2be57dbefa3d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic164a2b8759541bd92fd673e0a617119_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9911246a988f4400b2298393e4a8d174_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if917f69cb62f4aeab421b5233da141a9_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1003cf64787c47bfa079db8551f27546_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwothroughFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4ff0366c2954e079f8bfbc42ddd2255_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00400d75393341c0b8c51dd7dcaf9263_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68b902c3b614063bf94fc0cb7873a7b_I20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc984c2633c84830a7590e6783b2de69_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502f339e9a564d2fa057ffd43b430345_I20190307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-07</xbrli:startDate><xbrli:endDate>2019-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5361038870ba43a3836b3611390751a9_I20190625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-25</xbrli:startDate><xbrli:endDate>2019-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="board_of_director"><xbrli:measure>dyai:board_of_director</xbrli:measure></xbrli:unit><xbrli:context id="i3180a4adc61148acb883d0951ed14fe7_I20190625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263ac90ac6ab451aac269f8d91a7bb57_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae81b32c80540568b0ddbf678fb73fb_D20190628-20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-28</xbrli:startDate><xbrli:endDate>2019-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4e110274cd42e68c73b41957abca9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb877e64e5f4588b05eb59d2f1f303e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27724349c48a4973856d9b6cbe4f786e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3065e8cc19c4622bc9018bea3d70c6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3b28bef31b45d58d39978ccbae35a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27f58e0337f49bb8ec1e7259b6b9d13_D20160216-20160216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-16</xbrli:startDate><xbrli:endDate>2016-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a925883745043b79550f0b480045c4d_D20170816-20170816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-16</xbrli:startDate><xbrli:endDate>2017-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7591c510da7a48b593cb45d1dddbb122_I20170816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-12</xbrli:startDate><xbrli:endDate>2016-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25427c3bdaeb4b98b458ea7b34deb418_D20160112-20160112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-12</xbrli:startDate><xbrli:endDate>2016-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-11</xbrli:startDate><xbrli:endDate>2017-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfcfcf474ee74ca297efc69b74652e7b_D20170111-20170111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-11</xbrli:startDate><xbrli:endDate>2017-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b266eccec9447ddb9c6431bd35cf1b3_D20170101-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2601b2f77c479581fa9cf5d4cff3fd_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb224dd3f604e299d6ab6df8bc4eba6_D20170901-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5bfc1c71754fd5b496a1784ee4c239_D20180101-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied7940d17259403f80d1b1604a7b10e3_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib559063465144b6cb9251448720e1f2c_D20160101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f46b6e69ca64edd9b8fed76219f38f9_D20160101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0bcf71b74b44c64a5fefb97fc5d4f58_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b5030b61534a9995f73c86b9ce994a_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbfdfcf598049ba91e61b13c391bc2d_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b18c77ea83b43abad5be0ac6b14adb2_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c008cca145a43649702102a7b393308_D20200102-20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-23</xbrli:startDate><xbrli:endDate>2020-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013a834cf3654f739dbd6679b50f16e6_D20200323-20200323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-23</xbrli:startDate><xbrli:endDate>2020-03-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_1"></div><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Njgz_15616296-6d68-47ae-bc11-629ee7f61cf0">10-K</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8wLTAtMS0xLTM3MjA_125807e4-f69c-4302-80c7-4ad4d2521bd9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">For the fiscal year ended <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8xLTEtMS0xLTE5L3RleHRyZWdpb246NzE2NTg4NjI4MGJkNGUzZjk3ZDE3ZDk3NTQwMjE1MWZfNzY5NjU4MTM5NDUwMg_a43c43f0-58f3-4fed-a5b6-98653788dfe4">December&#160;31, 2019</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8zLTAtMS0xLTM3MjM_9c1062f7-7e57-4b55-a4c5-2e401e60e0e8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the transition period from _____ to ______</span></td></tr></table></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commission file number: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Njg5_7bec7009-667b-41af-adfc-ad6562f1c681">000-55264</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:center;"><img src="dyai-20191231_g1.jpg" alt="dyai-20191231_g1.jpg" style="height:45px;width:57px;"/><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">    </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzAw_50c96881-d104-484e-ba4e-2e9137b3f101">DYADIC INTERNATIONAL, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:46.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.665%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.242%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6MzcyZDE3NGRiODNiNDEwNWExZWExNTZjZDAxNjQwY2EvdGFibGVyYW5nZTozNzJkMTc0ZGI4M2I0MTA1YTFlYTE1NmNkMDE2NDBjYV8wLTAtMS0xLTM3Mzc_7458c678-c2d2-4f92-9615-7236ce10b588">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6MzcyZDE3NGRiODNiNDEwNWExZWExNTZjZDAxNjQwY2EvdGFibGVyYW5nZTozNzJkMTc0ZGI4M2I0MTA1YTFlYTE1NmNkMDE2NDBjYV8wLTItMS0xLTM3Mzc_88ff240f-c669-4602-9c46-c67112da4e17">45-0486747</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzI4_f4fab619-772a-4365-89cf-a7dd16c60eb9">140 Intracoastal Pointe Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzU5_9285358e-3852-427d-a51d-6e2379c005e6">Suite 404</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzcw_e6b10744-8e21-406c-8baa-6827fa58951c">Jupiter</ix:nonNumeric>, <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzc5_8a7c88e8-aea3-44bb-80ca-c02c2a83aab2">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzg4_9b06a7e2-7137-4e0a-a0bc-ebe905dd3e98">33477</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzk1_a1c13d4a-f8fb-4bc9-bead-469a98f09cd8">561</ix:nonNumeric>) <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2ODAw_8e37b3e6-d3d2-4774-b4a1-c6bbfd5435f8">743-8333</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.743%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.512%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.745%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTAtMS0xLTM3NzY_754ef2ba-b6ca-410f-b633-e4d6a4f35f32">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTEtMS0xLTM3NzY_7ffff225-ea08-4be4-8d21-1d5686c289fd">DYAI</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTItMS0xLTM3NzY_202937cc-12f1-4723-a1c0-1913bf18a44e">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(g) of the Act: None.</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  &#160;&#160; Yes &#9744; <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTQ5_4d145a8d-59a0-4c14-8aef-2856e85d7ccc">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#160;&#160; Yes &#9744; <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTUz_fbffc8ca-5c18-40e6-8a22-48ba3151559e">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTU3_d7d325cb-371b-412d-8ce3-2431806c1ae7">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                 &#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTYy_34a73433-a225-4717-995d-5bd784c68fc1">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:21.211%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.014%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.014%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.014%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.372%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.375%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Large accelerated filer &#9744;</span></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Accelerated filer &#9744;</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8xLTAtMS0xLTYzL3RleHRyZWdpb246NmQwMjVkYTZiZjVkNGI4Mjk5ZjZlMDNkMmE5ZjNhMzJfNjU5NzA2OTc2NjcxOA_5a784722-3d07-4994-a93c-f9be2587e52f">Non-accelerated filer</ix:nonNumeric> &#9746;</span></div></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Smaller reporting company <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8xLTQtMS0xLTYzL3RleHRyZWdpb246Y2ExZjMzNzdlZGJlNDAxYmE4OWYzNTc1MGEwNWFjZWVfNjU5NzA2OTc2Njc0Nw_a5ea4bdb-0b62-47e9-a3d1-176f719f9b24">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Emerging growth company <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8yLTQtMS0xLTYzL3RleHRyZWdpb246Y2U4OWU2YjdhM2E1NGI2Y2JiZTQzYjQ3MmU5MGVlN2VfNjU5NzA2OTc2Njc0Mg_6bcf6db9-280d-4d21-8750-7af66bac0a4c">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Ac</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">t.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc3NjAy_69c2741d-41e1-4215-8c3f-639abf600e1a">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (27,111,157 shares) computed by reference to the closing price of $6.26 as reported on the NASDAQ Stock Markets on June 30, 2019 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="usd" contextRef="ie8cd6541c2fd4adca3eeb4ed8924a2ca_I20190630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF8xNjQ5MjY3NDUxOTg1_e04b7486-e988-4f19-af70-fed83ed99b2a">169.7</ix:nonFraction>&#160;million. Shares of the registrant&#8217;s common stock held by executive officers, directors, and their affiliates have been excluded from this calculation. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As of March&#160;29, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="i97c30979e4144b5c936703e3411b72bd_I20200329" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF8zODQ4MjkwNzA2OTI0_fd4825e0-b321-48e9-ae2b-f2374a30a863">27,359,157</ix:nonFraction> shares of common stock outstanding.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_7"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.321%;"><tr><td style="width:1.0%;"></td><td style="width:8.276%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.202%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.522%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">TABLE OF CONTENTS</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_13">PART I</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_16">Business</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_19">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_19">13</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_22">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_25">Properties</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_25">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_31">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_34">PART II</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_34">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_37">Market for Registrant&#8217;s Common Equity, and Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_37">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_43">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_58">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_58">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 8.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_61">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_64">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_64">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Item 9A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_67">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_67">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_70">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_70">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_73">PART III</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_73">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 10.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_76">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_76">38</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 11.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_79">Executive Compensation</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_79">44</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 12.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_82">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_82">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 13.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_85">Certain Relationship and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_85">52</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 14.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_88">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_88">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_91">PART IV</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_91">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 15.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_94">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_94">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 16.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_97">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_97">55</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_100">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_100">55</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_103">INDEX TO FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_103">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_103">1</a></span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_10"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Information (other than historical facts) set forth in this Annual Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 7 &#8220;Management&#8217;s Discussion and Analysis&#8221;. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic&#8217;s control. These factors include, but are not limited to, (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic&#8217;s and third parties&#8217; research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies&#8217; willingness to adopt, utilize and approve the use of the C1 gene expression platform; (9) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd; (10) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (11) our expectations concerning the impact of the novel coronavirus identified as &#8220;COVID-19&#8221; on our operating results; and (12) other factors discussed in Dyadic&#8217;s publicly available filings, including information set forth under the caption &#8220;Risk Factors&#8221; in this Annual Report. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption &#8220;Risk Factors&#8221; and elsewhere in this Annual Report which could have a material adverse effect on our business, results of operations and financial condition. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Annual Report to conform these statements to actual results or to changes in our expectations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_13"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_16"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:28.654%;"><tr><td style="width:1.0%;"></td><td style="width:30.142%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:65.858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Business</span></td></tr></table></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and currently two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(formerly </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;. Prior to the Company&#8217;s uplisting to the NASDAQ, the Company&#8217;s common stock traded on the OTCQX market.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Technology</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the C1 cell line is unique compared to traditional filamentous fungal cells, and the C1 gene expression platform has the potential to be used in the discovery, development and manufacturing of biologic medicines and vaccines, given its anticipated competitive advantages compared to certain other leading pharmaceutical expression systems, such as CHO (&#8220;Chinese Hamster Ovary&#8221;) cells. Specifically, the C1 cell line has:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A unique morphology which translates into better growth conditions and very high secreted protein yield and has been used in industrial production for 20 years at up to 500,000-liter scale.</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Several significant potential operational advantages include:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">High productivity and low-cost synthetic media for the upstream fermentation steps;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">Potential for greater protein yield for certain downstream processing steps due to the high purity of secreted proteins;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">No virus-like particles or virus carryover from production cells thus eliminating the two purification steps typically involved in CHO production; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">Low pH viral inactivation and virus nano filtration.</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Wide pH and temperature operating conditions which has the potential to translate into more reliable and robust production processes.</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Shorter production cycle times than CHO which translates into the following time savings:</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">A significant reduction in the duration of the inoculation steps in comparison to CHO can be achieved with C1 fermentation; </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">Fermentation cycle time of 5-7 days which is one-half (1/2) to one-third (1/3) of the typical fermentation production time of CHO.</span></div><div style="text-indent:-18pt;padding-left:54pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">C1&#8217;s unique glycan structure is expected to facilitate more rapid glycoengineering work than that of yeast and other fungi that create cell lines having human types of N-Glycan pattern. This advantage has already enabled us to reach important milestones towards our goal to develop cell lines having human types of defined glycans structure, including Man3, G0, G0F, G2 and G2F.  </span></div><div style="padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Competition</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe our C1 gene expression platform has the potential to become a viable alternative to certain of the leading expression systems currently used in the biopharmaceuticals industry to produce vaccines, monoclonal antibodies, and other therapeutic proteins. C1 has some inherent benefits and potential competitive advantages compared to some of the industry standard expression systems for biologics such as CHO cells, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">E. coli</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Pichia, and Baculovirus as discussed below: </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Mammalian cells: They are currently the preferred hosts for most complex protein therapeutics due mainly to their ability to produce proteins with human-like glycosylation. This market is dominated by CHO cells. Disadvantages include the relatively longer time required for cell line development, and fermentation, expensive media and comparably low protein yields.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Bacterial: Bacteria such as </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">E. coli</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  are currently the easiest, cheapest, and quickest method for recombinant protein expression and are often used in laboratory settings as well as commercial production of certain non-glycosylated proteins. However, they produce toxic and pyrogenic cell wall components that may make them less suitable for the production of pharmaceutical or food components.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Yeast: In contrast to bacteria, yeast, such as Pichia, do not produce potentially toxic and pyrogenic cell wall components. Further, the genetic tools for yeast development are advanced and enable continued engineering of new strains that may become more suitable than CHO cell lines.  Disadvantages include the comparably lower protein yields than C1 and hyper-glycosylation.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Insect cells: Insect cells offer protein expression with posttranslational modifications similar to mammalian cells, ease of scale-up, and simplified cell growth readily adapted to high-density suspension culture for large-scale expression. Baculovirus expression systems are used for producing recombinant protein, especially for vaccine antigens. Disadvantages include the comparably lower protein yields than C1.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our C1 technology has the potential to become an alternative gene expression platform to CHO, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">E.coli</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, yeast, insect cells, and other organisms currently in use for developing and manufacturing protein-based biologics because of C1&#8217;s potential speed of development, higher protein yields, and low production costs, among other potential benefits.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Industry and Markets</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on research results from our collaborations and our ongoing discussions with leading pharmaceutical and biotech companies, contract manufacturing organizations (CMOs), leading academic institutions, as well as U.S. and foreign governmental agencies, we continue to believe that the biopharmaceutical market is an attractive opportunity to apply the C1 technology. The Company continues to evaluate potential opportunities to expand the application of our C1 technology, and is currently focused on penetrating the biologics market in the following segments:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Recombinant vaccines market for animal health</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Recombinant vaccines market for human health </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">New innovative biotherapeutics</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Biosimilars / Biobetters non-Glycosylated protein market</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Biosimilars / Biobetters Glycosylated protein market </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Metabolites / Primary and Secondary</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Diagnostic</span></div><div style="padding-left:18pt;margin-bottom:3pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of biologic medicines, such as antibodies, is growing significantly. However, biologic medicines are very expensive for both patients and health care systems, and the Company believes that such high cost is in part the result of the following bottlenecks in the development and manufacture of biologic medicines:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Low yielding and often slower gene expression systems currently used by the biopharmaceutical industry</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Expensive, often royalty stacked, cell-media in the case of CHO cell lines</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Long production time in the case of stable CHO cell lines</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Previous underfunded development efforts for a more efficient next-generation gene expression system</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The biopharmaceutical industry&#8217;s reluctance to utilize certain advances to develop next-generation gene expression systems for bio-manufacturing, such as application of cutting-edge synthetic biology, metabolic and glyco-engineering tools to generate more productive microorganisms with differentiating properties</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that the biopharmaceutical industry may benefit from a next-generation expression platform that is safe, reliable, productive and cost effective as such platform would facilitate the production of more affordable biologic medicines in larger volumes using smaller fermentation vessels. The Company also believes that by further engineering our C1 technology it will have the potential to be an alternative to CHO and other expression systems for certain biologic vaccines, drugs and other biologic products.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Potential Opportunity to Use C1 in Drug Discovery and Early Development Process</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While our focus has been and remains on developing stable C1 cell lines to speed up the development, lower production costs, improve the performance of biologic vaccines and to develop drugs at flexible commercial scales, we have identified biologics drugs discovery and early development process as one area where C1 also may add value based on our discussions with various pharmaceutical and biotech companies. This area includes the biologics drug discovery and early development process requires sufficient levels of proteins to be expressed as quickly as possible in order to identify new drug candidates within a limited time. Currently, HEK 293 cells (human embryonic kidney cells) are commonly used for this application. Given that C1 cells have demonstrated the capability to express and produce comparable and even larger quantities of protein than HEK 293 cells, we believe that C1 has the potential to help overcome certain protein expression challenges in the biologics drug discovery and development stages. We have had discussion with third parties, including our existing collaborators, to identify additional avenues to potentially adapt our C1 technology for this application.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Sub-licensing Agreements</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novovet and Luina Bio Sub-License </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2019, the Company entered into a sub-license agreement (the &#8220;Luina Bio Sub-License Agreement&#8221;) with Luina Bio Pty Ltd. (&#8220;Lunia Bio&#8221;) and Novovet Pty Ltd (&#8220;Novovet&#8221;). Under the terms of the Luina Bio Sub-License Agreement, the Company granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic&#8217;s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (&#8220;Novovet Up-Front Consideration&#8221;) in accordance with the terms of Novovet&#8217;s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#8217;s proprietary C1 gene expression platform. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alphazyme Sub-License </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2019, the Company entered into a sub-license agreement (the &#8220;Alphazyme Sub-License Agreement&#8221;) with Alphazyme, LLC (&#8220;Alphazyme&#8221;). Under the terms of the Alphazyme Sub-License Agreement, the Company granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic&#8217;s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a 7.5% ownership interest in Alphazyme (&#8220;Alphazyme Up-Front Consideration&#8221;) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic&#8217;s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of 18 months (&#8220;Exclusivity Period&#8221;) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional 2.5% ownership interest in Alphazyme. A portion of the technology transfer has been completed. However, Alphazyme has not signed off on the remaining portion of the technology. Efforts to complete the last step of their internal qualification of C1 has been delayed partly due to the travel restriction under the COVID-19 pandemic.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Research Partners and Contract Research Organizations (CROs)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Currently, the Company is conducting its C1 platform research programs at the following two contract research organizations:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(1) Research and Development Agreement with VTT Technical Research Centre of Finland, Ltd (&#8220;VTT&#8221;)</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since September 2016, the Company has been working with VTT Technical Research Centre of Finland, Ltd, a third-party contract research organization, to further modify and improve the Company&#8217;s C1 technology to ensure a safe and efficient expression system for use in speeding up the development and lowering the cost of manufacturing pharmaceutical products and processes. VTT is one of the leading research and technology organizations in Europe, and it has conducted research and development on fungi and other microorganisms for more than three decades. We believe that VTT has the required skills and experience in fungal strain development to help us further develop our C1 technology and achieve our goal and objectives.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, the Company extended its research and development agreement with VTT through June 2022. Under the terms of the extended agreement, the Company will pay VTT a total of EUR &#8364;2.52 million over the next three years to continue developing Dyadic&#8217;s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein expression projects. VTT is entitled to an additional success bonus up to EUR &#8364;450,000 based on the technical targets stipulated in the extended agreement. Meanwhile, Dyadic entered into a license agreement with VTT which granted Dyadic and its sublicensees the right to use synthetic C1 promoters developed by VTT, for an access fee. On October 25, 2019, the Company expanded the agreement with VTT to pay an additional EUR &#8364;690,000 over the next 1.5 years to reinforce its glycoengineering work. Dyadic retains the right to terminate the agreement with 90 days&#8217; notice. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(2) Collaboration Agreement with BDI</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA,  the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which companies are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D Agreements provided a framework under which the parties engaged in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next-generation biological vaccines and drugs. The goal of these projects was to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All data and products developed from the funded research projects will be owned by Dyadic. BDI also conducted gene expression and media development work coupled with fermentation optimization to improve the C1 technology&#8217;s production process for manufacturing vaccines, antibodies as well as therapeutic enzymes and proteins. Additionally, BDI conducted research and development on our behalf to express and produce a variety of C1-based biologic products to demonstrate C1&#8217;s capabilities and to identify potential animal and human pharmaceutical products that could be out licensed to third parties for commercialization. Those proteins included mAbs, Fc-Fusion constructs, Bi-specific antibodies, Fabs, VLP and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the BDI transaction, the Company paid EUR &#8364;1 million in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI was obligated and did spend a minimum amount of EUR &#8364;936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected by Dyadic for additional development and commercialization and BDI agrees to enter into an agreement with Dyadic for such additional development and commercialization, Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;1 million for a 50% share and EUR &#8364;8 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI the first EUR &#8364;1.5 million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic was obligated to purchase from BDI at least USD $1 million (the &#8220;SFA Commitment&#8221;) in contract research services specified by Dyadic over two years following the closing of the BDI transaction.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 2019, BDI has completed its services and the Company has fulfilled its funding obligation under the SFA Commitment. All research projects under the R&amp;D Agreements were completed. Subsequent to the completion of the RSA, the Company has engaged BDI to conduct certain other research activities on its behalf and anticipates continuing do to so from time to time.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Research and Development (&#8220;R&amp;D&#8221;) Programs</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s current research and development activities are focused on the following biopharmaceutical programs:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(1) Internal Research Programs</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C1 Production Host Improvement Programs</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has research and development agreements with VTT and others to further improve its C1 technology to become an even more robust, versatile and efficient therapeutic protein production platform which may be used to help bring biologic vaccines and drugs to market at lower cost with potentially improved performance. Ongoing projects include, among other things: (i) improving the genome sequence-accuracy for the application of system biology tools, (ii) improving the C1 genetic tools, (iii) further reducing the background protease(s) levels by identifying and deleting certain protease genes and/or modifying C1 fermentation processes, (iv) developing high expression C1 cell lines by genetic modifications where one or more specific integration sites are being used to increase productivity and to what we expect will help with future regulatory approvals, and (v) modifying the glycosylation pathway of C1 cells in order for C1 to express certain mAbs and other proteins with mammalian like glycosylation structures and to eliminate or modify certain unwanted glycan structures such as O-glycosylation.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have made certain improvements to our C1 technology platform through our collaborations with VTT, BDI and through our other research projects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Data demonstrating C1&#8217;s capability to express a variety of vaccines and therapeutic proteins including monoclonal antibodies (mAbs), Fab antibody fragments, Fc-Fusion proteins, and difficult-to-express genes such as virus-like particles (VLPs), Bi-Specific antibodies, and antigens, at a higher productivity level than other gene expression platforms.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Data from a large pharma collaborator demonstrating that the binding kinetics of mAbs produced from C1 are virtually indistinguishable from the binding kinetics of reference mAbs which were produced in CHO cells.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Expressed a third party bi-specific antibody which was assayed by the third party in an in vitro cellular activity assay which indicated that dose response curves for the C1 expressed bi-specific antibody were very similar to the CHO expressed bi-specific antibody.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Expressed a third party monoclonal antibody which was assayed by a third party who reported that the neutralizing activity assay demonstrated great similarity between C1-produced mAb and CHO-produced mAb.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Generated C1 strains that have lower background protease activity, while remaining healthy and viable.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Created a C1 protease expression library to quickly identify and eliminate protease genes to improve protein stability and productivity.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Developed and used a variety of novel genetic elements as well as molecular and metabolic engineering tools that can be used in biologic vaccine and drug development and manufacturing.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Demonstrated that C1 can be grown not only in stainless steel fermenters, but also in single use bioreactors (SUBs).  We conducted multiple bioreactor experiments using a 50L XDR-50MO Single Use GE bioreactor which showed that the expression level (productivity of 9.2 g/l for an early Certolizumab process) was virtually identical to the productivity achieved in the Stainless-Steel Bioreactor.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Improved C1 fed batch fermentation process with low cost defined media, as compared to the expensive, complex growth media being used with CHO cells. Continued optimizing both the media and the fermentation process to further increase mAb and other protein yields and productivity.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Achieved higher productivity levels than objectives for several target proteins that were developed for 3</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">rd</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> parties. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Glycosylated Therapeutic Programs</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s longer-term objective, which is ongoing and requires substantially more time and capital is to apply the C1 technology for the large therapeutic glycoprotein market. We believe that the rapid advances being made in genomics </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and synthetic biology, make the C1 fungal cell line a promising candidate to further engineer glycosylation pathways: (i) to produce therapeutic proteins having human like glycoforms structures such as G0, G2, G0F, and G2F; (ii) to reduce or eliminate O-glycosylation; and (iii) to create potentially improved immunogenicity in the case of vaccines.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial steps to develop C1 strains that produce mAbs with mammalian-like glycosylation are progressing at VTT. So far, we have achieved human-like glycan structure site occupancy level of approximately 95% for G0 and approximately 76% for G2. In addition to G0, only Man3 and GlcNAcMan3 remain in the glycan pattern. The next step is to reach C1 cell lines that produce proteins with G0F and G2F glycan structures. Based on research results we have to date, the Company believes that our C1 technology has the potential to become a useful platform for the development and production of therapeutic glycoproteins with human-like or potentially even superior glycan structures. We believe that, if successful, the glycoengineering of C1 cells may help to position the C1 technology to be an important production platform for developing and manufacturing glycosylated antibodies and other glycoproteins. These initial glycoengineered C1 cells have to date shown reduced gene expression levels when compared to the non-glycoengineered C1 cells. Several approaches are now being applied to reach our main goal &#8211; the production of therapeutic proteins by C1 having human-like glycoforms structure at high levels.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we have made substantial progress working with VTT since September 2016, there remains additional work and data needed to develop our C1 technology into a potentially safe and efficient expression system for use in speeding up the development and lowering the cost of animal and human biologic vaccines and drugs.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(2) Animal Health Programs</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Biologic Vaccines Programs - ZAPI</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continued our participation in the ZAPI vaccination program. ZAPI (www.zapi-imi.eu) is a research and development project funded as part of IMI EU program (Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement n&#176;115760)), with the assistance and partial financial support of IMI and the European Commission, and in-kind contributions from EFPIA partners. This project aims to develop a suitable platform for the rapid development and production of vaccines and protocols to fast-track registration of product developed to combat pandemic Zoonotic diseases that have the potential to affect human and animal populations. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our efforts to demonstrate C1&#8217;s ability to express antigens at target levels set by the ZAPI consortium have been met or exceeded. For example, we were asked to focus on expressing a specific antigen against the Schmallenberg virus (SBV), and the data obtained so far has indicated promising high expression levels of this antigen which we anticipate will be transferred to other groups within ZAPI who may carry out additional animal trials. Although the target expression level of the antigen against the Schmallenberg virus (SBV) was stated by ZAPI at the beginning of the project to be 100 mg/l, we have been able to demonstrate C1 expression levels of this antigen at approximately 17 times (17X) that level or approximately 1780 mg/l. In addition, the ELISA and Western Blot&#8217;s analysis of the results confirmed that the C1-expressed protein has similar performance as antigen produced by baculovirus and it was correctly folded. The high productivity level reached with the C1 expressed SBV antigen has significantly contributed to the recent ZAPI animal trials as well as to the achievement of one of the goals of the ZAPI project, which is to produce a sufficient number of vaccination doses quickly, at low cost using reduced fermentation capacity.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s C1-expressed antigens were tested in mice and cattle studies within the ZAPI project, and the resulting data indicated that the C1 technology produced antigen generated an immune response in both mice and cattle that protected the animals and showed no negative effects on the health of animals without any clinical signs of disease. We anticipate that more immunogenicity and safety testing will be conducted within the ZAPI project in the future. As a result, ZAPI expanded the scope of Dyadic&#8217;s involvement in the program, and provided additional funding from the ZAPI consortium in support of production of the two additional targets. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Animal Health Projects and Collaborations</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2019, we entered into two animal health collaborations with two of the top four leading animal health companies to use the C1 technology for expression and production of therapeutic proteins for companion and farm animal diseases. On October 28, 2019, we expanded one of the above research collaborations to express one additional protein.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under these collaborations, Dyadic will apply its proprietary and patented C1 gene expression platform to express different types of proteins to be evaluated by our collaborators for potential use in their research and commercial projects.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(3) Israel Institute for Biological Research (IIBR) </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2018, we entered into a research and development collaboration with the Israel Institute for Biological Research (&#8220;IIBR&#8221;) to further advance our C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies (biologics)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to combat emerging diseases and threats.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This project provides us with an opportunity to work with a renowned organization, aiming to integrate our C1 gene expression platform into an end to end product development and manufacturing capability to produce biologics, and if possible, to get some of these biologics through the regulatory approval process. All of the collaboration work is performed at IIBR&#8217;s laboratories using their in-house resources.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through this collaboration with the IIBR, a proprietary IIBR Fc-fusion enzyme known as Acetyl Choline Esterase enzyme, has been expressed using our C1 technology. This Acetyl Choline Esterase enzyme has previously been shown to provide certain countermeasures against nerve agents such as sarin and VX gas which are toxic and rapidly acting chemical warfare agents. The recombinant IIBR Fc-fusion enzyme, produced in HEK293 cells, has been shown to provide longer lasting protection than the common Acetyl Choline Esterase.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(4) Sanofi-Aventis Program</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, we entered into a funded proof of concept research collaboration with Sanofi-Aventis Deutschland GmbH, a company of the Sanofi group, one of the World&#8217;s top tier biopharmaceutical companies. This research collaboration is to apply our C1 platform to express multiple types of therapeutic compounds to overcome specific gene expression challenges and to further demonstrate the potential of C1 to become a platform of choice for manufacturing protein-based vaccine and biologic drugs.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have completed our tasks under the research collaboration plan, and C1 was successful in expressing more than half of the seven proteins at or above the production level goals initially set by Sanofi-Aventis. Sanofi-Aventis is in the process of evaluating the expression results the expressed proteins and their analytical data, and we are in discussion with them regarding next steps.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(5) Research and Commercialization Collaboration with Serum Institute of India</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#8220;Serum&#8221;). Under the terms of this collaboration, Serum anticipates applying Dyadic&#8217;s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for up to twelve (12) proteins in return for certain research funding, milestone payments and royalties for fifteen (15) years from the date of the first commercial sale. Currently, we are working on re-expressing those antibody genes provided by Serum that have already been expressed in earlier generations of C1 cells, by using one or more of the emerging glycoengineered C1 cell lines in order to allow Serum to carry out further purification and analytical tests to reach the quality attributes that are necessary for clinical trials and commercial manufacturing.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(6) Potential Commercialization Program at BDI</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our collaboration program with BDI, BDI was able to express a Virus Like Particle (VLP) and a basket of therapeutic proteins that are commonly used as animal and human vaccines and drugs, either glycosylated or non-glycosylated proteins (including among others, mAbs, Fabs, and bi-specific mAbs.) to determine which, if any, of these proteins might be potential candidates for future commercialization.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were able to demonstrate that C1 is capable of expressing certain types of antibodies at various yield levels as well as the ability to express other therapeutic proteins, which are difficult-to-express by other cell lines. In particular:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A Secreted Virus Like Particle (VLP) monomers was expressed at 2.27g/l by C1 and appears to have been properly assembled to form a 60-mers protein structure. Transmission Electronic Microscopy (TEM) analysis confirmed the correct structure of the VLP.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our first and initial attempt to express Blinatumomab, a bi-specific drug, was successful as the initial unoptimized expression level was 0.6 g/l (0.12 g/l/d). The initial expression level of Blinatumomab is a start in generating data </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">that we believe will help us to demonstrate the potential of C1 to be used as a production host for expressing more complex and difficult to express drugs such as bi-specific antibodies.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">We have reached the expression level of the antibody fragment Certolizumab using C1 as high as 12.0 g/l in 112 hours (2.6 g/l/d). Certolizumab is a constituting part of Cimzia Pegol, which is a recombinant, humanized and pegylated Fab antibody fragment. We are evaluating what further development work is required to pursue for optimizing the upstream and the downstream processes in order to establish a well-defined production process that may be ready for non-clinical and clinical registration studies. In addition, based on certain further modifications to the C1 cell line, such as the reduction or elimination of O Glycans, we may choose to conduct a variety of comparability and quality analytics with the C1 expressed Certolizumab together with our partner BDI and potentially other third parties.We have reached the expression level of the antibody fragment Certolizumab using C1 as high as 12.0 g/l in 112 hours (2.6 g/l/d). Certolizumab is a constituting part of Cimzia Pegol, which is a recombinant, humanized and pegylated Fab antibody fragment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(7) Monoclonal antibodies (mAbs), Fc-Fusion, and Fab</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company continues to develop relationships with business and research partners in the human biopharmaceutical industry. In addition to named projects mentioned above, the Company entered into three additional funded feasibility and expression research projects with top-tier human pharmaceutical companies to validate the C1 technology to produce high levels of mAbs and other therapeutic proteins. Together with other internally funded research programs, we were able to use C1 to express a variety of types of therapeutic proteins, including monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, and Fc-Fusion proteins using our C1 technology. So far, we were able to demonstrate C1&#8217;s ability to express various protein at the following level:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">an Fc-Fusion protein at 13.2 grams per liter (g/l) in 168 hours, or 1.89 grams per liter per day (g/l/d)</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a mAb protein at 24.5 g/l in 168 hours, or 3.5 g/l/day</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a Fab antibody fragment at 14.5 g/l/d in 164 hours, or 2.1 g/l/day</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a Bispecific protein at 1.04 g/l in 144 hours, or 0.17 g/l/day</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">A SBV antigen at a level of 1.8 g/l in 5 days, or 350 mg/l/day</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Most of the diverse proteins expressed by C1 as required by third parties that reached higher productivity levels than their target goals, including certain &#8220;difficult to express proteins&#8221;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that such results are promising and show greater productivity potential of C1 compared to the average expression yields of CHO cells which is the predominant production system currently used to manufacture glycosylated biopharmaceutical drugs. However, in order to potentially commercialize or capitalize on C1&#8217;s potential in producing glycoproteins, we will need to complete the glycoengineering of C1, maintain the productivity advantages shown in the non-glycoengineered C1 strains and be able to demonstrate a variety of biological and analytical data related to quality, performance, stability and safety.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(8) Metabolites and Other Market Opportunities</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also successfully applied metabolic modeling, synthetic biology and genome engineering techniques to demonstrate the potential benefits of using C1 as a primary metabolite-producing host organism. We believe that the knowledge and data generated in this program is expected to enhance our understanding of C1&#8217;s metabolic characteristics and help us in advancing our ongoing programs, as we continue to explore the development and commercialization of one or more primary and/or secondary metabolites. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, in early 2018, we began to conduct certain funded research activities to further understand if, or how the C1 technology may be applied for use in developing and manufacturing certain metabolites. The initial data from this metabolite project, where the Phase I data milestone was achieved, demonstrated that C1 has the potential to be engineered to produce certain metabolites. The Company is evaluating if, and how it may further develop and commercialize this potential metabolite product which may include the Company fully funding this on its own, or in collaboration with third parties.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is evaluating the potential go-to-market strategies for both the primary and secondary metabolites and may decide to continue internally funding such project to product commercialization or may in the future seek third-party funding in one or more collaborations, licensing or form other types of alternative structure(s), to further develop and monetize this potential opportunity. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that certain attributes of C1, together with our continuing platform research and development programs, provides us with the potential to create attractive research, licensing, partnering/collaboration and other revenue and funding opportunities in the animal and human biopharmaceutical industries. The third-party funded research projects mentioned above and others that we are seeking may help defray some of our research expenses, as we continue to develop and demonstrate the potential of our C1 technology. The Company will continue seeking research collaboration opportunities and partners to potentially commercialize C1-based products.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employees</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we had 6 employees located in the United States, and 3 key consultants located in Europe. None of our employees are represented by a labor union, and we consider our employee relations to be good.</span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Corporate information</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Founded in 1979 by Mark A. Emalfarb, our Chief Executive Officer, Dyadic has focused on the development of C1 expression platform since 1992, refining and optimizing the C1 technology to become an industry leading gene expression and protein production system.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Currently, Dyadic is a global biotechnology company with operations in the United States and a satellite office in the Netherlands and currently two research organizations performing services under contract to Dyadic in Finland and Spain. Dyadic was incorporated in Delaware in September 2002. Our principal corporate offices are located at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477; telephone number (561) 743-8333; website </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.dyadic.com.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic is required to file annual, quarterly and current reports, proxy statements and other information with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Investors may read and copy any document that Dyadic files, including this Annual Report on Form&#160;10-K, at the SEC&#8217;s Public Reference Room at 100&#160;F Street, N.E., Room&#160;1580, Washington, DC 20549. Investors may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, from which investors can electronically access Dyadic&#8217;s SEC filings.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain a website at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.dyadic.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. From time to time, the Company may use its website as a channel of distribution of material Company information, and financial and other material information regarding the Company is routinely posted on and accessible at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">http://dyadic.com/investors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We make available free of charge on or through our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, reports filed pursuant to Section&#160;16 and any amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. In addition, we have posted the charters for our Audit Committee, Compensation Committee, and Nominating and Governance Committee, as well as our Board Governance Principles and Code of Conduct, on our website under the heading &#8220;Investors&#8221;, and sub-heading &#8220;Corporate Governance.&#8221;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_19"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing in our common stock involves a high degree of risk. You should carefully consider the following material risks, together with the other matters described in this Annual Report and in our financial statements and the related notes thereto in evaluating our current business and future performance. We cannot assure you that any of the events discussed in the risk factors below will not occur. If we are not able to successfully address any of the following risks or difficulties, we could experience significant changes in our business, operations and financial performance. In such circumstances, the trading price of our common stock could decline, and in some cases, such declines could be significant, and you could lose part or all of your investment. In addition to the risks described below, other unforeseeable risks and uncertainties or factors that we currently believe are immaterial may also adversely affect our operating results, and there may be other risks that may arise in the future. Certain statements contained in this Annual Report (including certain statements used in the discussion of our risk factors) constitute forward-looking statements. Please refer to the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; appearing on page 4 of this Annual Report important limitations and guidelines regarding reliance on forward-looking statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not succeed in implementing our business strategy.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the December 31, 2015 sale of substantially all of the assets of our industrial technology business to DuPont&#8217;s Industrial Biosciences business for $75 million in cash (the &#8220;DuPont Transaction&#8221;), DuPont obtained certain rights to utilize the C1 technology for development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization. At the same time, Dyadic retained the co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, with Dyadic currently having exclusive ability to enter into sub-license agreements in that field (subject to the terms of the license and certain exceptions). We cannot predict whether DuPont intends to or will pursue the use of the C1 technology to develop or manufacture pharmaceutical products or whether or when we might receive royalties from DuPont. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents owned or licensed in by DuPont. Consequently, our business has changed dramatically as compared to the past as we no longer have any product revenue related to our enzyme business. We have begun to apply the C1 technology in the biopharmaceutical market, which has higher risks and a higher barrier to entry.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we attempt to adapt the C1 technology for use in the biopharmaceutical market, our business is subject to the execution, integration, and research and development risks that early-stage companies customarily face with new technologies, products and markets. These risks relate to, among other things, our ability to successfully further develop the C1 technology, products and processes, assemble and maintain adequate production and research and development (&#8220;R&amp;D&#8221;) capabilities, comply with regulatory requirements, construct effective channels of distribution and manage growth. We have encountered and will continue to encounter risks and difficulties frequently experienced by early stage companies in expanding and upgrading our intellectual property, regulatory, marketing, sales and R&amp;D capabilities, improving our accounting and financial reporting and internal controls infrastructure, and adapting to the rapidly evolving industries in which we operate. Additionally, we are subject to competition from much larger companies with more resources than us. Also, the market for developing and manufacturing pharmaceutical proteins produced from a filamentous fungus, such as the C1 fungus, is a market that is not yet established and is subject to a high level of regulatory hurdles from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other governmental bodies and there is a risk that such technologies will not be adopted by the pharmaceutical industry or governmental agencies and therefore not succeed and/or not grow at the rates projected or at all.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet commercialized any products for the biopharmaceutical market, and we may never be able to do so. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not know when or if we and/or our current and/or future collaborators and licensees will complete any of our or their product development efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved products. Even if we and/or our licensees and collaborators are successful in developing products that are approved for marketing, we and they will still require that these products gain regulatory approval and market acceptance. The biopharmaceutical industry is a high-risk industry in that even if we are successful at expressing certain proteins, these proteins may fail to be advanced or approved for use or sale for many reasons including their characteristics, biological activity, bio comparability, bio similarity, stability, glycosylation structures, containments, purity, performance, safety and regulatory reasons.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve certain technology, product and/or commercial milestones, access fees and royalties, launch products and/or processes, or achieve profitability. In addition, our expenses could increase if we are required by the FDA or other domestic and foreign regulatory authorities to perform studies or trials in addition to those currently expected, or if there are delays in completing additional safety studies such as toxicology and pathogenicity studies, clinical trials, preclinical studies, animal or human studies or the development of any of our or our collaborators&#8217; product candidates.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the evolving nature of our business, our operating history in past periods will not provide a reliable basis to evaluate our current business or predict our future performance. Any assessments of our current business or predictions regarding our future success or viability are likely not as accurate as they could be if we had a longer operating history in our new line of business.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a history of net losses, and we may not achieve or maintain profitability.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we have an accumulated deficit of approximately $41.4 million. Prior to the DuPont Transaction, our revenues were derived from licensing, licensing milestones and a very small amount of royalties from the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">licensing of the C1 expression system to third parties mainly within the industrial biotechnology markets, the operation of our industrial enzyme business and the collection of R&amp;D fees from third parties. Our profitability has strongly relied on, and will be even more reliant going forward on, third party industry and government research funding, licensing partnerships and other forms of collaborations. We believe that it is likely that if we do not sign license agreements or other forms of collaborations, we will incur losses because of our planned levels of R&amp;D and additional general and administrative expenditures that we believe is necessary to operate our business and further develop the C1 technology for use in the pharmaceutical business. The amount of our future net losses will depend, in part, on the rate of increase in our expenses along with other potential cost of unforeseen circumstances, our ability to generate research funding, government grants, receipt of access fees, milestones, royalty and other payments, and whether we are able to generate revenues by entering into license agreements or other forms of collaborations, launch new products and/or processes from future licensees or collaborators, and our ability to raise additional capital. The net losses we anticipate incurring over the next several years will have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D efforts needed to enhance and leverage the C1 technology for use in developing and manufacturing human and animal biopharmaceuticals, metabolites and viral vectors such as AAV, will require significant funding and increased staffing; therefore, we expect near-term operating and research expenses to continue, and maybe even accelerate, as we further develop our research and business plans, and our goals and objectives. Consequently, we will require significant additional revenue to achieve profitability. We cannot provide assurance that we will be able to generate any revenues from our focus and efforts as we intend to apply the C1 technology into the biopharmaceutical industry. If we fail to enter into new license agreements or other forms of collaborations or generate revenues and profit from additional research projects and government grants, the market price of our common stock will likely decrease. Further regulatory complications, competition from other technologies, or delays in our research programs and the adoption and use of the C1 technology by the biopharmaceutical industry may force us to reduce our staffing and research and development efforts, which may further affect our ability to generate cash flow.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are dependent on collaborations with third parties and if we fail to maintain or successfully manage existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability. We have a small number of research collaborations, and the nonperformance or loss of any collaboration could have a material adverse effect on our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our R&amp;D revenue is generated from a small number of research collaborations. These collaborations could be delayed or be discontinued, as they have in the past, at any time with little advance notice. If these research collaborations are lost or do not perform as expected, it could have a material adverse effect on our business, financial condition and operating results.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to enter into, maintain and manage collaborations in our target markets is fundamental to the success of our business. We currently rely on, and expect to continue to rely on, our current and future partners, in part, for research and development, manufacturing and distribution, sales and marketing services, and application and regulatory know how. In addition, we intend to enter into additional collaborations to conduct research, develop, produce, market, license and sell our technologies and products and processes we anticipate developing. However, we may not be successful in entering into collaborative arrangements with third parties. Any failure to enter into such arrangements on favorable terms could delay or hinder our ability to develop and commercialize our technologies, products and processes and could increase our costs of research and development and commercialization.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited or no control over the resources that any collaborator or licensee may devote to our programs.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of our current or future collaborators or licensees may, breach or terminate their agreements with us or otherwise fail to perform and conduct their required activities successfully and in a timely manner. Our collaborators or licensees may elect not to develop products arising out of our collaborative or license arrangements or may choose not to devote sufficient resources to the development, manufacture, market or sale of these products. If any of these events occur, we or our collaborators or licensees may not develop our technologies or commercialize our or their products.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reductions in collaborators&#8217; R&amp;D budgets may affect our businesses.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fluctuations in the R&amp;D budgets of government agencies, our customers, licensees, collaborators and research partners could have a significant impact on the interest in and demand for our technology. Private R&amp;D budgets fluctuate due to changes in available resources, consolidation in the pharmaceutical and other industries, spending priorities and institutional budgetary policies. Governmental agencies, which we periodically receive research funding from, also experience fluctuations in their R&amp;D budgets, which may negatively impact our ability to receive funding from such agencies. Our businesses could be </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">seriously damaged by significant decreases in life sciences and/or pharmaceutical R&amp;D expenditures by government agencies and existing and potential partners.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We heavily rely on contracts with third-party contract research organizations (&#8220;CROs&#8221;) to conduct our research and development, which may not be available to the Company on commercially reasonable terms or at all.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the DuPont Transaction, we no longer own a research and development laboratory and we became dependent upon the performance and research capacity of a number of third-party contract research organizations to conduct our research and development projects, which include services and programs in connection with the modification and enhancement of the Company&#8217;s C1 expression platform and to support our business development efforts for C1&#8217;s use in biopharmaceutical applications. The licensing and service arrangements with these third party CROs are not guaranteed to be renewed or continued on reasonable terms, if at all. The Company may be unable to maintain or expand its access to third party CROs to conduct our research projects. Failure to maintain and expand access to certain third party CROs could have a material adverse impact on the Company&#8217;s research projects, financial condition and operating results.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are heavily dependent upon the availability and performance of third-party research organizations. If we require research capacity and/or capabilities and are unable to obtain it in sufficient quantity, and quality or at terms and conditions that are acceptable to the Company or our third party collaborators we may not be able to offer our technologies or products for license, or sale, or we may be required to make substantial capital investments to build out that capacity or to contract with other research organizations on terms that may be less favorable than our current arrangements. In addition, if we contract with other research organizations, we may experience delays of several months in qualifying them or in starting up research programs at these facilities, which could harm our relationships with our licensees, collaborators or customers and we may be required to make a capital investment in connection with these arrangements. This could have a material adverse effect on our business, revenues or operating results.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, if we were unsuccessful in retaining a CRO with the requisite experience and skills we require and were required to build our own research facility, it could take a year or longer before such owned research facility is able to be brought online to carry out the necessary technology and product development efforts of the Company. Any funding and resources we utilize to acquire or build internal research capabilities could be at the expense of other potentially more profitable opportunities.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Conflicts with the CROs, collaborators and/or licensees could harm our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An important part of our strategy includes involvement in proprietary research programs. We may pursue opportunities in the pharmaceutical field that could conflict with those of our collaborators and licensees. Moreover, disagreements with DuPont, our current and/or future CROs, collaborators or licensees could develop over rights to our intellectual property, over further licensing of our technologies to other parties in certain pharmaceutical fields, or over other reasons. Any conflict with DuPont, our current and/or future CROs, collaborators or licensees could reduce our ability to obtain future collaboration agreements and negatively impact our relationship with existing collaborators or licensees, which could reduce our revenues and profits.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our current and/or future CROs, collaborators and/or licensees could also become competitors in the future. Our current and/or future CROs, collaborators and/or licensees could develop competing technologies or products, preclude us from entering into collaborations or license agreements with their customers, could fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of their technology and products and processes. Any of these developments could harm our technology development and value, product development efforts, revenue, profits and overall business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If issues arise with our current and/or future CROs, collaborators and/or licensees, we will need to either commercialize products resulting from our proprietary programs directly or by licensing to other companies, which could cause us to lose revenue or incur losses. Similarly, we may lose revenue or incur losses if we are unable to license our technology to new licensees on commercially reasonable terms or are unable to develop the capability to market and sell products and processes on our own.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial results as required by law.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We need to receive timely, accurate and complete information from a number of third parties in order to accurately and timely report our financial results. We rely on third parties to provide us with complete and accurate information regarding </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">research developments and data, revenues, expenses and payments owed to or by us on a timely basis. We will need to establish the proper controls related to obtaining and reporting information from our CROs, licensees and collaborators related to research results and other data, when milestones are earned, if any, when royalties are earned, if any, as well as other types of potential revenues and expenses. If the information that we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement. Although we may have contractual rights to receive information, such provisions may not ensure that we receive information that is accurate or timely. As a result, we may have difficulty in completing accurate and timely financial disclosures, which could have a material adverse effect on our business, financial condition and results of operations and the market price of our common stock.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial opportunity will be reduced or eliminated. Because of the competition and safety risks in the biopharmaceutical industry, any product candidates are subject to extensive regulation, which are costly and time consuming.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any biopharmaceutical products we or our current or collaborators or licensees develop through the C1 expression system will compete in highly competitive and regulated markets. Many of the organizations competing with us in the market for such products have more capital resources, larger R&amp;D and marketing staff, facilities and capabilities, and greater experience in research and development, regulatory approval, manufacturing and commercialization of technology and products. Accordingly, our competitors may be able to develop technologies and products more rapidly. If a competitor develops superior technology or products, or more cost-effective alternatives to our and our collaborators&#8217; or licensees&#8217; technologies, products or processes, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Customers may prefer existing or future technologies over the C1 expression system. Well-known and highly competitive biotechnology companies offer comparable or alternative technologies for the same products and services as our biopharmaceutical business. We anticipate that we, and our current or future collaborators and licensees will continue to encounter increased competition as new companies enter these markets and as the development of biological processes and products evolve.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pharmaceutical companies are usually more focused on the qualitative and safety aspects of the products rather than on the actual cost or potential cost savings of producing such safe pharmaceutical products. It is expected to be a very difficult task, and it is expected to take a very long time to get the biopharmaceutical industry to adopt a new expression system, including the C1 expression system. Even if the C1 technology delivers on its promise of expressing high volumes of low-cost proteins with the proper qualitative properties without negative side effects, it is still expected to take a very long time, if ever, to obtain adoption and use of the C1 expression system by both the pharmaceutical industry and governmental regulatory agencies.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We could fail to manage our growth, which would impair our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to take the following steps, among others, to manage our growth. If we fail to achieve one or more of these, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Balance our cash burn with technology and product development, advancement and value creation of such technologies and products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain and gain additional CROs, or other technology collaborators;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Maintain and gain additional collaborators, strategic partners technology licensees or other forms of structures;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">File, maintain and defend our intellectual property and protect our proprietary information and trade secrets;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Develop technology, products and processes that do not infringe on the intellectual property of third parties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Recruit, hire and maintain the required employees necessary to maintain and grow our business and to advance our technologies and products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Achieve technical and commercial success in our and our licensees&#8217; or collaborators&#8217; research and product development programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Implement and oversee our operational and financial control systems;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Operate successful recruiting and training programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Access the required manufacturing capacity;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Access additional growth capital;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Recruit and maintain consultants, board members and scientific advisory board members;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Manage scientific risks and uncertainties that may arise during our R&amp;D and regulatory programs; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limit litigation risks and uncertainties.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our revenue growth depends in part on market and regulatory acceptance of the C1 technology to develop and manufacture animal and/or human biopharmaceutical products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of our biopharmaceutical business will depend on our ability to develop, register, and introduce similar, new and improved technologies and products in a timely manner, at significantly lower manufacturing costs that address the evolving requirements of the pharmaceutical industry and potential customers. There is no assurance that the C1 technology or any product expressed from C1 will perform the same or better, save our customers money relative to existing gene expression technologies or those of our competitors, provide our customers with other benefits, obtain governmental safety and regulatory approvals, be registered or will gain market acceptance. If we fail to develop similar, new and better performing technologies, products and processes at significantly lower manufacturing costs, make fermentation yield improvements on our existing production processes, generate the necessary safety and regulatory data or gain registration and market acceptance of the C1 technology and C1 expressed products or processes, we could fail to recoup our R&amp;D investment and fail to capitalize on potential opportunities or gain market share from our competitors. Any failure, for technological, quality, safety, regulatory, or other reasons, to develop and launch improved technologies and new products, could negatively impact our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The dynamic and conservative nature of the biopharmaceutical industry, the unpredictable nature of the product development process and the time and cost of new technology adoption in the biopharmaceutical industry may affect our ability to meet the requirements of the marketplace or achieve market and/or regulatory acceptance. Some factors affecting market and regulatory acceptance of our technologies and products include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Availability, quality, performance and price of competitive products and processes;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Functionality and cost of similar, new and existing technologies and products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Timing of product introduction, performance and pricing compared to our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Scientists&#8217;, customers&#8217; and regulatory agencies&#8217; opinions of our technology and products&#8217; utility and our ability to effectively incorporate their feedback into future technology development or product offerings;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The status of C1 and other expression technologies including CHO, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">E.coli</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, other microbial, insect, algae, plant and other expression systems as to safety, quality, purity and expression levels, capital expenditure intensity, operating costs, and continually changing governmental and industry regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The impact of our own, DuPont&#8217;s and our collaborators&#8217; intellectual property, and that of our competitors</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Competition with and against much larger companies; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Regulatory hurdles, timing, costs and receipt of approvals.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expenses or losses associated with unsuccessful technology and product development activities or lack of market acceptance of our new technologies and products could seriously harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We must continually offer new products and technologies.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biopharmaceutical industry is characterized by rapid technological change, and the area of gene and protein research and platform development is a rapidly-evolving field. Our future success will depend on our ability to maintain a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity and cost.&#160;Rapid technological development by others could cause our products and technologies to become obsolete and it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Potential future regulations limiting our ability to sell genetically engineered products could harm our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We, our current and future collaborators and licensees expect to develop biologic products using genetically engineered microorganisms (GMOs). Products derived from GMOs may in some instances be subject to bans or additional regulation by federal, state, local and foreign government agencies. These agencies may not allow us or our collaborators and licensees to produce and market products derived from GMOs in a timely manner or under technically or commercially feasible conditions.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compliance with FDA, Environmental Protection Agency (EPA) and EU regulations could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products. The FDA currently applies the same regulatory standards to products made through genetic engineering as those applied to products developed through traditional methodologies. Regardless of GMO status, a product may be subject to lengthy FDA reviews and unfavorable FDA determinations due to safety concerns or changes in the FDA&#8217;s regulatory policy. The EPA regulates biologically-derived enzyme-related chemical substances not within the FDA&#8217;s jurisdiction. An unfavorable EPA ruling could delay commercialization or require modification of the production process or product in question, resulting in higher manufacturing costs, thereby making the product uneconomical. The EU and other countries also have regulations regarding the development, production and marketing of products from GMOs, which may be as or more restrictive than U.S. regulations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, we, DuPont, our current and future collaborators and licensees are subject to regulations in the other countries in which we operate outside of the U.S. and EU, which may have different rules and regulations depending on the jurisdiction. Different countries have different rules regarding which products qualify as GMO. If any of these countries expand the definition of GMO and increase the regulatory burden on GMO products, our business could be harmed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public views on ethical and social issues may limit use of our technologies.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success will depend in part upon our ability, our current and future collaborators&#8217; or licensees&#8217; ability, to develop pharmaceutical products discovered, developed and manufactured through the C1 expression system. Governmental authorities could, for social, ethical or other purposes, limit the use of genetic processes or prohibit the practice of using a modified C1 organism to produce biologic vaccines, drugs and other biologic products. Concerns about the C1 expression system, and particularly about the expression of genes from C1 for pharmaceutical purposes, could adversely affect their market acceptance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The commercial success of our current and future collaborations and our licensees&#8217; potential products will depend in part on public acceptance of the use of genetically engineered products including enzymes, vaccines, drugs and other protein products produced in this manner. Claims that genetically engineered products are unsafe for consumption or pose a danger to the environment, animals or humans may influence public attitudes. Our and our licensees&#8217; genetically engineered products may not gain public acceptance. Negative public reaction to GMOs and products could result in increased government regulation of genetic research and resulting products, including stricter labeling laws or other regulations, and could cause a decrease in the demand for our products. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, some or all of our products and processes may not gain public acceptance. Any of the considerations below could result in expenses, delays, or other impediments to our and our licensees&#8217; programs or the public acceptance and commercialization of products and processes dependent on our technologies and could have a material adverse effect on our business, financial condition and results of operations:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and genetically engineered products and processes, which could influence public acceptance of our and our licensees&#8217; technologies, products and processes;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">public attitudes regarding, and potential changes to laws governing, ownership of genetic material which could harm our intellectual property rights with respect to our genetic material and discourage collaborative partners or licensees from supporting, developing, or commercializing our products, processes and technologies; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">government regulations are changing rapidly, which likely will result in greater government regulation of genetic research and derivative technologies and products derived from such technologies, making approvals of such technologies and the products derived from such technologies to be delayed, more expensive with added risks.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and the CROs, collaborators and licensees are subject to various federal, state and local environmental laws and regulations relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees. These laws, regulations and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment. A violation of these laws and regulations or permit conditions can result in substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, new laws, new interpretations of existing laws, increased government enforcement of environmental laws, or other developments could require us or our contract research organizations to make additional significant expenditures. Present and future environmental laws and regulations and interpretations thereof, more vigorous enforcement of policies and discovery of currently unknown conditions may require substantial expenditures that could have a material adverse effect on our results of operations and financial position. Additionally, any such developments may have a negative impact on our contract manufacturers, which could harm our business.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may fail to commercialize the C1 expression system for the expression of therapeutic proteins, antibodies, vaccines, metabolites of other biologic products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet developed any C1-based biopharmaceutical products, conducted the necessary safety, efficacy, cost and regulatory studies, or completed the commercialization of any therapeutic proteins, antibodies and vaccines.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, drug companies have developed and commercialized only a small number of gene-based products in comparison to the total number of drug molecules available in the marketplace. Our biopharmaceutical business should be evaluated as having the same risks as those inherent to early-stage biotechnology companies because the application of the C1 expression system for the expression of pre-clinical and clinical quantities of therapeutic proteins, antibodies and vaccines is still in early development.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Successful development of the C1 expression system for biopharmaceutical purposes will require significant research, development and capital investment, including testing, to prove its safety, efficacy and cost-effectiveness. In general, our experience has been that each step in the process has been longer and costlier than originally projected, and we anticipate that this is likely to remain the case with respect to the continuing development efforts of our biopharmaceutical business.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have no experience submitting applications to the FDA or similar regulatory authorities and could be subject to lengthy and/or unfavorable regulatory proceedings.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we understand that many of our current and future collaborators or licensees may have a proven track record of experience submitting application to the FDA or other applicable regulatory authorities, we have no such experience. Neither we nor any collaborator or licensee has yet submitted any application with the FDA or any other regulatory authority for any product candidate generated through the use of the C1 expression system as it relates to the development and manufacture of pharmaceutical products. The FDA may not have substantial experience with technology similar to ours, which could result in delays or regulatory action against us. We and our current and future collaborators and licensees may not be able to able to obtain regulatory approval for C1 expressed products, which would harm our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The C1 expression system has been tested for use in the manufacturing of an enzyme in the production of wine, beer and fruit juices, and has generated promising safety and toxicity data for that enzyme. The C1 expression system could produce vaccines, antibodies, or therapeutic products and enzymes that have safety, toxicity, pathogenicity, immunogenicity and other issues associated with them. The C1 expression system may be subject to lengthy regulatory reviews and unfavorable regulatory determinations if it raises safety questions which cannot be satisfactorily answered or if results from studies do not meet regulatory requirements. An unfavorable regulatory ruling could be difficult to resolve and could delay or possibly prevent a product from being commercialized, or even the use of the C1 technology to produce future products which would have a material adverse effect on our growth and prospects. Additionally, future products produced by us or our current and future collaborators or licensees using the C1 expression system may not be approved by the FDA or other regulatory agencies in the U.S. or worldwide. There is no assurance that safety, toxicity, pathogenicity, immunogenicity and other issues will not arise in current or future product development and manufacturing programs due to media, fermentation, inherent properties or genetic changes in the C1 strain and fermentation process.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If these therapeutic protein products, antibodies or vaccines are not approved by regulators, we or our current and future customers or collaborators and licensees will not be able to commercialize them, and we may not receive research funding, upfront license fees, milestone and royalty payments which are based upon the successful advancement of these products through the drug development and approval process. Even after investing significant time and expense, any regulatory approval may also impose limitations on the uses for which we can market a product, and any marketed product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or manufacturer may result in new restrictions on the product, manufacturer and manufacturing facility, including withdrawal of the product from the market. In certain countries, regulatory agencies also set or approve prices, which may result in low or unprofitable margins and would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alternative technologies may not require microbial or other cell produced proteins.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research is being conducted with cell or gene based therapies and other technologies that offer a possible alternative to producing proteins as they are today based on microbial, organic matter containing Carbon, Hydrogen, and Oxygen or other organisms, that may allow genes to be directly inserted into cells that can be implanted into animals and humans directly, displacing the need for the existing methods used for development of biologic vaccines and drugs. If they are successful, these new methods may supplant or greatly reduce the need for microorganisms, Carbon, Hydrogen, and Oxygen or other organisms to produce these proteins externally as the injected cells in animals and human may be able to do so internally.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Business Risks That We Face</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may need substantial additional capital in the future to fund our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements may be substantial, particularly as we continue to further develop, engineer and optimize the C1 expression system and our other proprietary technologies, products and processes for licensing for research and development, and commercialization of potential animal and human pharmaceutical products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our need for additional capital, if any, will depend on many factors, including (i) the technical and financial success of our efforts to enter the biopharmaceutical industry, (ii) the progress and scope of our collaborative and independent R&amp;D projects and other ongoing and future potential projects, (iii) the receipt of future upfront fees, potential milestones, royalties and other payments from future licensees or other types of collaborations if any, (iv) our ability to obtain payments from other potential pharmaceutical business customers through research funding, milestones, license agreements and other forms of collaborative agreements, (v) the extent to which we can obtain licensees, or other types of collaborative partnerships for the research, development and commercialization of proteins in the biopharmaceutical industry, (vi) the effect of any acquisitions of other technologies and/or businesses that we may make in the future, and (vii) the filing, prosecution, enforcement and defense of patent claims and/or infringements by us, and our collaborators.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have very little leverage and if our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds to continue the development of our technologies and complete the development and commercialization of products, if any, resulting from our technologies. If the acquisition of additional funds is not possible or if we engage in future equity financings, dilution to our existing stockholders may result. If we raise capital through debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, sell certain assets of the company which will limit future opportunities, or grant licenses on terms that are not favorable to us. Without sufficient funding or revenue, we may have to curtail, cease, or dispose of, one or more of our operations and would have a material adverse effect on our business, financial condition, and future prospects.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in global economic and financial markets may have a negative effect on our business.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to a variety of market forces including, but not limited to, domestic and international economic, political and social conditions. Many of these forces are beyond our control. Any change in market conditions that negatively impacts our operations or the demand of our current or prospective customers could adversely affect our business operations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in the global financial, pharmaceutical and biotech markets may make it difficult to accurately forecast operating results. These changes have had, and may continue to have, a negative effect on our business, results of operations, financial condition and liquidity. In the event of a downturn in global economic activity, current or potential business partners may go out of business, may be unable to fund purchases or determine to reduce purchases, all of which could lead to reduced demand for our products and increased payment delays or defaults. We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn given certain fixed costs associated with our operations and difficulties if we over strained our resources. The timing and nature of a sustained recovery in the credit and financial markets remains uncertain, and there can be no assurance that market conditions will significantly improve in the near future or that our results will not continue to be materially and adversely affected.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face risks related to health epidemics, pandemics and other widespread outbreaks of contagious disease, pandemics, epidemics or other biological threats, such as COVID-19, that could significantly disrupt our operations and have a material </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">adverse effect on our business, our employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant outbreaks of contagious diseases, and other adverse public health developments, could have a material impact on our business operations and operating results. The recent outbreak of COVID-19 originating in Wuhan, China, in December 2019 has spread to multiple countries, causing the World Health Organization to declare this outbreak a &#8220;Public Health Emergency of International Concern&#8221; in January 2020, and the U.S. Department of Health and Human Services to declare a public health emergency to aid the U.S. healthcare community in responding to COVID-19. This virus continues to spread globally and, as of March 23, 2020, has spread to over 160 countries, including the United States and Europe, where several of our key executive management members and our third-party contract research organizations are located. The continued spread of COVID-19 globally could adversely affect our business operations in the United States and elsewhere, including our ability to carry on business development activities, and restrictions in business-related travel,  among others.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of COVID-19, or another infectious disease, pandemic, epidemic or other biological threat could result in delays or disruptions in our on-going research projects. We rely on third parties in the United States and Europe to conduct our research and development projects and to provide other services, and COVID-19 may affect service providers of such third-party contract research organizations and therefore negatively affect the operations of our on-going research projects. We may take temporary precautionary measures intended to help minimize the risk of infection from the virus for our employees, including temporarily requiring all employees to work remotely, suspending all non-essential travel worldwide and discouraging attendance at industry events, industry and other conferences, and in-person work-related meetings, which could negatively affect our business. Any interruption of business development activities, on-going research and development projects, or shutdowns or other business disruptions for us or any of the third parties with whom we engage, could materially and negatively affected business, financial condition, and results of operations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any significant infectious disease outbreak, including the COVID-19 pandemic, could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations. The extent to which COVID-19 could impact our business and research and development activities will depend on future developments, which are highly uncertain and cannot be predicted with confidence, and will depend on many factors, including the ultimate geographic spread of the disease, the duration of the outbreak, the effect of travel restrictions and social distancing efforts in the United States and other countries, the scope and length of business closures or business disruptions, and the actions taken by governments to contain and treat the disease.the pandemic. As such, we cannot presently predict the scope and extent of any potential business shutdowns or disruptions.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could delay our technology and product development programs, harm our R&amp;D efforts, and we may be unable to pursue research funding, licenses and other forms of collaborations or develop our own products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our planned activities will require retention and ongoing recruiting of additional expertise in specific areas applicable to our industries, technologies and products being developed. These activities will not only require the development of additional expertise by existing management personnel, but also the addition of new research and scientific, regulatory, licensing, sales, marketing, management, accounting and finance and other personnel. The inability to acquire or develop this expertise or the loss of principal members of our management, broad of directors, consultants, accounting and finance, sales, and scientific staff could impair the growth, if any, of our business. Competition for experienced personnel from numerous companies, academic institutions and other research facilities may limit our ability to attract and retain qualified management, directors, consultants, and scientific personnel on acceptable terms. Failure to attract and retain qualified personnel would inhibit our ability to maintain and pursue collaborations and develop our products and core technologies.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Personnel changes may disrupt our operations. Hiring and training new personnel will entail costs and may divert our resources and attention from revenue-generating efforts. In addition, we periodically engage consultants to assist us in our business and operations, these consultants operate as independent contractors, and we, therefore, do not have as much control over their activities as we do over the activities of our employees. Our directors and consultants may be affiliated with or employed by other parties, and some may have consulting or other advisory arrangements with other entities that may conflict or compete with their obligations to us. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inability to protect our intellectual property could harm our ability to compete.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success will depend in part on our ability to obtain patents and on our and DuPont&#8217;s (as part of the DuPont Transaction, patents were assigned to DuPont) and our current and future collaborators&#8217; and licensees&#8217; ability to maintain adequate protection of our and their intellectual property. If we, DuPont, or our current and future collaborators and licensees do not adequately protect our intellectual property, competitors may be able to practice our technologies and erode our competitive advantage. The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting their proprietary rights in these foreign countries.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, the patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our, and in certain instances the C1 patents assigned to DuPont, and our current and future collaborators and licensees proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We intend, from time to time, to apply for patents covering both our technologies and our products, while at other times, we only maintain such knowledge as trade secrets without applying for patents, as we deem appropriate. However, existing and future patent applications may be challenged and are not guaranteed to result in the issuing of patents. Even if a patent is obtained, it may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Others, including DuPont and our current and future collaborators and licensees, may independently develop similar or alternative technologies or design around our, DuPont&#8217;s or our current and future collaborators&#8217; and licensees&#8217; patented technologies. In addition, DuPont, our current and future collaborators, licenses, or other third parties may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages. If any third party is able to gain intellectual property protections for technology similar to our own, they may be successful in blocking us and our licensees from using C1 technology and/or commercializing products derived from the C1 technology.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies&#8217; patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that we were the first to invent the inventions covered by our pending patent applications, or that we were the first to file patent applications for these inventions or the patents we have obtained.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Dyadic will continue to review its existing and potential patent positions and rights. Based on our analysis if and when the commercial opportunities and patent enforceability are questionable, we may abandon certain patents in some countries. There is a risk that we will abandon potentially valuable patents.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock price.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on neither infringing patents and proprietary rights of third parties, nor breaching any licenses that we have entered into with regard to our technologies and products. Others have filed, and in the future are likely to file, patent applications covering genes or gene fragments, genetic elements, screening, gene expression and fermentation processes and other intellectual property that we may wish to utilize with the C1 expression system or products and systems that are similar to those developed with its use. If these patent applications result in issued patents and we wish to use the claimed technology, we may need to obtain a license from the appropriate third party.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third parties may assert that we and/or our current and future collaborators and licensees are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents. We could incur substantial costs and diversion of management and technical personnel in defending ourselves against any of these claims or enforcing our patents and other intellectual property rights. Parties making claims against us may be able to obtain injunctive or other equitable relief, which could effectively block our ability to further develop, commercialize and sell products, and could result in the award of substantial damages against us. If a claim of infringement against us is successful, we may be required to pay damages and obtain one or more licenses from third parties. In the event that we are unable to obtain these licenses at a reasonable cost, we and/or current and future collaborators and licensees could encounter delays in product commercialization while we attempt to develop alternative methods or products. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, unauthorized parties may attempt to steal, copy or otherwise obtain and use our C1 microbial strains, genetic elements, development and manufacturing processes, other technology or products. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">technologies, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import into the United States or other territories products, or information leading to potentially competing products, made using our inventions in countries where we do not have patent protection for those inventions. If competitors are able to use our technologies, our ability and our current and future collaborators&#8217; and licensees&#8217; ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be sued for product liability.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our current and future collaborators and licenses may be held liable if any product we or they develop, or any product which is made with the use or incorporation of, any of our technologies, causes injury or is found otherwise unsuitable or unsafe during product testing, manufacturing, marketing or sale. These claims could be brought by various parties, including other companies who purchase products from our current and future collaborators and licenses or by end users of the products.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we maintain product liability insurance, it may not fully cover all of our potential liabilities and our liability could in some cases exceed our total assets, which would have a material adverse effect on our business, results of operations, financial condition and cash flows, or cause us to go out of business. Further, insurance coverage is expensive and may be difficult to obtain and may not be available to us or to our collaborators and licensees in the future on acceptable terms, or at all. Inability to obtain sufficient insurance coverage at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products developed by us, or our collaborators and licensees.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign currency fluctuations could adversely affect our results.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the conduct of our business, in certain instances, we are required to receive payments or pay our obligations in currencies other than U.S. dollars. Especially since a large portion of our research and development is done in the EU and the CROs and certain consultants request payments in Euros. As a result, we are exposed to changes in currency exchange rates with respect to our business transactions denominated in non-US dollars.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fluctuations in currency exchange rates have in the past and may in the future negatively affect our revenue, expenses and our financial position and results of operations as expressed in U.S. dollars. Our management monitors foreign currency exposures and may in the ordinary course of business enter into foreign currency forward contracts or options contracts related to specific foreign currency transactions or anticipated cash flows. We do not hedge and have no current plans to hedge in the future, the translation of financial statements of consolidated subsidiaries whose local books and records are maintained in foreign currency.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) to offset future taxable income may be subject to certain limitations.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its NOLs, to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek to expand our business through the acquisition of, investment in and strategic alliances with companies, technologies, products, and services. If we are able to identify suitable acquisition, investment or strategic alliance targets, we may be unable to negotiate successfully their acquisition at a price or on terms and conditions acceptable to us. Acquisition, investments and strategic alliances involve a number of risks, including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential adverse effect on our cash position as a result of all or a portion of an acquisition, investment or strategic alliance purchase price being paid in cash;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential issuance of securities that would dilute our stockholders&#8217; percentage ownership;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unanticipated costs and liabilities, including the potential to incur restructuring and other related expenses, including significant transaction costs that may be incurred regardless of whether a potential strategic alliance, acquisition or investment is completed;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to effectively and quickly assimilate the operations, technologies, products and services or products of the acquired company or business;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to integrate acquired personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to oversee, retain and motivate key employees;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to retain customers;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">minimizing the diversion of management&#8217;s attention from other business concerns; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential loss of invested capital.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot assure you that, following an acquisition, investment or strategic alliance, we will achieve expected research and development results, anticipated synergies, revenues, specific net income or loss levels that justify such transaction or that the transaction will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or to provide funding for such business, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to oversee such investment(s) nor operate acquired businesses profitably or otherwise implement our growth strategy successfully.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our research activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and delays in our research efforts and financial reporting compliance, as well as significant increase in costs to recover or reproduce the data.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock has been, and is likely to continue to be, volatile. Biotechnology company stocks generally tend to experience extreme price fluctuations. The valuations of many biotechnology companies without consistent product sales and earnings are extraordinarily high based on conventional valuation standards such as price-to-earnings and price-to-sales ratios. These trading prices and valuations may not be sustained. Factors that may result in fluctuations in our stock price include, but are not limited to, the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in the public&#8217;s perception of the prospects of biotechnology companies.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Broad market and industry factors including market fluctuations or political and economic conditions such as war, recession or changes in interest and currency rates.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Announcements of new technological innovations, patents&#160;or new products or processes by us, DuPont or our current or future collaborators, licensees and competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Announcements by us, DuPont or our collaborators and licensees relating to our relationships or either of our relationships with other third parties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Coverage of, or changes in financial estimates by us or securities analysts;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Conditions or trends in the biotechnology industry;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in the market valuations of other biotechnology companies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limitations or expanded uses in the areas within the biopharmaceutical or other industries into which we can apply our technologies and products;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Developments in domestic and international governmental policy or regulations;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Announcements by us, DuPont, our current and future collaborators and licenses, or our competitors of significant acquisitions, divestures, strategic partnerships, license agreements, joint ventures or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The position of our cash, cash equivalents and marketable securities;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Any changes in our debt position;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Developments in patent or other proprietary rights held by us, DuPont or by others;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Negative effects related to the stock or business performance of DuPont, our current and future collaborators and licensees, or the abandonment of projects using our technology by our collaborators and/or licensees;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Scientific risks inherent to emerging technologies such as the C1 expression system;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Set-backs, and/or failures, and or delays in our or our current and future collaborators&#8217; and licensees&#8217; R&amp;D and commercialization programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays or failure to receive regulatory approvals by us, DuPont and/or our current and future collaborators and licensees;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Loss or expiration of our or DuPont&#8217;s intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological material owned by us and/or Danisco US, Inc., and VTT Technical Research Centre of Finland Ltd;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Lawsuits initiated by or against us, DuPont, or our current and future collaborators and licensees;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Period-to-period fluctuations in our operating results;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Future royalties from product sales, if any, by DuPont, our current or future strategic partners, collaborators or licensees;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Future royalties may be owed to DuPont by us, our collaborators, licenses, or sub-licensees under certain circumstances related to our DuPont Pharma License;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Short positions taken in our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Sales of our common stock or other securities in the open market;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock buy-back programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock splits; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Decisions made by the board related to potential registration of Dyadic&#8217;s stock under the Securities Act of 1933(as amended (the &#8220;Securities Act&#8221;), and/or up listing to another stock exchange.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we were to become party to a securities class action suit, we could incur substantial legal fees and our management&#8217;s attention and resources could be diverted from operating our business to responding to litigation.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our quarterly and annual operating results may be volatile.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our quarterly and annual operating results have fluctuated in the past and are likely to do so in the future. These fluctuations could cause our stock price to vary significantly or decline. Some of the factors that could impact our operating results include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Expiration of or cancellations of our research contracts with current and future collaborators and/or licensees, which may not be renewed or replaced;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Setbacks or failures in our and our current and future collaborators and licensees research, development and commercialization efforts;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Setbacks, or delays in our research and development efforts to develop and produce biologics.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Setbacks, or delays in our research and development efforts to re-engineer the C1 technology for its application and use in developing and producing biologics.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The speed, and success rate of our discovery and research and development efforts leading to potential licenses, or other forms of collaborations, access fees, milestones and royalties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The timing and willingness of current and future collaborators and licensees to utilize C1 to develop and commercialize their products which would result in potential upfront fees, milestones and royalties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">General and industry specific economic conditions, which may affect our current and future collaborators&#8217; and licensees&#8217; R&amp;D expenditures;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The adoption and acceptance of the C1 expression system by biopharmaceutical companies and regulatory agencies;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The addition or loss of one or more of the collaborative partners, grants, research funding, or licensees we are working with to further develop and commercialize our technologies and products in the pharmaceutical industry;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to file, maintain and defend our intellectual property and to protect our proprietary information and trade secrets;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to develop technology, products and processes that do not infringe on the intellectual property of third parties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The improvement and advances made by our competitors to CHO, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">E.coli</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, yeast, inset cells, plant and other expression systems;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The introduction by our competitors of new discovery and expression technologies competitive with the C1technology;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to enter into new research projects, grants, licenses or other forms of collaborations and generate revenue from such parties;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Scientific risk associated with emerging technologies such as the C1 expression system;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Failure to bring on the necessary research, CMO, CDMO and manufacturing capacity if required;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Uncertainty regarding the timing of research funding, grants or upfront license fees for new C1 expression system collaborations, license agreements or expanded license agreements; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays or failure to receive upfront fees, milestones and royalties and other payments.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A large portion of our expenses are relatively fixed, including expenses for personnel. Accordingly, if revenues do not grow as anticipated due to the expiration of research contracts or government research grants, the failure to obtain new contracts, licensees or other forms of collaborations or other factors, we may not be able to correspondingly reduce our operating expenses. Failure to achieve anticipated levels of revenue could, therefore, significantly harm our operating results for a particular fiscal period or for even prolonged periods of time.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not necessarily a good indication of our future performance. Our operating results in some quarters, or even in some years may not meet the expectations of stock market analysts and investors, potentially causing our stock price to possibly decline.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not expect to pay cash dividends in the future.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never paid cash dividends on our stock and do not anticipate paying any dividends for the foreseeable future. The payment of dividends on our shares, if ever, will depend on our earnings, financial condition and other business and economic factors deemed relevant for consideration by our board of directors. If we do not pay dividends, our stock may be less valuable because a return on investment will only occur if and to the extent that our stock price appreciates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our anti-takeover defense provisions may deter potential acquirers and depress our stock price.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain provisions of our certificate of incorporation, bylaws and Delaware law, as well as certain agreements we have with our executives, could make it substantially more difficult for a third party to acquire control of us. These provisions include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We may issue preferred stock with rights senior to those of our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We have a classified board of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Action by written consent by stockholders is not permitted;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our board of directors has the exclusive right to fill vacancies and set the number of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cumulative voting by our stockholders is not allowed; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We require advance notice for nomination of directors by our stockholders and for stockholder proposals.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These provisions may discourage certain types of transactions involving an actual or potential change in control. These provisions may also limit our stockholders&#8217; ability to approve transactions that they may deem to be in their best interests and discourage transactions in which our stockholders might otherwise receive a premium for their shares over the current market price.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our bylaws, provide that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Company, (B) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the Company to the Company or the Company&#8217;s stockholders, (C) any action or proceeding asserting a claim against the Company arising pursuant to any provision of the Delaware General Corporation Law or the Company&#8217;s Certificate of Incorporation or bylaws, or (D) any action or proceeding asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our executive officers, directors and principal stockholders (5% stockholders) together control approximately 30.2% of our 27,359,157 shares of outstanding common stock as of December&#160;31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Founder and Chief Executive Officer Mark Emalfarb, through the Mark A. Emalfarb Trust U/A/D October 1, 1987, as amended (the &#8220;MAE Trust&#8221;) of which he is the trustee and beneficiary, owned approximately 15.2% of our outstanding common stock as of December&#160;31, 2019. Further, the Francisco Trust U/A/D February 28, 1996 (the &#8220;Francisco Trust&#8221;), whose beneficiaries are the descendants and spouse of Mr. Emalfarb, owned approximately 13.8% of our outstanding common stock as of December&#160;31, 2019. We have historically been partially controlled, managed and partially funded by Mr. Emalfarb, and affiliates of Mr. Emalfarb. Collectively, Mr. Emalfarb and stockholders affiliated with Mr. Emalfarb controlled approximately 29% of our outstanding common stock as of December&#160;31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Emalfarb may be able to control or significantly influence all matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of Mr. Emalfarb may not always coincide with the interests of other shareholders, and he may take actions that advance his personal interests and are contrary to the desires of our other shareholders.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our existing officers, directors and principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in control and might affect the market price of our shares, even when a change may be in the best interests of all stockholders. Certain of our principal stockholders may elect to increase their holdings of our common stock, which may have the impact of delaying or preventing a change of control. Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and, accordingly, they could cause us to enter into transactions or agreements, which we would not otherwise consider.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not commence the publication of research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us or our business. We have no control over these analysts. If one or more analysts release a negative report or release a positive report and subsequently downgrade or change that report, potentially causing our stock price would likely decline. Additionally, if one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future issuances of shares of our common stock may negatively affect our stock price.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The sale of additional shares of our common stock, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, there were 27,359,157 shares of our common stock outstanding. Approximately 30.2% of these outstanding common shares are beneficially owned or controlled by our executive officers, directors and principal stockholders. Shares held by our affiliates and certain of our directors, officers and employees are &#8220;restricted securities&#8221; as defined by Rule 144 (&#8220;Rule 144&#8221;) of the Securities Act and subject to certain restrictions on resale. Restricted securities may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock has a relatively small public float. As a result, sales of substantial amounts of shares of our common stock, or even the potential for such sales, may materially and adversely affect prevailing market prices for our common stock. In addition, any adverse effect on the market price of our common stock could make it difficult for us to raise additional capital through sales of equity securities.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future sales of our common stock by existing stockholders, executive officers, or directors could depress the market price of our common stock and make it more difficult for us to sell stock in the future.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Emalfarb, our Chief Executive Officer, owns 18.8% of our common stock, and the Francisco Trust owns 13.8% of our common stock. Sales of our common stock in the public market by such stockholders or other significant stockholders, executive officers, or directors, could negatively impact the market price of our common stock. If one or more of these stockholders sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of our common stock could be negatively affected. These transactions and the perceived reasons for these transactions could have a negative effect on the prevailing market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The Company is exposed to credit risk and fluctuations in the values of its investment portfolio.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments can be negatively affected by liquidity, credit deterioration, financial results, market and economic conditions, political risk, sovereign risk, interest rate fluctuations or other factors. As a result, the value and liquidity of the Company&#8217;s cash, cash equivalents, and marketable and non-marketable securities may fluctuate substantially, which could result in significant losses and could have a material adverse impact on the Company&#8217;s financial condition and operating results.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We incur significant costs as a result of operating as an SEC registrant, and our management will be required to devote substantial time to compliance initiatives.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an SEC registrant, we incur significant legal, accounting and other expenses. In addition, the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as related rules implemented by the SEC, impose various requirements that require our management and other personnel to devote a substantial amount of time to compliance initiatives.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to evaluate the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management time on compliance-related issues. Moreover, if we are not able to maintain compliance with the requirements of Section 404, our stock price could decline, and we could face sanctions or investigation or investigations or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because we became a reporting company under the Exchange Act by means other than a traditional underwritten initial public offering, we may not be able to attract the attention of research analysts at major brokerage firms.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we did not become a reporting company by conducting an underwritten initial public offering, or IPO, of our common stock, and because we are not yet listed on a national securities exchange, security analysts of brokerage firms may not provide coverage of our company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we were to become a public reporting company by means of an IPO because they may be less familiar with our company as a result of more limited coverage by analysts and the media.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> &#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our common stock. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In addition, our customers, may adopt policies that include social and environmental requirements, or may seek to include such provisions in their contract terms and conditions. These social and environmental responsibility provisions and initiatives are subject to change, vary from jurisdiction to jurisdiction, and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity and the global scope of our operations. In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to modify our sourcing practices or make other operational choices which may require additional investments and increase our costs or result in inefficiencies. </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of the factors mentioned above, or the perception that we or those with whom we conduct business have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or the price of our common stock.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_22"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:67.105%;"><tr><td style="width:1.0%;"></td><td style="width:13.686%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.314%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unresolved Staff Comments</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_25"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:28.654%;"><tr><td style="width:1.0%;"></td><td style="width:30.142%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:65.858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Properties</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June&#160;30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a small satellite office in Wageningen, Netherlands. The Company occupies approximately 258 square feet with annual rental rate and common area maintenance charges of approximately $4,000. The lease will expire on January&#160;31, 2021, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our current and anticipated facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space is available to accommodate any expansion of our operations, but such space may not be available in the same building if and when such space is needed.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_28"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:58.771%;"><tr><td style="width:1.0%;"></td><td style="width:13.671%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.329%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal Proceedings</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not currently involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company&#8217;s or our Company&#8217;s subsidiaries&#8217; officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. </span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_31"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:58.771%;"><tr><td style="width:1.0%;"></td><td style="width:13.671%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.329%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mine Safety Disclosures</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable for our operations.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_34"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II</span></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_37"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.224%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.776%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</span></td></tr></table></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principal Market or Markets</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, Dyadic had two classes of capital stock authorized, common stock and preferred stock. Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;. Prior to the Company&#8217;s uplisting to the NASDAQ, the Company&#8217;s common stock was traded on the OTCQX market. There were no shares of preferred stock outstanding for the reported period. The trading symbol for Dyadic&#8217;s common stock assigned by the Financial Industry Regulatory Authority, Inc. is &#8220;DYAI.&#8221; The number of record holders of our common stock as of December&#160;31, 2019 was 60. There are no stock dividends within the last three years. Any future determination to pay dividends will be at the discretion of our Board of Directors (the &#8220;Board&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Securities Authorized for Issuance Under Equity Compensation Plans </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Part III, Item 12.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Treasury Stock </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Issuer Purchases of Equity Securities </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Repurchase Programs</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no repurchases of any class of the Company&#8217;s capital stock in 2019.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_40"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:73.099%;"><tr><td style="width:1.0%;"></td><td style="width:10.600%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:85.400%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selected Financial Data</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this Item.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_43"></div><div style="text-indent:36pt;margin-bottom:10pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:7.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in &#8220;Item 1A. Risk Factors&#8221; in this Annual Report. All forward-looking statements included in this Annual Report are based on information available to us as of the time we file this Annual Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_46"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and currently two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(formerly </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $75.0 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_49"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies, Estimates, and Judgments </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash consideration.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#8220;Topic 606&#8221;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input method, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Research and Development Expenses</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to the Company&#8217;s April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option (except for our CEO which is 5 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company&#8217;s annual review of its volatility assumption in 2018 and 2019, the Company determined that it would be appropriate to use the Company&#8217;s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting for Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company currently is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014.The United States Internal Revenue Service (the &#8220;IRS&#8221;) completed its review of the Company&#8217;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 to the Consolidated Financial Statements in Section F-1 for further information on the examination of the Company&#8217;s 2016 tax return.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#8217;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Recent Accounting Pronouncements </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_52"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Year Ended December&#160;31, 2019 Compared to the Year End December&#160;31, 2018 </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue and Cost of Revenue</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s revenue and cost of research and development revenue for the years ended December&#160;31, 2019 and 2018: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:60.426%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.982%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.984%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,681,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,295,451&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of research and development revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,459,701&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,027,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increases in revenue and cost of research and development revenue for the year ended December&#160;31, 2019 reflect ten research collaborations compared to six research collaborations for the year ended December&#160;31, 2018. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses for the year ended December&#160;31, 2019 increased to approximately $3,088,000 compared to $2,102,000 for the year ended December&#160;31, 2018. The increase primarily reflects the costs of additional internal research projects.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses - related party, for the year ended December&#160;31, 2019, decreased to approximately $869,000 compared to $1,216,000 for the year ended December&#160;31, 2018. The decrease is primarily due to completion of a research service agreement with BDI in June 2019.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses for the year ended December&#160;31, 2019, increased 22.0% to approximately $5,520,000 compared to $4,523,000 for the year ended December&#160;31, 2018. The increase principally reflects increases in noncash share-based compensation expenses of $717,000 related to 2019 stock options awards and options vested upon the April 2019 uplisting to NASDAQ, business development and investor relations costs of $186,000, insurance costs of $138,000, and legal costs and NASDAQ uplisting expenses of $125,000, offset by reductions in executive compensation costs, including the separation of the Company&#8217;s former CFO, of $168,000, which was a one-time expense in 2018.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Exchange</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Foreign currency exchange loss for the year ended December&#160;31, 2019, was approximately $28,000 compared to $21,000 for the year ended December&#160;31, 2018. The increase reflects the currency fluctuation of the Euro in comparison to the U.S. dollar. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Income</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income for the year ended December&#160;31, 2019, increased 10.1% to approximately $985,000 compared to $895,000 for the year ended December&#160;31, 2018. The increase reflects the higher yield on the Company&#8217;s investment grade securities, which are classified as held-to-maturity.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available in 2019 that will begin to expire in 2037. As of December&#160;31, 2019, and 2018, the Company had NOLs in the amount of approximately $19.7&#160;million and $9.1&#160;million, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the year ended December&#160;31, 2018, the Company&#8217;s current income tax benefit of $1.0 million was generated from the corporate Alternative Minimum Tax credit refund resulting from the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;).</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss for the year ended December&#160;31, 2019 was approximately $8.3 million compared to a net loss of $5.7 million for the year ended December&#160;31, 2018. The change was primarily due to increases in general and administrative expenses of approximately $1.0&#160;million, research and development expenses of approximately $0.6&#160;million, and the prior year income tax benefit from the corporate Alternative Minimum Tax credit refund of approximately $1.0 million.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_55"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. Between January 2016 and August 2018, the Company repurchased a total of 14,390,254 shares of its common stock from its existing cash on hand, for an aggregate purchase price of $21,814,530 at a weighted average price of $1.52 per share. As of December 31, 2019, our investment balance includes $29.7 million short-term investments with contractual maturities of twelve (12) months of less, including interest receivable, and $1.5&#160;million long-term investments with contractual maturities beyond twelve (12) months. In June 2019, the Company&#8217;s liquidity was further improved with the receipt of approximately $0.5&#160;million tax refund resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA. An additional $0.5&#160;million AMT tax refund is expected to be received through 2021.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including our business development and research expenses, as well as additional costs as an SEC reporting and NASDAQ listed company. We believe that our existing cash position and investments in short-term and long-term investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December&#160;31, 2019, cash and cash equivalents were approximately $4.8 million compared to $2.4 million at December&#160;31, 2018. The carrying value of investment grade securities, including accrued interest at December&#160;31, 2019 was $31.2 million compared to $39.1 million at December&#160;31, 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the year ended December&#160;31, 2019 of approximately $5.8 million resulted from a net loss of $8.3 million, offset by share-based compensation expense of $1.2 million, amortization of held-to-maturity securities of $0.2 million, BDI research and development activities of $0.3 million and changes in other operating assets and liabilities of $0.8 million. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the year ended December&#160;31, 2018 of approximately $4.4 million resulted from a net loss of $5.7 million, and changes in other operating assets and liabilities of $0.8&#160;million, offset by stock based compensation expense of $0.5 million, amortization of held-to-maturity securities of $0.7 million, and BDI research and development activities of $0.9 million. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities for the year ended December&#160;31, 2019 was approximately $7.7 million compared to $3.3&#160;million for the year ended December&#160;31, 2018. Cash flows from investing activities in 2019 and 2018 was primarily related to proceeds from maturities, net of purchases of investment grade debt securities.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided in financing activities for the year ended December&#160;31, 2019 was approximately $0.6 million compared to net cash used in financing activities of $2.3 million for the year ended December&#160;31, 2018. Cash flows provided in financing activities in 2019 were primarily related to proceeds received from the exercise of stock options. Cash flows used in in financing activities in 2018 were primarily related to repurchases of our common stock.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_58"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.766%;"><tr><td style="width:1.0%;"></td><td style="width:9.889%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.111%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 7A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quantitative and Qualitative Disclosures about Market Risk</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_61"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:88.304%;"><tr><td style="width:1.0%;"></td><td style="width:8.430%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 8.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements and Supplementary Data</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All financial statements required pursuant to this item, including the report of our independent registered public accounting firm, are presented beginning on page F-1.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_64"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.224%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.776%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_67"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.017%;"><tr><td style="width:1.0%;"></td><td style="width:11.012%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:84.988%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Controls and procedures</span></td></tr></table></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2019. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2019, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining adequate &#8220;internal control over financial reporting,&#8221; as defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2019 based on the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the assessment, our management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2019. This Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management&#8217;s report in this Report because we are a &#8220;smaller reporting company.&#8221;</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Controls Over Financial Reporting</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d- 15(d) of the Exchange Act that occurred during the year ended December&#160;31, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inherent Limitation on Effectiveness of Controls</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_70"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:59.502%;"><tr><td style="width:1.0%;"></td><td style="width:15.690%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:80.310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9B.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Information</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_73"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART III</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_76"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:87.426%;"><tr><td style="width:1.0%;"></td><td style="width:9.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.462%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 10.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Board currently consists of six directors serving on a classified board, consisting of three classes. The directors in each class serve a three-year term. The terms of each class expire at successive annual meetings so that the stockholders elect one class of directors at each annual meeting. Directors appointed due to an increase in the size of the Board may be filled by the Board for a term of office continuing only until the next election of directors by the Company&#8217;s stockholders. Our directors and executive officers and certain key employees as of December&#160;31, 2019 are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.754%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.175%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.914%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Age</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current Position(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director Since</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class and Year in Which Term Will Expire</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark A. Emalfarb </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer, Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2004</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class III-2022&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Ping W. Rawson </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(6)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ronen Tchelet, Ph.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vice President of Research and Business Development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew S. Jones</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Managing Director of Business Development and Licensing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Michael P. Tarnok </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(2)(3)(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman, Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2014</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class III-2022&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Jack L. Kaye </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(2)(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2015</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class II -2021</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Seth J. Herbst, MD </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(3)(4)(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2008</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class  I -2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Arindam Bose, Ph.D. </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(2)(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class  I -2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Barry C. Buckland, Ph.D. </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)(4)(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class II -2021</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Member of the Board of Directors.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Member of the Audit Committee (the &#8220;Audit Committee&#8221;).</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Member of the Compensation Committee (the &#8220;Compensation Committee&#8221;).</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Member of the Nominating Committee (the &#8220;Nominating Committee&#8221;).</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(5)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Member of the Science and Technology Committee (the &#8220;Science and Technology Committee&#8221;).</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(6)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Ms. Rawson was promoted to Chief Financial Officer in June 2019, and she previously served as the Company&#8217;s Chief Accounting Officer since March 2018. Prior to that, Ms. Rawson was the Company&#8217;s Director of Financial Reporting. </span></div><div style="text-indent:-9pt;padding-left:9pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXECUTIVE OFFICERS</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mark A. Emalfarb, President, Chief Executive Officer and Director</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mark A. Emalfarb is the founder of Dyadic, and currently serves as the President, Chief Executive Officer and a member of the Board of Directors of the Company. He has been a member of Dyadic&#8217;s Board and has previously served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015. Since founding the predecessor to Dyadic in 1979, Mr. Emalfarb has served as a Director, President and Chief Executive Officer for substantially all of that time and has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic&#8217;s patented and proprietary C1 fungal microorganism. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the patented and proprietary C1 fungus and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ping W. Rawson, CPA, MBA, Chief Financial Officer</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ping W. Rawson was appointed as our Chief Financial Officer in June 2019. She assumes the duties of the Company&#8217;s principal financial officer and principal accounting officer, and is responsible for all aspects of finance, accounting, tax and treasury. Ms. Rawson previously served as the Company&#8217;s Chief Accounting Officer since March 2018. Prior to joining Dyadic in June 2016 as our Director of Financial Reporting, Ms. Rawson served as a technical accounting management position for ADT security services, where she led accounting and financial reporting workstream for acquisition, integration and restructuring. Prior to that, Ms. Rawson was an accounting research principal for NextEra Energy, Inc. (Florida Power &amp; Light Company), where she was responsible for accounting research and new standards implementation. Ms. Rawson&#8217;s experience also includes prior employment at Deloitte LLP in New York City and Florida offices, where she was a subject matter specialist </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for derivatives, financial instruments and valuation, providing audit, SEC reporting, and capital markets consulting services to large banks and multinational public companies. Ms. Rawson holds both an M.B.A. in Finance, and an M.S. in Accounting from the State University of New York at Buffalo, and a B.S. in Economics from Guangdong University of Foreign Studies in China. She is a certified public accountant in the state of New York.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ronen Tchelet, Ph.D., Vice President of Research and Business Development </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ronen Tchelet, Ph.D. joined Dyadic in May 2014, and has been our Vice President of Research and Business Development since January 2016. Since&#160;joining&#160;Dyadic,&#160;Dr. Tchelet&#160;has been&#160;a key contributor to Dyadic&#8217;s transformation into&#160;a pharmaceutical biotech company. Prior to joining Dyadic, Dr. Tchelet was the founder and Managing Director of Codexis Laboratories Hungary kft. (&#8220;CLH&#8221;) and a Vice President of Codexis Inc. from 2007 through 2014. While&#160;at CLH, Dr. Tchelet&#160;established a state-of-the-art laboratory for strain engineering and all aspects of fermentation&#160;including process optimization and scale&#160;up. During this time period,&#160;Dr. Tchelet&#160;also led a collaboration that successfully developed&#160;C1 technology&#160;for the Biofuel and the Bio-Industrial enzymes applications. Dr. Tchelet&#8217;s&#160;experience in the pharmaceutical industry includes prior employment at TEVA Pharmaceutical Industries LTD (&#8220;TEVA&#8221;), API Division during the late 2000&#8217;s&#160;to 2006. While at&#160;TEVA, he served as a Chief Technology Officer of Biotechnology and led TEVA&#8217;s Biotechnology Research and Development fermentation plant in Hungary.&#160;Also, during the period of 2000 through 2005,&#160;Dr. Tchelet was the Manager of Quality Assurance&#160;for&#160;TEVA&#8217;s flag ship innovative drug, COPAXONE&#174;. Throughout his career, Dr. Tchelet has led several&#160;Biotechnology projects&#160;that have encompassed all aspects of&#160;research and&#160;development, operations management, and manufacturing&#160;of API&#8217;s and biologics.&#160;Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral work as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Matthew S. Jones, Managing Director of Business Development and Licensing</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Matthew S. Jones joined Dyadic as a consultant in May 2016 and serves as our consultant commercial officer / Business Development and Licensing to lead Dyadic&#8217;s strategic partnerships, licensing and commercial opportunities within and across the biopharmaceutical industry. A veteran of the life sciences industry with two decades of commercial deal making and leadership experience, Mr. Jones has developed and implemented strategies which have delivered revenue growth, organically and through acquisitions, for a diverse range of life science businesses both in Europe and the US. Prior to joining Dyadic, Mr. Jones served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016. Prior to that, Mr. Jones advised several private equity buy and builds and was also Vice President of Global Sales &amp; Business Development at Lonza Biologics, where he implemented new income-generating revenue streams and captured enterprise synergies in manufacturing, research and client/vendor relationships. From 2009 to 2012, Mr. Jones served as Executive Vice President of Business Development &amp; Marketing at Ricerca Biosciences LLC, responsible for strategic partnerships, royalty and asset license optimization and marketing effectiveness and where Mr. Jones supported the Bain Ventures trade sale of the business toward WiL research. From 2003 to 2009, Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc., where he was responsible for global biopharmaceutical and clinical commercial growth strategies. Earlier in his career, Mr. Jones also held senior level leadership roles within the biopharmaceutical industry with Alkermes, Inc. and GlaxoSmithKline plc. Mr. Jones is a graduate of Warwick University and London Business School.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NON-EMPLOYEE DIRECTORS</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Michael P. Tarnok, Chairman, Director</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Michael P. Tarnok joined the Board on June 12, 2014 and has served on the Company&#8217;s Audit, Nominating and Compensation Committees, and on January 12, 2015 Mr. Tarnok was appointed Dyadic&#8217;s Chairman of the Board. Mr. Tarnok is also currently a board member of Ionetix, Inc. In addition, Mr. Tarnok&#8217;s prior board service includes Global Health Council, and Keryx Biopharmaceuticals, Inc., where he also served as Chairman of the board of directors. Mr. Tarnok is a seasoned finance and operational executive with extensive pharmaceutical industry experience in a wide range of functional areas. He spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director-US Manufacturing and from 2000 to 2007 served as a Senior Vice President in Pfizer&#8217;s US Pharmaceutical Division. In this position, Mr. Tarnok managed multiple responsibilities for the division including, finance, access contracting, trade management, information technology, Sarbanes-Oxley compliance and the Greenstone generics division. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and a B.S. in Accounting from St. John&#8217;s University. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Jack Kaye, Director </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Jack L. Kaye joined the Board in May 2015 and currently serves as chairman of the Company&#8217;s Audit Committee. He also serves on the Company&#8217;s Compensation Committee. Mr. Kaye is currently the Chairman of the audit committee and a member of the compensation committee and special transaction pricing committee of uniQure B.V. where he has served since May 2016. Mr. Kaye&#8217;s prior board service includes Keryx Biopharmaceuticals Inc., a position he has held from 2006 to May 2016 where he served as Chairman of the audit committee and he was also a member of their nominating and governance committee. He also served on the boards of Tongli Pharmaceuticals (USA) Inc. and Balboa Biosciences, Inc., where he served as Chairman of both audit committees. In the past, Mr. Kaye was selected to participate on several dissident board slates which included the Astellas, Inc./OSI, Roche Pharmaceuticals, Inc./Illumina and the Horizon, Inc./Depomed M&amp;A transactions. Mr. Kaye was a partner at Deloitte LLP from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/ Sarbanes-Oxley issues. In addition, he has served as Deloitte&#8217;s Tristate liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Mr. Kaye served as Partner-in-Charge of Deloitte&#8217;s Tri-State Core Client practice, a position he held for more than twenty years. He earned a B.B.A. from Baruch College and is a Certified Public Accountant.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Seth J. Herbst, MD, Director</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Seth J. Herbst, MD has been on the Board since June 2008 and is a board-certified obstetrician/gynecologist who is also board certified in advanced laparoscopic and minimally invasive gynecologic surgery. Dr. Herbst is the founder and President of the Institute for Women&#8217;s Health and Body (&#8220;IWHB&#8221;) in May of 1997, an OB/GYN practice with multiple locations in Palm Beach County, Florida.&#160;He is the co-founder of Visions Clinical Research since 1999, which performs medical and surgical clinical trials throughout the United States. Dr. Herbst founded IWHB of Palm Beach, a Physician Management Group that currently employs 43 providers, which he actively directs the operations on a daily basis. Dr. Herbst is a member of the board of directors of Palms West Hospital in Loxahatchee, Florida. Dr. Herbst is also a consultant for multiple medical device companies in the United States and a member of medical advisory boards for these and other companies. He received his B.S. degree from American University in 1978 and his medical degree from Universidad del Noreste School of Medicine in Tampico, Mexico in 1983.&#160;Dr. Herbst completed his OB/GYN residency and was Chief Resident at Long Island College Hospital in Brooklyn, New York. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Arindam Bose, Ph.D., Director</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Arindam Bose, Ph.D. joined the Board on August 15, 2016 and serves on the Company&#8217;s Audit and Science and Technology Committees. Dr. Bose retired from Pfizer Worldwide Research &amp; Development in 2016 after 34 years in leadership roles in bioprocess development and clinical manufacturing.&#160;Dr. Bose&#8217;s final position at Pfizer was Vice-President, Biotherapeutics Pharmaceutical Sciences External Affairs and Biosimilar Strategy with responsibility for external sourcing, competitive intelligence and external influencing as well as for executing the technical development plan for Pfizer&#8217;s entry into biosimilars. He is widely recognized as a Key Thought Leader in the biopharmaceutical industry. Dr. Bose has served as the Chair of the Biologics and Biotechnology Leadership Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), the chief advocacy arm of the US pharmaceutical industry. His outstanding accomplishments and service to the profession have been recognized by his election as &#8220;Fellow&#8221; of 3 leading professional organizations: American Chemical Society, American Institute of Chemical Engineers and American Institute for Medical and Biological Engineering. Dr. Bose was elected to the US National Academy of Engineering in February 2017 for innovative research in biologics manufacturing. Dr. Bose currently provides consulting services in bioprocessing to several start-up biotechnology companies including a part-time process development management role at Akero Therapeutics (NASDAQ: AKRO). He received a Ph.D. in chemical engineering from Purdue University, a M.S. from the University of Michigan, Ann Arbor and a B. Tech from the Indian Institute of Technology, Kanpur.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Barry C. Buckland, Ph.D., Director </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Barry Buckland, Ph.D. joined the Board in January 2018. Dr. Buckland retired from Merck Research Laboratories in 2009 after 28 years of contributions to the Bioprocess R&amp;D group including more than 12 years as leader in the position of Vice President. Since leaving the Merck Research Laboratories, Dr. Buckland has headed up his own consulting company (BiologicB, LLC). He also is President of Engineering Conferences International (ECI), a not for profit organization which organizes prestigious conferences with an engineering focus. Dr. Buckland has chaired successful conference such as Microbial Engineering I and Vaccine Technology Conferences I to IV. He is also a visiting professor at University College London in the Biochemical Engineering Department and is the author or co-author of more than 70 publications. His previous board experience includes Enumeral Biomedical and Mucosis. Dr. Buckland was a Senior Advisor to Protein Sciences until they were purchased by Sanofi in 2017. Dr. Buckland became Executive Director of NIIMBL (National Institute for Innovation for </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturing Biopharmaceuticals) in 2017. Dr. Buckland was elected to the USA National Academy of Engineering in 1997. In 2008, Dr. Buckland was awarded the ACS Marvin Johnson award for Biotechnology. In 2009, Dr. Buckland was awarded the Discoverers Award by the Pharmaceutical Research and Manufacturers of America (PhRMA) for his role in the discovery and development of GARDASIL, an effective vaccine against HPV. He was one of three recipients.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Involvement in Certain&#160;Legal Proceedings</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None of our directors or executive officers have been convicted in any criminal proceeding during the past 10 years and none of them have been parties to any judicial or administrative proceeding during the past 10 years that resulted in a judgment, decree or final order enjoining them from future violations of, or prohibiting activities subject to, federal or state securities laws or a finding of any violation of federal or state securities laws or commodities laws. Similarly, no bankruptcy petitions have been filed by or against any business or property of any of our directors or officers, nor has any bankruptcy petition been filed against a partnership or business association in which these persons were general partners, directors or executive officers.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Related Party Relationships</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are no family relationships between or among any of our directors or executive officers.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are no arrangements or understandings between any two or more of our directors or executive officers, and there is no arrangement, plan or understanding as to whether non-management stockholders will exercise their voting rights to continue to elect the current Board. There are also no arrangements, agreements or understandings between non-management stockholders that may directly or indirectly participate in or influence the management of our affairs.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Board of Directors and Committees</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Board is responsible for directing and overseeing the business and affairs of the Company. The Board represents the Company&#8217;s shareholders and its primary purpose is to build long-term shareholder value. The Board meets on a regularly scheduled basis during the year to review significant developments affecting the Company and to act on matters that, in accordance with good corporate governance, require Board approval. It also holds annual meetings and acts by unanimous written consent when an important matter requires Board action between scheduled meetings.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a classified board of directors currently fixed at six members. The Board has four committees: Audit, Compensation, Nominating, and Science and Technology. Currently, Mr. Michael P. Tarnok serves as Chairman of the Board of Directors. Mr. Jack Kaye serves as Chairman of the Audit Committee, Mr. Michael Tarnok serves as Chairman of the Compensation Committee, Dr. Seth Herbst serves as Chairman of the Nominating Committee, and Dr. Arindam Bose serves as Chairman of the Science and Technology Committee.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Audit Committee. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Audit Committee has oversight responsibility for quality and integrity of our consolidated financial statements. A copy of the Charter of the Audit Committee is available on our website, located at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.Dyadic.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The committee meets privately with members of our independent registered public accounting firm, has the sole authority to retain and dismiss the independent registered public accounting firm and reviews its performance and independence from management. The independent registered public accounting firm has unrestricted access and reports directly to the Audit Committee. The primary functions of the Audit Committee are to oversee (i) the audit of our consolidated financial statements and (ii) our internal financial and accounting processes.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SEC and NASDAQ have established rules and regulations regarding the composition of audit committees and the qualifications of audit committee members. Our Board has examined the composition of our Audit Committee and the qualifications of our Audit Committee members in light of the current rules and regulations governing audit committees. Based upon this examination, our Board has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of our Audit Committee in accordance with the rules of the SEC and NASDAQ.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the SEC requires that at least one member of the audit committee have a heightened level of financial and accounting sophistication. Such a person is known as the audit committee financial expert under the SEC&#8217;s rules. Our Board has determined that Mr. Kaye is an audit committee financial expert, as defined in Item 407(d)(5) of Regulation S-K and is an independent member of our Board and our Audit Committee. Please see Mr. Kaye&#8217;s biography included in this Annual Report for a description of his relevant experience. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Committee. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The duties and responsibilities of the Compensation Committee are set forth in the Charter of the Compensation Committee. A copy of the Charter of the Compensation Committee is available on our website, located at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.Dyadic.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. As discussed in its charter, among other things, the duties and responsibilities of the Compensation Committee include evaluating the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company, including, but not limited to, our incentive and equity-based plans. The Compensation Committee evaluates the performance of the Chief Executive Officer, Chief Financial Officer and other key personnel of the Company on an annual basis and reviews and approves on an annual basis all compensation programs and awards relating to such officers and key personnel. The Compensation Committee applies discretion in the determination of individual executive compensation packages to ensure compliance with the Company&#8217;s compensation philosophy. The Chief Executive Officer makes recommendations to the Compensation Committee with respect to the compensation packages for officers other than himself.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Nominating Committee.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Nominating Committee&#8217;s functions include: establishing criteria for the selection of new directors to serve on the Board; identifying individuals believed to be qualified as candidates to serve on the Board; recommending for selection by the Board the candidates for all directorships to be filled by the Board or by the shareholders at an annual or special meeting; reviewing the Board&#8217;s committee structure and recommending to the Board the directors to serve on the committees of the Board; recommending members of the Board to serve as the respective chairs of the committees of the Board; developing and recommending to the Board, for its approval, an annual self-evaluation process of the Board and its committees and, based on those results, making recommendations to the Board regarding those Board processes; and performing any other activities consistent with the committee&#8217;s charter, our bylaws and applicable law as the committee or the Board deems appropriate. A copy of the Charter of the Nominating Committee is available on our website, located at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.Dyadic.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Nominating Committee does not currently have any formal minimum qualification requirements that must be met by a nominee to serve as a member of the Board. The Nominating Committee will take into account all factors it considers appropriate, which may include experience, accomplishments, education, understanding of the business and the industries in which we operate, specific skills, general business acumen and the highest personal and professional integrity. The Nominating Committee generally seeks individuals with broad experience at the policy-making level in business, or with particular industry expertise. While we do not have a formal diversity policy for Board membership, we look for potential candidates that help ensure that the Board has the benefit of a wide range of attributes. We believe that all of our directors should be committed to enhancing shareholder value and should have sufficient time to carry out their duties and to provide insight and practical wisdom based on experience. Each director must also represent the interests of all shareholders.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Nominating Committee currently has no fixed process for identifying new nominees for election as a director, thereby retaining the flexibility to adapt its process to the circumstances. The Nominating Committee has the ability, if it deems it necessary or appropriate, to retain the services of an independent search firm to identify new director candidates. The Nominating Committee has determined that it will consider any potential candidate proposed by a member of our Board or senior management. Any director candidate so proposed will be personally interviewed by at least one member of the Nominating Committee and our Chief Executive Officer and their assessment of his or her qualifications will be provided to the full Nominating Committee.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our policy and procedures regarding director candidates recommended by shareholders are contained in the Nominating Committee&#8217;s charter. The Nominating Committee may consider for inclusion in its nominations for new directors any candidates recommended by shareholders, but must consider any candidate for director recommended by (i) any shareholder beneficially owning more than 5% of our outstanding common stock for at least one year as of the date the recommendation was made or (ii)&#160;a group of shareholders that beneficially owned, in the aggregate, more than 5% of our outstanding common stock, with each of the shares used to calculate that ownership held for at least one year as of the date the recommendation was made. The Nominating Committee will consider the candidate based on the same criteria established for selection of director nominees generally. The Nominating Committee reserves the right to reject any candidate in its discretion, including, without limitation, rejection of a candidate who has a special interest agenda other than the best interests of the Company and the shareholders, generally.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Science and Technology Committee. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The responsibility of Science and Technology Committee is to periodically examine management&#8217;s strategic direction and investments in the Company&#8217;s biopharmaceutical research and development and technology initiatives. The duties and responsibilities of the Science and Technology Committee are set forth in the Charter of the Science and Technology Committee. A copy of the Charter of the Science and Technology Committee is available on our </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">website located at </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">www.Dyadic.com</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. As discussed in its charter, among other things, the duties and responsibilities of the Science and Technology Committee are following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Review, evaluate and report to the Board regarding the performance of the Vice-President, Research and Development (and, his or her team), the contract research organizations being considered or working on behalf of the Company in achieving the strategic goals and objectives and the quality and direction of the Company&#8217;s biopharmaceutical research and development programs.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Identify and discuss significant emerging science and technology issues and trends.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Review the Company&#8217;s approaches to acquiring and maintaining a range of distinct technology positions (including but not limited to contracts, grants, collaborative efforts, alliances and capital investments).</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Evaluate the soundness/risks associated with the technologies in which the Company is investing its research and development efforts.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Periodically review the Company&#8217;s overall patent strategies.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Code of Conduct and Ethics</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have adopted a Code of Conduct and Ethics, as amended, that applies to all employees, key consultants, officers, and directors of our company, including our principal executive officer, principal financial officer and principal accounting officer, or persons performing similar functions. Our Code of Conduct and Ethics is available on the &#8220;Corporate Governance&#8221; page of the &#8220;Investors&#8221; section of our website at www.dyadic.com. A copy of our Code of Conduct and Ethics can also be obtained free of charge by contacting our Secretary, c/o Dyadic International, Inc, 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any amendment to, or waiver from, a provision of our Code of Conduct and Ethics by posting such information on our website.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_79"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473%;"><tr><td style="width:1.0%;"></td><td style="width:13.646%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.354%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 11.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Compensation</span></td></tr></table></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Philosophy and Objectives</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The philosophy underlying our executive compensation program is to provide an attractive, flexible and market-based total compensation program tied to performance and aligned with the interests of our shareholders. Our objective is to recruit and retain the caliber of executive officers and other key employees necessary to deliver sustained high performance to our shareholders, customers, and communities where we have a strong presence. Our executive compensation program is an important component of these overall human resources policies. Equally important, we view compensation practices as a means for communicating our goals and standards of conduct and performance and for motivating and rewarding employees in relation to their achievements. The organization&#8217;s executive compensation program is designed to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Encourage the attraction and retention of high-caliber executives.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Provide a competitive total compensation package, including benefits.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reinforce the goals of the organization by supporting teamwork and collaboration.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ensure that pay is perceived to be fair and equitable.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Be flexible to potentially reward individual accomplishments as well as organizational success.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ensure that the program is easy to explain, understand, and administer.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Balance the needs of the both the Company and employees to be competitive with the limits of available financial resources.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ensure that the program complies with state and federal legislation.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company will consult with a compensation specialist to determine whether its overall compensation practices and policies are appropriate for the specific market conditions for the Company and the industries in which it operates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary Compensation Table</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the compensation paid or accrued to our &#8220;named executive officers&#8221; (as defined by the SEC&#8217;s disclosure requirements) during the fiscal years 2019 and 2018:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:18.117%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.698%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.635%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.957%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.377%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name and Principal Position</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Salary ($) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bonus ($)(1) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock Awards ($) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option Awards ($)(2)(3)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonequity incentive plan compensation ($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonqualified deferred compensation earnings ($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All other payments ($) (4)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total ($)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Mark A. Emalfarb</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"> (*)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">  </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">440,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">228,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, CEO and Director</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">393,012&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">468,891&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,161,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Ping W. Rawson </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">399,307&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Ronen Tchelet, Ph.D. </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(6)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">207,647&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VP of Research and Business Development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,759&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Matthew S. Jones </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(7)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82,954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409,404&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Managing Dir. of Bus. Dev and Licensing</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(*) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Emalfarb also serves on the Board, for which he receives no direct, indirect or incremental compensation.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> All 2019 bonuses were accrued at December&#160;31, 2019 and paid in January 2020. Mr. Emalfarb&#8217;s 2018 bonus was accrued at December&#160;31, 2018 and paid in January 2019.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Option Awards amount reported in this column represented stock options granted in 2018 and 2019 (including annual share-based compensation awards for all named executives, and Ms. Rawson&#8217;s awards upon promotions for 2019 and 2018 in the amount of $55,250 and $22,000, respectively), vesting upon grant, or the one or four-year anniversary in accordance with their individual employment agreement or consulting agreement. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Option Awards amount reported in this column represented the grant date fair market value of each option granted, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements. The table above does not include the value of the following performance-based vesting stock options, as the achievement of the conditions was not deemed probable at the grant date and the value of the awards was deemed zero in accordance with ASC 718. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Upon the Company&#8217;s uplisting to the NASDAQ in April 2019, 400,000 shares of performance-based vesting stock options granted to Mr. Emalfarb in 2016 became vested, and the related estimated value of the awards at the grant date in the amount of $392,000 was recorded in 2019 in accordance with FASB ASC Topic 718. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Upon the achievements of different conditions in 2019, 175,000 shares of performance-based vesting stock options granted to Ms. Rawson in 2018 became vested, and the related estimated value of the awards at the grant date in the amount of $91,250 was recorded in 2019 in accordance with FASB ASC Topic 718. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other payments includes following: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Mr. Emalfarb received $12,891 for car allowance in both years. The Company&#8217;s contribution to the 401(k) retirement plan were $11,200 and $11,000 for 2019 and 2018, respectively. He also received $204,000 and $445,000 for installment payments relating to his prior employment agreement for 2019 and 2018, respectively.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ms. Rawson received $8,807 and $7,996 for the Company&#8217;s contribution to the 401(k) retirement plan in 2019 and 2018, respectively. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Mr. Tchelet received $11,759 for sales commission earned in 2018.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(5) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ms. Rawson was promoted to Chief Financial Officer in June 2019, and she previously served as the Company&#8217;s Chief Accounting Officer since March 2018. Prior to that, Ms. Rawson was the Company&#8217;s Director of Financial Reporting. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(6) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts represent the compensation for services of Mr. Tchelet for the year ended December 31, 2018 and 2019, in accordance with the Sky Blue Biotech Agreement indicated below.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(7) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts represent the compensation for services of Mr. Jones for the year ended December 31, 2018 and 2019, in accordance with the Jones Consultant Agreement indicated below. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employment Arrangements</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, the Company had employment arrangements with certain of its named executive officers, each of which is described below.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Mark A. Emalfarb</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 21, 2016, the Company entered into an employment agreement (the &#8220;Emalfarb Agreement&#8221;) with Mr. Emalfarb. The Emalfarb Agreement has an initial term of three years and automatic renewals of two years at the end of each term, unless either party provides a notice of nonrenewal, and provides that Mr. Emalfarb be employed as our President and Chief Executive Officer and that we will cause Mr. Emalfarb to be elected as a member of the Board. The material terms of the Emalfarb Agreement are summarized below:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Base Salary and Bonus</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Emalfarb Agreement provided for an annual base salary of $375,000, which was increased to $405,000 in January 2019, to $475,000 in June 2019, and to $500,000 in January 2020, in recognition of his successful efforts in every area of the business in 2018 and 2019. The Emalfarb Agreement also provided for an annual bonus award, with the timing and amount of any such bonus determined in the sole discretion of the Compensation Committee of the Board, who determined to award Mr. Emalfarb a cash bonus of $200,000 for 2018 and $250,000 for 2019. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Stock Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Emalfarb Agreement provided Mr. Emalfarb the opportunity to be awarded annual stock option grants, each such annual option incentive stock option grant will be to purchase up to three hundred thousand (300,000) shares of common stock (the &#8220;Maximum Option Bonus&#8221;) based on performance achievements. Performance incentives will be based solely on the Compensation Committee&#8217;s evaluation of Mr. Emalfarb&#8217;s performance during that time period.  </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For fiscal years 2019 and 2018, Mr. Emalfarb received a stock option grant to purchase 300,000 shares of common stock for his annual performance, representing 100% of the Maximum Option Bonus. All options granted to Mr. Emalfarb for fiscal year 2018 vested immediately upon grant and have a five-year term from the date of grant. All options granted to Mr. Emalfarb for fiscal year 2019 vest annually in equal installments over four years and have a ten-year term from the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Exchange Stock Option</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In addition, Mr. Emalfarb received a stock option grant to purchase up to four hundred thousand (400,000) shares of common stock at an exercise price of $1.67, equal to the closing price of Dyadic common stock on June 21, 2016. The stock option would vest and become exercisable only if the Company&#8217;s shares of common stock commence trading on the NASDAQ Capital Markets or other stock exchange approved by the Board. The Stock Exchange stock option grant has a five-year term. All 400,000 stock options granted to Mr. Emalfarb in 2016 became vested, upon the Company&#8217;s uplisting to the NASDAQ in April 2019.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Licensing/Collaboration Transaction Stock Options. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A stock option to purchase up to six hundred thousand (600,000) shares of common stock shall be proportionally awarded, vest and become exercisable when each of three (3) Bona Fide Licensing / Collaboration Transactions are entered into with the Company. A Bona Fide transaction is defined as a license, joint venture or other collaboration for a specific biologic with the intent to commercialize and/or a license agreement that generates a cumulative five million dollars in non-refundable cash, or when either the vaccine or biologics pharmaceutical business categories are sold. On November 12, 2019, the Company entered into an amendment (the &#8220;Amendment&#8221;) to the Emalfarb Agreement. Pursuant to the Amendment, the stock options to be awarded to Mr. Emalfarb upon the Company entering into a first or second licensing and/or collaboration transaction, as provided in the Emalfarb Agreement, shall each be awarded on the date of the relevant licensing and/or collaboration transaction and shall each have a fixed exercise date on the tenth anniversary of the date of grant.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Severance Terms. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Emalfarb will be eligible for severance benefits comparable to other executives at his level. In addition, if Mr. Emalfarb&#8217;s employment is terminated by the Company without cause, by Mr. Emalfarb for good reason, or due to Mr. Emalfarb&#8217;s death or disability, then the Company shall fulfill its obligations as for annual base salary through the effective date of termination and he will be entitled to receive his accrued but unpaid vacation through the date thereof plus, in the sole discretion of the Compensation Committee, the Maximum Option Bonus and performance incentive may be awarded. In addition, all of Mr. Emalfarb&#8217;s unvested Stock Exchange Stock Options and Licensing/Collaboration Transaction Stock Options will vest immediately in the event milestones for which the options would have been awarded are achieved within one year from the date of termination or upon a change of control.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Change of Control</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the sole discretion of the Compensation Committee, Mr. Emalfarb may be awarded an additional bonus on or before the occurrence of a change of control.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Side Letter</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In connection with the execution of the Emalfarb Agreement, the Company and Mr. Emalfarb entered into a separate agreement (the &#8220;Side Letter&#8221;) under which the Company agreed to pay Mr. Emalfarb in monthly installments over the initial term of the Emalfarb Agreement, $1,335,000, equal to the amount of the severance payments that would have been payable under his previous employment agreement if Mr. Emalfarb resigned for &#8220;good reason&#8221; in connection with a change in control. All payments under this Side Letter have been made, and the Company has no additional obligation associated with this Side Letter as of June 2019.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ping W. Rawson</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with Ping Rawson&#8217;s appointment as the Company&#8217;s Chief Financial Officer in June 2019, the Board approved her base salary at $225,000 per year, which was increased to $231,750 per year in January 2020, which increase was consistent with annual increases for the majority of the Company&#8217;s employees. Ms. Rawson will also receive discretionary annual cash bonuses and other equity compensation as determined by the Company.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For fiscal year 2019, Ms. Rawson received stock option grants to purchase 100,000 shares of common stock for her annual performance in January 2019 and additional 25,000 options associated with her promotion to the CFO in June 2019. Ms. Rawson also received a cash bonus of $56,250 based on her annual performance. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with Ms. Rawson&#8217;s appointment as the Company&#8217;s Accounting Officer in March 2018, the Company granted Ms. Rawson a sign-on award of 50,000 stock options that will vest annually in equal installments over four years, and a conditional award of 50,000 stock options that would vest upon the Company&#8217;s becoming an SEC reporting entity. In November 2018, the Company granted Ms. Rawson a special performance-based award of 125,000 options, which would vest upon the Company&#8217;s successful uplisting to the NASDAQ or a national stock exchange. Ms. Rawson will be eligible for twelve (12) months of severance benefits, if her services are no longer required due to a change of control or any reason other than for cause. A total of 175,000 of the options vested upon the Company becoming an SEC reporting entity and listing on the NASDAQ in 2019.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ronen Tchelet, Ph.D. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We entered into a consulting agreement with Sky Blue Biotech kft, dated January 1, 2016 (the &#8220;Sky Blue Biotech Agreement&#8221;), to engage Mr. Tchelet to serve as our Vice President of Research and Business Development. The engagement term of the Sky Blue Biotech Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Mr. Tchelet provides notice of non-renewal any time after the one year anniversary date with not less than 90 days&#8217; notice. Mr. Tchelet is subject to an annual performance evaluation and adjustment of his base consulting fees, in the sole discretion of the Company. Mr. Tchelet was compensated EUR &#8364;180,000 per annum in 2018 for the consulting services provided, which was increased to EUR &#8364;185,400 per annum in January 2019, and to EUR &#8364;190,962 in January 2020, which increase was consistent with annual increases for the majority of the Company&#8217;s employees. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Tchelet is also eligible for a discretionary annual target bonus of up to 40% of his base contract amount if specific performance targets are met. For fiscal year 2019, Mr. Tchelet received a cash bonus of EUR &#8364;37,080. For fiscal years 2019 and 2018, Mr. Tchelet received stock option grants to purchase 75,000 and 100,000 shares of common stock for his annual performance, respectively. All options granted to Mr. Tchelet for fiscal years 2019 and 2018 vest upon the one-year anniversary and have a ten-year term from the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the engagement period, Mr. Tchelet shall be entitled to reimbursement of all business travel, entertainment and other business expenses reasonably incurred in the performance of his duties for the Company. Additionally, if the Company enters into a licensing agreement or research and development agreement sourced and developed by Mr. Tchelet during the engagement period, Mr. Tchelet shall receive the following: (i) a commission of up to 1% of the up-front licensing revenue and (ii) a commission of up to 2.5% of the research and development revenue. Commissions will be paid quarterly within 30 days of the Company&#8217;s receipt of payment. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Tchelet is subject to certain restrictive covenants, including Company ownership of Mr. Tchelet&#8217;s work product which shall remain the sole and exclusive property of the Company, non-disclosure for five years following the date of execution of the agreement or for three years following the termination of agreement whichever is last to occur, and non-solicitation for five years following the termination of the Sky Blue Biotech Agreement. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Matthew S. Jones</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We entered into a consulting agreement with Novaro Ltd. dated March 31, 2017 (the &#8220;Jones Consultant Agreement&#8221;) to engage Mr. Jones as our Managing Director Business Development and Licensing. The engagement term of the Jones Consultant Agreement is one year and will renew annually on the anniversary date of the agreement, unless the Company or Novaro Ltd. provides notice of non-renewal any time after the first annual anniversary date with then not less than 90 days&#8217; notice.&#160;Mr. Jones is subject to an annual performance evaluation and adjustment of his base consulting fees, in the sole discretion of the Company. Mr. Jones was compensated &#163;203,528 per annum in 2018 for the consulting services provided, which was increased to &#163;209,634 per annum in January 2019, and to &#163;215,923 in January 2020, which increase was consistent with annual increases for the majority of the Company&#8217;s employees. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Mr. Jones is also eligible for a discretionary annual target bonus of up to 40% of the base contract value if specific performance targets are met as specified in the Jones Consultant Agreement. For fiscal year 2019, Mr. Jones received a cash bonus of &#163;62,890. For fiscal years 2019 and 2018, Mr. Jones received stock option grants to purchase 50,000 and 100,000 shares of common stock for his annual performance, respectively. In March 2018, the Company granted Mr. Jones a special award of 50,000 stock options in recognition of his achievements in business development. All options granted to Mr. Jones during fiscal years 2019 and 2018 vest upon the one-year anniversary and have a ten-year term from the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the engagement period, Mr. Jones shall be entitled to reimbursement of all business travel, entertainment and other business expenses reasonably incurred in the performance of his duties on behalf of the Company. Mr. Jones is subject to certain restrictive covenants, including Company ownership of Mr. Jones&#8217; work product which shall remain the sole and exclusive property of the Company, non-disclosure for five years following the date of execution of the agreement or for three years following the termination of agreement whichever is last to occur, and non-solicitation for five years following the termination of agreement. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the outstanding equity award holdings held by our &#8220;named executive officers&#8221; (as defined by the SEC&#8217;s disclosure requirements) at December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:13.882%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.411%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.411%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.911%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.382%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.911%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.088%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.096%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option Awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock Awards</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity<br/>Incentive<br/>Plan<br/>Awards:<br/>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Option Expiration Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number<br/>of<br/>Shares<br/>or Units<br/>of<br/>Stock<br/>That<br/>Have<br/>Not Vested</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market<br/>Value<br/>of<br/>Shares<br/>or<br/>Units<br/>of<br/>Stock<br/>That<br/>Have<br/>Not Vested</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity<br/>Incentive<br/>Plan<br/>Awards:<br/>Number<br/>of<br/>Unearned<br/>Shares,<br/>Units or<br/>Other<br/>Rights<br/>That<br/>Have Not Vested</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity<br/>Incentive<br/>Plan<br/>Awards:<br/>Market<br/>or Payout<br/>Value of<br/>Unearned<br/>Shares,<br/>Units or<br/>Other<br/>Rights<br/>That<br/>Have Not Vested</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(#) exercisable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(#) unexercisable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(#)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(#)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(#)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark A. Emalfarb</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/20/2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/20/2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/3/2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">300,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ping W. Rawson</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,750&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/26/2026</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,945&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,945&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/3/2027</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2028</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/19/2028</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/19/2028</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11/16/2028</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2029</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6/28/2029</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ronen Tchelet, Ph.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/18/2026</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/3/2027</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2028</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.87</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2029</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew S. Jones</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/3/2027</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2028</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/19/2028</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.87</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/2/2029</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The options vest annually in equal installments over four years subsequent to the grant date. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The options will vest upon the one-year anniversary subsequent to the grant date. </span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pension Benefits</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) in place, under which participants may elect to defer up to 100% of their compensation up to a maximum amount determined annually pursuant to Internal Revenue Service regulations. Employee contributions may begin 90 days after the date of hire and are immediately vested.&#160;The 401(k) Plan provides a safe harbor basic match contribution for all eligible employees who make salary deferrals. The match contribution is equal to 100% of the employee&#8217;s salary deferral up to 4% of such employee&#8217;s annual deferred compensation.&#160;This match contribution is credited to the employee&#8217;s account and is 100% vested at the time of contribution.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Director Compensation</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the total compensation for our non-employee directors for the year ended December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:17.616%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.776%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Fees earned or paid in cash </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock awards ($) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Options awards</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">($) </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)(2)(3)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-equity incentive plan compensation ($) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nonqualified deferred compensation earnings ($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All other compensation ($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total ($)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael P. Tarnok</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Jack L. Kaye</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"> (4)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seth J. Herbst, MD</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Arindam Bose, Ph.D.</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">161,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Barry C. Buckland, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Directors who are also employees or officers of the Company or any of its subsidiaries do not receive any separate compensation as a director. Non-employee directors receive an annual retainer for Board service of $60,000, paid in equal monthly installments. The annual stock option award for non-employee directors is 50,000 options. Prior to June 25, 2019, a director who served as Chairman of the Board also received an additional annual retainer of $12,000 paid in equal monthly installments and a director who served as Chair of the Audit Committee also received an additional annual retainer of $9,600 paid in equal monthly installments. All options granted to directors prior to June 25, 2019 vest 25% upon grant and the remaining 75% will vest annually in equal installments over four years. Effective June 25, 2019, the following changes were made: (1) a director who serves as Chairman of the Board, Chair of the Audit Committee, and Chair of the Science and Technology Committee shall each receive an additional annual retainer of $15,000 and 25,000 stock options, and (2) all options granted to directors will vest upon the one-year anniversary subsequent to the grant date. Accordingly, additional 25,000 options were granted to Mr. Tarnok, Mr. Kaye and Dr. Bose on June 25, 2019, and monthly installments based on the new annual retainer rate were applied starting from July 2019.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Stock Option Awards represented the grant date fair market value of each option granted in 2019, computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be recognized by the named directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our consolidated financial statements. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Options to purchase 280,000 shares (Mr. Tarnok), 280,000 shares (Mr. Kaye), 350,000 shares (Mr. Herbst), 280,000 shares (Mr. Bose), and 85,000 shares (Mr. Buckland) were outstanding at December&#160;31, 2019.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2019, the following special awards were granted: (1) additional 25,000 options were granted to Mr. Kaye in recognition of the level of effort required of him in his role as the Chair of the Audit Committee and member of the Compensation Committee, and (2) additional 25,000 options were granted to Dr. Bose in recognition of his contributions to the Company&#8217;s R&amp;D strategies and accomplishments.  </span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_82"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.117%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 12.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth certain information regarding the beneficial ownership of our common stock as of December&#160;31, 2019 (except as noted below), by:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">each person known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">each of our directors, named executive officers; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">all of our directors and executive officers as a group.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amounts and percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares voting power, which includes the power to vote or direct the voting of a security, or investment power, which includes the power to dispose of or to direct the disposition of a security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within sixty (60) days of December&#160;31, 2019. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person&#8217;s ownership percentage, but not for purposes of computing any other person&#8217;s percentage. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed to be a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">beneficial owner of securities as to which such person has no economic interest. Except as otherwise indicated in these footnotes, each of the beneficial owners listed has, to our knowledge, sole voting and investment power with respect to the indicated shares of common stock.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the Company has 39,612,659 shares of common stock issued and 27,359,157 shares of common stock outstanding with the remaining 12,253,502 shares held in treasury. The beneficial ownership table below includes those shares of common stock underlying options that are currently exercisable or exercisable within sixty (60) days of December&#160;31, 2019, but excludes those shares issued or repurchased subsequent to December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:44.911%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.794%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.794%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.796%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;">Name and Address of Beneficial Owner</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Common Shares Held</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Exercisable within 60 Days</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Common Share Equivalents Beneficially Owned</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Percentage of Common Share Equivalents Beneficially Owned (%) </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">5% Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark A. Emalfarb </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,166,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,220,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,386,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The Francisco Trust U/A/D February 28, 1996 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,781,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,781,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.8%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Named Executive Officers and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark A. Emalfarb </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,166,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,220,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,386,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael P. Tarnok</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">188,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">194,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">382,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jack L. Kaye</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">252,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seth J, Herbst, M.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">289,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">319,063&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arindam Bose, Ph.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Barry C. Buckland, Ph.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ping W. Rawson</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">280,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">298,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ronen Tchelet, Ph.D.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">410,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Matthew S. Jones</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All current executive officers and directors as a group</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,477,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,011,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,488,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.7%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9 persons)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(*)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">    Less than 1%</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt;">Except as otherwise noted, the address for each shareholder is c/o Dyadic International, Inc., 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt;">Based on 27,359,157 shares of common stock outstanding as of December&#160;31, 2019. Shares of common stock subject to options that are currently exercisable or exercisable within 60 days are deemed outstanding for purposes of computing the percentage of the person holding such options but are not deemed outstanding for purposes of computing the percentage of any other person.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt;">Includes 4,166,987 shares held by Mark A. Emalfarb beneficially through the MAE Trust U/A/D October 1, 1987, of which Mr. Emalfarb is the sole beneficiary and serves as sole trustee. In addition, Mr. Emalfarb holds 1,220,000 shares of common stock underlying options that are presently exercisable. Based on the information available to us, the address of the MAE Trust U/A/D October 1, 1987 is 193 Spyglass Court, Jupiter, 33477.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt;">The trustee of the Francisco Trust is Adam Morgan, and the beneficiaries thereof are the spouse and descendants of Mark A. Emalfarb. The address of the Francisco Trust is 3128 San Michele Drive, Palm Beach Gardens, Florida 33418. Mr. Emalfarb disclaims beneficial ownership of such shares.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity Compensation Plan Information</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) was adopted by the Board on April 28, 2011 and approved by the Company&#8217;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#8217;s 2006 Stock Option Plan (the &#8220;2006 Plan&#8221;). Since the effective date of the 2011 Plan, all future equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company&#8217;s common stock </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provision of the 2011 Plan, the Board approved an increase of 1,500,000 shares each year to the plan on January 1, 2019 and 2020. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information about our equity compensation plans as of December&#160;31, 2019:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:48.588%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.737%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;">Plan Category</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Number of Securities</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">to be Issued Upon</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Exercise of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Outstanding Options,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Warrants and Rights(a) </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Weighted-Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Exercise Price of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Outstanding</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Options, Warrants</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">and Rights (b)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Number of Securities Remaining</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Available for Future Issuance</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Under Equity Compensation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Plans (Excluding Securities</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Reflected in Column (a)) (c)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,860,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.76</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,547,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Note:</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Includes options only.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_85"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.181%;"><tr><td style="width:1.0%;"></td><td style="width:9.311%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.689%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 13.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">One of our principal stockholders, the Francisco Trust, which owns 13.8% of our common stock, is administered by Mr. Adam Morgan as trustee. The beneficiaries of the Francisco Trust are the descendants and spouse of Mr. Emalfarb. Apart from these relationships, there are no family relationships among or between our officers, directors and beneficial owners of more than five percent (5%) of our common stock. In accordance with a divorce decree dated March 18, 2014, Lisa K Emalfarb, the former spouse of Mr. Emalfarb, is no longer a beneficiary of the Francisco Trust.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock Options Granted to Executive Officers and Directors</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have granted stock options to our executive officers and directors, as more fully described in the section above entitled &#8220;Executive Compensation&#8221;.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification Agreements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Related Party Transactions Policy</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Audit Committee charter requires that our Board review and approve, if the duty is not delegated to a comparable body of the Board, all related party transactions in accordance with the regulations of the SEC.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Independence of Directors</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In evaluating the independence of its members and the composition of the committees of the Board, the Board utilizes the definition of independence as that term is defined under the published listing requirements of NASDAQ. The NASDAQ independence definition includes a series of objective tests. For example, an independent director may not be employed by us and may not engage in certain types of business dealings with the Company. In addition, as further required by NASDAQ rules, the Board has made a subjective determination as to each independent director that no relation exists which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, the Board reviewed and discussed information provided by the directors and by the Company with regard to each director&#8217;s business and personal activities as they may relate to the Company and the Company&#8217;s management. We believe that Drs. Herbst, Bose and Buckland, as well as Messrs. Kaye and Tarnok qualify as independent directors. In addition, our Board has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of the Audit Committee in accordance with the rules of the SEC and NASDAQ.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_88"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:83.187%;"><tr><td style="width:1.0%;"></td><td style="width:10.126%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:85.874%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 14.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal Accounting Fees and Services</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the audit of our 2019 and 2018 consolidated financial statements, we entered into engagement letters with Mayer Hoffman McCann P.C.(&#8220;MHM&#8221;) which set forth the terms by which MHM agreed to perform audit services for us. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents fees billed, by our independent registered public accounting firm for professional services, in the years indicated, by category, as described in the notes to the table.</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Audit fees </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Audit-related fees</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Tax fees </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fees</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Audit fees consist of fees billed for professional services by MHM for audit and quarterly review of our financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filing or engagement for those years related to our periodic and current OTC Markets (2018), NASDAQ Capital Markets (2019), and SEC filings and registration statements. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Audit-related fees consist of fees billed for procedures performed by MHM in connection with the filing of registration statements on Form 10-12G and Form 10-12G/A. </span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Tax fees consist of fees billed for tax professional services by MHM with respect to the IRS audit and by an affiliate of MHM for the Netherlands subsidiary. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Report of Audit Committee</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Audit Committee&#8217;s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. The independent auditor and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval. Any proposed services not included within the list of pre-approved services or any proposed services that will cause the Company to exceed the pre-approved aggregate amount requires specific pre-approval by the Audit Committee. All audit fees, audit-related fees, tax fees, and other fees listed in the table above were approved by the Audit Committee pursuant to its pre-approval policies and procedures. </span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_91"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART IV</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_94"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.181%;"><tr><td style="width:1.0%;"></td><td style="width:9.311%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.689%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 15.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statement and Exhibits</span></td></tr></table></div><div style="margin-bottom:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(a)&#160;Financial Statement</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial statements and related notes thereto are listed and included in this Annual Report on Form 10-K beginning on page F-1. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(b)&#160;Exhibits</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:49.315%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.363%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Exhibit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Original No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date Filed</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed Herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1*#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit21form10.htm">Investment Shareholders Agreement with respect to Biotechnology Developments for Industry, S.L, and VLP The Vaccines Company, S.L.U.  dated June 30, 2017</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:49.315%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.363%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit31form10.htm">Restated Certificate of Incorporation dated November 1, 2004</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2#&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit32form10.htm">Second Amended and Restated Bylaws dated December 13, 2018</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit41form10.htm">Specimen Stock Certificate Evidencing Shares of Common Stock</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit42descriptionof.htm">Description of Securities</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1**#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit101form10.htm">Dyadic International, Inc. 2006 Stock Option Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2**#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit102form10.htm">Dyadic International, Inc. 2011 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3**#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit103form10.htm">Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4**#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit104form10.htm">Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5**#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit105form10.htm">Employment Agreement, dated June 16, 2016, and First Amendment dated January 23, 2017, by and between Dyadic International, Inc. and Mark A. Emalfarb</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5.1**#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000072/emalfarbeaamendmentno2.htm">Second Amendment to Employment Agreement between Dyadic International, Inc. and Mark A. Emalfarb, dated as of November 12, 2019</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">November 13, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7**#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit107form10.htm">Consulting Agreement, dated January 1, 2016, by and between Dyadic Netherlands B.V. and Sky Blue Biotech kft on behalf of Ronen Tchelet</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8**#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit108form10.htm">Consulting Agreement, dated March 13, 2017, by and between Dyadic International, Inc. and Novaro Ltd. on behalf of Matthew Jones</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9**#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit109form10.htm">Compensation Letter, dated March 26, 2018, by and between Dyadic International, Inc. and Ping W. Rawson</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1010form10.htm">Form of Director and Officer Indemnification Agreement</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit1011jupiterlease2.htm">Intracoastal Pointe Office Building Lease Agreement by and between Dyadic International, Inc. and Quentin Partners Co. dated December 30, 2010 and Renewal of Lease dated June 21, 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1012form10.htm">Pharma License Agreement with Danisco US, Inc. dated December 31, 2015</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1013form10.htm">Commission Contract with VTT Technical Research Centre of Finland Ltd dated September 2, 2016</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13.1&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000054/a101vttagreement.htm">Commission Contract with VTT Technical Research Centre of Finland Ltd dated June 28, 2019</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 5, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1014form10.htm">Research Services Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1015form10.htm">Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.  dated June 30, 2017</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1016form10i.htm">Feasibility Study Agreement with Sanofi-Aventis Deutschland GmbH dated September 7, 2018</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit1017form10.htm">License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000027/a101serumresearchandcommer.htm">Research and Commercialization Collaboration Agreement with Serum Institute of India Pvt</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000027/a101serumresearchandcommer.htm">. Ltd., dated May 7, 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 8, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000024/a101sublicenseagreementalp.htm">Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated May 5, 2019</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 8, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:49.315%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.363%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20&#8224;#</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000021/luinabiosub-license.htm">Sub-License Agreement among Dyadic International (USA), Inc., Luina Bio Pty Ltd. and Novovet Pty Ltd, dated April 26, 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 2, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20.1&#8224;#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000121380919000021/shareholdersagreement-.htm">Shareholders Agreement among Dyadic International (USA), Inc., JCL Biologics Pty Ltd and Novovet Pty Ltd, dated April 26, 2019</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 2, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Code of Ethics </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.1#</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1213809/000162828019000323/exhibit211form10.htm">Subsidiaries of the Registrant </a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-12G</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.1</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 14, 2019</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit311cert-mark10x.htm">Certification of Chief Executive Officer of Dyadic Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit312cert-ping10x.htm">Certification of Chief Financial Officer of Dyadic Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit321sect1350cert.htm">Certification of Chief Executive Officer of Dyadic Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit322sect1350cert.htm">Certification of Chief </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit322sect1350cert.htm">Financial</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit322sect1350cert.htm"> Officer of Dyadic Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:11.030%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:82.189%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;This filing excludes schedules and similar attachments pursuant to Item 601(b)(2) of Regulation S-K.&#160;A copy of any omitted schedule will be furnished supplementary to the SEC upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">**&#160;Identifies each management contract or compensatory plan or arrangement.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8224;&#160;Portions of the exhibits have been omitted pursuant to a request for confidential treatment.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">#&#160;Previously filed with the SEC.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;The Company elect to satisfy Regulation S-K &#167;229.406(c) by posting its Code of Ethics on its website at www.dyadic.com.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_97"></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:34.795%;"><tr><td style="width:1.0%;"></td><td style="width:26.991%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:69.009%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 16.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form 10-K Summary</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_100"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:30.796%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.027%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:58.177%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DYADIC INTERNATIONAL, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Mark A. Emalfarb</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark A. Emalfarb</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Ping W. Rawson</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ping W. Rawson</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:25.621%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.550%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.829%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Signature</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Date</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Mark A. Emalfarb</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer, Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark A. Emalfarb</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Ping W. Rawson</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ping W. Rawson</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael P. Tarnok</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman, Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael P. Tarnok</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Jack L. Kaye</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jack L. Kaye</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Seth J. Herbst</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Seth J. Herbst, MD</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/Arindam Bose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Arindam Bose, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/Barry C. Buckland</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Barry C. Buckland, Ph.D.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.728%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.072%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_103"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Index to Consolidated Financial Statements</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:90.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.468%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_106">Report of Independent Registered Public Accounting Firm &#160;</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_106">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_106">2</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_109">Consolidated Balance Sheets as of December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_109">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_109">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_115">Consolidated Statements of Operations for the Years Ended December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_115">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_115">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_118">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_118">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_118">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121">Consolidated Statements of Cash Flows for the Years Ended December 31, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121">8</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_121">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_124">Notes to Consolidated Financial Statements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"> &#160;&#160;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_124">F-</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#iec2c361ab60c4fe685fbbfdcc5343b30_124">7</a></span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_106"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;"><img src="dyai-20191231_g2.jpg" alt="dyai-20191231_g2.jpg" style="height:102px;width:684px;"/></div><div style="text-indent:36pt;text-align:center;"><span><br/></span></div><div style="text-indent:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Report of Independent Registered Public Accounting Firm</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the Board of Directors and</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders of Dyadic International, Inc.:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Opinion on the Financial Statements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have audited the accompanying consolidated balance sheets of Dyadic International, Inc. and Subsidiaries (&#8220;Company&#8221;) as of December 31, 2019 and 2018, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.  </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adoption of New Accounting Standards </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for leases as a result of the adoption of Accounting Standards Codification Topic 842, Leases, effective January 1, 2019, under the modified retrospective transition approach.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis for Opinion</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><img src="dyai-20191231_g3.jpg" alt="dyai-20191231_g3.jpg" style="height:36px;width:322px;"/></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have served as the Company&#8217;s auditor since 2008.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clearwater, FL</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March 30, 2020</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_109"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzQtMS0xLTEtMA_16e18d15-38c8-45f6-a9ca-a4438e2b960f">4,823,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzQtMy0xLTEtMA_7c2d1e58-f274-4ccc-b2a4-a747949576c4">2,386,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzUtMS0xLTEtMA_8fd1f701-95be-48eb-9d93-de3aab0cc015">29,399,146</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzUtMy0xLTEtMA_7a11f9d6-5e56-4313-8187-7dd81049cfee">38,816,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzYtMS0xLTEtMA_30e0694e-698e-426d-9446-4f959a3384c6">329,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzYtMy0xLTEtMA_301aea38-96d1-47e4-8df3-da7a4ebc95f1">294,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzctMS0xLTEtMA_80da95d8-376e-4e62-8f8c-d1fc1bc28e23">558,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzctMy0xLTEtMA_2bfe8fce-b436-48d9-bc09-4b1ee87761c3">318,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzgtMS0xLTEtMA_5b932739-71cc-401d-ad72-46d0d7aeaf16">250,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzgtMy0xLTEtMA_00857ee2-49d7-4220-bf65-a145b64c5877">506,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:zerodash" name="dyai:PrepaidResearchandDevelopmentinProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzktMS0xLTEtMA_b9d04f44-5a63-4ec2-b0a4-c5401a3d8d38">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:PrepaidResearchandDevelopmentinProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzktMy0xLTEtMA_70eeafdb-86fe-4c69-9500-279ebb40627c">253,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzEwLTEtMS0xLTA_4017e5d1-0e27-46db-8cba-8c6a551752d8">277,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzEwLTMtMS0xLTA_08244556-ba35-467d-9097-502e72784b3c">172,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzExLTEtMS0xLTA_272d54b8-2e7a-45b6-a684-89b73c1c413c">35,639,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzExLTMtMS0xLTA_a6f6b4e4-3fc2-4ceb-a22e-a7a841841bc4">42,748,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE0LTEtMS0xLTA_18b57ad5-f6c0-473e-8508-7e76fb56a43c">1,511,636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE0LTMtMS0xLTA_9fcaab18-c5d6-4cfb-bea9-dfeb8a6983c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term income tax receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE1LTEtMS0xLTA_affb28e6-fb54-4ed4-98a5-f129b8db0a2b">250,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE1LTMtMS0xLTA_1a3f00b8-7d4d-45d2-af32-c61868edb4bf">500,616</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE3LTEtMS0xLTA_cb577d6b-29b0-4faf-984a-e250a4cc7b07">51,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE3LTMtMS0xLTA_f763ad68-489a-41f9-8016-80cbb79b1341">52,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE4LTEtMS0xLTA_853a2301-c0f8-4eb2-be8f-9f3a75592d2c">37,452,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE4LTMtMS0xLTA_b680d7b9-de74-4c3b-bb58-ee8ce979c25a">43,300,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIyLTEtMS0xLTA_85cab857-83c2-474e-b548-3c9b0ff04b59">943,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIyLTMtMS0xLTA_79107053-050f-4683-b115-7079fc6d6d61">309,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIzLTEtMS0xLTA_fc2e383b-9bdb-45c3-aab0-6b18a72e5ded">566,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIzLTMtMS0xLTA_ddc6dab9-34a3-403e-85f6-f5ff18dd1c53">399,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred research and development obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI0LTEtMS0xLTA_37230636-f37c-4434-a5c7-a23401171dab">78,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI0LTMtMS0xLTA_0808c2b3-ae49-47e6-9cf2-cf5e1501f0d7">141,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI2LTEtMS0xLTA_0191ce85-4572-4bce-8445-857110f9068c">1,588,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI2LTMtMS0xLTA_f53e8461-4b1d-497d-952d-db331db1f8fe">849,638</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI4LTEtMS0xLTA_d79ce8c5-90b7-403f-85a0-fdf2170e4889"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI4LTMtMS0xLTA_034a257d-28b2-42cc-b2b9-6c4d3eb69eca"></ix:nonFraction></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGFmZjIxY2RmNDY0NWQyOTZkMDM0M2M3YzJhNzMzZl82NTk3MDY5NzY2Njk5_b0e78c5e-65e1-428d-9fff-1290fda78853"><ix:nonFraction unitRef="usdPerShare" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGFmZjIxY2RmNDY0NWQyOTZkMDM0M2M3YzJhNzMzZl82NTk3MDY5NzY2Njk5_d2c68de7-cadc-4f27-b126-1cb58093e80f">.0001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Authorized shares - <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzI3_5b9d707e-02c3-4ce3-941e-9bbd80e784c5"><ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzI3_757c08e4-b00d-4839-9ae9-90873c22bdf2">5,000,000</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_40317970-e462-419c-964b-c198d98da220"><ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_98517874-8301-4054-b595-50e9bb5408d7"><ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_a674094f-e64b-47d6-a578-3c3b966ed00a"><ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_b2ac4e57-6c06-4dcf-9b51-40dbb4cc6358">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTEtMS0xLTA_ee65ef9a-9aa6-439d-aad5-b5e47149e694">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTMtMS0xLTA_81ee4579-0220-40ca-ac05-a8b92079ab2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMmZiNDNhMGIwMDY0Y2ZhYjAyYWFhMzJhMTUwYTZlMl82NTk3MDY5NzY2Njk0_3edf8df5-8899-475e-b9e2-25a53779f431"><ix:nonFraction unitRef="usdPerShare" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMmZiNDNhMGIwMDY0Y2ZhYjAyYWFhMzJhMTUwYTZlMl82NTk3MDY5NzY2Njk0_b736d8c0-c0ab-4f00-b306-45ef1739e3c9">.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Authorized shares - <ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODQw_58a1f23e-1aa5-4d4c-aefb-5ec3c25c911b"><ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODQw_7caa78ac-b953-49c4-8729-d87fd517d96f">100,000,000</ix:nonFraction></ix:nonFraction>; issued shares - <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODUy_ad2829c9-fca5-4f5e-8e0d-500e4f8bacd3">39,612,659</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODY0_cc4241a8-fbd9-450e-8eb3-1b787c05c7a6">38,966,988</ix:nonFraction>, outstanding shares - <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODc2_306559e7-a9cb-493b-9d2b-68a0b79eecee">27,359,157</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODg4_1755d1f1-f6f3-48f9-a1c0-10d8d39e72fb">26,713,486</ix:nonFraction> as of December 31, 2019 and 2018, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTEtMS0xLTA_9e2ca88a-fe6a-4ad1-ae5b-740b8a2e386e">39,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTMtMS0xLTA_08dedf56-20d8-4d4a-ae6f-e48bde056ee5">38,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM1LTEtMS0xLTA_4421b511-762d-4610-bd7b-f40af6b17c8c">96,105,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM1LTMtMS0xLTA_d5becf62-d356-4d42-a8f6-489140929e95">94,385,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Treasury stock, shares held at cost -  <ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyNjhmZjdjNGYxMWQ0MTY1OWRjMTk1Y2E5YjY1Y2YxN182NTk3MDY5NzY2NzE5_95952751-7055-4269-8bf0-e7e0abfd0b9d"><ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyNjhmZjdjNGYxMWQ0MTY1OWRjMTk1Y2E5YjY1Y2YxN182NTk3MDY5NzY2NzE5_a7139cbe-e24b-48e3-baa8-1d0d0ca02a79">12,253,502</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTEtMS0xLTA_23e96a28-7f0e-47e9-83ca-09e5703b8c3b">18,929,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTMtMS0xLTA_ebb388a2-d4e4-4308-b523-f8b7b8d3bb96">18,929,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM3LTEtMS0xLTA_9fd604a9-56f4-4565-be77-50edea5b3ca1">41,351,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM3LTMtMS0xLTA_1b235c5e-2f19-41b1-963c-49624394e337">33,043,113</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM4LTEtMS0xLTA_b46c7229-4526-44bb-8268-d6897b82e1b9">35,864,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM4LTMtMS0xLTA_8d12afa6-006c-4488-88ef-aadacf197b4f">42,451,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM5LTEtMS0xLTA_0674b2f3-047e-45ba-a415-ce9f38ba828b">37,452,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM5LTMtMS0xLTA_05f70666-f275-4767-a033-b00f9d26d31d">43,300,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these audited consolidated financial statements</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_115"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzMtMS0xLTEtMA_fdcea574-4926-4023-a8d8-6cb12d88322f">1,681,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzMtMy0xLTEtMA_e523b3b0-7d55-4dc2-9999-8ed16f09c891">1,295,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs of research and development revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzYtMS0xLTEtMA_15968c4c-7551-4d2b-bf90-2f051e848f2a">1,459,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzYtMy0xLTEtMA_5ee59959-bc1a-4682-86e5-8bbdfe6c5e50">1,027,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzgtMS0xLTEtMA_44d28e2a-ccc7-4894-8c7f-5f2a9e6ce28f">3,087,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzgtMy0xLTEtMA_65a5981a-6848-4391-895b-c4ff1ee99087">2,101,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchandDevelopmentExpenseRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzktMS0xLTEtMA_b191bbd2-0dd6-4c55-a40f-af4e6184a8e7">868,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchandDevelopmentExpenseRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzktMy0xLTEtMA_0a88ace6-64d6-4039-b608-2fc9ae2688c6">1,215,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEwLTEtMS0xLTA_88d1e465-5cb4-4d18-9177-8d031f80ba25">5,519,922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEwLTMtMS0xLTA_247a98c4-13b3-4cc5-8c7f-fbd7ccc90bce">4,522,676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency exchange loss (gain), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzExLTEtMS0xLTA_f155b0ec-30a3-430f-91dd-28f30b092b98">27,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzExLTMtMS0xLTA_379707f8-8b0c-4830-993d-f25a0a08b0c4">20,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEyLTEtMS0xLTA_53d19d48-4272-4ce3-b58f-400da0765ef7">10,963,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEyLTMtMS0xLTA_ce4eca07-bde0-451a-abd3-2b0b6c86cfdd">8,887,896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE0LTEtMS0xLTA_11212460-65e9-4c3e-889c-556b45f39d19">9,282,589</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE0LTMtMS0xLTA_427ba1d8-1c67-49e4-a356-9a2aae0116cc">7,592,445</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE4LTEtMS0xLTA_167c4222-9c61-491f-9f8f-3c3878680ca8">984,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE4LTMtMS0xLTA_d64378b4-dcc6-4d8b-8fa0-453d7eb607a6">894,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIxLTEtMS0xLTA_35c77c7b-34f1-4fe9-a83c-c36a9cdd669c">8,297,659</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIxLTMtMS0xLTA_d235da2b-9c27-4302-934f-4093fb04548b">6,697,913</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for (benefit from) income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIzLTEtMS0xLTA_0e41d4fa-db93-4e88-9ab2-22b51b5ed8e5">10,306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIzLTMtMS0xLTA_54c29dbd-2930-4446-ac50-2ff860a070d6">1,006,157</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI1LTEtMS0xLTA_4b33edee-0e9d-4fd0-9c2e-cc7926d80952">8,307,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI1LTMtMS0xLTA_5331a1d8-fdfb-45ea-969d-b4d3979b0321">5,691,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI3LTEtMS0xLTA_0ee3a4cc-5b46-4fc6-a608-36a3d3544917">0.31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI3LTMtMS0xLTA_07278768-0fc8-43c5-8c1c-041e51ec1a63">0.21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI5LTEtMS0xLTA_6ea55298-6dc0-4f81-8c37-728932c9b959">27,003,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI5LTMtMS0xLTA_b9bba129-7daa-4510-8668-e165a37d5532">27,673,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these audited consolidated financial statements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_118"></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:20.773%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.781%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.781%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.781%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.781%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.665%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">paid-in capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Total</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ae10429d4274acc9056aa942fe63b3d_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMS0xLTEtMA_ff72bf97-88f0-4fcc-ad22-6b98fbab93f0">38,936,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ae10429d4274acc9056aa942fe63b3d_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMy0xLTEtMA_1a67708c-c97b-4dc9-9f62-f81738900d69">38,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i3b4de0689e804b61b0bd848a5639b725_I20171231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtNS0xLTEtMA_bb13ae4d-9b78-4d0a-ba06-8abfd409fa09">10,609,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3b4de0689e804b61b0bd848a5639b725_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtNy0xLTEtMA_2c7bd5cc-4415-4e6b-87ea-32ef94f18fa8">16,625,873</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5e158a241d64af0ad4e2292194137b8_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtOS0xLTEtMA_1f4fcc7b-a1d7-443e-8165-920cd7ffc292">93,913,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic3b2621c2b374e3f8ec9d1de2ab3fc52_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMTEtMS0xLTA_502d63cb-126c-432e-815c-62868509193e">27,351,357</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMTMtMS0xLTA_2a61da81-a67d-4c16-94b8-5d2ebf6dbb2e">49,975,264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzUtOS0xLTEtMA_7d8b5df3-8da5-428e-aa05-7223ade41d3e">467,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzUtMTMtMS0xLTA_1e3b1f20-4aaf-4cbf-9e67-7ad5fcddfc01">467,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMS0xLTEtMA_2e4b2c20-86d4-4742-8a60-edd5bb767d93">30,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMy0xLTEtMA_4d15c341-6947-43a6-858a-338635c1ac19">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctOS0xLTEtMA_ff672f77-f27c-44f9-9728-d9cc24ec04da">4,470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMTMtMS0xLTA_1f30456a-4673-4188-bc07-848415c16a67">4,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchases of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktNS0xLTEtMA_77d8d4b0-9054-42d8-8ec9-2da520de839f">1,644,325</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktNy0xLTEtMA_9a36f254-1da7-4091-9c53-5a6968d8f6b5">2,304,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktMTMtMS0xLTA_423a3a11-ff50-4b51-b551-a63e6afe74b1">2,304,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16e3dd249fbe405fbe111f88491fcb2e_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzEzLTExLTEtMS0w_53c96666-c5d2-4297-84cc-8e81538cc7e1">5,691,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzEzLTEzLTEtMS0w_4d182b78-7435-4b23-84fc-763bf3fcc8a3">5,691,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i88159e705b6a4615876d7c6373a3230c_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTEtMS0xLTA_326e16f4-33aa-447a-be87-f2332d4a905a">38,966,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88159e705b6a4615876d7c6373a3230c_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTMtMS0xLTA_dbd0dfcc-176a-441b-bf0b-fcb1c2789d82">38,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTUtMS0xLTA_af782202-a2a8-4ef4-9889-a3e3d1ccc2ed">12,253,502</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTctMS0xLTA_da63f2c0-7ba3-4aa5-a722-dd4e8507bf36">18,929,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecbd8cb44d614d22957374499806e91c_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTktMS0xLTA_d6907e74-c9dc-47de-b81e-e9948bebfcce">94,385,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i65ba3c275bba44c591c298eb6a627117_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTExLTEtMS0w_8f00f78b-fad8-4055-bb7e-74daecec9af0">33,043,113</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTEzLTEtMS0w_4e058f2a-52cb-4d4a-9f07-a18913674a9a">42,451,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE3LTktMS0xLTA_949ff35c-b49d-4ae3-a253-d6aa9b71959a">1,171,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE3LTEzLTEtMS0w_72551999-894a-4cd5-8e3b-e0da1b624b54">1,171,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTEtMS0xLTA_48f13f9f-f961-4f51-b191-183ba0624fc9">645,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTMtMS0xLTA_0df240f6-7fdd-48ed-8e2d-44ecc58f25e5">646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTktMS0xLTA_ece3d72d-b8fe-4bfc-a094-d7528d1b9560">549,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTEzLTEtMS0w_44d3fd80-35dd-4696-81e0-f6dbb6727e48">550,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib5edff09f5d5488092a0f305677b0c0d_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzIzLTExLTEtMS0w_16fe195d-18ba-49d0-9bbc-41fd6c3a3f13">8,307,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzIzLTEzLTEtMS0w_f68a4b62-d26a-43c8-9a4f-fe786a5240ee">8,307,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTEtMS0xLTA_17a9e800-a7e4-4f65-8a7a-e5676477f612">39,612,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTMtMS0xLTA_90a07b31-63fa-45db-b995-0042e2552f43">39,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i08882e216601446183c1dc051db938c0_I20191231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTUtMS0xLTA_4f2abe5e-ce4e-4920-a4a8-ed1e66974b0b">12,253,502</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i08882e216601446183c1dc051db938c0_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTctMS0xLTA_2495db75-4353-4971-9c09-d7aed732f063">18,929,915</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12769ae146f64d729004412e0968967d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTktMS0xLTA_54b686c0-d8b9-4d9e-b04f-c7fff479d2dc">96,105,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8345599e828744799c4f0e1e745684b5_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTExLTEtMS0w_c3f6ae28-2c5d-4be6-a186-ccb2aa545dab">41,351,078</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTEzLTEtMS0w_f38ca00d-0db3-4e9f-811d-c1bf058d8516">35,864,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these audited consolidated financial statements</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_121"></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Net loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzQtMS0xLTEtMA_4018658c-dfcb-4604-9500-38f323ff604c">8,307,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzQtMy0xLTEtMA_1b322641-6fc2-4b9a-9ab0-68e9ce60be20">5,691,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Adjustments to reconcile net loss to net cash used in operating activities: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Stock-based compensation expense </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzYtMS0xLTEtMA_0bf4f7fd-f030-48b3-ad1a-e65f96f38cc9">1,171,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzYtMy0xLTEtMA_d50889b9-ec3e-43cb-934d-6f30add4f257">467,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Amortization of held-to-maturity securities, net </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzctMS0xLTEtMA_6e921891-db3f-4763-89cf-d6c453165e2e">198,208</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzctMy0xLTEtMA_c0ffd104-24db-43de-a37e-8c51792e189f">676,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Foreign currency exchange loss (gain), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzktMS0xLTEtMA_6ac793dd-b5bf-4090-b8c8-9b8baed83eca">27,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzktMy0xLTEtMA_dd605038-8167-4691-b7b9-fc9545448028">20,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Changes in operating assets and liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzExLTEtMS0xLTA_40b0c735-12ff-4367-b0ae-38b4c4a7b7ca">35,471</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzExLTMtMS0xLTA_52c23901-c9f2-4bc3-a6bf-9cfaed01e6f0">195,601</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEyLTEtMS0xLTA_155b7b0d-4723-4d09-8542-b2adf0b8e946">252,772</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEyLTMtMS0xLTA_0679a615-3ee7-4484-85a6-21d437b42134">59,984</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Income tax receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEzLTEtMS0xLTA_b0cd758c-c549-4f96-bf23-2b7a05e66360">506,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEzLTMtMS0xLTA_48f903c3-ae92-4947-83be-e65782efc7e9">1,007,482</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Prepaid research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="dyai:IncreaseDecreaseinPrepaidResearchandDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE0LTEtMS0xLTA_64075fba-8e1b-4237-ac21-4080cb84e51b">253,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="dyai:IncreaseDecreaseinPrepaidResearchandDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE0LTMtMS0xLTA_a71d58eb-43c0-4757-bc42-4833be10ad70">913,013</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE1LTEtMS0xLTA_af90248d-e480-4b3c-a1e8-6575e15333af">105,707</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE1LTMtMS0xLTA_9c272562-891c-45c6-8017-18a2318cb0a9">17,395</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE3LTEtMS0xLTA_87e45281-865b-4555-9aae-fc93178ce28e">657,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE3LTMtMS0xLTA_15723c44-f8b8-4421-948f-fecf654636da">195,755</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE4LTEtMS0xLTA_2aa831b7-42d1-4ab7-98e5-2c664f58fe6e">166,399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE4LTMtMS0xLTA_4977a88b-e4eb-4e12-8b80-3ed313ebac82">251,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Deferred research and development obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE5LTEtMS0xLTA_fc2ab5c4-4b83-4074-aaa0-550d92eefc44">62,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE5LTMtMS0xLTA_5801eed1-8a01-4f06-8b8a-1204bf27d087">141,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Income taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIwLTEtMS0xLTA_ae0e69d0-a4c6-4eff-9d80-a8ae31939fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIwLTMtMS0xLTA_a9fcaae3-6727-42ca-be0a-ed19511feeee">100,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIxLTEtMS0xLTA_f5515310-5ea8-478c-b261-57d508eace02">5,782,892</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIxLTMtMS0xLTA_643a0d7f-d933-46de-8616-d3fc12f3a3f2">4,407,189</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:6pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:6pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Purchases of held-to-maturity investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI0LTEtMS0xLTA_233e54ee-b258-42ec-9645-3d3ad815a90c">47,615,550</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI0LTMtMS0xLTA_bd4bb7c7-9187-44a5-9ca4-4c8b6d4fa8f6">49,734,681</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Proceeds from maturities of investment securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI1LTEtMS0xLTA_47b9bfd0-3a8f-46dc-bd35-5172d8ae15a4">55,323,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI1LTMtMS0xLTA_18b496f1-2a4a-474e-9f1e-e1ebf97ede48">53,063,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Net cash provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI2LTEtMS0xLTA_7a7d0dca-775f-4ca8-bd8f-26e823dd4e05">7,707,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI2LTMtMS0xLTA_82648688-211a-4908-882f-b843dc9c2606">3,328,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Repurchases of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI5LTEtMS0xLTA_75813f02-5c8c-4e2d-b179-07c520b766d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI5LTMtMS0xLTA_ff2a1a93-d1f5-4ca2-a1fc-852c09f89d05">2,304,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Proceeds from exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMwLTEtMS0xLTA_d0860e1e-f3e5-4204-8ba8-06aaab56dca4">550,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMwLTMtMS0xLTA_c7709d65-2836-4e26-abac-66f1f7e879a4">4,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Net cash provided by (used in) financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMxLTEtMS0xLTA_fb1b88b0-988c-4e6e-a61e-41461edea209">550,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMxLTMtMS0xLTA_d5dc87ed-afdf-4edc-bdc8-e63284923da6">2,299,542</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMyLTEtMS0xLTA_9ca08f0c-2ff3-41ae-83d4-74ecbba5d5c8">37,516</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMyLTMtMS0xLTA_735662c5-3b2b-4175-b8c3-e1b7aa0854c5">21,622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Net decrease in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMzLTEtMS0xLTA_7b04c178-6189-47ab-9890-cf42a4196261">2,437,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMzLTMtMS0xLTA_c6af625e-f5ae-4d68-883b-e75f7c103cea">3,400,034</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM0LTEtMS0xLTA_d86e2b53-9dde-4653-972f-a049b55c3eb9">2,386,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM0LTMtMS0xLTA_1c272939-abb2-4afa-9b2f-6e04f26b6f10">5,786,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM1LTEtMS0xLTA_d6b70b9e-0065-4b0b-9f02-91ce61098323">4,823,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM1LTMtMS0xLTA_09a86570-88f4-4cf7-bdaa-ae942bf182c6">2,386,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Supplemental cash flow information</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash received from income tax refund</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM4LTEtMS0xLTA_aa8b3e6b-8552-4d79-b882-74b63b0a00bc">506,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM4LTMtMS0xLTA_47e47624-597f-4e35-b19c-5b46935e42ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these audited consolidated financial statements</span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_124"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Consolidated Financial Statements</span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_127"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 1:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzM_fd120f8f-9c9d-4df8-89de-4ff751e71c7f" continuedAt="i143c397525dc46c0bc62fb9cd8145489" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i143c397525dc46c0bc62fb9cd8145489" continuedAt="i70a26b038a4a4edfa5ddbb23cb7d8dc0"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;,or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and currently <ix:nonFraction unitRef="segment" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:NumberOfResearchOrganizationPerformingServiceUnderContract" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NTIwMjM_46f8a39f-10c1-495c-a369-00a73c63793e">two</ix:nonFraction> research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(formerly </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $<ix:nonFraction unitRef="usd" contextRef="i6c8e876d3f1e4b23851e168d3e26723c_D20151231-20151231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzExMjM_6664a21a-66c2-455e-bb23-5cc0cdd5a197">75</ix:nonFraction> million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;. Prior to the Company&#8217;s uplisting to the NASDAQ, the Company&#8217;s common stock traded on the OTCQX market.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODUx_05505847-02b3-4123-a114-40bc221c8e7b" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in <ix:nonFraction unitRef="segment" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDUzOTI_09423e72-bcd3-43d2-b838-ea92814f6681">one</ix:nonFraction> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQw_549328eb-d39a-4fda-9673-83a02ea0004c" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i70a26b038a4a4edfa5ddbb23cb7d8dc0" continuedAt="i9f34e6a91b3343a7b9aef2f8c1d3c96d"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ0_bbfa1433-4180-40b6-a95b-0366050f0312" continuedAt="i3c2ab1e9d3804be7a8aad6abd434b9d4" escape="true">Concentrations</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3c2ab1e9d3804be7a8aad6abd434b9d4">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company&#8217;s revenue was generated from <ix:nonFraction unitRef="customer" contextRef="i5de8574c1d5e40d3b0ee4417bbf0e3d9_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:ConcentrationRiskNumberofCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2NzM_8a57746e-a8d1-4578-bb95-4922286f9f8d">ten</ix:nonFraction> and <ix:nonFraction unitRef="customer" contextRef="i33feba3cff3d453ab0847ab48f7a65a6_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:ConcentrationRiskNumberofCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2Nzc_56727ec2-9e2a-465a-a888-8e80763ed3a3">six</ix:nonFraction> customers, respectively. At December&#160;31, 2019 and 2018, the Company&#8217;s account receivable was from <ix:nonFraction unitRef="customer" contextRef="i4937506a337c49d99f6df9684958c7bb_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:ConcentrationRiskNumberofCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2OTg_e4f9b4d9-92cb-4fb0-96a8-4ea1a8d885ef">five</ix:nonFraction> and <ix:nonFraction unitRef="customer" contextRef="i7acc47f3ac6c42bfafac0b07049ab969_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:ConcentrationRiskNumberofCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3MDE_bf6ad90a-917a-43e0-ac22-198b55557956">four</ix:nonFraction> customers, respectively. The loss of business from one or a combination of the Company&#8217;s customers could adversely affect its operations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. As of and for the year ended December&#160;31, 2019, the Company had <ix:nonFraction unitRef="customer" contextRef="i539512523cd84b16a4f3e7301273b71d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:ConcentrationRiskNumberofCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDE2OTA_e41d6860-78ac-4eb2-8ad6-61dc78fe26db">four</ix:nonFraction> customers outside of the United Sates (i.e. European and Indian customers) that accounted for approximately <ix:nonFraction unitRef="number" contextRef="i853d7cb039e94bbc88573c26b6d2967e_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3NDc_783a2b17-4908-45b5-a839-6d368da47cd3">71.5</ix:nonFraction>% or $<ix:nonFraction unitRef="usd" contextRef="id9853caf57ff412fbe8e87c65c083f8a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NTQ_399b573c-46fa-41df-9343-9d77dd02fcdf">1,202,000</ix:nonFraction> of total revenue and approximately <ix:nonFraction unitRef="number" contextRef="iac1ccd95b9f9482f99ac9a39b030913d_D20191001-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3ODA_f1c26b33-9f2e-4032-9eab-dcb19b86b553">69.5</ix:nonFraction>% or $<ix:nonFraction unitRef="usd" contextRef="id5d4c32edf3a47d5ace56c907b84788c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NTk_e1ce5393-0a3e-4986-80fb-d0cc623b3ed0">388,000</ix:nonFraction> of accounts receivable. As of and for the year ended December&#160;31, 2018, the Company only had one customer outside of the United States (i.e., European customer) that accounted for approximately <ix:nonFraction unitRef="number" contextRef="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI4MzI_6eae2f61-1024-4900-9b8d-522557767aa4">21.7</ix:nonFraction>% or $<ix:nonFraction unitRef="usd" contextRef="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NjQ_7f812eb3-21d7-4d71-8629-2aa2dc0fc08f">281,000</ix:nonFraction> of total revenue and <ix:nonFraction unitRef="number" contextRef="icc3379be565248d6aae983a9754e0b90_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI5Nzg_1dbbd28b-300b-4c19-a271-3b05f645d02e">100</ix:nonFraction>% of the Company&#8217;s accounts receivable was from the United States. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a few contract research organizations (&#8220;CROs&#8221;) to conduct its research projects. For the years ended December&#160;31, 2019 and 2018, one CRO accounted for approximately <ix:nonFraction unitRef="number" contextRef="i6c18e0290e174928ae53f25f7ad4d742_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY4OTU_59fb4b11-91ea-4d1d-83bd-10c6e3a28b22">86.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i794a21883a2f49e885e5e5758820ee30_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MDI_77869a5b-de5e-4f33-af30-ea2e16686875">88.4</ix:nonFraction>% of total research services we purchased, respectively. At December&#160;31, 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="i716bbd9d30fd4e1fb46f0dee71737323_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MTY_8ef8f6ab-df6a-4904-a1ec-0f8ae7d9c0cf">706,000</ix:nonFraction> or <ix:nonFraction unitRef="number" contextRef="i199ba6975f9b4d35a19f028f6e3ba9d2_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MDk_b4688d71-46d3-4aad-a0d2-6158bffed8d0">74.9</ix:nonFraction>% of accounts payable was related to this CRO. At December&#160;31, 2018, approximately $<ix:nonFraction unitRef="usd" contextRef="i46c48aca2c334edbae2d056c94cf1c1f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MjY_0ad1cbd5-ce86-487b-b442-9ec0faef4635">237,000</ix:nonFraction> or <ix:nonFraction unitRef="number" contextRef="i8bdff80401db4bfd883cc689a5f6c3ca_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MzY_e1aee11a-2e79-4131-863b-243d434cc544">76.8</ix:nonFraction>% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company&#8217;s CROs could adversely affect its operations. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM2_fa792225-82d9-4b5a-8dc7-cc45839a0cff" continuedAt="id2fa0b2b710e47c0b0938bb77fc69114" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id2fa0b2b710e47c0b0938bb77fc69114">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</ix:continuation> </span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM3_766e5811-79a8-4364-b7dd-0bf2c3490172" continuedAt="i4adfdff941fc4cbe85d3825b5a3ec8c7" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4adfdff941fc4cbe85d3825b5a3ec8c7">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheet.</ix:continuation> As of December&#160;31, 2019 and 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of December&#160;31, 2019 and 2018.</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM4_14c0c7d9-429e-4f45-9160-c9d4ad81cae9" continuedAt="i179b2da9e6764d66af650ca080e10ec0" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i179b2da9e6764d66af650ca080e10ec0">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzg3OTA_72f03e00-28fc-4f69-a33b-7f11ea4ae587"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzg3OTA_b1a72570-5c03-4bba-8c89-305f1c81a9c5">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts as of December&#160;31, 2019 and 2018.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i9f34e6a91b3343a7b9aef2f8c1d3c96d" continuedAt="i9163320f3cf040f09eec6e4d6fbc6fc7"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODUz_b3fe63cf-89d9-4474-9f9a-342f87055e4c" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i948cb60e266243f196d1d44762dba391_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzItMS0xLTEtMA_a59d1b31-f0b7-4cc0-9c69-bc57307014d7">432,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia68ec379e62f42fd82d9df05be6cc9e3_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzItMy0xLTEtMA_c35fa197-919b-4432-9073-90af4ade9a95">193,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie20de3bbc09b47a58d79e76de605acff_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzMtMS0xLTEtMA_158cac8e-d79e-4496-a4e9-c6a69d4f280e">125,984</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i003f72c2db6a4420aae1b41052590348_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzMtMy0xLTEtMA_4259483f-2ce0-4cd1-aeb7-a7a8b34bcd68">125,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzQtMS0xLTEtMA_fa5a32a1-6053-4dbe-b00d-31336240bb17">558,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzQtMy0xLTEtMA_f28cd958-6194-49a7-854d-9d68533e7c28">318,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU0_bd50b003-6ca3-40b3-a823-00c0ad1a68b9" escape="true"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzItMS0xLTEtMA_431fb574-7ab8-4537-a262-156c6e800384">173,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzItMy0xLTEtMA_2bd79042-0332-42b7-bfb4-983ffcadefc3">91,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzMtMS0xLTEtMA_4bc1dbb6-7de1-4ad3-a27d-bc0042171e5b">101,221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzMtMy0xLTEtMA_53d1fc52-7c0c-42c0-9da3-d8be84463bdb">77,249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzQtMS0xLTEtMA_406023b1-5aed-4388-844a-bfbd4ce3e76e">2,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzQtMy0xLTEtMA_504f0b9d-ff67-4292-bbf1-fc140f9e6afa">3,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzUtMS0xLTEtMA_d5c24b12-82ca-4478-9649-7dcae1b40565">277,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzUtMy0xLTEtMA_e282e4ab-1a30-43d1-8b33-682967810e8a">172,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzE_b29c2b84-82a6-4e61-892a-79e3540b1f77" continuedAt="if0a5ee75d68e407699668e1b89ecc04e" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investment</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company&#8217;s investments recorded under the equity method of accounting. </span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if0a5ee75d68e407699668e1b89ecc04e">Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.</ix:continuation> </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU1_e8f26551-4929-475a-8e0e-eb038161e103" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzItMS0xLTEtMA_42e5a926-103c-4996-8219-61017b967b49">766,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentInProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzItMy0xLTEtMA_965d599c-cb28-4f9e-8c1f-8d8e22852443">240,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzMtMS0xLTEtMA_2f7cbdc7-649d-48e2-9195-0e3c531da981">26,994</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzMtMy0xLTEtMA_7b31995c-1718-4d35-aa1c-e22733cf9ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzQtMS0xLTEtMA_27f09637-d49f-4f9d-91fb-814f6b5d3933">150,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzQtMy0xLTEtMA_b06cce63-0faa-4f75-8ef3-f32945dd5c64">68,996</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzUtMS0xLTEtMA_c4a6fd74-f9dd-453b-b02c-4e1097c11155">943,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzUtMy0xLTEtMA_992ed502-f640-47f6-b5ab-6196f9913769">309,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQx_32f008df-b301-473a-9210-309dbbd3a0b4" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzItMS0xLTEtMA_825a30af-f1c0-4a21-b003-c469fec4f921">474,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzItMy0xLTEtMA_14453f64-b458-4b99-8397-362f4b951d83">268,287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:AccruedResearchandDevelopmentinProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzMtMS0xLTEtMA_3ed31113-8cec-4e23-ba89-bdb2d41f2ea9">69,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:AccruedResearchandDevelopmentinProcessCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzMtMy0xLTEtMA_b20f0108-aee2-4561-a1d3-399220f73519">49,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzQtMS0xLTEtMA_67565263-b223-434a-9129-4c1722eb5d70">21,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzQtMy0xLTEtMA_df1eeefa-d0c3-47df-bb07-b3484e70871a">81,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzUtMS0xLTEtMA_abedb12d-a6f5-4d31-97f6-dd93dcf5d169">566,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzUtMy0xLTEtMA_9b7a26e2-d0c6-48e9-9b45-6a847416fd55">399,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i9163320f3cf040f09eec6e4d6fbc6fc7" continuedAt="ifc493eb26e624434a1b28cce80e54eba"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzI_b686a236-d0e2-4d07-a4df-2103e9932922" continuedAt="i55b4378bf41c4f8dbbbaa187671e6fc1" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#8220;Topic 606&#8221;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input method, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="ifc493eb26e624434a1b28cce80e54eba" continuedAt="ia5e2e2bfd46e4c978fa597da9cfb625b"><ix:continuation id="i55b4378bf41c4f8dbbbaa187671e6fc1"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ1_4d23b17c-7f07-4d09-9a4c-19001778ab5e" continuedAt="ie601efeef3464adba61bca1aaa6d2a6e" escape="true">Research and Development Costs </ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie601efeef3464adba61bca1aaa6d2a6e">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="dyai:ScheduleofResearchandDevelopmentCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ5_fd02828c-545b-4a64-a744-8d37b24f8133" continuedAt="i4a71a4360f6a4e898233745e608db1b6" escape="true">Research and development costs, including related party, during the years ended December&#160;31, 2019 and 2018 were as follows: </ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:6pt;"><ix:continuation id="i4a71a4360f6a4e898233745e608db1b6"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.571%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzItMS0xLTEtMA_60813269-87ce-4373-a28a-ed5e24a92fa1">2,578,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseOutsideContractedServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzItMy0xLTEtMA_2b1cfda2-df30-4229-8f2b-77bf6b85dce3">1,637,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzMtMS0xLTEtMA_00948f28-8339-40a0-a3aa-f73701967220">868,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzMtMy0xLTEtMA_f709ea0a-01b6-4e04-ab3a-adccd72719b1">1,215,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzQtMS0xLTEtMA_bbf08536-ae93-4dc4-b199-4271d64edb99">423,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzQtMy0xLTEtMA_d6689b64-3715-4e31-a422-ed39ebdb4547">376,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzUtMS0xLTEtMA_45c98ec0-00ce-43cf-b6a6-baab138b3928">85,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzUtMy0xLTEtMA_f9675c1f-2cc2-41d1-bafc-212e02cd8427">87,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzYtMS0xLTEtMA_03a0d3b7-1f78-4b2d-a761-781cca806d85">3,956,317</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzYtMy0xLTEtMA_0ba09246-e579-426b-a778-a65a2b0d8b05">3,317,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU3_d4461628-3316-41f9-b230-4e37d9488f4e" continuedAt="i736fdf211ef3465d8673e08c3d931bf4" escape="true">Foreign Currency Transaction Gain or Loss</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i736fdf211ef3465d8673e08c3d931bf4">The Company uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</ix:continuation> </span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQy_ca6435b5-d6bc-4262-b3fb-ea95da351cd2" continuedAt="i433af656de0a4c7ea6f673aaa40e600c" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="ia5e2e2bfd46e4c978fa597da9cfb625b" continuedAt="i124b34bc846a4b3dbfd5145ed445ad80"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i433af656de0a4c7ea6f673aaa40e600c">use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#8217;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</ix:continuation></span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQz_c07910da-5819-4cc4-85c4-af0ea2f1ee88" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014. The United States Internal Revenue Service (the &#8220;IRS&#8221;) has completed its review of the Company&#8217;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 for further discussion on the IRS examination of the 2016 tax return.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ2_8c6a0cc7-28fa-4a0e-a6a1-d99309e70337" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ3_93a13587-bde3-4e0f-a8a6-287b0ceabc49" continuedAt="icea53c9e51ed480bbaad6a3e746a5f55" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. </span></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="icea53c9e51ed480bbaad6a3e746a5f55">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.</ix:continuation> </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i124b34bc846a4b3dbfd5145ed445ad80" continuedAt="i45c8beccb5a642e0ab7f16e6c0524598"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ4_d5c7f5a4-d1b1-4924-a3dd-867d2743c1aa" continuedAt="i86ab2bd2478a48c5a49e5590a300ab27" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i86ab2bd2478a48c5a49e5590a300ab27">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the effect of the potential exercise of options to purchase <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzIxOTkwMjMyOTgwMzQ_74a978d9-aad9-4d4e-b649-cf5536f1a0cb">3,860,390</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzIxOTkwMjMyOTgwMzc_912d683d-4051-4bfb-b754-263ab25a2119">3,552,890</ix:nonFraction> shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzA_f2235335-3f75-41be-9042-1b1024e1c69d" continuedAt="i01558362bc6646e8b837edf56a9cd26d" escape="true"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2019 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve (12) months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures, as the Company&#8217;s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i45c8beccb5a642e0ab7f16e6c0524598"><ix:continuation id="i01558362bc6646e8b837edf56a9cd26d">In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</ix:continuation></ix:continuation></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_133"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 2:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE5MDM_6d105c0b-5201-4ae3-b4af-53406ac71de6" continuedAt="i00c7d73705464d61b28367115a5a8c66" escape="true">Cash, Cash Equivalent, and Investments </ix:nonNumeric></span></div><ix:continuation id="i00c7d73705464d61b28367115a5a8c66" continuedAt="ie34f561817f048bc9294f2d5e7e703d2"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE5MDQ_8082135e-5451-47d8-b018-53d9cc36e03b" continuedAt="ic04ba1a8d8164b4aa8f7659b344eebf3" escape="true">The following table shows the Company&#8217;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2019 and 2018:</ix:nonNumeric></span></div><ix:continuation id="ic04ba1a8d8164b4aa8f7659b344eebf3" continuedAt="ib640696fdbe94c3bae50d7fa9ac7f420"><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:33.871%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.884%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.469%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.055%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.475%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaca615a626c84646a9e3cd9ee505f251_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzUtMy0xLTEtMA_3d268abb-8069-480b-b7e6-c683373ca83f">1,010,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaca615a626c84646a9e3cd9ee505f251_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzUtOS0xLTEtMA_a25fb0a9-e1ad-48b7-8262-139993419112">1,010,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9923848bb21f4a459e82cf269761b053_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzYtMy0xLTEtMA_21505599-d075-4d91-b29d-4c927c6775b5">3,813,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9923848bb21f4a459e82cf269761b053_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzYtOS0xLTEtMA_70c8c0ce-7c7f-4e8e-ac23-470a14ec6920">3,813,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzctMy0xLTEtMA_778bb134-4ce6-4fdd-be4b-ce2f58c5a434">4,823,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzctOS0xLTEtMA_bebca66d-c85d-4375-aa32-103f3e49e86a">4,823,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityFairValueCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktMy0xLTEtMA_12e9a7de-594d-462a-bc7a-04b480bc35e8">29,387,053</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktNS0xLTEtMA_0d3a2a86-caf6-4211-a984-7f8cef527abd">5,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktNy0xLTEtMA_5fca3412-fa1f-4075-9dc6-3457e6d4e722">17,991</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktOS0xLTEtMA_78da03e8-efea-4a3a-a0d3-77915e036805">29,399,146</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityFairValueNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTMtMS0xLTA_3a3e9dee-3c16-45c1-ac80-e3661516a2c4">1,528,190</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTUtMS0xLTA_31dc7296-97cd-40e1-8c72-289e20ac2056">16,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:zerodash" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTctMS0xLTA_f5f77c80-c818-4cfc-a5f4-3644297a8800">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTktMS0xLTA_0cb0ef3b-47da-4c25-b4c9-0e9a023e4635">1,511,636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTMtMS0xLTA_fa68e3e5-57f2-41d5-9565-defaeb9c7d2e">35,738,787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTUtMS0xLTA_e16eb7b5-ab63-46d0-9e23-bd5fdbd9a24a">22,452</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTctMS0xLTA_dc164683-e01f-48d0-bbea-d06811fa94eb">17,991</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:InvestmentsandCashAmortizedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTktMS0xLTA_e077a4b9-ba20-4ee3-8b27-991c7b86b1ff">35,734,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:33.871%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.442%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.884%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.469%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.055%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.475%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzUtMy0xLTEtMA_343f7ed1-0988-4db8-83bd-3f46def3c3c2">1,048,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzUtOS0xLTEtMA_0eb5e3f2-230f-4a66-957b-65b8097806d5">1,048,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzYtMy0xLTEtMA_bc878b2d-3cde-4598-90cc-1dcbc22cce37">1,338,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzYtOS0xLTEtMA_e2b3e955-b23e-485c-ad3c-d5214da783d1">1,338,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzctMy0xLTEtMA_1bdeaaca-9ca4-4ce6-9fba-45ff692c0d81">2,386,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzctOS0xLTEtMA_c2d748fc-d583-453a-a0e9-1b5632e13659">2,386,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityFairValueCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktMy0xLTEtMA_296d73e7-de7b-463a-b224-9754f2cb50c0">38,731,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231" decimals="0" format="ixt:zerodash" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktNS0xLTEtMA_8adca827-0a53-4713-8726-15417d684da5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktNy0xLTEtMA_387f4cde-05c9-4490-a49c-931f351ea6db">85,321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktOS0xLTEtMA_ab8a9c64-e67a-4c52-8e1c-1332ce581d06">38,816,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTMtMS0xLTA_40a81bf4-0afb-41e0-a67d-10a7bdbb7d9a">41,117,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTUtMS0xLTA_fc7efc42-2cc0-44ff-bb7c-bf861c74fedb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTctMS0xLTA_f43c6ad4-d6ad-4f2a-8419-86b61c7b5d6f">85,321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:InvestmentsandCashAmortizedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTktMS0xLTA_c52e687c-4ee5-41e1-9926-5e0fd5478294">41,202,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature longer than 12 months from the applicable reporting date.</span></div></ix:continuation><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib640696fdbe94c3bae50d7fa9ac7f420">(4) The premium paid to purchase held-to-maturity investment securities was $<ix:nonFraction unitRef="usd" contextRef="ic730d04e8b0b4df4a4a422154c714345_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE2NDkyNjc0NDM1ODI_4f8f1779-23d4-44dd-b837-11ba55154906">233,550</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i530ce590a54f4e1294cb6cb83802e421_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE2NDkyNjc0NDM1Nzg_72221db4-07fe-4bf9-bff4-3f07b6651995">378,681</ix:nonFraction> for the years ended December&#160;31, 2019 and 2018, respectively.</ix:continuation> </span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie34f561817f048bc9294f2d5e7e703d2">The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of December&#160;31, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_136"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 3:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzQ0OTI_2a4d34b5-0780-407c-bc7f-cdac1d5e76ff" continuedAt="i1c9bb4af8a7b482389c20ede4531209e" escape="true">Research and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i1c9bb4af8a7b482389c20ede4531209e" continuedAt="i5e8e158e31a94d09aa36b5ebaa81e24b"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BDI </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA, the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;). </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTEyODE_d817c484-c349-4120-9e27-b9d41a8a4fa5">two</span>-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the BDI transaction, the Company paid EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="ia1d98d4756224c909d6e5d6c8a30310a_D20170630-20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3Mzc_f57f5c05-ddcd-426d-9239-d747604bd384">1</ix:nonFraction> million (the &#8220;RSA Initial Payment&#8221;) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a <ix:nonFraction unitRef="number" contextRef="i7e634d7aaec046188c2ed66d34824a19_D20170630-20170630" decimals="3" name="dyai:CollaborativeArrangementEquityInterestAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDI_ed1b1691-0acc-41e7-984b-1d1f552d2842">16.1</ix:nonFraction>% equity interest in BDI Holdings and a <ix:nonFraction unitRef="number" contextRef="i4169bf7db9fb46a59c822fcd3015e062_D20170630-20170630" decimals="3" name="dyai:CollaborativeArrangementEquityInterestAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDU_c9fcef18-3c27-4d31-96e8-f399b3f4e686">3.3</ix:nonFraction>% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630" decimals="-3" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDg_889875ab-caf8-49e3-b019-2dd2db4d4e28">936,000</ix:nonFraction> over <ix:nonNumeric contextRef="ic4223a15c84f40d98227848c11916461_D20170630-20170630" format="ixt-sec:durwordsen" name="dyai:CollaborativeArrangementDurationOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NTE_229e040c-6c8c-4966-8c4d-436d9c53f727">two years</ix:nonNumeric> in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between <ix:nonFraction unitRef="number" contextRef="ifa774688910149949c16b496a421bb9a_D20170630-20170630" decimals="2" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMTc_2329073e-fa8b-4ed3-a841-ec174eef373e">50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5b5457c0415a45cb96e692134cbf8975_D20170630-20170630" decimals="2" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjA_b530c2a8-ba27-4471-9d10-d2421bbf2845">75</ix:nonFraction>% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMDk_cdb2bc5a-0d98-464a-b4a1-e47a46db5ac3">1</ix:nonFraction>&#160;million for a <ix:nonFraction unitRef="number" contextRef="i7c228ac1d4cd4e89b60866a524343d7d_D20170630-20170630" decimals="2" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjM_3b95feb9-22b0-4649-b978-51604dc5f6ec">50</ix:nonFraction>% share and EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjk_fc97f13d-e542-420b-886c-f86d6142d766">8</ix:nonFraction>&#160;million for a <ix:nonFraction unitRef="number" contextRef="i840867cee002461092e9bb1d28ebe22d_D20170630-20170630" decimals="2" name="dyai:CollaborativeArrangementRevenueSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjY_332bb06b-3274-47e3-82cd-b6234e205b87">75</ix:nonFraction>% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i79c8a3fd19f84be7bcf4484ebc536193_I20170630" decimals="-5" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk0OTg_80a9648d-97f4-4590-8722-4f2df9c04011">1.5</ix:nonFraction>&#160;million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $<ix:nonFraction unitRef="usd" contextRef="ia10445b9bcd248c392f6a26e44521761_I20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk1MjI_861e843b-9f66-4601-a000-23342605c085">1</ix:nonFraction>&#160;million (the &#8220;SFA Commitment&#8221;) in contract research services specified by Dyadic over <ix:nonNumeric contextRef="i355318ed17ba4b0ba24061da681d9010_D20170630-20170630" format="ixt-sec:durwordsen" name="dyai:CollaborativeArrangementDurationOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk1NDU_5084c5cd-0f04-4217-9a4b-e84229d5159c">two years</ix:nonNumeric> since the closing of the BDI transaction. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has concluded that BDI is not a Variable Interest Entity (&#8220;VIE&#8221;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company&#8217;s consolidated financial results. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $<ix:nonFraction unitRef="usd" contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630" decimals="-5" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODA4NTQ_b74529f2-ec8d-4f12-ab10-493fd5648141">1.1</ix:nonFraction>&#160;million (EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODA4OTA_dc61bf18-8052-48ab-8e29-1b7194fde870">1</ix:nonFraction>&#160;million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $<ix:nonFraction unitRef="usd" contextRef="ia10445b9bcd248c392f6a26e44521761_I20170630" decimals="-6" format="ixt:numdotdecimal" name="dyai:CollaborativeArrangementOutstandingCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTQ0NTU_5ee35bf4-14b0-4a53-bcb9-fe008d3a42ad">1</ix:nonFraction> million paid by Dyadic was expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. As of December&#160;31, 2019, Dyadic has fulfilled its SFA commitment, and all research projects under the SFA were completed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were <ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="dyai:PrepaidResearchandDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0Xzc2OTY1ODE0MjI1OTU_3d7c1355-85be-494d-b3ad-8293a0473f52">none</ix:nonFraction> and approximately $<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="-5" format="ixt:numdotdecimal" name="dyai:PrepaidResearchandDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ2MjA_0420f51b-6854-49dd-b57b-b08334f27190">0.3</ix:nonFraction>&#160;million, respectively. For the year ended December&#160;31, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="dyai:ResearchandDevelopmentExpenseRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ3ODA_684d9f6e-3e30-4210-a4cf-ff877304ed6f">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="dyai:ResearchandDevelopmentExpenseRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ4MTI_e4550d41-15a7-462e-a975-ad729b2a6948">1.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i5e8e158e31a94d09aa36b5ebaa81e24b" continuedAt="if939df1e191245319d960d3c4a7fc089"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novovet and Luina Bio Sub-License </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2019, the Company entered into a sub-license agreement (the &#8220;Luina Bio Sub-License Agreement&#8221;) with Luina Bio Pty Ltd. (&#8220;Luina Bio&#8221;) and Novovet Pty Ltd (&#8220;Novovet&#8221;). Under the terms of the Luina Bio Sub-License Agreement, the Company granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary C1 gene expression platform&#160;for the exclusive and sole purpose of commercializing&#160;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a <ix:nonFraction unitRef="number" contextRef="i491f41e970764c248af615c0fd65548e_I20190426" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTYzMDQ_5415173d-e20f-47e2-a9b1-ea60f5268e60">20</ix:nonFraction>% equity interest in Novovet (&#8220;Novovet Up-Front Consideration&#8221;) in accordance with the terms of Novovet&#8217;s Shareholder Agreement (&#8220;Shareholders Agreement&#8221;), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#8217;s proprietary C1 gene expression platform. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a <ix:nonFraction unitRef="number" contextRef="i491f41e970764c248af615c0fd65548e_I20190426" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTc2NDU_2ef4c56c-3227-4e5e-860c-4d81aef706be">20</ix:nonFraction>% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alphazyme Sub-License </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2019, the Company entered into a sub-license agreement (the &#8220;Alphazyme Sub-License Agreement&#8221;) with Alphazyme, LLC (&#8220;Alphazyme&#8221;). Under the terms of the Alphazyme Sub-License Agreement, the Company granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary C1 gene expression platform&#160;for the purpose of commercializing&#160;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a&#160;<ix:nonFraction unitRef="number" contextRef="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTk1MjE_afd08974-210a-45cc-909c-21dbaf6bf20c">7.5</ix:nonFraction>%&#160;ownership interest in&#160;Alphazyme&#160;(&#8220;Alphazyme Up-Front Consideration&#8221;) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic&#8217;s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of&#160;<ix:nonNumeric contextRef="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505" format="ixt-sec:durmonth" name="dyai:CollaborativeArrangementExclusivityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTk4NjM_a28cbce2-4e34-4509-b6d0-9083fede2953">18</ix:nonNumeric>&#160;months (&#8220;Exclusivity Period&#8221;) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (<ix:nonNumeric contextRef="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505" format="ixt-sec:durmonth" name="dyai:CollaborativeArrangementOptionToExtendExclusivityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjAxODE_a41f6449-1953-4d2b-8e7d-854c739be4ee">12</ix:nonNumeric>) months in return for an additional&#160;<ix:nonFraction unitRef="number" contextRef="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505" decimals="3" name="dyai:CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjAyMjA_97f3c5de-cb68-4d68-ac53-a4f0a4253314">2.5</ix:nonFraction>%&#160;ownership interest in Alphazyme.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at December&#160;31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="if939df1e191245319d960d3c4a7fc089" continuedAt="id94984632f8c4d38a5574ac8c5b55556"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Commercialization Collaboration with Serum Institute of India</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#8220;Serum&#8221;). Under the terms of this collaboration, Serum anticipates applying Dyadic&#8217;s C1 technology to express up to twelve (<ix:nonFraction unitRef="antibody_and_vaccine" contextRef="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507" decimals="INF" name="dyai:CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjE2Njg_fae5b7f4-e196-4faf-8c91-79d683c1643e">12</ix:nonFraction>) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (<ix:nonFraction unitRef="protein" contextRef="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507" decimals="INF" name="dyai:CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjE5NDI_7412e460-1487-4370-8b24-04cb2f60168a">12</ix:nonFraction>) proteins in return for certain research funding, milestone payments and royalties for <ix:nonNumeric contextRef="if8a37c03b9a24f5f805e876d96fb8eca_D20190507-20190507" format="ixt-sec:duryear" name="dyai:CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjIwMzI_c1f9f2c1-9f3d-4513-be40-5a2d1fcf0826">15</ix:nonNumeric> years from the date of the first commercial sale.</span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id94984632f8c4d38a5574ac8c5b55556">For the year ended December&#160;31, 2019, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id144ebaa808a4539bac88f64f1ae1856_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="dyai:RevenueFromCollaborativeArrangementRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODIwNDA_2b741f4d-aaa6-4171-bd29-e5310f6f5673">118,000</ix:nonFraction> in research and development revenue from Serum.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_139"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 4:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjQ_bb43aa4f-04eb-4274-9bc0-714c18ad4f1d" continuedAt="ie61fc6a6b9ea409fa818c77307b19c56" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ie61fc6a6b9ea409fa818c77307b19c56" continuedAt="i02398a19f2c04cf594e1792d84638bfc"><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) was enacted on December 22, 2017 and become effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (&#8220;AMT&#8221;). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzIxOTkwMjMyNjIxNjE_0e11b0df-1579-4478-9dcb-9c155dc7ab8b">1,001,233</ix:nonFraction>. As of December&#160;31, 2019, we have received 50% or approximately $<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzIxOTkwMjMyNjIxNzc_f4daf02e-294b-470a-9d65-4d8854e60a66">0.5</ix:nonFraction> million refund for tax year 2018 and expect to receive the remaining 50% over tax years 2019 through 2021.</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjU_63dd83e4-fd0b-4073-bb04-d91faa2d052b" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of loss before income taxes are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.354%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzItMS0xLTEtMA_d6fc6264-7eb8-4e2a-a431-81da3e398e3c">8,274,712</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzItMy0xLTEtMA_50a2a2dd-bc58-44c0-874f-5a17bbd47545">6,622,695</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzMtMS0xLTEtMA_f5b5cbe3-64a1-4734-9af3-ad1df5d582a5">22,947</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzMtMy0xLTEtMA_1d7293a9-9d73-4c60-af9b-daf388dd7939">75,218</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total loss before provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzQtMS0xLTEtMA_564bf929-3b90-45f7-8f77-2a1068fbf2f9">8,297,659</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzQtMy0xLTEtMA_58314bb9-f836-4301-82d7-e0445c04cdeb">6,697,913</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjY_567e7e19-c70c-401b-804f-a83d44895259" escape="true"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of our (benefit) provision for income tax for the years ended December&#160;31, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:67.128%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.833%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.921%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current and deferred tax (benefit) expense </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzMtMS0xLTEtMA_b91593ad-c660-4041-a352-a2866568110d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzMtMy0xLTEtMA_ac1b2935-7793-4f0e-ab1e-795a0d7ff9a4">1,001,233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzQtMS0xLTEtMA_d779eb05-a7af-4673-b338-dc7ef25eca1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzQtMy0xLTEtMA_4829f91f-4a99-4713-a294-0070feef40a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzUtMS0xLTEtMA_d7ad54a2-b508-4745-a1c8-372967cd0ae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzUtMy0xLTEtMA_36cab6f7-62f7-4517-9ecb-7f8f13304b29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzYtMS0xLTEtMA_bfa5293d-226c-4eaa-844f-ba72edf44658">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzYtMy0xLTEtMA_1914c1c6-a9ba-450e-89a7-c665f937529a">1,001,233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to deferred income tax resulting to permanent differences, state taxes and a change in the deferred tax valuation allowance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5Njc_50825ad3-d8a0-405f-855d-546f5d995293" continuedAt="if200836d14e44571b97aeabeca3db75f" escape="true">The reconciliation between the statutory tax rate and the Company&#8217;s actual effective tax rate is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i02398a19f2c04cf594e1792d84638bfc" continuedAt="i6ad983024e1a4eadbd035b7d25a8eafc"><div style="margin-bottom:6pt;"><ix:continuation id="if200836d14e44571b97aeabeca3db75f"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.354%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at U.S. statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzItMS0xLTEtMA_34531614-a009-4cdd-9422-8602892258b3">21.00</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzItMy0xLTEtMA_3ae47eb2-a950-4b80-83f9-92f1ca00aa79">21.00</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzMtMS0xLTEtMA_d8c05795-5005-4d4d-8e1e-25ff7421f322">4.61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzMtMy0xLTEtMA_3d9b9826-650e-41a4-a797-f0e5c96bfa4f">4.25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzQtMS0xLTEtMA_157ddafa-13b8-473a-9ac1-c5087d546c88">6.49</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzQtMy0xLTEtMA_2b9453d0-c527-486b-a0b3-8124fba21bc9">0.44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzUtMS0xLTEtMA_ec16db70-babe-4fc6-a26d-f8dd0183dff1">30.99</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzUtMy0xLTEtMA_d7de0322-343a-4f35-a98d-6de20e67e5d3">10.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">True-up adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" sign="-" name="dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzYtMS0xLTEtMA_6ab07c12-e15e-41d5-ade5-25527cca137f">0.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" name="dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzYtMy0xLTEtMA_495350b9-01a8-4dfc-be5d-0bed3f15da64">0.17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzctMS0xLTEtMA_dbb60eb3-8c76-468e-9dc8-7deb6d08c982">0.07</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzctMy0xLTEtMA_09d94b68-f299-489b-83f3-cfa5376cb6b7">0.28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in tax rates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzgtMS0xLTEtMA_a329cdbd-be5d-4dde-a06c-99e7a33b848d">1.00</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzgtMy0xLTEtMA_b5201815-3e19-4f8c-a405-01e625fadbe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMT adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" format="ixt:zerodash" name="dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzktMS0xLTEtMA_a1c37dae-89a5-4ec2-8253-a8cccac2e0f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" sign="-" name="dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzktMy0xLTEtMA_be944b6e-d67c-4eaf-a5fb-2575459ccc90">0.06</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzEwLTEtMS0xLTA_c5eb820b-e357-4971-88ed-c72c4dedeaac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzEwLTMtMS0xLTA_c80629f5-9d3f-40fb-9f65-3b94c69535c0">14.95</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5Njg_451634c8-c810-48d9-bac8-a39684b1d3af" escape="true"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.354%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock option expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzMtMS0xLTEtMA_16898e65-1677-45ad-a3a9-0cc389e3dd56">275,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzMtMy0xLTEtMA_03b04e67-d99f-4007-8777-4b48ae0fc35a">242,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NOL carryforward</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzQtMS0xLTEtMA_88406cae-9613-43e7-b0eb-1bcd83f1ed5c">5,214,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzQtMy0xLTEtMA_c56254fb-dcc4-40ca-8e60-bea5b24ee062">2,668,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzYtMS0xLTEtMA_20b6f22e-fff0-43be-b41f-4890e8968c3e">1,656,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzYtMy0xLTEtMA_40db90bf-3fea-4a3c-b0f5-5ec8264d78d8">1,656,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzctMS0xLTEtMA_41e36e16-152b-470c-be75-3f0826dfbf99">4,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzctMy0xLTEtMA_1947e69b-7544-44cf-bd94-0d1c8407c6c0">11,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset, net of deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="dyai:DeferredTaxAssetLiabilityGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzgtMS0xLTEtMA_1ddd516f-c0d4-4295-a93b-35677afd30cb">7,150,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="dyai:DeferredTaxAssetLiabilityGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzgtMy0xLTEtMA_92f1471f-b89e-4773-a554-20f286079636">4,578,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzktMS0xLTEtMA_fc750c01-1f85-44e9-a2ec-468684f5151e">7,150,100</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzktMy0xLTEtMA_38fa9130-169d-44d4-b53c-135617103dc4">4,578,400</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzEwLTEtMS0xLTA_d0093dc1-9e82-460c-a9a7-c5ebfb8cf5f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzEwLTMtMS0xLTA_85884632-5020-480f-b7d0-1b8cb4e307c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on management&#8217;s evaluation, the net deferred tax asset was offset by a full valuation allowance as of December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available in 2019 that will begin to expire in 2037. As of December&#160;31, 2019, and 2018, the Company had NOLs in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NDgyMzc_791b0758-b244-483a-a7ae-87627d8ecdeb">19.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NDgyNDU_f7ccfc73-509f-4a2c-9552-71b19584f7c6">9.1</ix:nonFraction>&#160;million, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, <ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzMyNTM_3cf88e32-688a-4434-ac20-89a784b1f2bc"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzMyNTM_7a5de3f2-973c-45d9-be6a-32d4e409989d">no</ix:nonFraction></ix:nonFraction> liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company received a letter from the IRS informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and subsequently provided the IRS with all requested information under several Information Document Requests (IDRs). Thus far, the Company has not been informed of any issue. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indian Tax Deducted/Collected at Source</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income generated in India is subject to Tax Deducted at Source (&#8221;TDS&#8221;), which is a means of collecting income tax at the source when income is generated rather than a later date by the Indian government. The TDS amount paid can be used as foreign tax credit for US tax purposes. However, we do not expect to use the credit due to our loss from operation. As a result, </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6ad983024e1a4eadbd035b7d25a8eafc">the Company recorded a provision for income taxes of approximately $<ix:nonFraction unitRef="usd" contextRef="i46135fb3b51c476a969413b90769ef8e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NTYxMzI_97f21b84-c638-4dc5-978a-e915c6cba6b7">10,000</ix:nonFraction> as a result of TDS for the year ended December 31, 2019.</ix:continuation></span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_145"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 5:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzc2OTY1ODE0MDkzNTg_175aa56f-8845-44ff-9823-875478c05ca5" continuedAt="i1cd8e4f39ce74410919f2e1e68021741" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1cd8e4f39ce74410919f2e1e68021741" continuedAt="i1121c1a5d9664eaf97206f431c5a0c5f"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Jupiter, Florida Headquarters</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i067425fd93584c7f8114ab5e1571995d_I20191231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDYzNjk_065a1f01-4946-4397-9ef7-b3f55833c8ca">4,900</ix:nonFraction> square feet with a monthly rental rate and common area maintenance charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i8211dee89c274d37bf293694b115ff85_D20190101-20191231" decimals="-2" format="ixt:numdotdecimal" name="dyai:OperatingLeasesMonthlyRentalRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDYzNzI_fec71c9b-4ac2-46c7-83b3-ae205dfd5740">9,700</ix:nonFraction>. The lease expires on June&#160;30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The Netherlands Office</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a small satellite office in Wageningen, Netherlands. In 2018, the Company occupied approximately <ix:nonFraction unitRef="sqft" contextRef="i61fc32e45fcc49988560c5d708fe090a_I20181231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTA_55dac97a-d9bd-4ed7-9114-14430e04258e">258</ix:nonFraction> square feet with annual rentals and common area maintenance charges of approximately $<ix:nonFraction unitRef="usd" contextRef="ia67696ba89b140ea84bb3079e5ab8ed6_D20180101-20181231" decimals="-2" format="ixt:numdotdecimal" name="dyai:OperatingLeasesAnnualRentalRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTEwMjI_3d9bc8a1-6a47-411c-b814-6aad073c0eff">4,700</ix:nonFraction>. The lease expired on January&#160;31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the &#8220;New Lease&#8221;). The New Lease has a <ix:nonNumeric contextRef="i86a13c798877437492fa7b0a4354cb9c_I20190201" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTk_77682a65-284b-4727-9c00-ef215d8ba3a5">one year</ix:nonNumeric> term with an auto renew period till January 31, 2021, and includes a flexible office space with annual rentals of approximately $<ix:nonFraction unitRef="usd" contextRef="id91f496dcbb044758f163cbd859eb73a_D20190201-20190201" decimals="-3" format="ixt:numdotdecimal" name="dyai:OperatingLeasesAnnualRentalRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTM_defc248d-051a-4c3b-a3d7-1358bd9097b0">4,000</ix:nonFraction>. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">VTT Research Contract Extension</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, the Company extended its research contract (&#8220;Contract&#8221;) through June 2022 with VTT Technical Research Centre of Finland Ltd. (&#8220;VTT&#8221;). Under the terms of this Contract, Dyadic will pay VTT a total of EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i1ce85b8cbbff401ab8f9208885798348_I20190628" decimals="-4" format="ixt:numdotdecimal" name="dyai:CommitmentToPay" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2NjA_f51a492f-2e36-4654-ada1-f9c487fd2e8e">2.52</ix:nonFraction> million over the next <ix:nonNumeric contextRef="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628" format="ixt-sec:durwordsen" name="dyai:CommitmentDevelopmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY2OTU_ddbdd7bd-c941-488f-968b-b7da539d0796">three years</ix:nonNumeric> to continue developing Dyadic&#8217;s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i1ce85b8cbbff401ab8f9208885798348_I20190628" decimals="-4" format="ixt:numdotdecimal" name="dyai:CommitmentSuccessBonusAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2Njc_6f3c0bfa-cf84-491d-8eb0-e15730071ad6">450,000</ix:nonFraction> based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i5359f3a055db4f1886c3bd132f79cdb1_I20191025" decimals="-4" format="ixt:numdotdecimal" name="dyai:CommitmentToPayExpanded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2NzE_674445c5-b3c6-411f-a723-69f61e2ef634">690,000</ix:nonFraction> over the next <ix:nonNumeric contextRef="ia22c697beb7d4b0ab318ca61134fe993_D20191025-20191025" format="ixt-sec:duryear" name="dyai:CommitmentToPayExpandedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2Nzc_fab5e529-9265-404c-a4cc-157bee319812">1.5</ix:nonNumeric> years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with <ix:nonNumeric contextRef="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628" format="ixt-sec:durday" name="dyai:CommitmentsRightToTerminateContractNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2ODA_5cd38abe-8d9d-4323-b433-4d35ea4c429f">90</ix:nonNumeric> days&#8217; notice.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Purchase Obligations</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:LongTermPurchaseCommitmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzQ3MDI_bf2d7573-d34e-405f-8ee6-a34e566dca68" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2019:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:83.190%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.810%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzAtMS0xLTEtMA_33ff6109-bdf7-4d3b-af62-c3a206056ec2">2,762,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInSecondYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzEtMS0xLTEtMA_d0d19e71-8c15-47b2-91fd-f0a06c62ff40">1,103,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInThirdYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzItMS0xLTEtMA_34b45895-fff0-474c-a548-d92f29678c3c">496,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzYtMS0xLTEtMA_01d49584-d5cd-4485-a634-5121682160aa">4,362,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purchase obligations in the table above are primarily related to our contracts with the Company&#8217;s contract research organizations to provide certain research services. The contracts set forth the Company&#8217;s minimum purchase requirements that are subject to adjustments based on certain performance conditions. All contracts expire in 2022.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1121c1a5d9664eaf97206f431c5a0c5f">Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.</ix:continuation></span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_148"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 6:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODU_dc0dc32d-96a2-4496-8a01-f7a8c65549f9" continuedAt="ibfa02677e107455fbd99efc22a29ac42" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ibfa02677e107455fbd99efc22a29ac42" continuedAt="i5c842a2824f2400e970b9afe1dd1b93f"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Equity Plans</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) was adopted by the Board on April 28, 2011 and approved by the Company&#8217;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#8217;s 2006 Stock Option Plan (the &#8220;2006 Plan&#8221;). Since the effective date of the 2011 Plan, all future equity awards were made from the 2011 Plan, and <ix:nonFraction unitRef="shares" contextRef="ie8f1835196484e3c945b149529822d3d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzQ0MQ_da1a8a9a-b3fb-4799-97e6-e396912de42d">no</ix:nonFraction> additional awards will be granted under the 2006 plan. Under the 2011 Plan, <ix:nonFraction unitRef="shares" contextRef="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzUyMA_e1496400-3d58-4b57-b54d-20085d7fee4f">3,000,000</ix:nonFraction> shares of the Company&#8217;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provision of the 2011 Plan, the Board approved an increase of <ix:nonFraction unitRef="shares" contextRef="i28c9d6b0788b439c9ff3572a031dea3d_D20190101-20190101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4MjM_13b82368-7873-4629-beb2-cb9babb3398e">1,500,000</ix:nonFraction> shares each year to the plan on January 1, 2019 and 2020. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the Company had <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzkwNw_0588b73d-d21b-43c8-9e9c-bcbc03bb951d">3,860,390</ix:nonFraction> stock options outstanding and an additional <ix:nonFraction unitRef="shares" contextRef="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzk1NA_f68d97eb-449a-4a55-ae0f-e8d85cc80cfb">1,547,211</ix:nonFraction> shares of common stock available for grant under the 2011 Plan. As of December&#160;31, 2018, there were <ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzEwNDI_08c6b0b4-92a7-410d-ac9d-1134ec5bcd3b">3,552,890</ix:nonFraction> stock options outstanding and <ix:nonFraction unitRef="shares" contextRef="i87754620edec4143a42a41e6727c2af7_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzEwNzU_7c5771cc-15e0-4a98-98fb-aa8855030445">1,136,211</ix:nonFraction> shares of common stock available for grant under the 2011 Plan.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options are granted to purchase common stock at prices that are equal to the fair value of the common shares on the date the option is granted. Vesting is determined by the Board at the time of grant. The term of any stock option awards under the Company&#8217;s 2011 Plan is no more than <ix:nonNumeric contextRef="ia095586e60d44997a6ddefe3f667eb8a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4Mjg_8efc51f9-ccea-438d-840a-47cc19761f89">10</ix:nonNumeric> years except for qualified options granted to the CEO (<ix:nonNumeric contextRef="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4MzQ_e5b2c1b1-adb0-48b5-9f97-4978e1819f29">five years</ix:nonNumeric>) and certain contractors (<ix:nonNumeric contextRef="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4NDM_0d7558a4-92b6-476e-b8e3-8e4eb53329cb">two years</ix:nonNumeric>).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4NjY_84244c8b-ea72-4fb0-bf3c-7a3076ef1ef8">zero</ix:nonFraction>, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected stock price volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected stock price volatility was calculated based on the Company&#8217;s own volatility since the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatilities since 2016, as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected life of option. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., <ix:nonNumeric contextRef="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4OTM_96dc4f58-e8fd-40b2-9245-3265113603d6">5</ix:nonNumeric> years) and certain contractors (i.e., <ix:nonNumeric contextRef="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4OTY_27b7f650-6ebb-41a6-a0ca-c679cc4f69a8">2</ix:nonNumeric> years). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for lack of marketability.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company applies a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company&#8217;s common stock. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODY_0d596e74-beb3-48c8-8e74-bc1ef1f7de55" continuedAt="i30a47cc935e94e10b92e061aa710cc2c" escape="true">The assumptions used in the Black-Scholes option pricing model for stock options granted for the year ended December&#160;31, 2019 are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i5c842a2824f2400e970b9afe1dd1b93f" continuedAt="i457f6f830046412a82cdbb102b2325ef"><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="i30a47cc935e94e10b92e061aa710cc2c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:54.076%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.522%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.231%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjMwNTNkMTNmNDA0ZTRhMTg4NGM4YTA5ZjBkNTgxYzkxXzY1OTcwNjk3NjY2Nzg_16c362f4-7944-4ceb-9966-8dd4d408a838">1.69</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjMwNTNkMTNmNDA0ZTRhMTg4NGM4YTA5ZjBkNTgxYzkxXzY1OTcwNjk3NjY2ODU_2c818818-a9dc-4f2b-9aa9-7d0c91e04a0a">2.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNjMzZiMTFiNzA4NDRhMzA4MDM4MzhiZGQ0MmI3NDY2XzY1OTcwNjk3NjY2Nzg_cae72bc9-c1ed-4bde-a196-d9c89d71ff6a">2.24</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNjMzZiMTFiNzA4NDRhMzA4MDM4MzhiZGQ0MmI3NDY2XzY1OTcwNjk3NjY2ODU_7e4f47f9-7cad-482b-a799-024a1da5cc2c">2.96</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjE1ODBiMmY1OGZmMzRmZjE4MGFhNmM5NTNlMmU5MWU1XzY1OTcwNjk3NjY2NjQ_a6540d99-f143-4989-8a2f-95bdfbddfc1d">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjY4YWNjYjQyZDI5OTQ1MTFiNWNlNzRhZTQ4NDc0ODFhXzY1OTcwNjk3NjY2NjQ_5c59ff9d-e62d-424c-81fc-b14cb2d7bb65">&#8212;</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmYxNGZjMzY4MGZlNjQyOGFhNzNhNDBlZDU2YjMwMWY2XzY1OTcwNjk3NjY2ODE_d4cc273a-768f-4253-998c-442b78c41c0e">28.59</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmYxNGZjMzY4MGZlNjQyOGFhNzNhNDBlZDU2YjMwMWY2XzY1OTcwNjk3NjY2ODk_b413dc16-1c36-4447-88a1-51d4b1e43666">37.29</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMy0xLTEtMC90ZXh0cmVnaW9uOjQxMWVjMjAxY2FjNDRjOTRiZjllZDVjMjk4ODVkNTdhXzY1OTcwNjk3NjY2ODA_39add43b-0df6-4618-8723-e61cdc553637">27.80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMy0xLTEtMC90ZXh0cmVnaW9uOjQxMWVjMjAxY2FjNDRjOTRiZjllZDVjMjk4ODVkNTdhXzY1OTcwNjk3NjY2ODg_a9518b2e-0982-4179-90e7-ad726f2c3e98">30.36</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjg2MTkzYTAzYWE4OTQyYmNhMTA4MDU5ZDgyMmQyNjUwXzY1OTcwNjk3NjY2NzY_fac8afeb-b365-4571-ab0d-9ef43deecf70">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjg2MTkzYTAzYWE4OTQyYmNhMTA4MDU5ZDgyMmQyNjUwXzY1OTcwNjk3NjY2ODg_853aaf4e-f4b3-459f-81e6-26c9451890cc">6.25</ix:nonNumeric> Years </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i2cf44cd91f594d6e9d9f2be57dbefa3d_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjBjZGQ4YjcxMTk4YjRmOWM5MjQyM2U0N2YzMDhhODUyXzY1OTcwNjk3NjY2NzU_6b59493a-6ee9-43d8-bf4b-8f80016a14af">5</ix:nonNumeric> - <ix:nonNumeric contextRef="ic164a2b8759541bd92fd673e0a617119_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjBjZGQ4YjcxMTk4YjRmOWM5MjQyM2U0N2YzMDhhODUyXzY1OTcwNjk3NjY2ODc_216fd0d1-4208-4228-be28-909c5526fd0e">6.25</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount for lack of marketability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231" decimals="4" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmQzZTJjY2ZkNGM5ODRlMGNiOWEwYTM4ODJkZTdjZGMzXzY1OTcwNjk3NjY2NzA_f95f82ae-6253-4c75-a0bd-8ac14be5932d">0</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231" decimals="4" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmQzZTJjY2ZkNGM5ODRlMGNiOWEwYTM4ODJkZTdjZGMzXzY1OTcwNjk3NjY2Nzc_a1f779c6-3937-4213-80d2-8c5a781307e3">8.48</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231" decimals="4" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMy0xLTEtMC90ZXh0cmVnaW9uOmYzZTE0NmZmZWZmYzQ4MmNiN2YwMDU1NjJhYzAyOTVlXzY1OTcwNjk3NjY2NzA_6e598fe0-a20e-4da4-aded-b93b5a993509">9.35</ix:nonFraction>%</span></div></td></tr></table></ix:continuation></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODc_0684ba6b-142e-4d99-b142-1003f13de273" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the combined stock option activity under the Company&#8217;s Equity Compensation Plans:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.795%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.821%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.290%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtMS0xLTEtMA_160a74af-ea45-47a7-86cf-de65c0c719da">2,712,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtMy0xLTEtMA_1c5a8eb5-3114-420c-a849-ceb81015fdc6">1.62</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9911246a988f4400b2298393e4a8d174_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtNS0xLTEtMA_d06a1642-c33f-44e7-bdca-382981c548d5">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtNy0xLTEtMA_79c6b6c6-0a81-4b21-90f9-96ea2f29a725">69,090</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzItMS0xLTEtMA_5bdd2f54-87bc-4a21-b205-da8932096fd0">1,120,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzItMy0xLTEtMA_8ae8c6fc-2140-4632-9ef9-cd35f584e2d8">1.44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzMtMS0xLTEtMA_36121558-7c0e-4512-8a4a-e2f1ea79d96f">30,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzMtMy0xLTEtMA_733cb5fb-e35b-4afd-bbff-a20a049c0293">0.15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzQtMS0xLTEtMA_28677f60-35dc-47f8-aa80-b825c3e8824b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzQtMy0xLTEtMA_adfd197a-6c8e-40bf-b3a5-303b5a5cb51b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzUtMS0xLTEtMA_a7ec41bd-f67c-4f4a-ab21-04e4d2030899">250,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzUtMy0xLTEtMA_75e77f51-d9bd-4136-97bf-058fe3e9a6cf">1.69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtMS0xLTEtMA_18ba0725-c3b3-46e9-aa3e-232b7f9d0ee1">3,552,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtMy0xLTEtMA_5afdf2f1-f3d4-451b-8a1f-df5b32d391fd">1.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtNS0xLTEtMA_797d90e5-3444-49e1-95e0-12c57def8433">5.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtNy0xLTEtMA_bfb4c713-f0f3-472d-8e24-40b505cd51f7">1,149,461</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzctMS0xLTEtMA_73d44925-d2c3-449e-90b8-f31c66c2ce76">1,089,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzctMy0xLTEtMA_64dfe1df-11aa-4934-bb3b-63dce0a21024">2.26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzgtMS0xLTEtMA_5cdc185d-147c-456e-88b1-dd8978a18923">781,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzgtMy0xLTEtMA_d198b424-f0a9-4e32-8aa9-d8dc4bc81164">1.60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzktMS0xLTEtMA_31eeaaf5-6d1a-4654-8929-8f6e93116cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzktMy0xLTEtMA_a4dd04a0-4884-4ed1-90c4-54350be6cdb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEwLTEtMS0xLTA_76e32165-8b0a-4620-8b43-83420a7b900c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEwLTMtMS0xLTA_94fa2caf-46b5-4c2a-a0b0-58b29d18ab54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTEtMS0xLTA_0588b73d-d21b-43c8-9e9c-bcbc03bb951d">3,860,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTMtMS0xLTA_84fd193e-61ee-4f5d-a436-f3f54374e84f">1.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTUtMS0xLTA_f0fb34be-e176-4e32-a325-278b8b9a5769">5.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTctMS0xLTA_2aa7afc8-c5f9-49ca-acc8-f30613fbb48a">13,287,932</ix:nonFraction></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTEtMS0xLTA_871f7e64-49ed-4672-a006-b6e037009c86">2,747,073</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTMtMS0xLTA_7bca65ac-0266-4ef5-8f02-b10d6596b8dc">1.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTUtMS0xLTA_360cbbf8-e54d-476f-8213-0bae3cf17688">4.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTctMS0xLTA_c0969b3b-2e85-4ee6-99e7-bcf6372a354d">9,712,729</ix:nonFraction></span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Represents the following stock options granted:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">Annual share-based compensation awards on January 2, 2019, including: (a) <ix:nonFraction unitRef="shares" contextRef="if917f69cb62f4aeab421b5233da141a9_D20190102-20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMDU_e2ce9dc8-80fa-4844-83a9-1c43b60cd336">600,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1003cf64787c47bfa079db8551f27546_D20190102-20190102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMTI_39c1758f-ae26-400e-bef0-073c2bbfe27e">1.87</ix:nonFraction> per share granted to executives and key personnel, vesting upon grant, or <ix:nonNumeric contextRef="i1003cf64787c47bfa079db8551f27546_D20190102-20190102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4MzE_9c0052cb-34c9-43c9-af03-3e48aa29cee6">one year</ix:nonNumeric> anniversary, or vest annually in equal installments over <ix:nonNumeric contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4MTc_a07cce3b-65f1-4fd4-9475-9f76d5d82ebb">four years</ix:nonNumeric>, (b)<ix:nonFraction unitRef="shares" contextRef="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMjI_60e0e189-ea98-4361-87df-63f23bc8e9a6">300,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMjk_ce9e4cc5-8be8-4472-8c47-a60036d2d8cd">1.87</ix:nonFraction> per share granted to the Board, vesting <ix:nonFraction unitRef="number" contextRef="ia4ff0366c2954e079f8bfbc42ddd2255_D20190102-20190102" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4Mzc_67bdd6f1-720b-4ac2-be18-0e4765cbdec5">25</ix:nonFraction>% upon grant and the remaining <ix:nonFraction unitRef="number" contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4NDI_2f8e9603-c245-412c-a8e6-db0972b93e3e">75</ix:nonFraction>% will vest annually in equal installments over <ix:nonNumeric contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzgyNDYzMzcyMjgzMTM_d2834520-3df2-4aa6-9a38-9dfc204c4827">four years</ix:nonNumeric>, and (c) <ix:nonFraction unitRef="shares" contextRef="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMzc_41e46a3e-fc5b-427b-a18a-336394fe96c8">24,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNDQ_057affdd-6bcf-4ea5-9413-9d8021017f25">1.87</ix:nonFraction> per share granted to employees, vesting annually in equal installments over <ix:nonNumeric contextRef="i00400d75393341c0b8c51dd7dcaf9263_D20190102-20190102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4Njk_0ddec862-7045-474b-8470-182253ccde72">four years</ix:nonNumeric>. </span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">One-time awards granted on (a) January 2, 2019 of <ix:nonFraction unitRef="shares" contextRef="ia68b902c3b614063bf94fc0cb7873a7b_I20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNTI_e8581a8c-092a-486f-9147-aac2c3ec8b4a">50,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idc984c2633c84830a7590e6783b2de69_D20190102-20190102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNTk_1b8fb23c-7098-4777-a339-d71440b81d12">1.87</ix:nonFraction> per share granted to a contractor, vesting upon <ix:nonNumeric contextRef="idc984c2633c84830a7590e6783b2de69_D20190102-20190102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4ODE_f944f1db-b7fa-4302-8643-5d7bcd9ab6ea">one year</ix:nonNumeric> anniversary, (b) March 7, 2019 of <ix:nonFraction unitRef="shares" contextRef="i502f339e9a564d2fa057ffd43b430345_I20190307" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNjc_3eba5a7f-0aec-42bd-a5f7-085a5947ea04">15,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNzQ_543f45a0-0eed-49f2-8419-8aa03187e9ec">3</ix:nonFraction> per share granted to a contractor, vesting upon <ix:nonNumeric contextRef="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4OTM_eb307dd8-07ac-4af9-9cc4-68074dadc2eb">one year</ix:nonNumeric> anniversary, (c) June 25, 2019 of <ix:nonFraction unitRef="shares" contextRef="i5361038870ba43a3836b3611390751a9_I20190625" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzODI_19418424-8686-4be6-a7cb-f9ee669208bd">75,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzODk_370f62f4-54b0-4c38-89e4-ae51cdc5a1f3">5.83</ix:nonFraction> per share granted to <ix:nonFraction unitRef="board_of_director" contextRef="i3180a4adc61148acb883d0951ed14fe7_I20190625" decimals="INF" format="ixt-sec:numwordsen" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI5MDU_6001b08c-b89b-470e-9e51-8fdc6494c9ab">three</ix:nonFraction> members of the Board, vesting upon <ix:nonNumeric contextRef="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI5MTc_85a7e532-8cff-40ee-9342-e2500b4383f8">one year</ix:nonNumeric> anniversary, and (d) June 28, 2019 of <ix:nonFraction unitRef="shares" contextRef="i263ac90ac6ab451aac269f8d91a7bb57_I20190628" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzOTc_6c1944d0-c264-4a5a-84f4-edfec7b82077">25,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ae81b32c80540568b0ddbf678fb73fb_D20190628-20190628" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MDQ_e808c70b-d50a-4ceb-a105-530a9efb68cb">6.26</ix:nonFraction> per share granted to the Chief Financial Officer, vesting immediately.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Represents the following stock options exercised:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">A total of <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMyOTQ_923f554b-d296-4516-b3a2-fe0216a43555">781,500</ix:nonFraction> stock options exercised with a weighted average market price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MTU_2894e31b-7982-4452-a43c-b7bdc4e1fa11">1.60</ix:nonFraction>, including (a) net share exercise of <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MjU_07da2c3e-896f-49fa-a1b6-d15630cb9466">440,000</ix:nonFraction> stock options resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MzQ_30422e09-ff63-4433-ab23-c0ed7430684a">304,171</ix:nonFraction> shares of common stock, and surrender of <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0NDM_8dc47c97-8aa0-4f5b-8953-8685aa79914f">135,829</ix:nonFraction> shares, and (b) <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0NTI_4829824b-05e5-4acf-8196-c269df13e17f">341,500</ix:nonFraction> stock options exercised with cash payment.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average grant-date fair market value of stock options granted for the years ended December&#160;31, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk1NzU_0a4f7614-4ccc-4712-89a0-d379a3d513ec">0.69</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2MDQ_51c9bc76-d3ef-4743-bf50-584c677c7bc1">0.41</ix:nonFraction> respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended December&#160;31, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2MzM_693b2ff5-58a0-458f-b2e8-621efa677cdd">2,925,662</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Mzg_1a313147-0e9f-46e4-b807-1c0ad546a574">39,360</ix:nonFraction>, respectively. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i457f6f830046412a82cdbb102b2325ef"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, total unrecognized compensation cost related to non-vested stock options granted under the Company&#8217;s share option plan was $<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Njg_270cf66c-b80c-42b4-ac63-ab01d88d420e">222,330</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2NzM_77ba6407-5369-4c0d-8e5c-9c5787028ce0">162,786</ix:nonFraction>, respectively, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Nzg_af4612ee-5674-4a02-a239-0792c20963e0">1.83</ix:nonNumeric> years and <ix:nonNumeric contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2ODE_069cb310-6998-4ad2-8032-af04bd1bae9a">2.39</ix:nonNumeric> years, respectively. The Company will adjust unrecognized compensation cost for actual forfeitures as they occur.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. For the year ended December&#160;31, 2019, the Company recognized the expense related to the performance-based awards granted prior years upon the Company&#8217;s April 2019 uplisting to the NASDAQ of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e4e110274cd42e68c73b41957abca9b_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzY1OTcwNjk3ODY1ODI_d92c27e5-35ea-4f6f-9c56-8c54bf2fc407">483,000</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODQ_1b86b9da-aeed-4acd-951d-03a0a6815df8" escape="true"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.648%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.810%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3fb877e64e5f4588b05eb59d2f1f303e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzItMS0xLTEtMA_8f3c51d6-aee8-4962-8b84-42395a1781d8">1,069,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27724349c48a4973856d9b6cbe4f786e_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzItMy0xLTEtMA_9aff5b07-37fd-402c-b4f4-a1b4a65f4cdf">390,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3065e8cc19c4622bc9018bea3d70c6f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzMtMS0xLTEtMA_55eef2ea-b5d2-4941-8abe-9a53492707b9">101,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd3b28bef31b45d58d39978ccbae35a4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzMtMy0xLTEtMA_81501864-b807-4044-9182-4d287455ce62">76,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzQtMS0xLTEtMA_44f0e776-3790-46d8-bbfc-7e7f505f7e20">1,171,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzQtMy0xLTEtMA_4438e253-d71e-4572-b324-aeedfab945a6">467,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_154"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 7:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzI1NjY_38a38368-0435-433f-a2e1-4c205fc75fd3" continuedAt="i8da5f20dea984cc19b36ba5065e1f1dc" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i8da5f20dea984cc19b36ba5065e1f1dc" continuedAt="i1ca623f21be643348f4f6b879d84db54"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuances of Common Stock</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares of common stock issued for the years ended December&#160;31, 2019 and 2018 were <ix:nonFraction unitRef="shares" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU2MDI_529a7e67-7da4-4417-b237-1d66e050e224">645,671</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNjE_ca5fd1e9-acb1-444d-85ec-ce7530a6ff33">30,000</ix:nonFraction>, respectively, with a weighted average issue price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" decimals="2" name="dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU2MjE_52ce7f6f-2b09-4170-8d78-0f7dd8ab9646">1.60</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231" decimals="2" name="dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNjg_c7a0bbda-b213-4949-b632-436555fca469">0.15</ix:nonFraction>, respectively. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Repurchases and Buybacks </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Stock Repurchase Programs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 16, 2016, the Board authorized a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzOTk_fe3a9107-bbfc-41d2-8697-3542846d9e85">one</span>-year stock repurchase program, under which the Company was authorized to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNzI_655567d5-54d8-4a3f-a83f-0ebcb187495f">15</ix:nonFraction>&#160;million of its outstanding common stock (the &#8220;2016 Stock Repurchase Program&#8221;). The 2016 Stock Repurchase Program ended on February 15, 2017.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 16, 2017, the Board authorized a new <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU0MDc_b5a00c4c-c973-45db-864c-25377b84925f">one</span>-year stock repurchase program, under which the Company may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i7591c510da7a48b593cb45d1dddbb122_I20170816" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNzk_0e8680d1-35d0-46aa-b4e0-3faf2211e8b4">5</ix:nonFraction>&#160;million of its outstanding common stock (the &#8220;2017 Stock Repurchase Program&#8221;). On August 6, 2018, the Board authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzI1Njc_2fd7c052-c99d-4d69-9db9-afc8f4ff6d70" continuedAt="i2de8af5a754f4bcc9f108ba38d4bc81f" escape="true">The following table summarizes the Company&#8217;s stock repurchase activities:&#160;</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><ix:continuation id="i1ca623f21be643348f4f6b879d84db54" continuedAt="ibe0c229cb4334d409516b3af4666732c"><div style="margin-bottom:6pt;"><ix:continuation id="i2de8af5a754f4bcc9f108ba38d4bc81f"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:34.217%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.973%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.638%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Privately Negotiated Transactions:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 12, 2016 - Abengoa repurchased and retired shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItMS0xLTEtMA_eb677590-6a2a-459f-ae3a-effcd845b0f7">2,136,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItMy0xLTEtMA_1f1c9913-4e97-43b4-9db4-b9155fb2744a">1.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItNS0xLTEtMA_73a7fdd5-f5b6-496a-b9a9-b79dc5f77bc5">2,884,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i25427c3bdaeb4b98b458ea7b34deb418_D20160112-20160112" decimals="0" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItNy0xLTEtMA_810a8583-381b-4a87-aadd-0b8338103e62">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtMS0xLTEtMA_f92b355b-5043-493d-8b68-5d1e5eecea0f">2,363,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtMy0xLTEtMA_8dcde854-cad5-438d-b5d4-c59197cae296">1.54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtNS0xLTEtMA_efebfb02-73d4-45f1-a9a6-6afde516fa1b">3,639,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icfcfcf474ee74ca297efc69b74652e7b_D20170111-20170111" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtNy0xLTEtMA_d7de4bbf-0704-4f35-8537-505efda14ece">2,363,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzQtOS0xLTEtMA_dcd77273-ba23-48af-a15d-3dfffdc76a18">15,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through February 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtMS0xLTEtMA_6cbb6963-ef2a-491d-84d3-215fc19af738">7,863,980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtMy0xLTEtMA_7d172f16-ce64-4d4b-a6be-86e0f2d01bc1">1.58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtNS0xLTEtMA_10fa7011-0807-4a0f-bb71-6f5e9eb471cc">12,448,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9b266eccec9447ddb9c6431bd35cf1b3_D20170101-20170228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtNy0xLTEtMA_8e3458a5-f6ef-4196-9cb7-9efabf6c489b">7,863,980</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc2601b2f77c479581fa9cf5d4cff3fd_I20170228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtOS0xLTEtMA_e834afc3-4dc3-4606-ad00-a4b05a56a5ae">2,551,717</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7591c510da7a48b593cb45d1dddbb122_I20170816" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEwLTktMS0xLTA_fc627875-6ada-4d50-bbe5-cac5320d5816">5,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September through December 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTEtMS0xLTA_1fb9a14d-bf51-4725-a95c-f3b93eb639b2">381,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTMtMS0xLTA_b6272262-4a78-4172-be2b-aecd20dff446">1.41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTUtMS0xLTA_36cc69c9-8ed7-419d-bfc9-797a2278b260">537,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0cb224dd3f604e299d6ab6df8bc4eba6_D20170901-20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTctMS0xLTA_a83454b8-87d9-4f2c-8a65-89f376fcb79a">381,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTktMS0xLTA_6dd33c5e-6124-42e2-90ba-e9bd97c315b2">4,462,339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through August 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTEtMS0xLTA_dff8017b-93f2-4172-b5cd-27057bf8ef72">1,644,325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTMtMS0xLTA_19703baf-3461-4051-96d8-77c61c34b3f6">1.40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTUtMS0xLTA_2f11f899-7e1a-4346-a5d0-247ac4599a0a">2,304,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c5bfc1c71754fd5b496a1784ee4c239_D20180101-20180831" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTctMS0xLTA_f13da1c8-ea92-4cd2-b417-7217c223d386">1,644,325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied7940d17259403f80d1b1604a7b10e3_I20180831" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTktMS0xLTA_6dbd84dc-351d-47ed-b3f6-c8a778700957">2,158,297</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total open market and privately negotiated purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTEtMS0xLTA_6d9298fe-5cb9-4927-99ff-84f1f55fbb92">14,390,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTMtMS0xLTA_ef3eb98c-5c3d-4c87-9ce4-629511714d4f">1.52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTUtMS0xLTA_6fbd5244-5af5-4c3d-8560-bb811ba29785">21,814,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f46b6e69ca64edd9b8fed76219f38f9_D20160101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTctMS0xLTA_9fa7ef73-8c35-4ad4-8a72-548dab2ee850">12,253,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock </span></div></ix:continuation><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibe0c229cb4334d409516b3af4666732c">As of December&#160;31, 2019, and 2018, there were <ix:nonFraction unitRef="shares" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzMjQ_028c1017-e91b-4ef7-ad25-475206571d10"><ix:nonFraction unitRef="shares" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzMjQ_8a2a1622-8451-4a58-ba0c-2145cd2c3031">12,253,502</ix:nonFraction></ix:nonFraction> shares of common stock held in treasury, at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzOTU_b378a4c8-6473-45ba-83aa-cf45fdeed43c"><ix:nonFraction unitRef="usd" contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzOTU_ea67bead-69df-4653-b718-b2776ada3553">18.9</ix:nonFraction></ix:nonFraction> million, representing the purchase price on the date the shares were surrendered to the Company.</ix:continuation> </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="iec2c361ab60c4fe685fbbfdcc5343b30_157"></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 8:&#160;<ix:nonNumeric contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExMjA_a01f940a-57b7-4f01-900c-8779c682da52" continuedAt="i64829c9dc8be4b9188db52ff914850d6" escape="true">Subsequent Events </ix:nonNumeric></span></div><ix:continuation id="i64829c9dc8be4b9188db52ff914850d6"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March&#160;30, 2020, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our Research Contract with VTT</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the first quarter of 2020, we expanded our research contract with VTT Technical Research Centre of Finland Ltd. to pay an additional EUR &#8364;<ix:nonFraction unitRef="eur" contextRef="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="dyai:ResearchAndDevelopmentExpenseAdditional" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk4MTU4NzY_694b21ba-e592-4ff7-babe-5e5c93a27a0c">700,000</ix:nonFraction> over the next <ix:nonNumeric contextRef="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331" format="ixt-sec:durmonth" name="dyai:ResearchAndDevelopmentExpenseAdditionalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODE0NDM2NjM_871992a1-e41d-470e-982d-e2c8257d3964">19</ix:nonNumeric> months to accelerate the glycoengineering work.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Grant</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to executives and key personnel an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzkxOA_17bcd5a3-70b5-4fb6-a8f3-5b16aed8e19d">525,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzk2MQ_f0063175-9f24-4834-b4d4-443f040266c3">5.27</ix:nonFraction>. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzM_c9472d93-1ce1-40be-b972-3b905785428b">one</span>-year anniversary or annually in equal installments over <ix:nonNumeric contextRef="i43b5030b61534a9995f73c86b9ce994a_D20200102-20200102" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzY_40c34f9e-7af2-4195-9333-85cd662336de">four years</ix:nonNumeric>.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to the Board an aggregate of <ix:nonFraction unitRef="shares" contextRef="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzExNDI_f880b115-bb44-498a-af9e-ec775c7bba6d">325,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc4MDM_3709b06c-a2b2-422b-8027-894804b62827">5.27</ix:nonFraction>. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc3OTA_d684f154-2502-42b6-b981-631a93c5af69">one</span>-year anniversary.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to non-executive employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzEzODE_ab088695-fbcc-4a34-9f62-8c7de8953ca4">23,000</ix:nonFraction> stock options with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE0MjQ_620dfc80-e80a-4571-8d48-6207056531d6">5.27</ix:nonFraction>. The options will vest annually in equal installments over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ2OTQ_7df95ba7-825f-4aa9-b588-d426d336e7e5">four</span> years.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MjE_2be8c114-58ae-4acf-a124-d45be32c4ccb">15,000</ix:nonFraction> stock options to a consultant with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg3Njg_f2133754-ddab-4744-aaa8-a3f1aaa06ece">5.27</ix:nonFraction>. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MDA_a7899946-65d3-4626-88f3-03385835ab46">one</span>-year anniversary.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 23, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExMzY_aaf04bdd-8a80-48c0-8ad5-cc774cda4887">25,000</ix:nonFraction> stock options to a consultant with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExNTU_783f36ec-a1c6-48d0-b924-c205ca4e5a20">3.99</ix:nonFraction>. The options will vest <ix:nonNumeric contextRef="i013a834cf3654f739dbd6679b50f16e6_D20200323-20200323" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExNzA_d1d316b4-15c5-422e-8432-893c71e3a2eb">six months</ix:nonNumeric> from the date of grant.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States. As of the date of issuance of the financial statements, the Company&#8217;s operations have not been significantly impacted, however, the Company continues to monitor the situation.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">F-24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit42descriptionof.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5b233a46796f41a39db6a13dd55c67a8_21"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Exhibit 4.2</font></div><div style="text-indent:7.2pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration: underline;">DESCRIPTION OF SECURITIES</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">References to the &#8220;Company&#8221;, &#8220;our&#8221;, or &#8220;us&#8221; herein are, unless the context otherwise indicates, only to Dyadic International, Inc. and not to any of its subsidiaries.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Description of Capital Stock</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">                              </font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following is a summary of information concerning capital stock of the Company. The summaries and descriptions below do not purport to be complete statements of the relevant provisions of the Company&#8217;s Restated Certificate of Incorporation, amended as of November 1, 2004 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Restated Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) and Second Amended and Restated Bylaws, amended as of December 13, 2018 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Bylaws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), and are entirely qualified by these documents.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Capital Stock</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is authorized to issue up to 100,000,000 shares of common stock (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Common Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), par value $0.001 per share, and 5,000,000 shares of preferred stock (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Preferred Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), par value $0.0001 per share, the rights and preferences of which may be established from time to time by the Company&#8217;s board of directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;).</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Common Stock is registered under Section 12(g) of the Securities Exchange Act of 1934 and listed on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market under the ticker symbol &#8220;DYAI.&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Preferred Stock is not registered under Section 12 of the Exchange Act and there is no Preferred Stock currently outstanding.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Common Stock</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;">Shares Outstanding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. As of March 29, 2020, the Company had 27,359,157 shares of Common Stock outstanding.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;">Dividends</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Holders of our Common Stock are entitled to receive ratably, from funds legally available for the payment thereof, dividends when and as declared by resolution of the Board, subject to any preferential dividend rights which may be granted to holders of any Preferred Stock authorized and issued by the Board. Delaware law allows a corporation to pay dividends only out of surplus, as determined under Delaware law.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;">Voting Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Holders of Common Stock do not have cumulative voting rights and are entitled to one vote per share on all matters to be voted upon by stockholders.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;">Other Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Our Common Stock is not entitled to preemptive rights and is not subject to redemption, including sinking fund provisions, or conversion. Upon our liquidation, dissolution or winding up, the assets, if any, legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of all classes or series of Preferred Stock. The rights, preferences and privileges of holders of Common Stock are subject to the preferential rights of all classes or series of Preferred Stock that may be issued in the future.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;">Fully Paid</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. All outstanding shares of Common Stock are validly issued, fully-paid and non-assessable. This means the full purchase price for the outstanding shares of Common Stock have been paid and the holders of such shares will not be assessed any additional amounts for such shares. </font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Anti-takeover Effects of the Restated Certificate and Bylaws</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain provisions in our Restated Certificate and Bylaws could have the effect of impeding or discouraging the acquisition of control of us by means of a merger, tender offer, proxy contest or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">otherwise, including a transaction in which our stockholders would receive a premium over the market price for their shares, and thereby protects the continuity of our management. Specifically, our Restated Certificate or Bylaws contain the following provisions&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Staggered Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Board is composed of three classes of directors who serve staggered three-year terms so that only one-third of the directors are eligible for election at any annual meeting of stockholders, and cumulative voting in the election of directors is specifically denied.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Elimination of Stockholder Action by Written Consent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Any action permitted to be taken by the Company&#8217;s stockholders is required to be effected at a duly called annual or special meeting of stockholders and cannot be effected by a written consent.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Special Meeting of Stockholders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Company&#8217;s stockholders will not be permitted to call a special meeting of stockholders, and the only business matters permitted to be conducted at any annual or special meeting of stockholders will be business matters properly brought before that meeting in accordance with specified procedures.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Procedures for Stockholder Nominations and Proposals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Specific procedures are established for stockholder nominations for directors and stockholder proposals of business to be considered at an annual or special meeting of stockholders.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Board Vacancies and Removals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Board establishes the number of directors, and vacancies on the Board must be filled by a majority approval of the remaining directors, and directors may not be removed by stockholder action without cause.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Amendment or Repeal of Bylaws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Board is empowered to adopt, amend or repeal the Bylaws, while our stockholders may adopt, amend or repeal the Bylaws only upon an affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Undesignated Preferred Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Board has the power to designate and establish new classes of preferred stock having terms that the Board determines to be advisable.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration: underline;padding-left:13.8pt;">Approval of Certain Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">With respect to extraordinary matters that are brought to the Company&#8217;s stockholders for a vote, including the sale of all or substantially all of our assets, a merger, a consolidation, the conversion of the Company into another type of entity or the amendment of the Restated Certificate, unless that matter is affirmatively recommended by the Board, its approval will require the affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The foregoing provisions of our Restated Certificate and Bylaws and other provisions pertaining to the limitation of liability and indemnification of directors may be amended or repealed only with the affirmative vote of the holders of at least two-thirds of the voting power of all then outstanding shares of stock entitled to vote.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, if in the due exercise of its fiduciary obligations, the Board were to determine that a takeover proposal was not in the Company&#8217;s best interest, shares of Common Stock or Preferred Stock could be issued by the Board without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Diluting the voting or other rights of the proposed acquirer or insurgent stockholder group&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Putting a substantial voting block in institutional or other hands that might undertake to support the incumbent Board&#59; or</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">Effecting an acquisition that might complicate or preclude the takeover.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The effect of all of the foregoing provisions may be to delay or prevent a tender offer or takeover attempt that a stockholder may determine to be in his or her best interest, including attempts that might result in a premium over the market price for the shares held by the stockholders.</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Anti-takeover Effects of Delaware Law</font></div><div><font><br></font></div><div style="text-indent:7.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to Section 203 of the Delaware General Corporation Law (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Section 203</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date such person became an interested stockholder, unless the business combination or the transaction in which such person became an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person that, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>exhibit1011jupiterlease2.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit1011jupiterlease2</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1048;"><!-- exhibit1011jupiterlease2001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1011jupiterlease2001.jpg" title="slide1" width="1048" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"></FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311cert-mark10x.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic61ef389b10a472197f7a0d5a879724d_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div style="text-align:right;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Certification of Principal Executive Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and Securities and Exchange Commission Release 34-46427</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;I, Mark</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> A. Emalfarb</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Annual report on Form 10-Q of Dyadic International Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:7.593%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.754%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title&#58; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47;&#160;&#160; Mark A. Emalfarb</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark A. Emalfarb</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312cert-ping10x.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic7a6f5a8fea74f9e96ef6bec3c159505_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div style="text-align:right;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Certification of Principal Executive Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and Securities and Exchange Commission Release 34-46427</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;I, Ping W. Rawson, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"> I have reviewed this Annual report on Form 10-K of Dyadic International Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:7.593%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.754%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; </font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">By&#58; &#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title&#58; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;&#160;&#160; Ping W. Rawson<br><br>Ping W. Rawson<br>Chief Financial Officer<br>&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321sect1350cert.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3d2d3ff299b54e698d33c9a44928d8e9_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In connection with the Annual Report of  Dyadic International Inc. (the &#34;Company&#34;) on Form 10-K for the fiscal year ended December&#160;31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:7.593%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.754%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58; &#160;<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br>Name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>Title&#58; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;&#160;&#160; Mark A. Emalfarb<br><br>Mark A. Emalfarb<br>Chief Executive Officer<br>&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322sect1350cert.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1b346f5ea53a4a42976565fae7dc7d38_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In connection with the Annual Report of  Dyadic International Inc. (the &#34;Company&#34;) on Form 10-K for the fiscal year ended December&#160;31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Ping W Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.557%;"><tr><td style="width:1.0%;"></td><td style="width:7.593%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.613%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.682%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.754%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 30, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58; &#160;<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br>Name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>Title&#58; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;&#160;&#160; Ping W. Rawson<br><br>Ping W. Rawson<br>Chief Financial Officer<br>&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>dyai-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dyai="http://www.dyadic.com/20191231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyadic.com/20191231">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.dyadic.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
        <link:definition>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails">
        <link:definition>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails">
        <link:definition>2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails">
        <link:definition>2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentandInvestments" roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestments">
        <link:definition>2110102 - Disclosure - Cash, Cash Equivalent, and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentandInvestmentsTables" roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables">
        <link:definition>2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentandInvestmentsDetails" roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails">
        <link:definition>2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentandInvestmentsDetails_1" roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1">
        <link:definition>2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandCollaborationAgreements" roleURI="http://www.dyadic.com/role/ResearchandCollaborationAgreements">
        <link:definition>2113103 - Disclosure - Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandSublicensingAgreementsDetails" roleURI="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails">
        <link:definition>2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.dyadic.com/role/IncomeTaxes">
        <link:definition>2115104 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.dyadic.com/role/IncomeTaxesTables">
        <link:definition>2316303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTextualDetails" roleURI="http://www.dyadic.com/role/IncomeTaxesTextualDetails">
        <link:definition>2417409 - Disclosure - Income Taxes - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>2418410 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesBenefitProvisionforIncomeTaxDetails" roleURI="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails">
        <link:definition>2419411 - Disclosure - Income Taxes - (Benefit) Provision for Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationIncomeTaxesDetails" roleURI="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails">
        <link:definition>2420412 - Disclosure - Income Taxes - Reconciliation Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxAssetsDetails" roleURI="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails">
        <link:definition>2421413 - Disclosure - Income Taxes - Deferred Income Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.dyadic.com/role/CommitmentsandContingencies">
        <link:definition>2122105 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTables">
        <link:definition>2323304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTextualDetails" roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails">
        <link:definition>2424414 - Disclosure - Commitments and Contingencies - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseObligationsDetails" roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails">
        <link:definition>2425415 - Disclosure - Commitments and Contingencies - Purchase Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.dyadic.com/role/ShareBasedCompensation">
        <link:definition>2126106 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.dyadic.com/role/ShareBasedCompensationTables">
        <link:definition>2327305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTextualDetails" roleURI="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails">
        <link:definition>2428416 - Disclosure - Share-Based Compensation - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAssumptionsDetails" roleURI="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails">
        <link:definition>2429417 - Disclosure - Share-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2430418 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityTextualDetails" roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails">
        <link:definition>2431419 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationExpenseDetails" roleURI="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails">
        <link:definition>2432420 - Disclosure - Share-Based Compensation - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.dyadic.com/role/ShareholdersEquity">
        <link:definition>2133107 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.dyadic.com/role/ShareholdersEquityTables">
        <link:definition>2334306 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTextualDetails" roleURI="http://www.dyadic.com/role/ShareholdersEquityTextualDetails">
        <link:definition>2435421 - Disclosure - Shareholders' Equity - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityStockRepurchaseDetails" roleURI="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails">
        <link:definition>2436422 - Disclosure - Shareholders' Equity - Stock Repurchase (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.dyadic.com/role/SubsequentEvents">
        <link:definition>2137108 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.dyadic.com/role/SubsequentEventsDetails">
        <link:definition>2438423 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dyai_ResearchandDevelopmentExpenseRelatedParty" abstract="false" name="ResearchandDevelopmentExpenseRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_DeferredTaxAssetLiabilityGross" abstract="false" name="DeferredTaxAssetLiabilityGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CommitmentsRightToTerminateContractNoticePeriod" abstract="false" name="CommitmentsRightToTerminateContractNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_DuPontDaniscoMember" abstract="true" name="DuPontDaniscoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ConcentrationRiskNumberofCustomers" abstract="false" name="ConcentrationRiskNumberofCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_JupiterFloridaHeadquartersLeaseMember" abstract="true" name="JupiterFloridaHeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" abstract="false" name="DebtSecuritiesHeldtomaturityFairValueCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" abstract="false" name="DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_NovovetMember" abstract="true" name="NovovetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentInProcessCurrent" abstract="false" name="ResearchAndDevelopmentInProcessCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" abstract="false" name="CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CommitmentDevelopmentPeriod" abstract="false" name="CommitmentDevelopmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_VTTTechnicalResearchCentreofFinlandLtdMember" abstract="true" name="VTTTechnicalResearchCentreofFinlandLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dyai_ContractResearchOrganizationsMember" abstract="true" name="ContractResearchOrganizationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ServiceFrameworkAgreementMember" abstract="true" name="ServiceFrameworkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" abstract="false" name="CollaborativeArrangementOptionToExtendExclusivityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" abstract="false" name="ResearchAndDevelopmentExpenseContractedServicesRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_SerumMember" abstract="true" name="SerumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" abstract="false" name="IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" abstract="false" name="ResearchAndDevelopmentExpensePersonnelRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CommitmentSuccessBonusAward" abstract="false" name="CommitmentSuccessBonusAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ResearchServicesAgreementMember" abstract="true" name="ResearchServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_OperatingLeasesMonthlyRentalRate" abstract="false" name="OperatingLeasesMonthlyRentalRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_LeaseTypeAxis" abstract="true" name="LeaseTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dyai_PrepaidResearchandDevelopment" abstract="false" name="PrepaidResearchandDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" abstract="false" name="ResearchAndDevelopmentExpenseOutsideContractedServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" abstract="false" name="CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dyai_CommitmentToPayExpandedPeriod" abstract="false" name="CommitmentToPayExpandedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" abstract="false" name="ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" abstract="false" name="DebtSecuritiesHeldtomaturityFairValueNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_NonexecutiveEmployeesMember" abstract="true" name="NonexecutiveEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" abstract="true" name="SharebasedCompensationAwardTrancheTwothroughFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" abstract="false" name="IncreaseDecreaseinPrepaidResearchandDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_NetherlandsOfficeLeaseMember" abstract="true" name="NetherlandsOfficeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_AccruedResearchandDevelopmentinProcessCurrent" abstract="false" name="AccruedResearchandDevelopmentinProcessCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_LeaseTypeDomain" abstract="true" name="LeaseTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" abstract="false" name="ResearchAndDevelopmentExpenseIncludingRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_A2011PlanMember" abstract="true" name="A2011PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" abstract="false" name="CollaborativeArrangementMinimumObligationForResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" abstract="false" name="DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementEquityInterestAcquired" abstract="false" name="CollaborativeArrangementEquityInterestAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_A2006PlanMember" abstract="true" name="A2006PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_PrepaidResearchandDevelopmentinProcessCurrent" abstract="false" name="PrepaidResearchandDevelopmentinProcessCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" abstract="false" name="DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementDurationOfAgreement" abstract="false" name="CollaborativeArrangementDurationOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" abstract="false" name="TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="dyai_IndustrialTechnologyBusinessMember" abstract="true" name="IndustrialTechnologyBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_OperatingLeasesAnnualRentalRate" abstract="false" name="OperatingLeasesAnnualRentalRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CommitmentToPayExpanded" abstract="false" name="CommitmentToPayExpanded" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" abstract="false" name="NumberOfResearchOrganizationPerformingServiceUnderContract" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" abstract="false" name="DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dyai_CollaborativeArrangementExclusivityPeriod" abstract="false" name="CollaborativeArrangementExclusivityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" abstract="false" name="DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ConsultantMember" abstract="true" name="ConsultantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" abstract="false" name="CollaborativeArrangementMaximumObligationForResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseAdditional" abstract="false" name="ResearchAndDevelopmentExpenseAdditional" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_AlphazymeMember" abstract="true" name="AlphazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" abstract="false" name="CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dyai_BDIHoldingsMember" abstract="true" name="BDIHoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_RevenueFromCollaborativeArrangementRecognized" abstract="false" name="RevenueFromCollaborativeArrangementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_BDIMember" abstract="true" name="BDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ExecutivesandKeyPersonnelMember" abstract="true" name="ExecutivesandKeyPersonnelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" abstract="false" name="ScheduleofResearchandDevelopmentCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dyai_CommitmentToPay" abstract="false" name="CommitmentToPay" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" abstract="false" name="CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dyai_VLPbioMember" abstract="true" name="VLPbioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_CollaborativeArrangementOutstandingCommitment" abstract="false" name="CollaborativeArrangementOutstandingCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_InvestmentsandCashAmortizedCost" abstract="false" name="InvestmentsandCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" abstract="false" name="CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_CollaborativeArrangementRevenueSharingPercentage" abstract="false" name="CollaborativeArrangementRevenueSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" abstract="false" name="CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dyai_PubliclyAnnouncedRepurchasePlansMember" abstract="true" name="PubliclyAnnouncedRepurchasePlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ContractorMember" abstract="true" name="ContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dyai_ResearchAndDevelopmentExpenseAdditionalTerm" abstract="false" name="ResearchAndDevelopmentExpenseAdditionalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>dyai-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dyai-20191231.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_58879b5a-b9c2-4985-85d8-7e39f34d5ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47e76739-c00b-4827-ab6a-dbc690bc8b85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58879b5a-b9c2-4985-85d8-7e39f34d5ce9" xlink:to="loc_us-gaap_AccountsPayableCurrent_47e76739-c00b-4827-ab6a-dbc690bc8b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9e8b6a2d-fd74-4327-b56e-fc3350d4cfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58879b5a-b9c2-4985-85d8-7e39f34d5ce9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9e8b6a2d-fd74-4327-b56e-fc3350d4cfb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0a0e3bb2-41c0-4c2f-a115-fdc326d0e383" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_58879b5a-b9c2-4985-85d8-7e39f34d5ce9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0a0e3bb2-41c0-4c2f-a115-fdc326d0e383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a2a81d1b-7dad-4277-aa28-5137fe9b8ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7016d0f1-058d-4d02-a0b7-8bbc82f8a7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2a81d1b-7dad-4277-aa28-5137fe9b8ef3" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7016d0f1-058d-4d02-a0b7-8bbc82f8a7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_89d683df-93fc-4060-a402-e5fe4a59d552" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2a81d1b-7dad-4277-aa28-5137fe9b8ef3" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_89d683df-93fc-4060-a402-e5fe4a59d552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c21202e9-507d-4d73-9a19-849b219543d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2a81d1b-7dad-4277-aa28-5137fe9b8ef3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c21202e9-507d-4d73-9a19-849b219543d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5887a7b2-6b9a-461c-b23b-49a829218535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2a81d1b-7dad-4277-aa28-5137fe9b8ef3" xlink:to="loc_us-gaap_AssetsCurrent_5887a7b2-6b9a-461c-b23b-49a829218535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1eb8c6e6-3e8e-4f75-8039-5e15aa4e9c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:to="loc_us-gaap_PreferredStockValue_1eb8c6e6-3e8e-4f75-8039-5e15aa4e9c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_99121eca-e0cd-464f-a91d-84c375b9ca50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:to="loc_us-gaap_CommonStockValue_99121eca-e0cd-464f-a91d-84c375b9ca50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1eeba716-2a06-4ea3-9e56-48f8911c1a10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1eeba716-2a06-4ea3-9e56-48f8911c1a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_85397d40-d34f-4a60-ac95-dbc576237b76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:to="loc_us-gaap_TreasuryStockValue_85397d40-d34f-4a60-ac95-dbc576237b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87acb9d3-1330-4d14-b3e4-cbab2f9ed603" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2a884e0b-570c-4e07-aca8-f1d7cfd445aa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87acb9d3-1330-4d14-b3e4-cbab2f9ed603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_908d1898-274c-46e7-ace2-91cabe79932b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_908d1898-274c-46e7-ace2-91cabe79932b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_8ec3996e-5c7e-48c4-b036-ef235e09815c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_8ec3996e-5c7e-48c4-b036-ef235e09815c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_0242ab2a-b534-4996-b660-a487c44e74b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_InterestReceivableCurrent_0242ab2a-b534-4996-b660-a487c44e74b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a82681fc-aa21-49f5-bae5-f64e2ec9388c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a82681fc-aa21-49f5-bae5-f64e2ec9388c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a80d9f1f-a0e1-42d7-8afb-93e12a599949" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a80d9f1f-a0e1-42d7-8afb-93e12a599949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0bf701a3-bb67-4e0b-bdfd-0f4f93a1e0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0bf701a3-bb67-4e0b-bdfd-0f4f93a1e0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent_e2403325-b72a-4349-a7a4-5e60dc6db29f" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopmentinProcessCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02ff8ee2-f383-4ccb-abdb-1ee42c930519" xlink:to="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent_e2403325-b72a-4349-a7a4-5e60dc6db29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b88fbb1b-4bda-4e90-a03c-e5bab60ab096" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bdf8aec5-8bad-43d5-a7dd-681f5908c78a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b88fbb1b-4bda-4e90-a03c-e5bab60ab096" xlink:to="loc_us-gaap_StockholdersEquity_bdf8aec5-8bad-43d5-a7dd-681f5908c78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c3d51932-76f4-475f-aced-d6c15a809b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b88fbb1b-4bda-4e90-a03c-e5bab60ab096" xlink:to="loc_us-gaap_LiabilitiesCurrent_c3d51932-76f4-475f-aced-d6c15a809b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a006cf95-85d6-484f-89fc-b93735416964" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b88fbb1b-4bda-4e90-a03c-e5bab60ab096" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a006cf95-85d6-484f-89fc-b93735416964" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6faa0614-fe50-4b0d-823c-6cb442d5d433" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_8232e56c-6025-4e6d-954c-ee075f33af48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6faa0614-fe50-4b0d-823c-6cb442d5d433" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_8232e56c-6025-4e6d-954c-ee075f33af48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09e76e01-f46a-4fe5-90cf-db8688214344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6faa0614-fe50-4b0d-823c-6cb442d5d433" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09e76e01-f46a-4fe5-90cf-db8688214344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_93b84f22-05ac-4bf1-8bfe-094b54d24fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_93b84f22-05ac-4bf1-8bfe-094b54d24fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b583032d-6819-4258-9362-b9e6d6e92ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b583032d-6819-4258-9362-b9e6d6e92ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_5c7da9ca-da78-4643-9584-3609c4d9d3c7" xlink:href="dyai-20191231.xsd#dyai_ResearchandDevelopmentExpenseRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:to="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_5c7da9ca-da78-4643-9584-3609c4d9d3c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7df28ebc-939a-47ae-ab28-fa0c5bf12020" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7df28ebc-939a-47ae-ab28-fa0c5bf12020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_25413151-6dfe-4744-b008-03c22208543b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cb4ef93f-a7f9-404b-be12-1cadbca798ab" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_25413151-6dfe-4744-b008-03c22208543b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_056511fc-c57c-4b2e-bcd9-34acf8dbeeea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a303e763-ad44-450d-8356-b1fab66dc051" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_056511fc-c57c-4b2e-bcd9-34acf8dbeeea" xlink:to="loc_us-gaap_CostsAndExpenses_a303e763-ad44-450d-8356-b1fab66dc051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85545532-12b9-44cc-915e-6a48824deb34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_056511fc-c57c-4b2e-bcd9-34acf8dbeeea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85545532-12b9-44cc-915e-6a48824deb34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7187d646-391d-4f31-802b-9e268489b0b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6b61ea64-fcc1-463e-a727-9f984d00541a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7187d646-391d-4f31-802b-9e268489b0b9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6b61ea64-fcc1-463e-a727-9f984d00541a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fe854b70-a953-45a2-aa2b-cef98f9c24b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7187d646-391d-4f31-802b-9e268489b0b9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fe854b70-a953-45a2-aa2b-cef98f9c24b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6585edd7-eeeb-461d-a6e4-c552921ce7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_NetIncomeLoss_6585edd7-eeeb-461d-a6e4-c552921ce7f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1bffc14f-e30e-4dd3-a1eb-81ed2161a93c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_ShareBasedCompensation_1bffc14f-e30e-4dd3-a1eb-81ed2161a93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_33da1d2b-ef9b-45fc-85c8-3fe2cd207166" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_33da1d2b-ef9b-45fc-85c8-3fe2cd207166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c492a9b7-165a-43bf-b2fa-30b14f544aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c492a9b7-165a-43bf-b2fa-30b14f544aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_b8136b40-a7f1-4dbb-9f55-bc9537e67083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_b8136b40-a7f1-4dbb-9f55-bc9537e67083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9efd2f9-41a3-40f3-a916-85270acfeb50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9efd2f9-41a3-40f3-a916-85270acfeb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f412e386-5347-4028-85bd-de6ad3d2cd46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f412e386-5347-4028-85bd-de6ad3d2cd46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_64ba6358-032c-402f-adf8-bee288d36e35" xlink:href="dyai-20191231.xsd#dyai_IncreaseDecreaseinPrepaidResearchandDevelopment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_64ba6358-032c-402f-adf8-bee288d36e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1518c75e-df9a-484b-bceb-8c2b765115b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1518c75e-df9a-484b-bceb-8c2b765115b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13bdd282-8226-4dab-ac30-58c14ecfeedd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13bdd282-8226-4dab-ac30-58c14ecfeedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c2b27188-b853-42c9-9ca4-47c2dae7dede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c2b27188-b853-42c9-9ca4-47c2dae7dede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23dfdc0e-5bbd-49f4-9d9e-c1631201d2da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23dfdc0e-5bbd-49f4-9d9e-c1631201d2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1c99ebe8-d1e4-4cce-ba5f-d996602e9aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4781fb01-e31a-4200-955c-52ad07b651fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1c99ebe8-d1e4-4cce-ba5f-d996602e9aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f2c583-118b-4f3e-909d-425c67be1754" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e4fde7c-9844-4b87-b809-a1dd5f5c3200" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f2c583-118b-4f3e-909d-425c67be1754" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e4fde7c-9844-4b87-b809-a1dd5f5c3200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae17b708-3fc7-4470-929a-ca6b4454c6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f2c583-118b-4f3e-909d-425c67be1754" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae17b708-3fc7-4470-929a-ca6b4454c6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b614b07-7348-46d0-a138-147f32676313" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f2c583-118b-4f3e-909d-425c67be1754" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b614b07-7348-46d0-a138-147f32676313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45f4999f-a758-417a-9c33-96667d6c998f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35f2c583-118b-4f3e-909d-425c67be1754" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45f4999f-a758-417a-9c33-96667d6c998f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e61046a4-1296-4f00-8995-f66978ef9d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_34b5439e-4b94-4f58-b8dc-b69e4436ce22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e61046a4-1296-4f00-8995-f66978ef9d9a" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_34b5439e-4b94-4f58-b8dc-b69e4436ce22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_586e28ae-58ab-4881-8d2d-32034faff00c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e61046a4-1296-4f00-8995-f66978ef9d9a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_586e28ae-58ab-4881-8d2d-32034faff00c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ceabed7-312a-416c-933a-439877292780" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_39f49032-d41e-495c-8090-5be8f6a54d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ceabed7-312a-416c-933a-439877292780" xlink:to="loc_us-gaap_PrepaidInsurance_39f49032-d41e-495c-8090-5be8f6a54d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f0f17139-60e1-4b27-ad0a-88d500aa95df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ceabed7-312a-416c-933a-439877292780" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f0f17139-60e1-4b27-ad0a-88d500aa95df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_a248b378-9742-4c22-88ae-bebcb3374d04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6ceabed7-312a-416c-933a-439877292780" xlink:to="loc_us-gaap_PrepaidTaxes_a248b378-9742-4c22-88ae-bebcb3374d04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6b0d70b4-694c-4652-ae90-8909a15da955" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentInProcessCurrent_2e0777d0-575f-490b-a181-9f8cf1504ede" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_6b0d70b4-694c-4652-ae90-8909a15da955" xlink:to="loc_dyai_ResearchAndDevelopmentInProcessCurrent_2e0777d0-575f-490b-a181-9f8cf1504ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ebf001ef-d55b-4a5d-bbb2-8a6c73f2ffc9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_6b0d70b4-694c-4652-ae90-8909a15da955" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ebf001ef-d55b-4a5d-bbb2-8a6c73f2ffc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_7749a080-4c72-4049-8d05-fd82521bc8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_6b0d70b4-694c-4652-ae90-8909a15da955" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_7749a080-4c72-4049-8d05-fd82521bc8d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_caf80a19-eeda-451b-bc40-d85f7d6538cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57ab91b5-a7cc-4183-a06d-cfc5a63ddae7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_caf80a19-eeda-451b-bc40-d85f7d6538cb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_57ab91b5-a7cc-4183-a06d-cfc5a63ddae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent_0211a1df-8dbe-4288-8f74-f4cefcc277b1" xlink:href="dyai-20191231.xsd#dyai_AccruedResearchandDevelopmentinProcessCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_caf80a19-eeda-451b-bc40-d85f7d6538cb" xlink:to="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent_0211a1df-8dbe-4288-8f74-f4cefcc277b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_12d78e25-04f5-4587-92d0-f8fbfb92ad5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_caf80a19-eeda-451b-bc40-d85f7d6538cb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_12d78e25-04f5-4587-92d0-f8fbfb92ad5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_0091f0b1-1a00-423b-a025-dffae20ea39d" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_65fa39eb-3384-44ae-8218-9dbac0ca049c" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_0091f0b1-1a00-423b-a025-dffae20ea39d" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_65fa39eb-3384-44ae-8218-9dbac0ca049c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_bc4dc80a-4a1a-4466-bedd-d6479fc5f70d" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_0091f0b1-1a00-423b-a025-dffae20ea39d" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_bc4dc80a-4a1a-4466-bedd-d6479fc5f70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_58fb56f4-2c58-4753-82ae-ea52a357b61d" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_0091f0b1-1a00-423b-a025-dffae20ea39d" xlink:to="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_58fb56f4-2c58-4753-82ae-ea52a357b61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_09d428bd-68da-4d80-a05a-3c39023db962" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_0091f0b1-1a00-423b-a025-dffae20ea39d" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_09d428bd-68da-4d80-a05a-3c39023db962" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestments"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_22fd90fd-53b5-414a-a7a7-039e72d94650" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_b1141ac1-8dc0-438a-b36f-0126fb0b2a72" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_22fd90fd-53b5-414a-a7a7-039e72d94650" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_b1141ac1-8dc0-438a-b36f-0126fb0b2a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_fd0108d0-2c2a-4fd6-804a-911ccc18ee55" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_22fd90fd-53b5-414a-a7a7-039e72d94650" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_fd0108d0-2c2a-4fd6-804a-911ccc18ee55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_825db557-39eb-484c-a5f0-1a0706ad4024" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_22fd90fd-53b5-414a-a7a7-039e72d94650" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_825db557-39eb-484c-a5f0-1a0706ad4024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_eebf4bef-35a8-4b16-965a-dee373d4a3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_93533615-964c-4620-9699-0ec8eff7bd31" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_eebf4bef-35a8-4b16-965a-dee373d4a3d9" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_93533615-964c-4620-9699-0ec8eff7bd31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_8719d7f7-042f-4302-b28a-043621fb25bf" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_eebf4bef-35a8-4b16-965a-dee373d4a3d9" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_8719d7f7-042f-4302-b28a-043621fb25bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_ba7e6dda-f7fb-4848-8b07-eb4666b3c115" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_eebf4bef-35a8-4b16-965a-dee373d4a3d9" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_ba7e6dda-f7fb-4848-8b07-eb4666b3c115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9280ecbc-56b8-430e-8ac8-5aad8ed5cb63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_eebf4bef-35a8-4b16-965a-dee373d4a3d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9280ecbc-56b8-430e-8ac8-5aad8ed5cb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_InvestmentsandCashAmortizedCost_1fefa1d6-88cb-49a0-a5dd-ee105760168c" xlink:href="dyai-20191231.xsd#dyai_InvestmentsandCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59cf89e4-4c8b-42b1-9ea7-c7f4314728ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_1fefa1d6-88cb-49a0-a5dd-ee105760168c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59cf89e4-4c8b-42b1-9ea7-c7f4314728ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_cab2a873-bf76-4bcb-ad16-3e68cdf3fffd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_1fefa1d6-88cb-49a0-a5dd-ee105760168c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_cab2a873-bf76-4bcb-ad16-3e68cdf3fffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_db0c560c-f6ac-45b1-a4a2-e58985e193b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_1fefa1d6-88cb-49a0-a5dd-ee105760168c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_db0c560c-f6ac-45b1-a4a2-e58985e193b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9480b51b-aadf-476f-8967-2a1338894a92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_7bbb443e-ca2d-443f-80d6-9c3934b7cf15" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9480b51b-aadf-476f-8967-2a1338894a92" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_7bbb443e-ca2d-443f-80d6-9c3934b7cf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_e3a743e9-ea36-401b-9968-6cb19faf2e2e" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9480b51b-aadf-476f-8967-2a1338894a92" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_e3a743e9-ea36-401b-9968-6cb19faf2e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65a16152-8001-44ca-b01c-7e8eff3aa7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_2e5db44d-9ddb-4678-8375-d8a71ec9b325" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65a16152-8001-44ca-b01c-7e8eff3aa7bc" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_2e5db44d-9ddb-4678-8375-d8a71ec9b325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_ecf7ba40-6878-4ee4-8067-97e856ce3d4d" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_65a16152-8001-44ca-b01c-7e8eff3aa7bc" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_ecf7ba40-6878-4ee4-8067-97e856ce3d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_02d4557d-706d-41f6-8349-0786997851ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ece042c-2d9f-4700-84d9-7422ce2242c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_02d4557d-706d-41f6-8349-0786997851ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ece042c-2d9f-4700-84d9-7422ce2242c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f44dc5fe-284a-4331-8274-07b51eb91728" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_02d4557d-706d-41f6-8349-0786997851ce" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f44dc5fe-284a-4331-8274-07b51eb91728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_a6a83659-e21e-4857-8a89-2c8a8f957586" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_02d4557d-706d-41f6-8349-0786997851ce" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_a6a83659-e21e-4857-8a89-2c8a8f957586" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dyai_InvestmentsandCashAmortizedCost_f410f25c-4ce1-4c65-ae52-fe6bc629bd39" xlink:href="dyai-20191231.xsd#dyai_InvestmentsandCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_bc66720b-9263-4221-af7e-18cd21b894d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_f410f25c-4ce1-4c65-ae52-fe6bc629bd39" xlink:to="loc_us-gaap_InvestmentsAndCash_bc66720b-9263-4221-af7e-18cd21b894d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c83da136-8d6a-4b54-8705-01cf42a44048" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_f410f25c-4ce1-4c65-ae52-fe6bc629bd39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c83da136-8d6a-4b54-8705-01cf42a44048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4064f615-c8ae-4894-8a6a-ea86599836aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost_f410f25c-4ce1-4c65-ae52-fe6bc629bd39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4064f615-c8ae-4894-8a6a-ea86599836aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchCollaborationandSublicensingAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_496fc9c0-b762-4201-ae6f-0bd22cd29c80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b9663e3c-c1fb-4222-bc43-0aadd573db53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_496fc9c0-b762-4201-ae6f-0bd22cd29c80" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b9663e3c-c1fb-4222-bc43-0aadd573db53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_39f5afeb-d6f0-45dd-a122-d294b0a361a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_496fc9c0-b762-4201-ae6f-0bd22cd29c80" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_39f5afeb-d6f0-45dd-a122-d294b0a361a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesBenefitProvisionforIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_3256d5d2-b3b4-4c27-a09c-ec66c3a1cc11" xlink:href="dyai-20191231.xsd#dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_99b1274a-5da5-4146-94df-f6b4eb4915f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_3256d5d2-b3b4-4c27-a09c-ec66c3a1cc11" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_99b1274a-5da5-4146-94df-f6b4eb4915f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_0bd0931e-92c5-4f15-9c1e-30ba70d76377" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_3256d5d2-b3b4-4c27-a09c-ec66c3a1cc11" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_0bd0931e-92c5-4f15-9c1e-30ba70d76377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c94d2780-6c5f-4e21-aa08-97484e7418b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_3256d5d2-b3b4-4c27-a09c-ec66c3a1cc11" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c94d2780-6c5f-4e21-aa08-97484e7418b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesReconciliationIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90c8ad3a-c194-4fd0-8f3e-31737a657bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90c8ad3a-c194-4fd0-8f3e-31737a657bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bee5a770-857a-4775-ad13-27c3e6c529a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bee5a770-857a-4775-ad13-27c3e6c529a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9b4c0f62-3db1-4166-ae38-1dce73d51ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9b4c0f62-3db1-4166-ae38-1dce73d51ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_391a7702-ac0f-47f5-9e3d-af7ef9823d91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_391a7702-ac0f-47f5-9e3d-af7ef9823d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_5271dde1-5db3-4444-9a9f-eaeeed1adc2d" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_5271dde1-5db3-4444-9a9f-eaeeed1adc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_65a22336-0756-485d-b923-ac74cbd8c9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_65a22336-0756-485d-b923-ac74cbd8c9ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9caf2beb-168f-42a9-9c81-490e55d2df5a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9caf2beb-168f-42a9-9c81-490e55d2df5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_71185bf5-9fbf-4f18-ab9d-4151b71ee63c" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cbf5731c-d4e6-4994-92a8-502cefaf10a5" xlink:to="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_71185bf5-9fbf-4f18-ab9d-4151b71ee63c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesDeferredIncomeTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8320afe-55f5-44b6-afcb-a8760bfa9cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DeferredTaxAssetLiabilityGross_be28ad63-3698-4415-9b9a-2714b1bcb7a0" xlink:href="dyai-20191231.xsd#dyai_DeferredTaxAssetLiabilityGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8320afe-55f5-44b6-afcb-a8760bfa9cf0" xlink:to="loc_dyai_DeferredTaxAssetLiabilityGross_be28ad63-3698-4415-9b9a-2714b1bcb7a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ab38785e-a172-4cd6-810f-5c43002feec0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8320afe-55f5-44b6-afcb-a8760bfa9cf0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ab38785e-a172-4cd6-810f-5c43002feec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DeferredTaxAssetLiabilityGross_cb20e248-029e-453f-9635-243978f14430" xlink:href="dyai-20191231.xsd#dyai_DeferredTaxAssetLiabilityGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_deb4da34-d297-4a63-8e3d-f7d564ec7f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_DeferredTaxAssetLiabilityGross_cb20e248-029e-453f-9635-243978f14430" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_deb4da34-d297-4a63-8e3d-f7d564ec7f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a0dc1e98-472a-4e31-a1ce-c10ed5a913dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_DeferredTaxAssetLiabilityGross_cb20e248-029e-453f-9635-243978f14430" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a0dc1e98-472a-4e31-a1ce-c10ed5a913dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_611b219d-371c-4efb-aa73-8200369e61d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_DeferredTaxAssetLiabilityGross_cb20e248-029e-453f-9635-243978f14430" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_611b219d-371c-4efb-aa73-8200369e61d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_657b37bc-6350-4fc9-ba82-93e0bfbb5ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dyai_DeferredTaxAssetLiabilityGross_cb20e248-029e-453f-9635-243978f14430" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_657b37bc-6350-4fc9-ba82-93e0bfbb5ae4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesPurchaseObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_ea0b3771-cdec-4989-9c8a-20f8dcc8f168" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_67636509-a3aa-47aa-aad8-b0ad980daeb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_ea0b3771-cdec-4989-9c8a-20f8dcc8f168" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_67636509-a3aa-47aa-aad8-b0ad980daeb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_e3013b6f-824d-402a-8050-1438223a4c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_ea0b3771-cdec-4989-9c8a-20f8dcc8f168" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_e3013b6f-824d-402a-8050-1438223a4c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_7f54fced-316e-43f2-a8ab-5b12a010bd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_ea0b3771-cdec-4989-9c8a-20f8dcc8f168" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_7f54fced-316e-43f2-a8ab-5b12a010bd3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTextualDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityStockRepurchaseDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>dyai-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dyai-20191231.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="extended" id="i7195ebd3df0e4a738e9d4887cdc08b27_c02a02e9-eb15-4edc-9fd2-a36fbe89d870"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i659c1337bd024c23bb2f443ebaba7315_8d59eeb9-ee14-44e3-97ce-574adba799b6"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i92defad517ac4a739f072b4eb891ab06_4d813ad8-09ce-4f43-b40e-d12d02d2058b"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ie8ae0c87250543a4bc33a10979de27b2_01474c19-c17b-4d10-ae28-56a6c9ab1581"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3610d041c2de4f3fbfbf54c73dff8eb3_1bd1a3ae-5069-4d6b-9096-341f446f5c85">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae291b1f-feb8-42a5-85da-b103acf2ee91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae291b1f-feb8-42a5-85da-b103acf2ee91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d22d40f8-39f2-470a-99d1-337894e95a26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockholdersEquity_d22d40f8-39f2-470a-99d1-337894e95a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6278a206-7f8e-4910-9116-b45d6cff60cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6278a206-7f8e-4910-9116-b45d6cff60cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_154a71a0-c9f8-4af0-bff1-84e0a10e43d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_154a71a0-c9f8-4af0-bff1-84e0a10e43d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c6a713ab-e6aa-42ec-b4b9-e7fe368ad69a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c6a713ab-e6aa-42ec-b4b9-e7fe368ad69a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b3c6add1-3a4e-482d-a9d4-99bfcc3303c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b3c6add1-3a4e-482d-a9d4-99bfcc3303c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9615a0d1-6c8e-43aa-a1a7-bd235944ca41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9615a0d1-6c8e-43aa-a1a7-bd235944ca41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5cecf9f-e400-486d-82a4-935c8455481c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_NetIncomeLoss_a5cecf9f-e400-486d-82a4-935c8455481c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_193e75d1-db8b-43d8-8181-dd2fbbdc34f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a215bc53-30b1-4251-b16f-fe4acd4b25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:to="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5276480e-7cf7-44a8-a48f-9c852e936a15_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:to="loc_us-gaap_EquityComponentDomain_5276480e-7cf7-44a8-a48f-9c852e936a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:to="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7501a383-5ce4-474a-bdb5-cd98362d20c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_CommonStockMember_7501a383-5ce4-474a-bdb5-cd98362d20c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b8b8e65-1e50-41ba-973e-970a80c2131f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_TreasuryStockMember_2b8b8e65-1e50-41ba-973e-970a80c2131f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9abb8f1a-11f2-4c53-be76-6767e96fd3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9abb8f1a-11f2-4c53-be76-6767e96fd3a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_df04774d-7ad0-4e2a-b872-90b50aba81d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_RetainedEarningsMember_df04774d-7ad0-4e2a-b872-90b50aba81d4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="iab8de69130164f0dace145aebcb168a0_9b489772-ad0c-46c7-ba56-2b32db7a1f10"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="ib1f376ad7abd42049dc1fad7e4bd6e10_3d4d94ad-3cd8-4554-b074-f9c469b91f8a"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ib62d0f01652848eab67f99c6b4102130_231f6f82-9d11-4f03-8ba2-9fac947edecd"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i60983e9f54d7470885cb239ce7e694c7_a4e6d538-c779-4002-8edd-e20345fddcf0"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended" id="i500474afd1f3411bb46be1b0b96c51e7_b24803ec-cc7b-43a0-9848-371912390a59">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_d731c002-019c-49a9-aad1-17d3152f5e7c" xlink:href="dyai-20191231.xsd#dyai_NumberOfResearchOrganizationPerformingServiceUnderContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_d731c002-019c-49a9-aad1-17d3152f5e7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_234003ac-6054-4dc1-9090-338baf6d0103" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_234003ac-6054-4dc1-9090-338baf6d0103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b4985ce4-46f0-4597-8acf-7d8911ccde0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b4985ce4-46f0-4597-8acf-7d8911ccde0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConcentrationRiskNumberofCustomers_92287df4-b31a-471d-958b-4b258cd6cc03" xlink:href="dyai-20191231.xsd#dyai_ConcentrationRiskNumberofCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_dyai_ConcentrationRiskNumberofCustomers_92287df4-b31a-471d-958b-4b258cd6cc03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2f203fed-4296-4dc6-bcf8-addf7909cc32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2f203fed-4296-4dc6-bcf8-addf7909cc32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d589e17d-1794-49f2-bc5f-c079a8bde1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d589e17d-1794-49f2-bc5f-c079a8bde1f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_db55e4c2-3b24-406a-8789-d5f6c3edee27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AccountsReceivableNet_db55e4c2-3b24-406a-8789-d5f6c3edee27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9b8297a5-d49c-481f-896a-2d117c1683b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9b8297a5-d49c-481f-896a-2d117c1683b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2cb055d5-6455-4a0a-9030-403ac5a4242b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2cb055d5-6455-4a0a-9030-403ac5a4242b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b919b010-9462-41f7-9ec2-b3cffd7be947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b919b010-9462-41f7-9ec2-b3cffd7be947" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2a80cf0-1b88-4390-9f89-07c4cf33f51e_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2a80cf0-1b88-4390-9f89-07c4cf33f51e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DuPontDaniscoMember_380e6b28-f4bd-4b59-88bc-6adb6140a9e7" xlink:href="dyai-20191231.xsd#dyai_DuPontDaniscoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:to="loc_dyai_DuPontDaniscoMember_380e6b28-f4bd-4b59-88bc-6adb6140a9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractResearchOrganizationsMember_6ceea767-8cf9-4030-a1dd-9f95231d58c7" xlink:href="dyai-20191231.xsd#dyai_ContractResearchOrganizationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:to="loc_dyai_ContractResearchOrganizationsMember_6ceea767-8cf9-4030-a1dd-9f95231d58c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1ded76f-6476-4a26-be9f-3a59f0f6f665_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1ded76f-6476-4a26-be9f-3a59f0f6f665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IndustrialTechnologyBusinessMember_d67b262c-b210-494b-a956-abdb159d8f21" xlink:href="dyai-20191231.xsd#dyai_IndustrialTechnologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:to="loc_dyai_IndustrialTechnologyBusinessMember_d67b262c-b210-494b-a956-abdb159d8f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_157dddef-6d26-4421-90b8-4634bbf90958_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:to="loc_srt_SegmentGeographicalDomain_157dddef-6d26-4421-90b8-4634bbf90958_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:to="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7ead9165-c169-469d-8a21-a24bd661cf40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:to="loc_us-gaap_NonUsMember_7ead9165-c169-469d-8a21-a24bd661cf40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_46ee0bfe-238a-4fb9-ab48-cdcc9f30a81e" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:to="loc_country_US_46ee0bfe-238a-4fb9-ab48-cdcc9f30a81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_47d074c6-e3d0-4546-b063-11a12f2f9c87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_47d074c6-e3d0-4546-b063-11a12f2f9c87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_47b2b741-2831-4135-a6b5-6c6d8a734600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_47b2b741-2831-4135-a6b5-6c6d8a734600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8bad205c-1d0d-4019-8bb0-ae2b0300082f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8bad205c-1d0d-4019-8bb0-ae2b0300082f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_63638213-02cb-4af9-a6fd-0e921d62879b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_SalesRevenueNetMember_63638213-02cb-4af9-a6fd-0e921d62879b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_bfc486d5-c474-46d4-8aad-d0096b487a31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_AccountsReceivableMember_bfc486d5-c474-46d4-8aad-d0096b487a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_68a88427-767c-4ae3-9fe4-e10c5f398130" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_AccountsPayableMember_68a88427-767c-4ae3-9fe4-e10c5f398130" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended" id="i42ecd2becb0d4da1bdbeed18d4b686ac_72060cce-ee29-4507-8bc4-bfadd040878e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e4ba64a2-38ef-4cfa-92ae-f0f7d0e3b299" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e4ba64a2-38ef-4cfa-92ae-f0f7d0e3b299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_646db54b-41be-46bb-afd7-f1965afd9dae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_646db54b-41be-46bb-afd7-f1965afd9dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_1ffb7aa9-4819-4003-953e-0bb01dc008c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:to="loc_us-gaap_BilledRevenuesMember_1ffb7aa9-4819-4003-953e-0bb01dc008c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember_7e0b49c4-9a2c-4e06-a15a-61a1423c40a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:to="loc_us-gaap_UnbilledRevenuesMember_7e0b49c4-9a2c-4e06-a15a-61a1423c40a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="ib0c3d5854b034f5a845f5a9eeb88677d_f7bfe777-5ba4-415e-b4e5-1044eaad4601"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="extended" id="if051e4c8398b44c8a9f29b9c1762493b_a66e4e76-d84d-4db4-9ac4-349671240c55"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="extended" id="i30a471ed4c6c469499bf8b33a167d1e1_a77e281c-bd68-4a3f-b0ed-69a0af7f37a0"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="extended" id="i0674a0fe13d1453d8b82307d659eeb8e_f188eb74-4a81-4851-b5f1-0eb72b218c6c"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestments"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="extended" id="i3dc743b2bdb5495ca78b4d31f6b992a1_deb84394-14a8-4a2c-bc69-0a9c51dec542"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="extended" id="i3b05afed2b6f46438fbdd42950b8f651_6971eda0-450c-4252-8fae-8a5e830bcfcc"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="extended" id="i0049a4e601094646b6c271ac81e14d43_f92d2649-88f8-45bc-9960-47c7ddc08a2a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67d9911c-edcc-4232-8bf3-eb62cbaddf47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67d9911c-edcc-4232-8bf3-eb62cbaddf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f561a993-b994-4299-a2b2-99b17aacaf23" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f561a993-b994-4299-a2b2-99b17aacaf23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_cc36c689-e4ae-458d-83b3-2cbd4ee53661" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_cc36c689-e4ae-458d-83b3-2cbd4ee53661" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_64ce7b98-2ef2-4a53-9d31-85ab8cb88194" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_64ce7b98-2ef2-4a53-9d31-85ab8cb88194" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_acf8ec3e-eeb0-465a-aa9b-e9272159b155" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_acf8ec3e-eeb0-465a-aa9b-e9272159b155" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_eea62223-758e-40bd-a6d1-01113ca5e08b" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_eea62223-758e-40bd-a6d1-01113ca5e08b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_b2925394-b502-40ea-9393-ab60fc4a123b" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_b2925394-b502-40ea-9393-ab60fc4a123b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_9ba4289e-8392-4f99-9028-47adf4dedf21" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_9ba4289e-8392-4f99-9028-47adf4dedf21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a8453416-bb9c-41d4-8305-71b797460e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a8453416-bb9c-41d4-8305-71b797460e3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_93b98671-5186-4c56-b39a-eef98768d8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_InvestmentsAndCash_93b98671-5186-4c56-b39a-eef98768d8b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50543adc-0329-487f-9d30-6673b4d2cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50543adc-0329-487f-9d30-6673b4d2cc49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c9bccfc-ad35-4987-8d0a-98be283fb7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c9bccfc-ad35-4987-8d0a-98be283fb7f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_InvestmentsandCashAmortizedCost_5772dcc9-153b-42b3-9181-145dd34e1ae6" xlink:href="dyai-20191231.xsd#dyai_InvestmentsandCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_InvestmentsandCashAmortizedCost_5772dcc9-153b-42b3-9181-145dd34e1ae6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_cb540754-abdb-4906-9a16-5682da470264" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_cb540754-abdb-4906-9a16-5682da470264" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad969e5c-5c18-4eb0-b9d6-6b965690eda2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ad969e5c-5c18-4eb0-b9d6-6b965690eda2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_83033cd8-bdfc-4338-9889-1177dd7d5111" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_83033cd8-bdfc-4338-9889-1177dd7d5111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4eb104bb-c0ab-4e77-b257-a989340a03ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4eb104bb-c0ab-4e77-b257-a989340a03ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ef04f2a1-4701-420f-a8f9-4eafa544a2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:to="loc_us-gaap_CashMember_ef04f2a1-4701-420f-a8f9-4eafa544a2a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2187d2a1-4967-40cb-9e40-9ee1919a63a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2187d2a1-4967-40cb-9e40-9ee1919a63a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ef6bad6-ac9a-4bf7-820e-513b0b15274c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ef6bad6-ac9a-4bf7-820e-513b0b15274c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b708ad9-a35d-4a73-8fe4-3650483a5405" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b708ad9-a35d-4a73-8fe4-3650483a5405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1f41f8d0-5cdc-4158-b21a-91b965720344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1f41f8d0-5cdc-4158-b21a-91b965720344" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="extended" id="i1c8eb22dc9f44125896c76cbb69a27fa_ddffbc46-12eb-4cf8-a78c-1cb9c0f5f348"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchCollaborationandSublicensingAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="extended" id="i7d0341db77c7406abde348980769ba45_314e3657-245a-42ba-8d72-f9a84113f936">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementDurationOfAgreement_70f7d229-ff56-4afe-947b-89b7a9c12989" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementDurationOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementDurationOfAgreement_70f7d229-ff56-4afe-947b-89b7a9c12989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_a9f9d07e-8d99-437e-a666-70330a3c753f" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_a9f9d07e-8d99-437e-a666-70330a3c753f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementEquityInterestAcquired_5b69082a-18fd-4590-9988-74a88724a2db" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementEquityInterestAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementEquityInterestAcquired_5b69082a-18fd-4590-9988-74a88724a2db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_f82d45b1-c702-402f-b58b-3433dd0963f1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_f82d45b1-c702-402f-b58b-3433dd0963f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementRevenueSharingPercentage_f3339ebc-d758-46ef-80c1-b9b03e588dc1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementRevenueSharingPercentage_f3339ebc-d758-46ef-80c1-b9b03e588dc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_55a20d02-d5cf-4fda-9f35-711912c02028" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_55a20d02-d5cf-4fda-9f35-711912c02028" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_74409a1d-c34a-4a9e-b2c4-1931bfe6d20d" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_74409a1d-c34a-4a9e-b2c4-1931bfe6d20d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOutstandingCommitment_1e23692a-4faa-4f89-a393-4736d751a6eb" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOutstandingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOutstandingCommitment_1e23692a-4faa-4f89-a393-4736d751a6eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopment_81642a1d-c846-4f0a-9e01-a0a274bac68d" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_PrepaidResearchandDevelopment_81642a1d-c846-4f0a-9e01-a0a274bac68d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_c7dc8ffb-d7cd-46a2-a26d-01185efb4f7e" xlink:href="dyai-20191231.xsd#dyai_ResearchandDevelopmentExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_c7dc8ffb-d7cd-46a2-a26d-01185efb4f7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc58d8ee-414e-495a-a867-ac39a716ca66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc58d8ee-414e-495a-a867-ac39a716ca66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementExclusivityPeriod_2f59ed1a-03a2-4369-a8de-4b1415c23cc1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementExclusivityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementExclusivityPeriod_2f59ed1a-03a2-4369-a8de-4b1415c23cc1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_56dcfd72-87e6-48ff-b856-67bed4486dd3" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_56dcfd72-87e6-48ff-b856-67bed4486dd3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_21a432fe-beec-43ba-a8aa-a09c3583feac" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_21a432fe-beec-43ba-a8aa-a09c3583feac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_53e801b9-fd71-441e-b81c-d84f03fc3a82" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_53e801b9-fd71-441e-b81c-d84f03fc3a82" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_5524442a-525c-4547-83a1-03545442acc5" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_5524442a-525c-4547-83a1-03545442acc5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_3b9e415f-ce97-451d-8130-6abb7a478657" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_3b9e415f-ce97-451d-8130-6abb7a478657" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_RevenueFromCollaborativeArrangementRecognized_6136dba6-7610-490f-b90c-716098de1bc1" xlink:href="dyai-20191231.xsd#dyai_RevenueFromCollaborativeArrangementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_RevenueFromCollaborativeArrangementRecognized_6136dba6-7610-490f-b90c-716098de1bc1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6833ceaa-0cac-418f-b42c-924d83468dff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:to="loc_us-gaap_ProjectMember_6833ceaa-0cac-418f-b42c-924d83468dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:to="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchServicesAgreementMember_66ca9311-8be6-47b4-8ee0-faca8575e9a1" xlink:href="dyai-20191231.xsd#dyai_ResearchServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:to="loc_dyai_ResearchServicesAgreementMember_66ca9311-8be6-47b4-8ee0-faca8575e9a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ServiceFrameworkAgreementMember_de18e18b-9011-48c6-ba4c-93d29f923c43" xlink:href="dyai-20191231.xsd#dyai_ServiceFrameworkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:to="loc_dyai_ServiceFrameworkAgreementMember_de18e18b-9011-48c6-ba4c-93d29f923c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ffae3086-6e1d-4e49-9231-db3bbfe689dc_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:to="loc_srt_OwnershipDomain_ffae3086-6e1d-4e49-9231-db3bbfe689dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:to="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIHoldingsMember_91ab8d18-dddb-4598-9c08-0e21cbe2bf98" xlink:href="dyai-20191231.xsd#dyai_BDIHoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_BDIHoldingsMember_91ab8d18-dddb-4598-9c08-0e21cbe2bf98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VLPbioMember_21fffdf3-de02-45ac-ba7d-ddc1544be202" xlink:href="dyai-20191231.xsd#dyai_VLPbioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_VLPbioMember_21fffdf3-de02-45ac-ba7d-ddc1544be202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIMember_ace45fc2-b40c-4e13-9e4d-afaabe2f95d1" xlink:href="dyai-20191231.xsd#dyai_BDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_BDIMember_ace45fc2-b40c-4e13-9e4d-afaabe2f95d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cec481-3dbe-4f62-b110-e39c9ea55bc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cec481-3dbe-4f62-b110-e39c9ea55bc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_91a608c4-0694-4c8e-846f-7945716bd6af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:to="loc_us-gaap_CollaborativeArrangementMember_91a608c4-0694-4c8e-846f-7945716bd6af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_224076ef-11f7-4103-9943-e86d76cde566_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:to="loc_srt_RangeMember_224076ef-11f7-4103-9943-e86d76cde566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:to="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d9d63e6-3445-4a6e-9792-1d06a917163a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:to="loc_srt_MinimumMember_9d9d63e6-3445-4a6e-9792-1d06a917163a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06a28412-2461-4b85-a458-d95685b19fcc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:to="loc_srt_MaximumMember_06a28412-2461-4b85-a458-d95685b19fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef05e5a9-1853-410a-a894-28c9ac071baf_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef05e5a9-1853-410a-a894-28c9ac071baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SerumMember_9e372fc8-a5d0-4df8-823a-fdc88eb7d3a8" xlink:href="dyai-20191231.xsd#dyai_SerumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:to="loc_dyai_SerumMember_9e372fc8-a5d0-4df8-823a-fdc88eb7d3a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bf5e81e5-dace-4be4-b46f-c85508ba6fd8_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bf5e81e5-dace-4be4-b46f-c85508ba6fd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AlphazymeMember_10595fcd-ba80-4b32-8310-378fdd31a82e" xlink:href="dyai-20191231.xsd#dyai_AlphazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:to="loc_dyai_AlphazymeMember_10595fcd-ba80-4b32-8310-378fdd31a82e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NovovetMember_bb0009ec-e656-44c7-b026-6060d091fee0" xlink:href="dyai-20191231.xsd#dyai_NovovetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:to="loc_dyai_NovovetMember_bb0009ec-e656-44c7-b026-6060d091fee0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxes" xlink:type="extended" id="ifa4873641ef84ceab2b0d74e4bba4f78_f9e29d3b-817e-4b70-90b5-165237394aae"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="extended" id="i580f5fdc1753418cac8fb6f527cc9dde_5b1eac44-3997-4a8e-8d40-4ec4543bbf4e"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="extended" id="i34e0c8806c1d4561be76c81d8d9947e2_fd077aa1-adf7-41c9-a6e2-4014026d1c8c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_60caafd8-dcd8-4165-853c-026201c32d79" xlink:href="dyai-20191231.xsd#dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_60caafd8-dcd8-4165-853c-026201c32d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_b2d75de8-e182-4061-a108-a83b98c02618" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_b2d75de8-e182-4061-a108-a83b98c02618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b566910-8ed9-4fcb-92e7-279b53ae99e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b566910-8ed9-4fcb-92e7-279b53ae99e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a451e232-c2c5-4e46-bed5-b19912aab04a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a451e232-c2c5-4e46-bed5-b19912aab04a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_57052ac7-08c8-4ead-b3b1-a15742e27c50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_57052ac7-08c8-4ead-b3b1-a15742e27c50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8824c67-25d6-4cc2-ae35-a147b016950e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8824c67-25d6-4cc2-ae35-a147b016950e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfFinanceIndiaMember_b51d97b0-2fdf-402b-9b46-4097c62560c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfFinanceIndiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:to="loc_us-gaap_MinistryOfFinanceIndiaMember_b51d97b0-2fdf-402b-9b46-4097c62560c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended" id="i25026137e33341b88cc54c5811e9dfd4_8b62b00a-3721-44af-a34d-0dd24fe53381"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesBenefitProvisionforIncomeTaxDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="extended" id="i8e41bcfddca0438ebfcb83c46326321d_349b7029-2b39-43d6-9bae-b02a7c2738ee"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesReconciliationIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="extended" id="i59a765d03cf3439b82d4488d289e126b_500cce09-7a80-441c-acc3-b4fd858c13dc"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesDeferredIncomeTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="extended" id="i48b1586ca2c047d88ac411c5323627c9_9e3e21d4-5eca-4e55-be4e-4a6b51f1fe02"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="extended" id="i86d2478866394de5b953d644e2062a0a_411bf0d2-21aa-4d4a-be94-3de82a352bc8"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ib19c218bd80e4ba4a1fc3a1397a54e1c_fdd105c0-e5ed-4ce4-9122-0b0c6ef9eb45"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="extended" id="i2a0339cdf6784d29818940dac3a0504c_b086d4d9-90b2-4d55-8668-e16f7ac44e3e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_05001f99-44a3-48ed-a7e2-8d5351640428" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_05001f99-44a3-48ed-a7e2-8d5351640428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesMonthlyRentalRate_d986900e-77a7-45b7-b3db-f98fb2c8d257" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesMonthlyRentalRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_OperatingLeasesMonthlyRentalRate_d986900e-77a7-45b7-b3db-f98fb2c8d257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesAnnualRentalRate_c7455155-e654-4838-83a0-e6146213e317" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesAnnualRentalRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_OperatingLeasesAnnualRentalRate_c7455155-e654-4838-83a0-e6146213e317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_44c32ac8-61dd-4821-a4f0-93d85158b2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_44c32ac8-61dd-4821-a4f0-93d85158b2dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPay_25ea064e-abd8-4602-b32b-a8b6ba2d26b2" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPay_25ea064e-abd8-4602-b32b-a8b6ba2d26b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentDevelopmentPeriod_26c3e80d-6360-4f8f-9444-a71e532d8381" xlink:href="dyai-20191231.xsd#dyai_CommitmentDevelopmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentDevelopmentPeriod_26c3e80d-6360-4f8f-9444-a71e532d8381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentSuccessBonusAward_4c317496-38d9-42e5-9dca-d19911110062" xlink:href="dyai-20191231.xsd#dyai_CommitmentSuccessBonusAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentSuccessBonusAward_4c317496-38d9-42e5-9dca-d19911110062" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpanded_2ce2041e-327e-4a11-ad3d-109d8a0c762b" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpanded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPayExpanded_2ce2041e-327e-4a11-ad3d-109d8a0c762b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpandedPeriod_0d6845ab-8107-421f-85cb-4dd14f5df262" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpandedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPayExpandedPeriod_0d6845ab-8107-421f-85cb-4dd14f5df262" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod_ebecf685-e15c-4e8c-91b9-420fdb5da25b" xlink:href="dyai-20191231.xsd#dyai_CommitmentsRightToTerminateContractNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod_ebecf685-e15c-4e8c-91b9-420fdb5da25b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:to="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeDomain_e4ba8bd9-97d7-414f-a118-5dc485c93817_default" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:to="loc_dyai_LeaseTypeDomain_e4ba8bd9-97d7-414f-a118-5dc485c93817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:to="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_JupiterFloridaHeadquartersLeaseMember_999734e4-d236-49a8-8d50-2e92c43fb458" xlink:href="dyai-20191231.xsd#dyai_JupiterFloridaHeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:to="loc_dyai_JupiterFloridaHeadquartersLeaseMember_999734e4-d236-49a8-8d50-2e92c43fb458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NetherlandsOfficeLeaseMember_5540d17a-d3d9-4203-bb9e-7b993b44e633" xlink:href="dyai-20191231.xsd#dyai_NetherlandsOfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:to="loc_dyai_NetherlandsOfficeLeaseMember_5540d17a-d3d9-4203-bb9e-7b993b44e633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:to="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7147bc88-5e9d-4273-b024-33edaa9ee7e0_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7147bc88-5e9d-4273-b024-33edaa9ee7e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_b969d460-b546-4ff2-9b88-6ed037a846ee" xlink:href="dyai-20191231.xsd#dyai_VTTTechnicalResearchCentreofFinlandLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:to="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_b969d460-b546-4ff2-9b88-6ed037a846ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesPurchaseObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="extended" id="ic876fe039155489c8614dd114fe304f7_e529079c-7048-4687-8735-b7d4e7626557"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="extended" id="i4f2e2d3708074b21bfd05f2b5069528e_215e2f8f-b921-44d1-a810-e6df67f152c0"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="extended" id="ic8d3172960ee49808dccdaa1245cc011_9deea491-57a6-4572-a17e-1009b3ebc41f"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="extended" id="i23a499b05f6c454f8d32cfde3835e947_60b12833-78b5-42e3-ad8a-7794794f80e3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f139260c-04c0-4ace-93c8-50c04721eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f139260c-04c0-4ace-93c8-50c04721eb4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59573b2e-1f7d-499f-a1d1-936f1d879d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59573b2e-1f7d-499f-a1d1-936f1d879d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e220f707-b5f0-4399-b9e0-d1f02fa9572f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e220f707-b5f0-4399-b9e0-d1f02fa9572f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6f059ca-9aad-4072-a280-37c77585d1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6f059ca-9aad-4072-a280-37c77585d1fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ef38ec3-9ac6-4165-b056-d7cbdebdcb44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ef38ec3-9ac6-4165-b056-d7cbdebdcb44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ce4855d0-c566-4940-92a0-cffd70ac660d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ce4855d0-c566-4940-92a0-cffd70ac660d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_de96c289-2edd-4717-928d-9ad17eb79084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_de96c289-2edd-4717-928d-9ad17eb79084" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bdb2683-072a-4c9c-9ce6-24951225b294" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bdb2683-072a-4c9c-9ce6-24951225b294" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61e9c051-9100-46c2-a5aa-f8c49c236b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61e9c051-9100-46c2-a5aa-f8c49c236b7d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3751a1c2-a4f1-41c7-8ea1-a541afc9543c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3751a1c2-a4f1-41c7-8ea1-a541afc9543c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f5731ee-c6a2-491c-be55-cc166745d873" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f5731ee-c6a2-491c-be55-cc166745d873" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4ecd9ea4-68d1-4b2b-af45-c3a601ca8365" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensation_4ecd9ea4-68d1-4b2b-af45-c3a601ca8365" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fd0a21e2-07b8-4fec-8d34-6198f59d15ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:to="loc_us-gaap_PlanNameDomain_fd0a21e2-07b8-4fec-8d34-6198f59d15ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:to="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2006PlanMember_75179b9e-e8a9-448f-af4e-9b17269528f2" xlink:href="dyai-20191231.xsd#dyai_A2006PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:to="loc_dyai_A2006PlanMember_75179b9e-e8a9-448f-af4e-9b17269528f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2011PlanMember_bc774ffc-754e-42a2-9cd4-1c548a6a44da" xlink:href="dyai-20191231.xsd#dyai_A2011PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:to="loc_dyai_A2011PlanMember_bc774ffc-754e-42a2-9cd4-1c548a6a44da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a28d872a-8352-4351-9272-5170bb6fca7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a28d872a-8352-4351-9272-5170bb6fca7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3864c0cc-166c-46f2-be76-feead0ea5891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3864c0cc-166c-46f2-be76-feead0ea5891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_da842b01-5240-467e-8a54-924bacd97b55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:to="loc_us-gaap_PerformanceSharesMember_da842b01-5240-467e-8a54-924bacd97b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_321ac3cf-b675-4d64-bc67-02ed466d81d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_321ac3cf-b675-4d64-bc67-02ed466d81d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_24dd52cb-7b92-4d93-b2e2-3b21b8a101b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_24dd52cb-7b92-4d93-b2e2-3b21b8a101b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractorMember_259a5e86-5fce-42a5-a31a-1489cf4f47b6" xlink:href="dyai-20191231.xsd#dyai_ContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:to="loc_dyai_ContractorMember_259a5e86-5fce-42a5-a31a-1489cf4f47b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="extended" id="i2276db5ff8aa471ba27691a580e5f5d5_30930efb-9832-4333-85ce-9978761e0740">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7b9ce2bf-eb3b-4f14-b130-cc321105db59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7b9ce2bf-eb3b-4f14-b130-cc321105db59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3b9bb22f-07ef-4230-87da-43458864a2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3b9bb22f-07ef-4230-87da-43458864a2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf653a7e-aead-468b-89ba-ec52150ec506" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf653a7e-aead-468b-89ba-ec52150ec506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c20a922-5ed5-48b7-9e5d-de685dca1d99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c20a922-5ed5-48b7-9e5d-de685dca1d99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8b8e730d-cb70-4fae-b897-e2a67af07e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8b8e730d-cb70-4fae-b897-e2a67af07e7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3ce69fa3-4977-4b6d-bdd9-f3a3d787ab72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3ce69fa3-4977-4b6d-bdd9-f3a3d787ab72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_5514217c-166f-450f-964d-7eb4e9963df1" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_5514217c-166f-450f-964d-7eb4e9963df1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:to="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_913476db-5c69-4f02-8a80-e7ed925cbbc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_913476db-5c69-4f02-8a80-e7ed925cbbc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:to="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48b0bdee-4236-4efa-89b5-a6726c1c13a4_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:to="loc_srt_RangeMember_48b0bdee-4236-4efa-89b5-a6726c1c13a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:to="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64d8d757-cd29-4022-8eda-a6680e99ed33" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:to="loc_srt_MinimumMember_64d8d757-cd29-4022-8eda-a6680e99ed33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16c55f2b-bd30-4782-88a2-99cce4b0af9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:to="loc_srt_MaximumMember_16c55f2b-bd30-4782-88a2-99cce4b0af9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i98d5c64015dc404c8c9c55450abdaf91_d11ce762-9d5d-49b2-8ee9-f0b5387887c9"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="extended" id="i58f43285ac3f437bb4db3c3adc945ac4_cd8c72da-3b77-422f-92b7-cf6dc463e63d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7febfa08-1592-488d-9209-883954d41c92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7febfa08-1592-488d-9209-883954d41c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0295ac7e-3e6c-4f96-b51b-48a07a75d0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0295ac7e-3e6c-4f96-b51b-48a07a75d0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_9b4c9e61-6b60-4f5d-96e4-e54705da61d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_9b4c9e61-6b60-4f5d-96e4-e54705da61d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8ed3222b-c598-48c2-b5ee-2b83d2e1cd08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8ed3222b-c598-48c2-b5ee-2b83d2e1cd08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ff9c4306-2afd-4de7-9e88-a0337ded1600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ff9c4306-2afd-4de7-9e88-a0337ded1600" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21a4816d-584d-42a5-9e92-8975b3504bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21a4816d-584d-42a5-9e92-8975b3504bf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_8a643f1e-46e1-40d4-b8a2-4c9aab62ef0f" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_8a643f1e-46e1-40d4-b8a2-4c9aab62ef0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_155ab4cf-bd08-489f-a4b4-ec7539415388" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_155ab4cf-bd08-489f-a4b4-ec7539415388" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_74de16ff-9d29-4025-acb5-5662c85fc19c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_74de16ff-9d29-4025-acb5-5662c85fc19c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_fe1e052a-3d80-4862-a0e8-78d68b4372e9" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_fe1e052a-3d80-4862-a0e8-78d68b4372e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_6a68f680-cedb-4a25-ad43-735dae12df10" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_6a68f680-cedb-4a25-ad43-735dae12df10" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_692bf096-e914-44c9-9fab-562eec1c49d6" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_692bf096-e914-44c9-9fab-562eec1c49d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_9aedbd56-3de7-441f-8fc1-bcef4633c89a" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_9aedbd56-3de7-441f-8fc1-bcef4633c89a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8496130-30be-4165-aea5-0942f0147d42_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8496130-30be-4165-aea5-0942f0147d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1c76c37-e6ad-40bc-8bc9-fb7dcb9be2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1c76c37-e6ad-40bc-8bc9-fb7dcb9be2e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ExecutivesandKeyPersonnelMember_90eb6df1-3be1-414a-98a4-bb767d1bcaaf" xlink:href="dyai-20191231.xsd#dyai_ExecutivesandKeyPersonnelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_ExecutivesandKeyPersonnelMember_90eb6df1-3be1-414a-98a4-bb767d1bcaaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_2cff933b-4c06-445f-ab57-8042e12d5cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_us-gaap_DirectorMember_2cff933b-4c06-445f-ab57-8042e12d5cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EmployeeMember_e0b9dd26-50a6-4f27-9762-5e93edeff722" xlink:href="dyai-20191231.xsd#dyai_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_EmployeeMember_e0b9dd26-50a6-4f27-9762-5e93edeff722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractorMember_570ef466-39b4-453f-8e11-32bff02c5b76" xlink:href="dyai-20191231.xsd#dyai_ContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_ContractorMember_570ef466-39b4-453f-8e11-32bff02c5b76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_deb637f6-87a9-476d-a6a0-26724320ef24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_deb637f6-87a9-476d-a6a0-26724320ef24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1622af6d-0e68-4c16-9e58-313e6d1fc6df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:to="loc_us-gaap_VestingDomain_1622af6d-0e68-4c16-9e58-313e6d1fc6df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:to="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3392431b-cc4d-4d79-8518-504dabe680fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3392431b-cc4d-4d79-8518-504dabe680fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_e053c40d-1215-457d-8ca8-8dacf1d549c7" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:to="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_e053c40d-1215-457d-8ca8-8dacf1d549c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="extended" id="if48eb2d068714744882145aa9543edee_2a065d79-e0dd-4f66-99e2-7f3c909dd0eb">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49c3770b-e34a-465a-a0e3-1eb84c6ddece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49c3770b-e34a-465a-a0e3-1eb84c6ddece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e3fca1a-c0af-4fef-8376-b0c332909c6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e3fca1a-c0af-4fef-8376-b0c332909c6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_86b085ac-7a10-4ad7-8e2b-25392baac211" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_86b085ac-7a10-4ad7-8e2b-25392baac211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_14f88ecd-ed75-4ead-92ca-802b8d6bc23b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_14f88ecd-ed75-4ead-92ca-802b8d6bc23b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="extended" id="ia047909b1a7e4652b9d321d095e3e73a_e8eb2a3d-34bd-454d-935f-f31f6d5c2124"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="extended" id="i9757715f2d144820826c31619fcaabe1_d7d465e0-2dcb-4719-a93c-5d2e8c561afd"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTextualDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="extended" id="i9b007320a4f54c7991fdafc2c8d8170d_b3f63116-3546-45ac-800d-5a69076b7ffc"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityStockRepurchaseDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="extended" id="i3e76249a051c4567868d1dd574b03744_b6ea9e11-83d0-4c5c-b933-5aab27eb5782">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_03d77b58-e61e-4797-b202-54ab7cfcccf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_03d77b58-e61e-4797-b202-54ab7cfcccf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a7b5cd5f-f9f5-492c-ac23-439fbba79a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a7b5cd5f-f9f5-492c-ac23-439fbba79a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c1566242-17e9-4f88-9778-432758cf5385" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c1566242-17e9-4f88-9778-432758cf5385" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5f4270b-9de5-4544-8eae-df7af5fa15b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5f4270b-9de5-4544-8eae-df7af5fa15b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_afe5c2f1-9055-4c88-893a-bcf3295817fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_afe5c2f1-9055-4c88-893a-bcf3295817fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PubliclyAnnouncedRepurchasePlansMember_48ef0041-e2a3-420a-bb70-5bbd2f0b7c21" xlink:href="dyai-20191231.xsd#dyai_PubliclyAnnouncedRepurchasePlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:to="loc_dyai_PubliclyAnnouncedRepurchasePlansMember_48ef0041-e2a3-420a-bb70-5bbd2f0b7c21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/SubsequentEvents" xlink:type="extended" id="if9d217bd1c554564b6acf35cb7c1a70f_fff4b7f1-997a-455c-9323-4434f3c0fc3a"/>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie480549e1b2e4675808bde61f8732c07_c4e96a9e-81c9-4e21-a4bf-7921a004155d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f8cd468-baeb-4a7c-909b-78fd01c18260" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f8cd468-baeb-4a7c-909b-78fd01c18260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8bda47fa-60fd-4da1-8652-4689c315f5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8bda47fa-60fd-4da1-8652-4689c315f5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12a02bb2-c5a4-4561-9af9-96c01edb3cde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12a02bb2-c5a4-4561-9af9-96c01edb3cde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditional_9b9dcc22-11b3-42b4-9a3d-344fd7c797fa" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditional"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseAdditional_9b9dcc22-11b3-42b4-9a3d-344fd7c797fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_6cdee52a-e826-417c-b8a1-9ea9e194082e" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditionalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_6cdee52a-e826-417c-b8a1-9ea9e194082e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1f2eeba-e161-4f9a-a106-161d91497e7d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:to="loc_srt_RangeMember_b1f2eeba-e161-4f9a-a106-161d91497e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:to="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3f5a85b-3e5d-4497-b9eb-218d98fe4b65" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:to="loc_srt_MinimumMember_f3f5a85b-3e5d-4497-b9eb-218d98fe4b65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_596dafbf-563c-4c37-87cb-9c529035795b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:to="loc_srt_MaximumMember_596dafbf-563c-4c37-87cb-9c529035795b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_763657d9-c18f-466f-b95b-a4cc69604e53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_763657d9-c18f-466f-b95b-a4cc69604e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ExecutivesandKeyPersonnelMember_e0fcf89e-9428-4b90-b526-576fd22e51fc" xlink:href="dyai-20191231.xsd#dyai_ExecutivesandKeyPersonnelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_ExecutivesandKeyPersonnelMember_e0fcf89e-9428-4b90-b526-576fd22e51fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_375842a5-da54-4e7c-842e-b4670b10c556" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_us-gaap_DirectorMember_375842a5-da54-4e7c-842e-b4670b10c556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NonexecutiveEmployeesMember_0566ac3e-a006-44a4-ae0e-8979819f718d" xlink:href="dyai-20191231.xsd#dyai_NonexecutiveEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_NonexecutiveEmployeesMember_0566ac3e-a006-44a4-ae0e-8979819f718d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConsultantMember_a7fbbc48-ea6e-4d79-8eec-a156f085f66a" xlink:href="dyai-20191231.xsd#dyai_ConsultantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_ConsultantMember_a7fbbc48-ea6e-4d79-8eec-a156f085f66a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ed284b-2894-45bb-a9e5-88fa75009f63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ed284b-2894-45bb-a9e5-88fa75009f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49abb604-f2bc-48f1-8bbe-c2163ad34113" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49abb604-f2bc-48f1-8bbe-c2163ad34113" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d8890bf-859c-47c7-bc52-61123801f33a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d8890bf-859c-47c7-bc52-61123801f33a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bc720fb0-a4ee-4ea4-8a52-12d92cbb03ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:to="loc_us-gaap_SubsequentEventMember_bc720fb0-a4ee-4ea4-8a52-12d92cbb03ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>dyai-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dyai_VLPbioMember_970086ed-5375-479f-8057-84f2dc999453_terseLabel_en-US" xlink:label="lab_dyai_VLPbioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VLPbio</link:label>
    <link:label id="lab_dyai_VLPbioMember_label_en-US" xlink:label="lab_dyai_VLPbioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VLPbio [Member]</link:label>
    <link:label id="lab_dyai_VLPbioMember_documentation_en-US" xlink:label="lab_dyai_VLPbioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VLPbio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VLPbioMember" xlink:href="dyai-20191231.xsd#dyai_VLPbioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_VLPbioMember" xlink:to="lab_dyai_VLPbioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_LeaseTypeDomain_b57153ff-a0dd-4cda-9541-9fc5ea5498af_terseLabel_en-US" xlink:label="lab_dyai_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type [Domain]</link:label>
    <link:label id="lab_dyai_LeaseTypeDomain_label_en-US" xlink:label="lab_dyai_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type [Domain]</link:label>
    <link:label id="lab_dyai_LeaseTypeDomain_documentation_en-US" xlink:label="lab_dyai_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeDomain" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_LeaseTypeDomain" xlink:to="lab_dyai_LeaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_fa6b78b6-4914-44c0-8e26-8604b5b27ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_57f76897-0afe-4af1-baf4-77f27f35ae72_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_2308975f-bb38-4324-bb09-2daf3e17aa0b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_39aef363-7cca-4c92-98f5-ac280c7ff2da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdbb68db-ab50-4b26-a983-eead75f6c1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_bc90e370-5174-4b80-9eb3-03ab5a653c97_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e414c55-5ad1-4142-b970-b3cbd57c6017_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested awards, compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_430efe78-85b3-4f52-b3f6-04ec98ee0ece_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0d78446a-3ce5-4c80-8d42-54b2c2d0cee6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f46626a3-a4b9-4dd0-b9a4-ecde7abb4d61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8d024434-6bcd-40af-a7c9-723c9c01b41f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_8623ede9-4c6d-43c0-b088-ae112c1d4e5d_terseLabel_en-US" xlink:label="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research organization performing service under contract</link:label>
    <link:label id="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_label_en-US" xlink:label="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Research Organization Performing Service Under Contract</link:label>
    <link:label id="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_documentation_en-US" xlink:label="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Research Organization Performing Service Under Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:href="dyai-20191231.xsd#dyai_NumberOfResearchOrganizationPerformingServiceUnderContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:to="lab_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_41b230ff-3cd5-44e8-9b4d-b11ba3eb55d1_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel related costs</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Personnel Related Costs</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Personnel Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:to="lab_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d28a7050-6db5-42e7-b017-16876e0f4ad9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_e3ae9457-86bf-4917-95aa-07cdc3e70b69_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0c1a370a-991a-4fae-a09e-32eb53becd22_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_51cf0cb1-e103-44a2-bdcb-63dc2e492a60_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_cd0b1bb3-aad6-4e62-8530-0da5126e5846_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to obtain exclusive commercial sub-license for number of proteins</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:to="lab_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_81c5ff05-d10b-4683-a3eb-a89e06cf5371_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of board of directors</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ee8a9975-be2e-4851-8730-3e7d1c0a39ff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35138477-b34f-4a87-8ca7-30e251607300_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d31d417f-28b9-4a38-b5cc-1c4fd0d10b61_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_73d06223-5166-451f-b96f-dd3e2a7010b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchServicesAgreementMember_87f039c0-5412-47d0-b940-2e9b07d26859_terseLabel_en-US" xlink:label="lab_dyai_ResearchServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSA</link:label>
    <link:label id="lab_dyai_ResearchServicesAgreementMember_label_en-US" xlink:label="lab_dyai_ResearchServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Agreement [Member]</link:label>
    <link:label id="lab_dyai_ResearchServicesAgreementMember_documentation_en-US" xlink:label="lab_dyai_ResearchServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchServicesAgreementMember" xlink:href="dyai-20191231.xsd#dyai_ResearchServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchServicesAgreementMember" xlink:to="lab_dyai_ResearchServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7c3597de-2bc5-462d-8e38-a172702b76d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_426d1f57-2b1b-4e9a-a803-0ed20b5e33ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_df909be7-a050-4675-a3e6-92de6f6580c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b8eef6cf-c828-48cc-b216-04d9b257ae04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f34d126d-3fb2-4449-8ea2-9e67ca91ee30_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_cb7e0b41-8f99-49d2-824a-9e45d8849286_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income tax</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_eaa1020c-694d-4a35-b4be-19244222438d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_45b69fa9-a6c2-444d-a761-98b4ddf609d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00c47023-92b8-459b-b1fa-fffd8dcc476d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_faea0acd-758a-4d8b-9441-c7b8ddf4b81a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange loss (gain), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_46287bbc-18d3-4707-9963-a24ac56be061_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ec874894-affe-4b74-b7dc-05b8afcdfa91_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_e5832bb6-6823-4430-bfe2-65c264fe9c50_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a222f85f-a2cb-434a-903d-271536aa5b8f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b68f25a2-4a3f-406c-87e5-57f909280a1e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_86f42dae-9386-41a3-859a-3398b5e9a7ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8975d192-fcd6-421f-b975-e2aacf1cab5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d53a4e6-962d-409b-8967-5d35d0e79f7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_89983ac5-9472-44f4-9f63-8545bb1fe5d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_52c0a48e-0ef1-4512-a438-8298f3fff00c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_8d8d1525-9828-4d16-b64c-3cc7f05fc3c5_negatedTerseLabel_en-US" xlink:label="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_label_en-US" xlink:label="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Research and Development</link:label>
    <link:label id="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_documentation_en-US" xlink:label="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:href="dyai-20191231.xsd#dyai_IncreaseDecreaseinPrepaidResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:to="lab_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_27bbd23b-fe9f-40d9-9391-03cb679c2c68_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred research and development obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_AlphazymeMember_48e68810-a3e7-49ad-8757-6eb1f85f4266_terseLabel_en-US" xlink:label="lab_dyai_AlphazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphazyme [Member]</link:label>
    <link:label id="lab_dyai_AlphazymeMember_label_en-US" xlink:label="lab_dyai_AlphazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphazyme [Member]</link:label>
    <link:label id="lab_dyai_AlphazymeMember_documentation_en-US" xlink:label="lab_dyai_AlphazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alphazyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AlphazymeMember" xlink:href="dyai-20191231.xsd#dyai_AlphazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_AlphazymeMember" xlink:to="lab_dyai_AlphazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_8954c470-a932-4423-ab25-84ad9a4cf5ea_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for lack of marketability</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1d4ad2c0-e0b8-4cba-aa85-6722840a8eed_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6eaf49fa-0076-4529-a2c2-6fdbd4979051_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentToPayExpanded_4bb37d18-616d-4007-b8e7-9c02634306e5_terseLabel_en-US" xlink:label="lab_dyai_CommitmentToPayExpanded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to pay, expanded</link:label>
    <link:label id="lab_dyai_CommitmentToPayExpanded_label_en-US" xlink:label="lab_dyai_CommitmentToPayExpanded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay, Expanded</link:label>
    <link:label id="lab_dyai_CommitmentToPayExpanded_documentation_en-US" xlink:label="lab_dyai_CommitmentToPayExpanded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay, Expanded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpanded" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpanded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentToPayExpanded" xlink:to="lab_dyai_CommitmentToPayExpanded" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_fbe707b1-44c5-48de-af15-8aad3093a9d9_negatedLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term Investments, gross unrealized holding loss</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_71ec2803-4247-4ac3-bc26-c85b1d6c171a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_InvestmentsandCashAmortizedCost_0114a0b8-2784-4b8b-9d57-76032de77959_totalLabel_en-US" xlink:label="lab_dyai_InvestmentsandCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investment, adjusted cost</link:label>
    <link:label id="lab_dyai_InvestmentsandCashAmortizedCost_label_en-US" xlink:label="lab_dyai_InvestmentsandCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash, Amortized Cost</link:label>
    <link:label id="lab_dyai_InvestmentsandCashAmortizedCost_documentation_en-US" xlink:label="lab_dyai_InvestmentsandCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_InvestmentsandCashAmortizedCost" xlink:href="dyai-20191231.xsd#dyai_InvestmentsandCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_InvestmentsandCashAmortizedCost" xlink:to="lab_dyai_InvestmentsandCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_47d72f84-0867-4d68-93c7-ba4e2d59148e_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to extend exclusivity period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Extend Exclusivity Period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Extend Exclusivity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:to="lab_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_7304bc68-6ecd-42d2-9340-c4a8ad27af21_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalent, and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa1e1f9a-1fa0-4c61-80fd-e63ccec7effb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementExclusivityPeriod_2a32e614-b6d6-415d-9a41-0cbf07d82c3f_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusivity period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementExclusivityPeriod_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Exclusivity Period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementExclusivityPeriod_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Exclusivity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementExclusivityPeriod" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementExclusivityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementExclusivityPeriod" xlink:to="lab_dyai_CollaborativeArrangementExclusivityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2c8ebed1-f319-40f8-960a-648109e29651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d92d7747-3664-40a0-b6af-47aed3380826_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_97a9797c-cfdd-424e-8136-34b744f48880_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_58f60863-32a8-4146-a0d0-ed0f2836823a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of held-to-maturity investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e658a352-b55a-4a80-94be-e3c96dd6dddc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f026e36f-b5bf-45b1-8f55-3cbb693175be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of options that will vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8588b9c3-dee0-463a-8f6f-e5632ee43119_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ba318f9b-660c-4779-9b41-6b0e664064f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_fe05d543-acc5-45cd-99fc-e98cf1c73782_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation for payment for research and development, minimum</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Minimum Obligation For Research And Development</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Minimum Obligation For Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:to="lab_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3a11a34e-8e7d-419b-b896-549bb3ae05c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dfc85a81-cae5-4c84-92cc-c100bc748c84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdbff15f-c5a5-40f9-bac4-30d09d509acf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_2988773e-39b4-4e07-8ac9-397516e8ee85_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f0d49da7-81f5-4716-824f-19ec1880b444_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4bf436a5-8ac2-4282-8efc-4dc75637cf5d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c93d30d-3858-46fe-9424-9bed23a39bdc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_LeaseTypeAxis_eac1fd14-0b33-4eaa-afbe-65b06ac9ff95_terseLabel_en-US" xlink:label="lab_dyai_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type [Axis]</link:label>
    <link:label id="lab_dyai_LeaseTypeAxis_label_en-US" xlink:label="lab_dyai_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type [Axis]</link:label>
    <link:label id="lab_dyai_LeaseTypeAxis_documentation_en-US" xlink:label="lab_dyai_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeAxis" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_LeaseTypeAxis" xlink:to="lab_dyai_LeaseTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_cbde89fc-08e9-4204-8c94-50ba2050d83d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent_fdd66f8a-0ef1-4484-9eee-ec51b6bb255c_terseLabel_en-US" xlink:label="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent_label_en-US" xlink:label="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development in Process, Current</link:label>
    <link:label id="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent_documentation_en-US" xlink:label="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development in Process, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:href="dyai-20191231.xsd#dyai_AccruedResearchandDevelopmentinProcessCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:to="lab_dyai_AccruedResearchandDevelopmentinProcessCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e9c1e84-7cc7-46ad-a029-071905fbb751_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c4642fe7-4741-4e1d-b9a7-fc267a17018b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_e9844260-bac1-4cfc-beac-53f874fae1b4_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research funding, milestone payments and royalties, period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:to="lab_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9b37fd2b-584f-48d6-8efd-9abc117b1d62_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_396172fa-4066-4661-bdb9-081fc0b0a56f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d3d02eb8-0ebe-4f90-ae56-04b998b1bf32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_543fed5d-783f-4910-9a02-d32f72fac583_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_94265375-2afc-41e2-b13c-b0a5cd36ca47_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, gross unrealized holding gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a02f0e85-ce25-46ca-a344-fa1df7621c2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1751c8a5-ca92-4353-ad57-d0c90e479959_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_adf8b007-6a80-43d2-b0a0-938900a1d456_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d7cdbe2f-2ec7-4fb1-adbf-93d96bd4db87_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested awards, compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_00bc4ce2-a0a1-4a6b-966b-69e5be0c0020_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_11e8bc0e-56f4-4693-9132-28534e032845_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ad08a272-2592-473a-8106-7231eb550988_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_7793f661-2f81-4e12-8cbf-7a789969712a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period under program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42967d13-fbe0-44f0-bad8-98f1618c7259_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e5134d02-0166-46f0-b625-cb8ff2ff15bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7fe195ce-e11d-490a-8112-fc49aa375dfc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_a631137f-5c0f-4278-b257-db82fcff9d30_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracted services - related party</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Contracted Services, Related Party</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Contracted Services, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_15187ccb-a297-4281-9d89-db9dea7057bf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_NonexecutiveEmployeesMember_e4e85ac6-a205-4cd0-aeda-4e189df5c2fd_terseLabel_en-US" xlink:label="lab_dyai_NonexecutiveEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive Employees</link:label>
    <link:label id="lab_dyai_NonexecutiveEmployeesMember_label_en-US" xlink:label="lab_dyai_NonexecutiveEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive Employees [Member]</link:label>
    <link:label id="lab_dyai_NonexecutiveEmployeesMember_documentation_en-US" xlink:label="lab_dyai_NonexecutiveEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NonexecutiveEmployeesMember" xlink:href="dyai-20191231.xsd#dyai_NonexecutiveEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_NonexecutiveEmployeesMember" xlink:to="lab_dyai_NonexecutiveEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_c6ea3b1b-d744-46a7-8469-9a828b483fba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of non-cash stock option compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_002476b5-cd7f-4c0f-8c6c-644358bb40ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from income tax refund</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7b733ed9-59ba-44d2-ab76-fe6975202960_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, expired (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_caad28e8-8377-4323-879c-1c584706acf3_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of building rented</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0acb1de2-9779-4352-9603-140a76e294d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a8ca7df1-341f-4949-840e-fe11cb282158_netLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares Purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c672c83d-a271-42dc-8f61-870d352f38ad_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ExecutivesandKeyPersonnelMember_3acff069-5c79-4493-b6dd-407546a621d2_terseLabel_en-US" xlink:label="lab_dyai_ExecutivesandKeyPersonnelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executives and Key Personnel</link:label>
    <link:label id="lab_dyai_ExecutivesandKeyPersonnelMember_label_en-US" xlink:label="lab_dyai_ExecutivesandKeyPersonnelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executives and Key Personnel [Member]</link:label>
    <link:label id="lab_dyai_ExecutivesandKeyPersonnelMember_documentation_en-US" xlink:label="lab_dyai_ExecutivesandKeyPersonnelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executives and Key Personnel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ExecutivesandKeyPersonnelMember" xlink:href="dyai-20191231.xsd#dyai_ExecutivesandKeyPersonnelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ExecutivesandKeyPersonnelMember" xlink:to="lab_dyai_ExecutivesandKeyPersonnelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_dbde2cd9-65f3-4fe9-bdfb-c6c4431b6d2c_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f2b79c38-0425-43cd-b368-5721060a3e2e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_RevenueFromCollaborativeArrangementRecognized_ff874077-6f11-4346-8379-26f3a8130220_terseLabel_en-US" xlink:label="lab_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative arrangement, recognized</link:label>
    <link:label id="lab_dyai_RevenueFromCollaborativeArrangementRecognized_label_en-US" xlink:label="lab_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Recognized</link:label>
    <link:label id="lab_dyai_RevenueFromCollaborativeArrangementRecognized_documentation_en-US" xlink:label="lab_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:href="dyai-20191231.xsd#dyai_RevenueFromCollaborativeArrangementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:to="lab_dyai_RevenueFromCollaborativeArrangementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_25f2b48f-c468-4480-92a9-8017242cab0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_7048ea01-15ae-48e8-a6a7-508581c61510_negatedTerseLabel_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True-up adjustment</link:label>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_label_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, True-Up Adjustment, Percent</link:label>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_documentation_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, True-Up Adjustment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:to="lab_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1007b893-44f0-4e14-bff4-498380a0b452_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4e96b15f-14eb-4d28-a449-9544f67b188a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bb46acb5-22e0-4e40-a71e-8874d4c5c5de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0be2aa26-d1d6-4009-bfdc-8cfd5dd42a2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8fc37580-9057-46dc-876e-4f5cc9ff033d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35517fac-3ea1-431d-a8dc-5f24df5c22a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b33bfa87-1b6b-40c1-aa11-8bc431792fb9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledRevenuesMember_02f8d967-bf0e-49f6-ae08-56cdd2801ab6_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledRevenuesMember_label_en-US" xlink:label="lab_us-gaap_UnbilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledRevenuesMember" xlink:to="lab_us-gaap_UnbilledRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_914ec702-6dad-4d09-890c-ba702401b9b9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledRevenuesMember_eaa0f5b1-4400-420c-bfef-b8e0726ec5e9_terseLabel_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed receivable</link:label>
    <link:label id="lab_us-gaap_BilledRevenuesMember_label_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledRevenuesMember" xlink:to="lab_us-gaap_BilledRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c7b81cb0-4bd3-4f74-ba50-563740910025_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components Of Income Tax (benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_279c0a8f-a882-4d5c-aa5b-401003740ad2_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investment, fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_e7cca809-05e9-4cf7-bc12-2c72110aadd9_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc074355-e466-4d6f-8e0a-7a074f7afdaf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9b1d7d98-63a5-4195-b7f0-c6ca046d17bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f4e921c1-5426-411b-b0a3-3f346148e1d9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_BDIHoldingsMember_5705499b-75f1-468f-9b72-58bf668de761_terseLabel_en-US" xlink:label="lab_dyai_BDIHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI Holdings</link:label>
    <link:label id="lab_dyai_BDIHoldingsMember_label_en-US" xlink:label="lab_dyai_BDIHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI Holdings [Member]</link:label>
    <link:label id="lab_dyai_BDIHoldingsMember_documentation_en-US" xlink:label="lab_dyai_BDIHoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI Holdings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIHoldingsMember" xlink:href="dyai-20191231.xsd#dyai_BDIHoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_BDIHoldingsMember" xlink:to="lab_dyai_BDIHoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentDevelopmentPeriod_b840bb7e-e0d9-4552-b8c5-f18ce0bb022c_terseLabel_en-US" xlink:label="lab_dyai_CommitmentDevelopmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment development period</link:label>
    <link:label id="lab_dyai_CommitmentDevelopmentPeriod_label_en-US" xlink:label="lab_dyai_CommitmentDevelopmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Development Period</link:label>
    <link:label id="lab_dyai_CommitmentDevelopmentPeriod_documentation_en-US" xlink:label="lab_dyai_CommitmentDevelopmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Development Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentDevelopmentPeriod" xlink:href="dyai-20191231.xsd#dyai_CommitmentDevelopmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentDevelopmentPeriod" xlink:to="lab_dyai_CommitmentDevelopmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_116fc179-2b3d-425c-85b7-3ac5589a9293_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation for payment for research and development, maximum</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Obligation For Research And Development</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Obligation For Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:to="lab_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_fa1a5b3e-04ac-432f-88bd-815620c0ad3b_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest consideration receivable upon extension of exclusivity period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:to="lab_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_e7e1311d-6f3e-43dc-9429-e9fd24fdb384_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses - various</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1bcd67a-347a-4456-b5c6-401a78ba9741_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0d0e32d5-9b99-488f-baba-89a0ddaad17a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_d5bbc8fc-36c3-42be-9dca-ec7352bc6341_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research contract, expansion, term</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Additional, Term</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Additional, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditionalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseAdditionalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_JupiterFloridaHeadquartersLeaseMember_fe6e63ff-4d75-4458-9c24-9e7452bceb20_terseLabel_en-US" xlink:label="lab_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter, Florida Headquarters Lease</link:label>
    <link:label id="lab_dyai_JupiterFloridaHeadquartersLeaseMember_label_en-US" xlink:label="lab_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter, Florida Headquarters Lease [Member]</link:label>
    <link:label id="lab_dyai_JupiterFloridaHeadquartersLeaseMember_documentation_en-US" xlink:label="lab_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jupiter, Florida Headquarters Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:href="dyai-20191231.xsd#dyai_JupiterFloridaHeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:to="lab_dyai_JupiterFloridaHeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_d44edffd-3fa7-40f8-90d1-447118589cf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_526d9bc1-08ba-432c-86fd-4f56c590e5e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c4f140e0-0f64-4a48-b803-4ecfd5ad760c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Price Paid per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_c7c80149-b9e9-4be2-9dea-e384e9e00273_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d193fb22-5d3c-49ef-91fb-9b3e517468ab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a414c7ae-2ef4-4a1c-b4b3-6de818077029_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_129d6228-3e82-44e7-9286-ea72a4184b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d250f636-c018-4e4c-a994-75a0b882b301_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e0d1b02f-4b01-4830-89fe-43fb8ed459ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_45154e51-feb8-49b9-b0b5-03712b6fc0ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3a862d10-6782-4fe4-a68e-613480a91c16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sign on, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_39a59364-fc30-4c92-8c25-73fc3a22d766_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d041fa33-481b-4b4a-bc64-4a3e89cde1d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_88b3c246-2cdf-4b3b-956c-ea91e8b31e7e_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, cash (in shares)</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_47ef73f0-0b39-423f-a65e-1259d5167112_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_ab49c06b-a6d5-4361-9460-1e34a51b24e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_53cdccab-9fe2-4224-a605-ad64a51902b5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_93f85086-c728-4b17-a7ef-0a9d8c258f92_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_79eeb54b-0e06-49b1-a0f5-e0b809f09422_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1a51bd72-5af2-4291-ba64-b5df2c1aa7db_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_88c48298-7836-4b97-8b1a-64b47fec0c0e_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, forfeited (in shares)</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_4c9c8a04-6a08-40b4-a98f-b699e5f585e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_940aaf28-5f4d-45a4-92cc-07b5dc0b399d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares held at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9535d9e5-40b6-497c-9f29-888fb2d65996_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_dce6d2cd-1877-4356-a6ce-3337bdd74bba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0bcb4e47-b655-4b90-aed2-305983b9c3bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a0689b71-f8cd-4622-ab2e-06f4e6dc2d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_925bfd7f-e934-4465-8320-bf5783e25879_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8cf77d35-1919-46fe-a5cb-658ff6e036c6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_47f17801-e704-4fe7-b67e-8ea4a563460a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_261d6167-3258-4b4c-9dea-540a7b016288_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_919a4e4e-bb11-4cfc-a02d-8172814e894d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_01ca946d-2c84-4cb8-b822-a6bf944b8727_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f2df7f66-80a0-42c7-80df-e80ffba968b0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_84f43ce7-ba52-4061-b8c1-32c6cd4c841a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_6b2fc883-6022-4488-aef2-391e7a9ad51a_terseLabel_en-US" xlink:label="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average issued price (in USD per share)</link:label>
    <link:label id="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:href="dyai-20191231.xsd#dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:to="lab_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentSuccessBonusAward_db5a2895-6b23-4023-8ce7-63666c9ef53b_terseLabel_en-US" xlink:label="lab_dyai_CommitmentSuccessBonusAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment success bonus award</link:label>
    <link:label id="lab_dyai_CommitmentSuccessBonusAward_label_en-US" xlink:label="lab_dyai_CommitmentSuccessBonusAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Success Bonus Award</link:label>
    <link:label id="lab_dyai_CommitmentSuccessBonusAward_documentation_en-US" xlink:label="lab_dyai_CommitmentSuccessBonusAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Success Bonus Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentSuccessBonusAward" xlink:href="dyai-20191231.xsd#dyai_CommitmentSuccessBonusAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentSuccessBonusAward" xlink:to="lab_dyai_CommitmentSuccessBonusAward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3ac60e35-e64c-4976-a458-6f8e796a3e74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_505933e5-ba8d-462d-b2c2-0b99368c5d62_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for research and development agreement</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment for Research and Development Agreement</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment for Research and Development Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:to="lab_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_544e6b3c-c5a4-4410-9bc7-3ccea82a5f87_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5e21036a-b8d7-42a9-a1d7-8f9e2731b2fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-Free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f73cdc30-6989-4bcb-a328-6ae8dceeb798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_156a563a-dc3b-4ef2-8154-2101cc4a5574_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentInProcessCurrent_837626c6-3f59-4e3f-a906-a4d37c0f92f2_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentInProcessCurrent_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development In Process, Current</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentInProcessCurrent_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development In Process, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:to="lab_dyai_ResearchAndDevelopmentInProcessCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ContractResearchOrganizationsMember_1695573e-e08b-411b-806d-2e2c4ed5de76_terseLabel_en-US" xlink:label="lab_dyai_ContractResearchOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Organizations (CRO)</link:label>
    <link:label id="lab_dyai_ContractResearchOrganizationsMember_label_en-US" xlink:label="lab_dyai_ContractResearchOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Organizations [Member]</link:label>
    <link:label id="lab_dyai_ContractResearchOrganizationsMember_documentation_en-US" xlink:label="lab_dyai_ContractResearchOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Organizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractResearchOrganizationsMember" xlink:href="dyai-20191231.xsd#dyai_ContractResearchOrganizationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ContractResearchOrganizationsMember" xlink:to="lab_dyai_ContractResearchOrganizationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_d274ac56-88b4-45fa-bd03-21f98545e24a_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_870731aa-6201-461b-aceb-872589f51aa4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a4d9abf0-b6fd-4981-839b-5fe21a83bff7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_455e79cc-cad4-4861-bab8-15bbb5fc7f04_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_80b2079b-9203-4473-a655-12af900998b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a6eca685-af55-4152-a19b-ad065e984bf8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_f67f034f-455d-403e-8a38-2dd6e22d5519_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, overhead and other</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Facilities, Overhead and Other</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Facilities, Overhead and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0fff269d-1fe6-4ce0-9f3d-7dd1b090b122_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_506c907f-eefc-47d1-916b-205b8fb747c7_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e9feed31-22f3-498a-bb77-ba7f7e259595_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2328deec-9b91-4a50-8ae2-ba363e374257_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5cecd9b3-e509-4d2c-814a-b3478c2c3f43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_A2011PlanMember_db3f8251-6903-41a6-9e04-451f1065988c_terseLabel_en-US" xlink:label="lab_dyai_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_dyai_A2011PlanMember_label_en-US" xlink:label="lab_dyai_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:label id="lab_dyai_A2011PlanMember_documentation_en-US" xlink:label="lab_dyai_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2011PlanMember" xlink:href="dyai-20191231.xsd#dyai_A2011PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_A2011PlanMember" xlink:to="lab_dyai_A2011PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6aaf986c-e677-4a08-9acd-6087a0727edc_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_f84502d8-a9bd-4eee-b649-905752bb0bd4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ef6f59a3-f264-4b2c-a220-c9706a460c68_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_PrepaidResearchandDevelopment_13be3391-6b02-4e59-ab9a-d33aac3fd7a3_terseLabel_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research and Development</link:label>
    <link:label id="lab_dyai_PrepaidResearchandDevelopment_label_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research and Development</link:label>
    <link:label id="lab_dyai_PrepaidResearchandDevelopment_documentation_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopment" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_PrepaidResearchandDevelopment" xlink:to="lab_dyai_PrepaidResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfcd448d-fc16-4586-a0be-876df28a9262_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d20c49d6-672e-446d-87a3-b9e734e25477_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae8cea12-c7e8-409e-85cf-bd84e8a1be02_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_bb6c9056-11ec-4306-871a-4395565324f7_terseLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term Investments, gross unrealized holding gain</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9eb1309a-69bd-489f-b1d7-4972e88b6a73_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_a25841f1-fd37-4fba-a1bc-b11060f81189_terseLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term Investments, fair value</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value, Noncurrent</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_aeb47c70-8600-44a9-90d3-f70bcea177ac_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_cbb47869-5399-40a7-9f98-e0745bd70da2_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antibodies and vaccines for development and commercialization</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:to="lab_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d7883112-dd98-485e-b7e6-6d508e5de616_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_43140c89-745d-40dc-89e9-2e207e14609d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_f290f805-2fd6-4f4d-aaa9-57c97b18970e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_BDIMember_28139b62-a36b-4206-b51b-084cacf6bb22_terseLabel_en-US" xlink:label="lab_dyai_BDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI</link:label>
    <link:label id="lab_dyai_BDIMember_label_en-US" xlink:label="lab_dyai_BDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI [Member]</link:label>
    <link:label id="lab_dyai_BDIMember_documentation_en-US" xlink:label="lab_dyai_BDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIMember" xlink:href="dyai-20191231.xsd#dyai_BDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_BDIMember" xlink:to="lab_dyai_BDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0ea0c966-b83f-4f1f-b863-e2103327bdc0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_933fa5c9-d8ce-4e74-9984-fb51c0116b3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_NovovetMember_84dc5974-7dac-485e-b0fb-c947f2e6e929_terseLabel_en-US" xlink:label="lab_dyai_NovovetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novovet [Member]</link:label>
    <link:label id="lab_dyai_NovovetMember_label_en-US" xlink:label="lab_dyai_NovovetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novovet [Member]</link:label>
    <link:label id="lab_dyai_NovovetMember_documentation_en-US" xlink:label="lab_dyai_NovovetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novovet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NovovetMember" xlink:href="dyai-20191231.xsd#dyai_NovovetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_NovovetMember" xlink:to="lab_dyai_NovovetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e8922f4c-9daa-4547-a58b-226e2a383143_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_025e0059-5551-4530-b4f1-4ab542d07268_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_e71e1225-844c-4887-ae2a-e6fe894eae9b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d3bda857-7b7f-4e9b-9123-5901dd679735_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7384b084-1057-4288-8716-8035b2dcdcd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7650fdda-2497-4788-a4d1-31f0a33a727e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ba6a3c14-f979-4272-a59c-504cf7f77311_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_91b860a9-2ba0-4885-8671-c0cad27244ad_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditional_7b347385-7861-4655-ac5f-37e2a14d2945_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research contract, expansion</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditional_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Additional</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseAdditional_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Additional</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditional"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseAdditional" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0c5a8a25-8de1-49f1-903e-0ae9439cb5c0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d18c1cde-a93f-4ca1-a539-5e6bbf0a7c72_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b9358976-e28e-44f8-8505-f476df60610f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_2635e5dc-2e9a-436f-9ec3-463662208317_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of held-to-maturity securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_OperatingLeasesMonthlyRentalRate_e398415c-c99e-4976-81bf-b1298f9b596f_terseLabel_en-US" xlink:label="lab_dyai_OperatingLeasesMonthlyRentalRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rental rate</link:label>
    <link:label id="lab_dyai_OperatingLeasesMonthlyRentalRate_label_en-US" xlink:label="lab_dyai_OperatingLeasesMonthlyRentalRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Rental Rate</link:label>
    <link:label id="lab_dyai_OperatingLeasesMonthlyRentalRate_documentation_en-US" xlink:label="lab_dyai_OperatingLeasesMonthlyRentalRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Monthly Rental Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesMonthlyRentalRate" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesMonthlyRentalRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_OperatingLeasesMonthlyRentalRate" xlink:to="lab_dyai_OperatingLeasesMonthlyRentalRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_502b2c65-2adc-46bf-84bf-cb73426f63fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6b4eb1f4-13c6-4648-b7f8-c28a614eb61c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_23b4cbcc-eb64-4406-81c8-814c49c29d94_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_592855e4-0400-45bd-9b97-a9db5ed67d6a_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for additional development and commercialization</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment for Additional Development and Commercialization</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment for Additional Development and Commercialization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:to="lab_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_083e3722-5f96-429f-a013-ba08176a1be0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2c8c1812-af37-4ec4-a112-b0740148b366_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a05ce3f2-4112-4df5-870f-23b4b1cc6450_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_baa80c2b-80cc-4458-a88c-fe3fb224e94b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fe8caef7-ac85-41e7-a7e8-65eeb53be3a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5f7a8622-4419-4282-b5ab-13fa0d7df158_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_919c5fa2-8e3a-46b2-944b-115b9b0bb8a1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_88de35f3-5cd2-4a21-99c7-700ac287a0ec_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of research and development revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1170b0e2-52f0-4770-b95b-3642a9676050_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5675795e-336f-4ff4-bcbe-e8c9b34dbe35_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinistryOfFinanceIndiaMember_76441c4f-43a4-48de-8d7e-c8f9503b5c07_terseLabel_en-US" xlink:label="lab_us-gaap_MinistryOfFinanceIndiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ministry of Finance, India</link:label>
    <link:label id="lab_us-gaap_MinistryOfFinanceIndiaMember_label_en-US" xlink:label="lab_us-gaap_MinistryOfFinanceIndiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ministry of Finance, India [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfFinanceIndiaMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfFinanceIndiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinistryOfFinanceIndiaMember" xlink:to="lab_us-gaap_MinistryOfFinanceIndiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_c355bb32-5d40-4b19-9daa-46232a940acf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b7c2d2d0-9981-46d4-ac78-e994a12a4cc9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_04755047-612c-4f63-9300-5a39de70ddae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_63760a92-cd8e-43b2-8650-e75ec904ba9a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b4e7e92c-e053-4ac6-8112-eaf6cc7385bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectorMember_1ab2ba0f-7325-49cf-8766-c5252aa41188_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_us-gaap_DirectorMember_label_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_78db0b10-4095-4df6-9fe6-51da8e3bd3cf_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_758662ed-489c-414d-9886-a66be51563b9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6e15e236-0ce4-475e-922d-262edff66d39_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23eb1f32-542f-4e35-9ddf-9d9f614e1969_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f221e1ab-0fe6-4c03-81a5-4fef8f56f753_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f812fe18-bf1e-47eb-85c1-3d531322c4a7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ea67c5c6-7205-4469-b97a-9d9ef0e4987f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f122a7f1-8fd4-4c63-9af2-ac9a4f7fc194_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_835045aa-9550-44b0-8844-db82a374f886_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_72365abf-bc00-418a-8b3e-b221e6f4da64_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_a75e4931-4ec2-4b91-ac39-aa975ccb0952_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ConcentrationRiskNumberofCustomers_2b77ea41-a632-4b66-bfdf-28d7b6a9a4dc_terseLabel_en-US" xlink:label="lab_dyai_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, number of customers</link:label>
    <link:label id="lab_dyai_ConcentrationRiskNumberofCustomers_label_en-US" xlink:label="lab_dyai_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label id="lab_dyai_ConcentrationRiskNumberofCustomers_documentation_en-US" xlink:label="lab_dyai_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConcentrationRiskNumberofCustomers" xlink:href="dyai-20191231.xsd#dyai_ConcentrationRiskNumberofCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ConcentrationRiskNumberofCustomers" xlink:to="lab_dyai_ConcentrationRiskNumberofCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_a4b170cc-1db9-434b-913e-99d905fe946b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_c40f391b-0390-4564-9f26-4d0dc2d2749d_terseLabel_en-US" xlink:label="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax cuts and jobs act, change in alternative minimum tax, income tax benefit</link:label>
    <link:label id="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_label_en-US" xlink:label="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit</link:label>
    <link:label id="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_documentation_en-US" xlink:label="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:href="dyai-20191231.xsd#dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:to="lab_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d70b210-c95a-406c-8299-2fa7297269d0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e46360c2-b607-4700-b5c8-72d2df0dc2c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d59e7d9a-f9ca-4eeb-b6e0-7347ab9ff1ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7dfc5632-12df-4570-a539-3c446be420db_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_7b3119a7-c692-4af3-a590-cc3ed61267f6_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_6be41c99-ddb0-4381-b649-18e8f15d855a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_cc24359c-9bdf-495a-ba5e-116040b814d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_24634890-e5e8-40e4-8e7f-e909e7151084_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d8dd09ea-80b7-4e00-b48e-ad5276610ded_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_3619c660-747d-4ed9-bfc1-97eff84fbd20_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37cda70c-2ddf-48f5-adc0-2d322d48a33d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_c73d1d5f-85ec-4c31-a26f-31061a4c5cd1_totalLabel_en-US" xlink:label="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_label_en-US" xlink:label="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Including True Up Adjustment</link:label>
    <link:label id="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_documentation_en-US" xlink:label="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Including True Up Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:href="dyai-20191231.xsd#dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:to="lab_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_51c5cc77-716d-4c00-9f2b-06818a2860e9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain or Loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1182f891-f8be-4b73-b049-66a6a99d87e5_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ConsultantMember_e1d774e3-dd53-4bea-a934-157a5c4430e6_terseLabel_en-US" xlink:label="lab_dyai_ConsultantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant</link:label>
    <link:label id="lab_dyai_ConsultantMember_label_en-US" xlink:label="lab_dyai_ConsultantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label id="lab_dyai_ConsultantMember_documentation_en-US" xlink:label="lab_dyai_ConsultantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConsultantMember" xlink:href="dyai-20191231.xsd#dyai_ConsultantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ConsultantMember" xlink:to="lab_dyai_ConsultantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8eb303fb-e9fe-4dc2-96a6-0f255e475304_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_925dbe70-3c4b-4480-900f-e79b1f1a827a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ServiceFrameworkAgreementMember_2ecac665-08b6-4b74-b628-3b06ca78baff_terseLabel_en-US" xlink:label="lab_dyai_ServiceFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFA</link:label>
    <link:label id="lab_dyai_ServiceFrameworkAgreementMember_label_en-US" xlink:label="lab_dyai_ServiceFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Framework Agreement [Member]</link:label>
    <link:label id="lab_dyai_ServiceFrameworkAgreementMember_documentation_en-US" xlink:label="lab_dyai_ServiceFrameworkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Framework Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ServiceFrameworkAgreementMember" xlink:href="dyai-20191231.xsd#dyai_ServiceFrameworkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ServiceFrameworkAgreementMember" xlink:to="lab_dyai_ServiceFrameworkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_a9372c49-8349-4610-b30f-085e7d598ff4_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_991c5177-32da-431a-b109-69c091d4927f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_c10cb50f-a711-42eb-9183-ccf41db48307_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_dd413db5-fd54-4fd3-86d0-1ecfede52f59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_b1a93370-b155-4cfb-98bf-e60195726861_terseLabel_en-US" xlink:label="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VTT Technical Research Centre of Finland Ltd [Member]</link:label>
    <link:label id="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_label_en-US" xlink:label="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VTT Technical Research Centre of Finland Ltd [Member]</link:label>
    <link:label id="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_documentation_en-US" xlink:label="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VTT Technical Research Centre of Finland Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:href="dyai-20191231.xsd#dyai_VTTTechnicalResearchCentreofFinlandLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:to="lab_dyai_VTTTechnicalResearchCentreofFinlandLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_958e768d-0364-4976-b822-51b560e930a7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_a8733391-2206-4c32-a801-38df963bfabc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_21baee7f-fea8-46ca-b083-f3ca4302436b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_112e3c6d-a8da-45fc-b8c4-906e4bc38fb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-Free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06caccda-53c4-4abb-8ca0-4f58eed4e24e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e3fcf021-19ac-4673-bd5c-7feea6fc4aeb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_46696b24-137b-4090-bc0a-b2ba995f4fd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0c222b5b-2f3b-475c-8962-e5b91aa9a458_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a122a83d-9728-4f52-a457-2662d1f0db95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f595c874-ce4c-4c99-b112-85d21421a9fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c60d7709-c8d7-45f9-aeb8-1d0075ebdf53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_9a919ffc-f398-4fd6-af80-88389b7c4d90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_83f634cc-c3c4-46f4-aa2c-689f893a08e6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_93de32d7-f351-4ffc-9bf8-cdc8bf17d340_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_de9bd3db-e808-4d41-8df1-8b5884092e6c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_98115109-7264-4dc3-b669-7062feef23ed_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fc7853a0-8f3f-4134-946d-5d60601582bc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock_243417cd-1a20-48b3-ba69-2ea7c8a0508a_terseLabel_en-US" xlink:label="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Costs</link:label>
    <link:label id="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock_label_en-US" xlink:label="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Costs [Table Text Block]</link:label>
    <link:label id="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock_documentation_en-US" xlink:label="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:href="dyai-20191231.xsd#dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:to="lab_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_561e7e22-217f-44cf-8f3a-0dad640dd167_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_56ec59d5-bcb1-4efc-b05d-37771eada138_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_4f806812-d354-48fe-87bb-870cd8476be2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c02f22d3-81a3-41b0-9e3a-08552c1ac788_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTextBlock_50350d8d-ef85-42f5-a5e3-bb035069d6d5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitments</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_b1ed8f3a-5558-4a96-adb0-0c3eabae3260_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5ec97eda-0ace-4699-a1bb-f1cf6f198cb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchandDevelopmentExpenseRelatedParty_91dc04ac-be64-4930-950b-c8fd507d41d1_terseLabel_en-US" xlink:label="lab_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development - related party</link:label>
    <link:label id="lab_dyai_ResearchandDevelopmentExpenseRelatedParty_label_en-US" xlink:label="lab_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Related Party</link:label>
    <link:label id="lab_dyai_ResearchandDevelopmentExpenseRelatedParty_documentation_en-US" xlink:label="lab_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:href="dyai-20191231.xsd#dyai_ResearchandDevelopmentExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:to="lab_dyai_ResearchandDevelopmentExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_062dc3a3-be63-4b96-9003-882d1880831b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_280f369b-bab5-489c-9417-1e28da8c5ad1_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investment securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_9cc94fb0-8148-4127-b965-cad3b7710f98_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments, adjusted cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_f663c531-1712-4816-afc0-adafabe5c660_negatedTerseLabel_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMT adjustment</link:label>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_label_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Alternative Minimum Tax, Percent</link:label>
    <link:label id="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_documentation_en-US" xlink:label="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Alternative Minimum Tax, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:to="lab_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_49b273af-e8a6-4291-9b74-0c4688b819bf_terseLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments, gross unrealized holding gain</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f4ed2388-0c71-4a0a-8698-4f236c03815b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ContractorMember_a0f99a02-f2f0-4b24-a9cb-7ec87a330371_terseLabel_en-US" xlink:label="lab_dyai_ContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractor</link:label>
    <link:label id="lab_dyai_ContractorMember_label_en-US" xlink:label="lab_dyai_ContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractor [Member]</link:label>
    <link:label id="lab_dyai_ContractorMember_documentation_en-US" xlink:label="lab_dyai_ContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractorMember" xlink:href="dyai-20191231.xsd#dyai_ContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ContractorMember" xlink:to="lab_dyai_ContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_53387aa4-376e-4eac-b7cf-22408a958a06_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementOutstandingCommitment_c9e07634-a0b6-449d-b385-ff39ba336d34_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementOutstandingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding commitment</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOutstandingCommitment_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementOutstandingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Outstanding Commitment</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementOutstandingCommitment_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementOutstandingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Outstanding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOutstandingCommitment" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOutstandingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementOutstandingCommitment" xlink:to="lab_dyai_CollaborativeArrangementOutstandingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_49f554aa-ab92-4271-8639-5fe0b7724772_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_511180e1-fd28-41a5-9bd6-e07b828c7974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4a909390-3f23-4e85-bb9e-e836a9706c3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DuPontDaniscoMember_6b6ca467-810c-445c-ae38-7d84dcc97bfd_terseLabel_en-US" xlink:label="lab_dyai_DuPontDaniscoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DuPont Danisco</link:label>
    <link:label id="lab_dyai_DuPontDaniscoMember_label_en-US" xlink:label="lab_dyai_DuPontDaniscoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DuPont Danisco [Member]</link:label>
    <link:label id="lab_dyai_DuPontDaniscoMember_documentation_en-US" xlink:label="lab_dyai_DuPontDaniscoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DuPont Danisco [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DuPontDaniscoMember" xlink:href="dyai-20191231.xsd#dyai_DuPontDaniscoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DuPontDaniscoMember" xlink:to="lab_dyai_DuPontDaniscoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a3d4a404-d710-4076-a86f-c21656c26af0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_13495973-1898-4838-9327-1b6397c82c48_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DeferredTaxAssetLiabilityGross_d12bc71c-10f0-426d-9bdf-64a6d2442df6_totalLabel_en-US" xlink:label="lab_dyai_DeferredTaxAssetLiabilityGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset, net of deferred tax liabilities</link:label>
    <link:label id="lab_dyai_DeferredTaxAssetLiabilityGross_label_en-US" xlink:label="lab_dyai_DeferredTaxAssetLiabilityGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset (Liability), Gross</link:label>
    <link:label id="lab_dyai_DeferredTaxAssetLiabilityGross_documentation_en-US" xlink:label="lab_dyai_DeferredTaxAssetLiabilityGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset (Liability), Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DeferredTaxAssetLiabilityGross" xlink:href="dyai-20191231.xsd#dyai_DeferredTaxAssetLiabilityGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DeferredTaxAssetLiabilityGross" xlink:to="lab_dyai_DeferredTaxAssetLiabilityGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f115ceec-100d-4202-b903-3d27c875d4e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_665ad28b-3f1c-4500-a71b-ab0a673dacbd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentToPay_4e1245f0-b236-496e-9224-f507dd44ecbf_terseLabel_en-US" xlink:label="lab_dyai_CommitmentToPay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to pay</link:label>
    <link:label id="lab_dyai_CommitmentToPay_label_en-US" xlink:label="lab_dyai_CommitmentToPay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay</link:label>
    <link:label id="lab_dyai_CommitmentToPay_documentation_en-US" xlink:label="lab_dyai_CommitmentToPay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPay" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentToPay" xlink:to="lab_dyai_CommitmentToPay" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent_adc6e61d-f0ca-4044-a14c-fcdc6743ec0f_terseLabel_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent_label_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research and Development in Process, Current</link:label>
    <link:label id="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent_documentation_en-US" xlink:label="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research and Development in Process, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopmentinProcessCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:to="lab_dyai_PrepaidResearchandDevelopmentinProcessCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de50e893-545b-4d48-a9a4-8100ce7d767c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5d78d00d-a631-409c-bf3d-da603e1b4a2d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, exercisable (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_4593c487-eeb9-42b2-9d10-3f5509fa21e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock repurchase activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d7d79f54-883d-46aa-8923-1dbddd302a2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_a4194780-1ca7-4200-9be1-1944801945ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa06e950-b300-44f2-9ee1-27fa5263b7dd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_547255ea-0d9a-4fa8-ac76-e01286700a5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_aa625da3-a084-4b08-8fa6-5d7415d918b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ba2bd3a0-07f5-4eaf-b906-010f8d33fdb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_EmployeeMember_de1e21dc-e6ec-4e71-97e9-a24c854cb9b0_terseLabel_en-US" xlink:label="lab_dyai_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_dyai_EmployeeMember_label_en-US" xlink:label="lab_dyai_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_dyai_EmployeeMember_documentation_en-US" xlink:label="lab_dyai_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EmployeeMember" xlink:href="dyai-20191231.xsd#dyai_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_EmployeeMember" xlink:to="lab_dyai_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_f81f4a8d-d05a-43ab-afc4-f6c2ca43d0ee_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_c7d41b15-7c02-4a7a-82cd-d5f916fe1a73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_66d0471c-8b6b-459a-a89b-38202a340b83_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_2985521e-7fef-4f7a-bcc6-5cb209628497_terseLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments, fair value</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value, Current</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod_e1870fbf-ffef-46fc-899e-5091e4d8606c_terseLabel_en-US" xlink:label="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, right to terminate contract notice period</link:label>
    <link:label id="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod_label_en-US" xlink:label="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Right To Terminate Contract Notice Period</link:label>
    <link:label id="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod_documentation_en-US" xlink:label="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Right To Terminate Contract Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:href="dyai-20191231.xsd#dyai_CommitmentsRightToTerminateContractNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:to="lab_dyai_CommitmentsRightToTerminateContractNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementRevenueSharingPercentage_0f2b7875-cb69-4d44-aefe-6bc5dbe5be2b_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue sharing, percentage</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementRevenueSharingPercentage_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Sharing, Percentage</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementRevenueSharingPercentage_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Sharing, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:to="lab_dyai_CollaborativeArrangementRevenueSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a5d1ff88-72da-4ebb-a346-914d483e8ba5_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79dbcbef-20b5-4213-b76e-b606701fd498_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CommitmentToPayExpandedPeriod_78600ad3-d3c5-41e7-a705-0a96fc6997dd_terseLabel_en-US" xlink:label="lab_dyai_CommitmentToPayExpandedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to pay, expanded, period</link:label>
    <link:label id="lab_dyai_CommitmentToPayExpandedPeriod_label_en-US" xlink:label="lab_dyai_CommitmentToPayExpandedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay, Expanded, Period</link:label>
    <link:label id="lab_dyai_CommitmentToPayExpandedPeriod_documentation_en-US" xlink:label="lab_dyai_CommitmentToPayExpandedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Pay, Expanded, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpandedPeriod" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpandedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CommitmentToPayExpandedPeriod" xlink:to="lab_dyai_CommitmentToPayExpandedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_915799c4-8f05-493a-93ca-ecf6e9472fd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1173c6fa-a5ea-4940-87fb-4efd5fdb7378_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a0561255-2f03-4009-b5e1-5aee37720d60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4368ca97-0b54-49da-a5c3-2c05b16f4ecc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_ebd11448-41b3-4893-9506-37cfbf8628a5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_d3141c0a-584f-4bab-a582-75df7b150f59_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_33dd5f62-f1f6-4540-92b2-082ce017f05b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_72385564-c26b-4cca-82e0-8cf60778049a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3e35f6db-5dfc-4c32-af6e-b2a2f2939889_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d6604103-1cd9-4beb-84d3-39ebb8b55978_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_47173ef3-d27b-4e56-940c-09cb0d321750_negatedLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments, gross unrealized holding loss</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2aab30ed-3393-4f69-9954-0540f1438468_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2194ac83-c089-4888-bbfc-87a4e1524999_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e3c2d3d8-6a42-4fed-b122-9ebcb9405c85_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_681892ad-930c-474e-8650-cbbb78213ef7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_5da9a720-e88b-4132-919b-264e11d6429c_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bade4b24-28a1-4ccc-8d7f-4baf6f073e96_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_OperatingLeasesAnnualRentalRate_a72d686e-eed3-43da-bbf7-fa5304a8e2b6_terseLabel_en-US" xlink:label="lab_dyai_OperatingLeasesAnnualRentalRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_dyai_OperatingLeasesAnnualRentalRate_label_en-US" xlink:label="lab_dyai_OperatingLeasesAnnualRentalRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Annual Rental Rate</link:label>
    <link:label id="lab_dyai_OperatingLeasesAnnualRentalRate_documentation_en-US" xlink:label="lab_dyai_OperatingLeasesAnnualRentalRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Annual Rental Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesAnnualRentalRate" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesAnnualRentalRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_OperatingLeasesAnnualRentalRate" xlink:to="lab_dyai_OperatingLeasesAnnualRentalRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_4095cbd7-5ece-4bb3-bba1-9ddf36ad1833_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_label_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:to="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_A2006PlanMember_e1218e98-e5bf-42c7-9d76-ebbae29cecf7_terseLabel_en-US" xlink:label="lab_dyai_A2006PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan</link:label>
    <link:label id="lab_dyai_A2006PlanMember_label_en-US" xlink:label="lab_dyai_A2006PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan [Member]</link:label>
    <link:label id="lab_dyai_A2006PlanMember_documentation_en-US" xlink:label="lab_dyai_A2006PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2006PlanMember" xlink:href="dyai-20191231.xsd#dyai_A2006PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_A2006PlanMember" xlink:to="lab_dyai_A2006PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fb5e72a9-5377-486d-a9a0-89c9bde4f7d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e4a22e4d-4ac6-49bf-a701-a525ab5dc57c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e8d01a8d-5a9d-42a6-9756-c55817bbb47d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ad41762f-eb4f-4b82-b1aa-59d29596a84d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0caed119-0c25-4727-a7e2-587f385f2368_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_NetherlandsOfficeLeaseMember_94258abb-a5c3-40f5-9109-ded63560abd4_terseLabel_en-US" xlink:label="lab_dyai_NetherlandsOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Netherlands Office Lease</link:label>
    <link:label id="lab_dyai_NetherlandsOfficeLeaseMember_label_en-US" xlink:label="lab_dyai_NetherlandsOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Netherlands Office Lease [Member]</link:label>
    <link:label id="lab_dyai_NetherlandsOfficeLeaseMember_documentation_en-US" xlink:label="lab_dyai_NetherlandsOfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Netherlands Office Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NetherlandsOfficeLeaseMember" xlink:href="dyai-20191231.xsd#dyai_NetherlandsOfficeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_NetherlandsOfficeLeaseMember" xlink:to="lab_dyai_NetherlandsOfficeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_309fc4c7-6cc4-4f65-9c5f-cad9fc3fadfc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_da3ac376-6a9f-4b6a-86be-262e8af5e281_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_99e06357-b0e5-47f3-9124-53272de42caa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6b56daaf-ddfc-4c76-b45d-854f795c530f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_489cc5fd-8b42-475f-a4aa-bdebbd9f0e43_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_121be64f-f2ed-43e3-ab7d-e4aa2b06e64a_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_90a67bc7-38f1-4aaa-b9f1-60c7163d4df8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_780d0d73-d10e-4ea8-9a1f-2bedbd7661bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2cc63272-4d71-4d17-9ea7-961763c059cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period, weighted average grant date fair value (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_4b14719f-fa1b-47bd-8eaa-bb8a74dec41b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_b6ca397b-795c-4952-b092-ee48ef8b14b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5fe26bdc-1da4-45a0-a29c-45f46ce521d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_698855a6-f513-4b6a-ad53-176405d52977_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a12bbffb-e9f9-4b91-9879-5206380e8b28_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_98e298ef-779b-4c85-82bb-24390a23823d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_091090af-0e76-4323-8c09-a02303939e14_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_e6b2266d-9db8-4a2b-95b8-bfdde3da5b83_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dc9fabb-2dc0-40a2-bc5f-b8570c7cc4a0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bdab9f97-f620-4cac-8a87-684ad9f5e98e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_1445295a-0236-418e-8ab5-7035a67fb69b_totalLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense, related party, net</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Including Related Party</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Including Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_b4e2271c-990e-4bf4-8f22-81e224efaef3_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_b2722ccb-3482-4b13-9487-c649d4ed7532_terseLabel_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, premium paid on purchase</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_label_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Premium Paid on Purchase</link:label>
    <link:label id="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_documentation_en-US" xlink:label="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Premium Paid on Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:to="lab_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_09c40127-f098-4a1d-901d-a9f2da0da8b9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e2a16c07-fad6-447e-a924-173c50000541_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_56b29942-40d5-476b-8f54-58b1a7c85ca7_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, common stock (in shares)</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_label_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock</link:label>
    <link:label id="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:to="lab_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c9654555-c825-4a2f-8f33-1db51a88613e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_a714be17-852e-4d0d-b32d-902dc8d950af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_264cc4d2-b8cf-4a69-83fc-0e54c628aad7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_a8c7b97f-f480-4a97-963e-f795efe91a67_terseLabel_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside contracted services</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_label_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Outside Contracted Services</link:label>
    <link:label id="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_documentation_en-US" xlink:label="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Outside Contracted Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:to="lab_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_811ebc91-d7e3-450c-80ae-ed97a35580a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7f28c6db-d76c-48e4-a752-72a4046cc4aa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6663878d-b572-4e68-b7e5-6b2a42c421d2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8538213a-af72-4fb9-a846-66303e4b8634_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_68867b1e-b7a9-4de2-be19-41bbc1b28804_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementDurationOfAgreement_10fd19d1-8fc3-4eac-ae81-d61a3c0797a2_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementDurationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of agreement</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementDurationOfAgreement_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementDurationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Duration Of Agreement</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementDurationOfAgreement_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementDurationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Duration Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementDurationOfAgreement" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementDurationOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementDurationOfAgreement" xlink:to="lab_dyai_CollaborativeArrangementDurationOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_db9c9e2d-50cb-4d81-92b4-1df605ebaa5c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_424c1bbf-bc5b-494e-b809-a6fd0769cc57_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, outstanding (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_48275411-efaf-41c6-b05d-1de94c1c20d9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_87f0b8a4-b183-4d59-aa60-74eac56a7c13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_201701fb-e379-409f-a3f4-665862a7e668_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding, beginning (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bbd4ec70-50a7-42e4-87ed-9527409f7f80_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding, ending (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_01c609ec-4d90-43e0-8775-f5a945d82d60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6ac834b7-7f4d-46a4-bea8-b09dc7a76774_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_ed965fad-eed8-46fa-9372-3c6a3409a304_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_939d84b7-6fab-45b4-a257-65f5a5e6277a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_272f59d7-5f53-4413-9e0e-a078b95a7c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_bb09e5ea-07b2-42e8-aa55-1e9cd025780c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d594caf-4f9c-4d7b-b32a-7863899654ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_59664fdd-f983-43ef-9465-5fb6e4610286_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_680a000f-4605-4f69-b627-819beeee48df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bb6652a9-88b2-4b6c-8ff6-10a64323d8b1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_0263472f-2325-4b81-aebc-5c786e88b5dc_terseLabel_en-US" xlink:label="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche Two through Five</link:label>
    <link:label id="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_label_en-US" xlink:label="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche Two through Five [Member]</link:label>
    <link:label id="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_documentation_en-US" xlink:label="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche Two through Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:to="lab_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_ef74a4db-5463-494c-ace9-6e569cd0098c_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f33e920d-f244-4616-b2fe-8dc4ad02b24f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_a9da4ecd-f43b-45b9-a95a-f6a9b7d2bc3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_IndustrialTechnologyBusinessMember_53e48158-1df0-4e52-8594-a9d63be59d9b_terseLabel_en-US" xlink:label="lab_dyai_IndustrialTechnologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial Technology Business</link:label>
    <link:label id="lab_dyai_IndustrialTechnologyBusinessMember_label_en-US" xlink:label="lab_dyai_IndustrialTechnologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial Technology Business [Member]</link:label>
    <link:label id="lab_dyai_IndustrialTechnologyBusinessMember_documentation_en-US" xlink:label="lab_dyai_IndustrialTechnologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial Technology Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IndustrialTechnologyBusinessMember" xlink:href="dyai-20191231.xsd#dyai_IndustrialTechnologyBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_IndustrialTechnologyBusinessMember" xlink:to="lab_dyai_IndustrialTechnologyBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_CollaborativeArrangementEquityInterestAcquired_83677207-be94-47f3-9f7c-82ab51dd8d21_terseLabel_en-US" xlink:label="lab_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest acquired</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementEquityInterestAcquired_label_en-US" xlink:label="lab_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Equity Interest Acquired</link:label>
    <link:label id="lab_dyai_CollaborativeArrangementEquityInterestAcquired_documentation_en-US" xlink:label="lab_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Equity Interest Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementEquityInterestAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:to="lab_dyai_CollaborativeArrangementEquityInterestAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_eb093e4c-bfce-4b7d-8b07-d0a1729406a1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred research and development obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2e98e354-ec2e-4516-b6e1-5cac19ef2d3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e715bf99-9452-4a27-86d3-ddb828bc2553_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_58376c40-a399-47f4-99b3-dc1b4b41674c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0516f11d-5ef4-4697-8ea3-845edec8011b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a7ae850c-9965-45e1-b6b2-a55f47c31d7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e9b6b134-f3d4-42fe-bbe9-8e6915a12904_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_PubliclyAnnouncedRepurchasePlansMember_fe680439-2dfa-4559-b3a3-1cb42f990811_terseLabel_en-US" xlink:label="lab_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Repurchase Plans [Member]</link:label>
    <link:label id="lab_dyai_PubliclyAnnouncedRepurchasePlansMember_label_en-US" xlink:label="lab_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Repurchase Plans [Member]</link:label>
    <link:label id="lab_dyai_PubliclyAnnouncedRepurchasePlansMember_documentation_en-US" xlink:label="lab_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Repurchase Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:href="dyai-20191231.xsd#dyai_PubliclyAnnouncedRepurchasePlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:to="lab_dyai_PubliclyAnnouncedRepurchasePlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_4b660dad-9948-43ff-8a04-0e71707ae8de_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dyai_SerumMember_4d3f60d7-19f5-4f06-ad03-676c60330dd3_terseLabel_en-US" xlink:label="lab_dyai_SerumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serum [Member]</link:label>
    <link:label id="lab_dyai_SerumMember_label_en-US" xlink:label="lab_dyai_SerumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serum [Member]</link:label>
    <link:label id="lab_dyai_SerumMember_documentation_en-US" xlink:label="lab_dyai_SerumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SerumMember" xlink:href="dyai-20191231.xsd#dyai_SerumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dyai_SerumMember" xlink:to="lab_dyai_SerumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_c3f516d1-e940-4de1-843e-f5a8d64632be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:to="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1a9033e-0acb-49dd-bbda-e5e9c1b8ec26_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_b017a12b-1116-4300-9170-1095d16db4c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_24db39be-0544-4415-b7b0-9d615d993b03_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_33cae48e-748c-4e26-926b-676f9c2c3d6d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fdbff25f-7b82-49ef-a8f8-37d68d33f214_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a7948955-f815-4e69-8634-d2e8e4002bd9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c83326af-2c44-4cf3-95c5-d0b3cca8ce1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_24593c94-dd2f-4650-844c-b23a1a50f701_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investment securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_4c8613fe-f122-403c-bc59-29958648e9a7_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investments, adjusted cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>dyai-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:62cd9607-c646-47d4-bb87-5f440e34d689,g:9aa84e3a-6ab2-4e1c-9b32-b3a92a5a8700-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dyai-20191231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_506058a9-02b5-4011-af46-f3b12c11997a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentType_506058a9-02b5-4011-af46-f3b12c11997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_071947b8-893d-4aff-97e8-97f7ec72d2c1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentAnnualReport_071947b8-893d-4aff-97e8-97f7ec72d2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_19e440da-9374-4f1a-8987-fa6c20919953" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentPeriodEndDate_19e440da-9374-4f1a-8987-fa6c20919953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d348c8d9-9065-4836-b26f-da246053b356" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentTransitionReport_d348c8d9-9065-4836-b26f-da246053b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_deedd446-0ff4-4678-96da-d95ef4e8cf34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityFileNumber_deedd446-0ff4-4678-96da-d95ef4e8cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_86adb004-be3e-4a04-9158-33007e237aa1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityRegistrantName_86adb004-be3e-4a04-9158-33007e237aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b8399664-8b0e-408a-b399-7fbcccf8192a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b8399664-8b0e-408a-b399-7fbcccf8192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1a14833-fcba-4639-bcd9-2cd238ca126a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1a14833-fcba-4639-bcd9-2cd238ca126a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bd1fb595-adf0-4d0f-8a6a-c04077d35565" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityAddressAddressLine1_bd1fb595-adf0-4d0f-8a6a-c04077d35565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_17a4e4ef-d410-427f-bb62-63d45f0f6e60" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityAddressAddressLine2_17a4e4ef-d410-427f-bb62-63d45f0f6e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b97ed37b-650c-484e-9efc-a7741bc29078" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityAddressCityOrTown_b97ed37b-650c-484e-9efc-a7741bc29078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_21783d19-8cd9-433e-b378-4716bfc773b0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityAddressStateOrProvince_21783d19-8cd9-433e-b378-4716bfc773b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7edaa6f6-6a07-43b2-8626-2724d13582fe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityAddressPostalZipCode_7edaa6f6-6a07-43b2-8626-2724d13582fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c38c2133-07e1-4150-b00b-6cdde819bc72" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_CityAreaCode_c38c2133-07e1-4150-b00b-6cdde819bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_253ed36c-4eb5-4084-8f41-02448ed4ea68" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_LocalPhoneNumber_253ed36c-4eb5-4084-8f41-02448ed4ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_404adab0-76ad-417c-826a-0bd7cb471ce9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_Security12bTitle_404adab0-76ad-417c-826a-0bd7cb471ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_14a79859-4a55-47cb-adb3-4e762d212349" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_TradingSymbol_14a79859-4a55-47cb-adb3-4e762d212349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b70eb3a6-224a-4589-9113-5033fa00bf47" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_SecurityExchangeName_b70eb3a6-224a-4589-9113-5033fa00bf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_68a0aed1-0036-488c-9e9b-345fc1941fe2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_68a0aed1-0036-488c-9e9b-345fc1941fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_6add666e-fc23-4b95-aca6-052cddbe9626" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityVoluntaryFilers_6add666e-fc23-4b95-aca6-052cddbe9626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_44ad9937-4801-45a2-ab4a-0136d722ede7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityCurrentReportingStatus_44ad9937-4801-45a2-ab4a-0136d722ede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0c4da2de-904b-4f8e-bbc8-9a3669319874" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityInteractiveDataCurrent_0c4da2de-904b-4f8e-bbc8-9a3669319874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6b75fdbb-8dcf-4850-b9b1-f007ef2aef34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityFilerCategory_6b75fdbb-8dcf-4850-b9b1-f007ef2aef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_76dc3b34-173a-4846-9392-65ada6b1ab11" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntitySmallBusiness_76dc3b34-173a-4846-9392-65ada6b1ab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b2210e68-e70a-41e3-b27c-550efcace26a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityEmergingGrowthCompany_b2210e68-e70a-41e3-b27c-550efcace26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fd0a5da7-68f8-464c-9472-73bcb9814a3e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityShellCompany_fd0a5da7-68f8-464c-9472-73bcb9814a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f230f7e9-b05b-4a38-8e7c-29a1f789f1e8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityPublicFloat_f230f7e9-b05b-4a38-8e7c-29a1f789f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1d84be56-7d8a-4191-8f62-903826487e80" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1d84be56-7d8a-4191-8f62-903826487e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a0a002c6-ddd5-4dc9-a1a0-9faa83f9d882" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_EntityCentralIndexKey_a0a002c6-ddd5-4dc9-a1a0-9faa83f9d882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e8fc9335-3f6d-43d9-9a49-950450f76cd0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_CurrentFiscalYearEndDate_e8fc9335-3f6d-43d9-9a49-950450f76cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33e80637-1313-45c8-93ae-0a310bc9ca39" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentFiscalYearFocus_33e80637-1313-45c8-93ae-0a310bc9ca39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1a976beb-7407-4db9-9d6c-1f9af37a6f1c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1a976beb-7407-4db9-9d6c-1f9af37a6f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2237dd21-3e27-4ec6-b6cf-c92398694528" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42d51d0d-d84e-4662-9011-a9024be089e8" xlink:to="loc_dei_AmendmentFlag_2237dd21-3e27-4ec6-b6cf-c92398694528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_094c608a-8be4-4347-a365-4232ce40002b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e0141afc-66a9-46af-b291-22c7cec7739e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_094c608a-8be4-4347-a365-4232ce40002b" xlink:to="loc_us-gaap_AssetsAbstract_e0141afc-66a9-46af-b291-22c7cec7739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e0141afc-66a9-46af-b291-22c7cec7739e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_105df0cb-7176-4678-b2bb-05ca199897a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_105df0cb-7176-4678-b2bb-05ca199897a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48733724-cdd5-4b44-8116-6e07312c180d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48733724-cdd5-4b44-8116-6e07312c180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_5ae6cd75-ccf6-4ef0-bdd9-d923b15cb98f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_InterestReceivableCurrent_5ae6cd75-ccf6-4ef0-bdd9-d923b15cb98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_441a4a9d-940a-4c5d-88dc-e19de19a3cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_441a4a9d-940a-4c5d-88dc-e19de19a3cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_e9db5887-17ca-4bdf-b100-bd4e0ddc2754" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_IncomeTaxesReceivable_e9db5887-17ca-4bdf-b100-bd4e0ddc2754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent_01ce6a7d-3b54-424a-b051-eda6ee02c42f" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopmentinProcessCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_dyai_PrepaidResearchandDevelopmentinProcessCurrent_01ce6a7d-3b54-424a-b051-eda6ee02c42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b457b616-1516-4ca9-a243-e8625fd5ff8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b457b616-1516-4ca9-a243-e8625fd5ff8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_61057551-99c9-402c-9c5d-64f6fffd2dad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f5c2585-c0c2-4964-a7a5-832e0b1edc66" xlink:to="loc_us-gaap_AssetsCurrent_61057551-99c9-402c-9c5d-64f6fffd2dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e0141afc-66a9-46af-b291-22c7cec7739e" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_82ffcf35-565f-4a22-9dd5-5d826cc57add" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_82ffcf35-565f-4a22-9dd5-5d826cc57add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_c830b7a1-60ca-431c-ab6e-98940c339319" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_c830b7a1-60ca-431c-ab6e-98940c339319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4af9c136-51e9-4eaa-a7df-3850662e5e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4af9c136-51e9-4eaa-a7df-3850662e5e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_de8e474a-f9f3-454c-aa21-90d2eddd49f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9a14946-8752-4b31-931c-8f4bf77853bb" xlink:to="loc_us-gaap_Assets_de8e474a-f9f3-454c-aa21-90d2eddd49f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_094c608a-8be4-4347-a365-4232ce40002b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_93b05081-4774-431a-9043-649cc4110fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:to="loc_us-gaap_AccountsPayableCurrent_93b05081-4774-431a-9043-649cc4110fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c050ca05-41e5-44f7-86f9-767992ed2865" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c050ca05-41e5-44f7-86f9-767992ed2865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7041b6ed-5ec6-4184-9a93-0061cb7d135f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7041b6ed-5ec6-4184-9a93-0061cb7d135f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d8c566d7-c81a-4275-9323-34fce989ad99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de726f45-ff5c-4779-b183-8f7e4de219d3" xlink:to="loc_us-gaap_LiabilitiesCurrent_d8c566d7-c81a-4275-9323-34fce989ad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_83440e9b-83a7-4f30-8876-caede9f0cbdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_83440e9b-83a7-4f30-8876-caede9f0cbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a3a1e5c1-5f85-428b-aed8-4e32228abb14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_PreferredStockValue_a3a1e5c1-5f85-428b-aed8-4e32228abb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1ba65474-4aea-4a6b-b828-4aedcf64c1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_CommonStockValue_1ba65474-4aea-4a6b-b828-4aedcf64c1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_84e08112-b0f4-4a36-8cd0-c359fd48c173" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_84e08112-b0f4-4a36-8cd0-c359fd48c173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c260cb92-aec6-45e6-8d59-1eec30e4728b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_TreasuryStockValue_c260cb92-aec6-45e6-8d59-1eec30e4728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1a957ca7-5b05-4ffa-9bba-6bde2caf7de8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1a957ca7-5b05-4ffa-9bba-6bde2caf7de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ae3b4e7-ddcd-48d1-b187-1843ede945c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8237793d-cfcd-4168-8343-c14737a113cb" xlink:to="loc_us-gaap_StockholdersEquity_9ae3b4e7-ddcd-48d1-b187-1843ede945c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_20d4af66-274e-4659-99c2-6fb22c69cfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7f275f5f-c3a7-4974-94fd-be98afb1b28a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_20d4af66-274e-4659-99c2-6fb22c69cfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d3749163-fe29-4117-ae4a-2a7b3ff9c6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d3749163-fe29-4117-ae4a-2a7b3ff9c6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2a284eda-b02b-4107-9304-5a4332bf88a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2a284eda-b02b-4107-9304-5a4332bf88a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_43e1ab9a-b0c5-4dce-880f-19ea01e89137" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_43e1ab9a-b0c5-4dce-880f-19ea01e89137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bb1f9573-8ca3-4b60-af3c-85f45c9993a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bb1f9573-8ca3-4b60-af3c-85f45c9993a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07bbee65-3e70-4146-bf91-2a7c3ba0ea03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07bbee65-3e70-4146-bf91-2a7c3ba0ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3028af29-4826-4219-a670-c89eb21ee654" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3028af29-4826-4219-a670-c89eb21ee654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a4e684b6-6f24-4c9e-91e7-2c7026a4afa6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_CommonStockSharesIssued_a4e684b6-6f24-4c9e-91e7-2c7026a4afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_87db6e84-248b-4a9f-9f24-385e672938fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_87db6e84-248b-4a9f-9f24-385e672938fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9e109c54-f4ac-4c02-9c8f-a406e70c3d45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea10fd-0570-4ee8-ae31-2fdd7132db5e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9e109c54-f4ac-4c02-9c8f-a406e70c3d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_fddbda56-cfb5-4baf-b92b-2df8fc742d21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_RevenuesAbstract_fddbda56-cfb5-4baf-b92b-2df8fc742d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a00a5f46-63cd-4336-8f17-e2c27e0c7369" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_fddbda56-cfb5-4baf-b92b-2df8fc742d21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a00a5f46-63cd-4336-8f17-e2c27e0c7369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7bc62402-9bbd-4568-8499-6e3e27a5f052" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7bc62402-9bbd-4568-8499-6e3e27a5f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9646d56b-b3ad-4d74-90c7-a0a9c19a96e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9646d56b-b3ad-4d74-90c7-a0a9c19a96e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_0f8e124d-fe9c-4484-8992-fb74fa4cb54a" xlink:href="dyai-20191231.xsd#dyai_ResearchandDevelopmentExpenseRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_0f8e124d-fe9c-4484-8992-fb74fa4cb54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_05bfc365-4c08-47a5-b67e-2df55b9cd016" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_05bfc365-4c08-47a5-b67e-2df55b9cd016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1e87c7e7-4afc-4c4b-a03f-8f927fa70674" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1e87c7e7-4afc-4c4b-a03f-8f927fa70674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1985228a-c969-4d94-8668-1f0102fa3a84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cb3cb0f8-69f0-4fa7-ba48-c09e20f787ac" xlink:to="loc_us-gaap_CostsAndExpenses_1985228a-c969-4d94-8668-1f0102fa3a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f168cf4d-960b-4876-917c-934f2995e5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_OperatingIncomeLoss_f168cf4d-960b-4876-917c-934f2995e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_134a3aa6-0dfa-4642-987e-b69e8487f7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_134a3aa6-0dfa-4642-987e-b69e8487f7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_a80562b0-c723-4719-8931-d05241ad6604" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_a80562b0-c723-4719-8931-d05241ad6604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cddd1ec5-a0c4-4dd2-ad3e-203648eb1328" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cddd1ec5-a0c4-4dd2-ad3e-203648eb1328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79ae4df7-da1c-4aef-b756-9a3b73a22609" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_NetIncomeLoss_79ae4df7-da1c-4aef-b756-9a3b73a22609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_254a7fe8-c4a7-4e1f-b246-eb7a0738fbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_254a7fe8-c4a7-4e1f-b246-eb7a0738fbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abba6670-fe1a-4fd0-a175-051378a865cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02f7fd21-171d-46f8-8653-7cfd9cfa8311" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_abba6670-fe1a-4fd0-a175-051378a865cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_287da0ab-7521-4401-abe3-ef3b3ec348ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_287da0ab-7521-4401-abe3-ef3b3ec348ad" xlink:to="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5276480e-7cf7-44a8-a48f-9c852e936a15" xlink:to="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7501a383-5ce4-474a-bdb5-cd98362d20c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_CommonStockMember_7501a383-5ce4-474a-bdb5-cd98362d20c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2b8b8e65-1e50-41ba-973e-970a80c2131f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_TreasuryStockMember_2b8b8e65-1e50-41ba-973e-970a80c2131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9abb8f1a-11f2-4c53-be76-6767e96fd3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9abb8f1a-11f2-4c53-be76-6767e96fd3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_df04774d-7ad0-4e2a-b872-90b50aba81d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef1cc687-a5af-4d64-9d90-be2369f0cde0" xlink:to="loc_us-gaap_RetainedEarningsMember_df04774d-7ad0-4e2a-b872-90b50aba81d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf157030-013e-41d2-b871-04d0c1838f85" xlink:to="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f6381f15-4a9a-4bb5-b3b0-6ee83f61b2d1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae291b1f-feb8-42a5-85da-b103acf2ee91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae291b1f-feb8-42a5-85da-b103acf2ee91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d22d40f8-39f2-470a-99d1-337894e95a26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockholdersEquity_d22d40f8-39f2-470a-99d1-337894e95a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6278a206-7f8e-4910-9116-b45d6cff60cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6278a206-7f8e-4910-9116-b45d6cff60cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_154a71a0-c9f8-4af0-bff1-84e0a10e43d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_154a71a0-c9f8-4af0-bff1-84e0a10e43d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c6a713ab-e6aa-42ec-b4b9-e7fe368ad69a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c6a713ab-e6aa-42ec-b4b9-e7fe368ad69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b3c6add1-3a4e-482d-a9d4-99bfcc3303c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b3c6add1-3a4e-482d-a9d4-99bfcc3303c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9615a0d1-6c8e-43aa-a1a7-bd235944ca41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_9615a0d1-6c8e-43aa-a1a7-bd235944ca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5cecf9f-e400-486d-82a4-935c8455481c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_NetIncomeLoss_a5cecf9f-e400-486d-82a4-935c8455481c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_193e75d1-db8b-43d8-8181-dd2fbbdc34f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_CommonStockSharesIssued_193e75d1-db8b-43d8-8181-dd2fbbdc34f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a215bc53-30b1-4251-b16f-fe4acd4b25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf2624eb-4c9a-4c4e-af64-832d8ee8df92" xlink:to="loc_us-gaap_StockholdersEquity_a215bc53-30b1-4251-b16f-fe4acd4b25dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dyai-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ac557ec-f70d-4e0c-bffc-3034d3d213cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ac557ec-f70d-4e0c-bffc-3034d3d213cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a36962e-a1a2-4463-bf92-63008cbb7f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ac557ec-f70d-4e0c-bffc-3034d3d213cf" xlink:to="loc_us-gaap_NetIncomeLoss_0a36962e-a1a2-4463-bf92-63008cbb7f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ac557ec-f70d-4e0c-bffc-3034d3d213cf" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4214a07a-34d5-47cb-b37c-a171b59726d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:to="loc_us-gaap_ShareBasedCompensation_4214a07a-34d5-47cb-b37c-a171b59726d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_005de12a-eb8b-4e21-9934-035cd0b3781c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_005de12a-eb8b-4e21-9934-035cd0b3781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cac7af50-77b2-4de7-9bee-299b73b54595" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cac7af50-77b2-4de7-9bee-299b73b54595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca1c0e53-7a65-4ddd-986c-7f7cf3131d46" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_b046144a-6540-430d-a6b2-5b642c9f1512" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_b046144a-6540-430d-a6b2-5b642c9f1512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8f6f4eb-9ec3-4ba6-ae75-22d9d737f277" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8f6f4eb-9ec3-4ba6-ae75-22d9d737f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_5e84c36a-2166-47f8-956f-706817da99b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_5e84c36a-2166-47f8-956f-706817da99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_0d886c28-34d9-4585-9b69-0d6a2565aa33" xlink:href="dyai-20191231.xsd#dyai_IncreaseDecreaseinPrepaidResearchandDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment_0d886c28-34d9-4585-9b69-0d6a2565aa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e596a365-420e-46d6-bf13-1cb563c45f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e596a365-420e-46d6-bf13-1cb563c45f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c8ea4535-866b-40a9-9545-b40cf50f8371" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c8ea4535-866b-40a9-9545-b40cf50f8371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ccf9705d-820b-4f54-9121-336440d04c21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ccf9705d-820b-4f54-9121-336440d04c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3001993c-e305-46f1-95c4-f7850d2eeb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3001993c-e305-46f1-95c4-f7850d2eeb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c347ca4c-851c-4ff1-88a0-df616a5c5c60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_623c4d6f-2b2c-4899-870e-d8fcd02ba1e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c347ca4c-851c-4ff1-88a0-df616a5c5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c24b1aa6-2b27-48f1-a241-c468bac063ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ac557ec-f70d-4e0c-bffc-3034d3d213cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c24b1aa6-2b27-48f1-a241-c468bac063ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dd20bdf-a183-43d3-b8f7-93030ba83727" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dd20bdf-a183-43d3-b8f7-93030ba83727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2eb65f5f-e600-4cfb-b9b6-30a44e158772" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dd20bdf-a183-43d3-b8f7-93030ba83727" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_2eb65f5f-e600-4cfb-b9b6-30a44e158772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_a9ef74f0-1986-4e19-bb2d-7008d3dd9c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dd20bdf-a183-43d3-b8f7-93030ba83727" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_a9ef74f0-1986-4e19-bb2d-7008d3dd9c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31c3c340-fc69-46cd-aa88-fedb0e6bcd49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dd20bdf-a183-43d3-b8f7-93030ba83727" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31c3c340-fc69-46cd-aa88-fedb0e6bcd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d45dd58-432c-4294-a3d6-6c758c14bf43" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d45dd58-432c-4294-a3d6-6c758c14bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_22aebf86-8159-476e-9f51-f8a5560d76f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d45dd58-432c-4294-a3d6-6c758c14bf43" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_22aebf86-8159-476e-9f51-f8a5560d76f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2c1a2643-b87b-4ea2-abf8-0a22c0c904a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d45dd58-432c-4294-a3d6-6c758c14bf43" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2c1a2643-b87b-4ea2-abf8-0a22c0c904a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f43195e-78ac-493e-8b09-95579c81352c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d45dd58-432c-4294-a3d6-6c758c14bf43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f43195e-78ac-493e-8b09-95579c81352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92be63ad-6295-4ada-b4f5-897425a6aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92be63ad-6295-4ada-b4f5-897425a6aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_929a51a8-6ffa-4b1d-ad77-dc15ff558a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_929a51a8-6ffa-4b1d-ad77-dc15ff558a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f991a54c-e8af-4ab6-b761-9231f085d4ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f991a54c-e8af-4ab6-b761-9231f085d4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02770cea-d30a-4320-8621-0f3b621f9643" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02770cea-d30a-4320-8621-0f3b621f9643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a2c61ed-e358-4018-8ec8-bde8c94f7906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_729e8220-802d-4f5a-b4c8-bd867e172404" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a2c61ed-e358-4018-8ec8-bde8c94f7906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_aa6b2d2c-e3ef-49e6-8251-42a740e6dc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a2c61ed-e358-4018-8ec8-bde8c94f7906" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_aa6b2d2c-e3ef-49e6-8251-42a740e6dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b46429ed-f30b-499b-aedc-1c91b774cc78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_ac53446b-4db1-4fa4-b239-b9168f54a535" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b46429ed-f30b-499b-aedc-1c91b774cc78" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_ac53446b-4db1-4fa4-b239-b9168f54a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9c25bb9c-671f-4fa6-bc7b-5e0dccf9a46b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9c25bb9c-671f-4fa6-bc7b-5e0dccf9a46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9ae53c9f-504c-4296-8e2b-43cbd6536023" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_UseOfEstimates_9ae53c9f-504c-4296-8e2b-43cbd6536023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_db89e8ac-1d9f-46eb-b6d1-997aa683e084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_db89e8ac-1d9f-46eb-b6d1-997aa683e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d484b694-9665-45ee-91f1-e8c25b93fb17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d484b694-9665-45ee-91f1-e8c25b93fb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_a2e9d44f-cd8d-4fd7-8069-d9f395f33f57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_a2e9d44f-cd8d-4fd7-8069-d9f395f33f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_94fc1b28-114e-45f2-b8f5-1a7a91b8d966" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_94fc1b28-114e-45f2-b8f5-1a7a91b8d966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_b53eeed4-8597-4249-8901-4fc30dad1058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_b53eeed4-8597-4249-8901-4fc30dad1058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ceb22489-435b-4915-86a5-d3be784d6c71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ceb22489-435b-4915-86a5-d3be784d6c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8e4a6061-cf91-4dc1-9229-c9e2da1ac417" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8e4a6061-cf91-4dc1-9229-c9e2da1ac417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_429b4fb9-8edd-4b9a-b6d2-f8c2e09782fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_429b4fb9-8edd-4b9a-b6d2-f8c2e09782fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3a019165-60de-484a-8874-42058c91a5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3a019165-60de-484a-8874-42058c91a5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_aa4d7908-5ade-4a15-bac6-6d9d863c00f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_aa4d7908-5ade-4a15-bac6-6d9d863c00f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7013e374-f409-407b-84e4-6074956f92a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7013e374-f409-407b-84e4-6074956f92a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ea7fed55-e6c9-49f7-8009-0729e5a3c7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ea7fed55-e6c9-49f7-8009-0729e5a3c7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b35149d1-9d76-4456-8da2-bec3baac57dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b35149d1-9d76-4456-8da2-bec3baac57dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_78f9a7cb-72a0-4cdf-9f7d-4bb6bfb0a442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12e539c7-236a-4982-ab11-6be34ab32045" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_78f9a7cb-72a0-4cdf-9f7d-4bb6bfb0a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f57bb547-2ca2-4009-9e9a-0f5a71012137" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f57bb547-2ca2-4009-9e9a-0f5a71012137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_00497903-25a4-4387-ae8a-7c47e74fb183" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_00497903-25a4-4387-ae8a-7c47e74fb183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8256b2c8-5360-4152-976c-6b1ef113f43d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8256b2c8-5360-4152-976c-6b1ef113f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_25c549a2-50d8-4c68-8b6e-a11921ef7c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_25c549a2-50d8-4c68-8b6e-a11921ef7c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock_2fce1ab0-1d4e-458b-8791-dcad42ddfe87" xlink:href="dyai-20191231.xsd#dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d933092-1fa8-4d7f-9a56-56da1661ead7" xlink:to="loc_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock_2fce1ab0-1d4e-458b-8791-dcad42ddfe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0721dbc6-bcd6-4ec0-ba58-4f21ecc87c06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0721dbc6-bcd6-4ec0-ba58-4f21ecc87c06" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a2a80cf0-1b88-4390-9f89-07c4cf33f51e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DuPontDaniscoMember_380e6b28-f4bd-4b59-88bc-6adb6140a9e7" xlink:href="dyai-20191231.xsd#dyai_DuPontDaniscoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:to="loc_dyai_DuPontDaniscoMember_380e6b28-f4bd-4b59-88bc-6adb6140a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractResearchOrganizationsMember_6ceea767-8cf9-4030-a1dd-9f95231d58c7" xlink:href="dyai-20191231.xsd#dyai_ContractResearchOrganizationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc46c229-036a-40ab-9afe-22e568ec933d" xlink:to="loc_dyai_ContractResearchOrganizationsMember_6ceea767-8cf9-4030-a1dd-9f95231d58c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a1ded76f-6476-4a26-be9f-3a59f0f6f665" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IndustrialTechnologyBusinessMember_d67b262c-b210-494b-a956-abdb159d8f21" xlink:href="dyai-20191231.xsd#dyai_IndustrialTechnologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_24a27088-f36a-4dba-b6b3-fe2b38d1e4c6" xlink:to="loc_dyai_IndustrialTechnologyBusinessMember_d67b262c-b210-494b-a956-abdb159d8f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_157dddef-6d26-4421-90b8-4634bbf90958" xlink:to="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_7ead9165-c169-469d-8a21-a24bd661cf40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:to="loc_us-gaap_NonUsMember_7ead9165-c169-469d-8a21-a24bd661cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_46ee0bfe-238a-4fb9-ab48-cdcc9f30a81e" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_92e0f086-bfb5-47ff-ad3d-f2e6a32cf358" xlink:to="loc_country_US_46ee0bfe-238a-4fb9-ab48-cdcc9f30a81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_47d074c6-e3d0-4546-b063-11a12f2f9c87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_47b2b741-2831-4135-a6b5-6c6d8a734600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c89c24a1-bd56-4e23-b4dc-5bc1fa35e776" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_47b2b741-2831-4135-a6b5-6c6d8a734600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bad205c-1d0d-4019-8bb0-ae2b0300082f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_63638213-02cb-4af9-a6fd-0e921d62879b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_SalesRevenueNetMember_63638213-02cb-4af9-a6fd-0e921d62879b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_bfc486d5-c474-46d4-8aad-d0096b487a31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_AccountsReceivableMember_bfc486d5-c474-46d4-8aad-d0096b487a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_68a88427-767c-4ae3-9fe4-e10c5f398130" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af7fede7-83f9-44d2-a692-e2cd680c4f8f" xlink:to="loc_us-gaap_AccountsPayableMember_68a88427-767c-4ae3-9fe4-e10c5f398130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8af089f8-907d-4474-93a0-e969e626b9fc" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_d731c002-019c-49a9-aad1-17d3152f5e7c" xlink:href="dyai-20191231.xsd#dyai_NumberOfResearchOrganizationPerformingServiceUnderContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract_d731c002-019c-49a9-aad1-17d3152f5e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_234003ac-6054-4dc1-9090-338baf6d0103" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_234003ac-6054-4dc1-9090-338baf6d0103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b4985ce4-46f0-4597-8acf-7d8911ccde0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b4985ce4-46f0-4597-8acf-7d8911ccde0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConcentrationRiskNumberofCustomers_92287df4-b31a-471d-958b-4b258cd6cc03" xlink:href="dyai-20191231.xsd#dyai_ConcentrationRiskNumberofCustomers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_dyai_ConcentrationRiskNumberofCustomers_92287df4-b31a-471d-958b-4b258cd6cc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2f203fed-4296-4dc6-bcf8-addf7909cc32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2f203fed-4296-4dc6-bcf8-addf7909cc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d589e17d-1794-49f2-bc5f-c079a8bde1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d589e17d-1794-49f2-bc5f-c079a8bde1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_db55e4c2-3b24-406a-8789-d5f6c3edee27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AccountsReceivableNet_db55e4c2-3b24-406a-8789-d5f6c3edee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9b8297a5-d49c-481f-896a-2d117c1683b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9b8297a5-d49c-481f-896a-2d117c1683b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2cb055d5-6455-4a0a-9030-403ac5a4242b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2cb055d5-6455-4a0a-9030-403ac5a4242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b919b010-9462-41f7-9ec2-b3cffd7be947" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c4cc78bb-99a5-4e70-9fc6-ab13b21b5e55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b919b010-9462-41f7-9ec2-b3cffd7be947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a89127b5-ec89-4d3a-950b-82210059708b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a89127b5-ec89-4d3a-950b-82210059708b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_646db54b-41be-46bb-afd7-f1965afd9dae" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_1ffb7aa9-4819-4003-953e-0bb01dc008c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:to="loc_us-gaap_BilledRevenuesMember_1ffb7aa9-4819-4003-953e-0bb01dc008c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember_7e0b49c4-9a2c-4e06-a15a-61a1423c40a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_75caaa53-ac0f-4ed9-ba56-d4180fcc4e55" xlink:to="loc_us-gaap_UnbilledRevenuesMember_7e0b49c4-9a2c-4e06-a15a-61a1423c40a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_82eeadd9-6015-4890-8631-188f8ce82c4f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e4ba64a2-38ef-4cfa-92ae-f0f7d0e3b299" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5f6b2b2b-e4ea-4e1c-a7f8-91b23f8825ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e4ba64a2-38ef-4cfa-92ae-f0f7d0e3b299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3abb4b11-609e-49ec-8474-e5bcf4016bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_911c3017-1af6-4ce7-991b-c95a43f73044" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3abb4b11-609e-49ec-8474-e5bcf4016bfb" xlink:to="loc_us-gaap_PrepaidInsurance_911c3017-1af6-4ce7-991b-c95a43f73044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_c9f85b4d-c2f5-4f89-9d33-e622b664474b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3abb4b11-609e-49ec-8474-e5bcf4016bfb" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_c9f85b4d-c2f5-4f89-9d33-e622b664474b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_dd0f8c19-e247-4998-8b64-aea0020259a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3abb4b11-609e-49ec-8474-e5bcf4016bfb" xlink:to="loc_us-gaap_PrepaidTaxes_dd0f8c19-e247-4998-8b64-aea0020259a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c723449-ac6f-47c0-9233-308f5eaa7f52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3abb4b11-609e-49ec-8474-e5bcf4016bfb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c723449-ac6f-47c0-9233-308f5eaa7f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c9b6852-9fc7-4ea5-bbc6-48624166dc18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentInProcessCurrent_97f01d0b-5023-4b55-9331-20c7b914bc3b" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentInProcessCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c9b6852-9fc7-4ea5-bbc6-48624166dc18" xlink:to="loc_dyai_ResearchAndDevelopmentInProcessCurrent_97f01d0b-5023-4b55-9331-20c7b914bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_93517514-4df1-4da6-ad74-f81108012cff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c9b6852-9fc7-4ea5-bbc6-48624166dc18" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_93517514-4df1-4da6-ad74-f81108012cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_15c44e56-cb33-4381-8f58-246836bf6364" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c9b6852-9fc7-4ea5-bbc6-48624166dc18" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_15c44e56-cb33-4381-8f58-246836bf6364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_92d97e4e-b4e0-4aee-bc2f-fe1b6c3cc8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c9b6852-9fc7-4ea5-bbc6-48624166dc18" xlink:to="loc_us-gaap_AccountsPayableCurrent_92d97e4e-b4e0-4aee-bc2f-fe1b6c3cc8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba1a758d-2424-48d6-97f4-009b18a622ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2def3951-ee4d-48f2-9ca5-b1cb0facadbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba1a758d-2424-48d6-97f4-009b18a622ed" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2def3951-ee4d-48f2-9ca5-b1cb0facadbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent_2586fb6e-7691-4f41-838e-b865574b89e3" xlink:href="dyai-20191231.xsd#dyai_AccruedResearchandDevelopmentinProcessCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba1a758d-2424-48d6-97f4-009b18a622ed" xlink:to="loc_dyai_AccruedResearchandDevelopmentinProcessCurrent_2586fb6e-7691-4f41-838e-b865574b89e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e20a8573-962d-43b3-8be6-a876121ff922" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba1a758d-2424-48d6-97f4-009b18a622ed" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e20a8573-962d-43b3-8be6-a876121ff922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_97f6e3d5-9e1c-4a98-b04a-ca1ff9fe701f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba1a758d-2424-48d6-97f4-009b18a622ed" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_97f6e3d5-9e1c-4a98-b04a-ca1ff9fe701f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_07a45d83-ed18-447d-a69c-831350d777ee" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseOutsideContractedServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices_07a45d83-ed18-447d-a69c-831350d777ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_cb957e55-2d74-4866-a1b7-705602ac65da" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty_cb957e55-2d74-4866-a1b7-705602ac65da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_67e1181e-0483-49ce-ae67-ba4f289e8065" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:to="loc_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts_67e1181e-0483-49ce-ae67-ba4f289e8065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_36297e01-45da-4160-afcb-fd89837ab9e1" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther_36297e01-45da-4160-afcb-fd89837ab9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_b49e5afa-ae8a-4aa8-88c1-737d2303f314" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6b1dcb9-9260-4879-a283-d2c4a1b611c1" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty_b49e5afa-ae8a-4aa8-88c1-737d2303f314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestments"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d4b45949-70fb-42dc-9beb-93eed5c28e12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1ef09216-d7f6-442d-a440-75b143bf6648" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d4b45949-70fb-42dc-9beb-93eed5c28e12" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_1ef09216-d7f6-442d-a440-75b143bf6648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6a55d66e-1e26-4f41-9e44-9bcd9fa9fdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a0d5c08c-10ee-4df0-b380-f9f9832e9524" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6a55d66e-1e26-4f41-9e44-9bcd9fa9fdfa" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a0d5c08c-10ee-4df0-b380-f9f9832e9524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CashCashEquivalentandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_a4ca0815-e384-4e2b-967e-d329829353e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a4ca0815-e384-4e2b-967e-d329829353e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ad969e5c-5c18-4eb0-b9d6-6b965690eda2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_83033cd8-bdfc-4338-9889-1177dd7d5111" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_251b9cf6-3ee0-4fe6-9bb4-18413616ed59" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_83033cd8-bdfc-4338-9889-1177dd7d5111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4eb104bb-c0ab-4e77-b257-a989340a03ce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ef04f2a1-4701-420f-a8f9-4eafa544a2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:to="loc_us-gaap_CashMember_ef04f2a1-4701-420f-a8f9-4eafa544a2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2187d2a1-4967-40cb-9e40-9ee1919a63a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1bcdd29b-f89e-4f12-ac0e-496f7965c21f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2187d2a1-4967-40cb-9e40-9ee1919a63a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ef6bad6-ac9a-4bf7-820e-513b0b15274c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7b708ad9-a35d-4a73-8fe4-3650483a5405" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7b708ad9-a35d-4a73-8fe4-3650483a5405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1f41f8d0-5cdc-4158-b21a-91b965720344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad427426-c665-45cc-a6e7-cb3e46b7ce11" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1f41f8d0-5cdc-4158-b21a-91b965720344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d59f4c1c-7171-4260-8336-20ddac651dff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67d9911c-edcc-4232-8bf3-eb62cbaddf47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67d9911c-edcc-4232-8bf3-eb62cbaddf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f561a993-b994-4299-a2b2-99b17aacaf23" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent_f561a993-b994-4299-a2b2-99b17aacaf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_cc36c689-e4ae-458d-83b3-2cbd4ee53661" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent_cc36c689-e4ae-458d-83b3-2cbd4ee53661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_64ce7b98-2ef2-4a53-9d31-85ab8cb88194" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent_64ce7b98-2ef2-4a53-9d31-85ab8cb88194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_acf8ec3e-eeb0-465a-aa9b-e9272159b155" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_acf8ec3e-eeb0-465a-aa9b-e9272159b155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_eea62223-758e-40bd-a6d1-01113ca5e08b" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent_eea62223-758e-40bd-a6d1-01113ca5e08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_b2925394-b502-40ea-9393-ab60fc4a123b" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent_b2925394-b502-40ea-9393-ab60fc4a123b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_9ba4289e-8392-4f99-9028-47adf4dedf21" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent_9ba4289e-8392-4f99-9028-47adf4dedf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a8453416-bb9c-41d4-8305-71b797460e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a8453416-bb9c-41d4-8305-71b797460e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_93b98671-5186-4c56-b39a-eef98768d8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_InvestmentsAndCash_93b98671-5186-4c56-b39a-eef98768d8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50543adc-0329-487f-9d30-6673b4d2cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50543adc-0329-487f-9d30-6673b4d2cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c9bccfc-ad35-4987-8d0a-98be283fb7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6c9bccfc-ad35-4987-8d0a-98be283fb7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_InvestmentsandCashAmortizedCost_5772dcc9-153b-42b3-9181-145dd34e1ae6" xlink:href="dyai-20191231.xsd#dyai_InvestmentsandCashAmortizedCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_InvestmentsandCashAmortizedCost_5772dcc9-153b-42b3-9181-145dd34e1ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_cb540754-abdb-4906-9a16-5682da470264" xlink:href="dyai-20191231.xsd#dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ded1652e-8c94-4b7e-8b58-340c841220d2" xlink:to="loc_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase_cb540754-abdb-4906-9a16-5682da470264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ResearchandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_af4dcc3f-fe91-485a-b0c2-1cda7c484a53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_957166b0-6a6d-4238-add4-a662bef8086f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_af4dcc3f-fe91-485a-b0c2-1cda7c484a53" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_957166b0-6a6d-4238-add4-a662bef8086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ResearchCollaborationandSublicensingAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a0b484b2-519c-4c32-bf9a-32976c55d0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a0b484b2-519c-4c32-bf9a-32976c55d0f3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6833ceaa-0cac-418f-b42c-924d83468dff" xlink:to="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchServicesAgreementMember_66ca9311-8be6-47b4-8ee0-faca8575e9a1" xlink:href="dyai-20191231.xsd#dyai_ResearchServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:to="loc_dyai_ResearchServicesAgreementMember_66ca9311-8be6-47b4-8ee0-faca8575e9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ServiceFrameworkAgreementMember_de18e18b-9011-48c6-ba4c-93d29f923c43" xlink:href="dyai-20191231.xsd#dyai_ServiceFrameworkAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_9490c304-7055-41a6-b783-e9626bfc1c26" xlink:to="loc_dyai_ServiceFrameworkAgreementMember_de18e18b-9011-48c6-ba4c-93d29f923c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ffae3086-6e1d-4e49-9231-db3bbfe689dc" xlink:to="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIHoldingsMember_91ab8d18-dddb-4598-9c08-0e21cbe2bf98" xlink:href="dyai-20191231.xsd#dyai_BDIHoldingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_BDIHoldingsMember_91ab8d18-dddb-4598-9c08-0e21cbe2bf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VLPbioMember_21fffdf3-de02-45ac-ba7d-ddc1544be202" xlink:href="dyai-20191231.xsd#dyai_VLPbioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_VLPbioMember_21fffdf3-de02-45ac-ba7d-ddc1544be202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_BDIMember_ace45fc2-b40c-4e13-9e4d-afaabe2f95d1" xlink:href="dyai-20191231.xsd#dyai_BDIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2bb9a274-129a-41a7-8c77-9b4f598827fd" xlink:to="loc_dyai_BDIMember_ace45fc2-b40c-4e13-9e4d-afaabe2f95d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8cec481-3dbe-4f62-b110-e39c9ea55bc9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_91a608c4-0694-4c8e-846f-7945716bd6af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21d0ed18-acbf-4d0f-9533-0524565553ce" xlink:to="loc_us-gaap_CollaborativeArrangementMember_91a608c4-0694-4c8e-846f-7945716bd6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_224076ef-11f7-4103-9943-e86d76cde566" xlink:to="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d9d63e6-3445-4a6e-9792-1d06a917163a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:to="loc_srt_MinimumMember_9d9d63e6-3445-4a6e-9792-1d06a917163a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06a28412-2461-4b85-a458-d95685b19fcc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3970ddbf-25d2-4ee1-839c-a4fe5746aab1" xlink:to="loc_srt_MaximumMember_06a28412-2461-4b85-a458-d95685b19fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ef05e5a9-1853-410a-a894-28c9ac071baf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SerumMember_9e372fc8-a5d0-4df8-823a-fdc88eb7d3a8" xlink:href="dyai-20191231.xsd#dyai_SerumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7de577-653b-4b0a-b3c1-0b77561a0542" xlink:to="loc_dyai_SerumMember_9e372fc8-a5d0-4df8-823a-fdc88eb7d3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf5e81e5-dace-4be4-b46f-c85508ba6fd8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_AlphazymeMember_10595fcd-ba80-4b32-8310-378fdd31a82e" xlink:href="dyai-20191231.xsd#dyai_AlphazymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:to="loc_dyai_AlphazymeMember_10595fcd-ba80-4b32-8310-378fdd31a82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NovovetMember_bb0009ec-e656-44c7-b026-6060d091fee0" xlink:href="dyai-20191231.xsd#dyai_NovovetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6867c729-4fcb-4412-b942-26a073db5777" xlink:to="loc_dyai_NovovetMember_bb0009ec-e656-44c7-b026-6060d091fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8c967640-4443-4a88-9227-8a96ed509f4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementDurationOfAgreement_70f7d229-ff56-4afe-947b-89b7a9c12989" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementDurationOfAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementDurationOfAgreement_70f7d229-ff56-4afe-947b-89b7a9c12989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_a9f9d07e-8d99-437e-a666-70330a3c753f" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement_a9f9d07e-8d99-437e-a666-70330a3c753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementEquityInterestAcquired_5b69082a-18fd-4590-9988-74a88724a2db" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementEquityInterestAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementEquityInterestAcquired_5b69082a-18fd-4590-9988-74a88724a2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_f82d45b1-c702-402f-b58b-3433dd0963f1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment_f82d45b1-c702-402f-b58b-3433dd0963f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementRevenueSharingPercentage_f3339ebc-d758-46ef-80c1-b9b03e588dc1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementRevenueSharingPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementRevenueSharingPercentage_f3339ebc-d758-46ef-80c1-b9b03e588dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_55a20d02-d5cf-4fda-9f35-711912c02028" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment_55a20d02-d5cf-4fda-9f35-711912c02028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_74409a1d-c34a-4a9e-b2c4-1931bfe6d20d" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization_74409a1d-c34a-4a9e-b2c4-1931bfe6d20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOutstandingCommitment_1e23692a-4faa-4f89-a393-4736d751a6eb" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOutstandingCommitment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOutstandingCommitment_1e23692a-4faa-4f89-a393-4736d751a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PrepaidResearchandDevelopment_81642a1d-c846-4f0a-9e01-a0a274bac68d" xlink:href="dyai-20191231.xsd#dyai_PrepaidResearchandDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_PrepaidResearchandDevelopment_81642a1d-c846-4f0a-9e01-a0a274bac68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_c7dc8ffb-d7cd-46a2-a26d-01185efb4f7e" xlink:href="dyai-20191231.xsd#dyai_ResearchandDevelopmentExpenseRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_ResearchandDevelopmentExpenseRelatedParty_c7dc8ffb-d7cd-46a2-a26d-01185efb4f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc58d8ee-414e-495a-a867-ac39a716ca66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc58d8ee-414e-495a-a867-ac39a716ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementExclusivityPeriod_2f59ed1a-03a2-4369-a8de-4b1415c23cc1" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementExclusivityPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementExclusivityPeriod_2f59ed1a-03a2-4369-a8de-4b1415c23cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_56dcfd72-87e6-48ff-b856-67bed4486dd3" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod_56dcfd72-87e6-48ff-b856-67bed4486dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_21a432fe-beec-43ba-a8aa-a09c3583feac" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod_21a432fe-beec-43ba-a8aa-a09c3583feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_53e801b9-fd71-441e-b81c-d84f03fc3a82" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization_53e801b9-fd71-441e-b81c-d84f03fc3a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_5524442a-525c-4547-83a1-03545442acc5" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins_5524442a-525c-4547-83a1-03545442acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_3b9e415f-ce97-451d-8130-6abb7a478657" xlink:href="dyai-20191231.xsd#dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod_3b9e415f-ce97-451d-8130-6abb7a478657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_RevenueFromCollaborativeArrangementRecognized_6136dba6-7610-490f-b90c-716098de1bc1" xlink:href="dyai-20191231.xsd#dyai_RevenueFromCollaborativeArrangementRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7a7711dd-6930-4471-81c1-be8f4f22f3b2" xlink:to="loc_dyai_RevenueFromCollaborativeArrangementRecognized_6136dba6-7610-490f-b90c-716098de1bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_069f92fc-860f-4ffb-9479-e2b956f07cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cbe4d6fc-b09e-4d00-9003-3a5663ba4213" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_069f92fc-860f-4ffb-9479-e2b956f07cdb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cbe4d6fc-b09e-4d00-9003-3a5663ba4213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_24afef5e-a96e-4073-a0ae-c37d6d55f580" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2d0fb793-5393-426d-a7d4-3281e819b1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24afef5e-a96e-4073-a0ae-c37d6d55f580" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2d0fb793-5393-426d-a7d4-3281e819b1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f8df756f-7bd6-4062-b490-af578144a078" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24afef5e-a96e-4073-a0ae-c37d6d55f580" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f8df756f-7bd6-4062-b490-af578144a078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_42b0318f-f818-4067-ab2e-6e86bda82ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24afef5e-a96e-4073-a0ae-c37d6d55f580" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_42b0318f-f818-4067-ab2e-6e86bda82ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dca63f24-bd21-4da3-8ebd-7f5bb5f14a25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24afef5e-a96e-4073-a0ae-c37d6d55f580" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dca63f24-bd21-4da3-8ebd-7f5bb5f14a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_214c6cc8-b130-40b9-8b6f-37ac7ca51423" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_214c6cc8-b130-40b9-8b6f-37ac7ca51423" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8824c67-25d6-4cc2-ae35-a147b016950e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfFinanceIndiaMember_b51d97b0-2fdf-402b-9b46-4097c62560c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinistryOfFinanceIndiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_756973d8-c99b-4d6b-9fa8-eb4932839c8d" xlink:to="loc_us-gaap_MinistryOfFinanceIndiaMember_b51d97b0-2fdf-402b-9b46-4097c62560c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d1c72db8-6888-4aaa-bce1-aa82f2e5523a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_60caafd8-dcd8-4165-853c-026201c32d79" xlink:href="dyai-20191231.xsd#dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit_60caafd8-dcd8-4165-853c-026201c32d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_b2d75de8-e182-4061-a108-a83b98c02618" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_b2d75de8-e182-4061-a108-a83b98c02618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6b566910-8ed9-4fcb-92e7-279b53ae99e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6b566910-8ed9-4fcb-92e7-279b53ae99e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a451e232-c2c5-4e46-bed5-b19912aab04a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a451e232-c2c5-4e46-bed5-b19912aab04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_57052ac7-08c8-4ead-b3b1-a15742e27c50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9d4bbd72-3e93-41ef-bba4-e56b455bb1d6" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_57052ac7-08c8-4ead-b3b1-a15742e27c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fd086d30-2c13-4bb0-bdaf-7c95fe5362a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4c13913-f272-4075-b9ec-4c4643ba43ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd086d30-2c13-4bb0-bdaf-7c95fe5362a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e4c13913-f272-4075-b9ec-4c4643ba43ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0a4a6ed2-ea16-426a-906f-76cec7636e17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd086d30-2c13-4bb0-bdaf-7c95fe5362a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0a4a6ed2-ea16-426a-906f-76cec7636e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_26f481ba-1dd6-4ded-b8af-977559dabcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd086d30-2c13-4bb0-bdaf-7c95fe5362a8" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_26f481ba-1dd6-4ded-b8af-977559dabcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesBenefitProvisionforIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52acd64e-60b7-4d59-a11b-7f4f932aed8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1a80c481-ab26-46d2-b5b2-e476a50b6939" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acd64e-60b7-4d59-a11b-7f4f932aed8c" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1a80c481-ab26-46d2-b5b2-e476a50b6939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e3dbc857-f954-4e97-a554-c8bda7d321e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acd64e-60b7-4d59-a11b-7f4f932aed8c" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e3dbc857-f954-4e97-a554-c8bda7d321e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1288b17a-3460-4a0b-9b37-fe25c58a1489" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acd64e-60b7-4d59-a11b-7f4f932aed8c" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1288b17a-3460-4a0b-9b37-fe25c58a1489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_421e1d82-a2b9-4179-a2f4-27f4af61f482" xlink:href="dyai-20191231.xsd#dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52acd64e-60b7-4d59-a11b-7f4f932aed8c" xlink:to="loc_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment_421e1d82-a2b9-4179-a2f4-27f4af61f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesReconciliationIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ed92df69-a3ef-45b1-942c-6c55085a185d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ed92df69-a3ef-45b1-942c-6c55085a185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_eeb0dc02-f84c-4111-b4a6-bea7f45a1b60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_eeb0dc02-f84c-4111-b4a6-bea7f45a1b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_fe0aa099-1436-4f2b-8590-dd4ea2659286" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_fe0aa099-1436-4f2b-8590-dd4ea2659286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0e701dbb-d9fe-476c-a31a-7b2b8cf4bb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0e701dbb-d9fe-476c-a31a-7b2b8cf4bb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_cb421597-bb4d-42d7-8750-acc38b1ad11f" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent_cb421597-bb4d-42d7-8750-acc38b1ad11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cead4ac1-591c-4ae5-a9ec-4092542b522f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cead4ac1-591c-4ae5-a9ec-4092542b522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f8f2a7d1-d05d-40db-8243-39be06e69210" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f8f2a7d1-d05d-40db-8243-39be06e69210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_eafe2051-18ee-46c6-8c84-4ebe7b43916d" xlink:href="dyai-20191231.xsd#dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent_eafe2051-18ee-46c6-8c84-4ebe7b43916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_298b6615-c7ef-4c70-ba5f-d7c6631e4ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af9d8471-897b-4e2a-9688-b224cd9795fc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_298b6615-c7ef-4c70-ba5f-d7c6631e4ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#IncomeTaxesDeferredIncomeTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fc26c5e7-2d1c-430d-958f-dcf0ad10c047" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fc26c5e7-2d1c-430d-958f-dcf0ad10c047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_138b384f-2077-4658-a377-c6f1dd5686a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_138b384f-2077-4658-a377-c6f1dd5686a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2e46dccf-8182-475a-a473-c4dfcc1add59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2e46dccf-8182-475a-a473-c4dfcc1add59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_01afc083-87d7-4d7e-905c-c912a803a02d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_01afc083-87d7-4d7e-905c-c912a803a02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_DeferredTaxAssetLiabilityGross_79d19a4c-5921-41de-967d-8596600728c9" xlink:href="dyai-20191231.xsd#dyai_DeferredTaxAssetLiabilityGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_dyai_DeferredTaxAssetLiabilityGross_79d19a4c-5921-41de-967d-8596600728c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c5066051-90ae-4fed-a3b2-78fe06e3be80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c5066051-90ae-4fed-a3b2-78fe06e3be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_02b8b58a-237d-4226-ba2d-4280b2bf4549" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d05003e-109b-4ab9-bc81-e629f4a335de" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_02b8b58a-237d-4226-ba2d-4280b2bf4549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97700fd7-c07f-4b99-a67f-b4b4480c0d11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4b4dda99-0543-4dfd-94fc-f2cc8a7900a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97700fd7-c07f-4b99-a67f-b4b4480c0d11" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4b4dda99-0543-4dfd-94fc-f2cc8a7900a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b015651a-8d3d-4e4d-a213-75afaf808ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTextBlock_ee7436a9-27f4-4c32-82e9-66b5d9593113" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b015651a-8d3d-4e4d-a213-75afaf808ccb" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTextBlock_ee7436a9-27f4-4c32-82e9-66b5d9593113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e034780a-b619-4361-9d3c-e35c84468110" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e034780a-b619-4361-9d3c-e35c84468110" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:to="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:href="dyai-20191231.xsd#dyai_LeaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dyai_LeaseTypeAxis_e4ba8bd9-97d7-414f-a118-5dc485c93817" xlink:to="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_JupiterFloridaHeadquartersLeaseMember_999734e4-d236-49a8-8d50-2e92c43fb458" xlink:href="dyai-20191231.xsd#dyai_JupiterFloridaHeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:to="loc_dyai_JupiterFloridaHeadquartersLeaseMember_999734e4-d236-49a8-8d50-2e92c43fb458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NetherlandsOfficeLeaseMember_5540d17a-d3d9-4203-bb9e-7b993b44e633" xlink:href="dyai-20191231.xsd#dyai_NetherlandsOfficeLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dyai_LeaseTypeDomain_b6514807-2215-4860-9c5f-89f6eb801242" xlink:to="loc_dyai_NetherlandsOfficeLeaseMember_5540d17a-d3d9-4203-bb9e-7b993b44e633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:to="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7147bc88-5e9d-4273-b024-33edaa9ee7e0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_b969d460-b546-4ff2-9b88-6ed037a846ee" xlink:href="dyai-20191231.xsd#dyai_VTTTechnicalResearchCentreofFinlandLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b586c31-5980-4810-921e-d59f752d87ae" xlink:to="loc_dyai_VTTTechnicalResearchCentreofFinlandLtdMember_b969d460-b546-4ff2-9b88-6ed037a846ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_6951b539-3f3f-46e1-acef-64bcbde9c475" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_05001f99-44a3-48ed-a7e2-8d5351640428" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_05001f99-44a3-48ed-a7e2-8d5351640428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesMonthlyRentalRate_d986900e-77a7-45b7-b3db-f98fb2c8d257" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesMonthlyRentalRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_OperatingLeasesMonthlyRentalRate_d986900e-77a7-45b7-b3db-f98fb2c8d257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_OperatingLeasesAnnualRentalRate_c7455155-e654-4838-83a0-e6146213e317" xlink:href="dyai-20191231.xsd#dyai_OperatingLeasesAnnualRentalRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_OperatingLeasesAnnualRentalRate_c7455155-e654-4838-83a0-e6146213e317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_44c32ac8-61dd-4821-a4f0-93d85158b2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_44c32ac8-61dd-4821-a4f0-93d85158b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPay_25ea064e-abd8-4602-b32b-a8b6ba2d26b2" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPay"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPay_25ea064e-abd8-4602-b32b-a8b6ba2d26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentDevelopmentPeriod_26c3e80d-6360-4f8f-9444-a71e532d8381" xlink:href="dyai-20191231.xsd#dyai_CommitmentDevelopmentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentDevelopmentPeriod_26c3e80d-6360-4f8f-9444-a71e532d8381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentSuccessBonusAward_4c317496-38d9-42e5-9dca-d19911110062" xlink:href="dyai-20191231.xsd#dyai_CommitmentSuccessBonusAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentSuccessBonusAward_4c317496-38d9-42e5-9dca-d19911110062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpanded_2ce2041e-327e-4a11-ad3d-109d8a0c762b" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpanded"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPayExpanded_2ce2041e-327e-4a11-ad3d-109d8a0c762b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentToPayExpandedPeriod_0d6845ab-8107-421f-85cb-4dd14f5df262" xlink:href="dyai-20191231.xsd#dyai_CommitmentToPayExpandedPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentToPayExpandedPeriod_0d6845ab-8107-421f-85cb-4dd14f5df262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod_ebecf685-e15c-4e8c-91b9-420fdb5da25b" xlink:href="dyai-20191231.xsd#dyai_CommitmentsRightToTerminateContractNoticePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0b925a6a-3443-430f-b307-d9a843d7b09c" xlink:to="loc_dyai_CommitmentsRightToTerminateContractNoticePeriod_ebecf685-e15c-4e8c-91b9-420fdb5da25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#CommitmentsandContingenciesPurchaseObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_062691d6-eb03-436a-bf88-1c1f9ff3dfec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_f29319db-9764-4968-93f1-50ce8a430368" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_062691d6-eb03-436a-bf88-1c1f9ff3dfec" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_f29319db-9764-4968-93f1-50ce8a430368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_3dc1eb8e-891d-4495-a8ef-52320adee9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_062691d6-eb03-436a-bf88-1c1f9ff3dfec" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_3dc1eb8e-891d-4495-a8ef-52320adee9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_8724d36f-8363-4a26-88c6-cec2e5c467f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_062691d6-eb03-436a-bf88-1c1f9ff3dfec" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_8724d36f-8363-4a26-88c6-cec2e5c467f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_193f74cf-a0ce-40bf-9d28-b96c2edbab3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_062691d6-eb03-436a-bf88-1c1f9ff3dfec" xlink:to="loc_us-gaap_PurchaseObligation_193f74cf-a0ce-40bf-9d28-b96c2edbab3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a96fd84-34d2-485b-b804-db2b1134c46a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3d52310c-3f93-4fa4-b7b3-ca134837b1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a96fd84-34d2-485b-b804-db2b1134c46a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3d52310c-3f93-4fa4-b7b3-ca134837b1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967a26a7-7122-48a7-b5bb-12043a94a53a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a1d0c524-8e20-4f27-95a9-fb77cc1b7630" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967a26a7-7122-48a7-b5bb-12043a94a53a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a1d0c524-8e20-4f27-95a9-fb77cc1b7630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6d065bf8-d585-4525-9e2e-60da506550da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967a26a7-7122-48a7-b5bb-12043a94a53a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6d065bf8-d585-4525-9e2e-60da506550da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_eb571752-ba55-4dbf-94f1-3d17f7846d46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967a26a7-7122-48a7-b5bb-12043a94a53a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_eb571752-ba55-4dbf-94f1-3d17f7846d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e20e420-eeec-4ad5-b206-e0b2ce2148a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e20e420-eeec-4ad5-b206-e0b2ce2148a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fd0a21e2-07b8-4fec-8d34-6198f59d15ab" xlink:to="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2006PlanMember_75179b9e-e8a9-448f-af4e-9b17269528f2" xlink:href="dyai-20191231.xsd#dyai_A2006PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:to="loc_dyai_A2006PlanMember_75179b9e-e8a9-448f-af4e-9b17269528f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_A2011PlanMember_bc774ffc-754e-42a2-9cd4-1c548a6a44da" xlink:href="dyai-20191231.xsd#dyai_A2011PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c9fb94a0-0dd6-49de-a61f-61bf7e083bc5" xlink:to="loc_dyai_A2011PlanMember_bc774ffc-754e-42a2-9cd4-1c548a6a44da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a28d872a-8352-4351-9272-5170bb6fca7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3864c0cc-166c-46f2-be76-feead0ea5891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3864c0cc-166c-46f2-be76-feead0ea5891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_da842b01-5240-467e-8a54-924bacd97b55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd8442f7-a8e2-48c1-bf08-221acc12653d" xlink:to="loc_us-gaap_PerformanceSharesMember_da842b01-5240-467e-8a54-924bacd97b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_321ac3cf-b675-4d64-bc67-02ed466d81d6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_24dd52cb-7b92-4d93-b2e2-3b21b8a101b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_24dd52cb-7b92-4d93-b2e2-3b21b8a101b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractorMember_259a5e86-5fce-42a5-a31a-1489cf4f47b6" xlink:href="dyai-20191231.xsd#dyai_ContractorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_dde69e58-307d-4eaa-8047-888e09f71b73" xlink:to="loc_dyai_ContractorMember_259a5e86-5fce-42a5-a31a-1489cf4f47b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c337dcf0-fbea-4883-97c4-ceb324737006" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f139260c-04c0-4ace-93c8-50c04721eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f139260c-04c0-4ace-93c8-50c04721eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59573b2e-1f7d-499f-a1d1-936f1d879d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_59573b2e-1f7d-499f-a1d1-936f1d879d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e220f707-b5f0-4399-b9e0-d1f02fa9572f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e220f707-b5f0-4399-b9e0-d1f02fa9572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6f059ca-9aad-4072-a280-37c77585d1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6f059ca-9aad-4072-a280-37c77585d1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ef38ec3-9ac6-4165-b056-d7cbdebdcb44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ef38ec3-9ac6-4165-b056-d7cbdebdcb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ce4855d0-c566-4940-92a0-cffd70ac660d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ce4855d0-c566-4940-92a0-cffd70ac660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_de96c289-2edd-4717-928d-9ad17eb79084" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_de96c289-2edd-4717-928d-9ad17eb79084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bdb2683-072a-4c9c-9ce6-24951225b294" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9bdb2683-072a-4c9c-9ce6-24951225b294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61e9c051-9100-46c2-a5aa-f8c49c236b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61e9c051-9100-46c2-a5aa-f8c49c236b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3751a1c2-a4f1-41c7-8ea1-a541afc9543c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3751a1c2-a4f1-41c7-8ea1-a541afc9543c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f5731ee-c6a2-491c-be55-cc166745d873" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f5731ee-c6a2-491c-be55-cc166745d873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4ecd9ea4-68d1-4b2b-af45-c3a601ca8365" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe9a38cf-e03d-4278-b0c5-322972a80be6" xlink:to="loc_us-gaap_ShareBasedCompensation_4ecd9ea4-68d1-4b2b-af45-c3a601ca8365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c79c8582-563f-43ce-beef-4de4bfc5e15c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c79c8582-563f-43ce-beef-4de4bfc5e15c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:to="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2e753dc9-ea05-4f96-b2de-2ffbcac75f7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_913476db-5c69-4f02-8a80-e7ed925cbbc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d27cd22d-4848-4d4a-802b-1edaab5d65d8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_913476db-5c69-4f02-8a80-e7ed925cbbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:to="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_48b0bdee-4236-4efa-89b5-a6726c1c13a4" xlink:to="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64d8d757-cd29-4022-8eda-a6680e99ed33" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:to="loc_srt_MinimumMember_64d8d757-cd29-4022-8eda-a6680e99ed33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_16c55f2b-bd30-4782-88a2-99cce4b0af9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2a0d70b6-e4f1-4532-b839-c70f7e546770" xlink:to="loc_srt_MaximumMember_16c55f2b-bd30-4782-88a2-99cce4b0af9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_940a0268-5f20-477d-8c19-11ff087ad4ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7b9ce2bf-eb3b-4f14-b130-cc321105db59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7b9ce2bf-eb3b-4f14-b130-cc321105db59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3b9bb22f-07ef-4230-87da-43458864a2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3b9bb22f-07ef-4230-87da-43458864a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf653a7e-aead-468b-89ba-ec52150ec506" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf653a7e-aead-468b-89ba-ec52150ec506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c20a922-5ed5-48b7-9e5d-de685dca1d99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c20a922-5ed5-48b7-9e5d-de685dca1d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8b8e730d-cb70-4fae-b897-e2a67af07e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8b8e730d-cb70-4fae-b897-e2a67af07e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3ce69fa3-4977-4b6d-bdd9-f3a3d787ab72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3ce69fa3-4977-4b6d-bdd9-f3a3d787ab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_5514217c-166f-450f-964d-7eb4e9963df1" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d677267d-709e-4f12-8460-12def0b4b34d" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability_5514217c-166f-450f-964d-7eb4e9963df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e599953f-8fb0-4dd3-a215-dda2ac5c8f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e599953f-8fb0-4dd3-a215-dda2ac5c8f09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c068fc16-5739-464b-b778-784f9a396305" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c068fc16-5739-464b-b778-784f9a396305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_78ff85b4-1a17-4762-a4ad-d92b8ee5e774" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_78ff85b4-1a17-4762-a4ad-d92b8ee5e774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c9644eb-6bad-4619-b5c0-0dcc0a9f0771" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c9644eb-6bad-4619-b5c0-0dcc0a9f0771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5df0edd-7c98-487e-af95-d65eb0b18b25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5df0edd-7c98-487e-af95-d65eb0b18b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7d227193-974b-4112-8252-42bc4868edce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7d227193-974b-4112-8252-42bc4868edce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a561806-7637-497a-a8e4-e80d16749156" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f95575f4-eb58-4c47-ac05-cd6361243a55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a561806-7637-497a-a8e4-e80d16749156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e599953f-8fb0-4dd3-a215-dda2ac5c8f09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1963055-13ce-4641-a579-3fb69b15fb01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d1963055-13ce-4641-a579-3fb69b15fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61270ca4-b63c-4a3d-ad71-e5569913bae8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61270ca4-b63c-4a3d-ad71-e5569913bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_513d23bf-81fe-4e24-86f3-53b4cb67e777" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_513d23bf-81fe-4e24-86f3-53b4cb67e777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_666f6aec-b518-4a18-94be-1383ba4a41e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_666f6aec-b518-4a18-94be-1383ba4a41e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_35172f4f-9b75-493c-92c1-2fe1a32a3c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_35172f4f-9b75-493c-92c1-2fe1a32a3c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dec71c6-5d54-46ca-957c-95d12b21bf81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f934c376-c1d6-414c-b967-c82182c48078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dec71c6-5d54-46ca-957c-95d12b21bf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e599953f-8fb0-4dd3-a215-dda2ac5c8f09" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_29530ff1-02bf-4352-8e72-5c97d65b9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_29530ff1-02bf-4352-8e72-5c97d65b9ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d51702bd-07ea-4749-932b-70b28cc44179" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d51702bd-07ea-4749-932b-70b28cc44179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_230ba901-61c6-47f8-85ed-a1c4690dfe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_230ba901-61c6-47f8-85ed-a1c4690dfe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1296618-94f9-4d8c-94e8-8b717d8978a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1296618-94f9-4d8c-94e8-8b717d8978a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca9b814d-1907-45c5-879e-69365b7f0ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca9b814d-1907-45c5-879e-69365b7f0ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5bba6c8a-ee30-4b71-9ade-eebd5762dbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b4040551-8a12-4f57-81cd-4bc98816384e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5bba6c8a-ee30-4b71-9ade-eebd5762dbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationStockOptionActivityTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bb23fd7-b78e-4a73-aac2-49f04e8d693c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bb23fd7-b78e-4a73-aac2-49f04e8d693c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a8496130-30be-4165-aea5-0942f0147d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1c76c37-e6ad-40bc-8bc9-fb7dcb9be2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5abd17-b793-4331-890d-6df605d41695" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1c76c37-e6ad-40bc-8bc9-fb7dcb9be2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_cbcc7d36-1c1e-4b5c-85c3-6bf3fd2e1112" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ExecutivesandKeyPersonnelMember_90eb6df1-3be1-414a-98a4-bb767d1bcaaf" xlink:href="dyai-20191231.xsd#dyai_ExecutivesandKeyPersonnelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_ExecutivesandKeyPersonnelMember_90eb6df1-3be1-414a-98a4-bb767d1bcaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_2cff933b-4c06-445f-ab57-8042e12d5cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_us-gaap_DirectorMember_2cff933b-4c06-445f-ab57-8042e12d5cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_EmployeeMember_e0b9dd26-50a6-4f27-9762-5e93edeff722" xlink:href="dyai-20191231.xsd#dyai_EmployeeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_EmployeeMember_e0b9dd26-50a6-4f27-9762-5e93edeff722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ContractorMember_570ef466-39b4-453f-8e11-32bff02c5b76" xlink:href="dyai-20191231.xsd#dyai_ContractorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_dyai_ContractorMember_570ef466-39b4-453f-8e11-32bff02c5b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_deb637f6-87a9-476d-a6a0-26724320ef24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1871f4d-dcd0-4a72-908f-f01548489647" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_deb637f6-87a9-476d-a6a0-26724320ef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1622af6d-0e68-4c16-9e58-313e6d1fc6df" xlink:to="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3392431b-cc4d-4d79-8518-504dabe680fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3392431b-cc4d-4d79-8518-504dabe680fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_e053c40d-1215-457d-8ca8-8dacf1d549c7" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_db552ce2-fc05-4d9f-93f7-10dd9f8bcec3" xlink:to="loc_dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember_e053c40d-1215-457d-8ca8-8dacf1d549c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ed7be49-fc87-42ef-8006-e448687a4002" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7febfa08-1592-488d-9209-883954d41c92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7febfa08-1592-488d-9209-883954d41c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0295ac7e-3e6c-4f96-b51b-48a07a75d0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0295ac7e-3e6c-4f96-b51b-48a07a75d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_9b4c9e61-6b60-4f5d-96e4-e54705da61d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_9b4c9e61-6b60-4f5d-96e4-e54705da61d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8ed3222b-c598-48c2-b5ee-2b83d2e1cd08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8ed3222b-c598-48c2-b5ee-2b83d2e1cd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ff9c4306-2afd-4de7-9e88-a0337ded1600" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ff9c4306-2afd-4de7-9e88-a0337ded1600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21a4816d-584d-42a5-9e92-8975b3504bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_21a4816d-584d-42a5-9e92-8975b3504bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_8a643f1e-46e1-40d4-b8a2-4c9aab62ef0f" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors_8a643f1e-46e1-40d4-b8a2-4c9aab62ef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_155ab4cf-bd08-489f-a4b4-ec7539415388" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_155ab4cf-bd08-489f-a4b4-ec7539415388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_74de16ff-9d29-4025-acb5-5662c85fc19c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_74de16ff-9d29-4025-acb5-5662c85fc19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_fe1e052a-3d80-4862-a0e8-78d68b4372e9" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet_fe1e052a-3d80-4862-a0e8-78d68b4372e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_6a68f680-cedb-4a25-ad43-735dae12df10" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock_6a68f680-cedb-4a25-ad43-735dae12df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_692bf096-e914-44c9-9fab-562eec1c49d6" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited_692bf096-e914-44c9-9fab-562eec1c49d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_9aedbd56-3de7-441f-8fc1-bcef4633c89a" xlink:href="dyai-20191231.xsd#dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48ea129e-a03f-4003-a25c-e57c17bbe277" xlink:to="loc_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash_9aedbd56-3de7-441f-8fc1-bcef4633c89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareBasedCompensationCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1d99d6d-43cf-42ce-bda3-3778d3c05f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1d99d6d-43cf-42ce-bda3-3778d3c05f7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e3fca1a-c0af-4fef-8376-b0c332909c6f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_86b085ac-7a10-4ad7-8e2b-25392baac211" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_86b085ac-7a10-4ad7-8e2b-25392baac211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_14f88ecd-ed75-4ead-92ca-802b8d6bc23b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fd527dca-f520-4ccd-bd82-17289be7f8ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_14f88ecd-ed75-4ead-92ca-802b8d6bc23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ec2ad5d-51cb-41ee-94c4-9ff5de93a531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_49c3770b-e34a-465a-a0e3-1eb84c6ddece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1e782f63-a679-4f30-a348-8a2f75683360" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_49c3770b-e34a-465a-a0e3-1eb84c6ddece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2b966474-72ae-4956-8c80-6ec04b7702a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0937a104-c427-41f9-a3e3-6c8b345cfb03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2b966474-72ae-4956-8c80-6ec04b7702a3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0937a104-c427-41f9-a3e3-6c8b345cfb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_15eb3bf3-b94e-4e0b-bd9e-677be883dd71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_b76425de-90dd-4ef0-b261-bbf8f53bef12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_15eb3bf3-b94e-4e0b-bd9e-677be883dd71" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_b76425de-90dd-4ef0-b261-bbf8f53bef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityTextualDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_dd53dcda-ec65-4a19-a0bc-131e7fa5d80f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_dd53dcda-ec65-4a19-a0bc-131e7fa5d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_8189e730-b959-401f-8b2a-97a20fa89d46" xlink:href="dyai-20191231.xsd#dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice_8189e730-b959-401f-8b2a-97a20fa89d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_48a05f07-56fe-4fa8-9b75-86c052cbd42a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_48a05f07-56fe-4fa8-9b75-86c052cbd42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_35016de6-5e8c-4658-b61a-3067bd15de0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_35016de6-5e8c-4658-b61a-3067bd15de0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_133539b0-9987-4f37-9f78-f3965b800cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_us-gaap_TreasuryStockCommonShares_133539b0-9987-4f37-9f78-f3965b800cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6464b937-f542-4002-83c1-fcbb70b194b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c26d66-64d6-4aff-87d0-d48d353a9355" xlink:to="loc_us-gaap_TreasuryStockValue_6464b937-f542-4002-83c1-fcbb70b194b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#ShareholdersEquityStockRepurchaseDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0229741a-4c5f-424a-a757-f74327e93547" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0229741a-4c5f-424a-a757-f74327e93547" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_afe5c2f1-9055-4c88-893a-bcf3295817fb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_PubliclyAnnouncedRepurchasePlansMember_48ef0041-e2a3-420a-bb70-5bbd2f0b7c21" xlink:href="dyai-20191231.xsd#dyai_PubliclyAnnouncedRepurchasePlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f6660928-ee96-49e9-a647-e318da6e7fe2" xlink:to="loc_dyai_PubliclyAnnouncedRepurchasePlansMember_48ef0041-e2a3-420a-bb70-5bbd2f0b7c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fcd72f7-dad8-46b2-a715-b82459f3fa60" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_03d77b58-e61e-4797-b202-54ab7cfcccf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_03d77b58-e61e-4797-b202-54ab7cfcccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a7b5cd5f-f9f5-492c-ac23-439fbba79a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a7b5cd5f-f9f5-492c-ac23-439fbba79a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c1566242-17e9-4f88-9778-432758cf5385" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c1566242-17e9-4f88-9778-432758cf5385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5f4270b-9de5-4544-8eae-df7af5fa15b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cc05a4cc-dfee-4e8e-a0de-5426276267c0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5f4270b-9de5-4544-8eae-df7af5fa15b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b89f3fe8-25c6-40ff-b83c-63c5a97e24b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5d41164f-ece0-493f-ab9d-3604b3e1b4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b89f3fe8-25c6-40ff-b83c-63c5a97e24b9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5d41164f-ece0-493f-ab9d-3604b3e1b4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dyai-20191231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.dyadic.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b322569b-08fb-4a40-891a-cda6cb45a209" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b322569b-08fb-4a40-891a-cda6cb45a209" xlink:to="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1f2eeba-e161-4f9a-a106-161d91497e7d" xlink:to="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f3f5a85b-3e5d-4497-b9eb-218d98fe4b65" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:to="loc_srt_MinimumMember_f3f5a85b-3e5d-4497-b9eb-218d98fe4b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_596dafbf-563c-4c37-87cb-9c529035795b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_527e67c3-7c29-439a-8c8e-08fd5b65f4a8" xlink:to="loc_srt_MaximumMember_596dafbf-563c-4c37-87cb-9c529035795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_763657d9-c18f-466f-b95b-a4cc69604e53" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ExecutivesandKeyPersonnelMember_e0fcf89e-9428-4b90-b526-576fd22e51fc" xlink:href="dyai-20191231.xsd#dyai_ExecutivesandKeyPersonnelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_ExecutivesandKeyPersonnelMember_e0fcf89e-9428-4b90-b526-576fd22e51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_375842a5-da54-4e7c-842e-b4670b10c556" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_us-gaap_DirectorMember_375842a5-da54-4e7c-842e-b4670b10c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_NonexecutiveEmployeesMember_0566ac3e-a006-44a4-ae0e-8979819f718d" xlink:href="dyai-20191231.xsd#dyai_NonexecutiveEmployeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_NonexecutiveEmployeesMember_0566ac3e-a006-44a4-ae0e-8979819f718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ConsultantMember_a7fbbc48-ea6e-4d79-8eec-a156f085f66a" xlink:href="dyai-20191231.xsd#dyai_ConsultantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e8654e34-c866-4e80-b77d-5435a2a007df" xlink:to="loc_dyai_ConsultantMember_a7fbbc48-ea6e-4d79-8eec-a156f085f66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_31ed284b-2894-45bb-a9e5-88fa75009f63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_49abb604-f2bc-48f1-8bbe-c2163ad34113" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8af3521f-6e13-4d61-8bcd-7c7cd86ac31d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_49abb604-f2bc-48f1-8bbe-c2163ad34113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d8890bf-859c-47c7-bc52-61123801f33a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bc720fb0-a4ee-4ea4-8a52-12d92cbb03ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b92f2222-22c9-4d2f-ad5e-f26ad4c366ec" xlink:to="loc_us-gaap_SubsequentEventMember_bc720fb0-a4ee-4ea4-8a52-12d92cbb03ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_dc1e0e27-ba9e-45e3-9fc8-cb336a4271de" xlink:to="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f8cd468-baeb-4a7c-909b-78fd01c18260" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f8cd468-baeb-4a7c-909b-78fd01c18260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8bda47fa-60fd-4da1-8652-4689c315f5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8bda47fa-60fd-4da1-8652-4689c315f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12a02bb2-c5a4-4561-9af9-96c01edb3cde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_12a02bb2-c5a4-4561-9af9-96c01edb3cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditional_9b9dcc22-11b3-42b4-9a3d-344fd7c797fa" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditional"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseAdditional_9b9dcc22-11b3-42b4-9a3d-344fd7c797fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_6cdee52a-e826-417c-b8a1-9ea9e194082e" xlink:href="dyai-20191231.xsd#dyai_ResearchAndDevelopmentExpenseAdditionalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_796c7855-42a2-455c-a19b-4e9f99f27d3c" xlink:to="loc_dyai_ResearchAndDevelopmentExpenseAdditionalTerm_6cdee52a-e826-417c-b8a1-9ea9e194082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>dyai-20191231_g1.jpg
<TEXT>
begin 644 dyai-20191231_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %!I;F<@4F%W
M<V]N   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.AZ:GR_XVUT^)?&VJZKN+1SW#>3GM&ORI_XZ!6%2=*ZSQOX-E\)6^@R2 _\
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MKXAUS_D8M2_Z^Y?_ $,U&&W8ZNQ[?^S7_P @_P 0_P#7:#_T%Z]OKQ#]FO\
MY!_B'_KM!_Z"]>WUE6_B,N'PH*^4?C;;+;_%G4R@P)4AD./4QJ#^HKZNKY9^
M.Y!^*MT!VMH0?^^:K#_&*I\(_P" MTT'Q2AB4X%Q:S1M[@ -_P"RUTO[2?\
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M_"%^*/\ H7=5_P# .3_"OKZBCZNNX?VI/^4^-M0T'5])B675-+O+*-VVJ]Q
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M>M?]<X__ $:E14^!FV'_ (T/5?F?+%(>AI:0]#7F'UI]D^'O^19TO_KSB_\
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>dyai-20191231_g2.jpg
<TEXT>
begin 644 dyai-20191231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %EU:V$@4VEM
M;6]N<P    'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BK_P  1" #<!;X# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MPDIQ4D%%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8/CK_DG?B/_ +!5U_Z*:OBVOM+QU_R3
MOQ'_ -@JZ_\ 135\6U<3RL=\2"BBBK//"BBB@ HHHH **** "BBB@ HHHH *
M*** /I;]G+_DG=__ -A63_T5%7K5>2_LY?\ ).[_ /["LG_HJ*O6JR>Y[V'_
M (40HHHI&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8/CK_ ))WXC_[!5U_Z*:OBVOM+QU_R3OQ
M'_V"KK_T4U?%M7$\K'?$B6WE2&YCDE@2X16!:*0L%<>A*D'\B*^G1\%/!&I>
M'UDM=*:TN;FV#1R+=RMY3LN0<%B#@GN*^7:^OE\0_P!E:]X-TR60+!JNGSI@
M]Y42%D_3>/QHD3A%!\W,NQ\DWUE/INH7%C>1F.XMI6BE0_PLIP1^8KK_ (4^
M!D\<>+A;WN1IUHGG76"07&<*@(Z$G] :U?CSH7]D_$=[R)-L.IP+."!QO'RL
M/T!_X%75>"+E/A_\+M.N2NS5O%.HQI%_>$.\+GZ!=Q'O(*;>AG"DE5:ELC.^
M-7@SPIX+T;38]!T@P7E],_[]KF5]J(!D89B,DLOY&MSP5\/O ^L_"FV\1ZAH
M9DN4M97GVW<R[VB+ G ? SMS^-0_M+_ZGPW_ +US_P"TJZ3X6VTMY^SZ+:V3
M?--;WD<:9QN8M( .?<U/0ZE"/UB4;*UO\CYA=@SLRJ$!.0HS@>W->Y?!WP!X
M1\9>"9+S6M(,UY;W;P/*MS*F\85@<!@!][' [5P?_"F_'W_0O2?^!$/_ ,77
MN'P1\,:QX5\)WUGK]DUG/+?&5$9U;*^6@S\I(Z@TV]###4I>T]^.GFCP71[?
M1[OXJPZ=)I,<NE7>IBT2V::4>7&TNP$,&!) .>2:]A^('P9\+V/@74[[P]I[
MVM]9PFX1OM$C@JO+ AF(^Z#^.*\:\,_\E<TC_L.0_P#H\5],:3XE34OB!XH\
M*7P5_LJPRPJW\<3PIO7'LQS_ ,#H9>'C"46I+=GQ]7H_P:\!67C;Q!=OK4;2
MZ;8Q NBN4\R1CA1D<XP&/!["N0\5Z#-X9\5:AI%PC*;:9E3=_$AY1OQ4@_C7
MO'@BV;P!H7A+0WVQZIXBOC<W:_Q+&(RVWVQ^[&/4M3;T,:%.]3WMD<)\;?"/
MAWP=<:3:^'=-^RO<+))-(9Y)"0"  -S$#J?TKRJO:_VDS_Q/M#'_ $[2?^A"
MO%*%L3B$E5:1]+?LY?\ ).[_ /["LG_HJ*O6J\E_9R_Y)W?_ /85D_\ 145>
MM5#W/6P_\*(4444C<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%4,GQ?TD 9_XG<1_*8'^E=YX@\0CPS^U)/?RL5MVE@@GYXV/;QJ2?8$AO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?'7_ "3OQ'_V"KK_
M -%-7Q;7VEXZ_P"2=^(_^P5=?^BFKXMJXGE8[XD%%%%6>>%%%% !1UZ45W'@
M;PLTTL>KWZ8B0YMT/\9_O'V':L*]:-&#G(Z,/0GB*BA$U?!/A9M,C.H:C$!=
MR#$:'K$O]"?T_.NPHHKY.M6E6FYR/M:%"%"FJ< KD_&?BE-+M'L;&7_3I!@E
M?^62GO\ 7T_.M+Q+XBAT#3R_#W,@(AB]3ZGV%>03SR7-Q)/.Y>21BS,>Y->A
M@,'[1^TGLOQ/,S+'>R7LJ?Q/?R_X)'G/7FBBBOHSY4**** /I;]G+_DG=_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;VUV;E)&$C?=62,?<S]35S6_%\UEK8T30-(EUK5!$)I8EF6&.!"< O(W )[
M F@KGB=/17.:!XPCUJ/489[&;3]3TS_CZL9V!9,C*D,.&4XX(JGX0\<77B^*
MSN;309X;":)C/>-.NR*0?\LU! 9_=@ !3L'/'3S.OK./B+15O_L+:Q8"[Z?9
MS=)YG_?.<UF_$!-4D\ ZNN@B0WQMR(Q%]\C(W;??;G%<CX>?X6:WX>BTB.#2
MH)VB$<L%W$L5R),8.2P#%\]P326MPE+E:7<]1HKDHKT?#SP):QZY>RZK+"PM
M[<QI^]N69CY<8!/)Q@9SVS4=MXXO[;5+.T\5>')M$CU"016MQ]J2=&<]$?;]
MQC^(]Z=KNR#G27O:'8T5AZ?XD^W>,M7T'[+Y?]FQ0R>?YF?,\P$XVXXQCU.:
MK1^+_,UWQ'IWV'']AP1S>9YW^OWH6QC;\N,8ZFELK_,JZ;M\CI:*\_@^)=_>
M>%H_$=EX5N)],6+S+F472*R8'S[%(S(%.03\N<'%;>K^-['3M#TV_LX)M1FU
M;8-/M(!AYRPW#KPH Y)/2FTT2JD6KI^9O7-]:6;PI=W4,#7$@BA660*9'/15
MSU/L*GKR;Q1XBU&_\3>#]/UW09M'O/[8BFC'GK/'(F"#AU[@D9!'?O7K)Z46
M]V_]=!1GS2<?3]3$?QMX5BD:.3Q-HZ.I*LK7\0(([$;JU[>XANX%FM9HYHG&
M5DC8,K#V(KS+X7^&- U7PS>7.J:)IM[.=3N5,MQ:1R/@/P,L":N6%E#X*^+5
MOI6D+]GTG7K227[&OW(IX^2RC^'*]A0E>R[K]+D<\K<SVO;\;'HM06E]:7\3
M26-U#<QJYC9X9 X##@J2.X[BN3T+Q[=>(=2DM=.\/S2+;7TEK>7 N%$=NJD@
M-D@%B<9VJ#CUK.TSQO9Z9H<-Y9Z!':6,^NR6%QY=QQ$Q?;YQ^7G)ZCC&>II+
M6WG_ ,#_ #+=2*_KM?\ R/1**PO$7B4Z)J&CV-O9_;+K5;OR$C\W9L0#+R=#
MD*.WZUGZAXTO&UJ[TSPOH$VMS6! O)!<I!'$Q&=@9OO-CL/SH*<DMSK:*QO#
M/B:U\4::]S:Q2V\L$K07-M.N)()%ZJW^-;-/8:::NADLT<$32SR+'&HRSNP
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M#*ZL2&XR<XXKJM=^&G@_Q!J<VJZYI0GNI%'F2FZE3A1@<*X X'I1I:_]=/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXM\(6VLW,*0M<22@(@( 59&5>I/. ,^]="[!$9W.%49)]!7$?![_ ))C8?\
M7:X_]'/7<54U9M(JFVXJYQ6G_$:SUOX@6^@Z)B>U^RRS3W#Q.GS C:$SC(Y.
M3@]JT?%7B>YT>ZT[2M'LTO=7U1V6WBE<I&BJ,L[D G:!Z=:R]1_Y+CHO_8(N
M/_0UJQXPT+4YM=T?Q%X>6"?4=+,B&TGD\L7,3C#*&['T/2I5K1OY_F_Z]";S
M]]+=6_)?\'YAIOB77+#Q-:Z%XQM;%)=01VL[S3V?RI&49:-E?E6QSU.:@;Q+
MXGUW6=2M_!]GI:V>ESFVEN=2>3]_* "RH$Z 9QDY^E<[KEQXBU/XC^"Y=7TZ
M'246[D\FS6Y$\I 3+NS*-H&,  9KN=16_DTJ0^ I-%2X>=C,\ZEHRV/F_P!6
M?OYQG.:?2[\_^'$FVVE_6FQD6_Q'C/@.^UV[T]X[VPN&LYK%7SFX#!0JMZ$L
M.<5!=^*_%OAK['?>+-.THZ7=7"02?8)9#+:%SA2V[AQGKC'XU#\/#I4.@ZCI
MNMK$-1@U1AJ/VQD9);ICD,A( (/&T8R,56^)":Y$T5]X@-G-X1L[V*::"SW+
M<E0PVE]V58!CR%QQ3TYEYV].G]+Y$-S]FVGJK_?KO^OS/3:Y_5/&>GZ3J,EG
M<PW321XR8T4CD9[L/6MY'62-70Y5@"#ZBO*_&O\ R-MW]$_] %<N(J2II6.V
MG%2.OMO'NEW5U%!'!=AY7"*61< DX_O5T]>+Z1_R&[+_ *^$_P#0A7M%.A-S
MC=BFE%V15AU33[BQDO;>^MI;6+=YDZ3*R)M^]E@<#'?TIO\ ;&F_V5_:?]HV
MG]G[=WVOSU\K&<9WYQC/O7DVJR/H]OXT\)P$K)J.H0&S _NW9"MCV&&JL(MO
MAG_A7B$Y'B/[%M)Y^R[O/S_WS71%<UK>7Z7^ZZ.655Q>J[_K;[[,]BMM7TV\
MTYM0L]0M9[) Q:YBG5HU ZY8'''>C^V--_LK^T_[1M/[/V[OM?GKY6,XSOSC
M&?>O)=28Z):>,_"-M^[;4+^#[$HZ!;HA6 'H,-5<1[?#/_"O$)W#Q']CVD\_
M9=WGY_[YH2YMNMOTO]UT#JN.Z[_K;[[,]EM-2L;\RBQO;>Y,+;9?)E5_+.,X
M;!X..>:;:ZMIU[927EE?VMQ:QE@\\4RNB;>N6!P,=Z\WU[4%\%>,/%,B?)%J
MFBB[@ Z>='^[P/<[E-<W DW@OPCXF\)1DFZNX;0VP)Y=[A5CDQ_P(&DM5I\O
M6]K#=3E=I>=_)6NOS/<K6ZM[VUCN;*>.X@E7='+$X=7'J"."*@GUG3+5YTNM
M1M(6MU5YEDG53$K="V3P#@XSUI=)T^/2=&L]/@&([6!(5^B@#^E<+:Z18ZG\
M<-=?4;:.Y%OI]LT:2KN0,=PW;3QG' /;)]:;MS67F5S-13>^AVTNNZ1!8)?3
M:K91VDGW+A[A!&WT;.#6'\0]>NM'^'5_J^A7:I/&L;0SH%D&"ZC(R"#P:YSP
M'X7T63Q-XO$VG6\T5OJ+000RQAHX490S!%/"Y)YQZ#TKG94$?[//B&VC)$5O
MJ4T42Y^X@N%P![4EK;Y/[[?YD\[V?FONO_D>P0:YIDEXEA_:=F;\H";83IYO
M3^YG/Z5-/JFGVMP\%S?6T,R1><T<DRJRQYQO()X7/&>E><?$+PWI.B_#BTGT
M^RABN[.YMGBNE0"7<9%!8OU).222>:N:EIEGJOQXM(]1@2XBBT,RK'(,H6$V
M 2O0XSD9[X/:JM=_-_@KB4VEKV3^]V.V_M[2/[-_M#^U;+[%G'VG[0GEY_WL
MXJU;7,%Y;I/:3QSPN,I)$X96'L1P:\V\->&M'?XN>+(WT^W:"U6W>"W:,&*-
MI$.]@G0,<=<>OK4_@2==!MO&"65A<W-O9ZW(L%E9("P!"\(I( '.<9%+3\+_
M )?YE\TKZ][?@W^AZ#=WMK86YN+ZYAMH5(!DFD"*"3@<GCDG%0)K6ER:DVGI
MJ5FUZHR;83J9!_P'.:\^^).MRZS\*M8:32=3T@Q20 ?;XT0MF1>5VLW3\*M>
M+O!6@:?\-KN>QLX;6\TZV-S;W\:@3B51NWF3[Q)(YR><TMDY,.9MVCV.^N[R
MVL+9KB^N(K:%/O2S.$5?J3Q26=]::C;+<:?=0W4#?=E@D#J?H1Q7G%J1XP\?
MZ+;^(H%FM[;08]06TF4%'GD(!8J>#@?EFNKTGPQI6A>*[R\TF5+0WL"^;IL.
MU8R0?]:$'0]LCBJ<;.S\_P &U^@HU'+6.VGXI/\ 4Z,G R>E4K/6M+U&XD@T
M_4K.ZFB.)(X)U=D^H!R*YCXI3RCPU9V$<CQ1:GJ5O97$B-@K$[?-SVR!C\:L
M:AX&\.P3:7=V4=OHD^G7"-#/;(D1<=#$Q_B#=,&DM=7WM^7^94I-.R[7_/\
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MFK,^.Q6%=.LU35UTMJ<'17>?\*3^(/\ T /_ "=M_P#XY1_PI/X@_P#0 _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dyai-20191231_g3.jpg
<TEXT>
begin 644 dyai-20191231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %EU:V$@4VEM
M;6]N<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S,W  "2
MD@ "     S,W  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML:=$]SJ>E0&TC!:5[6ZWLBCJVUE7('L<UN@Y (Z&N=\7W,\]BNB:;AK[4@4
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MA\57A>0G^Q;=\(@/%XX/+'U0'@#N>>E'B4-]HL89MLEGO!2RA_UMU*IRJX/
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit1011jupiterlease2001.jpg
<TEXT>
begin 644 exhibit1011jupiterlease2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!@# 2(  A$! Q$!_\0
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MDHHH 6BDI: "BDHH 6BDI: "DI:2@!:**2@ I:2B@!:*2B@!:2BB@ I:2B@
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MH *,T44@"BBDI@+1WI*6@ HHS1B@ HHHH *3O2T4 %&*** #%%%+0 E%+24
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M'#%YDCJB?WB<"JUKK.G7LFRWO(9&Z;5;F@"]11F@4 %+244 +1244 %%+10
M44E% !2TE+0 E%+10 444E !2TE% !1110 4444 +1244 % HI: $I:*2@!:
M*** "BDHH 6BBB@ HHHH ***2@!:*** &T=:*3\* %I:2EH .]%%!H ****
M"BBB@ HHHH *2EHH 2EHHH **** %HI** %HHI* "BEI,4 )2T=Z* "BEHH
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ML]GI=K;2$%XHE1B.F0*M58!1110 8YHHHH *6BDH 6BDI: $I:** $I:2EH
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M )2T44 %%)2T )2TE% !12T4 ,CW[/WF-WMTI])2T %%%% !1244 )2T48H
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M@=%GBDK$U+Q19:==FT,<T\RJ&9(4+%0?6EA\4Z;+I4NH[V2.%MCJRX8-Z8I
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M:** $HI:* $HI:3O0 E%+2&@#G?"!!BU/!R/M\F,'Z5%IT44GC75RZ*Y6.(
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MYP>XSUS7>P:3IULZO#901LIRI5 "#2W.EV-Y()+BTBE<=&= 318#,\&01PZ
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M&C$BJB%MP/I7%6QA_P"$5\JXUORT"E'M1$I<'/3U_&M[2[=8_%MHC%I"FEJ
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ML/QJKIWBNV6:]BU*[BC>.Z:.-3P=HZ47 /[7\1?] +_R**0ZKXA8?-H"D?\
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MUH M):6\5S)<I$JRR@!W Y;'3-2.BR(4=0RL.01D&N0UOQA;R0P#2KS$OVA
MP*_>4G!QFM33-4DDU36%N9@(+5UV[N HVY-%P+'_  C&BERYTZ#)_P!FI(-
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M8+,VD<*K P(*#ISUJ&\UBPL+9+FYN42*3[AS][Z56B\06&H6MP;&Z5Y(XF;
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M 2BBB@!:*2EH **3G/M2T %)2T4 )7+>/3_H&G_]?T?]:ZFJ6IZ3;:O%%'=
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MC\I/6M6F E+110 4444 %%%% !1124 +1110 E%+10 E+24M !1110 4444
M)FDHHH 6BBB@ S1110 444M "4M%% "44M% !244M "44M)0 M%%% "4M%%
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MI":3<8O+\O/RX]<>M.P%ZBBEI@)2TE+0 E &!BEI.: "EHHH **** "BBB@
MHI** %HI** %HHHH 2BEHH **3O2T %%)2T %%)10 M%%)0 M%)2T %)2T4
M%%)2T )2T44 %)2T4 %)2T4 %%%)0 M%%% !244M !124M !1110 4444 %%
M%% !1110 4444 ,[TM)BC\* %HQQ0** "EI"<"@,#TH 6CI110 M)103Q0 4
M4#I10 M)12T )2T4E "T444 %)110 4444 %+244 +1124 +1110 44E+0 4
M4E+0 E+110 E+244 +124M !1110 E+110 4E%% !2TE% "TE%% "T44E !1
M110 M%)2T %)2T4 )BBBEH **** "BBB@ I*6B@!***6@!**** "EHHH **2
MEH **2C- "T4E% "TE%+0 444E "TE%!Z4 %%%% "T444 %%(:6@ HHI* %I
M*6B@ I*6DH **** %HI** %I*** "EHHH *2BEH *2BEH **** "BDI: "BB
MDH 6DI:2@!:2BEH *2EHH ***2@!:*** "BBB@ HHHH **** "BBDH 6BBB@
M!E+24M !111TH * H'2EHH .U%'>B@ HHJA+JT<.M0Z8\;AYXRZ/_"<=1]:
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M>C[-.VZ %>8^<X/J* %MV\7BVBV0V!78,98],4GC74I+30(;5LBXO"J.(\G
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M61K?AW4;[6XM3L-16U>.+RQE,D=<TU/#NK75I<VNJZN;B*>/: J;=IR,']*
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M&:XK2=8%K!?746KM>P16YD$4W$B,/Z5CG6;I;--175[LWK$.(/)/EG_9Z47
M]-HKAM<UFXDFLGN)[NSLIK82&2!#G>>QK<\)7$ESI\I;41?1K(1&^,,%]&]Z
M -VC(JKJCW$6EW,EHI:=8V,8'<XKA])U&5[VT/\ ;5Q'=&1?/M[M=H;U"\4
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MYGE[EY^;.,46 QAX8U&TTJ(65\/MRSF>1F'R2$]01Z4EIX7NKK49;W5_(4M
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M6^NG8K/*S0J1C:F<"LCQO%'=/90VLV-0\SR@B'YMC#!S75V5JEE90VT8 6)
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M!V8/1JAN=*OX_$%[/<Z.=41R/L[LX"H/3%%AI&NV>C7RI:1K.]V)/)X*R)W
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MB@ HI*6@ HHHH 3!R#GCTI:** "BBB@ HHHH **** "BBB@!*6BDH 6BDI:
M$HHHH ***JW&IV-K)Y=Q=11/C.UV - %JC%4DUG39'")?0,S'  <9)I9-8TZ
M)V22]A5EX(+@$4 7.E'6JT&I65R',%U%($&6*L#M'O42ZWIC.%%_ 2> /,%
M%ZBHC=0B SF5/* R7SQ^=+%-'/&)(G#HW(93D&@"2EJ 74!N#;B9#*!DIGD#
MZ5-VH 6DJI/JMA;S&*:[AC<=59P#21:MI\\JQ17D+NQPJJX)- %VBDS10 M%
M)D49H 6BDH!H 6DHS5<W]H(C*;B/8K;"VX8!]* +-)4:W$3RM$LBEU )4'D
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MAK#TZZU24^(_.B3RRLGFMOSY;!3@#VK0N+V\\3:CI\4&GW%O#:SK+-),NW!
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M9%?<4)Z;A3 ZA949V174LAPP!Y%.KGM0;^S/%-C=)GR[_,$H!XW#E370T@#
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M2EH **** "BDHH 6BBB@ HHHH **** $I:** $HI:* "BBB@ HI*6@ HI**
M%I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q2T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4E+10 4444 %)2T
M4 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%%% "4"DI10 4M)10 M
M)2TE !111F@!:*** "DI:2@!:**2@!:*** "BDHH 6BBDH *6DHH 6BDI: "
MDI:2@ I:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* $I:**
M $I:** "DI:* $HI:2@!:**2@!:*** $I:2EH ***2@ S2T44 %%%)0 M%%)
M0 M%%% !1124 +1110 E+244 +1110 4E+10 E+110 E%+10 4444 %%)2T
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MNI^=/).T()WR$@Y'I^-,#HZ*J:9>M?V2W#0/ 22-C]1@XJW0 M%%% !24M%
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MKX')$['EJHZMINI:KK"0_:9+;3DBRS1-AG?TK.\'WD.E^'Y;FZ<Q6TMXP@W
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M^UU@3A$DAEMSB2.5<,OO65J*K_PL+2AMX^SO_6B&)Y/$WB&.(XD>V0*??::
M)I/&M@DQV07,ENK;6N%C.P'ZU:U7Q3IVDBW:8NXN5+1&,;MU8&D:UI5GX+>S
MNF"3PHT<D!'S,YST'>HM.M7CO/"T-W$1(L4IVOU'<4 ;EIXQM+V"Z,<-Q'-;
MQ%S$\9W$>PK"B\3W5SX/-Y-),DT=TNZ4+@%2_0>O Q6K>1#_ (39MJ\G3'X
MZ\U@V4\$O@.*T# RQWJ"2/NN9.] '56'BVSOK]+(P7$#RC,32QE1)]*PGOO$
MK>+?)4XMQ)Y/F^4=G/S#CZ<9K1\3C;K_ (?V_+_I!''X5U( ZXIB%%+244#%
MHI*6@ HHHH **2B@!:*2EH **2@<=: %HHI* %HHHH *2EHH **** "BBB@
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M@#J>U KG=%O]8CU5],U>)9&$?F1W$0^5AZ'WK:M+VWO5=K:59 CE&*GH1U%
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MYR#US6;'X+T2.=95M2=IR$+DJ#]* L9>GZ?#>^-+J2]1)GAM(L9&1D@9-5-
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M2X@>&09212K?0T#."BLH+X>$X)T#QF-R5/? S6H+>"P^(5O%:QI"LUHQ=5&
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M%%% !124M !24M% "444M !1110 4444 %%%% !24M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 )1110 444M !24M)0 M)VHHH  ,44M% "
M4M)2T %%%% !1110 E+124 +244M "4M)2T %%%% !244M !1124 %%+10 E
M+110 E Y%%% "TE+10 E%%% "TE+24 +1110 4444 %%)2T %%%% "$XI:**
M "BBB@!**6B@ HHHH ***2@ HI:* $I:** "DI:* "BBB@!*6BB@!*6BB@ I
M*6DH *6DI: "BBDH 6BD!R*6@ HI** %HHI* %HHHH **** "BBB@!*6DI:
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M[4_%YJ/A#2G5?M0BD;?;F3#2J"<?7%;P\%F/SK>#5+B&RF8LT*8ZD]CZ4_\
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M1>NX#O6A<>#]6O;1(+O6RRPE3$J1 #(]:N7GAO4#JDM]IVI_9S<*!-&Z;U)
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MM% !1110 444E "T44E "T444 %%%% "4M)2T )2T44 -=%D4HZAE/4$<&E
M &!2T4 )2T44 )2TE+0 44E% "T44E "T44E "T4E+0 44E+0 44E+0 4444
M )2T44 %%%% !24M)0 M%)10 M%%% !1110 4444 %%%)0 4M%% !1110 WH
M:7-%% !1110 M%)2T %%%)0 5FKI6WQ"^J^;]^W$/EX]#G-:=% '-7?AF]34
MKB]TC4VM#=',J,NY<^HI%\)-_8TME)?/)-<3+++,_.<'. .U=-12L!EWND&[
MU33[WS=HLBQVX^]D8JM<>'!<:Q>7SW#!;JU\@H!]WWK=I* ./?P;J4NG?V<^
MLG[*%PJ+$!],GTK9AT1X+V&X%QN$=G]F*D=?>MBDI@8EOX?,/AB31FN-V]&7
MS .F3GI6AI=D=.TNVLR^\PQA-V,9Q5NB@#F;GPM?+J-U<Z=JSVD=X=TJ;=W/
MJ*2W\'M#I-M8F]+F"\%R7*_>P<XKJ**5@,R_TC[;JVGWWF[19ER5Q][(Q61)
MX2O89+F/3-6>UM;EBSQ;<[2>N#VKJ:6F!AV?AQ+'4+*XBF)CM+8P!6Y+9.<D
MTESX<^UW^HW$MP=M[;B *!]P>M;M%(#CF\%ZC-IW]G7&M.UJH 55C )QTR?R
MK8L-$DM+^UN7N _D68M]H7&3G.?TK9HI@<KJ^BQVL&M7]P);J&\"$P1##+M[
MCW[_ (5R=]OOM/M[&VUN:^_>((K?RR"!_M'VKU4@$8(R*B2UMXVW)!&K>H4"
M@1C:EX>GN+^+4;"]-I=)#Y3';N#CZ4V#PP7M+U-2O'NY;U0KOC 4#I@5T%%
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M112T )2TE+0 F:6DHH *6DHH 6DHSF@T %%%% !DXI:3(HH **,T9H ****
M%HI,T9H 6DHHH *6BB@ I*** %I*,T4 +129HS0 4M)FB@!:**2@!:2BB@ H
MI:2@!:2BB@!:2BB@ I:2B@!:**2@!:2BEH **** "BDHH 6BDI: $HHHH **
M6DH 6BDHS0 4M)10 M)2TE "T4E+0 4E%+0 444E "T44E "TE'>B@ HHH-
M!112T )2TE&: %HI** %HI*.] !2TE% "T4E% "TF:** #-+2=Z* %HHI.]
M!111F@!:2BEH **2B@!:*** "DHI: "BBDH 6DHHH 6BDH[T %%+10 E+110
M 44E% "T44A('6@!:*2EH **** "BBB@ HHHH **** "BBB@!**6B@!****
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M>.C$9_&L70M6G:_M2-<=IW8"XMKM=H.>H6BX'H72LVTU^QO=4N--AD)GM_O
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MD8#ABW6M>C- &#X5\/2:!:SI-,)I)9,[A_= P!4^CZ3-IU_J5Q-,L@O)_,7
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MBDH 6BBB@ HHHH *2EI* "C-%&* %HHI* %HJM>ZA:Z=")KR988R<!F.!FJ
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MDI:* $I:*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI**
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M*2EH **** "BBB@ HHHH **** "DI:* "BBB@ HHHH **** $I:2EH ****
M$I:** (;FTM[M EQ"DJ@Y <9YKD],TRQF\8:O:R6<)ACCCVH4&!QVKLJP--L
MKJ'Q7JEU)%M@F5!&_P#>P*3 Q-=;3].\5P"XL#<6Z66U8DCW;>3VJUHMYH5U
MJ<,-KHDMO*I)21H<!3]:EUI-3M?%":C9Z<UW']D\O 8#G=FI+/6==EO8XIM
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MW20>HJ<7EJ>%N(L^F\5,#Z8HL M+29IJ2I*NZ-@R^H.:8#Z2C-(""2 1QUH
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MH5&0I#=?85JV/A*VU[4I"1)#I]H@B@$9*[S_ !'\3^=7="@NM7U.>]DC*O<
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M*** "BBB@ HI#1GF@!:*CEF2%2TCA5'<FB"9+B,21MN4]#0!)24M)0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !24M% !24M% "44M% "44M)0 5S?
MB^5KE;31HG"O>R?.<XP@Y)KI*Y :-_PD7B&]N=0BFCAMR(K?!*D^I'L:0%KP
MA.\,%SI$Y)DL)"JD]T/(-0+XHU*Z,MQ96,4MM"Y4IYG[QL'&0*ADTF7P[XDM
M;K3UFF@NE,4^[+D'L2?RK)NH4*S;M*N[75PS;3; A'.<@YZ4".ZO=2%MIPN
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MCDYZ5A7%K=1>$='D6TE=K:Y#O&%^8#)[4M0-B^\0:M'J<>FV>G)+<^0LKY?
M7/447&O:Q)<S16.FH5M^)'E?:"WHOK5C3U-QXGGO3%(BO9QA=ZXQR<CZ]*Y^
MZ'FZC?1ZO9WT\QD)ACA)V,G&.E,#=3Q9&WAW^TS;MYOF>4(0>K^F:2VU_4H;
MR.+5M/\ (CF1F22,[@N!G#5@6.EW@\+)BSD$UE?^<8"O+#\>O%;,NJ7FO2K9
M6=E-# T;K<//'C'R\ 4K@,'B?5I+8ZDFE@Z<#G._YROKBEUKQHME;VC6-LUS
M)=Q^8F> !6=_PD,FE>&/[,N=-N1=+&8%&SY6SD9S7,WFCZE9BQ34$N"LT!6%
M8224)/(('L:UIQOK+8RJ3:5H[G<Z%XP;4M.NY[NU,,UI'YKJIR"O;%-M/$VJ
M2M!/+IZ-:W#@!HI-S(#W(K(T"RELY-42QTR5(Y;1?(2<<28X.?KZ566$+-;3
M:-87UI>^8N^,@^6/7K]:SD]="XWMJ;5CJ>I?\)GJ*O IA1%##?G8@S@@>IIS
M^+-4$$E^FE 6*,>7?#E1U(%,4W=EXMU,"WE+7D \F15RH8+W/UK >V6XT>1+
MBTU*XU,A@0^[8I]?3'^%3<9U$-TM]XRL+J+.R;3RX!'8FK_B]BGAB]8$@A1R
M/J*R=$@F76=)=HG51IFPDJ1@YZ&M;Q?#)/X8O(XD+N5& HR3R*?0#FTL?"7]
MB)++/&LYA!)67Y@V.U7=+\17%GX<L%>%[F\N2R0H3@L!T)]JU=+\.Z7_ &=:
M22Z?#YHA7<63G..]4_$2RZ?JVFZI#:--;V@9)$C7)4-QD#VI:@36?B&]35(M
M.U:P^S/<*3$ZMN5B.WUJC'XC@TGPW%=6EB2LETT0BW=\G)I)KMO$OB'3I+2V
MF6VLV9WF="H)]!FJ=M9W/]@Z6AMY-RZIN8%3PNX\TV!KVGB/4AJ4=CJ.G+;R
M7$;-!A\Y(&<&J'AS6;RV@U2[U&+$$<SL\N_<0PP-E:.KP2OXPT:5879$63<X
M'"\=ZQ5M;B[TS6M%-I,DSSO/&Q7"N,Y S[TKL9H+XNOX8XKV\TU8[&5@-RR9
M= >A(_*NL5@Z!E.0PR#7FHL]/DM8[:#1;V2_.U7CD+!%/J3^M>CV\7DVL<6T
M#8@7 .<8%- <5H>JR:/X:U2^6,2M'>MA<XSD@5HQ^)=5AFM9+_2Q#:73JB.K
MY8$],BLN.RO%\'ZI$;:3S'O<JFWEAN'-;WB6!Y++35CC9BEW$2%&< =:6M@$
MO=<U&759;#1[-)VMP//DE;:H)[#WK2T?4'U*S,LL#02JQ1T8="/Z5@B[F\.:
MUJ+7%E--!=N)8Y(5W<XQ@U=L]5U**RAGO;)V:YN-JHB\Q(3P6IW Z"BDI:H
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M2L*DFG)-W&A57[H ^@I<#THI:R-A,48&<T44 )M&<X&?6G444 )@>E&,TM%
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M*]U=,.(HAG'U]*J,7+1$RDHJ[-EI%12S, !U)[5B:AXDBC8P:?$U[<YQLC'
M]R>E9\FDZYX@;.ISBRLVZVT)^9OJ:Z+3]-M=-MU@MHA&B],=35\L(;ZLS4IS
MV5D8]KH]_JB"76YB-Q!^SQ-A1CU]:W;>UAM(EB@C5$48  J4>U%1*;D7&"CZ
M@*7%)G-+4EA112%O:@!:*8)4SC>,_6G @\@YH =1110 4444 %%%% !1110
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M_CV_*M"BIO;L%)>[=]0I*6BH- HHI* %HHI* %HHHH **2EH ***2@!:***
M$HHI: "BBB@!*6DI: $-%%% !1110 44M9>M:Q'I< X\R>0[8H5^\[>E-)R=
MD*4E%79'KFL-90BWM4\V]F.V*('DGU]J;H&A_P!GH;J[837\W,DAYV_[(]J9
MH6BR0RMJ>HGS+^<<]Q$/[HK<K2345RQ,HIR?/+Y(*6DJKJ.H0:;9O<SMA5Z*
M.K'L!ZFLTFW9&K:2NRKX@UZVT#3GNISEL8CC!Y=O050\+:3.%?6=3&[4+SYC
MG_EDG91Z5AV6EW'BGQ.NHZEDV]F<F+.55NH0>I'4^]=^!@8%;S2IQY5N]_\
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M0G@F$\*RH04<!E/J#4@K,\.1O%X?LDD.2(A6G425I-&D7>*8M%%%(H**2EH
M**** "BBB@ HHIJ[N=P YXQZ4 .HHHH 2BB@T %+24M "4M%)0 4444 +4<L
MBQ1-(YPJ DGVIYK)\1RLNE_9T/[RZ=85_'K^E5"/-)(B<N6+8GAV-FM)+V3[
M]W(9/H.PK7J.WA6WMXX4&%C4*/PJ2B<N:384X\L4A:2BBI+,V_'GZG80=E9I
M3^ P/YUI=JSH/WNN7,G:&-8Q]3R?Z5HU<^B,X;MBTGTHHJ#0.U%%% !1110
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M8*BC)8] *\Z@%SX^\3^;(&&C63_*.TA']3_*IO&6LW.M:K%X8TE\EVQ<.O\
M+Z#O79Z-I-OHNF0V-LN$C')[L>YKJ2]C#F?Q/\#D;]O/E7PK?S9=151 J@
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M_<L:W!Q2XHHDW)W81BHJR.?\6>&9/$MG%;K>&W"/D@+D,*NZ'H=IH.GI:VJ
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M\09_X^;;'^X:/)\0_P#/S;?]\F@#:HK&,&ODG%W; =OD-+Y&NX_X^K?/^X:
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M<\)O%)&/L]H/?>:E5O$AQN2U QS\QZT ;F:,UANWB13\B6K#'KTJ,2^*<?\
M'O:?]]F@#H*:>Y/45@"7Q3Q^XM/^^S2&3Q2?^6%IG_?H KZWI6JVVKG7-%(>
M4QA)K=ND@']:2#QM"@\O4[*YLI5X8-&6'YBK'F>*]W%O:8_WZ1_^$G?.ZULB
M/=LY_2M>9-6DC+V;3O%CQXUT(*2UV$_WE(IDGCC1!_JKAICC@(A-,:UUN2+;
M)I>GLY[D_P#UJ6"VUNW8LFEZ>N><*<?TH_=]@M5[HA&N:_JS;=+TP6T1_P"6
MUUQ^E/MO"9NYO.UN[DO9 01'R(Q^%6UD\2 D_9+0#M^\/^%+%-XF4_/:VC9/
M_/0C'Z4>T:TBK"]DG\;N;$-M#;QA(8U11T"C%/)P*QC/XCSQ9VH_[:G_  JA
M>Q>*[N15V6Z0Y.Y4D(+#CO\ G63\S79:%W5->$$AM=.B-W>GC8G1/=CVJMI7
MAR>2Y_M/6I%N+S_EFH^[$/04RRL];L"PM-/LXMS99MYR_P!:O"?Q'C'V.U!]
M?,/^%:<Z2M$SY.9WD;(&.U+VK&^T>(_^?&U_[^G_  H\_P 19_X\K3'_ %U/
M^%9V-1=6\+Z;J\HFGC*3KTEC.UOSJC_PCFJVJ[+/79Q'Z2KN/YU<^T>(\_\
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M 5M_8;<V*V;QAH54+M/3 JS10 Q8U2-8T&%48 ':J\>FVL4UQ,D0#W/^M/\
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MV^E6-K8FQAMD6W.<QXR#GK5RDI@8:>#=!2X,XL$+$YP>5'X5MHBQJ%10J@8
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M^/9#AV_OGT'MZU?4 * !@>E+X5YC^)^0M%%%0:!2TG-% !2T44 %%%(IS^=
M"T444 %%)2T %)2T4 %%%% !1110 444E "T444 )2T44 %)2TE !2TE+0 4
M44E "T444 %%%% !1110 4444 )2T44 %%%% !1110 444E "TE+10 E+244
M +1244 +1110 44E+0 4E+10 4E+10 44E+0 E+110 4444 %%%% !1110 4
M444 %%%% !32P#!?6G4A&: "BCI37?:A;&?I0 H7!)[&G4R,EDR>M.H 6BBD
MH 6BDI: "BBB@ HHHH **** "DI:15"@ # % "T444 %%%% !1110 F****
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MI: "BBB@ HHHH *2EI* %HHHH **** "BBB@ HI*6@ HHHH *2EI* %HHHH
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MI*6@ I*6DH *6BB@ HI*6@ HHHH *2BEH **2B@!:*2EH **2C- "TE&:,T
M%+29HH *6DHH 6BBDH 6BDI: "BBDH 6BDHH *6DHH ***6@ HHHH ***2@
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M-]:3-:RN,2;.C_4?UK5'"@$Y]ZNI)2=T94HN$>5CO>EI**@U"BEI* "EI**
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M63:=K]2K#(-:%-IIV8"TE%+2 *2EI,<YH 6BBB@ HHHH ***2@!:3G/M2TE
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MU2ZNXK@L)(WDP5 &=W':H5*$G92"[.X66-R0KJQ'4 TZN:\/Z2T8NKZ+,!N
M4@7);:O9CZDU.FD:T!E]<;=GG$8Q4N$4[7"[-^BN,U67Q#HNQUUB*YDE<+'
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MSJ,E[;74OEOO7E#CC%&@&Z=#TE%)_L^  #_GF*K:?I^A:G:)=V^GP;&R 6B
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M8;KM'6K-% "4M%% !24M% !1110 4444 )12T4 %%%% !1110 4444 %%%%
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M110 4F1G%+24 +244M !1110 E+110 E+110 E%+24 +1110 44E+0 4444
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MDHH 6BBDH 6BDI: "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 2EHHH **** "BBB@ I**6@ HHHH 2EHHH *2EHH **** "BBB@ I**6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ::!12T %+28HH 6BBDH *
M6DI: $I:2B@ HHI: "DI:2@!:2EHH **2B@ I:** $I:** "BDI: "BBB@ H
MHHH **2EH **** "BBB@ HHI,T +129Q10 M%%% !1110 4444 %%%% " 8I
M:** "DI:* "BBB@ I*6B@!,TM)2T )2T44 )2T44 %)2T4 %%%% !124M !1
M110 4444 %%)10 M%)10 M)2TE "T44E "TE%% "T444 %%)2T %%%% !24M
M% !112=Z %HHHH **2EH **** "DI:* "BBB@ HHHH **** "BBB@!*6BB@
MHHHH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &TM)BEH !112T )2TE% "T4E+0 4444 )2TE% !12T4 %%)10 M%%% !
M24M% !1244 +244M !1124 +124M "44M% !1110 4444 %)2T4 (:**,4 &
M:*** %HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH **** "DI:*
M"BBB@ I*6B@ HHHH **** $I:** $-%+2'I0 4M)10 M%)2T %)2TE !112T
M %%%% !124M !1110 E+24M !1110 44E% !2T44 %%%% !1110 44E+0 44
M44 %%)2T %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1124 +1
M2#I2T %%%% !24M% !1110 4444 )1UH%% !12TE "TE+29YH 6DHHH *6BD
MH ***6@ HI*6@!**** %HI** %HHHH 2@444 +1110 E+24M !24M% "4M%%
M !1110 4E+10 4444 %%%)0 M%)10 4M)2T %%%% !1110 4444 %%%% !11
M24 +124M !124M !1110 4444 %)12T %%)10 M%%% !1110 4444 %%%% !
M1110 E%%% "TE+24 %+244 %%%% "T444 )2TE+0 44E+0 4E+10 4E%% !2
MTE+0 44E% "T444 %%%% !1110 4444 )2TE+0 4444 %%%% !1110 4444
M%%%)0 M%%% !1110 4444 %%%% "4M%% !1110 4444 %%%% !124M !1124
M +29HHH **** %HI*,T +244M !24F/FSG\*6@ I:** "BBB@!*6DI: $HHI
M: "DI:* $I:** "BBB@ I*6B@ HHI* %HHHH 2BEI.E !112T %%%)0 M%%%
M !1110 4444 %%%% !1110 4E%+0 E%+10 4444 %%)2T %%%)0 4M%)0 4M
M)10 M%%% !124M !1110 4444 %%)2T %%%% !1110 4E%% !112T )UHHHH
M .E%+24 +124M !124M !129I: $HHHH 6BBDH 6DI:* $I:2EH *2EHH **
M2EH **** "BBB@ I*6B@ HHHH **** "BBDH 6BBB@ HI*6@ HHHH **2EH
M**** "BBB@ HHHH **** $I:0T4 %%%+0 E%+24 &><8I:2EH 2@TM% "44M
M)0 M%)2T )2T44 %)2T4 )12T4 )2T44 )2TE+0 4444 %%%% !1110 E%+1
M0 4444 )2TE+0 E+24M !124M !124M "4M)2T )2T44 %%%)0 M%)2T %)2
MT4 %)2TE !2T44 %%%% !24M% "444M !2444 %%%&: %HI*6@!*6DHZ4 +1
M110 44E+0 444E "T44E "T4E+0 44E% "TE!HH **,T9H ***.M !111FD
M44M(:8!10** "EI*!0 M%%% !2444 %+110 E+24M !1124 +1110 4444 %
M%%% !1110 444E "T444 %%%% !1110 4444 %%%% "4M%% !1110 4444 )
MTHHHH *6DI: "DI:* $HHI: $I:*2@ I:2B@ HHI: $I:** "DI:* $HHHH
M6BBB@ I*6B@ HHHH **2B@!:*** "DI:* $HHHH *6DHH **6DH ***6@!**
M** %I*6DH **** %I*,\T4 +124M !1124 +1124 %+244 +24M)0 M%)10
MM%%% !2444 %%%% "TAHH]J "BBB@ HHHH 6BDI: $I:2B@!:**2@ HI:2@!
M:2BB@!*6BBD =:***  44=Z*  T44&F M)BBB@ HZT44 %%'2B@ HHZ44@"C
MO10*8!11WI: "BBDH 6BDHH *#110 =Z6DHH *6BB@ HHHH **** "BBB@ H
MI** %HHHH **** "BBB@ HHHH **** "BBB@!,T<TE+F@ I:2EH ***2@!:*
M** "BBB@!***6@!#THHI: "DHI: "BBB@ I*** %HHHH ***2@ HI:* "DHH
MH *6BB@ HI*6@!**6DH 6BDHH *6DI: "DHHH ***6@!**6DH **** "BBB@
M HHHH 6BBB@ I*** %I*!G'-% "TE%+0 E%%%  *6D%% "TE%% "TE%'>@ H
MHHS0 444=: "BBB@!:2BCO0 4=Z6DH **** "EHHH 2CM110 449]:3K0 4H
MZ<]:3O2YI %+244 '6BBBF 4449I %%)13 7O124N<T %%%':@ I*7M10 =:
M.:,44 %%&:* "BC-% !11]:.M !1110 M)2T4 %%)2T %%%)0 4M%)0 M)2T
M4 %%)2T %%%% !1124 +1110 4444 %%%% #:4=*** "EHHH *2BB@!:***
M"DHHH *6BB@!**** %HHHH **** "BBB@!****  T444 %+110 E+110 4E%
M% !1110 M%%% "4M%% !2444 %'2BB@ HHHH *#110 4444 %!HHH *.]%%
M!2T44 )1110 M%%% "&BBB@ HHHH *!110 4444 %%%% !2444 *:***  ]:
M6BB@ I*** #O1110 M%%% "4M%% "4444 %%%%( I***8"XH%%%( HHHI@%%
M%% !BD[T44 %%%% !2T44 '>DHHI %%%%,!>M(:**  4&BB@ -**** #%%%%
M  *6BB@ HHHH **** $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788607952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2017</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,671<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice', window );">Weighted average issued price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Period under program</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized repurchase amount</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, shares held at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,929,915<span></span>
</td>
<td class="nump">$ 18,929,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788177760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices', window );">Outside contracted services</a></td>
<td class="nump">$ 2,578,507<span></span>
</td>
<td class="nump">$ 1,637,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty', window );">Contracted services - related party</a></td>
<td class="nump">868,720<span></span>
</td>
<td class="nump">1,215,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts', window );">Personnel related costs</a></td>
<td class="nump">423,898<span></span>
</td>
<td class="nump">376,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther', window );">Facilities, overhead and other</a></td>
<td class="nump">85,192<span></span>
</td>
<td class="nump">87,363<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty', window );">Research and development expense, related party, net</a></td>
<td class="nump">$ 3,956,317<span></span>
</td>
<td class="nump">$ 3,317,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Contracted Services, Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Facilities, Overhead and Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Including Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseOutsideContractedServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Outside Contracted Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseOutsideContractedServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Personnel Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858165104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 558,530<span></span>
</td>
<td class="nump">$ 318,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">432,546<span></span>
</td>
<td class="nump">193,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 125,984<span></span>
</td>
<td class="nump">$ 125,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6864689504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,823,544<span></span>
</td>
<td class="nump">$ 2,386,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investment securities</a></td>
<td class="nump">29,399,146<span></span>
</td>
<td class="nump">38,816,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">329,711<span></span>
</td>
<td class="nump">294,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">558,530<span></span>
</td>
<td class="nump">318,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">250,308<span></span>
</td>
<td class="nump">506,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_PrepaidResearchandDevelopmentinProcessCurrent', window );">Prepaid research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">253,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">277,999<span></span>
</td>
<td class="nump">172,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,639,238<span></span>
</td>
<td class="nump">42,748,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investment securities</a></td>
<td class="nump">1,511,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Long-term income tax receivable</a></td>
<td class="nump">250,308<span></span>
</td>
<td class="nump">500,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">51,314<span></span>
</td>
<td class="nump">52,139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">37,452,496<span></span>
</td>
<td class="nump">43,300,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">943,378<span></span>
</td>
<td class="nump">309,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">566,003<span></span>
</td>
<td class="nump">399,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred research and development obligations</a></td>
<td class="nump">78,644<span></span>
</td>
<td class="nump">141,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,588,025<span></span>
</td>
<td class="nump">849,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">39,613<span></span>
</td>
<td class="nump">38,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">96,105,851<span></span>
</td>
<td class="nump">94,385,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(18,929,915)<span></span>
</td>
<td class="num">(18,929,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(41,351,078)<span></span>
</td>
<td class="num">(33,043,113)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,864,471<span></span>
</td>
<td class="nump">42,451,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 37,452,496<span></span>
</td>
<td class="nump">$ 43,300,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_PrepaidResearchandDevelopmentinProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development in Process, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_PrepaidResearchandDevelopmentinProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6865345120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,307,965)<span></span>
</td>
<td class="num">$ (5,691,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,171,079<span></span>
</td>
<td class="nump">467,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of held-to-maturity securities, net</a></td>
<td class="nump">198,208<span></span>
</td>
<td class="nump">676,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange loss (gain), net</a></td>
<td class="nump">27,725<span></span>
</td>
<td class="nump">20,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(35,471)<span></span>
</td>
<td class="nump">195,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(252,772)<span></span>
</td>
<td class="num">(59,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">506,866<span></span>
</td>
<td class="num">(1,007,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">253,446<span></span>
</td>
<td class="nump">913,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(105,707)<span></span>
</td>
<td class="num">(17,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">657,658<span></span>
</td>
<td class="num">(195,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">166,399<span></span>
</td>
<td class="nump">251,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred research and development obligations</a></td>
<td class="num">(62,358)<span></span>
</td>
<td class="nump">141,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,675)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,782,892)<span></span>
</td>
<td class="num">(4,407,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of held-to-maturity investment securities</a></td>
<td class="num">(47,615,550)<span></span>
</td>
<td class="num">(49,734,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from maturities of investment securities</a></td>
<td class="nump">55,323,000<span></span>
</td>
<td class="nump">53,063,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">7,707,450<span></span>
</td>
<td class="nump">3,328,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,304,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">550,188<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">550,188<span></span>
</td>
<td class="num">(2,299,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(37,516)<span></span>
</td>
<td class="num">(21,622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">2,437,230<span></span>
</td>
<td class="num">(3,400,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,386,314<span></span>
</td>
<td class="nump">5,786,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,823,544<span></span>
</td>
<td class="nump">2,386,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received from income tax refund</a></td>
<td class="nump">$ 506,866<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_IncreaseDecreaseinPrepaidResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_IncreaseDecreaseinPrepaidResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787389088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - (Benefit) Provision for Income Tax (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,001,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment', window );">Benefit from income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,001,233)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Including True Up Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858095136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 2,762,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">1,103,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">496,268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 4,362,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858119696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentTextBlock', window );">Purchase Commitments</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2019:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:83.190%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.810%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,762,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,103,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,362,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788760016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text">ConcentrationsThe Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div>The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheet.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div>Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investment</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company&#8217;s investments recorded under the equity method of accounting. </span></div>Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#8220;Topic 606&#8221;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input method, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development Costs Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transaction Gain or Loss</a></td>
<td class="text">Foreign Currency Transaction Gain or LossThe Company uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the </span></div>use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#8217;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014. The United States Internal Revenue Service (the &#8220;IRS&#8221;) has completed its review of the Company&#8217;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 for further discussion on the IRS examination of the 2016 tax return.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. </span></div>For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2019 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve (12) months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures, as the Company&#8217;s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div>In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787524928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Jupiter, Florida Headquarters</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June&#160;30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The Netherlands Office</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains a small satellite office in Wageningen, Netherlands. In 2018, the Company occupied approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expired on January&#160;31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the &#8220;New Lease&#8221;). The New Lease has a one year term with an auto renew period till January 31, 2021, and includes a flexible office space with annual rentals of approximately $4,000. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">VTT Research Contract Extension</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 28, 2019, the Company extended its research contract (&#8220;Contract&#8221;) through June 2022 with VTT Technical Research Centre of Finland Ltd. (&#8220;VTT&#8221;). Under the terms of this Contract, Dyadic will pay VTT a total of EUR &#8364;2.52 million over the next three years to continue developing Dyadic&#8217;s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR &#8364;450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR &#8364;690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days&#8217; notice.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Purchase Obligations</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2019:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:83.190%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.810%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,762,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,103,632&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,362,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The purchase obligations in the table above are primarily related to our contracts with the Company&#8217;s contract research organizations to provide certain research services. The contracts set forth the Company&#8217;s minimum purchase requirements that are subject to adjustments based on certain performance conditions. All contracts expire in 2022.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. </span></div>Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#8217;s consolidated financial position, cash flows or results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6864724864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at U.S. statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(4.61%)<span></span>
</td>
<td class="num">(4.25%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="num">(6.49%)<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">30.99%<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent', window );">True-up adjustment</a></td>
<td class="nump">0.18%<span></span>
</td>
<td class="num">(0.17%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign operations</a></td>
<td class="num">(0.07%)<span></span>
</td>
<td class="num">(0.28%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent', window );">AMT adjustment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(14.95%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Alternative Minimum Tax, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, True-Up Adjustment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6864459040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 07, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,860,390<span></span>
</td>
<td class="nump">3,552,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,925,662<span></span>
</td>
<td class="nump">$ 39,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Nonvested awards, compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,330<span></span>
</td>
<td class="nump">$ 162,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested awards, compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">2 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,171,079<span></span>
</td>
<td class="nump">$ 467,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Contractor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_A2006PlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_A2011PlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547,211<span></span>
</td>
<td class="nump">1,136,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Approved (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_A2011PlanMember', window );">2011 Plan | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_A2011PlanMember', window );">2011 Plan | Stock Option | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyai_A2011PlanMember', window );">2011 Plan | Stock Option | Contractor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_ContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_ContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyai_A2006PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyai_A2006PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyai_A2011PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyai_A2011PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779344112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March&#160;30, 2020, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our Research Contract with VTT</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the first quarter of 2020, we expanded our research contract with VTT Technical Research Centre of Finland Ltd. to pay an additional EUR &#8364;700,000 over the next 19 months to accelerate the glycoengineering work.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Grant</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to executives and key personnel an aggregate of 525,000 stock options with an exercise price of $5.27. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzM_c9472d93-1ce1-40be-b972-3b905785428b">one</span>-year anniversary or annually in equal installments over four years.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to the Board an aggregate of 325,000 stock options with an exercise price of $5.27. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc3OTA_d684f154-2502-42b6-b981-631a93c5af69">one</span>-year anniversary.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted to non-executive employees an aggregate of 23,000 stock options with an exercise price of $5.27. The options will vest annually in equal installments over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ2OTQ_7df95ba7-825f-4aa9-b588-d426d336e7e5">four</span> years.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2020, the Company granted 15,000 stock options to a consultant with an exercise price of $5.27. The options will vest upon <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MDA_a7899946-65d3-4626-88f3-03385835ab46">one</span>-year anniversary.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 23, 2020, the Company granted 25,000 stock options to a consultant with an exercise price of $3.99. The options will vest six months from the date of grant.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States. As of the date of issuance of the financial statements, the Company&#8217;s operations have not been significantly impacted, however, the Company continues to monitor the situation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858134672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) was enacted on December 22, 2017 and become effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (&#8220;AMT&#8221;). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of December&#160;31, 2019, we have received 50% or approximately $0.5 million refund for tax year 2018 and expect to receive the remaining 50% over tax years 2019 through 2021.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of loss before income taxes are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,274,712)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,622,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,947)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(75,218)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total loss before provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,297,659)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,697,913)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of our (benefit) provision for income tax for the years ended December&#160;31, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:67.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.918%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.833%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.921%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current and deferred tax (benefit) expense </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,001,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,001,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to deferred income tax resulting to permanent differences, state taxes and a change in the deferred tax valuation allowance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The reconciliation between the statutory tax rate and the Company&#8217;s actual effective tax rate is as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at U.S. statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.00)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.00)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.61)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.49)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">True-up adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.07)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in tax rates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMT adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.06&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.95)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock option expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">275,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NOL carryforward</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,214,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,668,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,656,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,656,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset, net of deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,150,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,578,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,150,100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,578,400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on management&#8217;s evaluation, the net deferred tax asset was offset by a full valuation allowance as of December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards available in 2019 that will begin to expire in 2037. As of December&#160;31, 2019, and 2018, the Company had NOLs in the amount of approximately $19.7&#160;million and $9.1&#160;million, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company received a letter from the IRS informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and subsequently provided the IRS with all requested information under several Information Document Requests (IDRs). Thus far, the Company has not been informed of any issue. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indian Tax Deducted/Collected at Source</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income generated in India is subject to Tax Deducted at Source (&#8221;TDS&#8221;), which is a means of collecting income tax at the source when income is generated rather than a later date by the Indian government. The TDS amount paid can be used as foreign tax credit for US tax purposes. However, we do not expect to use the credit due to our loss from operation. As a result, </span></div>the Company recorded a provision for income taxes of approximately $10,000 as a result of TDS for the year ended December 31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>346</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Cash, Cash Equivalent, and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CashCashEquivalentandInvestments</Role>
      <ShortName>Cash, Cash Equivalent, and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ResearchandCollaborationAgreements</Role>
      <ShortName>Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2133107 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalent, and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/CashCashEquivalentandInvestments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/IncomeTaxes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/CommitmentsandContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/ShareBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/ShareholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalent, and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails</Role>
      <ShortName>Research Collaboration and Sub-licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Income Taxes - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesTextualDetails</Role>
      <ShortName>Income Taxes - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Income Taxes - (Benefit) Provision for Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails</Role>
      <ShortName>Income Taxes - (Benefit) Provision for Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/IncomeTaxesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Income Taxes - Reconciliation Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Income Taxes - Deferred Income Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred Income Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Commitments and Contingencies - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails</Role>
      <ShortName>Commitments and Contingencies - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Commitments and Contingencies - Purchase Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Share-Based Compensation - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationTextualDetails</Role>
      <ShortName>Share-Based Compensation - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Share-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2431419 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432420 - Disclosure - Share-Based Compensation - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Shareholders' Equity - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareholdersEquityTextualDetails</Role>
      <ShortName>Shareholders' Equity - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Shareholders' Equity - Stock Repurchase (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails</Role>
      <ShortName>Shareholders' Equity - Stock Repurchase (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dyai-20191231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyadic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dyadic.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="dyai-20191231.htm">dyai-20191231.htm</File>
    <File>dyai-20191231.xsd</File>
    <File>dyai-20191231_cal.xml</File>
    <File>dyai-20191231_def.xml</File>
    <File>dyai-20191231_lab.xml</File>
    <File>dyai-20191231_pre.xml</File>
    <File>exhibit1011jupiterlease2.htm</File>
    <File>exhibit311cert-mark10x.htm</File>
    <File>exhibit312cert-ping10x.htm</File>
    <File>exhibit321sect1350cert.htm</File>
    <File>exhibit322sect1350cert.htm</File>
    <File>exhibit42descriptionof.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dyai-20191231_g1.jpg</File>
    <File>dyai-20191231_g2.jpg</File>
    <File>dyai-20191231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858137360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of loss before income taxes are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,274,712)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,622,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,947)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(75,218)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total loss before provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,297,659)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,697,913)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components Of Income Tax (benefit)</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of our (benefit) provision for income tax for the years ended December&#160;31, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"/><td style="width:67.128%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.918%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.833%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.921%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current and deferred tax (benefit) expense </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,001,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,001,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">The reconciliation between the statutory tax rate and the Company&#8217;s actual effective tax rate is as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax at U.S. statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.00)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.00)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes, net of federal benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.61)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-deductible items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.49)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">True-up adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.07)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in tax rates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMT adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.06&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.95)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The significant components of the Company&#8217;s net deferred income tax assets are as follows:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.354%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.811%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock option expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">275,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NOL carryforward</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,214,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,668,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,656,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,656,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset, net of deferred tax liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,150,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,578,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,150,100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,578,400)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786458816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Stock Repurchase (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2017</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 16, 2017</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Total Number of Shares Purchased (in shares)</a></td>
<td class="nump">2,363,590<span></span>
</td>
<td class="nump">2,136,752<span></span>
</td>
<td class="nump">7,863,980<span></span>
</td>
<td class="nump">381,607<span></span>
</td>
<td class="nump">1,644,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,390,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average Price Paid per Share (in usd per share)</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Amount</a></td>
<td class="nump">$ 3,639,929<span></span>
</td>
<td class="nump">$ 2,884,615<span></span>
</td>
<td class="nump">$ 12,448,283<span></span>
</td>
<td class="nump">$ 537,661<span></span>
</td>
<td class="nump">$ 2,304,042<span></span>
</td>
<td class="nump">$ 2,304,042<span></span>
</td>
<td class="nump">$ 21,814,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,551,717<span></span>
</td>
<td class="nump">$ 4,462,339<span></span>
</td>
<td class="nump">$ 2,158,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dyai_PubliclyAnnouncedRepurchasePlansMember', window );">Publicly Announced Repurchase Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Total Number of Shares Purchased (in shares)</a></td>
<td class="nump">2,363,590<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,863,980<span></span>
</td>
<td class="nump">381,607<span></span>
</td>
<td class="nump">1,644,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dyai_PubliclyAnnouncedRepurchasePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dyai_PubliclyAnnouncedRepurchasePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6859810848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,612,659<span></span>
</td>
<td class="nump">38,966,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,359,157<span></span>
</td>
<td class="nump">26,713,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">12,253,502<span></span>
</td>
<td class="nump">12,253,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779333776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;,or the &#8220;Company&#8221;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and currently two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Thermothelomyces heterothallica </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(formerly </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Myceliophthora thermophila</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#8220;DuPont&#8221;), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the &#8220;DuPont Transaction&#8221;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#8217;s NASDAQ Capital Market, under the symbol &#8220;DYAI&#8221;. Prior to the Company&#8217;s uplisting to the NASDAQ, the Company&#8217;s common stock traded on the OTCQX market.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#8220;FDIC&#8221;) and the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the Company&#8217;s revenue was generated from ten and six customers, respectively. At December&#160;31, 2019 and 2018, the Company&#8217;s account receivable was from five and four customers, respectively. The loss of business from one or a combination of the Company&#8217;s customers could adversely affect its operations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. As of and for the year ended December&#160;31, 2019, the Company had four customers outside of the United Sates (i.e. European and Indian customers) that accounted for approximately 71.5% or $1,202,000 of total revenue and approximately 69.5% or $388,000 of accounts receivable. As of and for the year ended December&#160;31, 2018, the Company only had one customer outside of the United States (i.e., European customer) that accounted for approximately 21.7% or $281,000 of total revenue and 100% of the Company&#8217;s accounts receivable was from the United States. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses a few contract research organizations (&#8220;CROs&#8221;) to conduct its research projects. For the years ended December&#160;31, 2019 and 2018, one CRO accounted for approximately 86.6% and 88.4% of total research services we purchased, respectively. At December&#160;31, 2019, approximately $706,000 or 74.9% of accounts payable was related to this CRO. At December&#160;31, 2018, approximately $237,000 or 76.8% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company&#8217;s CROs could adversely affect its operations. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investment Securities</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#8217;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheet. As of December&#160;31, 2019 and 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of December&#160;31, 2019 and 2018.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of December&#160;31, 2019 and 2018.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">432,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,984&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">558,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">318,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Equity Method Investment</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company&#8217;s investments recorded under the equity method of accounting. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Payable</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">399,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to research collaborations and agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#8220;Topic 606&#8221;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the input method, revenue will be recognized on the basis of the entity&#8217;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue related to sublicensing agreements: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the sublicense to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone payments: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#8217;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalties: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to licenses deemed to be the predominant item to which the</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Costs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs are related to the Company&#8217;s internally funded pharmaceutical programs and other governmental and commercial projects. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the years ended December&#160;31, 2019 and 2018 were as follows: </span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,578,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,637,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">868,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,215,536&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">376,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,956,317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,317,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transaction Gain or Loss</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#8217;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#8220;Income Taxes&#8221;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#8217;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining taxable income for the Company&#8217;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#8217;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#8220;unrecognized benefits.&#8221; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#8217;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014. The United States Internal Revenue Service (the &#8220;IRS&#8221;) has completed its review of the Company&#8217;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 for further discussion on the IRS examination of the 2016 tax return.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Income (Loss)</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#8217; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees and our Board of Directors (the &#8220;Board&#8221;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the years ended December&#160;31, 2019 and 2018, the effect of the potential exercise of options to purchase 3,860,390 and 3,552,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2019 </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve (12) months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures, as the Company&#8217;s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div>In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789352256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">$ 474,388<span></span>
</td>
<td class="nump">$ 268,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_AccruedResearchandDevelopmentinProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">69,795<span></span>
</td>
<td class="nump">49,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">21,820<span></span>
</td>
<td class="nump">81,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 566,003<span></span>
</td>
<td class="nump">$ 399,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_AccruedResearchandDevelopmentinProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development in Process, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_AccruedResearchandDevelopmentinProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6872212864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment </div>
<div>customer </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>customer </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract', window );">Number of research organization performing service under contract | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,681,076<span></span>
</td>
<td class="nump">$ 1,295,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,860,390<span></span>
</td>
<td class="nump">3,552,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberofCustomers', window );">Concentration risk, number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberofCustomers', window );">Concentration risk, number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside of United States | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ConcentrationRiskNumberofCustomers', window );">Concentration risk, number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside of United States | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.50%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside of United States | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 388,000<span></span>
</td>
<td class="nump">$ 388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_DuPontDaniscoMember', window );">DuPont Danisco | Industrial Technology Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sales of business</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_ContractResearchOrganizationsMember', window );">Contract Research Organizations (CRO) | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.60%<span></span>
</td>
<td class="nump">88.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_ContractResearchOrganizationsMember', window );">Contract Research Organizations (CRO) | Customer Concentration Risk | Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.90%<span></span>
</td>
<td class="nump">76.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 706,000<span></span>
</td>
<td class="nump">$ 706,000<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ConcentrationRiskNumberofCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ConcentrationRiskNumberofCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_NumberOfResearchOrganizationPerformingServiceUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Research Organization Performing Service Under Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_NumberOfResearchOrganizationPerformingServiceUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_DuPontDaniscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_DuPontDaniscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_IndustrialTechnologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_IndustrialTechnologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_ContractResearchOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_ContractResearchOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787499072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billed receivable </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">432,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,984&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">558,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">318,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses - various</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,249&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">766,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">240,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,996&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee wages and benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">474,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,666&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,003&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">399,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock', window );">Schedule of Research and Development Costs</a></td>
<td class="text">Research and development costs, including related party, during the years ended December&#160;31, 2019 and 2018 were as follows: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:63.835%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.571%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outside contracted services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,578,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,637,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contracted services - related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">868,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,215,536&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel related costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">376,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, overhead and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,956,317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,317,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Research and Development Costs [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858058512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Equity Plans</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) was adopted by the Board on April 28, 2011 and approved by the Company&#8217;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#8217;s 2006 Stock Option Plan (the &#8220;2006 Plan&#8221;). Since the effective date of the 2011 Plan, all future equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company&#8217;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provision of the 2011 Plan, the Board approved an increase of 1,500,000 shares each year to the plan on January 1, 2019 and 2020. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the Company had 3,860,390 stock options outstanding and an additional 1,547,211 shares of common stock available for grant under the 2011 Plan. As of December&#160;31, 2018, there were 3,552,890 stock options outstanding and 1,136,211 shares of common stock available for grant under the 2011 Plan.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options are granted to purchase common stock at prices that are equal to the fair value of the common shares on the date the option is granted. Vesting is determined by the Board at the time of grant. The term of any stock option awards under the Company&#8217;s 2011 Plan is no more than 10 years except for qualified options granted to the CEO (five years) and certain contractors (two years).</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend yield</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected stock price volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected stock price volatility was calculated based on the Company&#8217;s own volatility since the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#8217;s historical volatilities since 2016, as the DuPont Transaction resulted in significant changes in the Company&#8217;s business and capital structure.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected life of option. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 years) and certain contractors (i.e., 2 years). </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for lack of marketability.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company applies a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company&#8217;s common stock. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used in the Black-Scholes option pricing model for stock options granted for the year ended December&#160;31, 2019 are as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:54.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.522%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.971%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.69% - 2.50%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.24% - 2.96%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28.59% - 37.29%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">27.80% - 30.36%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2 - 6.25 Years </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 - 6.25 years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount for lack of marketability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0 - 8.48%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">9.35%</span></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the combined stock option activity under the Company&#8217;s Equity Compensation Plans:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,712,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.62</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.09</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$69,090</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(250,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,552,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.57</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1,149,461</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,089,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(781,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,860,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.76</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.69</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,287,932</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,747,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.65</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9,712,729</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Represents the following stock options granted:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b)300,000 stock options with an exercise price of $1.87 per share granted to the Board, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. </span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Represents the following stock options exercised:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">A total of 781,500 stock options exercised with a weighted average market price of $1.60, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b) 341,500 stock options exercised with cash payment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average grant-date fair market value of stock options granted for the years ended December&#160;31, 2019 and 2018 was $0.69 and $0.41 respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended December&#160;31, 2019 and 2018 was $2,925,662 and $39,360, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, total unrecognized compensation cost related to non-vested stock options granted under the Company&#8217;s share option plan was $222,330, and $162,786, respectively, which is expected to be recognized over a weighted average period of 1.83 years and 2.39 years, respectively. The Company will adjust unrecognized compensation cost for actual forfeitures as they occur.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Expenses</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company&#8217;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. For the year ended December&#160;31, 2019, the Company recognized the expense related to the performance-based awards granted prior years upon the Company&#8217;s April 2019 uplisting to the NASDAQ of approximately $483,000.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.648%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.810%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,069,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">390,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,171,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6658470768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. operations</a></td>
<td class="num">$ (8,274,712)<span></span>
</td>
<td class="num">$ (6,622,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign operations</a></td>
<td class="num">(22,947)<span></span>
</td>
<td class="num">(75,218)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">$ (8,297,659)<span></span>
</td>
<td class="num">$ (6,697,913)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6865188864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Textual (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 25, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dyai_VTTTechnicalResearchCentreofFinlandLtdMember', window );">VTT Technical Research Centre of Finland Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentToPay', window );">Commitment to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentDevelopmentPeriod', window );">Commitment development period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentSuccessBonusAward', window );">Commitment success bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentToPayExpanded', window );">Commitment to pay, expanded</a></td>
<td class="nump">&#8364; 690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentToPayExpandedPeriod', window );">Commitment to pay, expanded, period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CommitmentsRightToTerminateContractNoticePeriod', window );">Commitments, right to terminate contract notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_LeaseTypeAxis=dyai_JupiterFloridaHeadquartersLeaseMember', window );">Jupiter, Florida Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of building rented | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_OperatingLeasesMonthlyRentalRate', window );">Monthly rental rate | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_LeaseTypeAxis=dyai_NetherlandsOfficeLeaseMember', window );">Netherlands Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of building rented | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_OperatingLeasesAnnualRentalRate', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentDevelopmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment Development Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentDevelopmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentSuccessBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment Success Bonus Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentSuccessBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment To Pay</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentToPayExpanded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment To Pay, Expanded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentToPayExpanded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentToPayExpandedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment To Pay, Expanded, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentToPayExpandedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CommitmentsRightToTerminateContractNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments, Right To Terminate Contract Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CommitmentsRightToTerminateContractNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLeasesAnnualRentalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Annual Rental Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLeasesAnnualRentalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_OperatingLeasesMonthlyRentalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Monthly Rental Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_OperatingLeasesMonthlyRentalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_VTTTechnicalResearchCentreofFinlandLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_VTTTechnicalResearchCentreofFinlandLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LeaseTypeAxis=dyai_JupiterFloridaHeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LeaseTypeAxis=dyai_JupiterFloridaHeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_LeaseTypeAxis=dyai_NetherlandsOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_LeaseTypeAxis=dyai_NetherlandsOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871619232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning (in shares)</a></td>
<td class="nump">3,552,890<span></span>
</td>
<td class="nump">2,712,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,089,000<span></span>
</td>
<td class="nump">1,120,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(781,500)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending (in shares)</a></td>
<td class="nump">3,860,390<span></span>
</td>
<td class="nump">3,552,890<span></span>
</td>
<td class="nump">2,712,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, beginning (USD per share)</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share)</a></td>
<td class="nump">2.26<span></span>
</td>
<td class="nump">1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in USD per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired (USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, canceled (USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, ending (USD per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,747,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (USD per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, outstanding (Years)</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, exercisable (Years)</a></td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 13,287,932<span></span>
</td>
<td class="nump">$ 1,149,461<span></span>
</td>
<td class="nump">$ 69,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 9,712,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>dyai-20191231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:dyai="http://www.dyadic.com/20191231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dyai-20191231.xsd" xlink:type="simple"/>
    <context id="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8cd6541c2fd4adca3eeb4ed8924a2ca_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i97c30979e4144b5c936703e3411b72bd_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="idcb179b7b3654ae5a927e4f22b10ba19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44b49ea3f208487698c65394dc8f911a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ae10429d4274acc9056aa942fe63b3d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3b4de0689e804b61b0bd848a5639b725_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic5e158a241d64af0ad4e2292194137b8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic3b2621c2b374e3f8ec9d1de2ab3fc52_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i03982adf61bb47ecbd79d2ecd04079fa_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i16e3dd249fbe405fbe111f88491fcb2e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88159e705b6a4615876d7c6373a3230c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iecbd8cb44d614d22957374499806e91c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i65ba3c275bba44c591c298eb6a627117_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5edff09f5d5488092a0f305677b0c0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08882e216601446183c1dc051db938c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12769ae146f64d729004412e0968967d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8345599e828744799c4f0e1e745684b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c8e876d3f1e4b23851e168d3e26723c_D20151231-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:DuPontDaniscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dyai:IndustrialTechnologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-31</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i5de8574c1d5e40d3b0ee4417bbf0e3d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i33feba3cff3d453ab0847ab48f7a65a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4937506a337c49d99f6df9684958c7bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7acc47f3ac6c42bfafac0b07049ab969_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i539512523cd84b16a4f3e7301273b71d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i853d7cb039e94bbc88573c26b6d2967e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9853caf57ff412fbe8e87c65c083f8a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac1ccd95b9f9482f99ac9a39b030913d_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5d4c32edf3a47d5ace56c907b84788c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icc3379be565248d6aae983a9754e0b90_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c18e0290e174928ae53f25f7ad4d742_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i794a21883a2f49e885e5e5758820ee30_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i716bbd9d30fd4e1fb46f0dee71737323_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i199ba6975f9b4d35a19f028f6e3ba9d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46c48aca2c334edbae2d056c94cf1c1f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8bdff80401db4bfd883cc689a5f6c3ca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:ContractResearchOrganizationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i948cb60e266243f196d1d44762dba391_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia68ec379e62f42fd82d9df05be6cc9e3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie20de3bbc09b47a58d79e76de605acff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i003f72c2db6a4420aae1b41052590348_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaca615a626c84646a9e3cd9ee505f251_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9923848bb21f4a459e82cf269761b053_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iecd519b1fc8643db943ce2a10915099e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic730d04e8b0b4df4a4a422154c714345_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i530ce590a54f4e1294cb6cb83802e421_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ia1d98d4756224c909d6e5d6c8a30310a_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i7e634d7aaec046188c2ed66d34824a19_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i4169bf7db9fb46a59c822fcd3015e062_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:VLPbioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i2447768dc81342fbbc93c99cf36d4175_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="ic4223a15c84f40d98227848c11916461_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ifa774688910149949c16b496a421bb9a_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i5b5457c0415a45cb96e692134cbf8975_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i7c228ac1d4cd4e89b60866a524343d7d_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i840867cee002461092e9bb1d28ebe22d_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dyai:BDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i79c8a3fd19f84be7bcf4484ebc536193_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="ia10445b9bcd248c392f6a26e44521761_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i355318ed17ba4b0ba24061da681d9010_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dyai:ServiceFrameworkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i491f41e970764c248af615c0fd65548e_I20190426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:NovovetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-26</instant>
        </period>
    </context>
    <context id="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-05</instant>
        </period>
    </context>
    <context id="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dyai:AlphazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-05</startDate>
            <endDate>2019-05-05</endDate>
        </period>
    </context>
    <context id="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="if8a37c03b9a24f5f805e876d96fb8eca_D20190507-20190507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="id144ebaa808a4539bac88f64f1ae1856_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:SerumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46135fb3b51c476a969413b90769ef8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfFinanceIndiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i067425fd93584c7f8114ab5e1571995d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:JupiterFloridaHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8211dee89c274d37bf293694b115ff85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:JupiterFloridaHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61fc32e45fcc49988560c5d708fe090a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia67696ba89b140ea84bb3079e5ab8ed6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i86a13c798877437492fa7b0a4354cb9c_I20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-01</instant>
        </period>
    </context>
    <context id="id91f496dcbb044758f163cbd859eb73a_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dyai:LeaseTypeAxis">dyai:NetherlandsOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i1ce85b8cbbff401ab8f9208885798348_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-28</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="i5359f3a055db4f1886c3bd132f79cdb1_I20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="ia22c697beb7d4b0ab318ca61134fe993_D20191025-20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dyai:VTTTechnicalResearchCentreofFinlandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-25</startDate>
            <endDate>2019-10-25</endDate>
        </period>
    </context>
    <context id="ie8f1835196484e3c945b149529822d3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2006PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28c9d6b0788b439c9ff3572a031dea3d_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="i87754620edec4143a42a41e6727c2af7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia095586e60d44997a6ddefe3f667eb8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyai:A2011PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2cf44cd91f594d6e9d9f2be57dbefa3d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic164a2b8759541bd92fd673e0a617119_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9911246a988f4400b2298393e4a8d174_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if917f69cb62f4aeab421b5233da141a9_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i1003cf64787c47bfa079db8551f27546_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyai:SharebasedCompensationAwardTrancheTwothroughFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ia4ff0366c2954e079f8bfbc42ddd2255_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i00400d75393341c0b8c51dd7dcaf9263_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ia68b902c3b614063bf94fc0cb7873a7b_I20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="idc984c2633c84830a7590e6783b2de69_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i502f339e9a564d2fa057ffd43b430345_I20190307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-07</instant>
        </period>
    </context>
    <context id="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ContractorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-07</startDate>
            <endDate>2019-03-07</endDate>
        </period>
    </context>
    <context id="i5361038870ba43a3836b3611390751a9_I20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-25</startDate>
            <endDate>2019-06-25</endDate>
        </period>
    </context>
    <context id="i3180a4adc61148acb883d0951ed14fe7_I20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="i263ac90ac6ab451aac269f8d91a7bb57_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i1ae81b32c80540568b0ddbf678fb73fb_D20190628-20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-28</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="i4e4e110274cd42e68c73b41957abca9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3fb877e64e5f4588b05eb59d2f1f303e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27724349c48a4973856d9b6cbe4f786e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib3065e8cc19c4622bc9018bea3d70c6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd3b28bef31b45d58d39978ccbae35a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if27f58e0337f49bb8ec1e7259b6b9d13_D20160216-20160216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2016-02-16</startDate>
            <endDate>2016-02-16</endDate>
        </period>
    </context>
    <context id="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2016-02-16</instant>
        </period>
    </context>
    <context id="i9a925883745043b79550f0b480045c4d_D20170816-20170816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-08-16</startDate>
            <endDate>2017-08-16</endDate>
        </period>
    </context>
    <context id="i7591c510da7a48b593cb45d1dddbb122_I20170816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2017-08-16</instant>
        </period>
    </context>
    <context id="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2016-01-12</startDate>
            <endDate>2016-01-12</endDate>
        </period>
    </context>
    <context id="i25427c3bdaeb4b98b458ea7b34deb418_D20160112-20160112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-12</startDate>
            <endDate>2016-01-12</endDate>
        </period>
    </context>
    <context id="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-01-11</startDate>
            <endDate>2017-01-11</endDate>
        </period>
    </context>
    <context id="icfcfcf474ee74ca297efc69b74652e7b_D20170111-20170111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-11</startDate>
            <endDate>2017-01-11</endDate>
        </period>
    </context>
    <context id="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i9b266eccec9447ddb9c6431bd35cf1b3_D20170101-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="ifc2601b2f77c479581fa9cf5d4cff3fd_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0cb224dd3f604e299d6ab6df8bc4eba6_D20170901-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i4c5bfc1c71754fd5b496a1784ee4c239_D20180101-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ied7940d17259403f80d1b1604a7b10e3_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="ib559063465144b6cb9251448720e1f2c_D20160101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4f46b6e69ca64edd9b8fed76219f38f9_D20160101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dyai:PubliclyAnnouncedRepurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="ia0bcf71b74b44c64a5fefb97fc5d4f58_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i43b5030b61534a9995f73c86b9ce994a_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ExecutivesandKeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i5cbfdfcf598049ba91e61b13c391bc2d_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i9b18c77ea83b43abad5be0ac6b14adb2_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:NonexecutiveEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i9c008cca145a43649702102a7b393308_D20200102-20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-23</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <context id="i013a834cf3654f739dbd6679b50f16e6_D20200323-20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dyai:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-23</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dyai:segment</measure>
    </unit>
    <unit id="customer">
        <measure>dyai:customer</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="antibody_and_vaccine">
        <measure>dyai:antibody_and_vaccine</measure>
    </unit>
    <unit id="protein">
        <measure>dyai:protein</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="board_of_director">
        <measure>dyai:board_of_director</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV8yLTEtMS0xLTA_ba53f6d8-cd26-4785-a704-951913e56a8c">0001213809</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV83LTEtMS0xLTA_0023a8a1-7d05-4717-81d3-481f98eb64c6">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV84LTEtMS0xLTA_81c565b9-374f-4a31-9e07-66503cbb4d1d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGFibGU6ODhlNjczNGEzZTAwNDI2MDk2YjY5MDc2MDQ0MjU4NTUvdGFibGVyYW5nZTo4OGU2NzM0YTNlMDA0MjYwOTZiNjkwNzYwNDQyNTg1NV85LTEtMS0xLTA_502157b9-48ff-4d14-97b0-dc9e4899fa68">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF80L2ZyYWc6MzgyYzAyOTY0ODFkNGMxY2FlZTRlYzUyMDk5NzgzNTQvdGV4dHJlZ2lvbjozODJjMDI5NjQ4MWQ0YzFjYWVlNGVjNTIwOTk3ODM1NF83Njk2NTgxMzk0NDg5_698f3f57-f491-46cc-8b1f-d12e473a9c3a">--12-31</dei:CurrentFiscalYearEndDate>
    <dyai:CollaborativeArrangementDurationOfAgreement
      contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTEyODE_d817c484-c349-4120-9e27-b9d41a8a4fa5">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="if27f58e0337f49bb8ec1e7259b6b9d13_D20160216-20160216"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzOTk_fe3a9107-bbfc-41d2-8697-3542846d9e85">P1Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i9a925883745043b79550f0b480045c4d_D20170816-20170816"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU0MDc_b5a00c4c-c973-45db-864c-25377b84925f">P1Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia0bcf71b74b44c64a5fefb97fc5d4f58_D20200102-20200102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzM_c9472d93-1ce1-40be-b972-3b905785428b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5cbfdfcf598049ba91e61b13c391bc2d_D20200102-20200102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc3OTA_d684f154-2502-42b6-b981-631a93c5af69">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9b18c77ea83b43abad5be0ac6b14adb2_D20200102-20200102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ2OTQ_7df95ba7-825f-4aa9-b588-d426d336e7e5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c008cca145a43649702102a7b393308_D20200102-20200102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MDA_a7899946-65d3-4626-88f3-03385835ab46">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Njgz_15616296-6d68-47ae-bc11-629ee7f61cf0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8wLTAtMS0xLTM3MjA_125807e4-f69c-4302-80c7-4ad4d2521bd9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8xLTEtMS0xLTE5L3RleHRyZWdpb246NzE2NTg4NjI4MGJkNGUzZjk3ZDE3ZDk3NTQwMjE1MWZfNzY5NjU4MTM5NDUwMg_a43c43f0-58f3-4fed-a5b6-98653788dfe4">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEzNTc3MWNiYzk0NDg0NGEzMTYwNzI2MjdjZDViNTAvdGFibGVyYW5nZTo3MTM1NzcxY2JjOTQ0ODQ0YTMxNjA3MjYyN2NkNWI1MF8zLTAtMS0xLTM3MjM_9c1062f7-7e57-4b55-a4c5-2e401e60e0e8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Njg5_7bec7009-667b-41af-adfc-ad6562f1c681">000-55264</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzAw_50c96881-d104-484e-ba4e-2e9137b3f101">DYADIC INTERNATIONAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6MzcyZDE3NGRiODNiNDEwNWExZWExNTZjZDAxNjQwY2EvdGFibGVyYW5nZTozNzJkMTc0ZGI4M2I0MTA1YTFlYTE1NmNkMDE2NDBjYV8wLTAtMS0xLTM3Mzc_7458c678-c2d2-4f92-9615-7236ce10b588">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6MzcyZDE3NGRiODNiNDEwNWExZWExNTZjZDAxNjQwY2EvdGFibGVyYW5nZTozNzJkMTc0ZGI4M2I0MTA1YTFlYTE1NmNkMDE2NDBjYV8wLTItMS0xLTM3Mzc_88ff240f-c669-4602-9c46-c67112da4e17">45-0486747</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzI4_f4fab619-772a-4365-89cf-a7dd16c60eb9">140 Intracoastal Pointe Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2NzU5_9285358e-3852-427d-a51d-6e2379c005e6">Suite 404</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzcw_e6b10744-8e21-406c-8baa-6827fa58951c">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzc5_8a7c88e8-aea3-44bb-80ca-c02c2a83aab2">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzg4_9b06a7e2-7137-4e0a-a0bc-ebe905dd3e98">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2Nzk1_a1c13d4a-f8fb-4bc9-bead-469a98f09cd8">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2ODAw_8e37b3e6-d3d2-4774-b4a1-c6bbfd5435f8">743-8333</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTAtMS0xLTM3NzY_754ef2ba-b6ca-410f-b633-e4d6a4f35f32">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTEtMS0xLTM3NzY_7ffff225-ea08-4be4-8d21-1d5686c289fd">DYAI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NjY0MzQwN2ExOTUyNGY0OTk5YTYxYjU4NzFlYzU3MGIvdGFibGVyYW5nZTo2NjQzNDA3YTE5NTI0ZjQ5OTlhNjFiNTg3MWVjNTcwYl8xLTItMS0xLTM3NzY_202937cc-12f1-4723-a1c0-1913bf18a44e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTQ5_4d145a8d-59a0-4c14-8aef-2856e85d7ccc">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTUz_fbffc8ca-5c18-40e6-8a22-48ba3151559e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTU3_d7d325cb-371b-412d-8ce3-2431806c1ae7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc2OTYy_34a73433-a225-4717-995d-5bd784c68fc1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8xLTAtMS0xLTYzL3RleHRyZWdpb246NmQwMjVkYTZiZjVkNGI4Mjk5ZjZlMDNkMmE5ZjNhMzJfNjU5NzA2OTc2NjcxOA_5a784722-3d07-4994-a93c-f9be2587e52f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8xLTQtMS0xLTYzL3RleHRyZWdpb246Y2ExZjMzNzdlZGJlNDAxYmE4OWYzNTc1MGEwNWFjZWVfNjU5NzA2OTc2Njc0Nw_a5ea4bdb-0b62-47e9-a3d1-176f719f9b24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGFibGU6NzEwYWMzOWM1ZDhmNDA0ZmE1YzI3ZTk2OWJjYjg3MjAvdGFibGVyYW5nZTo3MTBhYzM5YzVkOGY0MDRmYTVjMjdlOTY5YmNiODcyMF8yLTQtMS0xLTYzL3RleHRyZWdpb246Y2U4OWU2YjdhM2E1NGI2Y2JiZTQzYjQ3MmU5MGVlN2VfNjU5NzA2OTc2Njc0Mg_6bcf6db9-280d-4d21-8750-7af66bac0a4c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF82NTk3MDY5Nzc3NjAy_69c2741d-41e1-4215-8c3f-639abf600e1a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie8cd6541c2fd4adca3eeb4ed8924a2ca_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF8xNjQ5MjY3NDUxOTg1_e04b7486-e988-4f19-af70-fed83ed99b2a"
      unitRef="usd">169700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i97c30979e4144b5c936703e3411b72bd_I20200329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xL2ZyYWc6ZDkzMDU2MjYwYWFmNDkzZWFmODI1NGE1N2FmYmE0MTgvdGV4dHJlZ2lvbjpkOTMwNTYyNjBhYWY0OTNlYWY4MjU0YTU3YWZiYTQxOF8zODQ4MjkwNzA2OTI0_fd4825e0-b321-48e9-ae2b-f2374a30a863"
      unitRef="shares">27359157</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzQtMS0xLTEtMA_16e18d15-38c8-45f6-a9ca-a4438e2b960f"
      unitRef="usd">4823544</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzQtMy0xLTEtMA_7c2d1e58-f274-4ccc-b2a4-a747949576c4"
      unitRef="usd">2386314</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzUtMS0xLTEtMA_8fd1f701-95be-48eb-9d93-de3aab0cc015"
      unitRef="usd">29399146</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzUtMy0xLTEtMA_7a11f9d6-5e56-4313-8187-7dd81049cfee"
      unitRef="usd">38816441</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzYtMS0xLTEtMA_30e0694e-698e-426d-9446-4f959a3384c6"
      unitRef="usd">329711</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzYtMy0xLTEtMA_301aea38-96d1-47e4-8df3-da7a4ebc95f1"
      unitRef="usd">294240</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzctMS0xLTEtMA_80da95d8-376e-4e62-8f8c-d1fc1bc28e23"
      unitRef="usd">558530</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzctMy0xLTEtMA_2bfe8fce-b436-48d9-bc09-4b1ee87761c3"
      unitRef="usd">318744</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzgtMS0xLTEtMA_5b932739-71cc-401d-ad72-46d0d7aeaf16"
      unitRef="usd">250308</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzgtMy0xLTEtMA_00857ee2-49d7-4220-bf65-a145b64c5877"
      unitRef="usd">506866</us-gaap:IncomeTaxesReceivable>
    <dyai:PrepaidResearchandDevelopmentinProcessCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzktMS0xLTEtMA_b9d04f44-5a63-4ec2-b0a4-c5401a3d8d38"
      unitRef="usd">0</dyai:PrepaidResearchandDevelopmentinProcessCurrent>
    <dyai:PrepaidResearchandDevelopmentinProcessCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzktMy0xLTEtMA_70eeafdb-86fe-4c69-9500-279ebb40627c"
      unitRef="usd">253446</dyai:PrepaidResearchandDevelopmentinProcessCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzEwLTEtMS0xLTA_4017e5d1-0e27-46db-8cba-8c6a551752d8"
      unitRef="usd">277999</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzEwLTMtMS0xLTA_08244556-ba35-467d-9097-502e72784b3c"
      unitRef="usd">172001</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzExLTEtMS0xLTA_272d54b8-2e7a-45b6-a684-89b73c1c413c"
      unitRef="usd">35639238</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzExLTMtMS0xLTA_a6f6b4e4-3fc2-4ceb-a22e-a7a841841bc4"
      unitRef="usd">42748052</us-gaap:AssetsCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE0LTEtMS0xLTA_18b57ad5-f6c0-473e-8508-7e76fb56a43c"
      unitRef="usd">1511636</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE0LTMtMS0xLTA_9fcaab18-c5d6-4cfb-bea9-dfeb8a6983c1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE1LTEtMS0xLTA_affb28e6-fb54-4ed4-98a5-f129b8db0a2b"
      unitRef="usd">250308</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE1LTMtMS0xLTA_1a3f00b8-7d4d-45d2-af32-c61868edb4bf"
      unitRef="usd">500616</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE3LTEtMS0xLTA_cb577d6b-29b0-4faf-984a-e250a4cc7b07"
      unitRef="usd">51314</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE3LTMtMS0xLTA_f763ad68-489a-41f9-8016-80cbb79b1341"
      unitRef="usd">52139</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE4LTEtMS0xLTA_853a2301-c0f8-4eb2-be8f-9f3a75592d2c"
      unitRef="usd">37452496</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzE4LTMtMS0xLTA_b680d7b9-de74-4c3b-bb58-ee8ce979c25a"
      unitRef="usd">43300807</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIyLTEtMS0xLTA_85cab857-83c2-474e-b548-3c9b0ff04b59"
      unitRef="usd">943378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIyLTMtMS0xLTA_79107053-050f-4683-b115-7079fc6d6d61"
      unitRef="usd">309060</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIzLTEtMS0xLTA_fc2e383b-9bdb-45c3-aab0-6b18a72e5ded"
      unitRef="usd">566003</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzIzLTMtMS0xLTA_ddc6dab9-34a3-403e-85f6-f5ff18dd1c53"
      unitRef="usd">399576</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI0LTEtMS0xLTA_37230636-f37c-4434-a5c7-a23401171dab"
      unitRef="usd">78644</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI0LTMtMS0xLTA_0808c2b3-ae49-47e6-9cf2-cf5e1501f0d7"
      unitRef="usd">141002</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI2LTEtMS0xLTA_0191ce85-4572-4bce-8445-857110f9068c"
      unitRef="usd">1588025</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI2LTMtMS0xLTA_f53e8461-4b1d-497d-952d-db331db1f8fe"
      unitRef="usd">849638</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI4LTEtMS0xLTA_d79ce8c5-90b7-403f-85a0-fdf2170e4889"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzI4LTMtMS0xLTA_034a257d-28b2-42cc-b2b9-6c4d3eb69eca"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGFmZjIxY2RmNDY0NWQyOTZkMDM0M2M3YzJhNzMzZl82NTk3MDY5NzY2Njk5_b0e78c5e-65e1-428d-9fff-1290fda78853"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjpkOGFmZjIxY2RmNDY0NWQyOTZkMDM0M2M3YzJhNzMzZl82NTk3MDY5NzY2Njk5_d2c68de7-cadc-4f27-b126-1cb58093e80f"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzI3_5b9d707e-02c3-4ce3-941e-9bbd80e784c5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzI3_757c08e4-b00d-4839-9ae9-90873c22bdf2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_40317970-e462-419c-964b-c198d98da220"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_98517874-8301-4054-b595-50e9bb5408d7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_a674094f-e64b-47d6-a578-3c3b966ed00a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjphMzdkNmJhYjRkYzE0MzE1OTE0ZDdiYzE4MDE4YThhYl82NTk3MDY5NzY2NzMz_b2ac4e57-6c06-4dcf-9b51-40dbb4cc6358"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTEtMS0xLTA_ee65ef9a-9aa6-439d-aad5-b5e47149e694"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMyLTMtMS0xLTA_81ee4579-0220-40ca-ac05-a8b92079ab2e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMmZiNDNhMGIwMDY0Y2ZhYjAyYWFhMzJhMTUwYTZlMl82NTk3MDY5NzY2Njk0_3edf8df5-8899-475e-b9e2-25a53779f431"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMmZiNDNhMGIwMDY0Y2ZhYjAyYWFhMzJhMTUwYTZlMl82NTk3MDY5NzY2Njk0_b736d8c0-c0ab-4f00-b306-45ef1739e3c9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODQw_58a1f23e-1aa5-4d4c-aefb-5ec3c25c911b"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODQw_7caa78ac-b953-49c4-8729-d87fd517d96f"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODUy_ad2829c9-fca5-4f5e-8e0d-500e4f8bacd3"
      unitRef="shares">39612659</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODY0_cc4241a8-fbd9-450e-8eb3-1b787c05c7a6"
      unitRef="shares">38966988</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODc2_306559e7-a9cb-493b-9d2b-68a0b79eecee"
      unitRef="shares">27359157</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZjE2OTdhNmEyYjM0NTMzYWNjNDIwMzg0MjY3OGIwMF82NTk3MDY5NzY2ODg4_1755d1f1-f6f3-48f9-a1c0-10d8d39e72fb"
      unitRef="shares">26713486</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTEtMS0xLTA_9e2ca88a-fe6a-4ad1-ae5b-740b8a2e386e"
      unitRef="usd">39613</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM0LTMtMS0xLTA_08dedf56-20d8-4d4a-ae6f-e48bde056ee5"
      unitRef="usd">38967</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM1LTEtMS0xLTA_4421b511-762d-4610-bd7b-f40af6b17c8c"
      unitRef="usd">96105851</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM1LTMtMS0xLTA_d5becf62-d356-4d42-a8f6-489140929e95"
      unitRef="usd">94385230</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyNjhmZjdjNGYxMWQ0MTY1OWRjMTk1Y2E5YjY1Y2YxN182NTk3MDY5NzY2NzE5_95952751-7055-4269-8bf0-e7e0abfd0b9d"
      unitRef="shares">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyNjhmZjdjNGYxMWQ0MTY1OWRjMTk1Y2E5YjY1Y2YxN182NTk3MDY5NzY2NzE5_a7139cbe-e24b-48e3-baa8-1d0d0ca02a79"
      unitRef="shares">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTEtMS0xLTA_23e96a28-7f0e-47e9-83ca-09e5703b8c3b"
      unitRef="usd">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM2LTMtMS0xLTA_ebb388a2-d4e4-4308-b523-f8b7b8d3bb96"
      unitRef="usd">18929915</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM3LTEtMS0xLTA_9fd604a9-56f4-4565-be77-50edea5b3ca1"
      unitRef="usd">-41351078</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM3LTMtMS0xLTA_1b235c5e-2f19-41b1-963c-49624394e337"
      unitRef="usd">-33043113</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM4LTEtMS0xLTA_b46c7229-4526-44bb-8268-d6897b82e1b9"
      unitRef="usd">35864471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM4LTMtMS0xLTA_8d12afa6-006c-4488-88ef-aadacf197b4f"
      unitRef="usd">42451169</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM5LTEtMS0xLTA_0674b2f3-047e-45ba-a415-ce9f38ba828b"
      unitRef="usd">37452496</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMDkvZnJhZzpjZjA2NTNkYjJkYjk0M2Y4ODVjYmY0MTIzMGYwZDA2ZC90YWJsZTpmMzE3OWUwZmRjZDE0MjMwYmNkMDU4ODIyMzRjYmFjZi90YWJsZXJhbmdlOmYzMTc5ZTBmZGNkMTQyMzBiY2QwNTg4MjIzNGNiYWNmXzM5LTMtMS0xLTA_05f70666-f275-4767-a033-b00f9d26d31d"
      unitRef="usd">43300807</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzMtMS0xLTEtMA_fdcea574-4926-4023-a8d8-6cb12d88322f"
      unitRef="usd">1681076</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzMtMy0xLTEtMA_e523b3b0-7d55-4dc2-9999-8ed16f09c891"
      unitRef="usd">1295451</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzYtMS0xLTEtMA_15968c4c-7551-4d2b-bf90-2f051e848f2a"
      unitRef="usd">1459701</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzYtMy0xLTEtMA_5ee59959-bc1a-4682-86e5-8bbdfe6c5e50"
      unitRef="usd">1027278</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzgtMS0xLTEtMA_44d28e2a-ccc7-4894-8c7f-5f2a9e6ce28f"
      unitRef="usd">3087597</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzgtMy0xLTEtMA_65a5981a-6848-4391-895b-c4ff1ee99087"
      unitRef="usd">2101628</us-gaap:ResearchAndDevelopmentExpense>
    <dyai:ResearchandDevelopmentExpenseRelatedParty
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzktMS0xLTEtMA_b191bbd2-0dd6-4c55-a40f-af4e6184a8e7"
      unitRef="usd">868720</dyai:ResearchandDevelopmentExpenseRelatedParty>
    <dyai:ResearchandDevelopmentExpenseRelatedParty
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzktMy0xLTEtMA_0a88ace6-64d6-4039-b608-2fc9ae2688c6"
      unitRef="usd">1215536</dyai:ResearchandDevelopmentExpenseRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEwLTEtMS0xLTA_88d1e465-5cb4-4d18-9177-8d031f80ba25"
      unitRef="usd">5519922</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEwLTMtMS0xLTA_247a98c4-13b3-4cc5-8c7f-fbd7ccc90bce"
      unitRef="usd">4522676</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzExLTEtMS0xLTA_f155b0ec-30a3-430f-91dd-28f30b092b98"
      unitRef="usd">-27725</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzExLTMtMS0xLTA_379707f8-8b0c-4830-993d-f25a0a08b0c4"
      unitRef="usd">-20778</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:CostsAndExpenses
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEyLTEtMS0xLTA_53d19d48-4272-4ce3-b58f-400da0765ef7"
      unitRef="usd">10963665</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzEyLTMtMS0xLTA_ce4eca07-bde0-451a-abd3-2b0b6c86cfdd"
      unitRef="usd">8887896</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE0LTEtMS0xLTA_11212460-65e9-4c3e-889c-556b45f39d19"
      unitRef="usd">-9282589</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE0LTMtMS0xLTA_427ba1d8-1c67-49e4-a356-9a2aae0116cc"
      unitRef="usd">-7592445</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE4LTEtMS0xLTA_167c4222-9c61-491f-9f8f-3c3878680ca8"
      unitRef="usd">984930</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzE4LTMtMS0xLTA_d64378b4-dcc6-4d8b-8fa0-453d7eb607a6"
      unitRef="usd">894532</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIxLTEtMS0xLTA_35c77c7b-34f1-4fe9-a83c-c36a9cdd669c"
      unitRef="usd">-8297659</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIxLTMtMS0xLTA_d235da2b-9c27-4302-934f-4093fb04548b"
      unitRef="usd">-6697913</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIzLTEtMS0xLTA_0e41d4fa-db93-4e88-9ab2-22b51b5ed8e5"
      unitRef="usd">10306</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzIzLTMtMS0xLTA_54c29dbd-2930-4446-ac50-2ff860a070d6"
      unitRef="usd">-1006157</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI1LTEtMS0xLTA_4b33edee-0e9d-4fd0-9c2e-cc7926d80952"
      unitRef="usd">-8307965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI1LTMtMS0xLTA_5331a1d8-fdfb-45ea-969d-b4d3979b0321"
      unitRef="usd">-5691756</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI3LTEtMS0xLTA_0ee3a4cc-5b46-4fc6-a608-36a3d3544917"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI3LTMtMS0xLTA_07278768-0fc8-43c5-8c1c-041e51ec1a63"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI5LTEtMS0xLTA_6ea55298-6dc0-4f81-8c37-728932c9b959"
      unitRef="shares">27003695</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTUvZnJhZzo0ZjJhMGE4NjdmM2I0MzQ4ODc5ODE3Mzk4ZmFmOTBiOC90YWJsZTplNDQxY2VmM2ZjYWI0YmY2OGNmYTIyYTQ5MjMxOTZjZS90YWJsZXJhbmdlOmU0NDFjZWYzZmNhYjRiZjY4Y2ZhMjJhNDkyMzE5NmNlXzI5LTMtMS0xLTA_b9bba129-7daa-4510-8668-e165a37d5532"
      unitRef="shares">27673300</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7ae10429d4274acc9056aa942fe63b3d_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMS0xLTEtMA_ff72bf97-88f0-4fcc-ad22-6b98fbab93f0"
      unitRef="shares">38936988</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7ae10429d4274acc9056aa942fe63b3d_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMy0xLTEtMA_1a67708c-c97b-4dc9-9f62-f81738900d69"
      unitRef="usd">38937</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3b4de0689e804b61b0bd848a5639b725_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtNS0xLTEtMA_bb13ae4d-9b78-4d0a-ba06-8abfd409fa09"
      unitRef="shares">-10609177</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3b4de0689e804b61b0bd848a5639b725_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtNy0xLTEtMA_2c7bd5cc-4415-4e6b-87ea-32ef94f18fa8"
      unitRef="usd">-16625873</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5e158a241d64af0ad4e2292194137b8_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtOS0xLTEtMA_1f4fcc7b-a1d7-443e-8165-920cd7ffc292"
      unitRef="usd">93913557</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3b2621c2b374e3f8ec9d1de2ab3fc52_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMTEtMS0xLTA_502d63cb-126c-432e-815c-62868509193e"
      unitRef="usd">-27351357</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzMtMTMtMS0xLTA_2a61da81-a67d-4c16-94b8-5d2ebf6dbb2e"
      unitRef="usd">49975264</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzUtOS0xLTEtMA_7d8b5df3-8da5-428e-aa05-7223ade41d3e"
      unitRef="usd">467203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzUtMTMtMS0xLTA_1e3b1f20-4aaf-4cbf-9e67-7ad5fcddfc01"
      unitRef="usd">467203</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMS0xLTEtMA_2e4b2c20-86d4-4742-8a60-edd5bb767d93"
      unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i532d2f0988e94d56acb670e5a4845b22_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMy0xLTEtMA_4d15c341-6947-43a6-858a-338635c1ac19"
      unitRef="usd">30</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic618bcb5feb64faabb23ce40558ff88a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctOS0xLTEtMA_ff672f77-f27c-44f9-9728-d9cc24ec04da"
      unitRef="usd">4470</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzctMTMtMS0xLTA_1f30456a-4673-4188-bc07-848415c16a67"
      unitRef="usd">4500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktNS0xLTEtMA_77d8d4b0-9054-42d8-8ec9-2da520de839f"
      unitRef="shares">1644325</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if0769ddc7f434a38ac79f19721ac79d2_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktNy0xLTEtMA_9a36f254-1da7-4091-9c53-5a6968d8f6b5"
      unitRef="usd">2304042</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzktMTMtMS0xLTA_423a3a11-ff50-4b51-b551-a63e6afe74b1"
      unitRef="usd">2304042</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i16e3dd249fbe405fbe111f88491fcb2e_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzEzLTExLTEtMS0w_53c96666-c5d2-4297-84cc-8e81538cc7e1"
      unitRef="usd">-5691756</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzEzLTEzLTEtMS0w_4d182b78-7435-4b23-84fc-763bf3fcc8a3"
      unitRef="usd">-5691756</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i88159e705b6a4615876d7c6373a3230c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTEtMS0xLTA_326e16f4-33aa-447a-be87-f2332d4a905a"
      unitRef="shares">38966988</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i88159e705b6a4615876d7c6373a3230c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTMtMS0xLTA_dbd0dfcc-176a-441b-bf0b-fcb1c2789d82"
      unitRef="usd">38967</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTUtMS0xLTA_af782202-a2a8-4ef4-9889-a3e3d1ccc2ed"
      unitRef="shares">-12253502</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i82b9ed64915c4c7d81f6f8af751f5d9d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTctMS0xLTA_da63f2c0-7ba3-4aa5-a722-dd4e8507bf36"
      unitRef="usd">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecbd8cb44d614d22957374499806e91c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTktMS0xLTA_d6907e74-c9dc-47de-b81e-e9948bebfcce"
      unitRef="usd">94385230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65ba3c275bba44c591c298eb6a627117_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTExLTEtMS0w_8f00f78b-fad8-4055-bb7e-74daecec9af0"
      unitRef="usd">-33043113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE1LTEzLTEtMS0w_4e058f2a-52cb-4d4a-9f07-a18913674a9a"
      unitRef="usd">42451169</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE3LTktMS0xLTA_949ff35c-b49d-4ae3-a253-d6aa9b71959a"
      unitRef="usd">1171079</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE3LTEzLTEtMS0w_72551999-894a-4cd5-8e3b-e0da1b624b54"
      unitRef="usd">1171079</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTEtMS0xLTA_48f13f9f-f961-4f51-b191-183ba0624fc9"
      unitRef="shares">645671</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id231eb250f3a4a71bce1ea903228e9e5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTMtMS0xLTA_0df240f6-7fdd-48ed-8e2d-44ecc58f25e5"
      unitRef="usd">646</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i505225a9b7c347a8ab61c4f7190c55af_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTktMS0xLTA_ece3d72d-b8fe-4bfc-a094-d7528d1b9560"
      unitRef="usd">549542</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzE5LTEzLTEtMS0w_44d3fd80-35dd-4696-81e0-f6dbb6727e48"
      unitRef="usd">550188</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="ib5edff09f5d5488092a0f305677b0c0d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzIzLTExLTEtMS0w_16fe195d-18ba-49d0-9bbc-41fd6c3a3f13"
      unitRef="usd">-8307965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzIzLTEzLTEtMS0w_f68a4b62-d26a-43c8-9a4f-fe786a5240ee"
      unitRef="usd">-8307965</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTEtMS0xLTA_17a9e800-a7e4-4f65-8a7a-e5676477f612"
      unitRef="shares">39612659</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6d2ef2c12f5a48ee92660c71afa97e9f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTMtMS0xLTA_90a07b31-63fa-45db-b995-0042e2552f43"
      unitRef="usd">39613</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i08882e216601446183c1dc051db938c0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTUtMS0xLTA_4f2abe5e-ce4e-4920-a4a8-ed1e66974b0b"
      unitRef="shares">-12253502</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i08882e216601446183c1dc051db938c0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTctMS0xLTA_2495db75-4353-4971-9c09-d7aed732f063"
      unitRef="usd">-18929915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12769ae146f64d729004412e0968967d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTktMS0xLTA_54b686c0-d8b9-4d9e-b04f-c7fff479d2dc"
      unitRef="usd">96105851</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8345599e828744799c4f0e1e745684b5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTExLTEtMS0w_c3f6ae28-2c5d-4be6-a186-ccb2aa545dab"
      unitRef="usd">-41351078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMTgvZnJhZzoxY2IyMDMxY2JmMjY0NTE3YmYwYzg3Y2ZiNWY2MWNkMy90YWJsZTpjNDdhN2NjODEyZmM0YmU0YTFkNDcxNzRmMzI2OGY2ZS90YWJsZXJhbmdlOmM0N2E3Y2M4MTJmYzRiZTRhMWQ0NzE3NGYzMjY4ZjZlXzI1LTEzLTEtMS0w_f38ca00d-0db3-4e9f-811d-c1bf058d8516"
      unitRef="usd">35864471</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzQtMS0xLTEtMA_4018658c-dfcb-4604-9500-38f323ff604c"
      unitRef="usd">-8307965</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzQtMy0xLTEtMA_1b322641-6fc2-4b9a-9ab0-68e9ce60be20"
      unitRef="usd">-5691756</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzYtMS0xLTEtMA_0bf4f7fd-f030-48b3-ad1a-e65f96f38cc9"
      unitRef="usd">1171079</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzYtMy0xLTEtMA_d50889b9-ec3e-43cb-934d-6f30add4f257"
      unitRef="usd">467203</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzctMS0xLTEtMA_6e921891-db3f-4763-89cf-d6c453165e2e"
      unitRef="usd">198208</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzctMy0xLTEtMA_c0ffd104-24db-43de-a37e-8c51792e189f"
      unitRef="usd">676644</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzktMS0xLTEtMA_6ac793dd-b5bf-4090-b8c8-9b8baed83eca"
      unitRef="usd">-27725</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzktMy0xLTEtMA_dd605038-8167-4691-b7b9-fc9545448028"
      unitRef="usd">-20778</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzExLTEtMS0xLTA_40b0c735-12ff-4367-b0ae-38b4c4a7b7ca"
      unitRef="usd">35471</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzExLTMtMS0xLTA_52c23901-c9f2-4bc3-a6bf-9cfaed01e6f0"
      unitRef="usd">-195601</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEyLTEtMS0xLTA_155b7b0d-4723-4d09-8542-b2adf0b8e946"
      unitRef="usd">252772</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEyLTMtMS0xLTA_0679a615-3ee7-4484-85a6-21d437b42134"
      unitRef="usd">59984</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEzLTEtMS0xLTA_b0cd758c-c549-4f96-bf23-2b7a05e66360"
      unitRef="usd">-506866</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzEzLTMtMS0xLTA_48f903c3-ae92-4947-83be-e65782efc7e9"
      unitRef="usd">1007482</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <dyai:IncreaseDecreaseinPrepaidResearchandDevelopment
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE0LTEtMS0xLTA_64075fba-8e1b-4237-ac21-4080cb84e51b"
      unitRef="usd">-253446</dyai:IncreaseDecreaseinPrepaidResearchandDevelopment>
    <dyai:IncreaseDecreaseinPrepaidResearchandDevelopment
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE0LTMtMS0xLTA_a71d58eb-43c0-4757-bc42-4833be10ad70"
      unitRef="usd">-913013</dyai:IncreaseDecreaseinPrepaidResearchandDevelopment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE1LTEtMS0xLTA_af90248d-e480-4b3c-a1e8-6575e15333af"
      unitRef="usd">105707</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE1LTMtMS0xLTA_9c272562-891c-45c6-8017-18a2318cb0a9"
      unitRef="usd">17395</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE3LTEtMS0xLTA_87e45281-865b-4555-9aae-fc93178ce28e"
      unitRef="usd">657658</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE3LTMtMS0xLTA_15723c44-f8b8-4421-948f-fecf654636da"
      unitRef="usd">-195755</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE4LTEtMS0xLTA_2aa831b7-42d1-4ab7-98e5-2c664f58fe6e"
      unitRef="usd">166399</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE4LTMtMS0xLTA_4977a88b-e4eb-4e12-8b80-3ed313ebac82"
      unitRef="usd">251617</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE5LTEtMS0xLTA_fc2ab5c4-4b83-4074-aaa0-550d92eefc44"
      unitRef="usd">-62358</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzE5LTMtMS0xLTA_5801eed1-8a01-4f06-8b8a-1204bf27d087"
      unitRef="usd">141002</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIwLTEtMS0xLTA_ae0e69d0-a4c6-4eff-9d80-a8ae31939fe1"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIwLTMtMS0xLTA_a9fcaae3-6727-42ca-be0a-ed19511feeee"
      unitRef="usd">-100675</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIxLTEtMS0xLTA_f5515310-5ea8-478c-b261-57d508eace02"
      unitRef="usd">-5782892</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzIxLTMtMS0xLTA_643a0d7f-d933-46de-8616-d3fc12f3a3f2"
      unitRef="usd">-4407189</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI0LTEtMS0xLTA_233e54ee-b258-42ec-9645-3d3ad815a90c"
      unitRef="usd">47615550</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI0LTMtMS0xLTA_bd4bb7c7-9187-44a5-9ca4-4c8b6d4fa8f6"
      unitRef="usd">49734681</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI1LTEtMS0xLTA_47b9bfd0-3a8f-46dc-bd35-5172d8ae15a4"
      unitRef="usd">55323000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI1LTMtMS0xLTA_18b496f1-2a4a-474e-9f1e-e1ebf97ede48"
      unitRef="usd">53063000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI2LTEtMS0xLTA_7a7d0dca-775f-4ca8-bd8f-26e823dd4e05"
      unitRef="usd">7707450</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI2LTMtMS0xLTA_82648688-211a-4908-882f-b843dc9c2606"
      unitRef="usd">3328319</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI5LTEtMS0xLTA_75813f02-5c8c-4e2d-b179-07c520b766d1"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzI5LTMtMS0xLTA_ff2a1a93-d1f5-4ca2-a1fc-852c09f89d05"
      unitRef="usd">2304042</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMwLTEtMS0xLTA_d0860e1e-f3e5-4204-8ba8-06aaab56dca4"
      unitRef="usd">550188</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMwLTMtMS0xLTA_c7709d65-2836-4e26-abac-66f1f7e879a4"
      unitRef="usd">4500</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMxLTEtMS0xLTA_fb1b88b0-988c-4e6e-a61e-41461edea209"
      unitRef="usd">550188</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMxLTMtMS0xLTA_d5dc87ed-afdf-4edc-bdc8-e63284923da6"
      unitRef="usd">-2299542</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMyLTEtMS0xLTA_9ca08f0c-2ff3-41ae-83d4-74ecbba5d5c8"
      unitRef="usd">-37516</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMyLTMtMS0xLTA_735662c5-3b2b-4175-b8c3-e1b7aa0854c5"
      unitRef="usd">-21622</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMzLTEtMS0xLTA_7b04c178-6189-47ab-9890-cf42a4196261"
      unitRef="usd">2437230</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzMzLTMtMS0xLTA_c6af625e-f5ae-4d68-883b-e75f7c103cea"
      unitRef="usd">-3400034</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM0LTEtMS0xLTA_d86e2b53-9dde-4653-972f-a049b55c3eb9"
      unitRef="usd">2386314</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM0LTMtMS0xLTA_1c272939-abb2-4afa-9b2f-6e04f26b6f10"
      unitRef="usd">5786348</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM1LTEtMS0xLTA_d6b70b9e-0065-4b0b-9f02-91ce61098323"
      unitRef="usd">4823544</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM1LTMtMS0xLTA_09a86570-88f4-4cf7-bdaa-ae942bf182c6"
      unitRef="usd">2386314</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM4LTEtMS0xLTA_aa8b3e6b-8552-4d79-b882-74b63b0a00bc"
      unitRef="usd">506866</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjEvZnJhZzo5ZTlkYjgzMGI2ZmU0MDFjODUyMDhjZWU2N2E2OGMwZS90YWJsZToyYmM2YmJkN2U2NWE0MjMxOGE2YjY4ODZmYzdkOGQ2My90YWJsZXJhbmdlOjJiYzZiYmQ3ZTY1YTQyMzE4YTZiNjg4NmZjN2Q4ZDYzXzM4LTMtMS0xLTA_47e47624-597f-4e35-b19c-5b46935e42ab"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzM_fd120f8f-9c9d-4df8-89de-4ff751e71c7f">Organization and Summary of Significant Accounting Policies&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Dyadic International, Inc. (&#x201c;Dyadic&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;,or the &#x201c;Company&#x201d;) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and currently two research organizations performing services under contract to Dyadic in Finland and Spain. Over the past two decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Thermothelomyces heterothallica &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(formerly &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Myceliophthora thermophila&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 31, 2015, the Company sold its industrial technology business to DuPont Danisco (&#x201c;DuPont&#x201d;), the industrial biosciences business of DuPont (NYSE: DD) for $75 million (the &#x201c;DuPont Transaction&#x201d;). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). DuPont retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either DuPont or certain licensors of DuPont, depending upon whether Dyadic elects to utilize certain patents either owned by DuPont or licensed in by DuPont.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. We believe that the C1 technology could be beneficial in the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles (VLPs), protein antigens, monoclonal antibodies (mAbs), Bi-Specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is aiming to develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC&#x2019;s NASDAQ Capital Market, under the symbol &#x201c;DYAI&#x201d;. Prior to the Company&#x2019;s uplisting to the NASDAQ, the Company&#x2019;s common stock traded on the OTCQX market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, the Company&#x2019;s revenue was generated from ten and six customers, respectively. At December&#160;31, 2019 and 2018, the Company&#x2019;s account receivable was from five and four customers, respectively. The loss of business from one or a combination of the Company&#x2019;s customers could adversely affect its operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. As of and for the year ended December&#160;31, 2019, the Company had four customers outside of the United Sates (i.e. European and Indian customers) that accounted for approximately 71.5% or $1,202,000 of total revenue and approximately 69.5% or $388,000 of accounts receivable. As of and for the year ended December&#160;31, 2018, the Company only had one customer outside of the United States (i.e., European customer) that accounted for approximately 21.7% or $281,000 of total revenue and 100% of the Company&#x2019;s accounts receivable was from the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses a few contract research organizations (&#x201c;CROs&#x201d;) to conduct its research projects. For the years ended December&#160;31, 2019 and 2018, one CRO accounted for approximately 86.6% and 88.4% of total research services we purchased, respectively. At December&#160;31, 2019, approximately $706,000 or 74.9% of accounts payable was related to this CRO. At December&#160;31, 2018, approximately $237,000 or 76.8% of accounts payable was to this CRO. The loss of business from this CRO or a combination of the Company&#x2019;s CROs could adversely affect its operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#x2019;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheet. As of December&#160;31, 2019 and 2018, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#x2019;s best estimate of the amount of probable credit losses in the Company&#x2019;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Billed receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;432,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unbilled receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;558,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses - various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company follows Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company&#x2019;s investments recorded under the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;766,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;240,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;943,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;474,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;566,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;399,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue related to research collaborations and agreements: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#x201c;Topic 606&#x201d;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the input method, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue related to sublicensing agreements: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone payments: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Royalties: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to licenses deemed to be the predominant item to which the&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are related to the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the years ended December&#160;31, 2019 and 2018 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outside contracted services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,578,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,637,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contracted services - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;868,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,215,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personnel related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;376,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Facilities, overhead and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,956,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,317,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Transaction Gain or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#x2019;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#x201c;Income Taxes&#x201d;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#x2019;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining taxable income for the Company&#x2019;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#x2019;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#x2019;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#x201c;unrecognized benefits.&#x201d; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#x2019;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014. The United States Internal Revenue Service (the &#x201c;IRS&#x201d;) has completed its review of the Company&#x2019;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 for further discussion on the IRS examination of the 2016 tax return.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize all share-based payments to employees and our Board of Directors (the &#x201c;Board&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the years ended December&#160;31, 2019 and 2018, the effect of the potential exercise of options to purchase 3,860,390 and 3,552,890 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2019 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve (12) months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures, as the Company&#x2019;s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <dyai:NumberOfResearchOrganizationPerformingServiceUnderContract
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NTIwMjM_46f8a39f-10c1-495c-a369-00a73c63793e"
      unitRef="segment">2</dyai:NumberOfResearchOrganizationPerformingServiceUnderContract>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i6c8e876d3f1e4b23851e168d3e26723c_D20151231-20151231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzExMjM_6664a21a-66c2-455e-bb23-5cc0cdd5a197"
      unitRef="usd">75000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODUx_05505847-02b3-4123-a114-40bc221c8e7b">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying audited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intra-entity transactions and balances have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDUzOTI_09423e72-bcd3-43d2-b838-ea92814f6681"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQw_549328eb-d39a-4fda-9673-83a02ea0004c">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ0_bbfa1433-4180-40b6-a95b-0366050f0312">ConcentrationsThe Company&#x2019;s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, and investment securities. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (&#x201c;FDIC&#x201d;) and the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.</us-gaap:ConcentrationRiskCreditRisk>
    <dyai:ConcentrationRiskNumberofCustomers
      contextRef="i5de8574c1d5e40d3b0ee4417bbf0e3d9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2NzM_8a57746e-a8d1-4578-bb95-4922286f9f8d"
      unitRef="customer">10</dyai:ConcentrationRiskNumberofCustomers>
    <dyai:ConcentrationRiskNumberofCustomers
      contextRef="i33feba3cff3d453ab0847ab48f7a65a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2Nzc_56727ec2-9e2a-465a-a888-8e80763ed3a3"
      unitRef="customer">6</dyai:ConcentrationRiskNumberofCustomers>
    <dyai:ConcentrationRiskNumberofCustomers
      contextRef="i4937506a337c49d99f6df9684958c7bb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI2OTg_e4f9b4d9-92cb-4fb0-96a8-4ea1a8d885ef"
      unitRef="customer">5</dyai:ConcentrationRiskNumberofCustomers>
    <dyai:ConcentrationRiskNumberofCustomers
      contextRef="i7acc47f3ac6c42bfafac0b07049ab969_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3MDE_bf6ad90a-917a-43e0-ac22-198b55557956"
      unitRef="customer">4</dyai:ConcentrationRiskNumberofCustomers>
    <dyai:ConcentrationRiskNumberofCustomers
      contextRef="i539512523cd84b16a4f3e7301273b71d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDE2OTA_e41d6860-78ac-4eb2-8ad6-61dc78fe26db"
      unitRef="customer">4</dyai:ConcentrationRiskNumberofCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i853d7cb039e94bbc88573c26b6d2967e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3NDc_783a2b17-4908-45b5-a839-6d368da47cd3"
      unitRef="number">0.715</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9853caf57ff412fbe8e87c65c083f8a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NTQ_399b573c-46fa-41df-9343-9d77dd02fcdf"
      unitRef="usd">1202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iac1ccd95b9f9482f99ac9a39b030913d_D20191001-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI3ODA_f1c26b33-9f2e-4032-9eab-dcb19b86b553"
      unitRef="number">0.695</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="id5d4c32edf3a47d5ace56c907b84788c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NTk_e1ce5393-0a3e-4986-80fb-d0cc623b3ed0"
      unitRef="usd">388000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI4MzI_6eae2f61-1024-4900-9b8d-522557767aa4"
      unitRef="number">0.217</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e964c9bfb9445f19cdf9aac99dc8ac6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc1MDU5NjQ_7f812eb3-21d7-4d71-8629-2aa2dc0fc08f"
      unitRef="usd">281000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc3379be565248d6aae983a9754e0b90_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzE2NDkyNjc0NzI5Nzg_1dbbd28b-300b-4c19-a271-3b05f645d02e"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6c18e0290e174928ae53f25f7ad4d742_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY4OTU_59fb4b11-91ea-4d1d-83bd-10c6e3a28b22"
      unitRef="number">0.866</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i794a21883a2f49e885e5e5758820ee30_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MDI_77869a5b-de5e-4f33-af30-ea2e16686875"
      unitRef="number">0.884</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i716bbd9d30fd4e1fb46f0dee71737323_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MTY_8ef8f6ab-df6a-4904-a1ec-0f8ae7d9c0cf"
      unitRef="usd">706000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i199ba6975f9b4d35a19f028f6e3ba9d2_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MDk_b4688d71-46d3-4aad-a0d2-6158bffed8d0"
      unitRef="number">0.749</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i46c48aca2c334edbae2d056c94cf1c1f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MjY_0ad1cbd5-ce86-487b-b442-9ec0faef4635"
      unitRef="usd">237000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bdff80401db4bfd883cc689a5f6c3ca_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzY1OTcwNjk4NDY5MzY_e1aee11a-2e79-4131-863b-243d434cc544"
      unitRef="number">0.768</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM2_fa792225-82d9-4b5a-8dc7-cc45839a0cff">Cash and Cash EquivalentsWe treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM3_766e5811-79a8-4364-b7dd-0bf2c3490172">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company&#x2019;s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheet.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODM4_14c0c7d9-429e-4f45-9160-c9d4ad81cae9">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. &lt;/span&gt;&lt;/div&gt;Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company&#x2019;s best estimate of the amount of probable credit losses in the Company&#x2019;s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzg3OTA_72f03e00-28fc-4f69-a33b-7f11ea4ae587"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzg3OTA_b1a72570-5c03-4bba-8c89-305f1c81a9c5"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODUz_b3fe63cf-89d9-4474-9f9a-342f87055e4c">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Billed receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;432,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unbilled receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;558,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i948cb60e266243f196d1d44762dba391_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzItMS0xLTEtMA_a59d1b31-f0b7-4cc0-9c69-bc57307014d7"
      unitRef="usd">432546</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia68ec379e62f42fd82d9df05be6cc9e3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzItMy0xLTEtMA_c35fa197-919b-4432-9073-90af4ade9a95"
      unitRef="usd">193065</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie20de3bbc09b47a58d79e76de605acff_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzMtMS0xLTEtMA_158cac8e-d79e-4496-a4e9-c6a69d4f280e"
      unitRef="usd">125984</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i003f72c2db6a4420aae1b41052590348_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzMtMy0xLTEtMA_4259483f-2ce0-4cd1-aeb7-a7a8b34bcd68"
      unitRef="usd">125679</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzQtMS0xLTEtMA_fa5a32a1-6053-4dbe-b00d-31336240bb17"
      unitRef="usd">558530</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpjZTE4OTI4OTBiMDc0YjY2YTAwNTQ3MzdiMDVmNjRkNC90YWJsZXJhbmdlOmNlMTg5Mjg5MGIwNzRiNjZhMDA1NDczN2IwNWY2NGQ0XzQtMy0xLTEtMA_f28cd958-6194-49a7-854d-9d68533e7c28"
      unitRef="usd">318744</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU0_bd50b003-6ca3-40b3-a823-00c0ad1a68b9">&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expenses - various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;277,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzItMS0xLTEtMA_431fb574-7ab8-4537-a262-156c6e800384"
      unitRef="usd">173890</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzItMy0xLTEtMA_2bd79042-0332-42b7-bfb4-983ffcadefc3"
      unitRef="usd">91725</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzMtMS0xLTEtMA_4bc1dbb6-7de1-4ad3-a27d-bc0042171e5b"
      unitRef="usd">101221</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzMtMy0xLTEtMA_53d1fc52-7c0c-42c0-9da3-d8be84463bdb"
      unitRef="usd">77249</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidTaxes
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzQtMS0xLTEtMA_406023b1-5aed-4388-844a-bfbd4ce3e76e"
      unitRef="usd">2888</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzQtMy0xLTEtMA_504f0b9d-ff67-4292-bbf1-fc140f9e6afa"
      unitRef="usd">3027</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzUtMS0xLTEtMA_d5c24b12-82ca-4478-9649-7dcae1b40565"
      unitRef="usd">277999</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTplNjY2MzhmMTU5NWU0ODUzODg5OGI4ODI2NjY4NDMzMy90YWJsZXJhbmdlOmU2NjYzOGYxNTk1ZTQ4NTM4ODk4Yjg4MjY2Njg0MzMzXzUtMy0xLTEtMA_e282e4ab-1a30-43d1-8b33-682967810e8a"
      unitRef="usd">172001</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzE_b29c2b84-82a6-4e61-892a-79e3540b1f77">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company follows Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 323-10, Investments - Equity Methods and Joint Ventures, which requires the accounting for investments where the Company can exercise significant influence, but not control of a joint venture or equity investment. See Note 3 for the Company&#x2019;s investments recorded under the equity method of accounting. &lt;/span&gt;&lt;/div&gt;Equity method investments are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU1_e8f26551-4929-475a-8e0e-eb038161e103">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts payable consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;766,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;240,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;943,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzItMS0xLTEtMA_42e5a926-103c-4996-8219-61017b967b49"
      unitRef="usd">766001</dyai:ResearchAndDevelopmentInProcessCurrent>
    <dyai:ResearchAndDevelopmentInProcessCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzItMy0xLTEtMA_965d599c-cb28-4f9e-8c1f-8d8e22852443"
      unitRef="usd">240064</dyai:ResearchAndDevelopmentInProcessCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzMtMS0xLTEtMA_2f7cbdc7-649d-48e2-9195-0e3c531da981"
      unitRef="usd">26994</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzMtMy0xLTEtMA_7b31995c-1718-4d35-aa1c-e22733cf9ad1"
      unitRef="usd">0</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzQtMS0xLTEtMA_27f09637-d49f-4f9d-91fb-814f6b5d3933"
      unitRef="usd">150383</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzQtMy0xLTEtMA_b06cce63-0faa-4f75-8ef3-f32945dd5c64"
      unitRef="usd">68996</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzUtMS0xLTEtMA_c4a6fd74-f9dd-453b-b02c-4e1097c11155"
      unitRef="usd">943378</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo2MTY2YzUyZGE2YTY0NjVmOTZkODAyOTM4N2NkMWEwMS90YWJsZXJhbmdlOjYxNjZjNTJkYTZhNjQ2NWY5NmQ4MDI5Mzg3Y2QxYTAxXzUtMy0xLTEtMA_992ed502-f640-47f6-b5ab-6196f9913769"
      unitRef="usd">309060</us-gaap:AccountsPayableCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQx_32f008df-b301-473a-9210-309dbbd3a0b4">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;474,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;566,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;399,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzItMS0xLTEtMA_825a30af-f1c0-4a21-b003-c469fec4f921"
      unitRef="usd">474388</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzItMy0xLTEtMA_14453f64-b458-4b99-8397-362f4b951d83"
      unitRef="usd">268287</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dyai:AccruedResearchandDevelopmentinProcessCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzMtMS0xLTEtMA_3ed31113-8cec-4e23-ba89-bdb2d41f2ea9"
      unitRef="usd">69795</dyai:AccruedResearchandDevelopmentinProcessCurrent>
    <dyai:AccruedResearchandDevelopmentinProcessCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzMtMy0xLTEtMA_b20f0108-aee2-4561-a1d3-399220f73519"
      unitRef="usd">49666</dyai:AccruedResearchandDevelopmentinProcessCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzQtMS0xLTEtMA_67565263-b223-434a-9129-4c1722eb5d70"
      unitRef="usd">21820</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzQtMy0xLTEtMA_df1eeefa-d0c3-47df-bb07-b3484e70871a"
      unitRef="usd">81623</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzUtMS0xLTEtMA_abedb12d-a6f5-4d31-97f6-dd93dcf5d169"
      unitRef="usd">566003</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTo4NWNhNDczZmVhMmI0MWM0YjBiYTA1ZDE3NTAyYmYzMi90YWJsZXJhbmdlOjg1Y2E0NzNmZWEyYjQxYzRiMGJhMDVkMTc1MDJiZjMyXzUtMy0xLTEtMA_9b7a26e2-d0c6-48e9-9b45-6a847416fd55"
      unitRef="usd">399576</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzI_b686a236-d0e2-4d07-a4df-2103e9932922">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue related to research collaborations and agreements: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company typically&#160;performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (&#x201c;Topic 606&#x201d;): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the input method, revenue will be recognized on the basis of the entity&#x2019;s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue related to sublicensing agreements: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the sublicense to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone payments: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee&#x2019;s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Royalties: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to licenses deemed to be the predominant item to which the&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ1_4d23b17c-7f07-4d09-9a4c-19001778ab5e">Research and Development Costs Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. R&amp;amp;D costs are related to the Company&#x2019;s internally funded pharmaceutical programs and other governmental and commercial projects.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dyai:ScheduleofResearchandDevelopmentCostsTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ5_fd02828c-545b-4a64-a744-8d37b24f8133">Research and development costs, including related party, during the years ended December&#160;31, 2019 and 2018 were as follows: &lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.835%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.571%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outside contracted services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,578,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,637,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contracted services - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;868,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,215,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personnel related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;376,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Facilities, overhead and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,956,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,317,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dyai:ScheduleofResearchandDevelopmentCostsTableTextBlock>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzItMS0xLTEtMA_60813269-87ce-4373-a28a-ed5e24a92fa1"
      unitRef="usd">2578507</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpenseOutsideContractedServices
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzItMy0xLTEtMA_2b1cfda2-df30-4229-8f2b-77bf6b85dce3"
      unitRef="usd">1637953</dyai:ResearchAndDevelopmentExpenseOutsideContractedServices>
    <dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzMtMS0xLTEtMA_00948f28-8339-40a0-a3aa-f73701967220"
      unitRef="usd">868720</dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty>
    <dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzMtMy0xLTEtMA_f709ea0a-01b6-4e04-ab3a-adccd72719b1"
      unitRef="usd">1215536</dyai:ResearchAndDevelopmentExpenseContractedServicesRelatedParty>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzQtMS0xLTEtMA_bbf08536-ae93-4dc4-b199-4271d64edb99"
      unitRef="usd">423898</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzQtMy0xLTEtMA_d6689b64-3715-4e31-a422-ed39ebdb4547"
      unitRef="usd">376312</dyai:ResearchAndDevelopmentExpensePersonnelRelatedCosts>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzUtMS0xLTEtMA_45c98ec0-00ce-43cf-b6a6-baab138b3928"
      unitRef="usd">85192</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther>
    <dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzUtMy0xLTEtMA_f9675c1f-2cc2-41d1-bafc-212e02cd8427"
      unitRef="usd">87363</dyai:ResearchAndDevelopmentExpenseFacilitiesOverheadandOther>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzYtMS0xLTEtMA_03a0d3b7-1f78-4b2d-a761-781cca806d85"
      unitRef="usd">3956317</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90YWJsZTpiNmVkNDhhNTA3OWQ0ZDg2YWNhM2RhOWNiMWYzNGQzNi90YWJsZXJhbmdlOmI2ZWQ0OGE1MDc5ZDRkODZhY2EzZGE5Y2IxZjM0ZDM2XzYtMy0xLTEtMA_0ba09246-e579-426b-a778-a65a2b0d8b05"
      unitRef="usd">3317164</dyai:ResearchAndDevelopmentExpenseIncludingRelatedParty>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODU3_d4461628-3316-41f9-b230-4e37d9488f4e">Foreign Currency Transaction Gain or LossThe Company uses the U.S. dollar as its functional currency, and it initially measures the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQy_ca6435b5-d6bc-4262-b3fb-ea95da351cd2">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain assets and liabilities on the balance sheets are measured at carrying values, which approximate fair values due to the short-term nature of these balances. Such items include cash and cash equivalents, accounts receivable, accounts payable, prepaid expenses, and accrued expenses. Investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company utilized various methods, including income, cost and market approaches to determine the fair value of its investments in equity interest, which may fall into Level 3 of the fair value hierarchy because of the significant unobservable inputs utilized in these valuation approaches. These inputs can be readily observable, market corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the &lt;/span&gt;&lt;/div&gt;use of unobservable inputs. Our key inputs included, but were not limited to, significant management judgments and estimates, including projections of the timing and amount of the project&#x2019;s cash flows, determination of a discount rate for the income approach, market multipliers, probability weighting of potential outcomes of legal and regulatory proceedings, and weighting of the valuations produced by the income, cost and market approaches.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQz_c07910da-5819-4cc4-85c4-af0ea2f1ee88">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, &#x201c;Income Taxes&#x201d;. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&#x2019;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining taxable income for the Company&#x2019;s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company&#x2019;s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company&#x2019;s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as &#x201c;unrecognized benefits.&#x201d; A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company&#x2019;s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provision of ASC 740. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for the years before 2014. The United States Internal Revenue Service (the &#x201c;IRS&#x201d;) has completed its review of the Company&#x2019;s 2015 tax filing on October 17, 2017, and no changes were required. See Note 4 for further discussion on the IRS examination of the 2016 tax return.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ2_8c6a0cc7-28fa-4a0e-a6a1-d99309e70337">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders&#x2019; equity but are excluded from net income (loss) under U.S. GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ3_93a13587-bde3-4e0f-a8a6-287b0ceabc49">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize all share-based payments to employees and our Board of Directors (the &#x201c;Board&#x201d;), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. &lt;/span&gt;&lt;/div&gt;For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzMwODQ4_d5c7f5a4-d1b1-4924-a3dd-867d2743c1aa">Net Loss Per ShareBasic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, warrants, restricted stock and convertible debt, were exercised or converted into common stock, calculated by applying the treasury stock method.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzIxOTkwMjMyOTgwMzQ_74a978d9-aad9-4d4e-b649-cf5536f1a0cb"
      unitRef="shares">3860390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzIxOTkwMjMyOTgwMzc_912d683d-4051-4bfb-b754-263ab25a2119"
      unitRef="shares">3552890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMjcvZnJhZzo1ZjAyMDI2YmNhZTM0OWRkYjhhYTBkMDlhNGJhYTQ1Yi90ZXh0cmVnaW9uOjVmMDIwMjZiY2FlMzQ5ZGRiOGFhMGQwOWE0YmFhNDViXzc2OTY1ODE0Njk3NzA_f2235335-3f75-41be-9042-1b1024e1c69d">&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2019 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2020. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) which modifies the disclosure requirements on fair value measurements. The effective date for the standard is fiscal years beginning after December 15, 2019, which for the Company is January 1, 2020. Early adoption is permitted. The new disclosure requirements for changes in unrealized gains and losses in other comprehensive income for recurring Level 3 measurements, the range and weighted average of significant unobservable inputs and the amended requirements for the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively. The Company does not expect ASU 2018-13 to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve (12) months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Companies are required to recognize and measure leases using a modified retrospective approach at either the beginning of the earliest comparative period presented or the beginning of the reporting period in which the entity first applies the new standard. ASU 2016-02 was effective for the Company beginning in the first quarter of 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures, as the Company&#x2019;s leases are one year or less and not required to recognize lease assets or liabilities under the new guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization of Purchased Callable Debt Securities. The amendments in this ASU shorten the amortization period for certain callable debt securities held at a premium. The amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for any stranded tax effects resulting from TCJA that was enacted on December 22, 2017. The new guidance will be effective for the Company beginning in the first quarter of 2019. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Non-employee Share-based Payment Accounting. The standard expands the scope of Topic 718 to include share-based payments issued to non-employees for goods or services, simplifying the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years with early adoption permitted, including adoption in an interim period. The Company adopted the standard on January 1, 2019. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE5MDM_6d105c0b-5201-4ae3-b4af-53406ac71de6">Cash, Cash Equivalent, and Investments &lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#x2019;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.871%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.055%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.475%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,813,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,813,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,823,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,823,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Short-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,387,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,399,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Long-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,528,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,511,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,738,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,734,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.871%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.055%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.475%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,048,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,048,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Short-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,731,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,816,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,117,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,202,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;_________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Notes:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1) Definition of the three-level fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 2 - Other inputs that are directly or indirectly observable in the markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 3 - Inputs that are generally unobservable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(3) Long-term investment securities will mature longer than 12 months from the applicable reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(4) The premium paid to purchase held-to-maturity investment securities was $233,550 and $378,681 for the years ended December&#160;31, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#x2019;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment&#x2019;s cost basis. As of December&#160;31, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired.</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE5MDQ_8082135e-5451-47d8-b018-53d9cc36e03b">The following table shows the Company&#x2019;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2019 and 2018:&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.871%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.055%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.475%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,010,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,813,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,813,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,823,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,823,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Short-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,387,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,399,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Long-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,528,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,511,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,738,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,734,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.871%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.442%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.055%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.475%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,048,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,048,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,338,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,386,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Short-Term Investment Securities &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Corporate Bonds &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,731,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,816,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,117,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,202,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;_________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Notes:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(1) Definition of the three-level fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 2 - Other inputs that are directly or indirectly observable in the markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;"&gt;Level 3 - Inputs that are generally unobservable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(3) Long-term investment securities will mature longer than 12 months from the applicable reporting date.&lt;/span&gt;&lt;/div&gt;(4) The premium paid to purchase held-to-maturity investment securities was $233,550 and $378,681 for the years ended December&#160;31, 2019 and 2018, respectively.</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaca615a626c84646a9e3cd9ee505f251_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzUtMy0xLTEtMA_3d268abb-8069-480b-b7e6-c683373ca83f"
      unitRef="usd">1010510</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaca615a626c84646a9e3cd9ee505f251_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzUtOS0xLTEtMA_a25fb0a9-e1ad-48b7-8262-139993419112"
      unitRef="usd">1010510</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9923848bb21f4a459e82cf269761b053_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzYtMy0xLTEtMA_21505599-d075-4d91-b29d-4c927c6775b5"
      unitRef="usd">3813034</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9923848bb21f4a459e82cf269761b053_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzYtOS0xLTEtMA_70c8c0ce-7c7f-4e8e-ac23-470a14ec6920"
      unitRef="usd">3813034</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzctMy0xLTEtMA_778bb134-4ce6-4fdd-be4b-ce2f58c5a434"
      unitRef="usd">4823544</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzctOS0xLTEtMA_bebca66d-c85d-4375-aa32-103f3e49e86a"
      unitRef="usd">4823544</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <dyai:DebtSecuritiesHeldtomaturityFairValueCurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktMy0xLTEtMA_12e9a7de-594d-462a-bc7a-04b480bc35e8"
      unitRef="usd">29387053</dyai:DebtSecuritiesHeldtomaturityFairValueCurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktNS0xLTEtMA_0d3a2a86-caf6-4211-a984-7f8cef527abd"
      unitRef="usd">5898</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktNy0xLTEtMA_5fca3412-fa1f-4075-9dc6-3457e6d4e722"
      unitRef="usd">17991</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzktOS0xLTEtMA_78da03e8-efea-4a3a-a0d3-77915e036805"
      unitRef="usd">29399146</us-gaap:HeldToMaturitySecuritiesCurrent>
    <dyai:DebtSecuritiesHeldtomaturityFairValueNoncurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTMtMS0xLTA_3a3e9dee-3c16-45c1-ac80-e3661516a2c4"
      unitRef="usd">1528190</dyai:DebtSecuritiesHeldtomaturityFairValueNoncurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTUtMS0xLTA_31dc7296-97cd-40e1-8c72-289e20ac2056"
      unitRef="usd">16554</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTctMS0xLTA_f5f77c80-c818-4cfc-a5f4-3644297a8800"
      unitRef="usd">0</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i9de4ae0dea714e10b5a7dd12e27992d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzExLTktMS0xLTA_0cb0ef3b-47da-4c25-b4c9-0e9a023e4635"
      unitRef="usd">1511636</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:InvestmentsAndCash
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTMtMS0xLTA_fa68e3e5-57f2-41d5-9565-defaeb9c7d2e"
      unitRef="usd">35738787</us-gaap:InvestmentsAndCash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTUtMS0xLTA_e16eb7b5-ab63-46d0-9e23-bd5fdbd9a24a"
      unitRef="usd">22452</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTctMS0xLTA_dc164683-e01f-48d0-bbea-d06811fa94eb"
      unitRef="usd">17991</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <dyai:InvestmentsandCashAmortizedCost
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZToxM2I2ODA4MWFjZTc0NmYzOGIwYzY2ZTExYzNhMTQwYi90YWJsZXJhbmdlOjEzYjY4MDgxYWNlNzQ2ZjM4YjBjNjZlMTFjM2ExNDBiXzEyLTktMS0xLTA_e077a4b9-ba20-4ee3-8b27-991c7b86b1ff"
      unitRef="usd">35734326</dyai:InvestmentsandCashAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzUtMy0xLTEtMA_343f7ed1-0988-4db8-83bd-3f46def3c3c2"
      unitRef="usd">1048272</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b1f5c0f0aab4da9addeb34e6837a259_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzUtOS0xLTEtMA_0eb5e3f2-230f-4a66-957b-65b8097806d5"
      unitRef="usd">1048272</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzYtMy0xLTEtMA_bc878b2d-3cde-4598-90cc-1dcbc22cce37"
      unitRef="usd">1338042</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i58f266f8c0c0490fa57d64fc24d8e4d9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzYtOS0xLTEtMA_e2b3e955-b23e-485c-ad3c-d5214da783d1"
      unitRef="usd">1338042</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzctMy0xLTEtMA_1bdeaaca-9ca4-4ce6-9fba-45ff692c0d81"
      unitRef="usd">2386314</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzctOS0xLTEtMA_c2d748fc-d583-453a-a0e9-1b5632e13659"
      unitRef="usd">2386314</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <dyai:DebtSecuritiesHeldtomaturityFairValueCurrent
      contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktMy0xLTEtMA_296d73e7-de7b-463a-b224-9754f2cb50c0"
      unitRef="usd">38731120</dyai:DebtSecuritiesHeldtomaturityFairValueCurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent
      contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktNS0xLTEtMA_8adca827-0a53-4713-8726-15417d684da5"
      unitRef="usd">0</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent>
    <dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent
      contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktNy0xLTEtMA_387f4cde-05c9-4490-a49c-931f351ea6db"
      unitRef="usd">85321</dyai:DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="iecd519b1fc8643db943ce2a10915099e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzktOS0xLTEtMA_ab8a9c64-e67a-4c52-8e1c-1332ce581d06"
      unitRef="usd">38816441</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:InvestmentsAndCash
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTMtMS0xLTA_40a81bf4-0afb-41e0-a67d-10a7bdbb7d9a"
      unitRef="usd">41117434</us-gaap:InvestmentsAndCash>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTUtMS0xLTA_fc7efc42-2cc0-44ff-bb7c-bf861c74fedb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTctMS0xLTA_f43c6ad4-d6ad-4f2a-8419-86b61c7b5d6f"
      unitRef="usd">85321</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <dyai:InvestmentsandCashAmortizedCost
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90YWJsZTo0ZmQ3N2Q0MTdiNDk0ODU0ODQ3NzY3Zjc0ODg2ZGI5Mi90YWJsZXJhbmdlOjRmZDc3ZDQxN2I0OTQ4NTQ4NDc3NjdmNzQ4ODZkYjkyXzEyLTktMS0xLTA_c52e687c-4ee5-41e1-9926-5e0fd5478294"
      unitRef="usd">41202755</dyai:InvestmentsandCashAmortizedCost>
    <dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase
      contextRef="ic730d04e8b0b4df4a4a422154c714345_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE2NDkyNjc0NDM1ODI_4f8f1779-23d4-44dd-b837-11ba55154906"
      unitRef="usd">233550</dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase>
    <dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase
      contextRef="i530ce590a54f4e1294cb6cb83802e421_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzMvZnJhZzo2ZDQ4N2YzOTRkZmQ0ZDFhOWNhZjQxZGNhZDA2NTFlMC90ZXh0cmVnaW9uOjZkNDg3ZjM5NGRmZDRkMWE5Y2FmNDFkY2FkMDY1MWUwXzE2NDkyNjc0NDM1Nzg_72221db4-07fe-4bf9-bff4-3f07b6651995"
      unitRef="usd">378681</dyai:DebtSecuritiesHeldtomaturityPremiumPaidonPurchase>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzQ0OTI_2a4d34b5-0780-407c-bc7f-cdac1d5e76ff">Research and Collaboration Agreements&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;BDI &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#x201c;RSA&#x201d;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#x201c;BDI Pharma&#x201d;), and a Service Framework Agreement (the &#x201c;SFA&#x201d;, and together with the RSA, the &#x201c;R&amp;amp;D Agreements&#x201d;), with VLP The Vaccines Company, S.L.U. (&#x201c;VLPbio&#x201d;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#x201c;BDI Holdings&#x201d; and together with BDI Pharma and VLPbio, &#x201c;BDI&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The R&amp;amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTEyODE_d817c484-c349-4120-9e27-b9d41a8a4fa5"&gt;two&lt;/span&gt;-year period, with a focus on advancing Dyadic&#x2019;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#x2019;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#x2019;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon closing of the BDI transaction, the Company paid EUR &#x20ac;1 million (the &#x201c;RSA Initial Payment&#x201d;) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#x20ac;936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#x2019;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#x20ac;1&#160;million for a 50% share and EUR &#x20ac;8&#160;million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &#x20ac;1.5&#160;million of the net income from Dyadic&#x2019;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1&#160;million (the &#x201c;SFA Commitment&#x201d;) in contract research services specified by Dyadic over two years since the closing of the BDI transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has concluded that BDI is not a Variable Interest Entity (&#x201c;VIE&#x201d;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company&#x2019;s consolidated financial results. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1&#160;million (EUR &#x20ac;1&#160;million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic was expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. As of December&#160;31, 2019, Dyadic has fulfilled its SFA commitment, and all research projects under the SFA were completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were none and approximately $0.3&#160;million, respectively. For the year ended December&#160;31, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.9 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Novovet and Luina Bio Sub-License &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 26, 2019, the Company entered into a sub-license agreement (the &#x201c;Luina Bio Sub-License Agreement&#x201d;) with Luina Bio Pty Ltd. (&#x201c;Luina Bio&#x201d;) and Novovet Pty Ltd (&#x201c;Novovet&#x201d;). Under the terms of the Luina Bio Sub-License Agreement, the Company granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to&#160;Dyadic&#x2019;s proprietary C1 gene expression platform&#160;for the exclusive and sole purpose of commercializing&#160;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (&#x201c;Novovet Up-Front Consideration&#x201d;) in accordance with the terms of Novovet&#x2019;s Shareholder Agreement (&#x201c;Shareholders Agreement&#x201d;), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#x2019;s proprietary C1 gene expression platform. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Alphazyme Sub-License &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 5, 2019, the Company entered into a sub-license agreement (the &#x201c;Alphazyme Sub-License Agreement&#x201d;) with Alphazyme, LLC (&#x201c;Alphazyme&#x201d;). Under the terms of the Alphazyme Sub-License Agreement, the Company granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to&#160;Dyadic&#x2019;s proprietary C1 gene expression platform&#160;for the purpose of commercializing&#160;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a&#160;7.5%&#160;ownership interest in&#160;Alphazyme&#160;(&#x201c;Alphazyme Up-Front Consideration&#x201d;) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic&#x2019;s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of&#160;18&#160;months (&#x201c;Exclusivity Period&#x201d;) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional&#160;2.5%&#160;ownership interest in Alphazyme.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Commercialization Collaboration with Serum Institute of India&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#x201c;Serum&#x201d;). Under the terms of this collaboration, Serum anticipates applying Dyadic&#x2019;s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#x2019;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.&lt;/span&gt;&lt;/div&gt;For the year ended December&#160;31, 2019, the Company recognized approximately $118,000 in research and development revenue from Serum.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
      contextRef="ia1d98d4756224c909d6e5d6c8a30310a_D20170630-20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3Mzc_f57f5c05-ddcd-426d-9239-d747604bd384"
      unitRef="eur">1000000</dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement>
    <dyai:CollaborativeArrangementEquityInterestAcquired
      contextRef="i7e634d7aaec046188c2ed66d34824a19_D20170630-20170630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDI_ed1b1691-0acc-41e7-984b-1d1f552d2842"
      unitRef="number">0.161</dyai:CollaborativeArrangementEquityInterestAcquired>
    <dyai:CollaborativeArrangementEquityInterestAcquired
      contextRef="i4169bf7db9fb46a59c822fcd3015e062_D20170630-20170630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDU_c9fcef18-3c27-4d31-96e8-f399b3f4e686"
      unitRef="number">0.033</dyai:CollaborativeArrangementEquityInterestAcquired>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NDg_889875ab-caf8-49e3-b019-2dd2db4d4e28"
      unitRef="eur">936000</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementDurationOfAgreement
      contextRef="ic4223a15c84f40d98227848c11916461_D20170630-20170630"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzY3NTE_229e040c-6c8c-4966-8c4d-436d9c53f727">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="ifa774688910149949c16b496a421bb9a_D20170630-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMTc_2329073e-fa8b-4ed3-a841-ec174eef373e"
      unitRef="number">0.50</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="i5b5457c0415a45cb96e692134cbf8975_D20170630-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjA_b530c2a8-ba27-4471-9d10-d2421bbf2845"
      unitRef="number">0.75</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMDk_cdb2bc5a-0d98-464a-b4a1-e47a46db5ac3"
      unitRef="eur">1000000</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="i7c228ac1d4cd4e89b60866a524343d7d_D20170630-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjM_3b95feb9-22b0-4649-b978-51604dc5f6ec"
      unitRef="number">0.50</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment
      contextRef="i2447768dc81342fbbc93c99cf36d4175_I20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjk_fc97f13d-e542-420b-886c-f86d6142d766"
      unitRef="eur">8000000</dyai:CollaborativeArrangementMaximumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementRevenueSharingPercentage
      contextRef="i840867cee002461092e9bb1d28ebe22d_D20170630-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzkyMjY_332bb06b-3274-47e3-82cd-b6234e205b87"
      unitRef="number">0.75</dyai:CollaborativeArrangementRevenueSharingPercentage>
    <dyai:CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization
      contextRef="i79c8a3fd19f84be7bcf4484ebc536193_I20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk0OTg_80a9648d-97f4-4590-8722-4f2df9c04011"
      unitRef="eur">1500000</dyai:CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization>
    <dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment
      contextRef="ia10445b9bcd248c392f6a26e44521761_I20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk1MjI_861e843b-9f66-4601-a000-23342605c085"
      unitRef="usd">1000000</dyai:CollaborativeArrangementMinimumObligationForResearchAndDevelopment>
    <dyai:CollaborativeArrangementDurationOfAgreement
      contextRef="i355318ed17ba4b0ba24061da681d9010_D20170630-20170630"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyNzk1NDU_5084c5cd-0f04-4217-9a4b-e84229d5159c">P2Y</dyai:CollaborativeArrangementDurationOfAgreement>
    <dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
      contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODA4NTQ_b74529f2-ec8d-4f12-ab10-493fd5648141"
      unitRef="usd">1100000</dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement>
    <dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
      contextRef="i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODA4OTA_dc61bf18-8052-48ab-8e29-1b7194fde870"
      unitRef="eur">1000000</dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement>
    <dyai:CollaborativeArrangementOutstandingCommitment
      contextRef="ia10445b9bcd248c392f6a26e44521761_I20170630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTQ0NTU_5ee35bf4-14b0-4a53-bcb9-fe008d3a42ad"
      unitRef="usd">1000000</dyai:CollaborativeArrangementOutstandingCommitment>
    <dyai:PrepaidResearchandDevelopment
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0Xzc2OTY1ODE0MjI1OTU_3d7c1355-85be-494d-b3ad-8293a0473f52"
      unitRef="usd">0</dyai:PrepaidResearchandDevelopment>
    <dyai:PrepaidResearchandDevelopment
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ2MjA_0420f51b-6854-49dd-b57b-b08334f27190"
      unitRef="usd">300000</dyai:PrepaidResearchandDevelopment>
    <dyai:ResearchandDevelopmentExpenseRelatedParty
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ3ODA_684d9f6e-3e30-4210-a4cf-ff877304ed6f"
      unitRef="usd">900000</dyai:ResearchandDevelopmentExpenseRelatedParty>
    <dyai:ResearchandDevelopmentExpenseRelatedParty
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzY1OTcwNjk3OTQ4MTI_e4550d41-15a7-462e-a975-ad729b2a6948"
      unitRef="usd">1200000</dyai:ResearchandDevelopmentExpenseRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i491f41e970764c248af615c0fd65548e_I20190426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTYzMDQ_5415173d-e20f-47e2-a9b1-ea60f5268e60"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i491f41e970764c248af615c0fd65548e_I20190426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTc2NDU_2ef4c56c-3227-4e5e-860c-4d81aef706be"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTk1MjE_afd08974-210a-45cc-909c-21dbaf6bf20c"
      unitRef="number">0.075</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <dyai:CollaborativeArrangementExclusivityPeriod
      contextRef="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTk4NjM_a28cbce2-4e34-4509-b6d0-9083fede2953">P18M</dyai:CollaborativeArrangementExclusivityPeriod>
    <dyai:CollaborativeArrangementOptionToExtendExclusivityPeriod
      contextRef="ia140d2bf41a04c4889405eeece40c229_D20190505-20190505"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjAxODE_a41f6449-1953-4d2b-8e7d-854c739be4ee">P12M</dyai:CollaborativeArrangementOptionToExtendExclusivityPeriod>
    <dyai:CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod
      contextRef="ia4bdd59c422749b29f4f8bdd12c6f17a_I20190505"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjAyMjA_97f3c5de-cb68-4d68-ac53-a4f0a4253314"
      unitRef="number">0.025</dyai:CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod>
    <dyai:CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization
      contextRef="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjE2Njg_fae5b7f4-e196-4faf-8c91-79d683c1643e"
      unitRef="antibody_and_vaccine">12</dyai:CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization>
    <dyai:CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins
      contextRef="id83d3cd5d7dc470d9a5ca497ca4b275b_I20190507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjE5NDI_7412e460-1487-4370-8b24-04cb2f60168a"
      unitRef="protein">12</dyai:CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins>
    <dyai:CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
      contextRef="if8a37c03b9a24f5f805e876d96fb8eca_D20190507-20190507"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NjIwMzI_c1f9f2c1-9f3d-4513-be40-5a2d1fcf0826">P15Y</dyai:CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod>
    <dyai:RevenueFromCollaborativeArrangementRecognized
      contextRef="id144ebaa808a4539bac88f64f1ae1856_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzIxOTkwMjMyODIwNDA_2b741f4d-aaa6-4171-bd29-e5310f6f5673"
      unitRef="usd">118000</dyai:RevenueFromCollaborativeArrangementRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjQ_bb43aa4f-04eb-4274-9bc0-714c18ad4f1d">Income Taxes &lt;div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) was enacted on December 22, 2017 and become effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. Federal corporate income tax rate from 35% to 21% and a change to the corporate alternative minimum tax (&#x201c;AMT&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The TCJA eliminated the corporate AMT and permits existing AMT credit carryforwards to be used to reduce the regular tax obligation in 2018, 2019, and 2020. Any AMT credit carryforwards that do not reduce regular taxes are eligible for a 50% refund in 2018 through 2020, and a 100% refund in 2021. Accordingly, we reclassified the balance of the AMT credit from the deferred tax asset to an income tax receivable in 2018. The corresponding balance in the valuation allowance has been reversed into income tax benefit in the amount of $1,001,233. As of December&#160;31, 2019, we have received 50% or approximately $0.5 million refund for tax year 2018 and expect to receive the remaining 50% over tax years 2019 through 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,274,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,622,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(75,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,297,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,697,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of our (benefit) provision for income tax for the years ended December&#160;31, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.918%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.833%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current and deferred tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,001,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,001,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The income tax provision differs from the expense amount that would result from applying the federal statutory rates to income before income taxes due to deferred income tax resulting to permanent differences, state taxes and a change in the deferred tax valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The reconciliation between the statutory tax rate and the Company&#x2019;s actual effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax at U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;True-up adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;AMT adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of the Company&#x2019;s net deferred income tax assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;275,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;NOL carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,668,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,656,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,656,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax asset, net of deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,150,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,578,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,150,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,578,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on management&#x2019;s evaluation, the net deferred tax asset was offset by a full valuation allowance as of December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had net operating loss (&#x201c;NOL&#x201d;) carryforwards available in 2019 that will begin to expire in 2037. As of December&#160;31, 2019, and 2018, the Company had NOLs in the amount of approximately $19.7&#160;million and $9.1&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 20, 2019, the Company received a letter from the IRS informing the Company that its 2016 federal tax return was selected for examination. In August 2019, the Company had a meeting with the IRS agent and subsequently provided the IRS with all requested information under several Information Document Requests (IDRs). Thus far, the Company has not been informed of any issue. As the IRS audit is still in progress, we are unable to predict when the audit will be concluded or whether any assessment will be proposed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Indian Tax Deducted/Collected at Source&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income generated in India is subject to Tax Deducted at Source (&#x201d;TDS&#x201d;), which is a means of collecting income tax at the source when income is generated rather than a later date by the Indian government. The TDS amount paid can be used as foreign tax credit for US tax purposes. However, we do not expect to use the credit due to our loss from operation. As a result, &lt;/span&gt;&lt;/div&gt;the Company recorded a provision for income taxes of approximately $10,000 as a result of TDS for the year ended December 31, 2019.</us-gaap:IncomeTaxDisclosureTextBlock>
    <dyai:TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzIxOTkwMjMyNjIxNjE_0e11b0df-1579-4478-9dcb-9c155dc7ab8b"
      unitRef="usd">1001233</dyai:TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzIxOTkwMjMyNjIxNzc_f4daf02e-294b-470a-9d65-4d8854e60a66"
      unitRef="usd">500000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjU_63dd83e4-fd0b-4073-bb04-d91faa2d052b">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,274,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,622,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(75,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,297,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,697,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzItMS0xLTEtMA_d6fc6264-7eb8-4e2a-a431-81da3e398e3c"
      unitRef="usd">-8274712</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzItMy0xLTEtMA_50a2a2dd-bc58-44c0-874f-5a17bbd47545"
      unitRef="usd">-6622695</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzMtMS0xLTEtMA_f5b5cbe3-64a1-4734-9af3-ad1df5d582a5"
      unitRef="usd">-22947</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzMtMy0xLTEtMA_1d7293a9-9d73-4c60-af9b-daf388dd7939"
      unitRef="usd">-75218</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzQtMS0xLTEtMA_564bf929-3b90-45f7-8f77-2a1068fbf2f9"
      unitRef="usd">-8297659</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTpmMWU1ZmExYmM5MTc0NDQyYjExMWNhYjg2Y2UyODE3Ny90YWJsZXJhbmdlOmYxZTVmYTFiYzkxNzQ0NDJiMTExY2FiODZjZTI4MTc3XzQtMy0xLTEtMA_58314bb9-f836-4301-82d7-e0445c04cdeb"
      unitRef="usd">-6697913</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5NjY_567e7e19-c70c-401b-804f-a83d44895259">&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of our (benefit) provision for income tax for the years ended December&#160;31, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.128%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.918%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.833%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current and deferred tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,001,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,001,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzMtMS0xLTEtMA_b91593ad-c660-4041-a352-a2866568110d"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzMtMy0xLTEtMA_ac1b2935-7793-4f0e-ab1e-795a0d7ff9a4"
      unitRef="usd">-1001233</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzQtMS0xLTEtMA_d779eb05-a7af-4673-b338-dc7ef25eca1d"
      unitRef="usd">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzQtMy0xLTEtMA_4829f91f-4a99-4713-a294-0070feef40a9"
      unitRef="usd">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzUtMS0xLTEtMA_d7ad54a2-b508-4745-a1c8-372967cd0ae8"
      unitRef="usd">0</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzUtMy0xLTEtMA_36cab6f7-62f7-4517-9ecb-7f8f13304b29"
      unitRef="usd">0</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzYtMS0xLTEtMA_bfa5293d-226c-4eaa-844f-ba72edf44658"
      unitRef="usd">0</dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment>
    <dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZTo0ZmRjOWZiMzc1Njc0ODY5OTQ2OWYyYTE1NjE2NWE4MC90YWJsZXJhbmdlOjRmZGM5ZmIzNzU2NzQ4Njk5NDY5ZjJhMTU2MTY1YTgwXzYtMy0xLTEtMA_1914c1c6-a9ba-450e-89a7-c665f937529a"
      unitRef="usd">-1001233</dyai:IncomeTaxExpenseBenefitIncludingTrueUpAdjustment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5Njc_50825ad3-d8a0-405f-855d-546f5d995293">The reconciliation between the statutory tax rate and the Company&#x2019;s actual effective tax rate is as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax at U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;True-up adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;AMT adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzItMS0xLTEtMA_34531614-a009-4cdd-9422-8602892258b3"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzItMy0xLTEtMA_3ae47eb2-a950-4b80-83f9-92f1ca00aa79"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzMtMS0xLTEtMA_d8c05795-5005-4d4d-8e1e-25ff7421f322"
      unitRef="number">0.0461</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzMtMy0xLTEtMA_3d9b9826-650e-41a4-a797-f0e5c96bfa4f"
      unitRef="number">0.0425</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzQtMS0xLTEtMA_157ddafa-13b8-473a-9ac1-c5087d546c88"
      unitRef="number">0.0649</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzQtMy0xLTEtMA_2b9453d0-c527-486b-a0b3-8124fba21bc9"
      unitRef="number">-0.0044</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzUtMS0xLTEtMA_ec16db70-babe-4fc6-a26d-f8dd0183dff1"
      unitRef="number">-0.3099</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzUtMy0xLTEtMA_d7de0322-343a-4f35-a98d-6de20e67e5d3"
      unitRef="number">-0.1025</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzYtMS0xLTEtMA_6ab07c12-e15e-41d5-ade5-25527cca137f"
      unitRef="number">-0.0018</dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent>
    <dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzYtMy0xLTEtMA_495350b9-01a8-4dfc-be5d-0bed3f15da64"
      unitRef="number">0.0017</dyai:EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzctMS0xLTEtMA_dbb60eb3-8c76-468e-9dc8-7deb6d08c982"
      unitRef="number">0.0007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzctMy0xLTEtMA_09d94b68-f299-489b-83f3-cfa5376cb6b7"
      unitRef="number">0.0028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzgtMS0xLTEtMA_a329cdbd-be5d-4dde-a06c-99e7a33b848d"
      unitRef="number">-0.0100</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzgtMy0xLTEtMA_b5201815-3e19-4f8c-a405-01e625fadbe0"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzktMS0xLTEtMA_a1c37dae-89a5-4ec2-8253-a8cccac2e0f8"
      unitRef="number">0</dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent>
    <dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzktMy0xLTEtMA_be944b6e-d67c-4eaf-a5fb-2575459ccc90"
      unitRef="number">-0.0006</dyai:EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzEwLTEtMS0xLTA_c5eb820b-e357-4971-88ed-c72c4dedeaac"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyOThkMThkNzUzZmU0NTVmODEzMDdmNGFkMGZiNTUxMy90YWJsZXJhbmdlOjI5OGQxOGQ3NTNmZTQ1NWY4MTMwN2Y0YWQwZmI1NTEzXzEwLTMtMS0xLTA_c80629f5-9d3f-40fb-9f65-3b94c69535c0"
      unitRef="number">0.1495</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzM5Njg_451634c8-c810-48d9-bac8-a39684b1d3af">&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The significant components of the Company&#x2019;s net deferred income tax assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.811%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;275,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;NOL carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,668,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,656,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,656,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred tax asset, net of deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,150,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,578,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,150,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,578,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzMtMS0xLTEtMA_16898e65-1677-45ad-a3a9-0cc389e3dd56"
      unitRef="usd">275000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzMtMy0xLTEtMA_03b04e67-d99f-4007-8777-4b48ae0fc35a"
      unitRef="usd">242700</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzQtMS0xLTEtMA_88406cae-9613-43e7-b0eb-1bcd83f1ed5c"
      unitRef="usd">5214200</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzQtMy0xLTEtMA_c56254fb-dcc4-40ca-8e60-bea5b24ee062"
      unitRef="usd">2668000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzYtMS0xLTEtMA_20b6f22e-fff0-43be-b41f-4890e8968c3e"
      unitRef="usd">1656500</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzYtMy0xLTEtMA_40db90bf-3fea-4a3c-b0f5-5ec8264d78d8"
      unitRef="usd">1656500</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzctMS0xLTEtMA_41e36e16-152b-470c-be75-3f0826dfbf99"
      unitRef="usd">4400</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzctMy0xLTEtMA_1947e69b-7544-44cf-bd94-0d1c8407c6c0"
      unitRef="usd">11200</us-gaap:DeferredTaxAssetsOther>
    <dyai:DeferredTaxAssetLiabilityGross
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzgtMS0xLTEtMA_1ddd516f-c0d4-4295-a93b-35677afd30cb"
      unitRef="usd">7150100</dyai:DeferredTaxAssetLiabilityGross>
    <dyai:DeferredTaxAssetLiabilityGross
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzgtMy0xLTEtMA_92f1471f-b89e-4773-a554-20f286079636"
      unitRef="usd">4578400</dyai:DeferredTaxAssetLiabilityGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzktMS0xLTEtMA_fc750c01-1f85-44e9-a2ec-468684f5151e"
      unitRef="usd">7150100</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzktMy0xLTEtMA_38fa9130-169d-44d4-b53c-135617103dc4"
      unitRef="usd">4578400</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzEwLTEtMS0xLTA_d0093dc1-9e82-460c-a9a7-c5ebfb8cf5f6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90YWJsZToyNzIyMjE0ZTgyMDQ0OTQzYTExNGNlNWEwZWVjMWEzOC90YWJsZXJhbmdlOjI3MjIyMTRlODIwNDQ5NDNhMTE0Y2U1YTBlZWMxYTM4XzEwLTMtMS0xLTA_85884632-5020-480f-b7d0-1b8cb4e307c5"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NDgyMzc_791b0758-b244-483a-a7ae-87627d8ecdeb"
      unitRef="usd">19700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NDgyNDU_f7ccfc73-509f-4a2c-9552-71b19584f7c6"
      unitRef="usd">9100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzMyNTM_3cf88e32-688a-4434-ac20-89a784b1f2bc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzMyNTM_7a5de3f2-973c-45d9-be6a-32d4e409989d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i46135fb3b51c476a969413b90769ef8e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzkvZnJhZzo5MjQ3MjYyZWZkZWM0YjI0OTgzM2Q3YmFhN2ExZmE0Mi90ZXh0cmVnaW9uOjkyNDcyNjJlZmRlYzRiMjQ5ODMzZDdiYWE3YTFmYTQyXzE2NDkyNjc0NTYxMzI_97f21b84-c638-4dc5-978a-e915c6cba6b7"
      unitRef="usd">10000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzc2OTY1ODE0MDkzNTg_175aa56f-8845-44ff-9823-875478c05ca5">Commitments and Contingencies&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Jupiter, Florida Headquarters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s corporate headquarters are located in Jupiter, Florida. The Company occupies approximately 4,900 square feet with a monthly rental rate and common area maintenance charges of approximately $9,700. The lease expires on June&#160;30, 2020, and thereafter, the Company will reconsider the square footage of the leased space to align with the staffing requirements of the future operations of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;The Netherlands Office&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains a small satellite office in Wageningen, Netherlands. In 2018, the Company occupied approximately 258 square feet with annual rentals and common area maintenance charges of approximately $4,700. The lease expired on January&#160;31, 2019, and thereafter, the Company entered into a new lease with the same lessor (the &#x201c;New Lease&#x201d;). The New Lease has a one year term with an auto renew period till January 31, 2021, and includes a flexible office space with annual rentals of approximately $4,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;VTT Research Contract Extension&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 28, 2019, the Company extended its research contract (&#x201c;Contract&#x201d;) through June 2022 with VTT Technical Research Centre of Finland Ltd. (&#x201c;VTT&#x201d;). Under the terms of this Contract, Dyadic will pay VTT a total of EUR &#x20ac;2.52 million over the next three years to continue developing Dyadic&#x2019;s C1 fungal expression system for therapeutic protein production, including C1 host system improvement, glycoengineering, and management of third-party target protein projects. VTT is subject to an additional success bonus up to EUR &#x20ac;450,000 based on the technical targets stipulated in the Contract. Dyadic and its sublicensees will also have the right to use synthetic promoters developed by VTT with an access fee. On October 25, 2019, the Company expanded the Contract to pay an additional EUR &#x20ac;690,000 over the next 1.5 years to reinforce the glycoengineering work. Dyadic retains the right to terminate the Contract with 90 days&#x2019; notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.190%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.810%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,762,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,103,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,362,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The purchase obligations in the table above are primarily related to our contracts with the Company&#x2019;s contract research organizations to provide certain research services. The contracts set forth the Company&#x2019;s minimum purchase requirements that are subject to adjustments based on certain performance conditions. All contracts expire in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. &lt;/span&gt;&lt;/div&gt;Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company&#x2019;s consolidated financial position, cash flows or results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i067425fd93584c7f8114ab5e1571995d_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDYzNjk_065a1f01-4946-4397-9ef7-b3f55833c8ca"
      unitRef="sqft">4900</us-gaap:AreaOfRealEstateProperty>
    <dyai:OperatingLeasesMonthlyRentalRate
      contextRef="i8211dee89c274d37bf293694b115ff85_D20190101-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDYzNzI_fec71c9b-4ac2-46c7-83b3-ae205dfd5740"
      unitRef="usd">9700</dyai:OperatingLeasesMonthlyRentalRate>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i61fc32e45fcc49988560c5d708fe090a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTA_55dac97a-d9bd-4ed7-9114-14430e04258e"
      unitRef="sqft">258</us-gaap:AreaOfRealEstateProperty>
    <dyai:OperatingLeasesAnnualRentalRate
      contextRef="ia67696ba89b140ea84bb3079e5ab8ed6_D20180101-20181231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTEwMjI_3d9bc8a1-6a47-411c-b814-6aad073c0eff"
      unitRef="usd">4700</dyai:OperatingLeasesAnnualRentalRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i86a13c798877437492fa7b0a4354cb9c_I20190201"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTk_77682a65-284b-4727-9c00-ef215d8ba3a5">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dyai:OperatingLeasesAnnualRentalRate
      contextRef="id91f496dcbb044758f163cbd859eb73a_D20190201-20190201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY0MTM_defc248d-051a-4c3b-a3d7-1358bd9097b0"
      unitRef="usd">4000</dyai:OperatingLeasesAnnualRentalRate>
    <dyai:CommitmentToPay
      contextRef="i1ce85b8cbbff401ab8f9208885798348_I20190628"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2NjA_f51a492f-2e36-4654-ada1-f9c487fd2e8e"
      unitRef="eur">2520000</dyai:CommitmentToPay>
    <dyai:CommitmentDevelopmentPeriod
      contextRef="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NDY2OTU_ddbdd7bd-c941-488f-968b-b7da539d0796">P3Y</dyai:CommitmentDevelopmentPeriod>
    <dyai:CommitmentSuccessBonusAward
      contextRef="i1ce85b8cbbff401ab8f9208885798348_I20190628"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2Njc_6f3c0bfa-cf84-491d-8eb0-e15730071ad6"
      unitRef="eur">450000</dyai:CommitmentSuccessBonusAward>
    <dyai:CommitmentToPayExpanded
      contextRef="i5359f3a055db4f1886c3bd132f79cdb1_I20191025"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2NzE_674445c5-b3c6-411f-a723-69f61e2ef634"
      unitRef="eur">690000</dyai:CommitmentToPayExpanded>
    <dyai:CommitmentToPayExpandedPeriod
      contextRef="ia22c697beb7d4b0ab318ca61134fe993_D20191025-20191025"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2Nzc_fab5e529-9265-404c-a4cc-157bee319812">P1Y6M</dyai:CommitmentToPayExpandedPeriod>
    <dyai:CommitmentsRightToTerminateContractNoticePeriod
      contextRef="ie8d4f52126064e539ac154f09ee0c35b_D20190628-20190628"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzE2NDkyNjc0NTE2ODA_5cd38abe-8d9d-4323-b433-4d35ea4c429f">P90D</dyai:CommitmentsRightToTerminateContractNoticePeriod>
    <us-gaap:LongTermPurchaseCommitmentTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90ZXh0cmVnaW9uOjhiY2EwMWMyYWZkNTRhZWQ4YjViOTU3NzBmZDhiMGJmXzQ3MDI_bf2d7573-d34e-405f-8ee6-a34e566dca68">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a schedule of commitments related to agreements to purchase certain services in the ordinary course of business, as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.190%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.810%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,762,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,103,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,362,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermPurchaseCommitmentTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzAtMS0xLTEtMA_33ff6109-bdf7-4d3b-af62-c3a206056ec2"
      unitRef="usd">2762175</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzEtMS0xLTEtMA_d0d19e71-8c15-47b2-91fd-f0a06c62ff40"
      unitRef="usd">1103632</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzItMS0xLTEtMA_34b45895-fff0-474c-a548-d92f29678c3c"
      unitRef="usd">496268</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligation
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDUvZnJhZzo4YmNhMDFjMmFmZDU0YWVkOGI1Yjk1NzcwZmQ4YjBiZi90YWJsZTphYzQ2NzU0MzdlYjE0ZmFiYjJlZDY2NTQyM2U3NTYwMC90YWJsZXJhbmdlOmFjNDY3NTQzN2ViMTRmYWJiMmVkNjY1NDIzZTc1NjAwXzYtMS0xLTEtMA_01d49584-d5cd-4485-a634-5121682160aa"
      unitRef="usd">4362075</us-gaap:PurchaseObligation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODU_dc0dc32d-96a2-4496-8a01-f7a8c65549f9">Share-Based Compensation&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Description of Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2011 Equity Incentive Plan (the &#x201c;2011 Plan&#x201d;) was adopted by the Board on April 28, 2011 and approved by the Company&#x2019;s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company&#x2019;s 2006 Stock Option Plan (the &#x201c;2006 Plan&#x201d;). Since the effective date of the 2011 Plan, all future equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company&#x2019;s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provision of the 2011 Plan, the Board approved an increase of 1,500,000 shares each year to the plan on January 1, 2019 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019, the Company had 3,860,390 stock options outstanding and an additional 1,547,211 shares of common stock available for grant under the 2011 Plan. As of December&#160;31, 2018, there were 3,552,890 stock options outstanding and 1,136,211 shares of common stock available for grant under the 2011 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options are granted to purchase common stock at prices that are equal to the fair value of the common shares on the date the option is granted. Vesting is determined by the Board at the time of grant. The term of any stock option awards under the Company&#x2019;s 2011 Plan is no more than 10 years except for qualified options granted to the CEO (five years) and certain contractors (two years).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected stock price volatility.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The expected stock price volatility was calculated based on the Company&#x2019;s own volatility since the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company&#x2019;s historical volatilities since 2016, as the DuPont Transaction resulted in significant changes in the Company&#x2019;s business and capital structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected life of option. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 years) and certain contractors (i.e., 2 years). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Discount for lack of marketability.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company applies a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to its April 2019 uplisting to the NASDAQ. The discount for lack of marketability is no longer applicable since the uplisting of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assumptions used in the Black-Scholes option pricing model for stock options granted for the year ended December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.522%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.971%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-Free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.69% - 2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.24% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;28.59% - 37.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;27.80% - 30.36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2 - 6.25 Years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount for lack of marketability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0 - 8.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;9.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the combined stock option activity under the Company&#x2019;s Equity Compensation Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,712,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$69,090&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,552,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1,149,461&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Granted&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Exercised &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(781,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,860,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$13,287,932&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,747,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9,712,729&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;_________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Notes:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Represents the following stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b)300,000 stock options with an exercise price of $1.87 per share granted to the Board, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(2) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Represents the following stock options exercised:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;A total of 781,500 stock options exercised with a weighted average market price of $1.60, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b) 341,500 stock options exercised with cash payment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted average grant-date fair market value of stock options granted for the years ended December&#160;31, 2019 and 2018 was $0.69 and $0.41 respectively, based on the Black-Scholes option pricing model. The intrinsic value of options exercised for the years ended December&#160;31, 2019 and 2018 was $2,925,662 and $39,360, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December&#160;31, 2019 and 2018, total unrecognized compensation cost related to non-vested stock options granted under the Company&#x2019;s share option plan was $222,330, and $162,786, respectively, which is expected to be recognized over a weighted average period of 1.83 years and 2.39 years, respectively. The Company will adjust unrecognized compensation cost for actual forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Compensation Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize all share-based payments to employees, consultants, and our Board, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company&#x2019;s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For performance-based awards, the Company recognizes related stock-based compensation expense based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. For the year ended December&#160;31, 2019, the Company recognized the expense related to the performance-based awards granted prior years upon the Company&#x2019;s April 2019 uplisting to the NASDAQ of approximately $483,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.648%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.810%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,069,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;390,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,171,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie8f1835196484e3c945b149529822d3d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzQ0MQ_da1a8a9a-b3fb-4799-97e6-e396912de42d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzUyMA_e1496400-3d58-4b57-b54d-20085d7fee4f"
      unitRef="shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i28c9d6b0788b439c9ff3572a031dea3d_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4MjM_13b82368-7873-4629-beb2-cb9babb3398e"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzkwNw_0588b73d-d21b-43c8-9e9c-bcbc03bb951d"
      unitRef="shares">3860390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6bc87413de324e139a2bbae4ce1ef2eb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzk1NA_f68d97eb-449a-4a55-ae0f-e8d85cc80cfb"
      unitRef="shares">1547211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzEwNDI_08c6b0b4-92a7-410d-ac9d-1134ec5bcd3b"
      unitRef="shares">3552890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i87754620edec4143a42a41e6727c2af7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzEwNzU_7c5771cc-15e0-4a98-98fb-aa8855030445"
      unitRef="shares">1136211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia095586e60d44997a6ddefe3f667eb8a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4Mjg_8efc51f9-ccea-438d-840a-47cc19761f89">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4MzQ_e5b2c1b1-adb0-48b5-9f97-4978e1819f29">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4NDM_0d7558a4-92b6-476e-b8e3-8e4eb53329cb">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4NjY_84244c8b-ea72-4fb0-bf3c-7a3076ef1ef8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic57a1ab1519e48ba8508c0a12fb42cfb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4OTM_96dc4f58-e8fd-40b2-9245-3265113603d6">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i52937a3a33884bd4b97b3d1578133279_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNjM4OTY_27b7f650-6ebb-41a6-a0ca-c679cc4f69a8">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODY_0d596e74-beb3-48c8-8e74-bc1ef1f7de55">The assumptions used in the Black-Scholes option pricing model for stock options granted for the year ended December&#160;31, 2019 are as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.522%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.971%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.231%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-Free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.69% - 2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2.24% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;28.59% - 37.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;27.80% - 30.36%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2 - 6.25 Years &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount for lack of marketability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0 - 8.48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;9.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjMwNTNkMTNmNDA0ZTRhMTg4NGM4YTA5ZjBkNTgxYzkxXzY1OTcwNjk3NjY2Nzg_16c362f4-7944-4ceb-9966-8dd4d408a838"
      unitRef="number">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjMwNTNkMTNmNDA0ZTRhMTg4NGM4YTA5ZjBkNTgxYzkxXzY1OTcwNjk3NjY2ODU_2c818818-a9dc-4f2b-9aa9-7d0c91e04a0a"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNjMzZiMTFiNzA4NDRhMzA4MDM4MzhiZGQ0MmI3NDY2XzY1OTcwNjk3NjY2Nzg_cae72bc9-c1ed-4bde-a196-d9c89d71ff6a"
      unitRef="number">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNjMzZiMTFiNzA4NDRhMzA4MDM4MzhiZGQ0MmI3NDY2XzY1OTcwNjk3NjY2ODU_7e4f47f9-7cad-482b-a799-024a1da5cc2c"
      unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjE1ODBiMmY1OGZmMzRmZjE4MGFhNmM5NTNlMmU5MWU1XzY1OTcwNjk3NjY2NjQ_a6540d99-f143-4989-8a2f-95bdfbddfc1d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjY4YWNjYjQyZDI5OTQ1MTFiNWNlNzRhZTQ4NDc0ODFhXzY1OTcwNjk3NjY2NjQ_5c59ff9d-e62d-424c-81fc-b14cb2d7bb65"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmYxNGZjMzY4MGZlNjQyOGFhNzNhNDBlZDU2YjMwMWY2XzY1OTcwNjk3NjY2ODE_d4cc273a-768f-4253-998c-442b78c41c0e"
      unitRef="number">0.2859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmYxNGZjMzY4MGZlNjQyOGFhNzNhNDBlZDU2YjMwMWY2XzY1OTcwNjk3NjY2ODk_b413dc16-1c36-4447-88a1-51d4b1e43666"
      unitRef="number">0.3729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMy0xLTEtMC90ZXh0cmVnaW9uOjQxMWVjMjAxY2FjNDRjOTRiZjllZDVjMjk4ODVkNTdhXzY1OTcwNjk3NjY2ODA_39add43b-0df6-4618-8723-e61cdc553637"
      unitRef="number">0.2780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzQtMy0xLTEtMC90ZXh0cmVnaW9uOjQxMWVjMjAxY2FjNDRjOTRiZjllZDVjMjk4ODVkNTdhXzY1OTcwNjk3NjY2ODg_a9518b2e-0982-4179-90e7-ad726f2c3e98"
      unitRef="number">0.3036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjg2MTkzYTAzYWE4OTQyYmNhMTA4MDU5ZDgyMmQyNjUwXzY1OTcwNjk3NjY2NzY_fac8afeb-b365-4571-ab0d-9ef43deecf70">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjg2MTkzYTAzYWE4OTQyYmNhMTA4MDU5ZDgyMmQyNjUwXzY1OTcwNjk3NjY2ODg_853aaf4e-f4b3-459f-81e6-26c9451890cc">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2cf44cd91f594d6e9d9f2be57dbefa3d_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjBjZGQ4YjcxMTk4YjRmOWM5MjQyM2U0N2YzMDhhODUyXzY1OTcwNjk3NjY2NzU_6b59493a-6ee9-43d8-bf4b-8f80016a14af">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic164a2b8759541bd92fd673e0a617119_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjBjZGQ4YjcxMTk4YjRmOWM5MjQyM2U0N2YzMDhhODUyXzY1OTcwNjk3NjY2ODc_216fd0d1-4208-4228-be28-909c5526fd0e">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability
      contextRef="idf72c98a04594ed3b387bbd7e2817b6c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmQzZTJjY2ZkNGM5ODRlMGNiOWEwYTM4ODJkZTdjZGMzXzY1OTcwNjk3NjY2NzA_f95f82ae-6253-4c75-a0bd-8ac14be5932d"
      unitRef="number">0</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability
      contextRef="i5eb115573e8242ff8eb5d96d6270aab3_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmQzZTJjY2ZkNGM5ODRlMGNiOWEwYTM4ODJkZTdjZGMzXzY1OTcwNjk3NjY2Nzc_a1f779c6-3937-4213-80d2-8c5a781307e3"
      unitRef="number">0.0848</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability
      contextRef="i482152e4729849e1a4bf3e6c289fd50e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTowNjA5ZWVkN2ZkMzA0YmIyODU4ODI0MzkwMmRiZDJlMy90YWJsZXJhbmdlOjA2MDllZWQ3ZmQzMDRiYjI4NTg4MjQzOTAyZGJkMmUzXzYtMy0xLTEtMC90ZXh0cmVnaW9uOmYzZTE0NmZmZWZmYzQ4MmNiN2YwMDU1NjJhYzAyOTVlXzY1OTcwNjk3NjY2NzA_6e598fe0-a20e-4da4-aded-b93b5a993509"
      unitRef="number">0.0935</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODc_0684ba6b-142e-4d99-b142-1003f13de273">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the combined stock option activity under the Company&#x2019;s Equity Compensation Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.795%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.821%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,712,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$69,090&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(250,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,552,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1,149,461&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Granted&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Exercised &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(781,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,860,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$13,287,932&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,747,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$1.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9,712,729&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;_________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Notes:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Represents the following stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b)300,000 stock options with an exercise price of $1.87 per share granted to the Board, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(2) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Represents the following stock options exercised:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;"&gt;A total of 781,500 stock options exercised with a weighted average market price of $1.60, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b) 341,500 stock options exercised with cash payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtMS0xLTEtMA_160a74af-ea45-47a7-86cf-de65c0c719da"
      unitRef="shares">2712390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtMy0xLTEtMA_1c5a8eb5-3114-420c-a849-ceb81015fdc6"
      unitRef="usdPerShare">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9911246a988f4400b2298393e4a8d174_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtNS0xLTEtMA_d06a1642-c33f-44e7-bdca-382981c548d5">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEtNy0xLTEtMA_79c6b6c6-0a81-4b21-90f9-96ea2f29a725"
      unitRef="usd">69090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzItMS0xLTEtMA_5bdd2f54-87bc-4a21-b205-da8932096fd0"
      unitRef="shares">1120500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzItMy0xLTEtMA_8ae8c6fc-2140-4632-9ef9-cd35f584e2d8"
      unitRef="usdPerShare">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzMtMS0xLTEtMA_36121558-7c0e-4512-8a4a-e2f1ea79d96f"
      unitRef="shares">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzMtMy0xLTEtMA_733cb5fb-e35b-4afd-bbff-a20a049c0293"
      unitRef="usdPerShare">0.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzQtMS0xLTEtMA_28677f60-35dc-47f8-aa80-b825c3e8824b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzQtMy0xLTEtMA_adfd197a-6c8e-40bf-b3a5-303b5a5cb51b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzUtMS0xLTEtMA_a7ec41bd-f67c-4f4a-ab21-04e4d2030899"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzUtMy0xLTEtMA_75e77f51-d9bd-4136-97bf-058fe3e9a6cf"
      unitRef="usdPerShare">1.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtMS0xLTEtMA_18ba0725-c3b3-46e9-aa3e-232b7f9d0ee1"
      unitRef="shares">3552890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtMy0xLTEtMA_5afdf2f1-f3d4-451b-8a1f-df5b32d391fd"
      unitRef="usdPerShare">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtNS0xLTEtMA_797d90e5-3444-49e1-95e0-12c57def8433">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzYtNy0xLTEtMA_bfb4c713-f0f3-472d-8e24-40b505cd51f7"
      unitRef="usd">1149461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzctMS0xLTEtMA_73d44925-d2c3-449e-90b8-f31c66c2ce76"
      unitRef="shares">1089000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzctMy0xLTEtMA_64dfe1df-11aa-4934-bb3b-63dce0a21024"
      unitRef="usdPerShare">2.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzgtMS0xLTEtMA_5cdc185d-147c-456e-88b1-dd8978a18923"
      unitRef="shares">781500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzgtMy0xLTEtMA_d198b424-f0a9-4e32-8aa9-d8dc4bc81164"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzktMS0xLTEtMA_31eeaaf5-6d1a-4654-8929-8f6e93116cec"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzktMy0xLTEtMA_a4dd04a0-4884-4ed1-90c4-54350be6cdb1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEwLTEtMS0xLTA_76e32165-8b0a-4620-8b43-83420a7b900c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEwLTMtMS0xLTA_94fa2caf-46b5-4c2a-a0b0-58b29d18ab54"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTEtMS0xLTA_0588b73d-d21b-43c8-9e9c-bcbc03bb951d"
      unitRef="shares">3860390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTMtMS0xLTA_84fd193e-61ee-4f5d-a436-f3f54374e84f"
      unitRef="usdPerShare">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTUtMS0xLTA_f0fb34be-e176-4e32-a325-278b8b9a5769">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzExLTctMS0xLTA_2aa7afc8-c5f9-49ca-acc8-f30613fbb48a"
      unitRef="usd">13287932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTEtMS0xLTA_871f7e64-49ed-4672-a006-b6e037009c86"
      unitRef="shares">2747073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTMtMS0xLTA_7bca65ac-0266-4ef5-8f02-b10d6596b8dc"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTUtMS0xLTA_360cbbf8-e54d-476f-8213-0bae3cf17688">P4Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZTpmMzMyNTYxN2EzOGI0ODI5OTVkN2YzOTdhMDAyY2IzMi90YWJsZXJhbmdlOmYzMzI1NjE3YTM4YjQ4Mjk5NWQ3ZjM5N2EwMDJjYjMyXzEzLTctMS0xLTA_c0969b3b-2e85-4ee6-99e7-bcf6372a354d"
      unitRef="usd">9712729</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if917f69cb62f4aeab421b5233da141a9_D20190102-20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMDU_e2ce9dc8-80fa-4844-83a9-1c43b60cd336"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1003cf64787c47bfa079db8551f27546_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMTI_39c1758f-ae26-400e-bef0-073c2bbfe27e"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i1003cf64787c47bfa079db8551f27546_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4MzE_9c0052cb-34c9-43c9-af03-3e48aa29cee6">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4MTc_a07cce3b-65f1-4fd4-9475-9f76d5d82ebb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMjI_60e0e189-ea98-4361-87df-63f23bc8e9a6"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iecf4c59c5ff84d498d8de4c5ab6bf4d8_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMjk_ce9e4cc5-8be8-4472-8c47-a60036d2d8cd"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia4ff0366c2954e079f8bfbc42ddd2255_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4Mzc_67bdd6f1-720b-4ac2-be18-0e4765cbdec5"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4NDI_2f8e9603-c245-412c-a8e6-db0972b93e3e"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2573f81d4069484a8f3c27162e1d4825_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzgyNDYzMzcyMjgzMTM_d2834520-3df2-4aa6-9a38-9dfc204c4827">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzMzc_41e46a3e-fc5b-427b-a18a-336394fe96c8"
      unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie7000ffe9889466f8d52753b99ce58c6_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNDQ_057affdd-6bcf-4ea5-9413-9d8021017f25"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i00400d75393341c0b8c51dd7dcaf9263_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4Njk_0ddec862-7045-474b-8470-182253ccde72">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia68b902c3b614063bf94fc0cb7873a7b_I20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNTI_e8581a8c-092a-486f-9147-aac2c3ec8b4a"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idc984c2633c84830a7590e6783b2de69_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNTk_1b8fb23c-7098-4777-a339-d71440b81d12"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="idc984c2633c84830a7590e6783b2de69_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4ODE_f944f1db-b7fa-4302-8643-5d7bcd9ab6ea">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i502f339e9a564d2fa057ffd43b430345_I20190307"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNjc_3eba5a7f-0aec-42bd-a5f7-085a5947ea04"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzNzQ_543f45a0-0eed-49f2-8419-8aa03187e9ec"
      unitRef="usdPerShare">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i2610638851ac4494a605bca2a9e13cbc_D20190307-20190307"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI4OTM_eb307dd8-07ac-4af9-9cc4-68074dadc2eb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5361038870ba43a3836b3611390751a9_I20190625"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzODI_19418424-8686-4be6-a7cb-f9ee669208bd"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzODk_370f62f4-54b0-4c38-89e4-ae51cdc5a1f3"
      unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors
      contextRef="i3180a4adc61148acb883d0951ed14fe7_I20190625"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI5MDU_6001b08c-b89b-470e-9e51-8fdc6494c9ab"
      unitRef="board_of_director">3</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ib3c735c7ddc94135aa62d5acb4e67207_D20190625-20190625"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4Xzc2OTY1ODE0MTI5MTc_85a7e532-8cff-40ee-9342-e2500b4383f8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i263ac90ac6ab451aac269f8d91a7bb57_I20190628"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMzOTc_6c1944d0-c264-4a5a-84f4-edfec7b82077"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1ae81b32c80540568b0ddbf678fb73fb_D20190628-20190628"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MDQ_e808c70b-d50a-4ceb-a105-530a9efb68cb"
      unitRef="usdPerShare">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzMyOTQ_923f554b-d296-4516-b3a2-fe0216a43555"
      unitRef="shares">781500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MTU_2894e31b-7982-4452-a43c-b7bdc4e1fa11"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MjU_07da2c3e-896f-49fa-a1b6-d15630cb9466"
      unitRef="shares">440000</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0MzQ_30422e09-ff63-4433-ab23-c0ed7430684a"
      unitRef="shares">304171</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0NDM_8dc47c97-8aa0-4f5b-8953-8685aa79914f"
      unitRef="shares">135829</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited>
    <dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzIxOTkwMjMyNzM0NTI_4829824b-05e5-4acf-8196-c269df13e17f"
      unitRef="shares">341500</dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk1NzU_0a4f7614-4ccc-4712-89a0-d379a3d513ec"
      unitRef="usdPerShare">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2MDQ_51c9bc76-d3ef-4743-bf50-584c677c7bc1"
      unitRef="usdPerShare">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2MzM_693b2ff5-58a0-458f-b2e8-621efa677cdd"
      unitRef="usd">2925662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Mzg_1a313147-0e9f-46e4-b807-1c0ad546a574"
      unitRef="usd">39360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Njg_270cf66c-b80c-42b4-ac63-ab01d88d420e"
      unitRef="usd">222330</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2NzM_77ba6407-5369-4c0d-8e5c-9c5787028ce0"
      unitRef="usd">162786</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2Nzg_af4612ee-5674-4a02-a239-0792c20963e0">P1Y9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzE2NDkyNjc0NTk2ODE_069cb310-6998-4ad2-8032-af04bd1bae9a">P2Y4M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e4e110274cd42e68c73b41957abca9b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzY1OTcwNjk3ODY1ODI_d92c27e5-35ea-4f6f-9c56-8c54bf2fc407"
      unitRef="usd">483000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90ZXh0cmVnaW9uOmY4YTM5Y2U0M2ZmMTRhOGJhNGY4NWNiMGE1MmFmMjQ4XzcwODQ_1b86b9da-aeed-4acd-951d-03a0a6815df8">&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.648%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.810%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,069,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;390,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;101,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,171,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fb877e64e5f4588b05eb59d2f1f303e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzItMS0xLTEtMA_8f3c51d6-aee8-4962-8b84-42395a1781d8"
      unitRef="usd">1069152</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27724349c48a4973856d9b6cbe4f786e_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzItMy0xLTEtMA_9aff5b07-37fd-402c-b4f4-a1b4a65f4cdf"
      unitRef="usd">390854</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3065e8cc19c4622bc9018bea3d70c6f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzMtMS0xLTEtMA_55eef2ea-b5d2-4941-8abe-9a53492707b9"
      unitRef="usd">101927</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd3b28bef31b45d58d39978ccbae35a4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzMtMy0xLTEtMA_81501864-b807-4044-9182-4d287455ce62"
      unitRef="usd">76349</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzQtMS0xLTEtMA_44f0e776-3790-46d8-bbfc-7e7f505f7e20"
      unitRef="usd">1171079</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNDgvZnJhZzpmOGEzOWNlNDNmZjE0YThiYTRmODVjYjBhNTJhZjI0OC90YWJsZToyZDkyNWNiODQ3MWE0NTk3YWFlNDI4YTE2YjAxM2I4Mi90YWJsZXJhbmdlOjJkOTI1Y2I4NDcxYTQ1OTdhYWU0MjhhMTZiMDEzYjgyXzQtMy0xLTEtMA_4438e253-d71e-4572-b324-aeedfab945a6"
      unitRef="usd">467203</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzI1NjY_38a38368-0435-433f-a2e1-4c205fc75fd3">Shareholders&#x2019; Equity&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The shares of common stock issued for the years ended December&#160;31, 2019 and 2018 were 645,671 and 30,000, respectively, with a weighted average issue price per share of $1.60 and $0.15, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Repurchases and Buybacks &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Stock Repurchase Programs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 16, 2016, the Board authorized a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzOTk_fe3a9107-bbfc-41d2-8697-3542846d9e85"&gt;one&lt;/span&gt;-year stock repurchase program, under which the Company was authorized to repurchase up to $15&#160;million of its outstanding common stock (the &#x201c;2016 Stock Repurchase Program&#x201d;). The 2016 Stock Repurchase Program ended on February 15, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 16, 2017, the Board authorized a new &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU0MDc_b5a00c4c-c973-45db-864c-25377b84925f"&gt;one&lt;/span&gt;-year stock repurchase program, under which the Company may repurchase up to $5&#160;million of its outstanding common stock (the &#x201c;2017 Stock Repurchase Program&#x201d;). On August 6, 2018, the Board authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s stock repurchase activities:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.651%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.973%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.638%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Average Price Paid per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Privately Negotiated Transactions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 12, 2016 - Abengoa repurchased and retired shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,136,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,884,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,363,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,639,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,363,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016 Stock Repurchase Program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January through February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,863,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,448,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,863,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,551,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017 Stock Repurchase Program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September through December 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,462,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January through August 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,644,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,304,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,644,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,158,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total open market and privately negotiated purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,390,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,814,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,253,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Treasury Stock &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2019, and 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU2MDI_529a7e67-7da4-4417-b237-1d66e050e224"
      unitRef="shares">645671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNjE_ca5fd1e9-acb1-444d-85ec-ce7530a6ff33"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU2MjE_52ce7f6f-2b09-4170-8d78-0f7dd8ab9646"
      unitRef="usdPerShare">1.60</dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice>
    <dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice
      contextRef="i5f71024c5ed54257ac7cb70bbc790091_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNjg_c7a0bbda-b213-4949-b632-436555fca469"
      unitRef="usdPerShare">0.15</dyai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNzI_655567d5-54d8-4a3f-a83f-0ebcb187495f"
      unitRef="usd">15000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7591c510da7a48b593cb45d1dddbb122_I20170816"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzNzk_0e8680d1-35d0-46aa-b4e0-3faf2211e8b4"
      unitRef="usd">5000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzI1Njc_2fd7c052-c99d-4d69-9db9-afc8f4ff6d70">The following table summarizes the Company&#x2019;s stock repurchase activities:&#160;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.217%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.651%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.973%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.638%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Average Price Paid per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Privately Negotiated Transactions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 12, 2016 - Abengoa repurchased and retired shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,136,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,884,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,363,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,639,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,363,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2016 Stock Repurchase Program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January through February 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,863,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,448,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,863,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,551,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2017 Stock Repurchase Program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September through December 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;537,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;381,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,462,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January through August 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,644,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,304,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,644,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,158,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total open market and privately negotiated purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,390,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,814,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,253,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItMS0xLTEtMA_eb677590-6a2a-459f-ae3a-effcd845b0f7"
      unitRef="shares">2136752</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItMy0xLTEtMA_1f1c9913-4e97-43b4-9db4-b9155fb2744a"
      unitRef="usdPerShare">1.35</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if57a17d4712e455d82e4e4b19b23f620_D20160112-20160112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItNS0xLTEtMA_73a7fdd5-f5b6-496a-b9a9-b79dc5f77bc5"
      unitRef="usd">2884615</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i25427c3bdaeb4b98b458ea7b34deb418_D20160112-20160112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzItNy0xLTEtMA_810a8583-381b-4a87-aadd-0b8338103e62"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtMS0xLTEtMA_f92b355b-5043-493d-8b68-5d1e5eecea0f"
      unitRef="shares">2363590</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtMy0xLTEtMA_8dcde854-cad5-438d-b5d4-c59197cae296"
      unitRef="usdPerShare">1.54</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtNS0xLTEtMA_efebfb02-73d4-45f1-a9a6-6afde516fa1b"
      unitRef="usd">3639929</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icfcfcf474ee74ca297efc69b74652e7b_D20170111-20170111"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzMtNy0xLTEtMA_d7de4bbf-0704-4f35-8537-505efda14ece"
      unitRef="shares">2363590</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie7f9c0575ceb4f10a24a50a759b6c5cf_I20160216"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzQtOS0xLTEtMA_dcd77273-ba23-48af-a15d-3dfffdc76a18"
      unitRef="usd">15000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtMS0xLTEtMA_6cbb6963-ef2a-491d-84d3-215fc19af738"
      unitRef="shares">7863980</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtMy0xLTEtMA_7d172f16-ce64-4d4b-a6be-86e0f2d01bc1"
      unitRef="usdPerShare">1.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6aefb3313cbd4ff2a1d1947ebe92dac1_D20170101-20170228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtNS0xLTEtMA_10fa7011-0807-4a0f-bb71-6f5e9eb471cc"
      unitRef="usd">12448283</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9b266eccec9447ddb9c6431bd35cf1b3_D20170101-20170228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtNy0xLTEtMA_8e3458a5-f6ef-4196-9cb7-9efabf6c489b"
      unitRef="shares">7863980</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ifc2601b2f77c479581fa9cf5d4cff3fd_I20170228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzYtOS0xLTEtMA_e834afc3-4dc3-4606-ad00-a4b05a56a5ae"
      unitRef="usd">2551717</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i7591c510da7a48b593cb45d1dddbb122_I20170816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEwLTktMS0xLTA_fc627875-6ada-4d50-bbe5-cac5320d5816"
      unitRef="usd">5000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTEtMS0xLTA_1fb9a14d-bf51-4725-a95c-f3b93eb639b2"
      unitRef="shares">381607</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTMtMS0xLTA_b6272262-4a78-4172-be2b-aecd20dff446"
      unitRef="usdPerShare">1.41</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia4bcaa2a3fec42ad910a887749d8a1ca_D20170901-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTUtMS0xLTA_36cc69c9-8ed7-419d-bfc9-797a2278b260"
      unitRef="usd">537661</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0cb224dd3f604e299d6ab6df8bc4eba6_D20170901-20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTctMS0xLTA_a83454b8-87d9-4f2c-8a65-89f376fcb79a"
      unitRef="shares">381607</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i03982adf61bb47ecbd79d2ecd04079fa_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzExLTktMS0xLTA_6dd33c5e-6124-42e2-90ba-e9bd97c315b2"
      unitRef="usd">4462339</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTEtMS0xLTA_dff8017b-93f2-4172-b5cd-27057bf8ef72"
      unitRef="shares">1644325</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTMtMS0xLTA_19703baf-3461-4051-96d8-77c61c34b3f6"
      unitRef="usdPerShare">1.40</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i47164fb9fd1a4fef924693ec117a7f74_D20180101-20180831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTUtMS0xLTA_2f11f899-7e1a-4346-a5d0-247ac4599a0a"
      unitRef="usd">2304042</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4c5bfc1c71754fd5b496a1784ee4c239_D20180101-20180831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTctMS0xLTA_f13da1c8-ea92-4cd2-b417-7217c223d386"
      unitRef="shares">1644325</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ied7940d17259403f80d1b1604a7b10e3_I20180831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzEyLTktMS0xLTA_6dbd84dc-351d-47ed-b3f6-c8a778700957"
      unitRef="usd">2158297</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTEtMS0xLTA_6d9298fe-5cb9-4927-99ff-84f1f55fbb92"
      unitRef="shares">14390254</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTMtMS0xLTA_ef3eb98c-5c3d-4c87-9ce4-629511714d4f"
      unitRef="usdPerShare">1.52</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib559063465144b6cb9251448720e1f2c_D20160101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTUtMS0xLTA_6fbd5244-5af5-4c3d-8560-bb811ba29785"
      unitRef="usd">21814530</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4f46b6e69ca64edd9b8fed76219f38f9_D20160101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90YWJsZTowY2NjZjg4MDdhYWI0OWJlODU3MTZjOTI4ZWM0MjQyZC90YWJsZXJhbmdlOjBjY2NmODgwN2FhYjQ5YmU4NTcxNmM5MjhlYzQyNDJkXzE1LTctMS0xLTA_9fa7ef73-8c35-4ad4-8a72-548dab2ee850"
      unitRef="shares">12253502</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockCommonShares
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzMjQ_028c1017-e91b-4ef7-ad25-475206571d10"
      unitRef="shares">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzMjQ_8a2a1622-8451-4a58-ba0c-2145cd2c3031"
      unitRef="shares">12253502</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="idcb179b7b3654ae5a927e4f22b10ba19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzOTU_b378a4c8-6473-45ba-83aa-cf45fdeed43c"
      unitRef="usd">18900000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i44b49ea3f208487698c65394dc8f911a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzIzOTU_ea67bead-69df-4653-b718-b2776ada3553"
      unitRef="usd">18900000</us-gaap:TreasuryStockValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExMjA_a01f940a-57b7-4f01-900c-8779c682da52">Subsequent Events &lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March&#160;30, 2020, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Our Research Contract with VTT&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the first quarter of 2020, we expanded our research contract with VTT Technical Research Centre of Finland Ltd. to pay an additional EUR &#x20ac;700,000 over the next 19 months to accelerate the glycoengineering work.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2020, the Company granted to executives and key personnel an aggregate of 525,000 stock options with an exercise price of $5.27. The options will vest upon &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzM_c9472d93-1ce1-40be-b972-3b905785428b"&gt;one&lt;/span&gt;-year anniversary or annually in equal installments over four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2020, the Company granted to the Board an aggregate of 325,000 stock options with an exercise price of $5.27. The options will vest upon &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc3OTA_d684f154-2502-42b6-b981-631a93c5af69"&gt;one&lt;/span&gt;-year anniversary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2020, the Company granted to non-executive employees an aggregate of 23,000 stock options with an exercise price of $5.27. The options will vest annually in equal installments over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ2OTQ_7df95ba7-825f-4aa9-b588-d426d336e7e5"&gt;four&lt;/span&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2020, the Company granted 15,000 stock options to a consultant with an exercise price of $5.27. The options will vest upon &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MDA_a7899946-65d3-4626-88f3-03385835ab46"&gt;one&lt;/span&gt;-year anniversary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 23, 2020, the Company granted 25,000 stock options to a consultant with an exercise price of $3.99. The options will vest six months from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States. As of the date of issuance of the financial statements, the Company&#x2019;s operations have not been significantly impacted, however, the Company continues to monitor the situation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <dyai:ResearchAndDevelopmentExpenseAdditional
      contextRef="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk4MTU4NzY_694b21ba-e592-4ff7-babe-5e5c93a27a0c"
      unitRef="eur">700000</dyai:ResearchAndDevelopmentExpenseAdditional>
    <dyai:ResearchAndDevelopmentExpenseAdditionalTerm
      contextRef="i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODE0NDM2NjM_871992a1-e41d-470e-982d-e2c8257d3964">P19M</dyai:ResearchAndDevelopmentExpenseAdditionalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzkxOA_17bcd5a3-70b5-4fb6-a8f3-5b16aed8e19d"
      unitRef="shares">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8dba85e6dbe14d5a8c2ed17d1bb0ce1c_D20200102-20200102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzk2MQ_f0063175-9f24-4834-b4d4-443f040266c3"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i43b5030b61534a9995f73c86b9ce994a_D20200102-20200102"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE2NDkyNjc0NDQ1MzY_40c34f9e-7af2-4195-9333-85cd662336de">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzExNDI_f880b115-bb44-498a-af9e-ec775c7bba6d"
      unitRef="shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icc7b72c140374bbbb24f348e583b9a74_D20200102-20200102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzc2OTY1ODEzOTc4MDM_3709b06c-a2b2-422b-8027-894804b62827"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzEzODE_ab088695-fbcc-4a34-9f62-8c7de8953ca4"
      unitRef="shares">23000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie370b8ecda9f47d08250fce2fe4a61f4_D20200102-20200102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzE0MjQ_620dfc80-e80a-4571-8d48-6207056531d6"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg4MjE_2be8c114-58ae-4acf-a124-d45be32c4ccb"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic9a083a85cfb4bd8a0240fb99cc559a2_D20200102-20200102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzIxOTkwMjMyNTg3Njg_f2133754-ddab-4744-aaa8-a3f1aaa06ece"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExMzY_aaf04bdd-8a80-48c0-8ad5-cc774cda4887"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iea74ecbcfc94472a955ec2ed8aa02b50_D20200323-20200323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExNTU_783f36ec-a1c6-48d0-b924-c205ca4e5a20"
      unitRef="usdPerShare">3.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i013a834cf3654f739dbd6679b50f16e6_D20200323-20200323"
      id="id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTcvZnJhZzowYjFlY2JlMDg0ZGU0MGM4OGEyZDg0ODdhNDUzNzIxMC90ZXh0cmVnaW9uOjBiMWVjYmUwODRkZTQwYzg4YTJkODQ4N2E0NTM3MjEwXzY1OTcwNjk3NzExNzA_d1d316b4-15c5-422e-8432-893c71e3a2eb">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6715402320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,171,079<span></span>
</td>
<td class="nump">$ 467,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,069,152<span></span>
</td>
<td class="nump">390,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 101,927<span></span>
</td>
<td class="nump">$ 76,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6865096848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DYADIC INTERNATIONAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0486747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">140 Intracoastal Pointe Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">743-8333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,359,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6865425408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalent, and Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 4,823,544<span></span>
</td>
<td class="nump">$ 2,386,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments, adjusted cost</a></td>
<td class="nump">29,399,146<span></span>
</td>
<td class="nump">38,816,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments, adjusted cost</a></td>
<td class="nump">1,511,636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and Investment, fair value</a></td>
<td class="nump">35,738,787<span></span>
</td>
<td class="nump">41,117,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investment, gross unrealized holding gain</a></td>
<td class="nump">22,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investment, gross unrealized holding losses</a></td>
<td class="num">(17,991)<span></span>
</td>
<td class="num">(85,321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_InvestmentsandCashAmortizedCost', window );">Cash and Investment, adjusted cost</a></td>
<td class="nump">35,734,326<span></span>
</td>
<td class="nump">41,202,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,010,510<span></span>
</td>
<td class="nump">1,048,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,813,034<span></span>
</td>
<td class="nump">1,338,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase', window );">Held-to-maturity, premium paid on purchase</a></td>
<td class="nump">233,550<span></span>
</td>
<td class="nump">378,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent', window );">Short term investments, fair value</a></td>
<td class="nump">29,387,053<span></span>
</td>
<td class="nump">38,731,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent', window );">Short term investments, gross unrealized holding gain</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent', window );">Short term investments, gross unrealized holding loss</a></td>
<td class="num">(17,991)<span></span>
</td>
<td class="num">(85,321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments, adjusted cost</a></td>
<td class="nump">29,399,146<span></span>
</td>
<td class="nump">$ 38,816,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent', window );">Long term Investments, fair value</a></td>
<td class="nump">1,528,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long term Investments, gross unrealized holding gain</a></td>
<td class="nump">16,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long term Investments, gross unrealized holding loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments, adjusted cost</a></td>
<td class="nump">$ 1,511,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Fair Value, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Fair Value, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-maturity, Premium Paid on Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_InvestmentsandCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments and Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_InvestmentsandCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871940544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,936,988<span></span>
</td>
<td class="num">(10,609,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 49,975,264<span></span>
</td>
<td class="nump">$ 38,937<span></span>
</td>
<td class="num">$ (16,625,873)<span></span>
</td>
<td class="nump">$ 93,913,557<span></span>
</td>
<td class="num">$ (27,351,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 467,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,644,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock</a></td>
<td class="num">(2,304,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,304,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,691,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,691,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">38,966,988<span></span>
</td>
<td class="nump">38,966,988<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 42,451,169<span></span>
</td>
<td class="nump">$ 38,967<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">94,385,230<span></span>
</td>
<td class="num">(33,043,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,171,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,171,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">781,500<span></span>
</td>
<td class="nump">645,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 550,188<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,307,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,307,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">39,612,659<span></span>
</td>
<td class="nump">39,612,659<span></span>
</td>
<td class="num">(12,253,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 35,864,471<span></span>
</td>
<td class="nump">$ 39,613<span></span>
</td>
<td class="num">$ (18,929,915)<span></span>
</td>
<td class="nump">$ 96,105,851<span></span>
</td>
<td class="num">$ (41,351,078)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788274992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 173,890<span></span>
</td>
<td class="nump">$ 91,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - various</a></td>
<td class="nump">101,221<span></span>
</td>
<td class="nump">77,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 277,999<span></span>
</td>
<td class="nump">$ 172,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779513616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text">The assumptions used in the Black-Scholes option pricing model for stock options granted for the year ended December&#160;31, 2019 are as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:54.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.522%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.971%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.231%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="8" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-Free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.69% - 2.50%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.24% - 2.96%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28.59% - 37.29%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">27.80% - 30.36%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2 - 6.25 Years </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 - 6.25 years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount for lack of marketability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0 - 8.48%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">9.35%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the combined stock option activity under the Company&#8217;s Equity Compensation Plans:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.795%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.284%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.821%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,712,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.62</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.09</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$69,090</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(250,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,552,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.57</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1,149,461</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Granted</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,089,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Exercised </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(781,500)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,860,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.76</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.69</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$13,287,932</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,747,073&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$1.65</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.61</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9,712,729</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Represents the following stock options granted:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">Annual share-based compensation awards on January 2, 2019, including: (a) 600,000 stock options with an exercise price of $1.87 per share granted to executives and key personnel, vesting upon grant, or one year anniversary, or vest annually in equal installments over four years, (b)300,000 stock options with an exercise price of $1.87 per share granted to the Board, vesting 25% upon grant and the remaining 75% will vest annually in equal installments over four years, and (c) 24,000 stock options with an exercise price of $1.87 per share granted to employees, vesting annually in equal installments over four years. </span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">One-time awards granted on (a) January 2, 2019 of 50,000 stock options with an exercise price of $1.87 per share granted to a contractor, vesting upon one year anniversary, (b) March 7, 2019 of 15,000 stock options with an exercise price of $3 per share granted to a contractor, vesting upon one year anniversary, (c) June 25, 2019 of 75,000 stock options with an exercise price of $5.83 per share granted to three members of the Board, vesting upon one year anniversary, and (d) June 28, 2019 of 25,000 stock options with an exercise price of $6.26 per share granted to the Chief Financial Officer, vesting immediately.</span></div><div style="text-align:justify;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(2) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Represents the following stock options exercised:</span></div><div style="text-indent:-9pt;padding-left:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt;">A total of 781,500 stock options exercised with a weighted average market price of $1.60, including (a) net share exercise of 440,000 stock options resulting in the issuance of 304,171 shares of common stock, and surrender of 135,829 shares, and (b) 341,500 stock options exercised with cash payment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of non-cash stock option compensation expense</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock option compensation expense was allocated among the following expense categories:&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.648%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.810%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,069,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">390,854&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,171,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779355232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research and Collaboration Agreements</a></td>
<td class="text">Research and Collaboration Agreements<div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BDI </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 30, 2017, the Company entered into a strategic Research Services Agreement (the &#8220;RSA&#8221;) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (&#8220;BDI Pharma&#8221;), and a Service Framework Agreement (the &#8220;SFA&#8221;, and together with the RSA, the &#8220;R&amp;D Agreements&#8221;), with VLP The Vaccines Company, S.L.U. (&#8220;VLPbio&#8221;), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (&#8220;BDI Holdings&#8221; and together with BDI Pharma and VLPbio, &#8220;BDI&#8221;). </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xMzYvZnJhZzpkYWVhZTU5M2FlYzA0NDJiOWEwYjQwYzM0ODE2NTQ0NC90ZXh0cmVnaW9uOmRhZWFlNTkzYWVjMDQ0MmI5YTBiNDBjMzQ4MTY1NDQ0XzE2NDkyNjc0NTEyODE_d817c484-c349-4120-9e27-b9d41a8a4fa5">two</span>-year period, with a focus on advancing Dyadic&#8217;s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team&#8217;s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic&#8217;s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the BDI transaction, the Company paid EUR &#8364;1 million (the &#8220;RSA Initial Payment&#8221;) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR &#8364;936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI&#8217;s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR &#8364;1&#160;million for a 50% share and EUR &#8364;8&#160;million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR &#8364;1.5&#160;million of the net income from Dyadic&#8217;s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1&#160;million (the &#8220;SFA Commitment&#8221;) in contract research services specified by Dyadic over two years since the closing of the BDI transaction. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has concluded that BDI is not a Variable Interest Entity (&#8220;VIE&#8221;), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company&#8217;s consolidated financial results. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1&#160;million (EUR &#8364;1&#160;million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1 million paid by Dyadic was expensed as the related research services are performed by BDI. BDI has completed its services under the RSA in June 2019, and the entire amount of the RSA Initial Payment was expensed. As of December&#160;31, 2019, Dyadic has fulfilled its SFA commitment, and all research projects under the SFA were completed.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019 and 2018, the prepaid research and development collaboration related to BDI recorded on our consolidated balance sheets were none and approximately $0.3&#160;million, respectively. For the year ended December&#160;31, 2019 and 2018, research and development expenses related to BDI were recorded as research and development - related party in our consolidated statements of operations in the amount of approximately $0.9 million and $1.2 million, respectively.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novovet and Luina Bio Sub-License </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2019, the Company entered into a sub-license agreement (the &#8220;Luina Bio Sub-License Agreement&#8221;) with Luina Bio Pty Ltd. (&#8220;Luina Bio&#8221;) and Novovet Pty Ltd (&#8220;Novovet&#8221;). Under the terms of the Luina Bio Sub-License Agreement, the Company granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary C1 gene expression platform&#160;for the exclusive and sole purpose of commercializing&#160;certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (&#8220;Novovet Up-Front Consideration&#8221;) in accordance with the terms of Novovet&#8217;s Shareholder Agreement (&#8220;Shareholders Agreement&#8221;), and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic&#8217;s proprietary C1 gene expression platform. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Alphazyme Sub-License </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 5, 2019, the Company entered into a sub-license agreement (the &#8220;Alphazyme Sub-License Agreement&#8221;) with Alphazyme, LLC (&#8220;Alphazyme&#8221;). Under the terms of the Alphazyme Sub-License Agreement, the Company granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to&#160;Dyadic&#8217;s proprietary C1 gene expression platform&#160;for the purpose of commercializing&#160;certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In consideration of the license granted pursuant to the Alphazyme Sub-License Agreement, Dyadic will receive a&#160;7.5%&#160;ownership interest in&#160;Alphazyme&#160;(&#8220;Alphazyme Up-Front Consideration&#8221;) upon the successful transfer of C1 technology, additional milestone payments and a percentage of royalties on net sales, if any, which incorporate Dyadic&#8217;s proprietary C1 gene expression platform. The Alphazyme Sub-License Agreement has an initial exclusivity period of&#160;18&#160;months (&#8220;Exclusivity Period&#8221;) beginning on the date the technology transfer has been completed. Following the Exclusivity Period, the sub-license will be nonexclusive. At any time prior to the expiration of the Exclusivity Period, Alphazyme has the option to extend the Exclusivity Period for an additional twelve (12) months in return for an additional&#160;2.5%&#160;ownership interest in Alphazyme.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investments in Alphazyme. The Company will account for its investment in Alphazyme under the equity method, given that it has the ability to exercise significant influence, but not control, over Alphazyme. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December&#160;31, 2019, the technology transfer of the C1 platform has not completed and Dyadic has not received the Alphazyme Up-Front Consideration. Therefore, no revenue form the Alphazyme Sub-Licensing Agreement was recorded at December&#160;31, 2019.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon receipt of the Alphazyme Up-Front Consideration, Dyadic will become a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company will agree to certain customary rights, covenants and obligations.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Commercialization Collaboration with Serum Institute of India</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 7, 2019, the Company entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (&#8220;Serum&#8221;). Under the terms of this collaboration, Serum anticipates applying Dyadic&#8217;s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic&#8217;s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.</span></div>For the year ended December&#160;31, 2019, the Company recognized approximately $118,000 in research and development revenue from Serum.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6873449792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2019 </div>
<div>board_of_director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089,000<span></span>
</td>
<td class="nump">1,120,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors', window );">Number of board of directors | board_of_director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781,500<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet', window );">Exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock', window );">Exercise of stock options, common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited', window );">Exercise of stock options, forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash', window );">Exercise of stock options, cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember', window );">Executives and Key Personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ContractorMember', window );">Contractor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Executives and Key Personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors | Share-based Compensation Award, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors | Share-based Compensation Award, Tranche Two through Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Sign on, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Sign on, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Contractor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_ContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_ContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6873174432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 23, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 25, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 02, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089,000<span></span>
</td>
<td class="nump">1,120,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseAdditional', window );">Research contract, expansion | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentExpenseAdditionalTerm', window );">Research contract, expansion, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember', window );">Executives and Key Personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember', window );">Executives and Key Personnel | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember', window );">Executives and Key Personnel | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors | Stock Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember', window );">Non-executive Employees | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember', window );">Non-executive Employees | Stock Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ConsultantMember', window );">Consultant | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (USD per share) | $ / shares</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dyai_ConsultantMember', window );">Consultant | Stock Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Executives and Key Personnel | Stock Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Executives and Key Personnel | Stock Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Additional</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentExpenseAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Additional, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentExpenseAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_ExecutivesandKeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_NonexecutiveEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dyai_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dyai_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001213809-20-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213809-20-000018-xbrl.zip
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M=MQ:WSEJ'7UEK8];H^;Y!CSS[7C_: ,UOV^Q*?"M?ST'\OQA#5 : IDGI54
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M<VU#)DVD%#=D]L7G7 +P 8M)8+ UB90J!,T^%BS1 ,PXTB8*F5!V#G9@/AP
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MGDM:9\8EMK"8F 13;&UB)-,\TA&.765JLD"16=J-^RPH@MWN6^5"S,!%=&1
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MSR<8 9I+Z?A0SITM^L-2*V2$>"..L6A0$K%&PI5MB%AK%*DH-)(OO4<T#+;
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M\)9R=T&8MR#,C6G"M/"#,6L8$28-*@UM)!JC!M(L2B*%$VZUSZ#?6A#=B]*
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MTG-?@*6XGL,0EV(\_N:+6%SPFY5G)(MO66?8&XC<[R//BU=-#E_/?UAIK4K
M$&8*@=(=F@C( >,&3:0@B"'&N'G-Y'!Z:'PZ_26:>(/^" Y!%#A"T('H=,;4
M,$DFTE0-H,]IRIBBB FA4>NBCDK<;5?6)=!PMW?@F_9SHXQW[R(<^&I[1? &
M^@.--RB&ZC H#C.W#;:NKC$X%(/+8S\5Q55B]@]7<_@C$#V]'+S!Y1PEZ,UP
M7Q[!#%Q[WQ0><J.H^G&5F0H_"#](40P"'@9:C(J5BL8G"?ZNOQ^?*:P-\QRF
M4):4<C;\0 R&KYPWD!\ZU@0S)1LD1JZ^!-:-1!G2P)2@)(P4$B9>>@_<^R;F
M &IE,*XC]2KYA*,?()UN.A@ L9D.D%">]9RSH#,*S(G)1RYCW.1"^:2K=3$0
MP68I7*?8R$4?D])V4OO<,0?#3KD]8K?1#MXXTHG_###!*V/]-/7;Y/MNF_QC
M,Y5RP&->88H_5GZ3^"__5/ML'ILE3(#%0:7B$*^:)>R-?A J8D()F/C.44=C
M%#<X9Z!,2QTG5$6)56C!$G[*$KR%V8$IFD H!2PA%XZN'9$X\[)W[570P'N-
M:V\47> E\):\EEU "UU8JY%3,Z WD,UN-0\"6+#3P6%]=P6T#N.'YJU97Y++
MYX*Z#"8,T[QA@/XV^K-N]LL&-PYOW!!TC;KQ#6.M6];V-L*R@6OE:5)C6@GN
MAE-SG]N#T0I&OWO<P\]OXI40T47/U4VV0FY],L;=>Y[E3*>'+*4^.XF'M^3L
MGZ[G@M=+L"O1IVCICM-ZR&7_22RLYD8@4\POFL["P*,%@C\:@J_^)FK_ ID6
MC.J)X?CX(51O%'D4<:KN09:/KMLCZ)VJ:U6#N326QK6YH6WS?/M[$^VO'\(S
MJ_"N#;1WOD7VV\=X^_O?1WM'!^XXH&MJ<X-A==YD>^??CK<_[H7-]9WN7AOF
M>J0[8$2QO6XKW5Y7H_)XASHY:>_\RO$.77=\P[?CO?9^N@]_6ZY&R]$QVS_:
M[S376\?-[@9\;ATVS_^VK:.O8*2M@I'F:H.JL^W5'TR 119CW" ZC!N4<]H0
MG*B&Y=)@EL2&8>L\N]?8%;=S]EYA"GS^ZN?/=*&0.\CI7S9="-''8[Z[-YK@
MSW=>0LF._<@^# L8<S&?[NRG9L=?;F3'>WCC;!]FVSK7G?V/?W=@#&<P3KK]
M?<\=XX":'UW9K<VC_>_?+K/CL'7Z0S CJ-2R$<K(;98SO"&(1@T41S9&'+@R
MIK\^-.XQM+%9T/$7HYF7T2P$R>,)DHWK_9_/+D;J<7WTPUHK1[40)[\2)Z.?
MBY.O(#J^XKTC?=C$,,Z/6W@/_YWNM]V:?"'-[E?6_/BMT\)7Q4GSX$<DE8VT
MY V<A+I!79YT$K.P$0L;18#6H:#JUX?X_+XXN3$E<^Z"-_8G41*W:_N665(N
MTNOCNV!$N72I018,BS+" K1:GK]XS>DG6>[?U1FYEY^F\&I'\#V86^84RI.T
M\$993_14*CK.%>E*);O&Q4#TM,AU$;BB/:F^*=>3O!%_7!,LF:FS1&Z C4N@
M?,YQWA*%[A;/G ,Y]!L!S>+0=#IC@?7FFBS9J:C=JAK\ <#UJ7_/+=UVW=#G
M6:@]2'R?M(Y61S\BKG!,$4@49%"#8L0:B2*V$1$NI(W"T"!QHU@)QL']G^0%
M7CE<YGZ%+1ZNIU+7/!H6@]2.9IQ W6X*<7  1.BHM%MNI2@W*%8$=I)Y(>&"
MZRYUH/JJREV-+D]G, H [WUJHL\ML"ZC#WHKZAXFLQUQO(P06D8L+G<]%G]X
M4A\.RMS&W%B3FYXR3O"X9U4G*]S[^H 6?DC_$ZW@*/ Y0LY' H_!, ;7[PDI
MW+V_AST3D+ \;39XXYIV7%JAK)P9+KGPZDC'Y5>Z6>$REMUNA<ZHE+#&O178
M0=;3]='(_QV69X;X["71!SEZE@+G,/#(_U1<:=/G ,& AKVTY$G#0B]-,RF3
M*!TQBA2VF@JM!#%&4J.!:U&!E?BQY9E41,(EX(H*7M$I_KG48-/G)_>&79T-
MJOM7N=3GH>RD:K.3B0&H9S!ZXVVQU\2N7!5S!N\@K?6O9]OM _3#A%3&-(D:
MAB=)@UK$ 9'CL&%A\8G1G$L,[ I%?&5<R:T&:.6&!>+LP+>58-?C]4]0JJ*=
MPF-J33J7ZZ7EQ7*@4T"\0>8^.O*#[M(\F*"O0P'-?5*M.7,E@4QU"%Z9GR<Z
MJLKC6PG:[HH&Q,V[H '6E;S'73D5<# LZ@3]'J![48@<V$W@Z@NY>D.%&]IT
M#W9<(AS4Q7Y6F.+JQI^?<LV9YHRK'H3 2-1A"6#,'0_!P$FN*.SC ]&O$GG)
MY2[1.8\5"7G,#4642J8XB>*0&$(1DC&6VM$Y#D."^22=;[4V[T3HY<YSSQ!+
MG-P>#KRN#PQU3/GAZZ+\\^WU+R[V=5I:P5OA#^"T"68F;$CBJJDFSIUJ0,.T
MF,14D% D$5EZ#W*+,.[DUA7RKP29PY8IRLXN5ON.='&C7C(CNL0--0W7M]>^
M-C=:[5UW#-GVSN?MG=7VQGKP82_8V=C<V-EHK6V\(/YPBXV.UX#NKA"_1J&\
MNW+J"=PHK$B$A(Q"1:V)$F9=<3VE&*%$DO!'O/1D ZK]OEGIPWB7&R>H3B8R
M&?_WG_6ACG@E9E<<LN,GA2RR#FB/?U9O#R>[6'KDJ4S^/LPOO-D'IB%S(XY!
MA0!Y^4YT3L6H<*=13HSFTO2>?-0_-UIFMH =9RO IG\OQS59P7'T&*F7"5X!
M>?THY>M6&+[7>7:/G$GQ>&=+XR<_,LI/"Y2IZF2;=Z## ?HZ#'1V\NJ'3QON
M>/2U[5;;R;@GR+J8R]RW&\#Y^HY=7ZSD[#.9YSC _C.H![\NP'>_X/@_E#+&
MVH?+>7L 9=S:QPGP.)7IIZS[+S%_@PX.<^<H^,>OM78$QNGGU9UVL/776W'/
M>.S#T?0=$/"GU:WNG*GQ""6_%XC[:(A+;\#91]!\_F']SYU98E3:9[,NH;<&
MIAN@E4<2T;^[> MY,B.#O@-91DOOZSS?.TF46<&KA228C4'?#>6>4A+\IG(\
M5Y)@]=%$P<*T>#5TR9?>[Z3%<; I?!3Z\<7!(^#60AS,QJ#OAG:(+"R#!Y4'
M'Q:FP8(P[TF8&"^]_]K+39%U3HP.=@?"VL EF;B:?0M;83; ^0IPD(0+8^$A
MA0->V H+NKPO7;*E]Y_SK.\@:Q:6PHS [Q4@W9,*@U=@*9"%H;"@R_O29;+T
M_I,Y$)T 1 (P:@>[A8$P(V!\!;A'T,) >$B90!<&PH(N[TF7!"V];\(SP:ZP
M9C *UM/"[>T<Y@MK85: ^0HP\$DEP^WTD45.\&+M'GOMGBZ#^IE6;Y%#O9 ,
M]Y ,M,ZAGM<DZH7:,F>#OAMRSJ#:,M<&+5LX.1=T>5^ZC,&@+>LEN4(H.U?K
MO)3U-X(-7R.I+.&RXS:Z^]R)3!T?9AUX;] 4 ^"_A;]?GJP;?![FZE 495&)
M\OF)LQT7GM39P)57@. +3^K#"IYHX4E=T.4]Z9*&2^]WZP*QF^."KNYLR84G
M=3: ^0HPD."%2?*0DB%>F"0+NKPO71)GDO3$@3]&?6R'N%#;L"A<64)G8ZSV
M1&=4I-ZVN! ?:UE/EP7%2SNE&'8&OLEVWY2#6M@=,X(0KP"+GU2ZO *[(U[L
M!UT0YGT)DR5+[[^X4R'2@:_6Z"4%7.C4WR=R.@(AL^&@JL,=N%VD"]MD-N#]
M"I"4Q O;Y"&E1[*P319T>4^ZC-#2^PMK8Q<DAC=2RK#'[K#?[_CO(A\]D2=K
M86LLL-)CY9-*BU=@:_"%J;&@R_O2)5UZO^8/F"O<L5].1H!Q(0YR4TD-?\#=
M:GF&G>B5)_VL7AQIYQZ8"(V,[9*%$3(;F/ *T)<DLV^$S$^V;_F[E"^/Y\M:
MF".OAD)C$##PJAPPQTL+OU-5/\UVI(7IL<! CX%/*B->@^GQ>&7.%K;':R',
M.%QZO^V/-=SJE:?M05\+PV$VP/@*<&\&#8<7M%-PL78SNG:+/:JS(306DF$V
M)</XG)_%)M4%=LXB=LZ@WC+7QBP*%W[.!6'>ES"CI??K:6[\ 0[+P<:944.?
MJ[=M;:KJ;:=K6=YW[S'!QPR0P,7-GB!4MG"#+A#4(^C"#?K DN/Q#H);&!RO
MAC#YTOL+<;&6=?NF5RQ\H3,$RU> @'1Q0NC#2H;'.^MA85.\%L),L"M X*O1
MC(+MTQY8$8=IW^T570-@B[07?# ] ^:%R[TK[WLKXV)KZJ]JX2QLC]G B5>
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M/"+K'.)UV KOEEU-Y^!T:IR(M*1&-+7H:UJH\:"[ 7[^+0]PO$3/3I^%!=K
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MUAWH?4%-&$P#@P0YYJBO)\ONFXS07]SV&E _5)&> NW\\"A-?G@,__?H#=?
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M>[:^IYD(2ZC\@%@H6%JK/%+"G9"I9M(M;P[^(:2J(WZ/ ^#^XSK[.QCL7O!
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MCV4?+?=,.W!&ZNEP_S3F94%H-;:WDE;MA\K:A(MM5LPVJU^@2;4,N*=^I!P
M"TP%'ILRNZH?X\X9G]]R,Q&*'."!3AUK")\Q3-#FAUSP\(/2BG=9IV:$:A-Z
M>,Y/#D40NF)&JT);P'HY4!V!W,SZ" 0J1YC#9\(<GA]A#K=U;BP C[PW*E-F
M719RH:GK02>"*R'AKR^%-9P.]IY.*@.)$OD1[<?8IU :5P[F*<P-]+F>BGQA
M*45*D"GO[LB6H"%@_^80;:*[LKVV670[2/B]B:C2,[O >0Z_J*BSA5"@\IW
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MXC$3<3L?=0:@!.<89Y*535F-VLA+,K?DB!:X$U/_2[$55D,]]#3>XC;F*1O
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M*@_RMR93<#FJIH@&%_YD9(1=OL<A'D*"CXV2AQ6"*<+6,O.D8HEH0EVCZ&)
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MM!_[8&"ON)1@#D#6%+3UR82"0]+L#^E[9A.W"!<<+DXQF[L8B+)#/3*X*8%
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M/.*[3.;TQ^Z5<:Y*<VFE*#281EV*GXPHZX:.+@66SYG6Z'9),$L/#>K,>L]
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M>OCR'7GE:[4MO9RZ8L(^NC[W'9=[[.MDXCJ"6I;6TA12R]+C<Q"HKN4(ZEK
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M#&6X G>['@,CQR)0-W*5*(#@86U$"9CG"V7&LG6B=J^60E6V;L@[+;*=1E[
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MU@RPK6XE^FQ5'(\H^[WV.$T@4/D<]XH+.X$ @0"! ($ @0"!0%-!P#)[;4(
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MF3V;$( 0H-D(0-V:MBT%SNP>YC[U2,1K+.)DY,C3)3M'($ @0"! ($ @0"!
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M3[4B$:^&B).1(T^7[!R! ($ @0"! ($ @0"! ($ @0"! (' P5*M*/&R$6A
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M"JP/*/A-W D_$>Q&A'>N(U@H;A-/#AV9[&HV]X*%$(775?,<"6 I&[9 =19
MGPD,)_4)-0FG.G5# 8^&Q\._[FPFQBY\ [- +15C4SDT2.<<L=@\#.[<L4""
M1WPB@/;A* C9B$>N X^-@6(%RD_@2W@WH)I[ZX(CQ(2>,4#"-( [?@@8R$/5
ME_0,N0>OA4\M&<R-M&4H4CP;4_JM_7?1ZHB:!QUY0Y3 L&MW*![H.Z3X+%F8
MD<*--LS*@5M<(%J*6>O#.X[D.M(;KI>35W1F/):WQ* >.+W\T.9&I9X'D8M7
MG(<"9>%.O+MWQ_'T' =^IS6E8YO]KM+DLCOY* J\)!;OM-:W\D.\V60T=6IV
MQ=&A,RQ2+O_W-%PN86[%Z2@4_,>I5(]S[MV#KKPY*[S\"C6W$^G).%MFPM:X
M7F&8WF"E/@#(.#%@P&5.GX[05$T"SPON8?G*Y'*010*L"6!C/%7*'X#=+YH-
M!$[T=OW /TWAA(TU.>6]\D[I0 D@V9A]$(Z8C42HT*IM&<QN6</-JYTB)7N*
MD'IZA2MDU((G<9 27RW!Y2< _F KD= >GT?B//UA+=R5YRT2;NQ&8&T7YZXO
M22:?JY5K.#0MVY;ZI4N%]'RT[IE*]U8"$OK+OMFS>EN^WW9SR[2V?=EM]Y]X
M[]:G#LQ^CV:\[QGWK&'-9EP_&M.,7V'&_5UG_$"MY2M6[NUA;Z/_"B'=+WPF
MJKG_\]IIAL^><!47$V4B57#?E(__$=>JX&7A2AV<KCEWQQ@J<'@TS>)1!X@?
M=DU[E_EO"A'K\*%>:!RU<#<*LV[BP/G!^#T/QQ$[^>4M(P [=@#[JD/P2BAV
MV1FIQ6OEA;M^^'MBOSUI$PHW%(6_8-#F/XD;XVXFOIE[)]0F1"'&0_C<5.[C
M+H4[<<%E+-U1D/XDO($TT20!C9. "\]C03P5X9J^$[,;Q^SO,GB_RML]1%_^
MY#A"3"8[<EY'YO$!0#(6!1XL7-.7JUN:Z6?7F7+AL6N3?0?H#'X\18\>1[_'
M:4Y%V5HI)O[R@JFD)43;ECRZ$]6JF8S;;QO=/?1HV1\!*R=W3\_D)\0@Q*@?
M8NPK?9\@@R"#(*.1D#%HD9-!B$&(45V!KQIBD)-!D$&046F!)\@@R"#(J CG
M"#((,@@R"#((,O9,-:O;V4M3^^.&C'UL9T_DGY=.TZQ&TN):+:!*6OP=IL,^
MF>SO?"$JE;Q8.M_2Y$5VTGEZWN(^>/X2NOV\:55*>5_4:JS39?<6354S#'W;
M:._#+CR'1I63GF=XBZ3:I-I-6R:2;I-NDVX?E###/2WG2+5)M4FUR6R3;I-N
MDVZ3;I-NDVZ3;I-NDVZ3;A^Q;EN]'H7)J[)#NH<$C.K0\$;$4_:[R?XFPE$4
M&^SSAZ--4CDBK'Q<%D6UL;+7JD*F2<75_,CSSTBU:ZG:%4D\)=TFW2;=?F'"
MV'TRVZ3:I-H-5&TRVZ3;I-NDVZ3;I-L59 [I-NDVZ3;I]E'I]H"6VY794#S"
MDLN+T/7'?,;>!Y$PV/74_) =JUJSRDLJO#P> ]"DE))>?S_-!9N>44*J717F
MD&I3)BCI-NGV4>DV%5Z2:I-J-U*UR6R3;I-NDVZ3;I-N5Y YI-NDVZ3;I-M'
MI=M6SZ(P>57V21M=>/F>A^&"79KL?>+\\+@_7MD6I<222K&+$DNH_))RQDBU
MCTFU*1^4=)MTNYFZ3>67I-JDVHU4;3+;I-NDVZ3;I-NDVQ5D#NDVZ3;I-NGV
M4>DVE5\^8UOQ+.8C3Z0%=P<K=;1:#Q4-VE+L_K7^)WNG] W2N><8]^\DBMW)
M8I4E57N[+T$LHO/'OM#KUWCVS.XN+U1>XVF]9;K(L\JL^."&PHF#,&+WTX#Q
M4##N10$3L[D7+ 0\* A9,)FXCH!+@@F+IX)=!C-XHP5^)?^9,#>.6)2,(G?L
M\M"%N\8!\X.8P=C"O1/RLDC,><AC 79V-A=^Q&,W\!F/&&=C/0F3?0G\T_39
MV<=1;ASXST^X!Y_$'-XF9!.8Q?N AX"!(KR#>>)\?E$[B@:;<W?,7)^)_^!-
M,Z#'U%O !U',/6\F_#@RV?>I2$>-XL#YP8*YFMH]CHKC^^6S<B/6E<_1=\!8
MUZ$+U\<!^SWQ!;.!G7;+&AJY=Y1TQJF*,;[\Y92[(; QI:UZ%<D#_=)C^=8
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M\A9#*:@!*IA$<@6GU6SINA8>L**X$G;@>W0X<HM?K?5E%RLW'Z^'<2?"132
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MV"%MHL;:EK&#WY3JIA_()B^/OK0&HK1G)W&K*+U>TOMKR!DZ/T_)>7\.TU^
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MY#DEV-P+'B3S#Z\N63*'@4/QGT1$\3LV#X,[=RS&!IL&]P*@Q8 +>2ROGG,
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M",X?#'RM#;R>-5O@_)>0UY]J^L,#2T%CQ$29UY)&(DTB1DD&YZ2B*G*=O;_
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M@@P <>7(, #B0@#QDAM[G%(@F"/*@\O<.$1DF8I(>T&4H3&#96IN2B4+R3D
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M^UWO!W$(Y'\F\O^]5?GX\$+LL%=,($)30ISE$,!A&Q'3CGMNE5-E<H2)&SO
MPD81R(NL(2K6/"\"Z+A@=+P\75M03UGV:<B;5.ZD\PQ9Z1(R/MD8,(DRX;*\
M0A02+Z-!]MIC9+V2(ZO%BC,*Y,\.!TM@Q>M=.K)*K+C2^"7@ ]K/AO;GTUR8
M".&4PP%Q11GB 1NDLU='CMJ0L-/1<-G<I((62M7J%._5P*<5R,,!&#YQUP@
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M5]TZA8ET%C.9B5QDC$5YD % 9AP@*E,2J-IE#L,>GFX"3VS[Y]N#6',=YG%
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M%-#,HU_42YWP M:XK;+6+.VL^!PLLK ;S5:(F14)678S;$$WZ;S/?%3UQZG
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MQC>\]M(A)U>]^ \SUW:^8151:$P,V?7VP.*R@\E@^M^YSZRPO1QSA?::E:P
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M:\]$HQY6_-@J27M@,8L,1:/-!'(VWE[\^5<, 5H_BZ6/[Y#LLB.Q<Q9W/OP
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M;!Z/AX@0.4Z-K=3=:3*$!:XE@ :JLAS[OYB*H,6H!H&Q4V>:,LQW24"EUQ0
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MJ&Y^9.TV%3H)\@+I6QN0U0B3\:>V".<%D06W1O 7I1!N]#<' Q2L4P.#*'%
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MQ%=E[7H1[T7\48MXSVF?!*?M..027Z;2EYHD,LD)TZDF7(:4L,3G =,RSK#
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MO<OF^VUKY]O0[8>_\<W$:K^?_#GI [ZD47,4BYHC\G907* ,!\ FRC$JPV/
MG:F$OO>C+_'(8BJ8R3_Q#M%EF_[Z[OUF_!/]]5\5:?FM VAF3_KP?L?GH+W
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M\]P9H6VVS E2!24TGI"H/>_K/+",23PZYQ:XH50F3V4.IB+C&<]<X5J >R*
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M+;[O>3J_[(FYB_]E<URG_+YOA&'AQ]-C!\*>J6^F/G<XWS\X^;P+_^Q=?+B
MYZ1[!W_W]K>V+W:W7&_OC]>?=__XU-D[^/!U]W(AX=,=L?_'VZ_P3[9WL ?O
M]);N?3SDNP>[9WOL$'[[]NQ3;X?N'6Q?7&HCG'&1T9QRHM-4$6Z=(XHS1F2>
M,EAD)J3) -3 I$B?S9G#JN/;/U;MC+R%T:>&T6\\RVUA="5@="Y85GM>>,.(
M5B(EW,B4R"PH FJ26H!6K0O5PNACPNB*I8T] YK]?G8FN9[T_1BK<3>'HW5Q
MQ3:C[(52ZN69Q+YLE<#]E,!".34G;2H*)8A(4T&XXXY(3SUAL*@%9S1DC*V]
MXALY;:ODM"ED+1*N!"MND?"[(>$<'7;**,ERDF,@(Z>:$R# !0FI%U;E)F@>
M$ F9:)%PY8HEO&SG\MZ@3YQW$Y V#(GHC'WO2O/:MCS."Z&YL-BSM:ZCV%M@
MOQ^P+Q0+HZ)P3@=-:&:P6D*FB=*6$BM268#2SJV4:Z_R#;Y2G5-7'9-6,W.J
M1<%ORD5])(8[S>%IT? 'H>&,YC(#FBQS*< ?*PB7N2$Z-1F!=>/!:$:-56NO
MT@W.5RX5]1E"8NOAO>\D_C[-,5F24M+Z=A\?[K^=\WX#W%>KO]/?JG.+X$>;
M9>G'Y=^-,&PVLM!J@?MI@84*8M[2W($2)T8;3WC )$Z6.Q*D<Z##,Q<"77N5
MI1OJ*BENR^2TSM\6*G\X,VZA\C&A\GRNV*+S:<88R7BF 2HS0;22CN3.L]3G
MA1<N6WM%TV6.X18J5X(QOVSO,):T()-AHJ=%+5K?\#.DR;%\R9U2NR^5,'GC
M1W:^DDD+\G<"^84:7;DV:6$I(YX*//QS /+."P+RP0IK-<V*@%X1S)-HO2*M
MH_@G@<0?% O10N&30^%<\P@E,I$:15*J)>$N6&* XY+4>)<%*IS.>83"HCTN
M6SFF^[)]PW4Q[60P+9;=.H1?:!3$Y;KI^(NMNCK5N(-%_UJ(OP_$VX6@7V/R
MU..AGRURPG/IB7)6DL)YD[M46B490GSZR!#_XIT9K=_W92+BCPCZ;1'QNR/B
MC/2FRBEN<DD"PXYI4AG,A<N(#5ID16Y-;@I$1';5_F\1\4>3WI?MWIT%1#3U
M -O8W^?HWWW(V=YV'\8:C_;:;.?[(_SQ/.?5&5/6&5<Y,[ASGN@TMT0I7^@L
M,Y)+M_9J:;)SZ^%M/;PM*'X?WGN7GFDM0CXA0LXXL!%QS03)/ 4.'*0EFJ>"
MI-3G3 3MC$]7MT_-,P3)U@%\WTG<W#UX@C"'E^WJ>&H:?&LOLCO5 >J._:@?
M2Y;O=OJ=WJ0'/VM/^QX$^I\7:#&U6>%T[-PB"/>6$<E$1K2TUFK+?!K:5L*M
M2[C%R:<.!6ZA\<= XQP?]HISDWOB\B+V;0Q$BV (K*[@0@$^JC2>DN4M+JXF
M&7[9CN$I."PT=GH>%8?OWUOR16F+QV75-_M1;NPYW^J).^F)[;.H(R*-WCP"
MI6\D2PWQF2@(5P4E4GJ0F()9[KSS6MO5=9R\[%:(;=WBGQ",5S*:H\7=[X.[
MNS/<E6G.5!!$N2P0G@(W5R$7)#.*VQS#F"T0=,HWU".7;&L!]\8*Q].VLU=:
M$][>&?1^C>^>J@/GE9Q;+,;8T09L\G''EVWSS=/C(RYHGG$KB94T)5PZ14"(
M)-&9RB4WU&7Z2C/-!XK"/1L[+4KVG3?$+1OKFI[ Z-;I!$"!_A@$LC<<8*/=
M$NM6+^L!BB6ME_7KU5'*$CWRBYU YX5_>>?-Y1TDZ]:,;8O%ML7BRO;%:ULL
MWD/MMFT5V_9P;5O%527%*S66MJUBVU;QN6R<]V,PH)+!,'IQ?%7^\W$M]^^&
M2:LUD?^SHOZ.%?<D7NM(G)3N\IF.-;10IC!9+KCV0BM6>!X8,S0UFJJCG65'
M.>GB44Y_TG.#<?WU9?_#%:\#_*'YK"Z-B_8D_+<*#.B[WZJ62.7[$[ <?].E
M=_,_^'U0SB($TF?JIF@<D'L7.^>[I]OIIX/C\]VMM_![&,O!]M>]/_:Z>Q^W
MSSY]A/%_W+[8__V* Q*>!=<>O.ON;^V<[6V]%7M;>R>[!]OI(?M #P]^Z\(8
MOAX>[/)+O7-H+I7TN2 T+PK"A79$9UJ1U-I,*I\Y)W+0 H583U<PJ^!9]U%;
MS92#5A.UFF@%-!'GABNOL\!2R661*VESD2GNK R*4ATUT95CK%83/3=--)>^
MG)F4^[P@3BD\"4L+(@O4289+[=-@,Z%!$W&V7K2:Z%F&LKWLO(Z]_;\2JT>C
M<T"@,SUR;6;'RS-6ZJB'_O%?@[+\?6ZQRQ;Y[X7\"\V-I.1I;K4G*J<9X9DO
MB$F](=18)[- O1-V[17(">7K[$FP_\5'*K<9'"\/#W\ 96[Q\/OAX8P)6Y$S
MP8,ASEH.3-AJ(GV>$N.U,(Q[G^8,F/!ZGLLG\LJ\>#QL3S7N.XGO?.GUR)XD
MNN\ 3K[X[F"("<V)!8  (WDU$CA>,-S_&%_][W%U%Z"^D806\N\%^0NUVUEJ
M<E@Z3P!F4Z# QA/#:< J;JF7*I<V\VNOZ'HN\G6Q@NZ/54>KU?2UMYCX_"EP
MBXG?%Q/GBKBGSJC4!)(%KPG7F24F#8((;R7+N2NDDRTFKCP-?ME>W_WQB1^U
MKMZ7QW7CPK;P?2_X7BC0SJG/<D]S0@4SA!<I]N H!*!Y"O#M@@E*K;WBZ[SU
M8+0>W1;V5H3.MK#W(-B;L5:J>.%S94@A."><VT",4YRDCEK)T\+F,:&7MB=9
MJTM97[;GMMGSLZ3,]9BS.0BSM$W\JCM+!EX-9^ZW9%8\9S7P>.PW%FB[K .:
M)/#S/T:#LCW(NY\N6*C73IUS@N:!V-2!+F *VRYGAF0B+PH=7)9:L_:J6*<B
M7:<KZ,%X:4%M/ZW+]V=%SL<CT"UR/@)RSEBT8H'R@@)WELH37A09T4)PPM+
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M<MQ<W.EA-$?TCZTGQ]US._!]4 ?>8U)AQ=?FDBDKY!HY,M2C\7DR1LMT//]
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M*>1*"IK<$TTN0JY,8N]@K5$4'%B@D@EI2A@"K1&93T1)K1>6^=)%Y[,2<OW
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MFTTLE$TI!"2=3XA'"U8_)PQ@2F-*,%&)BH=Y)0^/VMW3&/L7O/JIB@]CCG$
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M,:Q0/^[P46U^^$773FS_;=A>3W'?5F^NPFQ^ALE\'VT<'X\#:[2Q>G#:V/>
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M$D[F4D/C!?T]!0QGFYS[1$0LR;DOAX#U<P1TP'8IE11QJS3B1%'D(G7(1A^
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MDAP8,Q?.(LVL13YQD4*,@3/_L-,-C\*!LHQ/6\9HI7+1!B1-2(C#C".G"(
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M'VQ=*P=T10G7+LDN7]<JMJ0;EZ]L8M)V9E/T!SCOE/6:]6*5-?A@]A&T.Q(
M%#EEO#PP-/!'S^K7LV&PU^C448]1@<$$"[[24+RZLN.LNX>GS]21&P\I:=&6
M@J7;0!_&G.?C1T;=)'[ZBPE(,XASH51V* -#J116AKI.=-)#+O;\$\\7KPBD
MG#-+$RN]80-KBFW?P72\?1%8O?N@;OB3E\C=.=J[@(I@':H'1%1%_FP]:Y9>
MV3@AV2\$M#SZGO2,7XB#N0#8,!WB$!?TZ1PY,DHNF%84J:+\O..7Y]Z(I%QY
MLUJF](&;.,/[0EJ<[/REN>:/$[:C5-3>8[].6MY/@/BT[5(FY 0H?8[F0%**
M7$7;F\C:FP<3S)3,HGU6F?D1&X>W&F$+DU?9G*\S>6NR"-[+Z([W\*;LWBK>
M=X"9;SLXV:NIF$LN(,&("%__1Y/D5;S\0"5OA*=?![)]3B^^59@#N:H+G#WU
M:[J=>=OSJ _5V<MK6N5A@904):MT!:::8)F=LFS7(BS+E:YZQA4/>37?KJLF
M <9WC&74O: <8FX7??KA_P!02P,$%     @ <(A^4 JMYM4'(   KDP! !4
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M@VFS<[P&49><[7JLJ*. FF?P\WR I6ULF-X@\I9KRW(LFV0,$65%@@=%LI;
M 0=J;1-S\1BH[NTJUF!%-36T/6A"*#2YS#+Q%! *3X98GP-Q ACWRCDGFWA6
M*]%TR<^N:2#V%7PU#KP;PR??3Z=?/\%P NCS+!UXW XU9$.9%R0$;<@\K@@I
M)T*SS$YX!C0UB<LWP+8)/_1WQX_:2MF;+247\P;5>Y@ -O71#S$>_ R#T:>2
M2MH?OAN/(DQN\0&75 B.=LS@>B>%=,0;+XD"35/4*7!W+XWA8<+G]MUNP@?S
MW?"AL=BK&9&E'"0DZXK]B&!M#H$%(D-"5.#0Y:$B$E#!!TU]H*Z)!7D*6(/3
M.IR$UD-4Q(9R_BB20@6D1,KRKC!BC,8>Y;2N,RFN^S/DOKG<4PLMIL'-=(S8
M,W."$Z,S.OQ&Y;)%D$C2D2E<\%VP39*YOIOTUOILV%,+54\Z^]/+^<;1,)6\
MRO[P PPCXNIY2G7,;IZ76<Y99";6H?<?G#!"2::=EJT./==@ZE(HWI0?M?1R
MCRA_?7%?<&_Q^\JW9M[YPN>/,.UC/W>!['F%YF[+#>_3/#*$FI>-SB_PS]].
M?[\X/WM]]N[T_<G%&_SMOB);TVI=<6T"O=(]I-]A>AV+OAU-)CV=O:>:29)!
M49Q:-!'+<5;I&"2&HRI)T>2X[0Z*.IL:I:63Z73<#[-I":XO1M>\Z^& ."B-
M@Z+H)$O0B3@ET7( Q65!")^E;;>[L0Y6EURUW3FQ>INCBBKJ[WDM@NM?80BY
MC^&9 Z,!]9:EQA4%1TL<C9FD8+6UG&$DU61%7H-G2V^M;0)";4;L)_V*#MID
M[@(LL$QZ. #(3J!S:+(CDLI  C!.6/0I1&^<]6T.6N\!J3&PL_SWT2C-W2<8
M?^Y'F)RC!]5S(J!3PSFARD=47F88(64@U,F@9.(RQT;9=NL@=<GT[<6(AWYF
M%2U4S+>YWD ZN;.!M!AJ+R@KJ.#S"!E'RI4E3FB.GB_:90V.@V]B_QY%U:68
MM2HWZNFBSM;NZLW%!9[W,$_^P54;(R\53?(N>I*\L25U5."B;241FKHHDTLB
MFJ<\ZNVZ[%)@6H4$#25>S5C\'1?FL1_@4$_297_8GTS'*)_/<$-1DS*W$"(2
ML]R-,!Z(#]R2[&E4:,]*V9(6YN()7%TZ.:YJ,&KJHQI)7H_&*,CA]2Y;O+H8
M^^'$QR*:O_O^L#B+OT+&SZ"_U^-*,L$4(SKA0B>-+)DP%%4L(N><6B5%$]]J
M"XQ;GC6W];FKLJ>5HNK=:_P$A<_##TMQ!E5:L9(2$94I3A('$F)R1$@?LTT!
M )H<I*S 4CW2\+B^8\0CB$\H7ZE*#"64)H%E'[1.D2IV^$CC2>>[+>7W)<$J
M!WQGJ5=TNS_#< :O<;BK:BN<?HV#6:D;5DZ+\?]4YJ!52BHE<'+S@'-=1K3K
M3 '17F(T+!,$T<@9WQIKEUSTV@1JK;H#G2 L[R>?7YR]_+=_G+U]=?K^_/3_
M_/'FXC]K;HFO:+W=UOA30VEUFO#RY/P?K]^>_;/J8<*W1ML); WP>D<))5W^
MW7CTN8^M_7KU!\Z(-\/7_:$?QC))T-_X/#_2ZQEF32J%"T6Y="BS8,12'H@#
MKJVT+M#0),-P<XA[9]7YJ_D!(SI>[^'3K,1Y$SC+2Q<Q>SIH!EY+DF-D&-8)
M]-@--\1E9V6B%-VP)N[-T] ZY10THM6#C+NZ"JN8GCF* &E2UJ YC+-/16B3
MTZ\PCGT412\#NN3!4.*=$NC4>%YRB .)&"W8["*7H8DK^22R+GD&AV)156U5
M(]&:T=^Z2TNCE\:R'%#;()@G$H5-G%*1*.X3-0%]J=PD3-\<8@5A+!]F*:L@
M)4/0#PREQD<B7I>;C$J5$A\13&Y21>61(^^CG_ZVX,K]F;*[%NI56OGHQ_ K
MFOF$5KY$B'/Q]%C(.3*9<504B$P)PT6&J"R#Q)EFWHDF%V)6P_D.C&AM:E30
M2\5L@<\PF>>*7;/UY'(TGO;_>X[H++\;PV5_=MD3(GF6T(JC$4?Z*HPVK8J6
MB P\)DX-TTVRFS="UZ7CDP,QJ+[6CK)E'J7CW@5#F%8EE3]D$GCV1-" \T!)
MZ7T3SZ[REOG!ZF0<B%VM5%@SQ:F4^(!7</WWF^&B_N_#>ZDHLEZP3.@@:3E8
MP+@F!?1ULU(D1'11#6A#VQ3:W0YFIPYG#F;'FBFR+=GNW7/M10<Y\7)L52ZL
M29I%J3>ET=YR0WW,$-K4^-H$W)8W"']<8NVCM(9T6GU7-DO&05A-E) &P7&+
MN$(B";1/(N$"+ANY7!OAV_(:X@]*JOU55R>[Z3ZR<FGRD3N5/2V#UT*5,V]>
M2ON6\N8I6Q( N+5):+A?6G5-CM.6'6_"&ON#L*:Y8AJ:I 7(5XN2FBNO:?>8
M8C8:!23EDI%C2[Y&+/%JY,&4,TG5YI!C-[B;4,_](-0[H&(/X&8M7GGI,1%2
MXI83R[E&[\\'XJ.@1-G().!R#:E)'=TGD6VTNTE_M!V(FNIJ'QDN7;CL(8VY
M81:MJBU'%#PZXJ(OUV8C3QX,B@T.1J1[X#;BT@^V55Y=:0WI].CK,3TN4DZ1
M E$!_3WILB0N.2"1:<&0%0FA'H99C^+<B&0_V*9[2U4>8F/K-M"XM:_1.0A@
M26(@2[D5(,&K3))S6I>G&[QO5.IN8XP;\>R'VYIOH\)ZEP)1"/?*?F(P,AWW
MXQ32HBSHW1\L??(=C/NC]'",BSS!TZ\EHOD [_T43G.&..T)E7E45A#&;"C9
M!D <=>7="A6U"<",:E,(XJ##;)3 L"I]PX',"4PDSI8<W_(H;K#4$<]24EE%
M@73M4F[9D2\\=I?M*S(&6G"@FN&X'N)97A[VV7 O ?<\2B086LXDHR%2&K2T
M'(/.Z'604LFH0Y-B!0W&TJ5$AN^(]<=F5>L<M.NC^KO35P7-9*"&&"'+A<=$
M<>8*2Y@T67!MT,-L589D0XA=RJGXCLC<B -'R9-463KGRFT\A?B8\1AO"T'0
M,]4F:?1<V]1UVS5/\LA78;][CN[+@6/84=",2NTE8=QI% /&:=:Y4E-:.V,A
M8\#>9+ME5SNZ^S6+B]%)1,*,85T]_IXHA36$ _0&';J$696=LA1)T.@L2J$C
M\"9/9&Z,\'NX=+$OR=9=NJBKOC9W+] 6H9&Z@7:6UT)55@.W'HBR'HV/M8S8
MQ!/!H$/([#-*J$G^\$YHN^25'XITS;7:\%KGV?B#'RXR6?TPG1?1CJ]&^;S_
M8=C/_>B'T\5!$PKLW6C0GU?VO(-KLWN*NW6T_]W%"@/<]][G3A .+NMCR[Q#
MLK\HN\6'D_RBNR/)?=5@CR-U['7F!Z_*:W&# TK_;K?'TL(C@S^*-A[F;QY:
M,>L1'$E'&XKD.,O%G0<^)GZ18;2H5WZ=:'1H!6Z#Z5B+SJYBJU3C8)-W63 6
MP7^8#/KGY0$.IDM-+E$N?SAK#'?<V"8'4%L_EK/S\-\,)[.Q'T;H"9>EHX*3
M)!G&9DY%8JFC1 6P67LEDVD4Z]P%TJ4CM=H<6?,VT&Y*J%>PJPSJ[E!O!I=I
M9H8)1_3\&:O #?&)>F)M4I1Z[U1JLC6Z'E*7HMS6]*BDF-KOB\T3.WJ>2QN$
ML<09R8F,G&/G&%0'"#$(862B3;(=ED%TZ>SF0+9B>^%W;0OC7O;LL7S;>]T?
MV;%]3!B5')Y[7=UR,M!D:)!$N_G#QXH37]Y@L8XZSU1"4]*D:L9J.%4J']^M
MQ/SF_K-J'*@Q)N&J6AX/PO4V$,\L(R[;F)FB\D%2]!-ECQ_OKTL.304.K*Q\
M7%'B-9_*+<F(""4CE#(I!Z_AVSM2$#*E##))2@4BO4HDA(!VU.MH1.8YQS:/
MSC\*JTON346R--!)]2>5%\-<CD)[QDCGJ:6XQ!I>"O4Z8A-5)"?+%6<AVM3$
MR7D$4Y=\GC8,J:*-#GH]A?DWVQU'\'I6=7\\K^=)8=3S>N[=K[E]2-!G2SUS
M!*"\.Z=8N?LG*4E699.T$C8V*8^V%M'>6:O(GM$5W+PXL&+(ROC@6"CO9T:<
MF,P*XJE.).:HO!:IW"YJDH/Z%+*.^4@5&/,@^;.J<NK<I5^,=,/7B"EGS+.4
M2:FT3"2WEMAL),DR0HZ1&W._..4:MWFK;COF$%5D1F,5U-T>7#]TQI.QP!6A
M,BL<NC7$<73UL\TA!\=]4DVNF#X.JV->4@.#4E$M7?.55L^&^1, A_:;-H!R
M)!]J6R'MZ4\]$NXOW+C;+-X[+QY1ZEBF@1'F*3KN7&#H7YZ(3#E[X!2\<&FC
M56/[OAOL)2VZ.YM-)_T$-]=JX?9%N)Y6&4<$@0AA)9'2 [$<[9=+P4<:/<8L
M<?_AKNV_"W[4(9BRP2945575?9EM)="'".](!]>%%'&Q(-*7B[I2:Q(@E6?/
MI7'H(69#*\RCQT%TP1?K%KLJ*NT %'L'X\EH.(3! N1\L>@I] B4SI*4>Q9$
M&B5P'N!D *^X%\H$S2HP:V7?7?#2ND6H_55T !Z]]G'A;9Y]AO%'\.DF>Z='
M7<*P))3G+HM'FRQ%J2A/1!2.<I&"TWQ_,JT'T(6;4MUB5"5EM7S?Z,&-,D3X
MK>[S3L[^DVU6>)IG*]A[OV#T1&^[)TYOV')[@;5(AWZJSSWBR4V;;B^XEOOG
MZV[1W![M\IP<S8DH$1213'KBC3>$HFMM>')2MRD'_ 2NO1:_5Q"FWUHL/4U'
MEXN>7OO^^-_]8'9[V!48D\S'<H<HHM46UI,@=$;(7.=  _=FLQ5OFUZ[$.>U
M8,B=9:V9&NJX2(_!.XEQ=CF;K^U_#,<01Q^&_?^&5(K*WV;P)<JH311]NI(+
MEI,FEJ)L'&,Q1F8![N?=[,";IW%L&=.UO:MZ%"I5UM71R%5>*[@!;+E*02E#
MYAL<TLI(O,JT>):&:I\DY;(5N99P="&^ZR*W=E55M3.==<+X?32,-[DX$+(,
MD(E0'F/.P#1QY>&+!"",2-*+U"0_ZFEH[=?V)3$XH8303.'@Y[DLG.)7SA$*
MT4+.)B2QV:GGEAU_#RO\CFS9?I'?41]'7>>7,%O#7#(9;8GD&7T3RDG@Z*!0
M*31G.7 5<LNE?CM6'7VU;TVK^DH[ZIJ_A#EX SHE3[+)\[7$$EL*+T&06NL@
M(F/-?,J[4+Z'E?](/-M#9_5R7C_[_J!LM[P>C4OAC+O#6 +^]S&B+>C]X ;[
MMQ>Q'+=H=D,D2@=;I@@0ZZ,EROMD(:D8=)/B;E70=V&GN#%#CZ?M6F^]W&YQ
M^>%U;;'KU_^NST5Z+$/VK 1C-N+4<9ZBZYP2 6!4&4V9MIL=MC_148TZQ"?#
M^[70;KV;5_U)'(PFLS'TE(O9NGF%Y%+MC =&'& 0$DV6@DE3RM:TF%$;(^R"
M6UJ=&_?G2QM]-0_>OF65!>ZM$21DH]%4X/A]0GLA ,><LL@Y-WD]9*LMV2-F
M#[2D3DW='#+:3X%&I6DD67L,JQ02V4O/"2CKK +F1&A24V_;:/^(.0+'H,V.
M&NJ:GR@M#26Y%3T%#*6,SL0Z;0CW3 AKG?2N";D:^(D'#^E,"$%* 21ZG@A^
MA;*C2#(7A1,RF')_LCLAW<'N:!R<EY6COFW4VHD3!1#>(%Y'P M<N"A*S3EM
MB8Z!N>PS![[9I>GV)PH'NP[R79)P%X4>?3TI>W/?1(9Q+]-,<9PR:/2EC)X$
MRB(Q4+: A?<F-"E55 7],<^<.:B$9B<1EQ*Z*-I88H51)%EO&$07!._*F7/7
M5Y+=&5GS8'H;A7;E- 1B-L%+2K1%N!(P>K84#9Y#82D=022Y6;[QH4]#_C\/
M:ZFUXBMRMS'98L.F1WF22IE$3+D\*UG&@$Q(1ZBQVCEC%8N-GKR\#^5PVX8"
M(E#)(^')%1^BU-"6R1$C.2_EU,L;DO_CMPTK<6;WS<)MM-3>6#_(H,NXCD25
M@7 K2TDRP8CE1J(0T#V%X)CA=F^[O$LBXZ%,<"5BM)7\ 8FQ9-R]]E9HA<$"
M+W4IK3+$>NL(C_A7=LHHJX^5!7.H8^2#TV-'^1_QIL8B$;UW+P.G:CX]-GZP
MC/K[ ZEQA_JI;>0L&<U<12)CJ>P9M2(>T*/+H$/4W(4DW$93K?&AYHKI@/BT
MX300QW5YN)HSXK,!PFQ,G 7K9&IR%^ IUZO#QY3;:/OA^[M[::!CFSK1BN29
M0 N:-"Z"06'\8*A"=<<LN9>2RB;O8S;8U#E27EUSPAU>T4?GZ-V]6DFUS"7Y
M-)9BNQ*G4RE-Z EXBXNSPR7:-WF%[6 )3YTX2#T&17?7<T-W:ZG$R\O1 (<U
M&E\K[,,88.>KL1NTNK^#M2WT?>]YWO1WI[-Y+9TPZ$<83LJC8[=][W'K<[>.
MZ@ETCP'N*^,W0_P2K@NO[R"YY7^^OSS6@JDXRMWO5#]LI.J(6]R47FY^[^>@
MUC=65PX-GVY:ZN;EZ/+3:%CFU2A_6RB6/E!'4AMW4U6&NPVNTNWRZVY*MR?3
MZ;@?9M/"[(O1.S_?]I!.Y^@B)<%HCN$,>D8>RJ7>D#C'B,;%-N_O/ YK_\CY
MIO7R;F4I(=0?SM!\+]XE'@U7Z "_F$S[L1><U@)$))&5VP*<\U(Q4!#J?4K*
MB!14DY3[/3!W(19OP+>'T?AAM%KQ[&QKP.A4HY:&Y9DBY3,$DG2F1)8L1\\0
M-$I(!NJ%9KY)0M_ND+MUSM E$NZBTX8QSQ*R7V$(N3^=/R)<W@I X+>_K;/B
M;M)#U<5VZR'5V7%>]+"H"+4 <5N$ZF(\@S\^G:3_.[N.RGN"*YU40B,D0KG:
M4!Z7HBX2B%I'X5F,;+,[S]OVO*])>PTXD?U@3;>KID//N<"XD9ZHY.?7_C5Q
M,F62=9 0I&,J-UE0MX?:A76T/9_N6[3&*JVVFB[,Z#8XT:!3)Q@0QR/BS.52
M>\1O!0W>T&2T,$VJ\6\/M0NKYQ&HUU:EU:AW/O73\N#<6_SD5A,EXK0H3\X1
M'<NS3%!.BSR=/RIG)1C);- M"+@KX [M8!^0A@=1[V$\NO<01\-2CG+>9/4-
ME">;K^K+;3>82ALFISE#G/8_?_/@WR,[5JL_9 P=621)@B;2.8E6R5NB*(^0
M?6;4-WG8;W.(>S]XL[*GNWHYF2X\B#*-9MC>U9T/]QR-UB?A,?1& <F<*+%9
MH,5F1ABOE0FQB0VL@+T+#F%C7CYX1>? &J^V1F\"?+6AATDO "AO#.)4QA-I
MC"J7A@7A)@I X\Z=/QI'UX'N@LO807)6T?%!6?G[J"Q;,_Q8&,#"Z^BY("/-
MFA.1 BL/&6OB05C"4@0CDF*^37&X70%WP7/L(!OWUNU!F?CRHQ]^P ^\@@SC
M,92GL*^?UR[9LM?:' Q&7_PP0D\X5F83)Q['@M,I8R &(LVSX;*S7"3'CD70
M+<;1I2)%'>)M*R;42:[?9 3W(\1W,(XE4%3<L)2 $96"(!+_(\Z[3, #0,*I
M%_EFE^/V +$)Z=2/0;J#ZNN@QO+^YE7YQ*L^_L-RQM3W@W)5D',A-*%&Z7*E
M()'@N,!I8F0,R4;7IM14#?";,%3_& P]FLZ/LK2?#N>/*=V&:M%G'B 0IBW:
M;NX=<=&R\H(\*)5XRJI)ONWND#=AIOF?Q\P*^CW<VGPRF,)XZ,NG?NL/^Y>S
M2_S8C<$WC%D5BA.10RX[_);XX,KE+\6"80!:;%9S<%\DFS#-_AA,.[SF#K,=
M?N.^WO[HVHFMLQG^1.-5M\*W&4BEC? 'KO_2&[B_P[07K.#49R!*E?=O9< H
M-I=J>]9H&K)W,3=)'7P"UYZW=N^V?=/TU?PR0R\ MSYI081V%H=<#A^#\P1=
M5!E8B,%XNI%I>KR?+FT[UV3!O0NZU41=S9':)-KU05AC%1#/#"<REG*$#.->
M%:6@E&> >!C:[[:7<;#:\RV(TTI/M:[\/\KH&#@%+E&WW &12F3BM%"$2^&,
MS4PBKNK&H\(<N'[),$&0R0M9LA4-D1YGIBV;/-DDI25$D]L\0K\:3A<L9&V=
M/TGR[171SC#.LRFO?W;[4.]E^?M:"\.T2)N8G'_T8_C53\K-PV\?F-]"]#1%
M!L6ZF_+F$PB&<S4"B8Q"4MXQD9I446XQF"X<QAV<D(<F05,ZO\3O^].7?CR^
MRJ/Q%S].DYL;@3W-6. ,(QEA,*Z2D$LM25.>"$;]: >:I2:)'EOB[,(9W#%(
M6$MU[?BU",^''^;U09>!]DHZA# A$I0 Q: Y.A*\Y<0)0#<H!.5!'F9A78NQ
M"V=DAU]MZZBL9:V@T>5E_]LM__E>T <8QOZ.KQ0_TER%>D";@MW[/>+U'>WQ
M@O.3C3:54)-WFQ_I;N_;R9LWWE9N#6\O/]+MNUFIRS"!LS#H?[C>E6TCRT<Z
M:BK730=8:2?R87<]\!1-L&$D)L!EW=GYN89'R66;8D1CKYO4,GH(95]?X6&+
MKV;P9O@[RN[B"PP^PV\H^8^XZ!@MM**.>.%+^AK^49Z%(H'ZY"Q-'D(3'W1#
M?%V(R"OQY;YKT$)#U5S-->#.RZE-^D_T@7L@*!.A%+WG,A%),<RR%/T6)H7E
M7'@9[U>6;$J<;\BZ$#,?EC([:J4U62X^]L?7J$Q6Z,X"1DM,HP<M,B?>^D!4
M8-Q31D,2X8!<N076A<CVL%3932<-HXW5>SB[.#1K6MK?8]D$XKYNW^H^=H\L
M'FVOE4A:Q!-K>MH[E-BHW6:":AA K.[Q9()VZ-.^,</&;;<2W%/#:".\\^DH
M_GDV[_:D9++TIU?5A?A('ZV$N>FP#B;45K/ZZ:X.*.+#S_WEKQ<'*M5%_$@?
MK62[Z;"J"/7C:(#>X*24'9]>[2RVNZU4$LPCT.H/?4^/9%5;+<30S!.YVTL=
M>_58FTV$T]H"W>EM;@+?PZ=%/%)56&O:;B&T38:QM_!F80+_-8/A]/3SKD6"
M'[1101B/PJH]Z'T(LJ:I^B)X4OV+$+G\$9 N?_O+_P-02P,$%     @ <(A^
M4,2+LNQ01P  /.0" !4   !D>6%I+3(P,3DQ,C,Q7V1E9BYX;6SMO5EW6SF2
M+OK>OR)O]NM%)>:A5E>?I?10Y7.<:5_;677.$U< "%@\29%J#LYT__H;H$@-
MU,1A@Z0E5U>[-%![?XCX $0 ,?S'__CS;/##%QQ/^J/AWWX4?^$__H##-,K]
MX>>__?C;I]?,__@__O/?_NT__A_&_O?/'][^\'*49F<XG/[P8HPPQ?S#'_WI
MZ0__RCCY_8<R'IW]\*_1^/?^%V#L/^=_]&)T_G7<_WPZ_4%RR5=_._ZKE2D'
MRQU+5ENF7=8L1N^8*5IS5#I;'_[?SW\- %ZC F8A2J91)!:BDBPJ"!(,>,?Y
M_*&#_O#WO]9_(DSP!QK<<#+_]F\_GDZGYW_]Z:<__OCC+W_&\> OH_'GGR3G
MZJ?EIW]<?/S/6Y__0\T_+4((/\U_>_G12?^N#])CQ4__^Y>W'],IG@'K#R=3
M&*:K%]#K\_3R#Z^C,3]=_)(^.NG_=3+_^[>C!-.Y>AX=P@_W?J)^QY8?8_5'
M3$BFQ%_^G.0?__/??OCA0G(P3N/1 #]@^6'QY6\?WMQ&VA].?\K]LY\6G_D)
M!@-"/'_"].LY_NW'2?_L?(#+GYV.L=R+?CGD"LI4./]>G_;3SIA."<@XS2(R
M^BD.*\$[Q'C7TW?'?/DLEK' ;##M$/'M9W>*=W0&_2X%?.O1':"=/XB=X5G$
M<9=0;SSW&LXER%6$]9'Y*^1^^DL:G?TT![=<6&&87PVG_>G7-\,R&I_-9_[C
M6.EI?0(D@I 7<_K?'WS>-8Q$AOZP7W_ZEKY=/+0BZ@@M_CG%8<;\XP_]_+<?
M^TX$@S&K7#AJ<,ICR-I[EW+B/DK72UP"EQ@81F%HI<^TTI<L&2A;(OJ0::G?
M5L8OWOWZ\=W;-R]//KUZ^?/)VY-?7[SZ^(]7KSY]W$; ]S]L9^FNB7-%M-:$
M))1R,7.IDU0Q2MI$%4:()&AA>CZ;@!A)M"@TT[2?LN 2,N,T9/I,"-%V+MKW
M,":>G.*TGV"-36(#.=]\<CNA/S""%0T$69?6;(2#5,D="G<R:HP^"(C<]G3V
M0D'VC >2NRY:L4AF#LM"DM*RY,;'+C3P\1/]^\NK7S]]?/?ZW?M7'TX^O:'?
M[BK]>Y[:J>370;XB=?2 /'DG#3=:@8Y)*1 \N)!1NBA[7&BGDP@L"1>9SH(S
M0.F9L6!3 %IGO.A:ZA\_O7OQO_[Q[NW+5Q\^OOK_?GOSZ?]T*?T[GMY,"X^-
M9$4;R@J>N1:)YH(NJD3Z/Z.3HQ6_>(RJ)V(6H("6'6X#:<-&%GBP3&E!RY4M
M)GDSMTB7PQF,THT7#JH]/+K<P <0<3#_:6\V89\!SGL?I^2:U.V)QH]OZ,M)
MKUCE1:D["@1@.D9#OD/DS")Z5:R(,HL[M__YUE]@$N?[_^(-9 <(_Q,.II/E
M3ZK>:%J+A4G][_=#N=#4]H-[,TSD>DWP)5[\[YOAQ^DH_7XZ&F1RXU[]UXQV
MXP^CP>#U:/P'C',O%FDEK4%,ISKRI)%!L9IY);.GT><29(N1;XCSIEBN*'PR
M7@IH8<9M:>=5Y[13EDQ'^]/+!3=H?#_^,!K3X_[V(]^51B]&9V>C"X@?3VF'
MF[R93&:8>[0R!A%%886V+:;)N6;>9&!1< 6I2,309*+<@V?_M&BJQU'W2KC-
M#;$K-VX/N)>ES)H7S\BHD4P[#BR$3%I4S@>-P8"T;=;/52A/FQ$[BOXV&>2N
M9#C)_W<VF=9U<O)I=)+S7-@P> _]_&;X L[[4QC,R5M/EC(Q^IS\]KDC^ %I
M )/^%#_B^$L_X7L<]T?Y Z;1YPN5_1,&,^Q9Z3Q(;IDC X'I0.99$,*296RR
M3:58GDH+:K4>V-,FZE'1XC;M52=KX,5R_'(V[@\_7\"\6*;GOWQW7L%.7OV)
MX]2G,?:$(:=/ &<IT&S54#B+I0CF-7)R2%"KW&Z-W CJTZ9F8]7=)IMN1+;Y
M1+@;<+*$5T%D:('D(S'1Q*A'.ZZ@LAZR#;!'KMV/]%E2K2/%W6::V95IGZI(
M9N.OUVS.DT0B&1.TJ A<KI8%D RTEYE!R)JLC5A24HJKY%IPZ@%,3YL]72GC
M-D]LISR9TWF)[,5H,OT%IZ>CW M6&."$T::Z12LB- AP+&:I3- Z@6[B*ZX#
M[ADQIPOUW*:0VY5"O^*41#(ZP[>CR:0')F$JH3#4G!.?;69> O%9F>2U,=J+
MU((K-U \;5)L+_#;VO>MSI=$4.@,D3)'3Z-4V3,O/'V;98DQ)Z7+X<Z7.CDJ
M 2E,3$8QQ:.@'=X(%H6M9SD:4M91FMR$Z8\=E>QPCOX)X@![J0CCN.+T;D7K
MB<B21>\$XSKS)+SRQ9NF9^AS&!W.X6MA*\V/AW>0Y5TG?#]<!"'\-0U&9%7^
M[<?I>(97/QP-I_CG]-5@_L*__3C!S_6+SNAPP:[JTX^&]0#@Y,_^I&>DL]IS
M9"X5Q[0&ST#[PD+R1F)0%D1;=MR%JD.R/!!/] !YMM#V?<396>H-3HI7,+V<
M;XIK@>JM1#AU28D[476Y]]\7IO4 $7;7WJB5Z/?&"RPB)>L= P.E7OV2-9(#
M9Q&ELJ'PE)%_XWRX$09W>#IL(O$&-+AF=/TR-Y1[SG !RBM&UJEFVFD@=X3V
MT92#5[:&P"3=V/S[Y5J<WCY=@0XT=/_UX1;B;7"I?,,M74"29.=[M(8)-.2'
MB @L.-H%@^/@>9)"B2;7.W=@>0HZWU7$#6;Y/;<_"W !8O1% !.B7E]6QRBB
ML\PZZS#8DA6H-M=[#Z!Z"DSH3NP-;HT_X)3&A_D5C(?]X>?) E4N7#NG,W.0
MB:DHH1K"D@4>#8<(7N0FR__=<)X""SH0]+VWI__QTXI@R!7^O=LXR1<G'__Q
M^NV[?W4:G'KUT&91D??@7@F&A.@SVB 4%U87GB&AT 8PIBBL!]X+4?O@2"^D
MI<2T38Y%,);)J&2.#D016T>[OQM_AF'_O^=W[C#,'V=G9S#^.BH?^Y^'_=)/
M,)R>I#2:#:?UWFHTZ*<^3K91PW8OVEDU'8QO15U1%.4L9 <Q:\EUR$D4^A9U
MS!8%[ZFL<]"0F4K9LWJ(RB)WFI60M TQB.)AK^K:N]H.K+[UU$B&+B\TY8ST
MVB-$ZTH(R48M.-E"O$<2*+9X6@VS$(PFIF(^ GU;( 7M,&/*>U7C_)1H?TI<
MO.XP*KQKK*N9+)R\%0S%Z.RTX]Z;%*4*"1TMICJY'FBTV2C/DG.!:<XE\Y@S
M0\F5-B7G5/:[;'ZB$<Q@\+)NQH,]*O+F:P^DT ?&OJ)8PWGU24NFA58+$:.V
M$47D,=AD!+I>E-ISA8FE5%,U%' 6: XSY>:B"AQ,V#$YX%?\X]H8QJ,A?9GF
M9S*3=^,7IS#\C&^&US_1'Z8^*?#J&B!I0N=C9"% 35%S!+(DRR *%:6(!DV3
MD^Z=D6]KU%>V]GZ=5</R7?F $R1;\?0Z5][CN*;_T4L7,7V_D=+'+T;#Z1C2
MM)>=$JE.4B(\63D! @/(@@F7E3"R&'3IL?FQ(X;]F_K[Y=G2+=BGJAH<()&<
M$F*>O"9Q?@3:)]Z5GV<3DLAD<E)*?]"'*9X,,WTLS]*T_P5/)A.<3FA'ITU
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M0A4?V:_<D6"+4L6(NRMUWF0G/?\:,^F[55;>!^!0.2-[5/VH0Q5T>.Y>\7S
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M;U"9D[CDTN^VAJV-Y3O5FFJOZ_)/C]N/)SG/%0B#:YCG1T)G9S2!^C5W=S[
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MOOVSJ8U(,FJCK 8.[CW0%E;Y.N!:GET]B.XP9UF=Z7(]CNR@B+VSI60C74[
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M.+K1UL,<V$+4FZ;2+GY<_ZG]EO[SW_Y_4$L#!!0    ( '"(?E [>HF'K!\
M )9!   4    9'EA:2TR,#$Y,3(S,5]G,2YJ<&?M>0DXE&_;]RU$4I;L8DI$
M)&5)UHE"*0DQLDUV@^R[81(BVX20)8J0=9)]R92UDBU;9!M+=L8^QIAY[_[O
ML_SK>8[O>;[W.[[M>)US7(?KON]KKO/ZG>=]GN?O-)1OE'& 65/]NCI 144%
M^( ?@()C3E3S0=@ @)86( H  #U 0Z4 ' !GC."%9A@"H 'G5.#<(.WYS[\
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M;5:G*[5</BL)53[&;AEA"MJJWKW2+IS%L."%6SLKX6JY/I^Y[D>%B,(;UUY
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M:B86/VJ%,%J\C7S;PC3:6N )3;+_C!\(+4=QS&=I=Q7=7+=T+[ET;6#WRPA
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M8'3!J&'3TKNOHQ9!J5R?6I$,[T +,[5 -Z3FL00V,&+-@BD (ZZ( G2Y:U,
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MTMDBO2[4V@>E!;+;O*.?C5W7]8ZW ULL*_ ]O4S[OVE *(/_ 5!+ P04
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MU+0&@QWL7>ZJ:/_!%;!M_MK_ARO\P1_\P1_\P1_\WPX]P VP!4P!1D 3L ;
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M#7E0;?+;5DVV4'J(&(RSC->DL:@Z]F:NBV@RSA0%M-?1HH%4#$F_"T\D+:(
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MK*;=/W,E,.<]W5*QR#N'K2-?K-LK7[-!AV^&^)9+W51X0%T"D8,EQA+R(*U
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M\AN)3!30+G>8U.EE$[,P4+! "<J)>+PN\X5LZ[Q6.!&'27>FPZY2T<(MY$E
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M=OEL6 Y__Z/(QQ=2NJN%TGG?:G^>IDAL-%6/[BXUQ!\,DS5PP2;\^W*SE?G
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M9:#L0.4W-7]+*K$K'8E20X\(343,4KV;KS@=*_D^Z/&@_<OC3R2\N_W" 9'
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MQV-%O8JC09J(/B.M=BN6K'A?M66SO$P?W,1?\986QKG1)73WI7!P[W:)[[K
MZT\KV(WJ)HK/!%[+,:A]Q@8[IF'G<+.YOV(U(2O]K^L7'V4V-A'/M1F@KMHL
ME'@N$>]T+VQV:7\.5^ZK&0WEUIZ6>38T?E7$O#*:A9S__IMW3DE%%[PE?5R<
MIK&@D89SSOX>5KH%C5:*]OGJS<4Z#PBL1,=]&*5T7\_G=UG$GS[ME&#.QF\
M$(UVAKKO]BYK%+;EEF*IT4NE1$=:-,PO7G$L)U-;!W;6XGH54>]X[5CV4V%W
M>[4<0IWRJASE(5TB*;<*-JJ^(\U['MVNJ&^4_0/"EDF$RDV,T+#5L':5"<4/
MJ^4&!D;?;H1DC.?%EE:?B7O9<-F=[!RB$.ORX6:PH0>K;D6\+QG0?6,]8\:-
MQOOBX;I*6=D"6OF\Q\ LKR1JY.H/2YF6RGGO2=Z[8;*$8S5V9A9GJ]45;QFJ
MYKFCI3X]VU;N$<BV+4KRP2=H:**J<;Q=&SF9Q9/[UNC(!V$?W#]"/1LR/=/]
M(G_9->HJ73*2F/MC!A!!PKKWZK?EI3/4HPOI7@>JK?M#]3L$I0,K1P>)SO8W
M<R5BH5KSD$A^O/[96"\AR#E: SW4;$!>LE[P15BH<K^K?,2MV%4G:;7MM<6_
M4;1*!4&3,![P&;OVJ7:G;*V;:$==?R>^0 YJ_$P\*5!?C$11N$V>&/IPJ6D*
M)OI8+]*4LH-R#DCI]GK"A@LX**^?27R[50J%1RG8.$3:KH.J+U4AW1-$WQ]H
M?!&Y4.=*5DJ3B)^G\0^8FZ[N MD_EML^N9#;H]0IGSB?_/+J9I8SFM *L[14
M:X/E]7LY76DG:AAD!]6J6*/O?\NN^%7?9J#!%S>8%^<A61Y='S'EP'F\K58Z
MK&"^V\%0176-)[9A6DWTO9"L&5'$OA7F##V<U H2J^N#HV_/9/YA=)IH\/E9
M^8TOK%CWHL.PED]80H6IH T]K!3Q4M^+.[2U5E7S9 TW?]ZMTB4=GB7>;L3B
M*\UIK/>3RZH,R4A;$E9J4#IN  8K&HDRXD$-J:B*5(<+B=@8ZU]#2H1F[<9J
M@:5CM@X.(3U_R;O(8:1>&\@)*U+> +45N?S5A,J88OUK6TT"PB8P2Q\HE1..
M1T2YWDTQ_,[1Q@:T'RS4%SP?!T/9*#(>3 VM.\1*]?VY6)T8K"?[?#=-W['5
M+YDDU.7S!P=[HI:,%;DQH,C<N##6)10-+V1HK(>_@$LUIZX#5VC?E'YT'K[@
M3 M2EZR^*GEH$KA_Z5W%WPO]HU[0(\ .=J9::)79]@KI^!0P7 0$2F-"1H[-
MN.IJD1 >T_6V^31MB6Y#%&C0I825Y%)ZU$UBK%WE8.?49O<STM;N#KBMRZ?E
MLGVD_:TC++>/B.*ODQ2Y^F36"9)=9AT7[$/QO&SX>E:!<3H47FZ_!#F[SD66
M\.21Q#\=E?IJ>LA9BE.IV@:"!LNF"%RC=-^A24,M4GIPRKO*-07V:Z:'U_P^
M QX!)JT'SZ;%??F.><S9,GX>(AQKONG+'/$K=C!"RHU;=\.$[CO3 .U0RH/Z
MV]M"A<==_]B':Q.+9*@?>[F<&/$^R. .06H6KMHYDMT-^V!V=Z;"K' Q(R&M
MHH0RX<4;YA-X$8NMUCT%9<DJ]LX>Z=A:A-;<P_M.SUE7Q3Z>ZJE!3'=^=? <
MW8&IRX?WS,T'_0(&K:S'![2JMH($DK[ZD8WY9\GAN0_ F1ZA[%R]5X7$(XF7
M176680,6"^G;E"=E#MH;53_<T:<R>F#,4=(V,K#"_*$B4;;E8SLK*%?"GN7&
M-\E!VR>GBX>7;-)!_.MR9"W!_G.K\M ^S:A-WG'GL6<%3 DR_KR,=(I*U3<P
ML4*&;K]F6(=>\@!+'UCNKDR:]L^>%A=W/'7S\PE^>S-6SY#B1%(KY$K=8$W'
MF,.*EX<(**C_E:3+7(RA3CS)2U]S^='L2VL  , #*"^;X/(XGS!*&8<B4R&J
MJADS:D(+/++6<>G\\KUY/MX/B5/</!Q][N5!WX39[LVK?Q'5CL,5YT7SBYY2
M&9^7KD#P<+NUDPU?H%?: K:)HTA;ON24*!R"_#<ZEI;[! B@9XR##VPEOWR$
M(N]SJ% W5=T.&IW$$@)?WX/ZS--77:<$1L,=8MK_%PW]53/:LTX1N3@*[Z0-
MSS*\)M6TW (+S)1'<!J![6\G#0D]2>(U;LE/@Q*1^Q9>S:RU)"V_?'J<<;7@
MSJ/_D#.9=A=GH%+5HV?G<U9>WC<C*O><_2%*3]:R7UEX#&927S4$:AL?TB6I
M=++[!10)6?BKS( ./3FU><)2VQK2GT,&"=2A7IT=%%A8Q2U[9%Y],0+VVKS*
M]/+J@P60,),X@,43L,@C +DVQW-DCKK1_!?^<2HZ&U%N!!'90[,.:BD?EB11
M.6OK#\Q&C@"#JZ\@8_CZQ?A9&[@^I]DREM!QOVR3$<SX(2: <&.>2>+*EJ"B
M7'XD:V?.P0_BA84ZEI.@]Z;*Z7M:QCL$?%$FN!H9YG^PZ]LS%1^NC-?7'-U?
MK=@#2J+ 7\;"+PFD3V%6)@27H?-D1@_5*N))$AADDU80MK*9M<]E00\FHH8%
M,WX< 3P/#'<*-^U]-G;V; $^2X_[,6)W*,=A1'5[E_=->!'W>K(>0V'@38-2
M"^_A(=0[AV<-4W&A;UN;WW[,_32U#?WS(KYX5N('Q-4>Z'U \I,S[SIGE&][
M:MOF?J19KGNS\YV3%GBJ4Q:)(=Y0.(?.+W3HS%]*DWGX;$EHL#TMI*T#X;)#
M-?G9**'P+@Q9NA120_Y0'<P>C0%))3CI=%CJ3QD@EQ[;R9_E/_8'&:!387I?
M?-[3\RW3;9*_.85(G.H0#IIU 63QSXC=R0=&!')FZWYWX*-GS-AB^W_QP:"9
M[E/"I-6::*2_]LF5A:(P7VEVK*N_*O-DHXG_FA4-1U!XH<SDGD6Y&C\O=+S:
M*.ODY52G'0W19AG5F1RSN16SXUHWF*876&R:.YMB**1P\_/,1Z'*RC@[.8A5
M:%9;[>0:-8EU%/&8.F[V"C=#!9E2Q\WO[0;SX,,0/2'8:0=N5,NM?;TPS,H1
M8*0A*IBPM+N7J;2Q+=0=LKE50;Z\J3G1?0307N0<:1O:J.W<_YWPROW^_?1O
M^C?]?Z>CD7\!4$L#!!0    ( '"(?E!1U^CE31(  *TL   4    9'EA:2TR
M,#$Y,3(S,5]G,RYJ<&?M5WDXE.O??\8VEL3(3L<V91EF[#LE8NC892PYQ0P:
MR]C&$B'2D2EB1"5+2%D&V4,DLIU*:(A!UNR#A#(JO]'IG/.[?N_O>J]WN][W
MO:Z?SW-]G^=[W\_WN3_WY[[O/S[/[M#N!,!M9FQJ#(! (. <_0)V)[G73X9A
M/0# W!R0 P" %6 "Z0 ,](R3WC"+QP),]!Q$SQTRL_:>@#  </<NB@)@>M\!
M>EN?'H#HXO=O][&/?>QC'_O8Q[\H'(.]7<5ML;Z^?K@@>I,YF?&[G^"E^X8'
MR4Q_Y@W$E.\YHXH& !")?^5_>0O6C+WQ]KW%/O:QCWWL8Q__VE!65-+25E31
M5M805U+65E;55E+YIWUT%P($ ]Z *R .V )8P)=^^0$X8,^0[$YRB)W'X_VU
M$0A<$-P5X^?F#D?[^2+"7/T12G!%!*![+,S?%>WMCA=W<_?$XO2D5QN?2HMC
M,7K2*#5S17-_0_?S6&1XH+MMN(4=.MP;K861/J;/R:X;IAWFZ^_KCG<5#_/U
MP05IA^E)?A]=FY[O=2,D]74#,1[:-D;&/RKH+3W)'W,)#0V%AZK _0(]$4I:
M6EH(166$LK("O4(AZ (.[QJF@ N2^C& D7L0.A#KC\?ZX<3WVJYN?L%X/<G@
M8"Q&V\/50\T-@U%3<'-5P2@H*6%<%5PQ*DH*&!45C(::DJ:RAY*;Y ]Z#/I/
M=O_@0)_OW!@TPMW'W=<=AP^BKX820A+Q/\M)7Z(_2?_I\M,UTFNT#0/=7?'N
M1O30W]M@!445!64-NS\V&*ZBKJZ+^(<Z7<0_3/3_8+7T=3%H;?3>G/P"?Z>W
M=0_X[^VV#U;_[RWU[RKIG;\G].'I9X^-C4T7\??,_W8I$#^.'CW[\Z#2OQ3_
M7\ ^R3[)/LD^R3[)/LD^R?\ODK_,KCN.[G!#Z59V=P0P!,#,S"S,3& 69A96
M,)B5'<)!]QCL?%S<!R""?,)"@GR" B(_24N('#YR6$!0$BYY1$86)@\3%D>H
M(.24I>5@<GN#@,"LK.QL[+P<'+QRHH*B<O]I[+8 $%9 &N3$")($&" @1@AH
M]SD@!@ @9M!W_/%? &)@9&)F ;.RL7/0"VJX 080(R,#$R,S,Q,3_6TD_3W
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M:9X+Y"(+R^2?$_O!\>\%>'?X;U!+ P04    " !PB'Y0#/0WX$+'   WG@@
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MZ2D^"1%$B <0RRB%. T02UB449[:2)E/4%.3P,XF0)<"[%@%=LR:@<XPL"I
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M@]U-8WITBYWV#$OVP)JDP8.:ZPZ^<=M^,!9HRG\$&R/ UHI!*J7W)]&GFO5
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MK%]E_<'*^W7/ZA\T<;#WJ6<97>C60FY71+8;^ED<(,;U&)1*+B"*1*1'(Q1
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M(0EQ4;FKT$Q-^+0Q8(L5[)NC.PDT!IF/=>^RUB;P:VV5XR+M=?UI)Y.C]=+
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MJ>.\#G9J/+E.'EC(.WM!:S X%410'Y)N7X6;]E78"S+XV+X%6Y-GS1',+JC
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M>YVXZ(<^L4MCOQ@#CXO#=??TA\7#HR_&^A&B3EZHSR8Q)#I"_V.,B/WZP]N
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M24 @$A&'.$3:DXM1AGG$8X7BKACS5X=)_L66K3ZQ_0K,7T=QXCJTE:F2S6O
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M>*+?FS T_4/W;V^_&]'R1(6E>"674LVWF^LZOEYMMK.J+%(E! 40$<V!E>9
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M>W4]C^!(7E=._FGU0:X-O_V\6K_??M'S^\F4>9O1M. R5Q @PSQ(J +@*E7
M'#:RC/,2%6Y>4C#5IL97G64FQ.1F+LW)QJDS,-FNDM;$>A/5&)G\49OI&HX<
M;N@M/;07&=#83MS88^GN[P6'/:A+&$Z[<;W&X*A>.);A)00JPM\D]LP8I3CE
MD '])P<(%1A0C#E0>A5@$"))D%--WAMRIL;>5POOSVM5 Q;=;S%6$G,J504H
MQX5>6:7^J9(8E(64K,B9S&DV^RK7\Y7XM*7K[6A(G\N,A_<K^7F^7)I;+$;U
M+[@,CW*A*HI+J+T6E)G2-5COG K*0)8KFHI*J*S +<IOEV)DC#N)\1#6$J+"
M:[MA&@Q8])W29<>(\&F.=W"(VBJB%?6R;2).[;W;(N+LXWYKW._+M>2KSTO3
M:>*)?N_*:,U(1GBA* 18,ZT)08. (*29(2L882ECF%H5M;HC9VIKW+&:R99^
M3UBKJ!LAW$+5CA "8!69$$Y@,M6L7MV#R9D-[H 0D@UNB1J5#>[8>\X&]S[N
M7\7JO?K[:B5,.9Q/<OUMSN7FTVHA9A@+F1<J!P47VE^@, .$\ I4:4HYQ!5-
M)7>M8W5=U-0XH2G3I+>YZ^-M[G%$Q5K_O-PY%C#MP=K6;PB!8'378;,UV-5J
MUL!UBB9&T[!5KOK1"%WGZH:TT2M=]5M]K=;5G2<\N8-NS$;=_.?MOW?S;W11
M9V!_GV]F65:E+)40%%"E %55"A@I&,A+!"DIJS)U.R&]+6IRW&%N-^O0#O/#
MD;+)'T9=U_N9VQ!;4D80X&)3AB]F[IQQ%XZ@G'%;VKB<<=?J"\ZX_X0?9YBW
M;7^82KVKI7YEVU&^**NB(H4$N4E]1DHAP#B30&).6(X$DVX-;:Y*F1I3-$HF
M>RWOMZ-W0-2.'0;C%)D8W"%R9H1>"$*2P75!H_) KZWG%-#_8;_9_^M\.=]L
MUS_>JY_G2W,"]VXIYK3K+%,BE'&DYW].$4!Z]P&PJ"3@6)$BS4V--:<B"'W"
MIL8%G:[&<6ZU?4AJ?=W(H!=@.TX(!5MD:KB-6(1@#AM,0G)%K[Q1*</&\G/F
ML'K&CT!NW ]V\9,\+PK&<KWM$$AO.UA&VI;9)<SUO@.EE#L59NH7-S42N7DI
M[UO&[0[:=GP2#L/(C#($/F=&L4,E)*?<D3@JJ]A9?\XKED_Y,<N3?NR].HHT
MJ#?9K.)00)$"_>4QM;H% I17&$A"$,T@19P3%T*Y*F5J/&*4-,OJ<8"DF1._
MK9: 'OV;:=6UT<C7/2-]3C>N8VY'*X.1C,PF,4!T9IE>D$*2RW5!HW)*KZWG
M5-+_8<_CT 7=;-ZKI[6DF]WZ1WUOVP0-IJ@J"OT'*#/( 5)E#DB>IJ"@.1&R
M2H6@3OWB;DJ:&I/4BII9T*G:-IKUBN*\C:_E46@(U&*?A'H"YGX0>@^,H.>@
M-X6->PQZS^:+4]"[#W@>@CY_7:Q^2'G4R[?=HI=Y95H'0<"%J2R;,PAP6:1
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M2;:VSWD&W'>7GN^67W?;S2_RFUQDW6&L0%DN6 &4*!! 2N0 ER(%F>1*"EE
M5;B%U-^6-34.J75+,L>0^!XL[1@D$$*1R>,0\F#R=HRB#TD+6(1"I1:8!(U)
M[Q$W;M3Y?;LOXLHM'O$X[_['T].3Y%^6<TX7'^5&DP[_\EJ[1&NY,F51]7=#
M_+(5[1>=993D>97J;6M1 ,25]CXP4T"6:4:*"I:XS*S/L5TD3XU"M.[)7OFD
MTSYIU#>'UJT!B;; YRK-:50LCJ!C81V9C"8%L\,9<"RX1SK;#0N[VV&M#W2]
MA[!.+QSO<-7'SI-#4Z\7>!Z&FK/6)_UL7;R5%%A6)18@S4OM.9*J! Q#"(J,
M%281,T^ITQ;TY.U3(_JFSH;1SJL&[BEREJ=_OGC$/K:SAL+]?.V:R4$/QDX$
MC'NB=<VVBZ.HJQ_R#4S])IMCK?/D7(JK/,])!B!,2U.) P**#5A8*%+F3%'&
MW=K%W9 TM5E\4#3Y)/EN71_9N8:=WD+5;E8'P2KR##_H^#!*OO)=3,)&E-X2
M-G(8Z1V;+V-'[SW@1A.;]7;VT5RL=K&A&:/25*56DF* 2DX!2W$.5,XIRE.(
M\I+9D,+9>Z=& ;5JCB43SZ'JG^D# (@\KRUMMYZ_-RSMF:WZB:.9JO]V/DO/
M7SG*G+QA1S<#;_UZY"*(^X.?Q\UF]]Q$/'R<;_[U\UK*=TL]=S0]F-ZS;3?M
M699!F?-2Z+7=1!D4BFO_G"- TE(BQG.LF'O[BA$4GQQC:%6!T369M\K6_:\?
MDN=&WY%*)+H.OYT[,L5!C<R" 2+6CO(!C\Q_2 P 2?U5Z2"HNWL_)+_>^:J,
M5YO1<]PF4<'15?>_1IU'SQ$)5@W25[[?\E<7OE&:MA^7H@G?-TW2#YW7WBTW
MV_6N"<;0$C;7?]6X,#.3M<2Y7MV*7"]LB#(&,*<I0*K 4@HD(9(N2UQ(Y::V
MC!WZ#1ZIZED[/.@@VBU4+S4TL:]9_4;%>;V( 5_(-2&H?J/R?@QDS[D]B@S/
M&AVKY^?5LF[E\)I^G6_IHNGH8*X>UM^D^'FU_GFWW:VEJ56D59 SF2NN4IB!
MC% .4&G*CHF"@TI)24O%$956!PO>&DR-B1L#VGRF=:MUHE;K1-5Z)_-6<?\^
M,.ZC9,?"4;&/3+4M[&VCF%;]KF',Q^-A:$Q(.AL"%OKPA2]HP0]G)<8M_.&+
MT44!$.\7^3'CF[;-S1/]KCUIN=T8I[IQPA>+U9_U+$-E24H&$<CRB@&4DA0P
MGE+ (*.$% HI47G4 ;$0;341QR\#LE<TH9VF;DQG@[H=MX4"<1PVZ[2M:VTW
M^CXD!S0?[Z+I3%X.^(2D*QNQHQ*4 P[GE.3RJ!\)_3*G;+YH4A&63<>M+ZN%
M?GYCBB!M?\Q2#B%D!0-0Y9J!*NV(85)"( M&,DH)106VZ<)@*]#)^1JA\<*3
MD9$L#EK7);\V1WK_S_^!85;][T36^KNQT5WX[:@H)*B1>>B7,R3?]J/FS#JV
M4(2DG+LR1^4;6P3.R<;ZN4#NSOOM%[F>T0Q"BG,!2 6Q.8B#0%-*!6!90I&I
M5#!B562Z7\S4MG2U4@,=EP8_3U_%&967<$_Z41KND)R $-4':22]K-MQ8NU=
M3^/TTWY3_JU2TF0ZRGW#$',OT&5,SFM'YM-6_Y/FFU_T\"WVGY.;F2I(P7&%
M )?(M'\B!+ L@P 7 F8(9I0HX;'U&:+31/=$M;I--ZBFS,U*)287:ZT=%]:T
M9G&CFD'C9D=(T8=AI++WG1E=_KFA+V-)<FK*0](,4AW\;LPY^KP9M0]2*Q2B
MJ5%(?$,RXB!]1N7-$,B=LVN0=WJ7FVW>="A@>PA!Y64JJBHE@&-1F9 ? JAD
M&&0B3:M",J&*W"VP][:PJ;E@QQ/0N9+L;4CMZ"\44)'I[8C4#HHF?T0*ZKT/
M2>!*L;?EC5TA]J[E5RK#WG]F(&/(DXK4E&1$*0Y43LP^392 *IP"C'-,6,61
M($[1@5>E3)0CM&LUI.ST%30=6<(7H]'H01Y7D7YH>YL%=&=ZD8C""B>"7H8.
MKMEZDP>N?MBW(UB=#VB\$"&__U_Y8X9S5>:(<\#KN*E2(4 IY*#$1&&2TQ1;
M-OVY)6%J$[]1,FFU3&HU$ZVG:^.O<R#[YWT0>&+O>%R1\>CO=</ZP7V]SM\[
M<C^O&V9=]O&Z]4'/! *SL3 !/<TQKHGV7"U-?$^3E9L+F4/M_:N\R/2ZKE=X
MPA0&7'#,5%:)'+E%_?=)F]PTKW5,#DIZ)>OV VRWU >#+?;T=T7,/5+=!HF@
MX>6] L>-";>Q_2*0V^HA7U?@[;-<?YXO/_]]O?IS^\6\G"Y_Z-\3)G+!@,2I
MW@T(E $LE/Z#%1BCE$!96F4$WY$S.;YH%K].UZ11-FFU=74.KD-KZR(,!FP<
M1\$5*P]WH1>)P4[#];>/[#KTFGCI0/1_W,^-^%63RH]?Z?I?<OOS;BDV;6XK
MP5E6F&+$%315/03/ 2M+_=>TA$I*!7,I7/R'ZV*F1@2UEDFC9E+KZ>8RW #3
MSE<8#E'DJ7^)3H02</THA'00;D@:U3/HM_;<);CSZ8'G@F^_FW0Q^:JY6IPI
M7N$BIRG *E< 93D"!)4"%*),RS0K,&1\]DVNV<KY;/!4DLLW_%A>O"]Z7>!W
M8^(G31CX3^UE:V*&S[18ZPX/O2\8SI!V/#7T1V^\:X56Q^2G5LO;>0O^9X;7
M<8AR:G@FZF7.#:_;>_/D\,;'?7H@\2]2[!9RI;K"8G0IWIB"DZNO9H/R>K79
M;I[,">7AO@RB'&45%R"C, 4(,^T_4.T_0$DKCFE:I)C:MSAR5V!JGD5G@@GB
MV%?0,V$#1V8DM1TNO6T\!N;./F0$N".SD#W2R1^U$5;%C,* [](W*.X@C-46
M*,I@./;[\4>ROYV/QWM'[-;C;_5I,YX![PE9&6=6E)FL)(0 9I7V1Q%7QC.E
M(!54E"@5(BN=ZDQ>%S.Y=</$:[?51_AQE1+9+.\AJLX,JA$S)>:_4=$E=KF5
M**?7UR5-H)3)S?/J_D\/N.2ZB)X[=6U?KY;;^7)G4N&;1BRKY4:SA>0%$05@
MG&4 25/U*BT$R*NJRB05-,NQ\_V7AR+3XQ-MA\<]F,\8.%R1148V-O'<# *^
MW @_) =CDH,U@2_:!N 9_ [.1Y?QK^<&(';UYF[(^SS+<M<)'K]IFYLPK7V7
M.:1P6N(, I&;WBY828 K4R.I2KG J"J9A$X5NF\(FAK7:0U!JV)":YU=>_[=
M0M2.V4+@%)FYNI2L@Y)Q&N;=02)H;>];LL8M\WW'XHN*W_<^[\<)'^66SI=2
MO*7KI>::[D**IU!!:'H\930'*&,I(-+LI7!10)Y17F$G[^BZF*GQP2/GN^?=
MPN1O)4*3,'=-H+J!IAT;#,<H,A=T"B:=AA%N]_I!"$D#-R2-2@+]UIY3P)U/
M>Q:"6"T_/\GU<]=:SE3#F=?EPP^GDD6:%ZG  DB%"X"@*@ M9 X8,[\HB2B%
M4ZZVA<RI4<.^1^)!5\?+/1N@[8@B,'R16<-H"_00/2=7,(QRJ.N!4]"J$!9B
MQRT,88_#16T(AT<''.9^E%]; 1_6J\]K^MR6_&29%/49;E$4&"!*2D"%]D52
MGDO*J,QAZ5Z:_(:PJ3%.K6MR4#9IM?4LQ=J+L\/Y;@#TQCCE]0+.[[CW#B+!
M#WUOR1O_Z/>.Y5</@.\],R1&:1\1O=^'%Y*32@J]<='?%8!*0@#-& ,JXZI4
M&<&<.9ULW) S->YHSQ?W>MKLV9UPM2., &A%Y@H?H#P#DF["$#X@Z5+4"P0D
MW;3W>D#2[8][!"1=OXEN#U@_RGJ'_X&NMS]F)!,\190#)NOFA'D*2)$RP+$2
M15H)E G[#K768J?&%R>1%^(H\@(DZT;MY*O1VR'ZQ7X(^KDD'K#13TMN1+.T
M:C\DK>+)AVC0.H0318%XI""B4%"[A0TY(]8;+&3_MO%"A)PM/ D,<G_:-P3@
MO&+A;ZNMO%:C)2VAX#G-#=GG #&]G20:$X Q%!G&*<XSIPKSUI*GQO>U)]XJ
M_K_NE>(<"+KEWC(&E+$WFD<Z=R@F1NWX17.<X0I[:6\K?.1;>D=,+J_E75_@
M1UC_1R[$T^I7NC6-97\<&LRVU5-F$*<J+PD#C+("($PX("BK0"8A%A3S@MKY
MI);RID=.J_6V.3&>'_KP;CS[\-X#FW!.D&(IP!G" &6P GI=* "G(F=5E:6*
M.-6Y#@GV"&6N:["3,[ W#PD5_[7;;.N8THWC)>@]Q.T6A( X1EX&WDAVW";Z
M(3&J@^T*/+?*1ZB+9(E.2-:_)W)4KK>T_YSA;1_S.'*P*?7XN- 3;4G-I]HF
M>?IC;0G0F2K+G!=Y!K(J@YKU,U-HC:> "JJTN(*79>I0]S:(4E:S;/S"MX^_
M/K4$]=PWJR(,DL59Q2B83ZW*[9%!70]3\^'[!6XCC)'#H<>88S726<@(8^9V
M3!(*X][3D\%"QCM4"87'R5E+L)=ZK'S&_SDLI6:)W:XZU^<HHN[WY5JK\WDY
M_V\I_D[GR\X=1(3!*J<*2$Q+@"#) &$5 BE')<8,9X0IZQ/X8;I,<B=TQ3G_
MO%YM-LE.&T$7QH3$;%I-NL!G;8L#U0X<.8O%<+SQ>'DG_SAZ]-B@Q%AT?P\0
M?'@<UL'QAFFD53#^<+DM@F$ [ET"!XH8;P$,@\7)\A?HE0/K;+Y7K^GFR\^+
MU9^;?:"$0E+ '.L--:\R@&A* 2[K0MHP+WF:XZQPO'*X+6QRR]<^JF*E$J-M
M4JOK'8S2"[3M-4,8^*+?+'@CYU]WLP>2*&4WK\E[F:J;/9;?++K9]XR'$VW2
M_<P[5NLV9X2FBA":0J"@2@$RO6 IX0Q4DN.*YGF:5_:!*>=OGQI3'/1S<(\N
M(+/P1X< $7G.'U2[GU9C 8:#]S<$E)'\.1=PW#RS6\;W^EH7#XWG/=W2]\0?
MNODA3P^'+DR;@6]RN9._R6W[#2OR7#,112"O2@F0-$%T%5< 0I1B2@I,4ZOF
M +U2IL94K7Z.CLM5_"P]EJ&HQ'95C'Y)J^!#HE6,D!78"T)0Y^2JH'&]DCY;
M+]R1W@][^2$+_?-J71\3/J[7>J@;=V>WW6SITIPR'7* 9IS(M"IS[9JDK 0(
M$0%8C@N@5$Z8=E)*D2,')\5!]-1XX4A)4X:IU=)I 7<!WLK5B01G=#_H2._D
M2/&'Y!CDU_%!=G*A(H$]FG\5"G17[\L#MSNNF<L;Q_3;/"P]<^I\WN#G\9D7
MF=:4*_ZO#W3]?EUO>\4_Z&(G/\AU'3XZ0T05!:(44$8@0+#* "YS @HE4U95
M$.G_N?A_%C*GQOJ-RLG&Z/Q@4B22;T;=Y*??/[U)OLIULC%:WZYM[(V]G>\8
M&-'HQ%^#^:D!4RNLO[%-9I9(:IW-Q712:QW.LW2 **2?:2-V5*_3 8=S']3E
M4>_LSK6D&_E&-O]]M_RPEE_I7'3=R]ND@L>EJ-N7-[5R9D6693B5&5 "FM!.
M6@#"1 FTS\HPQ+PB%?+H).ZGS41#J5K5NVJAFSJ%9F743DXK8SGGC?J,F!VM
M11R T;).:\63GSH33-> I!N+KB2@&8K:@.2Q?PA\,E('(!@X8=5'D['S60>@
M=27==<C;!N1(O=ML=E*\V:VUIZB9>;YJ2+K^W?NO=87!M]_EFL\W4LP0)2G)
M20IR!7. I-[5,T8DD#@O*:G2DN=6]?F]-9B:K]<I9J[D:H<O67WMK\P9:"0L
MSPECXAO[#+&&LU$^:;1/&O4?&L_OH?$*D]:&9&]$X(PJ'_R"9U8Y*3%^AI4/
M1E<SK;Q>Y!.?N/NP6F[?T.5\PU?MV7O)2DY160&<I1P@5'! 98Y!)3 2G).*
M*:ON9;<$3(V\&A635D>7&+0KX%D</@Z$)#+?G*+A<]UZ#1:7>+MA\(P51.<(
MDV-(W&T,^N/<KCPW8O#:;:U/(])Z/C? A;NHGO11FNI)FD$?=]LOJ[6);#M\
MYO%YM5MNLQG-!:(H14!460I06I6 XE(!#K.R*#DLJ7+L]>RKRM1X\5?ZO<Y[
M>&/.5M?M,9-V\.I3BTVR_4*WR:_T1_*?<IN\DOL*AB9B5(^<_KW^-_U"#Q?0
M;R0=?,'HXS.*4WA9QLT4\V@-20Z6''^PL26P:S@(SN ^HI\VXSN+@U"[ZC4.
M>Z-O-^Q_K!;Z/73]X^?Y0M/2+,L1*4B5@PR;8%ZL74>2PPIDK,Q)Q3'DR*H^
M]DT)4R/*1LEDKV72J.G:^OH<QSNN9 AT(M.4*S >?:YO&#^XP_7Y>T?N;7W#
MK,NNUK<^Z)6KUIRQ/='O];G:+W/*Y@LMX^\FI6HF,LAXE7&0I2;H%I;"W!@H
M4"):"H@0%*JT*09A(<MI@H]0"*+3UO2M;8[\'Y*EK /0Q?&O%JT5UH4X;'"W
MV5$&0S/VYK)#RR3>UJHF/^V5_=M#4NL;#CJG+*]0$(Z6Q34$2M<,+1MP[F1@
M];YBS PK&UO.,JBL'O'L,7#@C"XY4659P:4T3)L*S;0I!(RD.<@%U.Y350@D
M*Y>R.Y<BID:P3T;&_E+5F49[L+3;% Y#*#)I'BD7H5K.;=.#UOV_E#)NF?^;
M5EY4];_]R<$3_'$I+NNH[;/TRK*@ F(&<J6]+%2D*:!5Q@!E*2VK7%#.K,[=
M705/;3MUI'=]S;\YTOQ__@\,L^I_)]*C+*/U0#AS1C!XQV.2&MFV+&.,S$E7
M="*13;_LEZ(@*T1ZB,GN>:\,AWT+D]4'^F.&9 91H;=[#.8E0*24@$"(@#+E
MOP5"DCO4'SE[^=1HYZCQSG:5?*4N5:?/<;/8LPU (S)+' 'QM$H^# +"*4W
M&Y#1$@%L@7$-]+]J^9U0_M-GQ@S6OZKM63C^]<]X4%(; ':]8/9\^6&]XG*S
M=_>IX*4L,P%4RBE *4* 9H@#Q?4O*I1+GMH3EI/HJ=%9%S"YOM&^P&%2NPV!
M!?=% S8R,W:8WJRI7P>JULK[U#1RP]F!6J/A/1+Q!L7=C9N]H.ME;K<WCL?K
M7I:>L+[?&P:TQGMEP@WT6F-B@ILR?H?,KU<_#A_12U#=/>=/NA9M]-Q18MB[
MY78]7V[FO(YPF E9I!*3'!2H8  )A $E%)EHN)3+2E1EQ9W[ZL70=&HKSN/G
MS^LZ.4-/QU;/)N7K(5D=;/#HS!=EF.TV^9,8O,BK6FT 8'7HSK&5QZFN"?N1
M''^N-36I;7WH8H]/$F(?DKW%3>Q0X-:",4<E>%_"*,J.W]0P)N97.R)&%3A@
MY6'W]6(W]&KCMDUKWW_*^><O6RD>O\DU_2SWT3I=B9H=79@&L]FL$!46YC*(
MEGFFMS6$ Z9R 00MTUQF#%'H=#3\ C9,;;7J] :T45QOE+K(.7Y0O2XP^Y#(
M@[W)3_^IO9N-8][R2WQI'%:XZ7X5_D)KWQ$2#TF'1=*"<128>01'8O (O"Z^
MS%@&7S%'-F/\M?1EQNGJ*OM"JGBNO_R+%+N%?*^>3([H;OVCO@MY]>/U@FXV
MA]YJJ" Y1[@"4C("$&00$)&9G,VB2(FB,)-68:B.<J>VSG5J'U(SUX=H<&KJ
MXKOWM[,< <L%*#RNL2](C&(&ST[A-@/SCZ?:08C3U,X-I:!T;"EZ7 IUP^."
M]AP?'])YW7226"WF_,=A9HA*5$05"&"LO7A44@HP@3G(!!-"Y"FDT*GR]2U!
M4R.C0]L5U]"NFU#:D4P(@"*SR@&;AZ31,OFC_6\41KD'2?C6ZU=DO4#O]=L6
M7V^^WO-Y/U9XY-PDWFP^2B[GW\R2T96U1AE!%4Y!QFEEXCY30)C,@/Y7A%/]
M9T&=6.&6H*FQ0J=G<E#4C1QN(FI'#B%PBDP.5R"*4$KV'A A*>&FK%$IX9[%
MYY1P]_.>)07IYLOC4IC_F&"N;W2AMUF;Q^UKNE[_T%NHYLJ"TK24I$@!RS4U
M(*3TCD9J?H"5H@4L<U8)IU- *ZE3(XNZXX.Y_^7F!WG0V[&0H!7B=OP1',?8
M^Y<.POJ'(Y4?$KI-.JU#7]HXH12TGJ"5X'$K"KI@<5%3T.GAH8<LY\DO)OCT
M*!2UWO(>O/$"5; H) 6I(!0@13&@O#)E!3.(RRI-:>%V>>ZGQ]1(Z_@0QIRS
MK99FR,S?+M.X7&MF>8Z4Z^%,-/QCG_ ?07\%[)H'C^/BQSG$\4(SSJ&.FRHO
M=,CCA=?M0Q^_U_F7BVYB88T4<QBN.5HNN9:C/;H2%H+F@*88 <12#+"B)2A$
MA;)"D PSYS+1-V1-C1*/5&W<N6-EDY]^6VUE4GA4A[X%M:4K%P; V [<&78G
M>H:M_WP'C-!UGV^)&[W>\QV[K]5YOO?(D#/D7U:;S<]:T>;-._WR]U_ENKZK
MV[R2:K4^-#>6FY_U7^>?ES-&(1,Y34%:J<(T(5(FC[C4T*<*BSQ7@EEU(!FN
MRM3(IU4K6>TU]SF-]AH4E_/JV%"/<Z+]DS'C;XF99\G!DN1@2L)J6Y+CVX&'
MI+4G]('W$$S#'XE[:?,"A^9#4+M^K#[HC1YY1&^?ORY6/V1W,BQD)F$F.)"E
MY)H;JPR02A) (>*X0)P19E7V[\J[IT9VG78.F2AG8/5SUD ((I-0IYA/)=/S
M[XQ]QHT_'".EU-C#XI8O<]WPWH28LT?&RWBYKNM)2LN-C[CQSV:]G;W_<ZFG
M^I?YUS<K$Q8U4SA3B&(!1%I0@'+* %4< 55RR"G*12JE#?]<>??4^&>O7O)'
MHZ#E%+P&6S\3#00C,A,YX& ]YWHL[G%6]%-'CHK^V[F3<NVUH\S+'GNZ>=GW
M$;\M5IV8)D7MCIBFD7H']RO=[M;S[8_WZO_(A7A:=7__)+GYKSE0X)5 &<L*
M4/$4 D0K"C#D>D(7BF2EDAFM<I?=E9<64YOKG1&-M__<Z&L.=%8JF2^_R4V3
M/K_9&^"V[_(;*;LM5W3\(]/+*?3&@OILJ-/9C("Q FQ7X+G[MT_WQ\%YFS4(
MQY [+#]%1MU<#<+J?%\U[&5^U/EWJ8F8+K2H1_$\7\Y-"1K3@K'MTS,K2Y$B
M4S04LY(!5! **"8,Y!BFD.8H9=B))._(FQH=MNK6$Y&>*.S&>_=@MF.X@.!%
MYK)CW$YU[1J A>,K2U1",M,]D:-RD*7]YVQC^YA7(6*V/3"48:[MJENR?J;S
M=1W@T)7!@ 07!<PDJ)14 "GMAC'.2U!P!E-20HQ(9=^MQD'RU+CFTY?5>EOG
M*QYY6IN'1&F]FSQ\I\*Z#D-@<3P4"]C(/&34/G*2'BX\J(?$:-\UXG(O^>*$
MLU,YXSAXCU;<."CNKM6.W;&[4_O8X85C5D)VM_.L+K+'"P95)=Q\-"F&3RN3
M1SA?TJWL<@M_6VWG7#:=TF8RPU6JF *J7A)*I=U/0B0H4I)))'"9EE9!:#["
MI[8J'*G_D*R- ::ZX;8S89_KGBQK(TQC;FV%5\4_N\&Q6"PB0AYYO3A!N];=
M5 K<:[]/_4X:_=M&CA'1]JJ_&!SUT>LS!D'?MXBC$WR611[MWOD212"=K+U1
M)-+M'5XKR$+_O&IV*$?)[1_E-[G<29/AWC3:Y.9;^EG.4@59A:L"<%824P0,
M 2J5!"7CA6"R8-(N0=-+^M36D%;/9-,H^F 6B595)^IR' .KE2(>LM&7BB/5
MC\N-F!YN#=Z?.KP_C(*WTUH1#_?1%HN@^+LN%G[XW5DM'%\ZYG+A9^_9>N'Y
M$K<%HT[P6_^8_?YI1@N1*84QJ*"@ $G& ,U1"4AFRD+F$C-:V*P"AU=.C=I_
M7\Y-D:)/>K;9WL4=X=//T'Y61Z;=WW][]_3V3?+IZ?'I[:?AL_G2QLMSXJ[Q
M7/M9<TQ<=7\QT[@Z.B$^>M\HL_-2_V[*7?F-9[K[<CL7\\7.S-K#:<';[WRQ
M$U(T(8#/7W<-W[]7;^G:% W:Z'E<%QYJNE3.*B(89WH[#U-6  2S'+"JE(#I
MS7R59DH@XE3-)XA64YO-QT8=W;$GLC6KN1KF!\/,I;!L33->7>WBR>2G^;+Y
MR;7,79BQMKO-&GT$(S/3R> =#$K>G@S>Z]/!ZZPR+DI3I.XA>(O?H$ '+2$0
M1+%QZPV$Q/*B.$'0EP]O'_/V^U>ZU)+;LZ@*EVE*10Y$SC6%9[("M$H+D%)2
M*EX28EF^X+ZHJ?'R16L94U&T4?AAR(GK-92=SE<'8C?::6K;;\74V.Q@&W!T
M>@TV_T8U_O"]5-L:!Q@'-;*YCHQ+6YNS-[Q8DYOKEO2UO+GQQ,LT.]#*S-O4
MFG?+]@M/LJ(BA". E>9@1'(*2,XID%R5DJ **I'/EG4]?_$T7K>#*ZI:32G2
M3*D+A>--JUI3[99Y.\LQ1M7.=7ZI0?HKUG3>6UHWF0G$EB,,Q)1:&%Q3\R_5
MO* 'Y]!M"_I$.;KD<CY[J[<$VQ^/0N@)MFG_\\M\*;-9EE4Y+Q4%U)3K002E
M %>* 225*)1@55Y9':CT2IF:(]XHFK0J/G0_)$;9Y/W2]GJE%]@[#G@HN"*3
MJ#=2]AZC#1('%MN<'Z?JYPV#$?-#[4D>$5?_N\=Q(VW,VWN05A\.-_WAC*9%
MF<&B %"E.4#:@0*LD!DHJ)1Y5<%4E';YSWU2_E+3_^G/U?#I#P=,?R>X7G+Z
M]R$59/K#B-,?OOSTAR[3'WI._\X?>:N4-%7^#^44/NH=TD=I])\OYK6G\=O*
M;%5W^F-LL<\I07F).2452%F!M(,@C*O <P!Y6K"L5$AR[K%!]-5GHKM K2HX
MZ)K,M_+9,:?1>X#L]GI1\1Z)C#H3CBK$),:*Y-2,A^3$D"Y5:!^_$6[?-A34
MD)LS;UU&W8$-1>Q\FS7X?7YL>M(MHBT+(IG(,H0P0!G3KI1I'4J*M 1YQ153
MN(38+DJD1\;4'*G3QB=N?'<-0CLJ&PA,9)8Z;P83O#I[C_DA^>2:F%&IHL?.
M<Q;H^ZCG4?N.;>2_=WJU>/O-1"8?]6S),Y3QE(("(P40,Q5;"@Q!50A5L:Q(
M54&<2AO?DC2UR7Y0-&DT=3SFOHFHY6%U")QB'SF?0Y3\$:> \#TL@I[ZWA0V
M[MGM/9LO3F#O/N!;R'=IO,CF</;C?/.O5W+)OSS3];_:XD1Y+D2A2@A4IDJ
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M7!")VP[N2-X+MX2[M/Q^6[@KSPR\OJUSM-ZO/ZQ7W^;:D)DHRQ1E:0XR+@A
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M3JWZ0%C*FQI7["^2CG0^JFC<:IX8U=WOX/IPM[^*"X3F6#=R X#TNIVS@"?
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MR=_U![>;=\L/<CU?B7_*^><O6ZW;-[FFGV7]RS=T*W^F\[6)M),SR'EI+H4
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M$3WI208(K@@H8%KF.)680:MPD5XI4YOTQ_KIU5)K:.F6]&/9/^^#(11YWKN
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M<6(Y0%,L3<8U]WK]/>W-C0CV'H.]RZ#U.2#RXP&U1[ M+H"C+U2ZL!L2/O,
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MR+8^,N(3[/4=XN %XI;\A?[/IG(\K\HJ\/"S!^Q^TWA<,$>>>M\:N09['Z^
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MV9?+^?C3Y^5/G')Z_V_G?](\1*>I(4%+3:2)DGAO#5%92IJ$C-JZ__O3GQR
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M8B@/CH8&5L3FNO3=@\*1Y$P"-4!0BLB%":5CJ GE8BKSRAFN8Y5N!]O)&=;
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M8R"7 K'E;D=2OG1!8F7FZX^5WUP+^_5TL9J7@[91*205I<D1@ZQQL29#'%H
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M/1+"+CU+C@#L_D0/>^>L/F(KJ[$IR+Y8$X!,GBT6J<O=O!F#1SY+]N8>FS&
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M9LMA95 425<,P0Z)R)PB[N&>$V-S25(*G^H,8NGKM'F0XY!>S<^12FDG4?>
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M922.6Z"JAW#_.!R:9+[.$&K@M8N/,JKVJ+0>9(G&1ZY)MFUR!,>A[\4DH)O
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MW^.FCE9T! &))O.2R!UK@:E;:QBYNK2+>'Y?D?2#IHV*Y:BU2"B("4R#RKZ
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M1=75(47X=VE_L@+?<>?14F@<O:X5^+4X)XH W@;!2G ^JQW*$(^SZ'&3:@-
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MB'=;OC/.U*DL31\?:7X/_B;#B?P?^ )02P,$%     @ <(A^4'KN-9DU"0
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M$@:U_]A8>CZEC$?DTKJ#E/KL">^B.N+U^)^V],V]7?H/&-"87=QD2FY3.1'
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M_5*03BG8_L^7<\IG<4E(7U?J_0-02P,$%     @ <(A^4$L-$@)Q!0   B4
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M06?K(L1+GBR1Q$PPN,LX26*DV4:9AC"+526RW55U4'$ME6IS$9^BB"2ET6U
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MQ-K-:)XV3\<*G8X)Y01Z0E'S[DQPT")"9X89Y=P/%PR#<>U8ZB3@C+HS"FZ
M^,G@W8G4GPQQZ^!=GI< [3(A*"Z"J+"AY9R:NA@^\?JDZJRU %BJ:6@I!@I"
MBN2O>T,K';,\.N8HE9ET^?C('*<U3^'YHW0QL\]:6D!8X+;DABIY'L+&W(_:
MN0TXLX_B[#:WP$BX]6%Z\.C0(<D79;RT8 VE%0!.UM6S#EVC-P@:@R4E2#3*
M-;F'I#O0&T1Y7ZQ&G!:!YLZ_K'J$"7$V]5P0.RY8Z8FGI"=./>.\JQFGH2N6
M)"Q\]C6A:@976J*)@H3U!U>+3^4L.',?8<4D%DF%\XAY:<>L\K(2V=K(7T-0
M::;0Q<4QM()A<'38>JS+C 3 ">&#H+XW+.**@?@)S\'GF4H[#DA 4#0[%DFI
M;Z/L:B7BRR/B'RNZ$P!M0H'W*H $9R*@*2!DGBZ)W =?O,':#G W\TY5*VX
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M2P$"% ,4    " !PB'Y0K+MK?UGL @ U4R( $0              @ $
M9'EA:2TR,#$Y,3(S,2YH=&U02P$"% ,4    " !PB'Y0%.>&*X<0  ">L
M$0              @ &([ ( 9'EA:2TR,#$Y,3(S,2YX<V102P$"% ,4
M" !PB'Y0"JWFU0<@  "N3 $ %0              @ $^_0( 9'EA:2TR,#$Y
M,3(S,5]C86PN>&UL4$L! A0#%     @ <(A^4,2+LNQ01P  /.0" !4
M         ( !>!T# &1Y86DM,C Q.3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M '"(?E [>HF'K!\  )9!   4              "  ?MD P!D>6%I+3(P,3DQ
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( '"(?E"2[Z<I%5$  )!\   4
M      "  =F$ P!D>6%I+3(P,3DQ,C,Q7V<R+FIP9U!+ 0(4 Q0    ( '"(
M?E!1U^CE31(  *TL   4              "  2#6 P!D>6%I+3(P,3DQ,C,Q
M7V<S+FIP9U!+ 0(4 Q0    ( '"(?E ,]#?@0L<  #>>"  5
M  "  9_H P!D>6%I+3(P,3DQ,C,Q7VQA8BYX;6Q02P$"% ,4    " !PB'Y0
MFP5/A_%R  "?004 %0              @ $4L 0 9'EA:2TR,#$Y,3(S,5]P
M<F4N>&UL4$L! A0#%     @ <(A^4-],Z_8_ 0  "@(  !P
M ( !.",% &5X:&EB:70Q,#$Q:G5P:71E<FQE87-E,BYH=&U02P$"% ,4
M" !PB'Y0>NXUF34)   :2   &@              @ &Q) 4 97AH:6)I=#,Q
M,6-E<G0M;6%R:S$P>"YH=&U02P$"% ,4    " !PB'Y0>N"6L!H)  "G00
M&@              @ $>+@4 97AH:6)I=#,Q,F-E<G0M<&EN9S$P>"YH=&U0
M2P$"% ,4    " !PB'Y0 =4<@G4%   ))0  &@              @ %P-P4
M97AH:6)I=#,R,7-E8W0Q,S4P8V5R="YH=&U02P$"% ,4    " !PB'Y02PT2
M G$%   ")0  &@              @ $=/04 97AH:6)I=#,R,G-E8W0Q,S4P
M8V5R="YH=&U02P$"% ,4    " !PB'Y0D;K<]*D/   09@  &@
M    @ '&0@4 97AH:6)I=#0R9&5S8W)I<'1I;VYO9BYH=&U02P4&      \
,#P "!   IU(%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788210048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchAndDevelopmentInProcessCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 766,001<span></span>
</td>
<td class="nump">$ 240,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal expenses</a></td>
<td class="nump">26,994<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">150,383<span></span>
</td>
<td class="nump">68,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 943,378<span></span>
</td>
<td class="nump">$ 309,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchAndDevelopmentInProcessCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchAndDevelopmentInProcessCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858085968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalent, and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalent, and Investments</a></td>
<td class="text">Cash, Cash Equivalent, and Investments <div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company&#8217;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2019 and 2018:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,387,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,399,146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,528,190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,511,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,738,787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,734,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,731,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,816,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,117,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,202,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature longer than 12 months from the applicable reporting date.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4) The premium paid to purchase held-to-maturity investment securities was $233,550 and $378,681 for the years ended December&#160;31, 2019 and 2018, respectively. </span></div>The Company considers declines in market value of its investment portfolio to be temporary in nature. The Company&#8217;s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment&#8217;s cost basis. As of December&#160;31, 2019, the Company does not consider any of its investments to be other-than-temporarily impaired.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791576544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of stock repurchase activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s stock repurchase activities:&#160;<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:34.217%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.651%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.973%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.638%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Privately Negotiated Transactions:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 12, 2016 - Abengoa repurchased and retired shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,136,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,884,615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,639,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through February 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,448,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,551,717&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September through December 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,462,339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through August 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,304,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,158,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total open market and privately negotiated purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,390,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,814,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,253,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6873830864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and Sub-licensing Agreements (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 07, 2019 </div>
<div>antibody_and_vaccine </div>
<div>protein</div>
</th>
<th class="th"><div>May 05, 2019</div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 26, 2019</div></th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Duration of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement', window );">Payment for research and development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_PrepaidResearchandDevelopment', window );">Prepaid Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchandDevelopmentExpenseRelatedParty', window );">Research and development - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868,720<span></span>
</td>
<td class="nump">$ 1,215,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember', window );">Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod', window );">Ownership interest consideration receivable upon extension of exclusivity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember', window );">Novovet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Alphazyme [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementExclusivityPeriod', window );">Exclusivity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod', window );">Option to extend exclusivity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Serum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization', window );">Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins', window );">Option to obtain exclusive commercial sub-license for number of proteins | protein</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod', window );">Research funding, milestone payments and royalties, period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_RevenueFromCollaborativeArrangementRecognized', window );">Revenue from collaborative arrangement, recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement', window );">Payment for research and development agreement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization', window );">Payment for additional development and commercialization | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Revenue sharing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Revenue sharing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | BDI Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementEquityInterestAcquired', window );">Equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | VLPbio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementEquityInterestAcquired', window );">Equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | BDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Duration of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment', window );">Obligation for payment for research and development, minimum | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment', window );">Obligation for payment for research and development, maximum | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | BDI | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Revenue sharing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember', window );">RSA | BDI | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementRevenueSharingPercentage', window );">Revenue sharing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ServiceFrameworkAgreementMember', window );">SFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementDurationOfAgreement', window );">Duration of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment', window );">Obligation for payment for research and development, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_CollaborativeArrangementOutstandingCommitment', window );">Outstanding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementDurationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Duration Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementDurationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementEquityInterestAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Equity Interest Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementEquityInterestAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementExclusivityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Exclusivity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementExclusivityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Obligation For Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Minimum Obligation For Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option To Extend Exclusivity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementOutstandingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Outstanding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementOutstandingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment for Additional Development and Commercialization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment for Research and Development Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_CollaborativeArrangementRevenueSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Revenue Sharing, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_CollaborativeArrangementRevenueSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_PrepaidResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_PrepaidResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchandDevelopmentExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchandDevelopmentExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_RevenueFromCollaborativeArrangementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Collaborative Arrangement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_RevenueFromCollaborativeArrangementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dyai_SerumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dyai_SerumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_BDIHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_BDIHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_VLPbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_VLPbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dyai_BDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dyai_BDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ServiceFrameworkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ServiceFrameworkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6864943520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue</a></td>
<td class="nump">$ 1,681,076<span></span>
</td>
<td class="nump">$ 1,295,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of research and development revenue</a></td>
<td class="nump">1,459,701<span></span>
</td>
<td class="nump">1,027,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,087,597<span></span>
</td>
<td class="nump">2,101,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_ResearchandDevelopmentExpenseRelatedParty', window );">Research and development - related party</a></td>
<td class="nump">868,720<span></span>
</td>
<td class="nump">1,215,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,519,922<span></span>
</td>
<td class="nump">4,522,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange loss (gain), net</a></td>
<td class="nump">27,725<span></span>
</td>
<td class="nump">20,778<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,963,665<span></span>
</td>
<td class="nump">8,887,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,282,589)<span></span>
</td>
<td class="num">(7,592,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">984,930<span></span>
</td>
<td class="nump">894,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(8,297,659)<span></span>
</td>
<td class="num">(6,697,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">10,306<span></span>
</td>
<td class="num">(1,006,157)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,307,965)<span></span>
</td>
<td class="num">$ (5,691,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">27,003,695<span></span>
</td>
<td class="nump">27,673,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_ResearchandDevelopmentExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_ResearchandDevelopmentExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787568416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalent, and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities</a></td>
<td class="text">The following table shows the Company&#8217;s cash, available-for-sale securities, and short-term and long-term investment securities by major security type as of December&#160;31, 2019 and 2018:<div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,010,510&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,813,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,823,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,387,053&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,898&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,399,146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Long-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,528,190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,511,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,738,787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,452&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,991)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,734,326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:33.871%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:4.442%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.884%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.055%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.475%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,048,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money Market Funds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,338,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,386,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Short-Term Investment Securities </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Corporate Bonds </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,731,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,816,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,117,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85,321)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,202,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notes:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Definition of the three-level fair value hierarchy:</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 2 - Other inputs that are directly or indirectly observable in the markets</span></div><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">Level 3 - Inputs that are generally unobservable </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3) Long-term investment securities will mature longer than 12 months from the applicable reporting date.</span></div>(4) The premium paid to purchase held-to-maturity investment securities was $233,550 and $378,681 for the years ended December&#160;31, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787524928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Issuances of Common Stock</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares of common stock issued for the years ended December&#160;31, 2019 and 2018 were 645,671 and 30,000, respectively, with a weighted average issue price per share of $1.60 and $0.15, respectively. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Repurchases and Buybacks </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Stock Repurchase Programs </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 16, 2016, the Board authorized a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDUzOTk_fe3a9107-bbfc-41d2-8697-3542846d9e85">one</span>-year stock repurchase program, under which the Company was authorized to repurchase up to $15&#160;million of its outstanding common stock (the &#8220;2016 Stock Repurchase Program&#8221;). The 2016 Stock Repurchase Program ended on February 15, 2017.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 16, 2017, the Board authorized a new <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVjMmMzNjFhYjYwYzRmZTY4NWZiYmZkY2M1MzQzYjMwL3NlYzplYzJjMzYxYWI2MGM0ZmU2ODVmYmJmZGNjNTM0M2IzMF8xNTQvZnJhZzpiYWU4YzBjZWZlZDQ0YzY1OTRiMjMxMTU1ZGYxNTFiOS90ZXh0cmVnaW9uOmJhZThjMGNlZmVkNDRjNjU5NGIyMzExNTVkZjE1MWI5XzE2NDkyNjc0NDU0MDc_b5a00c4c-c973-45db-864c-25377b84925f">one</span>-year stock repurchase program, under which the Company may repurchase up to $5&#160;million of its outstanding common stock (the &#8220;2017 Stock Repurchase Program&#8221;). On August 6, 2018, the Board authorized an extension of this stock repurchase program through August 15, 2019. The 2017 Stock Repurchase Program ended on August 15, 2019. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s stock repurchase activities:&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:34.217%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.651%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.973%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.638%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Treasury Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Privately Negotiated Transactions:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 12, 2016 - Abengoa repurchased and retired shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,136,752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,884,615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 11, 2017 - Pinnacle Family Office Investments L.P. repurchased shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,639,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,363,590&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2016 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through February 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,448,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,863,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,551,717&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017 Stock Repurchase Program:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September through December 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">537,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">381,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,462,339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January through August 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,304,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,644,325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,158,297&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total open market and privately negotiated purchases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,390,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,814,530&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,253,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Treasury Stock </span></div>As of December&#160;31, 2019, and 2018, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871958176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-Free interest rate, minimum</a></td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-Free interest rate, maximum</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">28.59%<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">37.29%<span></span>
</td>
<td class="nump">30.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability', window );">Discount for lack of marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">8.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858060912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit', window );">Tax cuts and jobs act, change in alternative minimum tax, income tax benefit</a></td>
<td class="nump">$ 1,001,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received from income tax refund</a></td>
<td class="nump">506,866<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">19,700,000<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Provision for (benefit from) income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfFinanceIndiaMember', window );">Ministry of Finance, India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Provision for (benefit from) income tax</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfFinanceIndiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfFinanceIndiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788159040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Income Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option expense</a></td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 242,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">5,214,200<span></span>
</td>
<td class="nump">2,668,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">1,656,500<span></span>
</td>
<td class="nump">1,656,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyai_DeferredTaxAssetLiabilityGross', window );">Deferred tax asset, net of deferred tax liabilities</a></td>
<td class="nump">7,150,100<span></span>
</td>
<td class="nump">4,578,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(7,150,100)<span></span>
</td>
<td class="num">(4,578,400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyai_DeferredTaxAssetLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset (Liability), Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyai_DeferredTaxAssetLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dyai-20191231.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "dyai-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dyai-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dyai-20191231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dyai-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dyai-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dyai-20191231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 434,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 6,
    "http://www.dyadic.com/20191231": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 12
   },
   "keyCustom": 59,
   "keyStandard": 287,
   "memberCustom": 23,
   "memberStandard": 30,
   "nsprefix": "dyai",
   "nsuri": "http://www.dyadic.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.dyadic.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Income Taxes",
     "role": "http://www.dyadic.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - Commitments and Contingencies",
     "role": "http://www.dyadic.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Share-Based Compensation",
     "role": "http://www.dyadic.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133107 - Disclosure - Shareholders' Equity",
     "role": "http://www.dyadic.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Subsequent Events",
     "role": "http://www.dyadic.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Cash, Cash Equivalent, and Investments (Tables)",
     "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables",
     "shortName": "Cash, Cash Equivalent, and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.dyadic.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.dyadic.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.dyadic.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dyai:NumberOfResearchOrganizationPerformingServiceUnderContract",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Textual (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i948cb60e266243f196d1d44762dba391_I20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentInProcessCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Cash, Cash Equivalent, and Investments (Details)",
     "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails",
     "shortName": "Cash, Cash Equivalent, and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Research Collaboration and Sub-licensing Agreements (Details)",
     "role": "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails",
     "shortName": "Research Collaboration and Sub-licensing Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i1c3a85f5e98d4a53ab11b6f0911a2bee_D20170630-20170630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "dyai:CollaborativeArrangementPaymentforResearchandDevelopmentAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Income Taxes - Textual (Details)",
     "role": "http://www.dyadic.com/role/IncomeTaxesTextualDetails",
     "shortName": "Income Taxes - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dyai:TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "role": "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Income Taxes - (Benefit) Provision for Income Tax (Details)",
     "role": "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails",
     "shortName": "Income Taxes - (Benefit) Provision for Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Income Taxes - Reconciliation Income Taxes (Details)",
     "role": "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails",
     "shortName": "Income Taxes - Reconciliation Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Income Taxes - Deferred Income Tax Assets (Details)",
     "role": "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred Income Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i1ce85b8cbbff401ab8f9208885798348_I20190628",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "dyai:CommitmentToPay",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Commitments and Contingencies - Textual (Details)",
     "role": "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails",
     "shortName": "Commitments and Contingencies - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i1ce85b8cbbff401ab8f9208885798348_I20190628",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "dyai:CommitmentToPay",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Commitments and Contingencies - Purchase Obligations (Details)",
     "role": "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails",
     "shortName": "Commitments and Contingencies - Purchase Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "idcb179b7b3654ae5a927e4f22b10ba19_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Share-Based Compensation - Textual (Details)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
     "shortName": "Share-Based Compensation - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Share-Based Compensation - Assumptions (Details)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
     "shortName": "Share-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i8853d6b75f244901a1248e0453b9d94b_D20190101-20191231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i44b49ea3f208487698c65394dc8f911a_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431419 - Disclosure - Share-Based Compensation - Stock Option Activity - Textual (Details)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i3180a4adc61148acb883d0951ed14fe7_I20190625",
      "decimals": "INF",
      "lang": null,
      "name": "dyai:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "board_of_director",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432420 - Disclosure - Share-Based Compensation - Compensation Expense (Details)",
     "role": "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Shareholders' Equity - Textual (Details)",
     "role": "http://www.dyadic.com/role/ShareholdersEquityTextualDetails",
     "shortName": "Shareholders' Equity - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Shareholders' Equity - Stock Repurchase (Details)",
     "role": "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails",
     "shortName": "Shareholders' Equity - Stock Repurchase (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i79c459a1868c4afc9365087bca90cdbf_D20170111-20170111",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.dyadic.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i5fd3ae8c678a44aea6057dde9499f103_D20200101-20200331",
      "decimals": "INF",
      "lang": null,
      "name": "dyai:ResearchAndDevelopmentExpenseAdditional",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i7ae10429d4274acc9056aa942fe63b3d_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "i7ae10429d4274acc9056aa942fe63b3d_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InvestmentIncomeAmortizationOfPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Cash, Cash Equivalent, and Investments",
     "role": "http://www.dyadic.com/role/CashCashEquivalentandInvestments",
     "shortName": "Cash, Cash Equivalent, and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Research and Collaboration Agreements",
     "role": "http://www.dyadic.com/role/ResearchandCollaborationAgreements",
     "shortName": "Research and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai-20191231.htm",
      "contextRef": "id76dd43892f945ffb79d82dd26ebf8a5_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.dyadic.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dyai_A2006PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2006 Plan [Member]",
        "label": "2006 Plan [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "A2006PlanMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_A2011PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2011 Plan [Member]",
        "label": "2011 Plan [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "localname": "A2011PlanMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_AccruedResearchandDevelopmentinProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Research and Development in Process, Current",
        "label": "Accrued Research and Development in Process, Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchandDevelopmentinProcessCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_AlphazymeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alphazyme [Member]",
        "label": "Alphazyme [Member]",
        "terseLabel": "Alphazyme [Member]"
       }
      }
     },
     "localname": "AlphazymeMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_BDIHoldingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BDI Holdings [Member]",
        "label": "BDI Holdings [Member]",
        "terseLabel": "BDI Holdings"
       }
      }
     },
     "localname": "BDIHoldingsMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_BDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BDI [Member]",
        "label": "BDI [Member]",
        "terseLabel": "BDI"
       }
      }
     },
     "localname": "BDIMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_CollaborativeArrangementDurationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Duration Of Agreement",
        "label": "Collaborative Arrangement, Duration Of Agreement",
        "terseLabel": "Duration of agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDurationOfAgreement",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CollaborativeArrangementEquityInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Equity Interest Acquired",
        "label": "Collaborative Arrangement, Equity Interest Acquired",
        "terseLabel": "Equity interest acquired"
       }
      }
     },
     "localname": "CollaborativeArrangementEquityInterestAcquired",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_CollaborativeArrangementExclusivityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Exclusivity Period",
        "label": "Collaborative Arrangement, Exclusivity Period",
        "terseLabel": "Exclusivity period"
       }
      }
     },
     "localname": "CollaborativeArrangementExclusivityPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Obligation For Research And Development",
        "label": "Collaborative Arrangement, Maximum Obligation For Research And Development",
        "terseLabel": "Obligation for payment for research and development, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumObligationForResearchAndDevelopment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Minimum Obligation For Research And Development",
        "label": "Collaborative Arrangement, Minimum Obligation For Research And Development",
        "terseLabel": "Obligation for payment for research and development, minimum"
       }
      }
     },
     "localname": "CollaborativeArrangementMinimumObligationForResearchAndDevelopment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization",
        "label": "Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization",
        "terseLabel": "Number of antibodies and vaccines for development and commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Option To Extend Exclusivity Period",
        "label": "Collaborative Arrangement, Option To Extend Exclusivity Period",
        "terseLabel": "Option to extend exclusivity period"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionToExtendExclusivityPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins",
        "label": "Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins",
        "terseLabel": "Option to obtain exclusive commercial sub-license for number of proteins"
       }
      }
     },
     "localname": "CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_CollaborativeArrangementOutstandingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Outstanding Commitment",
        "label": "Collaborative Arrangement, Outstanding Commitment",
        "terseLabel": "Outstanding commitment"
       }
      }
     },
     "localname": "CollaborativeArrangementOutstandingCommitment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period",
        "label": "Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period",
        "terseLabel": "Ownership interest consideration receivable upon extension of exclusivity period"
       }
      }
     },
     "localname": "CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment for Additional Development and Commercialization",
        "label": "Collaborative Arrangement, Payment for Additional Development and Commercialization",
        "terseLabel": "Payment for additional development and commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment for Research and Development Agreement",
        "label": "Collaborative Arrangement, Payment for Research and Development Agreement",
        "terseLabel": "Payment for research and development agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentforResearchandDevelopmentAgreement",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period",
        "label": "Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period",
        "terseLabel": "Research funding, milestone payments and royalties, period"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CollaborativeArrangementRevenueSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Sharing, Percentage",
        "label": "Collaborative Arrangement, Revenue Sharing, Percentage",
        "terseLabel": "Revenue sharing, percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueSharingPercentage",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_CommitmentDevelopmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment Development Period",
        "label": "Commitment Development Period",
        "terseLabel": "Commitment development period"
       }
      }
     },
     "localname": "CommitmentDevelopmentPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CommitmentSuccessBonusAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment Success Bonus Award",
        "label": "Commitment Success Bonus Award",
        "terseLabel": "Commitment success bonus award"
       }
      }
     },
     "localname": "CommitmentSuccessBonusAward",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CommitmentToPay": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment To Pay",
        "label": "Commitment To Pay",
        "terseLabel": "Commitment to pay"
       }
      }
     },
     "localname": "CommitmentToPay",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CommitmentToPayExpanded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment To Pay, Expanded",
        "label": "Commitment To Pay, Expanded",
        "terseLabel": "Commitment to pay, expanded"
       }
      }
     },
     "localname": "CommitmentToPayExpanded",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_CommitmentToPayExpandedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment To Pay, Expanded, Period",
        "label": "Commitment To Pay, Expanded, Period",
        "terseLabel": "Commitment to pay, expanded, period"
       }
      }
     },
     "localname": "CommitmentToPayExpandedPeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_CommitmentsRightToTerminateContractNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments, Right To Terminate Contract Notice Period",
        "label": "Commitments, Right To Terminate Contract Notice Period",
        "terseLabel": "Commitments, right to terminate contract notice period"
       }
      }
     },
     "localname": "CommitmentsRightToTerminateContractNoticePeriod",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_ConcentrationRiskNumberofCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentration Risk, Number of Customers",
        "label": "Concentration Risk, Number of Customers",
        "terseLabel": "Concentration risk, number of customers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberofCustomers",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consultant [Member]",
        "label": "Consultant [Member]",
        "terseLabel": "Consultant"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ContractResearchOrganizationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Research Organizations",
        "label": "Contract Research Organizations [Member]",
        "terseLabel": "Contract Research Organizations (CRO)"
       }
      }
     },
     "localname": "ContractResearchOrganizationsMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractor [Member]",
        "label": "Contractor [Member]",
        "terseLabel": "Contractor"
       }
      }
     },
     "localname": "ContractorMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Current",
        "terseLabel": "Short term investments, gross unrealized holding gain"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain, Noncurrent",
        "terseLabel": "Long term Investments, gross unrealized holding gain"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedGainNoncurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Current",
        "negatedLabel": "Short term investments, gross unrealized holding loss"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss, Noncurrent",
        "negatedLabel": "Long term Investments, gross unrealized holding loss"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityFairValueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Fair Value, Current",
        "label": "Debt Securities, Held-to-maturity, Fair Value, Current",
        "terseLabel": "Short term investments, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityFairValueCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityFairValueNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent",
        "label": "Debt Securities, Held-to-maturity, Fair Value, Noncurrent",
        "terseLabel": "Long term Investments, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityFairValueNoncurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DebtSecuritiesHeldtomaturityPremiumPaidonPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Held-to-maturity, Premium Paid on Purchase",
        "label": "Debt Securities, Held-to-maturity, Premium Paid on Purchase",
        "terseLabel": "Held-to-maturity, premium paid on purchase"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityPremiumPaidonPurchase",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DeferredTaxAssetLiabilityGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Asset (Liability), Gross",
        "label": "Deferred Tax Asset (Liability), Gross",
        "totalLabel": "Deferred tax asset, net of deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityGross",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_DuPontDaniscoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DuPont Danisco [Member]",
        "label": "DuPont Danisco [Member]",
        "terseLabel": "DuPont Danisco"
       }
      }
     },
     "localname": "DuPontDaniscoMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Alternative Minimum Tax, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Alternative Minimum Tax, Percent",
        "negatedTerseLabel": "AMT adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAlternativeMinimumTaxPercent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, True-Up Adjustment, Percent",
        "label": "Effective Income Tax Rate Reconciliation, True-Up Adjustment, Percent",
        "negatedTerseLabel": "True-up adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUpAdjustmentPercent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ExecutivesandKeyPersonnelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Executives and Key Personnel [Member]",
        "label": "Executives and Key Personnel [Member]",
        "terseLabel": "Executives and Key Personnel"
       }
      }
     },
     "localname": "ExecutivesandKeyPersonnelMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), Including True Up Adjustment",
        "label": "Income Tax Expense (Benefit), Including True Up Adjustment",
        "totalLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitIncludingTrueUpAdjustment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_IncreaseDecreaseinPrepaidResearchandDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Research and Development",
        "label": "Increase (Decrease) in Prepaid Research and Development",
        "negatedTerseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseinPrepaidResearchandDevelopment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_IndustrialTechnologyBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Industrial Technology Business [Member]",
        "label": "Industrial Technology Business [Member]",
        "terseLabel": "Industrial Technology Business"
       }
      }
     },
     "localname": "IndustrialTechnologyBusinessMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_InvestmentsandCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments and Cash, Amortized Cost",
        "label": "Investments and Cash, Amortized Cost",
        "totalLabel": "Cash and Investment, adjusted cost"
       }
      }
     },
     "localname": "InvestmentsandCashAmortizedCost",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_JupiterFloridaHeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Jupiter, Florida Headquarters Lease [Member]",
        "label": "Jupiter, Florida Headquarters Lease [Member]",
        "terseLabel": "Jupiter, Florida Headquarters Lease"
       }
      }
     },
     "localname": "JupiterFloridaHeadquartersLeaseMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_LeaseTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Type",
        "label": "Lease, Type [Axis]",
        "terseLabel": "Lease, Type [Axis]"
       }
      }
     },
     "localname": "LeaseTypeAxis",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dyai_LeaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Type",
        "label": "Lease, Type [Domain]",
        "terseLabel": "Lease, Type [Domain]"
       }
      }
     },
     "localname": "LeaseTypeDomain",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_NetherlandsOfficeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Netherlands Office Lease [Member]",
        "label": "Netherlands Office Lease [Member]",
        "terseLabel": "Netherlands Office Lease"
       }
      }
     },
     "localname": "NetherlandsOfficeLeaseMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_NonexecutiveEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-executive Employees [Member]",
        "label": "Non-executive Employees [Member]",
        "terseLabel": "Non-executive Employees"
       }
      }
     },
     "localname": "NonexecutiveEmployeesMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_NovovetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novovet [Member]",
        "label": "Novovet [Member]",
        "terseLabel": "Novovet [Member]"
       }
      }
     },
     "localname": "NovovetMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_NumberOfResearchOrganizationPerformingServiceUnderContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Research Organization Performing Service Under Contract",
        "label": "Number of Research Organization Performing Service Under Contract",
        "terseLabel": "Number of research organization performing service under contract"
       }
      }
     },
     "localname": "NumberOfResearchOrganizationPerformingServiceUnderContract",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_OperatingLeasesAnnualRentalRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Annual Rental Rate",
        "label": "Operating Leases, Annual Rental Rate",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesAnnualRentalRate",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_OperatingLeasesMonthlyRentalRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Monthly Rental Rate",
        "label": "Operating Leases, Monthly Rental Rate",
        "terseLabel": "Monthly rental rate"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyRentalRate",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_PrepaidResearchandDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Research and Development",
        "label": "Prepaid Research and Development",
        "terseLabel": "Prepaid Research and Development"
       }
      }
     },
     "localname": "PrepaidResearchandDevelopment",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_PrepaidResearchandDevelopmentinProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Research and Development in Process, Current",
        "label": "Prepaid Research and Development in Process, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchandDevelopmentinProcessCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_PubliclyAnnouncedRepurchasePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Publicly Announced Repurchase Plans [Member]",
        "label": "Publicly Announced Repurchase Plans [Member]",
        "terseLabel": "Publicly Announced Repurchase Plans [Member]"
       }
      }
     },
     "localname": "PubliclyAnnouncedRepurchasePlansMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseAdditional": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Expense, Additional",
        "label": "Research and Development Expense, Additional",
        "terseLabel": "Research contract, expansion"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseAdditional",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseAdditionalTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Expense, Additional, Term",
        "label": "Research and Development Expense, Additional, Term",
        "terseLabel": "Research contract, expansion, term"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseAdditionalTerm",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseContractedServicesRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": {
       "order": 2.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Contracted Services, Related Party",
        "label": "Research And Development Expense, Contracted Services, Related Party",
        "terseLabel": "Contracted services - related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseContractedServicesRelatedParty",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadandOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": {
       "order": 4.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Facilities, Overhead and Other",
        "label": "Research And Development Expense, Facilities, Overhead and Other",
        "terseLabel": "Facilities, overhead and other"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadandOther",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Including Related Party",
        "label": "Research And Development Expense, Including Related Party",
        "totalLabel": "Research and development expense, related party, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": {
       "order": 1.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Outside Contracted Services",
        "label": "Research And Development Expense, Outside Contracted Services",
        "terseLabel": "Outside contracted services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails": {
       "order": 3.0,
       "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Personnel Related Costs",
        "label": "Research And Development Expense, Personnel Related Costs",
        "terseLabel": "Personnel related costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchAndDevelopmentInProcessCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development In Process, Current",
        "label": "Research And Development In Process, Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessCurrent",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ResearchServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research Services Agreement [Member]",
        "label": "Research Services Agreement [Member]",
        "terseLabel": "RSA"
       }
      }
     },
     "localname": "ResearchServicesAgreementMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ResearchandDevelopmentExpenseRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Expense, Related Party",
        "label": "Research and Development Expense, Related Party",
        "terseLabel": "Research and development - related party"
       }
      }
     },
     "localname": "ResearchandDevelopmentExpenseRelatedParty",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_RevenueFromCollaborativeArrangementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Collaborative Arrangement, Recognized",
        "label": "Revenue from Collaborative Arrangement, Recognized",
        "terseLabel": "Revenue from collaborative arrangement, recognized"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementRecognized",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_ScheduleofResearchandDevelopmentCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Research and Development Costs [Table Text Block]",
        "label": "Schedule of Research and Development Costs [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Costs"
       }
      }
     },
     "localname": "ScheduleofResearchandDevelopmentCostsTableTextBlock",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dyai_SerumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Serum [Member]",
        "label": "Serum [Member]",
        "terseLabel": "Serum [Member]"
       }
      }
     },
     "localname": "SerumMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ServiceFrameworkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service Framework Agreement [Member]",
        "label": "Service Framework Agreement [Member]",
        "terseLabel": "SFA"
       }
      }
     },
     "localname": "ServiceFrameworkAgreementMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Issued in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average issued price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability",
        "terseLabel": "Discount for lack of marketability"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Board of Directors",
        "terseLabel": "Number of board of directors"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofBoardofDirectors",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Cash",
        "terseLabel": "Exercise of stock options, cash (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCash",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Common Stock",
        "terseLabel": "Exercise of stock options, common stock (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStock",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Forfeited",
        "terseLabel": "Exercise of stock options, forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodForfeited",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dyai_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net",
        "terseLabel": "Exercise of stock options, net (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodNet",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dyai_SharebasedCompensationAwardTrancheTwothroughFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Award, Tranche Two through Five [Member]",
        "label": "Share-based Compensation Award, Tranche Two through Five [Member]",
        "terseLabel": "Share-based Compensation Award, Tranche Two through Five"
       }
      }
     },
     "localname": "SharebasedCompensationAwardTrancheTwothroughFiveMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit",
        "label": "Tax Cuts and Jobs Act, Change In Alternative Minimum Tax, Income Tax Benefit",
        "terseLabel": "Tax cuts and jobs act, change in alternative minimum tax, income tax benefit"
       }
      }
     },
     "localname": "TaxCutsandJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dyai_VLPbioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VLPbio [Member]",
        "label": "VLPbio [Member]",
        "terseLabel": "VLPbio"
       }
      }
     },
     "localname": "VLPbioMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dyai_VTTTechnicalResearchCentreofFinlandLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VTT Technical Research Centre of Finland Ltd [Member]",
        "label": "VTT Technical Research Centre of Finland Ltd [Member]",
        "terseLabel": "VTT Technical Research Centre of Finland Ltd [Member]"
       }
      }
     },
     "localname": "VTTTechnicalResearchCentreofFinlandLtdMember",
     "nsuri": "http://www.dyadic.com/20191231",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r94",
      "r127",
      "r129",
      "r243",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]",
        "terseLabel": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r228",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r8",
      "r27"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r15",
      "r21",
      "r226",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r128"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r134",
      "r136",
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r136",
      "r158",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r38",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.",
        "label": "Allowance for Doubtful Accounts Receivable",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of building rented"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r224",
      "r234"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r40"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": {
       "order": 2.0,
       "parentTag": "dyai_InvestmentsandCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "totalLabel": "Investment, gross unrealized holding gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": {
       "order": 3.0,
       "parentTag": "dyai_InvestmentsandCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTotalLabel": "Investment, gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r137",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]",
        "terseLabel": "Billed receivable"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r24",
      "r61"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r62",
      "r65",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r96",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalent, and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r61",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r210"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president.",
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior executive officer responsible for overseeing the financial activities of the entity.",
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r113",
      "r229",
      "r237"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r86",
      "r87",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r86",
      "r87",
      "r204",
      "r205",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r86",
      "r87",
      "r204",
      "r205",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r82",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r86",
      "r87",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r86",
      "r87",
      "r204",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r123",
      "r124",
      "r128"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred research and development obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of research and development revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r170",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "dyai_DeferredTaxAssetLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "NOL carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r171",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "dyai_DeferredTaxAssetLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r185",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "dyai_DeferredTaxAssetLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r170",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "dyai_DeferredTaxAssetLiabilityGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock option expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectorMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Director [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r121",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per common share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r71",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Tax at U.S. statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "negatedTerseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Foreign operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedTerseLabel": "Non-deductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r176",
      "r177",
      "r191"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesReconciliationIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee wages and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Nonvested awards, compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Nonvested awards, compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r25",
      "r56",
      "r65",
      "r108",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r200",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r200",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r200",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r70",
      "r175"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r207",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign currency exchange loss (gain), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r209",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transaction Gain or Loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Foreign",
        "verboseLabel": "Provision for (benefit from) income tax"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails",
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "dyai_InvestmentsandCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-maturity, Current",
        "terseLabel": "Short-term investment securities",
        "totalLabel": "Short term investments, adjusted cost"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "dyai_InvestmentsandCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-maturity, Noncurrent",
        "terseLabel": "Long-term investment securities",
        "totalLabel": "Long term investments, adjusted cost"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r67",
      "r92",
      "r193"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r173",
      "r174",
      "r180",
      "r181",
      "r184",
      "r194",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r35",
      "r227",
      "r240"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivableNoncurrent": {
     "auth_ref": [
      "r12",
      "r232"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Noncurrent",
        "terseLabel": "Long-term income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedTerseLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred research and development obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedTerseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of held-to-maturity securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r65",
      "r104",
      "r105",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails_1": {
       "order": 1.0,
       "parentTag": "dyai_InvestmentsandCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "totalLabel": "Cash and Investment, fair value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r225",
      "r236"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table Text Block]",
        "terseLabel": "Purchase Commitments"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinistryOfFinanceIndiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government of India.",
        "label": "Ministry of Finance, India [Member]",
        "terseLabel": "Ministry of Finance, India"
       }
      }
     },
     "localname": "MinistryOfFinanceIndiaMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r60",
      "r78",
      "r230",
      "r241"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside of United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r29"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r1",
      "r5"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses - various"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r53",
      "r100"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-maturity Securities",
        "negatedTerseLabel": "Purchases of held-to-maturity investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares or units awarded to employees for meeting certain performance targets.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r137",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r2",
      "r5",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r3",
      "r5",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r58",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received from income tax refund"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r51",
      "r100"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.",
        "label": "Proceeds from Sale and Maturity of Held-to-maturity Securities",
        "terseLabel": "Proceeds from maturities of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from sales of business"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r161"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Second Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Third Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CommitmentsandContingenciesPurchaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]",
        "terseLabel": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r21",
      "r65",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r167",
      "r246"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r65",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r116",
      "r235"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r125",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Research and development revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Available-for-sale Securities, Short-term and Long-term Investment Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components Of Income Tax (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Schedule of non-cash stock option compensation expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r137",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r142",
      "r150",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of stock repurchase activity"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Sign on, vesting period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-Free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-Free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationCompensationExpenseDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Approved (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period, weighted average grant date fair value (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r144",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding, ending (USD per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding, beginning (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share instruments newly issued under a share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r135",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Price per share (in usd per share)",
        "verboseLabel": "Weighted average exercise price, exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, expired (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, canceled (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Compensation Award, Tranche One [Member]",
        "terseLabel": "Share-based Compensation Award, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r65",
      "r137",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of share-based compensation awards.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of options that will vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r156",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationAssumptionsDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, exercisable (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, outstanding (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r70",
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails": {
       "order": 3.0,
       "parentTag": "dyai_IncomeTaxExpenseBenefitIncludingTrueUpAdjustment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesBenefitProvisionforIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r115",
      "r116",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r115",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Period under program"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r99"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails",
      "http://www.dyadic.com/role/ShareBasedCompensationTextualDetails",
      "http://www.dyadic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CashCashEquivalentandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average Price Paid per Share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r37",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r33",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r14",
      "r115",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchases of common stock (in shares)",
        "netLabel": "Total Number of Shares Purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r33",
      "r117",
      "r120"
     ],
     "calculation": {
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock",
        "terseLabel": "Treasury stock, shares held at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.dyadic.com/role/ShareholdersEquityTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.dyadic.com/role/ShareholdersEquityStockRepurchaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ResearchCollaborationandSublicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]",
        "terseLabel": "Unbilled receivable"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r172",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r80",
      "r81",
      "r83",
      "r84",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule for share-based compensation.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule for share-based compensation.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/ShareBasedCompensationStockOptionActivityTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.dyadic.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.M)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5)(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r247": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r248": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r249": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r251": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r252": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2,12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "305",
   "URI": "http://asc.fasb.org/topic&trid=2122426"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5144-111524"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'HQIM#V5^,X.^*33_7B0ZT/3[L[L?M6OW?N#QIR'[Q+1^'%D_0]02P,$%
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MA/1R,67_:W@/590/3F(?VZ;JQM_%]JWKFWIJ)5JIRV_7X_$T'B_7?Y29PO@
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M<VAE970Y+GAM;'U386_;(!#]*X@?4!*2I5%D6VHZ39NT25&GK9^)?;91@?,
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M_,O&_C>(#GPJR8T?H<Y_L,60T+AP//BSF<9L,ASV\P]BRS<N_P!02P,$%
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M4V%OVR 0_2N('U 2QVVJR+;4M*HZ:9.B5ML^$_MLHP+G HZ[?U_ KN=MUKX
M=]Q[]^XXL@'-JVT!''E74MN<MLYU!\9LV8+B]@H[T/ZF1J.X\Z9IF.T,\"J"
ME&3)9G/#%!>:%EGTG4R18>^DT' RQ/9*<?/K"!*'G&[II^-9-*T+#E9D'6_@
M!=SW[F2\Q6:62BC05J F!NJ<WFT/QS3$QX ? @:[.)-0R1GQ-1A?JIQN@B"0
M4+K P/UV@7N0,A!Y&6\3)YU3!N#R_,G^&&OWM9RYA7N4/T7EVIS>4E)!S7OI
MGG%X@JF>:TJFXK_"!:0/#TI\CA*EC2LI>^M032Q>BN+OXRYTW(?Q9I].L'5
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MV&PHJ'PX?L*S'<=L-+SIIA_$YF^<_P%02P,$%     @ <(A^4+=FN4B( @
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M.W3 =#T@#%#8!P $.4X @O,:10"%?09 D.,0(#C]T3JW<6@? Q#D.@=P!4!
M>L>K^*Q!.$P<.G 10.L,QV%JZT"@S*$#UP&T3G*,0EL' CFJ,X)+ 5KG.4;8
MUH% D4,'K@9HG>H8K:XZ"+2U=(+%Y=I2?C-MA?!*=N],3[-8G5N7 S:7\S_X
MV/=\)_Q6=\([,ZFN>',17QF35/D2/JFS4JE6:YXT]"KU,%%C/O8;XT2R?NJE
M@KFA*_X"4$L#!!0    ( '"(?E"AWK1"[@$  &8%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;'5486^;,!#]*\@_H Y.0F@$2$VK:9,V*>JT[;,#
MEX!J8V8[H?OWLPUEC%Z_8-_YW7MW-G=9K_2+J0%L]"I%:W)26]OM*35E#9*;
M.]5!ZT[.2DMNG:DOU'0:>!6"I*!LM4JHY$U+BBSXCKK(U-6*IH6CCLQ52J[_
M'$"H/B<Q>7,\-Y?:>@<MLHY?X#O8']U1.XM.+%4CH36-:B,-YYP\Q/M#ZO$!
M\+.!WLSVD:_DI-2+-[Y4.5GYA$! :3T#=\L-'D$(3^32^#URDDG2!\[W;^R?
M0NVNEA,W\*C$KZ:R=4Y2$E5PYE=AGU7_&<9ZMB0:B_\*-Q .[C-Q&J42)GRC
M\FJLDB.+2T7RUV%MVK#VPTER/X;A 6P,8%- &G3H(!0R?^*6%YE6?:2'N^^X
M?^)XS]S=E-X9KB*<N>2-\]X*%B<9O7FB$7,8,&R&B2<$=>R3!,,D#NQ=.,/#
MUVB&ZQ"^GJLG'^AO4()-(-C\5^)N42*&27&1+2JR10CN%R((AJUPD00521""
M>"&"83ZX[QTJLD,(U@L1#+/!15)4)$4(M@L1#),L1.CL/Y>@+Z'#352J:QNF
MR\P[#9$'%OKD'WR80-^XOC2MB4[*NFX+/7%6RH)+977GGJYV0V\R!)RMW^[<
M7@^M/QA6=>-4H]-H+?X"4$L#!!0    ( '"(?E!\)>6^LP$  -(#   9
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MV?AB@;$Y3]&6Q^@+!':+0%S?!1"46,A@%3(P!F-;5;%LV(PQR+!L&!J#1DD
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M;]F\N(HQ"4K2>U#77:L9/ <4*JFWB=KS<1*-@63]-&31/.F+OU!+ P04
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M-RYX;6Q]E>&.G" 0QU_%^ "G@*)[V36YM6G:I$TVU[3]S+KL:@[% KM>W[Z
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M0&X*DDA!$)$.D<)S\1ODA;OC-P1,"H:!70,I+3 I0:AP%28E5XLS='<.@>2
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MV?N3NCCJ'Q#\\Z\8R_\!4$L#!!0    ( '"(?E C,T</4@(  %<'   9
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M!V#0@1' (X$(%@A!@= (A".!&!; H  &5I!8*6TQJ-V;VH"":)#XD4T$VD2
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M ";F*D[CC\3K<.ZU3:"ZG.@9?H#^.1VEB=#*T@X<1C6(,9+05?'G='\@%N\
MOP:8U68?V4Y.0KS9X&M;Q8DU! P:;1FH6:[P!(Q9(F/CS\(9KY*V<+O_8']Q
MO9M>3E3!DV"_AU;W5?P81RUT],+TJYB_P-)/$4=+\]_@"LS K1.CT0BFW&_4
M7)06?&$Q5CA]]^LPNG7V)R1;RL(%>"G :P'VO7@AY_R9:EJ74LR1]+.?J/V+
MTSTVLVELTHW"G1GSRF2O=9YG);I:H@5S\!B\P628K!AD^%<1'!3!CB#;$*2[
M+$R0!0DR1Y#_YS*_<>DQ.X<9'0;O"$YW15@H#PKE :'B1LACR$8H39.,9#@L
M5 2%BH 0N1$J[H3R3P23Q[ .">J0.YT4WTZ.W$TNSPA.[B:'-I?*?K/?J3P/
MHXI.0IO[Z6Y1)X0&PYD\&/.]>2;6@$&G[79G]M)_+#[08EK> ;0^1O4_4$L#
M!!0    ( '"(?E!48BM*K ,  %$1   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;)58;8^C-A#^*X@?L-AC8\,JB72;]+:56FEUI[:?V<39H .< KNY
M_OO:P*5@C_<V^1#>GAD_,_8S8UA==/NM.RG51]_KJNG6\:GOS_=)TNU/JBZZ
M.WU6C7ERU&U=].:R?4FZ<ZN*PV!45PD0(I*Z*)MXLQKN/;6;E7[MJ[)13VW4
MO=9UT?[[H"I]6<<T_G'C2_ERZNV-9+,Z%R_JJ^K_/#^UYBJY>CF4M6JZ4C=1
MJX[K^!.]?V2I-1@0?Y7JTLW.(QO*L];?[,5OAW5,+"-5J7UO713F\*:VJJJL
M)\/CG\EI?!W3&L[/?WC_/ 1O@GDN.K75U=_EH3^MXRR.#NI8O%;]%WWY54T!
MI7$T1?^[>E.5@5LF9HR]KKKA/]J_=KVN)R^&2EU\'X]E,QPOXQ.93V:X 4P&
M<#6@_%T#-AFPJP&\;\ G _Z_0?JN03H9I!^E)"8#\5$#.1E(QR 9LSM,UZ[H
MB\VJU9>H'5?<N; +F]Y+LR#V]N8P_\,S,V.=N?NVX5RNDC?K:,(\C!A88+(E
M9NMC8(G8^0B1+B&_8 /E2\QG!).2)>81P] K)C$)N68%T*S X( M' #N@*$.
MV." +QPP)V4C1@R89L"P3!"6.]'L$%R:0N;B'GT<2 IS?POB'"7.$>+<(3YB
M*)F-1.Y$EB]^3A"H#0],2HI22Q%JS@K:CA@YST$.J1#N8O1Q+&<BD"F!TA$(
M'>'0$3X= ,;<&?9A5(#,!$Y'HG0D0L<1\A;#.$+>89@<)Y*A1#+/ >5.^K>9
M'S"5E$AWU?@X+B00AO/)43ZY'U!HHNWRQ&HD^7@YH($R2Q$6U*VA"(A(MXR^
M#UJ2P:L;!81,*!Z\OE%V0TKP2D.14B.8VQ&X5]1H2@AQFX(/LZC0-./UA2(%
M1O" "[PF4'%#6G =4U^ OGXFT$(8&0L'C"N5^E+ELYZ\=(&+B^8?#QAP=0'Y
M^3K83J#Y! =B!5R @ DP4& AL"FX85< N&P V1?XL?J-G*9< G7JQ0X#4B;F
MP"4I7(B "=%M'> KS*ZWX)(#7&. :<QI00\3R!-]<"Q<C(!T:!%H98"+$>0-
M4XZ+#!"12>)F%P.%9A%7(B!]3H;VK+@2V0U]CN$R8XC,O&A14*"G,UR+#&EA
MTMVGHJ#0.(%]/")8&2B1#)<7XS=D%5<-0U3C9]4',>:NH63V7F@_-OQ1M"]E
MTT7/NC>OF,.+X%'K7AF'Y,XX/*GB<+VHU+&WI]*<M^-+_GC1Z_/T 2.Y?D79
M_ =02P,$%     @ <(A^4&M?;AR6 @  X@D  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&ULE5;;CILP$/T5Q <L&',)*X*44%6MU$K15MT^.\1)T *F
MMI-L_[ZV82DQ0[=]P1?.')\9V^/);HR_B#.ETGEMZE:LW;.4W:/GB?),&R(>
M6$=;]>?(>$.D&O*3)SI.R<$8-;47^'[L-:1JW3PS<SN>9^PBZZJE.^Z(2],0
M_FM+:W9;N\A]FWBJ3F>I)[P\Z\B)?J/R>[?C:N2-+(>JH:VH6.MP>ER[&_18
MH$0;&,1S16]BTG>T*WO&7O3@\V'M^EH1K6DI-051S946M*XUD]+Q<R!UQS6U
MX;3_QO[1.*^<V1-!"U;_J [RO'97KG.@1W*IY1.[?:*#0Y'K#-Y_H5=:*[A6
MHM8H62W,URDO0K)F8%%2&O+:MU5KVEO_)TD',]@@& R"T: /SJ(!'@RP9>#U
MRHRK'X@D><;9S>'];G5$'PKTB%4P2SUI8F?^*6^%FKWF81)GWE43#9AMCPDF
M&#0B/,4^+A% 2VR#F7EPOT Q1\01O (&G<#&'D^=B *8( 0)0D,0WD4AL:(
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M*&K5+!G,&P2.*ME?+S)UJ-NO4?.][-_<]A=U<=9OI?WKJ_'U_U!+ P04
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M2:W.0=WM@D-F-QNZ17:9KFUONRK;AV8=-:;W-&-,3**3=>J9NX[! R8=,G.
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M98[1)=./SE B&0V^XU?H'\/OXDA^?4SKOQRJ^B_%H=2?0-H#M50?B-54'H(
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M,I 11P)#!;W!TD\ERW&*)85+N"!O$L+; I7O42L/)+;G0L,95JQ[(!MZ3#?
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M]3I2#)%ZT&! C!VEOY5HJ%DS[=_W8Q@I+TC!=.28L]U /5,,,08^M[J6,_$
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M*7)J7.N>P4M[XQTU%P:ZF5W:23=P\4?=0"ZZL NIN=P^$5OH0KH0%=6WI;R
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MAQ4C.#5,*&QBA7_R.[ "SP% .QP-W+AGBRF 'J 'SQ9PF)/)T!W=!%Z%<YH
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M\/GZPOF!R+3T?5:8<A!F-WRWWDE?943]3T&Z/>#>=?]]_Z>^\S'A\OD=$_)
MEC(-*GI;@O;X6)2_=JSN^JVN3L)%BGNN-^2JA\#Z&2)AU0$#13\W??3S^T^$
MD3]KWUT!96/U\.)M5OBOJ2T'D#'?B,?V<,4G)X*.9T+SW#4:Q+#O3O"A!EM:
M, HOT\VT ,,#FQ[RZEW6!SSUW5=Q^TTX:70]MM%RQ\)6%F_JHJ1#I0YI?I]P
M6D#2':42UKM,<]I=57&CUB\4M.);8VH)!JYZ&;:72J+]8Q']1(W101DQUCG<
M^KZK:RP7L?_I,T)B/)M\-\0*0QNJ&!E> S@?]EQ\8ENOZ<?(@CCUMJ<=TX2^
MO?,Z1<,\:4J70PGFD I1F&JVSL2\CY'I0?-QUY\^[*$M0?44_1.6('7H)\W8
MX=:Y*J1XKX:S_O";>BX>#F-Q2.[@N#]N?94QIT^?8+U.#LMD>TN%U2E0R\2L
M--]^!I9E(+P<2Z<Q[LI4^$P6"3\BP#C+:@?>""H8.Q^<D:OVU?D9B0/,,R0]
MBZQ??!@:)%1I&54R(:PY+ 81L=;:O*52VA[K'0CT30 TQP^XBYB(]P_;ITBT
M\73 G=[F4]< ST3H<<[^@3J^R=I<C3&N"4)5C34WW<-=+C8G)]S#9<:SDG-J
M:=CNJN'6)Q&W@CO8VE"@\>&^PH/V5XD#<W&+$DB1!W=N47L184 OTGGBP-ZA
MAY@H[,R4Q^7U"=PYAQL/_P5'U[UU>Z1$UW8)N7]P77:W_:G;1L<!\B!!!_,:
M^F38S1$X0,=BN.JJ[,IV7 =&&+M+CT )I2B:G1!O3T;S??33]57TJIW6P5A(
M';?9OD'F&C5G7+$5'U,&J" +J5WPRA5!/DZ?0S.8=/66H!VZH4)YR <*?+K,
M2+1\IS3J#;M;')]^]\8P:8D^QR%PY.IP=X>MWS%<DDD=%I4E>U=*9AE#+Q#%
M"@RE]5@%'+XHUU(^Q9C)#KN=%H^E0?8]:GTL4VB FZL!A:VUT.)88@7+E2;5
M<8%J"H*VH2R\RS[HJ[H,C&T2D M8V%R?4=M[#KU?49]6)@AHB)'WPZA>#L9Z
M3$OI=\D%LDM1="25Q<%#!BO*1N_$"Q]<'S);-YVQ+[99OV!<%_]K-F_2!VD;
MDK1<+P)YHC%31@O1S17<@AV8+"* \I.I3NUB]GU^LRF(DN1K6Q[TH5XH/(AE
M=?6-PQ1ZKI2GTQ!("1;!2PB$.H=^3()"FME6+;ZQ,LFZ("/Y#T:48N+0-^2A
MC:J?TUS-+FRNC,*),I]&ZK:%7P1%)A@E7/N[]E$"><#A4$C3<,<U D@+]J2+
MO "F#)D[J73=0OR2,C6(P[RP[VA,F/W@/@H7FODPOZ5'?;13E&DM8[[M".UZ
M.[O4.2J!JY+*V;(JA,_*P<=W\V@TN@UYCG39T@V>TA]//(DO01"30X,P==;T
M9Q&FTL(&>5N;Y5>#_EC/OZ[WVZ#6TXP&S\3@U_8@&2L^F+QSA'H5LZQETS8S
MO2VSVN-/ P)+=P/(:C+LC[I \J'X @R=F=K[ U!1U&?11ME[+P5S/^;1!7"=
M#;;?:6G!7;=%P)>-9BR!(-(^B]-(0[N$?_D30.G]?NTU=??(?8%[T/W(Z^YM
M^=VKPSYBB9K\Z35\9G7AWBE%@H]?QH]M$E=C\"9@ NC9I&;G+T3C$MH+5J %
M7Y/[MQ]X, 5OIVA9 .5]LWY$;=X> W)]3?),J HKA2.Q1OAK7CSV,'?4H')-
MH.6"I%R2#;16-&;B#<#N T1CX3MJ5Z,V.8K%KC2U&?#9E:W14&X5CRE 0):V
MQSZD%"X)U/$^9<P%E713W(<]BUPL/J58.=9,S9N5#6@=G"3;F#A0#D6B]^&N
M;-CWWE"U[4'I =>3.9_%$B')1DD?#5KU;L77&IY&/^UZ;ZGPZZ5=GQ7;VUK9
M.&PSZ$YG>.U3,*S1374#FZ#1N(E2$D6*P:9TL+46![ZT<^$*R*.:Q(5*M; ?
M_\MEQJE6Q+8-U*C$C5']1@P,93Y-Z):475=SBKJE-0["]U?+ YIHZ]&CEJ+/
MJ!XQ*"%>^= GH?#].U61IO;A&VLYUH%KQYPS\@8@60/,_C,(_%_J!7V?UR/<
MUO\H74('Y )(Z(,SX:R;)PU8P \!FD>4#%="HUO),&?'!9"T?RHG+[=W%_2?
MQ]$]X+9D]&3[1DMK*L#[HIZ)7%=4U^0J>SN@N*+>"67QD/B;[+(]J3$^-&[+
M-D-45 @'#KFD16,B6B.CT@)-)["M"A!F<(EL]>?"+#$<Z#@Y\O3-0_=9TECK
M</8<930IHD]8^RE-]R*W-[N=K,J,M")9#B9YSP:SD"P0'EG$Z,0A)Z\K:Q2C
MSTE]*N'HU2[B"F\*\0F!GUE5PDHP ENX#VN8A_(NF!A0 1"/'<10E9J<8"'%
M6/S=0_+/)XPB"^6\'Y.G:/J'"'GM4W0(>>[E.'K__M(G*^G/SPIMS\S6*;29
MB?\KQ;;_2F'M!,FLJWFD<V\?*M5V0!R0).E5 E3L"8.[H]5#NN7BO*F84J30
M()IA)>Z;JNW=^J$25V.(2 (HX!G59BF,?3\_K#8I6D97F7R#5##9T4*9*27W
M>8'&MX@6]MOEO6<1S!J2O9 T[Z/9_S$'COR0[0+JYD=LH/MSLI_S!U2'%8((
MNU!;&A/0E]A*$RU=-M@K=$2:<V+<$8'M=\EKS\"6>%B2NPPCU2Z0\$I4-"QY
MN-#X! 7G&_/>)WK/ = $^HNO1.O^M+1$\+T[C$'DK0_&@Z^:4\5R/OY>:S0I
M6BU4/^IC4Q\JF85=RH+># "M+$31MDD\Z%16D7A1$E7VJ?"OYJ<216MQHR6E
MA,H04.&;YNNC$U#[CY+'_3;;)'+_5&5R6W96Y2E,%5V9LK.2OO&;!66SIC]*
M5/9#_FYA^52+?,=1G2 C^<5VB$/_OTG39LV=%M&NNZS5:8:>$:J(' IAQJ0J
M)898S@V903NA#H3HO'"2*DW7Q4V0EGB:]YB8ON@ O\86^QP20>O:[9MR4/O*
M0CX%BBN55Q4]LL'JWDO5V/<N.T[QPR_4,DH?+Q+B$;YLY1KNS8/WB$4;+)T*
M$$J4'06-!6LA4W7W;AA$1=+D=5H>MI1WGNT/7$S[70ZB@ JX\Q,$W$",;CJ5
M5R^8]=.7?3\.3)'TZC,R+6D%9I)8)D#C&%;_IL@2+>-0X[X-Y4Y8+P@.=,B&
MT.-PM\5:B^Q]T>@H9_"ARTUUWCP4-D]AIV9NV+EY<I$Q=:"YFGK[%"-T93E:
MK.'8ZOOV(GH/.)>F88B$7$_;<N?&"NF7$G!DI&NV^*6%BUMKR (5@^N-I^,N
MR<I+4OCY<"H^<Q=#N99J[^P0+3E1T2T6I*Y&XH4MY-O]++KR^? O3*UHE"K&
MX2XU.?TOQ6T57:R\Z1!3;+PV]TR6#=MTF>SXM)HP]67!K(A2=Y#P4U"WQHQA
MJ6M?F]$6ITZX5!V7"&"ICDI>O>4::I&754TQ-JXVC8<Q!FD&T&<T_$8D8LE;
M4RG"?0W'B972./I8PF9P*"?%_W@3AMS11E*LP)T;Q[$.!Z]+:3E,U*VXF"?Q
M G@@-3"H8)]8>S0?3MMAF'JX7,^:2QB;JGH #/9F>1\DUU6X0$+>.0MR;9?8
M1W.8\35K'2;)M,@S!P)Q*J5."L.4Q>'^@6;4*-#AH/;>:-BGY'0,N;CGBBXF
M;TQ IAY Y71^X?XR-2I^1AQ/9$_<Y7[J&J6;;%&B7ZS@B"N=+/.%J>IU1YU6
M@-R]K)1UF*FT0&3#6_=J& \&PW@T'A^18+29F),\$+I%/3KRU<"$)PE,[Z2,
M-3DYZ12TVFW0OEQP9IMPG58:GB)[Y-.*O:'F!(<,JJ!);1 Q075UI-)@4/XT
M>7F[*+J\QN>)F0CQ:#Z)YTB?X5^S> 9D9;:<GKL>3.;U,WBVG,S/H[/Y-!X-
M%^>2YV"7V%V65F9;SN/9=*FSP;^6P_'Y,S! +ZXOF-XUQ0OCUW\+ "^EO#*K
M3.9F^-5I(3*ED4'>AT/2<\XU;22I*-3KOW>-@G S$/"@X4!@PQ5U7=I@SS<\
MDM*>G$0:-!22+:#/_$ U_=F1Y*]D&UZ*GNC $Q *S21%FU.*U=00FJ8&M9;E
M%!2W7,.%8!JPMQ 1OD\HY^?8B2P)^BZ1 <'MQG$KM4G7HZ&DJ+;GJNZ+K'HI
MZB#'!Y#3%0P!"O=JV!\,SJ-OS%_7'@PQ%YR]<^>A1/!LTI\-S_$_([BP'XJ\
MMV9V3928&KZ<S?H3N&R#_F0273HXMM'>\:"_7 (?@;&BF_*0]D"PY>P@TDD&
M?=C#&?SOO)TT#/H#) SP.9"%RY8B][@QA\3$H?W@^C,,,I-D:9NQK$#7UP!.
MPTD?B=0WSQ".MD,-ZEB;*;3D1HTJ=!SGM:DUY^[6JV@$E!$#MN&OR2B>PU\?
M/KX/Q( (2><D'L$CH+2S!;W>W6:0V'&%[?NFLW@Z&)B_.--J$D_PUR&-V&RN
MX) GN#<VA6L>#Z>#& 0(& K[!>)P/[<@R)E[$5%.7SVG2H<M4D);JM]5$^SD
MN^;F363!2O=![OE)M>I=_R1M!U3<=56^H2*W)JS1U2*1%D"F6!0/13)AC<_X
M?D'O<BFL[RLHDD(KJGT=[%K.WI1[;_;_/M(=@8AV6XL$0?73NR3@M='ZGKIH
M5]6O911J(J_]-)VMG%/P]+O6.O?-2J$G-N(0C<93M'[THP>;.AS8_%6M'N"U
M3;H6P3'9',/X6"/T\&1;UTQ(@ <-$FO.I:<X&8PKFFV37WE+Q 6TKT(_^EZ#
M5=O:D#F:&SM$;[DUCY3X?8=_8DU)[J;61JZ?2Q"O1X:OVZJ6N_B8C^]];]E
M9?&51UFR7XK@P*:N^TRLXKNLE#?&\R/R=QC::!<'*W@^!&^X[,_#&+RE#[RM
MQ^ ]'UZ9%Z9&U=%2[&(Z;*W0?+R:6KWXLRF;EU&$:->, HL\_<JM)?HN>W$T
M:+.UF:"H38K=>[SDAZ6[LQP-I;56'&I&KKB,MXH7IC8_[CO(\#$EP&O%%9?-
M0TTHL  G=;%4N!9R&W(8V^&6FQ/M-T^F(XV\QWDT&P[;2"L.%J :O'07V$2N
M1HQWYLE5L:(*EL!6Z4- ]'=7GRNR'1RP!VC9'M!!JB=/D7+D 7DMJD/J@LII
M_8<UT^AJGU$[-NZ.3&EFTB3FD&NUWATR<*Q_^J 5B.AK]5SY= WJCLT<@'S=
MOE^+OHL.P*+B'C?K+.'2,E=$']/UMVBTY7.",[T&C6GE:M4(F>:H?S:@9I5U
MSMN!S.=G0A1NKER->N>GK.ATDUPJR=+<OB,>4S1FZ14/ILVT"_8I^37!_[K^
MF8"\&(+/)CRI#BB;]>VFQ01T=:V4@@*DI1&=^KJU>R_UP!*;!H#XI^L:!W>>
M*C@Y,<UXK5X+R\D HMF@-DKDT];.HW*,UG/4*-/B0L8K,;M32 LPNZQI=#SZ
M\N^P0QX?5VH0_N6PPXB?.'J[*<ILG41_3I.UU-]I+__B36\/]M6$\MU7BGGU
M<4/*B76>=QE;X W1G\1+D$<K'!,5TG3OTNO0G4JM/ZD!N=/CI*HQO(X5?-#Y
MR6&!F#AT+UVX0K:R1#F=%\-5TIB?D:/>Y(NKL8VBPJ@$:TLL'>F=W)F(<%_6
M710:!K#768#ZX>F0-6V#F.IH)&B'=W<F(&EKM1GM\.%5KU#-X7U\($("T@NP
M\(\8*YD&L":X<*G6J-I267Z$!3!"7".]#N?U"Q)JPH[8#DATO\G%Y?SJF0.C
MZ:+E]+CN*1]=]1N/;=)^;$'AIU#TZ#JYFI\*"U;QB/Y(DFU*12& A-B(K _P
M*MV:T#SM?F87BZ_51T4B! 18Z!0-ASB=]G-#% K7/AI*W2/MCP$RX2;]2BJ^
M'!7C41M@VX V0*#]?'/C=4YM"!^]P>@&LAXY66/1ZM>C*(AT'0;'N8Q'E2IU
M7"=:JME3Q)C12,H(P&)NJ*OGBIJEZ+)@$QQ9\#;+-Y1*83,5X*OGW7VZA+B1
ME(J3)A'7C E3<4?]Z<AGIWYQE1&_(CM#KRN;%R7^ .OIJ<;>[C:\.^3W%&+C
M0G6J)Q!F7+28"ZX2_YC&@G&2J_/%P$@/%+S 'TO6NX38;IY619J#.)ZF);G.
MJ/JG5Y<8'JX=+J<%V DI88GQ(A0-P@ 5"8Z*;HO\H*Y/ [K)=$#FC"!K;^^.
MEJ<EN6EWT.A/P2P^)^>:U'106(FX%K52 N7INUB0H 9L]00L(150;@OB07(T
MG&N&VW.WCW<"1(E$:VV<,VH/U?RZD[IX9K$DWB5/-1 9<,R6 Y.]KTB$R<\.
MA4!(07E3O$WU<\3<DU_[/N^!:7:P;VUOD89+HUTN!R!(/;D6-R#;9&@?U7*:
MT4<?$]!:#4TD<N(2HF%K2*,*$29F,O'E+VP^M;IW73*?'#DG Y=8H^-0<JSD
M+1:HY7*[[<K;:V+#:%R+Y[-1/)Q/B4)&PW@X&,>S\8BIRF0YBT>SA:_"%(_A
M[0&\?</!F;PR$Q*AB^)])[<8&\X]I3%.*2,QPVU4<LH(T)7G$2VIM+4,\**\
M3W(QM%02=DEE0AHN< 66^M%T,BEJW#&CND[=#@,!PD66VMOM;+"F;8P+46WM
M>,)5Q_V2K/(_&O6![R&U^^2;_V(/($T_EO:4&TJP*#9?4NDD^Q2A:49;EI&%
M 9T+&VS'(GU :D49J7H].0FUPX1D^WGKGELS=\]M::?:C]Z2DIQQ74S\;R-D
MS4"+VQR'?8U!3:/^(*M-DFVE_R/%=-51ZRB^>S)O0A5XR%A:([ER#%S;4UKT
M^N;@+:8QF]",1;< UPX,.5_1PE6GZ-<DQ%]3"1@VOC9;U)OU.=*#*<V86T9O
M),[.ONF\NK#+ ]F[0B.K$XNYD9[V$Z\*5**??.-W]>PXG%8.6@6])3-MF\:Z
M+-=P$)U$]JY5SY@">^NS%OK$%G_W0"T3Z23#37^E(4%YV,C9KZGP4J']KS&R
MKTHWYI"LN8+\Q5^X.A!?,/&#<:A8MJ(X@%6";>S>^\N0(0(]I')K#KG8$YA.
MY5P9LZWZ%F6?M73DJK]G=$F,<K8ME3X+R:-ZS3%GNTGKI4\:C_-"_;-K54#J
M@Z8+;SCH\=,F$=8$U'^HO[[+,:P:'43X/)#'Z37\-8B>T?*P8E"0QF(N Y=E
MW*%/>_[BWZV36&J6HTE]JA]* PYQY;LU$!5/*\V)%]G)AR/7QQX-!C/Q*WUD
M2+3L#UZQ^\,VLIH24VLH4K@.?;R<F&QIVB^!02D=ORC%>INL4V\TM)]1IJ&5
M<?0S,4QI@+\/6J5UHO7<BN9FR#'*120;^79$[3S4]'RB54K$.G%D@J]X9RJ,
MF%RE0>QD0BFK*3MB;,.SE44][3RVVV!N*[5YI25YTW<P06V3=$1(&FN,E2'4
M]K(O>G;''=/8^+=)=M0ZUO>?HGA!Z>AB(^-KY^Q*>W!=ZY8IV4_5DMD:=.^L
M'9&_*>Y.<-1/28HMI@>@%](>(@7^L9[+&+XCX#3J,-MXJ6/!QM:6[-M9!5V^
M@H9B=($#81R6.)G'(]A4>]NKVB%S".2AB;%="V4;"):KPO\Q3;:.KA'$U?'L
M#UF5I1:5^R]5Q_0)65X4#^;8:QE0)QAB1MQ&SRXLGT)6T+"36RW+PW<2DJE!
MFTPY["ZK;'Y!0(7%1DP2&$Q#GS(9U:X<7);<.-L;5ZM)1Y4 4\8!NU*YX.9
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M.U-(,2JJ'C_#\%/>XE3_R2+;\Y@=#>"+17^R^"9:]C'WI,VF#<>(%MU_"D&
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MA[J8# NXTD3FF.-PP ]>\XRKM'G&J873<'B1'*I&.<48G1?8SEQFY:N"B8>
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M43XN2&S0_@:A"<87QC*CK0M[F#4*8W*M6I>H)9^^<P(JF>"#8KCU=?GR54$
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MS14F=&8V>HB2%7N<8]B6#M/,%^S5,@7/#KG6CC[_;6F#C:S!GD@$];R[-06
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M#/QG!'?J0Y'WUAACS;% G$=[-NM/X#X,^B!37;HDK+;LA_&@OUQ&PP&,%=V
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MJ^$8S>CQ$LB?K(>KM[2-  <QF0,I'--!3",4PZ)72SJ>^6AYW![PV>>T!9Z
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MEY;V 8C?&>#-@UK(^<:&396Q<O5*6MN5I#M7))T^F")I=]#'Q8!K E YXG=
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MK.Q#!H&S*C5$R^)@Z>G?X<DP%Q81J]7XSY$Z<^Z H^-G ("&+W08N?_F<V0
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M>\&?89H.FSMSG49R:=)(OB1D8(FYLU7^(8=(LB^6=5]_Z=!R2ZGTP*%;XSC
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M9F**\Q=$H)DAUK19X68O"MT*7QD89(-9KO&^*P.$/%:[;XMB]^Y_4$L#!!0
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M     %]R96QS+RYR96QS4$L! A0#%     @ <(A^4"?HAPZ"    L0   !
M             ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !P
MB'Y04E[H!NT    K @  $0              @ &9 0  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !PB'Y0F5R<(Q &  "<)P  $P
M@ &U @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '"(?E!!EL\&
M=0,  "@1   8              "  ?8(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !PB'Y023,E1  $  "G$0  &
M@ &A#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ <(A^
M4 =(;0%J @  4 @  !@              ( !UQ   'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( '"(?E [O2LK1@,  "P,   8
M      "  7<3  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !PB'Y0B1??H<(#  "M#P  &               @ 'S%@  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ <(A^4.6#*KMB!   >Q,  !@
M             ( !ZQH  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( '"(?E#V=)UJL@$  -(#   8              "  8,?  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !PB'Y0%9XP8[4!  #2
M P  &               @ %K(0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ <(A^4*X^'(^T 0  T@,  !@              ( !5B,
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( '"(?E#Y1J:9
MM0$  -(#   9              "  4 E  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ <(A^4/^:Q]^T 0  T@,  !D
M ( !+"<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !P
MB'Y024UMQ[0!  #2 P  &0              @ $7*0  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( '"(?E 3CB@#M0$  -(#   9
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M970Q-RYX;6Q02P$"% ,4    " !PB'Y0L7VO ^ !   !!0  &0
M    @ &G-0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M '"(?E!$#_S@M@$  -(#   9              "  ;XW  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ <(A^4&?3,\;3 0  G 0  !D
M             ( !JSD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !PB'Y0[^ME/+<!  #2 P  &0              @ &U.P  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '"(?E!$K\K<C ,
M )41   9              "  :,]  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ <(A^4/ &)2H( @  ]04  !D              ( !
M9D$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !PB'Y0
MNC0H1 ,"  !\!0  &0              @ &E0P  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( '"(?E /-2J, P(  'L%   9
M      "  =]%  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ <(A^4&QT4XT& @  ?@4  !D              ( !&4@  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !PB'Y0A!\2.TT"  "G!@
M&0              @ %62@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( '"(?E!W#>I!H0,  )4/   9              "  =I,  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ <(A^4& BF.UG
M!   T1@  !D              ( !LE   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !PB'Y0(S-'#U("  !7!P  &0
M@ %050  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '"(
M?E!J&3S^'0(  (X%   9              "  =E7  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ <(A^4.K#9RH4 @  ^P4  !D
M         ( !+5H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " !PB'Y0&C%6R6T"  "W"   &0              @ %X7   >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( '"(?E#'BB%?/ (  "T'
M   9              "  1Q?  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ <(A^4&UR2<R? @  *@H  !D              ( !CV$
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !PB'Y0J;?M
M8MP!  "8!   &0              @ %E9   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( '"(?E!48BM*K ,  %$1   9
M  "  7AF  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M<(A^4&M?;AR6 @  X@D  !D              ( !6VH  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !PB'Y0$]QYU7T#  #)#@  &0
M            @ $H;0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( '"(?E I:-(%400  "87   9              "  =QP  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ <(A^4"$N+!<Z @
MD 8  !D              ( !9'4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " !PB'Y0TM%'54<"  !,!P  &0              @ '5
M=P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( '"(?E#M
MN-=)_@(   P,   9              "  5-Z  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ <(A^4&[ 8M8%!   1A4  !D
M     ( !B'T  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M" !PB'Y0-E_@9ZA^   QW $ %               @ '$@0  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " !PB'Y0,VUNW7$"  " #0  #0
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4!08     -0 U &4.   S"P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
